U.S.-China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research

Harbin Veterinary Research Institute
Chinese Academy of Agricultural Sciences
Harbin, China

8-10 January 2019

Monday, 7 January

Some participants arrive at the Aoluguya Hotel (No. 800, the 3rd Road of Chuangxin, Harbin)

Evening activity for those that have arrived: group tour of the Harbin Ice Festival (proposed)

Tuesday, 8 January

7:50 Shuttle bus from Aoluguya Hotel to Harbin Veterinary Research Institute (HVRI)
(No 678 Haping Road, Xiangfang Qu, Haerbin, Heilongjiang Province, China 150060)

WELCOME AND OPENING REMARKS

9:00 **Welcome, Introductions, and Opening Remarks**
Chairs: Zhigao Bu

1. Welcome on behalf of Chinese Academy of Agricultural Sciences (CAAS): , **Kongming Wu**, Vice-President of CAAS
2. Remarks on Behalf of U.S. National Academies of Sciences, Engineering, and Medicine: **Benjamin Rusek**, Policy and Global Affairs, U.S. National Academy of Sciences (NAS) and **Diane Griffin**, Johns Hopkins Bloomberg School of Public Health and Vice-President of NAS

9:15 **Session 1. Keynote Addresses** *[20 min each]*
Chairs: Benjamin Rusek

1. **Prof. George F. Gao**, Director-General, Chinese Center for Disease Control and Prevention
   Oversight for Research on Viral Pathogens with Pandemic Potential – the Perspective from China
2. **Prof. Linda Saif**, Ohio State University
   Emerging swine coronaviruses and their interspecies transmission

Q&A/Discussion *[15-20 min]*

10:15 Coffee and Tea Break

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004070

EMERGING INFECTIOUS DISEASES

Goal for Sessions 2 and 3: Consider progress in understanding two diseases of concern to China and the U.S., including the health and economic implications and what advances in understanding may be enabled by recent scientific and technical developments such as gene editing.

10:30 Session 2. Swine Fever *[15 min each]*

Chairs: Linda Saif and **Hualan Chen**

1. **Prof. Xiaodong Wu**, China Animal Health and Epidemiology Center)
   Current Situation and Control Strategy of African Swine Fever in China
2. **Prof. Zhigao Bu,** Harbin Veterinary Research Institute, CAAS *Characterization of African Swine Fever Virus Isolated from China*
3. **Dr. Douglas Gladue**, U.S. Department of Agriculture
   Editing African swine fever virus field isolates for live attenuated vaccines: Current live attenuated vaccine status
4. **Prof. Hengsheng Ouyang,** Jilin University
   Genome-edited pigs protected from classical swine fever virus
   Q&A/Discussion *[10-15 min]*

Proposed discussion questions

- What is known about the epidemiology, health, and economic impacts of Africa Swine Fever?
- What is the latest progress on developing effective countermeasures and limiting the spread of this disease?
- What critical areas remain unknown or what are key challenges to preventing and responding to Africa Swine Fever outbreaks? How can new scientific and technical advances contribute to research and development?

11:45 Session 3. Influenza

Chairs: Linda Saif and **Hualan Chen**

1. **Overview: Perspectives on international collaborations for influenza research** *[10 min each]*
   Prof. Hualan Chen Harbin Veterinary Research Institute, CAAS
   Influenza Vaccine Research in China and Globally
   Prof. David Swayne, U.S. Department of Agriculture
   Collaborating on Influenza Research from the U.S. perspective
2. **Panel Discussion**
   Speakers provide 5 minutes opening remarks on the topics identified below, followed by discussion facilitated by the session Chairs
   Prof. Dayan Wang, National Institute for Viral Disease Control and Prevention, China CDC
   Human Infection with Zoonotic Influenza
   Prof. Chengjun Li, Harbin Veterinary Research Institute, CAAS
   Interactions between Influenza Viral RNP Complex Proteins and Host Cellular Factors

Proposed discussion questions

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004071

- What is known about the epidemiology, health, and economic impacts of Influenza?
- What is the latest progress on developing effective countermeasures?
- What critical areas remain unknown or what are key challenges to preventing and responding to influenza outbreaks? How can new scientific and technical advances contribute to research and development?

12:45 **Group Photo**

13:00 **Lunch**

VIRAL PATHOGENS: SCIENCE AND RESPONSIBILITY

Goal for Sessions 4, 5, and 6: Discuss relevant pathogen properties that researchers may seek to alter, and why, as part of studying viral pathogens with pandemic potential. Illustrate challenges and opportunities posed by new strategies such as use of gene editing, rational design approaches, other strategies enable by advancing biotechnology. Discuss the associated issues in the ethical planning and conduct of such research so that it can be conducted safety and securely.

14:30 **Session 4. Understanding and Engineering Viral Pathogens with Pandemic Potential** *[20 min each]*

Chairs: Diane Griffin and **George F. Gao**

1. **Ralph Baric**, University of North Carolina
   Advances in Understanding and Altering Pathogen Properties
2. **Prof. Weiwen Zhang**, Tianjin University
   Cutting Edging New Biotechnology: Strategies and Tools for Engineering

15:10 Coffee and Tea break

15:45 **Session 5. Bioethics and Responsible Planning for Pathogen Research** *[15 min each]*

Chairs: Diane Griffin and **George F. Gao**

1. **Prof. Zhiming Yuan**, Wuhan Institute of Virology, CAS
   Biosafey and Bioethics in Medical Research
2. **David Relman**, Stanford University
   Tradeoffs between benefits and risks in pathogen research
3. **Prof. Jianwei Wang,** Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College
   Biosafety Management of Synthetic Biology: Challenges and Progress
4. **Associate Prof. Yang Xue**, Tianjin University
   Biosafety and Bioethis Considerations in Dual-Use Risks Management – China's Efforts and Future Works

16:45 **Session 6. Panel on Science and Ethics in Research with Pathogens with Pandemic Potential**

Chairs: **Diane Griffin** and **George F. Gao**

Chairs facilitate a discussion between **Ralph Baric, Weiwen Zhang, Zhiming Yuan, David Relman, Jianwei Wang, Yang Xue** and the audience. *[45 min]*

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004072

Proposed discussion questions

- *What do recent advances in biotechnology, such as genome editing, enable researchers to achieve in improved characterization and alteration of the properties of pathogenic viruses?*
- *What do you see coming in the near term? What still remains very challenging and why?*
- *Because research on viral pathogens can raise security concerns, how do you think about making decisions on whether or not to conduct such research or about modifying research proposals? What are the responsibilities and best practices of the PI to ensure that pathogen research is conducted safely and securely over the course of the project?*
- *What ethical and policy challenges remain and what actions do you think are needed to help overcome these challenges?*

17:30 Transportation from HVRI

18:30 Dinner at Restaurant

Wednesday, 9 January

07:50 Transportation to HVRI

VECTOR AND HOST ENGINEERING

Goal for Session 7: Research to understand and prepare for viral pathogens may also involve work conducted on the hosts or vectors of such pathogens, for example to better understand host-pathogen responses and vector transmission. Discuss how advances in areas such as gene editing are affecting such research and best practices for safely and responsibly conducting such studies

9:00 **Session 7. Vector and Host Engineering: Safety and Security** *[15-20 min each]*
Chair: Jim Le Duc and **Zhiming Yuan**

1. **Prof. Qian Han**, Hainan University
   Biochemical Pathway of a Mosquito Innate Immunity, Melanization
2. **Stephen Higgs**, Kansas State University
   Best practices in safety and security for working with arthropods that serve as pathogen vectors, including responsible research with gene drive modified vectors

Q&A/ Discussion *[20 min]*

10:00 Coffee and tea break

10:30 **Session 7 resumes**

3. **Highlights of Recent Research:**
   Prof. Tongyan Zhao, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
   Vector Competence of Emerging Mosquito Borne Virus in China
4. **Prof. Gong Cheng**, Tsinghua University
   A Gut Commensal Bacterium Promotes Arbovirus Infection in Mosquitoes

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004073

Q&A/ Discussion *[30 min]*

Proposed discussion questions

- *What do recent advances in biotechnology, such as genome editing, enable researchers to achieve in studying and manipulating hosts and vectors of viral pathogens*
- *What do you see coming in the near term? What still remains very challenging and why?*
- *What are the responsibilities and best practices of the PI to ensure that pathogen research is conducted safely and securely over the course of the project?*
- *What ethical and policy challenges remain and what actions do you think are needed to help overcome these challenges?*

12:00 Lunch

EFFECTIVE OVERSIGHT SYSTEMS

Goal for Session 8: Discuss the systems of institutional review and oversight in China and in the US for safe and secure conduct of laboratory research on viral pathogens with pandeminc potential. Focus on the institutional systems including the important role of leadership in promoting institutional cultures that support responsible research practices.

13:30 Session 8. Best Practices in Laboratory Safety and Security for Pathogen Research

Chairs: Mifang Liang and **Joe Kanabrocki**

1. **Joseph Kanabrocki**, ***University of Chicago*** *[20 min]*
   Institutional review and oversight for research on viral pathogens with pandemic potential – a U.S. perspective
2. **David Franz** and **Zhiming Yuan** *[20 min together]*
   The Role of Leaders in Laboratory Safety: Culture and governance to steer toward behavior changes

Facilitated Discussion

Chair facilitates a discussion with the speakers and audience [25 min]

Proposed discussion questions

If assessment of anticipated risks and benefits results in the decision to undertake an experiment that involves characterizing or manipulating a pathogen with pandemic potential:

1. *How should the research-conducting institution oversee this research to ensure that it is conducted safely and securely over the course of the project? Does this oversight happen at one point or at multiple points over the course of the project?*
2. *What are the responsibilities of institutional leadership in promoting the culture of responsible conduct of science?*
3. *Are there particular scientific or experimental practices that should be incorporated into research design and conduct that can maximize safety and security for studies carried out to understand or alter the properties of pathogens with pandemic potential?*

14:40 Special Topic: One Health in China *[20 min]*

Chairs: Mifang Liang and **Joe Kanabrocki**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004074

Understand how a One Health approach is shaping research to understand and address viral pathogens in China
Prof. Jiahai Lu, Sun Yat-sen University
Q&A/Discussion *[10 min]*

15:10 Coffee and Tea Break

RECENT RESEARCH AND PERSPECTIVES

Goal for Sessions 9 and 10: Gain further shared insights into how research communities are addressing issues in biosafety, biosecurity, and bioethics, particularly as applied to research on emerging infectious diseases caused by viral pathogens

15:30 **Session 9. Chinese Biosafety, Biosecurity, and Bioethics** *[15 min each]*
Chair: Mifang Liang and **Joe Kanabrocki** (give some opening comments)

1. **Dr. Peijun Zhai**, CNAS
   Overview of Laboratory Biosafety Management System in China
2. **Prof. Jiancheng Qi**, National Biological Protection Engineering Center, China
   Development and Application of Laboratory Biosafety Equipment in China
3. **Prof. Yunzhang Hu**, Institute of Medical Biology, Chinese Academy of Medical Sciences
   Kunming National Primate Research Center of High-Level Biosafety
4. **Prof. Ruifu Yang**, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
   Microbial Forensics: Building Capability for Source Tracing of Bioterrorism Pathogen.

Q&A/Discussion *[30 min]*

17:00 Transportation from HVRI to Restaurant

18:30 Dinner and optional group outing

Thursday, 10 January

7:50 Hotel shuttle bus transport to HVRI

9:00 **Special Topic: Update on Acute Flaccid Myelitis**
Diane Griffin, Johns Hopkins Bloomberg School of Public Health [20 min]
Review of what is currently known about the cause of Acute Flaccid Myelitis
Q&A/Discussion [*10 min]*

9:30 **Session 10: Chinese Perspectives on Emerging Infectious Diseases** *[15 min each]*
Chair: Pei-yong Shi and **Zhengli Shi**

1. **Prof. Changjiang Weng,** Harbin Veterinary Research Institute, CAAS
   DDX19, A novel Viral RNA Sensor, Regulates IFN Signaling upon Viral Infection
2. **Prof. Zhengli Shi,** Wuhan Institute of Virology, CAS
   Risks of MERS-cluster coronaviruses in China

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004075

3. **Prof. Haixue Zheng**, Lanzhou Veterinary Research Institute, CAAS,
   Rational Design of Master Seed Virus to Improve the Safety and Effectiveness of Foot and Mouth Disease Vaccine

10:15 Coffee and Tea Break

10:45 Session 10, cont'd

4. **Prof. Rui Gong**, Wuhan Institute of Virology, CAS
   Development of Neutralizing Antibodies Domains as Therapeutic Candidates Against Infectious Diseases
5. **Prof. Longding Liu**, Institute of Medical Biology, Chinese Academy of Medical Sciences
   Development of inactivated EV71 Vaccine (Human diploid cell) and Pathogenic Study of EV71 Infection in Rhesus Macaque
6. **Prof. Chengfeng Qin**, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
   Zika Virus Neurotropism the Bad and the Good

Q&A/Discussion *[30 min]*

12:00 Special Session 11

Chair: Pei-yong Shi and **Zhengli Shi**

1. **Prof. Chunbo Lou,** Institute of Microbiology, CAS
   Large Gene Cluster and Regulatory Manipulation for Activating the Cryptic Natural Product Clusters in Streptomyces
2. **Prof. Xiaoli Xue,** Key Laboratory of Synthetic Biology, Shanghai Institute of Plant Physiology, CAS
   Creating a Functional Single-chromosome Yeast

12:30 Lunch

13:00 Visit the Unit 731 Museum

LOOKING FORWARD (CLOSED SESSION, BY INVITATION ONLY)

Goal for Sessions 12: Identify shared priorities and potential opportunities for future discussions to advance safety and security

14:30 Session 12: China-U.S. Collaboration: Opportunities to Prevent Future Pandemics

Chairs: James Le Duc, Zhiming Yuan, Diane Griffin, and Zhigao Bu

Cooperating to combat emerging infectious diseases that affect China and the U.S. - Cooperation on laboratory safety: biocontainment research and collaboration across borders (including discussion on building a network of BSL-4 laboratories concept http://science.sciencemag.org/content/362/6412/267 and other collaborations between Chinese and American scientists)

16:00 Visit Harbin International Ice and Snow Festival

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004076

18:30 Transport to Restaurant

Friday, 11 January

AM and PM: transportation provided to airport

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004077

U.S.-China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research

TRAVEL MEMORANDUM

TO: Harbin Travelers
FROM: Nicole Cervenka
SUBJECT: Travel Information for Harbin, January 2019

ARRIVALS

Traveler	Flight Number	Arrival	Time	Ticket Number	Cell Number
Gladue, Douglas*	MU 5197	January 6	9:25 PM		
Bowman, Katherine	CA 1639	January 6	10:15 PM	999 7270588053	[redacted]
Rusek, Ben	CA 1639	January 6	10:15 PM	999 7270588052	
Higgs, Stephen	CA 1639	January 6	10:15 PM	999 7270588051	
Baric, Ralph	MU 5619	January 7	12:10 AM	006 726776464647	
Swayne, David*	MU 5619	January 7	12:10 AM		
Franz, David	CA 1623	January 7	2:50 PM	890 0745539926	
Shi, Pei-yong	G1205 (Train)	January 7	4:56 PM	(Train)	
Griffin, Diane	MU 5197	January 7	9:40 PM	781 7267764604	
Kanabrocki, Joseph	CA 1639	January 7	10:15 PM	999 7270587808	
LeDuc, James +1	CA 1639	January 7	10:15 PM	999 7267764578	
Relman, David	CA 1639	January 7	10:15 PM	999 7267764580	
Saif, Linda	CA 1639	January 7	10:15 PM	890 0745523287	

*May not be able to attend (due to USG shut down) If for some reason you are delayed or rerouted onto another flight, please e-mail or text Ben Rusek (brusek@nas.edu[redacted]) and let him know your new flight information.

IMMIGRATION AND CUSTOMS PROCEDURES

While on the plane to your first destination in China, you will receive a landing card to complete. You will need some of the information in this memo to fill out the card so please print it and take it with you. After departing the plane, you will pass through immigration, following the signs for foreign citizens. China has now started requiring fingerprinting of travelers at immigration checkpoints so you may need to go to a machine to do this before entering the immigration line. The immigration officer will check your passport and visa. After you clear immigration if you checked a bag you will then collect your luggage. After you have your bags, you will go through customs. You should select the "GREEN" channel if you have nothing to declare. If you go through the Green channel, you will not be asked to complete a Baggage Declaration Form. From there, you will enter the transfer hall, recheck your baggage, go through security for domestic flights, and go to your gate. When you arrive in Harbin, you can pick up your rechecked bag at baggage claim.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004078

GROUND TRANSPORTATION TO HOTEL

Upon arrival in Harbin, you will be met at the airport by a driver and an English-speaking volunteer from the Harbin Veterinary Research Institute (HVRI). They will be holding a sign with HVRI, your name written in English or "NAS," and will take you to the **Aoluguya Hotel** (see address in hotel section) where you will stay while in Harbin. The area immediately outside of baggage claim may be crowded, you may have to take a second look, but the driver will be there. Should your flight be delayed, a driver will wait for you. Some people arrive on the same flights (see arrivals table) or at the same time so you may wish to communicate before arriving in Harbin and meet up on the plane or at the airport.

If you cannot find the driver after having thoroughly looked for the sign with your name, please take an OFFICIAL TAXI ONLY (do not take a taxi van) to the Aoluguya Hotel (see address below). The airport taxi stand is well marked after you leave the customs and immigration part of the airport. The cost of a taxi ride to the hotel from HRB is RMB 120 ¥ (approximately $18). The Chinese currency is the Renminbi, abbreviated RMB, and the unit is the Yuan, abbreviated as ¥ or CNY; currently 1 USD = 6.88 CNY/RMB. You can use the currency exchange offices at the airports. Please ask for a receipt from the driver as you will need it for reimbursement. It is not customary to tip the drivers. Please pay by the meter in the taxi. DO NOT ACCEPT offers from unofficial drivers under any circumstances.

EMERGENCY CONTACT NUMBERS

Ben Rusek, traveling to Harbin	**U.S. Cell Phone (phone and data):** [redacted]
Katie Bowman, traveling to Harbin	**U.S. Cell Phone** [redacted]
Micah Lowenthal, in Washington, D.C.	**U.S. Cell Phone:** [redacted]
Rita Guenther, in Washington, D.C.	**U.S. Cell Phone:** [redacted]
Nicole Cervenka, in Washington, D.C.	**U.S. Office Phone: +1-202-334-2615**

Kentlands Travel
1-800-552-6425, after hours: **1-888-565-9174, 1-301-948-2448** (NAS Travel Code PGA190018)

U.S. Embassy in China	**(86-10) 8531-3300** (in Beijing, China)
No. 55 An Jia Lou Lu	**(86-10) 8531-4000** (Emergency Contact Number)
Beijing, China, 100600	BeijingACS@state.gov
U.S. Consulate General in Shenyang	**(86-24) 2322-1198**
U.S. Consulate General in Shanghai	**(86-21) 8011-2200**
1469 Huai Hai Zhong Road	ShanghaiACS@state.gov
Shanghai, China, 200031	

YOUR HOTEL IN HARBIN

Aoluguya Hotel
Address: No. 800 Chuangxin 3rd Road
Harbin, China, 150001

敖麓谷雅
黑龍江省哈爾濱市創新三路 800 號
Telephone: +86 451 85932358

SEE MAP AT THE END OF THIS MEMO

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004079

Aoluguya Hotel Information				
Traveler	**Arrive**	**Depart**	**Confirmation #**	**# of nights**
Gladue, Douglas*	January 6	January 11		5
Bowman, Katherine	January 6	January 11		5
Higgs, Stephen	January 6	January 11		5
Rusek, Ben	January 6	January 12		6
Baric, Ralph	January 7	January 11		5 (early AM arrival)
Swayne, David*	January 7	January 11		5 (early AM arrival)
Relman, David	January 7	January 10		3
Shi, Pei Yong	January 7	January 10		3
Griffin, Diane	January 7	January 11		4
Franz, David	January 7	January 11		4
Kanabrocki, Joseph	January 7	January 11		4
LeDuc, James +1	January 7	January 11		4
Saif, Linda	January 7	January 11		4

*May not be able to attend. Again if for some reason you are delayed or rerouted please e-mail or text Ben Rusek (brusek@nas.edu[redacted]) and let him know.

MEETING LOCATION

The workshop will be held at the Harbin Veterinary Research Institute (HVRI), a ~45-minute drive from the hotel. A shuttle bus will take you from the hotel to HVRI each morning and return you to the hotel every evening. **The shuttle bus will leave the hotel for the HVRI at 7:50 AM on the first day of the meeting.** The HVRI campus is located at:

Harbin Veterinary Research Institute

Weihai N Rd, Xiangfang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150060

中国农业科学院哈尔滨兽医研究所

中国黑龙江省哈尔滨市香坊区威海北路 邮政编码: 150060

SEE MAP AT THE END OF THIS MEMO

MEALS

The Aoluguya Hotel has restaurants on the premises. Breakfast each morning is included with your room. Most lunches and dinners will be provided. We will reimburse reasonable expenses for other meals up to $101 per full day and $75 for the first and last days (travel days).

TRAVEL ISSUES

If you have any issues during travel (e.g., weather delays), inform Ben and to rebook contact:
Kentlands Travel, 1-800-552-6425, **after hours:** 1-888-565-9174
nas@uniglobekentlands.com
Reference number: PGA190018

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004080

DEPARTURE INFORMATION

HVRI has arranged drivers to take you from the hotel to the airport to leave Harbin. **Specific departure information will be provided by HVRI staff or Ben during the meeting.** Please confirm your departure details with Ben at least one day prior to your departure.

DEPARTURES

Traveler	Flight Number	Departure	Time	Ticket number
Relman, David	CA 1644	January 10	11:50 AM	999 7267764580
Shi, Pei Yong	CZ 6318	January 10	3:30 PM	784 7270588034
Swayne, David*	MU 5620	January 11	7:15 AM	
Baric, Ralph	CZ 6219	January 11	8:25 AM	006 726776464647
Gladue, Douglas*	CZ 6219	January 11	8:25 AM	
Kanabrocki, Joseph	CA 1640	January 11	8:30 AM	999 7270587808
Saif, Linda	CA 1640	January 11	8:30 AM	890 0745523287
Franz, David	CA1644	January 11	11:50 AM	890 0745539926
Griffin, Diane	CA 1644	January 11	11:50 AM	999 7267764606
Bowman, Katherine	CA 1644	January 11	11:50 AM	999 7270588053
LeDuc, James +1	CA 1644	January 11	11:50 AM	999 7267764578
Higgs, Stephen	HU 7786	January 11	5:25 PM	
Rusek, Ben	CA 1644	January 12	11:50 AM	999 7270588052

*May not be able to attend

TRAVEL TIPS

Getting Around

Taxis are inexpensive and convenient to use. To make communication easier, have the hotel write your destination in Chinese. Be aware that some drivers will attempt to negotiate the price of a ride and that asking them to run the meter will help avoid potential conflicts.

You can also use the app **DiDi,** which is similar to Uber of Lyft in the U.S. If you plan on using the app, download it from your smart phone's app store and set it up on your phone before you leave.

The bus system in Harbin is the most convenient public transportation option. Signage is in Chinese, but the stops should be announced in both Chinese and English. Passengers can pay by touching on with an "IC" card or by putting ¥1 or ¥2 into the fare box as they board the bus.

If for some reason you need a car and driver while in Harbin, you may request a car at the hotel front desk. Please arrange for payment directly with the hotel or with the car and driver service. Taxis can also be called by the concierge. It is helpful to have the hotel concierge write your destination in Chinese for the driver. Likewise, have the hotel address in Chinese for your return.

What to Pack

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004081

The weather will likely be cold at around 15°F. Therefore, it is a good idea to bring plenty of warm clothes, a hat, gloves, etc. The meeting will begin with business attire (coat and tie) and hope that it becomes less formal as the meeting proceeds.

Be sure to bring any medications or other items you will need, preferably in a carry-on just in case your luggage is delayed. **Many common over the counter medications are not available in China.**

A list of useful items includes: plenty of business cards, a travel alarm clock, warm layers, a hat, gloves, a small flashlight, pocket-packs of tissues and wet wipes, cold medication, Imodium, a camera and chapstick. It is best not to bring anything that would be an attractive target for thieves, such as expensive camera equipment. You will have to decide whether to bring a laptop computer. If you do bring one, it is generally a good idea to keep it with you at all times.

Money

You may want to obtain some Chinese money of your own for souvenir shopping, drinks, entertainment, and sightseeing. The exchange rate on December 12, 2018 was 6.88 Yuan per dollar. For purchases or exchanges, please bring cash, debit cards, or credit cards. Traveler's checks are much less useful and very inconvenient – only a few banks in China will change them – so we do not recommend that you bring them. Some ATM machines will accept international cards, including Bank of China and China Merchants Bank, and provide instructions in English. If an ATM requires a six-digit PIN, try adding two zeros to the front of your number. There are also Western Union locations in almost every China Post 中国邮政 and Agricultural Bank 农业银行; look for the yellow western union sign.

Some shops and restaurants will accept international credit cards. However some only accept Union Pay branded cards. It's always good to have one with you in case of emergency, but you should **not** rely on being able to use credit cards for all your purchases. Even some businesses that say that they take credit cards only take Chinese network credit cards (not Visa, MasterCard, or Amex). If you bring cash, please make sure that the bills are clean. Worn, stained, marked, or old bills are often rejected in China. When carrying Chinese currency an assortment of denominations is useful, as you might not always be able to change large bills. (Many people use their phone and the Chinese app WeChat to pay for purchases.)

Health Concerns

Drinking tap water in China is **not** recommended. Please drink bottled water whenever possible. The air quality in Harbin averaged around 100AQI (moderate) in December and January 2018, but has recently reached the 300s (hazardous). The U.S. Department of State recommends sensitive individuals should consider limiting prolonged outdoor activities, and that everyone should avoid outdoor exertion when the air quality is at hazardous levels.

Global Assistance for Travelers

Before you travel please enroll in the U.S. Department of State Smart Traveler Enrollment Program (STEP) https://step.state.gov/step/. All travelers funded by NAS have been placed on the International **SOS Global Assistance Program** http://www.internationalsos.com/en/, **(member number 11BMMS000238)** while in Harbin. As a traveler for NAS, you can utilize this resource by calling an International SOS Assistance center, which has physicians, multilingual coordinators, operations managers, logistics support personnel and medical and security professionals on hand to speak with you 24/7. SOS can give medical advice, arrange for you to be seen at a nearby medical center (pre-evaluated for quality), arrange for prescription medications, or even arrange for evacuation, if needed. Note that this is assistance, not insurance, but SOS

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004082

and NAS can arrange payment for services and work out reimbursement from your insurance later. The NAS membership number is 11BMMS000238. Your closest assistance center in China will be the Beijing office (+86-10-6462-9100). SOS International Alarm Centers can also be contacted in Hong Kong at (852) 2528 9900 and in the United States at (215) 942 8226. See the International SOS card or download the SOS App before you travel, which is the fastest way to access help in case of an emergency. NAS staff has experience working with International SOS and can provide assistance if requested; please ask for our assistance should you have medical concerns. Ben will have hard copies of SOS cards.

International SOS Recommended Hospital in Harbin

HEILONGJIANG PROVINCIAL HOSPITAL HARBIN, CHINA
No.82 Zhongshan Road
Xiangfang District,
Harbin
P.R. China 150036
Tel: + 86 0451 8802 5770

International SOS Affiliated Medical Joint Venture Clinics & Assistance Center

BEIJING OFFICE
Suite 105, Wing 1
Kunsha Building, No 16 Xinyuanli
Chaoyang District
Beijing
P.R China 100027
Tel: +86 (0) 10 6462 9199
Fax: +86 (0) 10 6462 9117

Additional information on medical providers specializing in treating foreigners for general medical, dental and orthodontic problems are available at https://china.usembassy-china.org.cn/

Information on vaccinations and other health precautions, such as safe food and water precautions and insect bite protection, may be obtained from the Centers for Disease Control and Prevention's hotline for international travelers at 1-877-FYI-TRIP (1-877-394-8747) or via the CDC's Internet site at: https://wwwnc.cdc.gov/travel/destinations/traveler/none/china

For information about outbreaks of infectious diseases abroad consult the World Health Organization's (WHO) website at http://www.who.int/en. Further health information for travelers is available at: http://www.who.int/countries/chn/en/

REIMBURSEMENT INFORMATION

For travel being funded by NAS, after you return to the United States, you will use an electronic Travel Expense Report (eTER) to request reimbursement for reasonable travel expenses, including:

- **Taxi cabs, shuttles, and public transportation expenses for meeting related trips are reimbursable.** *Sedan services are only reimbursable if the cost is comparable to a taxi fare.*
- **Meal costs** (based on actual expenses not paid by NAS; NAS does not reimburse for alcohol).
- **Incidental expenses**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004083


Please retain all receipts for any expenses over $75 incurred during travel on Academy business, including original airline receipts, even if they were direct billed to NAS. No charges over $75 can be reimbursed without an accompanying receipt. This includes items such as airfare, taxi charges, and meals as described above. It is Academies policy that all travel expense reports (TER) are completed within 25 days of travel. Sponsors may reject expenses not submitted on time. If you have questions, or trouble completing your TER, please contact your travel coordinator for assistance.

Please complete your Travel Expense Reimbursement (TER) via Concur, our online reimbursement tool (https://www.concursolutions.com) or download the mobile app (https://www.concur.com/en-us/mobile). Your Concur sign-in information, password, and detailed instructions for completing your TER will be sent in a separate email from your travel coordinator.
*If you are having trouble logging in to Concur, please contact the Travel Office traveloffice@nas.edu.

Your pre-populated TER will contain your itinerary and all items billed directly to the Academies. Please enter all out-of-pocket expenses and upload a PDF (when using the Concur website) or a picture (when using the Concur app) of receipts for all transportation costs and all other expenses over $75. When you have entered your reimbursable expenses, please notify your travel coordinator. Please DO NOT CLICK "Submit Report".


The Travel code for this trip is PGA190018.

Map of the airport, hotel and HVRI:



Hotel location, zoomed in:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004084



FOIA Confidential Treatment Requested by Univ of Texas System

From: TEMI-production@journals.tandf.co.uk
Sent: Wednesday, April 3, 2019 4:11 AM
To: chenxw@wh.iov.cn;Xie, Xuping;Shi, Pei yong
Subject: Emerging Microbes & Infections - Author Query (TEMI 1598291) #TrackingId:3386191

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Authors,

Could you please advise me on the query below at the earliest.

Regards,

Malathi
Emerging Microbes & Infections

From:malathi@novatechset.com
Sent:28-03-2019 01:21
To:xuxie@utmb.edu,malathi@novatechset.com
Cc:mastercopy_ti@novatechset.com,tandfteam@novatechset.com
Subject: Emerging Microbes & Infections - Author Query (TEMI 1598291)

Dear Xuping Xie,

I am writing to you on behalf of the journal, ***Emerging Microbes & Infections***. Thank you very much for sending in the corrections to your article, **Genetic and biochemical characterizations of Zika virus NS2A protein**. I have gone through your corrected proofs and request you to respond to the below queries at the earliest to avoid any delays in the publication process.

Queries:

Please note, you have removed the affiliation ([b]University of Chinese Academy of Sciences, Beijing, People's Republic of China) of author (Xinwen Chen), but according to T&F policy, the affiliation should not be removed once the manuscript has been submitted for publication. Can you please confirm if the author was not present in that affiliation when the research was conducted? If yes, then we can remove the affiliation, otherwise we will retain the affiliation as is in the proof.

Please advise how to proceed with affiliation.

Please reply to all recipients of this message.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057837

Thanks in advance for your understanding in this regard.

Best wishes,

Malathi Boopalan
On behalf of Emerging Microbes & Infections
Taylor and Francis
4 Park Square
Milton Park
Abingdon
Oxfordshire
OX14 4RN
UNITED KINGDOM
Email : TEMI-production@journals.tandf.co.uk

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057838

From: TEMI-production@journals.tandf.co.uk
Sent: Thursday, April 4, 2019 1:56 AM
To: chenxw@wh.iov.cn;Xie, Xuping;Shi, Pei yong
Cc: chenxw@wh.iov.cn;Shi, Pei yong
Subject: RE: Emerging Microbes & Infections - Author Query (TEMI 1598291) #TrackingId:3386191

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you, Xuping and Xinwen.

Regards,

Malathi
Emerging Microbes & Infections

From:xuxie@UTMB.EDU
Sent:03-04-2019 07.29 PM
To:chenxw@wh.iov.cn,xuxie@UTMB.EDU,peshi@UTMB.EDU,malathi@novatechset.com
Cc:peshi@UTMB.EDU,chenxw@wh.iov.cn,TEMI-production@journals.tandf.co.uk
Subject:RE: Emerging Microbes & Infections - Author Query (TEMI 1598291)

Dear Malathi,

Please process as Dr. Chen suggested. I am sorry for confusing and any inconvenience it have caused.

Best,

Xuping

From: 陈新文 <chenxw@wh.iov.cn>
Sent: Wednesday, April 3, 2019 4:19 AM
To: TEMI-production@journals.tandf.co.uk
Cc: Xie, Xuping <xuxie@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Emerging Microbes & Infections - Author Query (TEMI 1598291) #TrackingId:3386191

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Malathi,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057834

Please retain the affiliation as is in the proof. I am the professor of [b]University of Chinese Academy of Sciences, Beijing, People's Republic of China.

All my best regards,

Xinwen

-----原始邮件-----

发件人:TEMI-production@journals.tandf.co.uk

发送时间:2019-04-03 17:10:54 (星期三)

收件人: chenxw@wh.iov.cn, xuxie@utmb.edu, peshi@utmb.edu

抄送:

主题: Emerging Microbes & Infections - Author Query (TEMI 1598291) #TrackingId:3386191

Dear Authors,

Could you please advise me on the query below at the earliest.

Regards,

Malathi
Emerging Microbes & Infections

From:malathi@novatechset.com
Sent:28-03-2019 01:21
To:xuxie@utmb.edu,malathi@novatechset.com
Cc:mastercopy_ti@novatechset.com,tandfteam@novatechset.com
Subject: Emerging Microbes & Infections - Author Query (TEMI 1598291)

Dear Xuping Xie,

I am writing to you on behalf of the journal, ***Emerging Microbes & Infections***. Thank you very much for sending in the corrections to your article, **Genetic and biochemical characterizations of Zika virus NS2A protein**. I have gone through your corrected proofs and request you to respond to the below queries at the earliest to avoid any delays in the publication process.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057835

Queries:

Please note, you have removed the affiliation ([b]University of Chinese Academy of Sciences, Beijing, People's Republic of China) of author (Xinwen Chen), but according to T&F policy, the affiliation should not be removed once the manuscript has been submitted for publication. Can you please confirm if the author was not present in that affiliation when the research was conducted? If yes, then we can remove the affiliation, otherwise we will retain the affiliation as is in the proof.

Please advise how to proceed with affiliation.

Please reply to all recipients of this message.

Thanks in advance for your understanding in this regard.

Best wishes,

Malathi Boopalan
On behalf of Emerging Microbes & Infections
Taylor and Francis
4 Park Square
Milton Park
Abingdon
Oxfordshire
OX14 4RN
UNITED KINGDOM
Email : TEMI-production@journals.tandf.co.uk

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057836

From: LeDuc, James W.
Sent: Wednesday, May 1, 2019 12:34 PM
To: David Franz
Cc: Benjamin Rusek;Micah Lowenthal
Subject: Re: George Gao, NAS

Very well deserved. Great news!

Sent from my iPhone

On May 1, 2019, at 9:49 AM, David Franz <davidrfranz@gmail.com> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Excellent! Thanks, dave

David R. Franz
Gettysburg, PA
(240) 674-0797

On May 1, 2019, at 10:31 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

George Gao was elected as a NAS foreign associate this year.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Wednesday, May 01, 2019 9:40 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Subject: George Gao, NAS

Congratulations are in order.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008869

Newly elected foreign associates, their affiliations at the time of election, and their country of citizenship are:

...

Gao, George F.; director general, Chinese Center for Disease Control and Prevention; dean, medical school, University of Chinese Academy of Sciences; vice president, National Natural Science Foundation of China; and professor, Institute of Microbiology, Chinese Academy of Sciences, People's Republic of China (People's Republic of China)

Micah Lowenthal, Ph.D. | Director
Committee on International Security & Arms Control (CISAC)
The National Academy of Sciences | 500 Fifth Street NW, Washington, DC 20001 USA
mlowenthal@nas.edu | +1.202.334.3074

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008870

U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research

Harbin Veterinary Research Institute | Chinese Academy of Agricultural Sciences

January 8-10, 2019
Harbin, China

To address the interconnected life science challenges associated with combating infectious diseases and further enhance cooperation between China and the United States in the areas of global health, biosafety, and biosecurity, the U.S. National Academy of Sciences (NAS), and the Chinese Academy of Agricultural Sciences (CAAS) in partnership with representatives from other Chinese institutions held the fourth *U.S. China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security* in tandem with a *Workshop on Responsible Conduct in the Use of Gene Editing in Pathogen Research* on January 8-10, 2019 at the CAAS Harbin Veterinary Research Institute (HVRI) in Harbin, China. HVRI is one of three institutes in China that operate a Biological Safety Level-4 (BSL-4) laboratory.

The meeting, ultimately titled *U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research* was the latest in a series designed to share information on research relevant to combating emerging diseases of concern to the U.S. and China, promote common understanding of high biological containment laboratory safety, security and responsible research risk management, and build relationships among members of the U.S. and Chinese research communities who conduct infectious disease research. The special focus on research that uses gene-editing technology provided angave the opportunity to allowfor participants to discuss ways to create norms and reduce risks when using these tools for research.

Several themes emerged during the workshop. The first was a focus on the importance of pursuing an integrated, One Health-based approach to understanding the causes and addressing the effects of animal and human diseases. Some of the issues raised included the short-term intended and unintended effects of recent disease control strategies, as well as a need for collaboration amongst experts and across regions on medical, ecological and ecosystems science to ensure human and animal health.

The second was a growing appreciation for the widespread use of gene-editing tools, particularly those based on the CRISPR-Cas9 system, that are being integrated into many new research efforts. New gene editing techniques to cut, edit, activate and repress genes with greater accuracy and at much lower costs go well beyond longstanding methods of selective breeding of hosts and pathogens and allow researchers to quickly explore changes not readily achieved in the past. Although the benefits to society are potentially enormous, there is the

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002712

potential for malevolent application or for the technology to contribute to potentially (?) dangerous "bioerror," that is, for researchers to inadvertently create a modified organism that has an unintended disastrous impact. Many of the technical talks including those on vaccine development, vector engineering, host engineering, and synthetic biology included details on the researchers' use of gene editing tools and techniques. During the presentations the importance of gene editing to facilitate genetic modifications wasere highlighted but participants also discussed how they assessed risks and untended consequence of using the tools as well as best practices to ensure the appropriate and safe use of this technology in the future. See box on Gene Editing below.

A third theme was the importance of establishing and maintaining strong institutional cultures and norms to support the safe and responsible conduct of science. The sessions included several discussions on possible collaborations between Chinese and American scientists and institutions to ensure the responsible conduct of scientific research, ways to reduce research risk, and ways to ensure that gene editing techniques are used safely and ethically across the life science enterprise in the future.[1]

Throughout the workshop and during tours of the HVRI high containment security and training centers, experts also shared information to ensureregarding the safe and secure operation of high containment biological laboratories. Topics discussed included combating emerging infectious diseases in livestock, safely doing research on insect vectors in high biological containment, inactivation/decontamination procedures for African swine fever virus, improving the public health response to disease outbreaks, training and vetting high containment laboratory workers, and the safe and sustainable operation of high containment laboratories more broadly.

NAS has helped to shape the international dialogue on the risks and the multitude of challenges associated with planning for, building, sustaining, and safely and securely running operating high containment laboratories. Before the meeting the directors of the Galveston National Laboratory (of the University of Texas Medical Branch) and the Wuhan Institute of Virology (of the Chinese Academy of Sciences) jointly published an editorial in *Science* that calls for the creation of a global network to bring together the leaders of institutes that operate laboratories at the highest biological safety level, BSL-4, to ensure the safe, secure and sustainable operation of these facilities.[2] The final session of the meeting included a discussion on of the idea led by the authors of the editorial. During the discussion the director of China's Centers for

Formatted: Font: Italic

[1] Although the meeting agenda was not designed to focus on human gene editing, the research project led by He Jiankui, formally an associate professor in the Department of Biology of the Southern University of Science and Technology in Shenzhen, China that lead to the birth of two children with edited DNA was universally condemned by the meeting participants.

[2] "One solution is to establish an [BSL-4] network that enables the sharing of best practices, collaboration, transparency, and exchange of specimens and technology." The authors noted that their partnership "benefited from meetings jointly sponsored by the U.S. National Academy of Sciences and the Chinese National Academy of Sciences..." Network for Safe and Secure Labs. James W. Le Duc and Zhiming Yuan, Science. 19 Oct 2018. Vol. 362, Issue 6412, pp. 267 [HYPERLINK "http://science.sciencemag.org/content/362/6412/267"].

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002713

Disease Control and the leadership of the Chinese institutes that operate China's three BSL-4 labs indicated that they support the idea and will work with NAS to develop and create a network. After the workshop the group started planning (and raising funds to support) an international meeting of BSL-4 laboratory leaders to take place in the near future~~later in 2019 or in 2020~~ at a location to be determined. The next bilateral dialogue between the groups will likely take place in Kunming, China at the Kunming National Primate Research Center, another Chinese institute that is in the process of opening~~operates~~ a BSL-4 laboratory, towards the end of 2019.

****

BOX 1

GENE EDITING

Comment [MOU1]: Assume the Spin Box and extra discussion of Steve's work is to satisfy the 'other half' of the mission of the meeting.

Comment [MOU2]: Does the spin box go all the way through the list of references? If so, should that just be another section of the paper, rather than a box?

Gene editing involves altering the DNA of a cell or organism. Modifications can include deletions, insertions, or other changes to the genetic code, generally carried out to change characteristics of a gene's expression. A particular edit might aim to "knock out" the gene and render it non-functional. Alternatively, precise changes to the nucleic acid sequence may be made to affect properties of the protein that results from the gene's transcription and translation. Edits are carried out for a number of other purposes, as well.

Researchers have been making alterations to nucleic acid sequences for many years, but tools developed since approximately 2012 – particularly the CRISPR-Cas9 editing system – have significantly increased the flexibility, efficiency, accuracy, speed, and ease (including lower cost) of making these changes. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas9 (CRISPR-associated protein 9) were discovered in bacteria, where they form part of an immune mechanism for responding to infection. The basic system has since been adapted and repurposed as a key research tool and the use of gene editing is now widespread in research laboratories (Doudna and Charpentier 2014). A designed guide RNA sequence aligns with and binds to a target DNA sequence in the genome. The Cas9 protein then makes a double strand DNA cut. This cut can be repaired in various ways, including end joining or filling in with a donor DNA template to lead to sequence alterations.

Approximately a third of the presentations during the workshop referred to CRISPR and Cas9-based gene editing tools in some fashion. The key areas discussed during the workshop included:

- **Vaccine development efforts**. Use of gene editing to generate an attenuated version of a double-stranded DNA virus (Gladue)
- **Vector engineering**. Use in generating a mosquito that lacks an immune system associated enzyme (Han)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002714

- **Host engineering**. Introduction of a human receptor domain into the mouse to create a model for viral infection (Baric); Creation of a pig designed to be resistant to a viral disease of interest (Ouyang)
- **Synthetic biology**. Design of gene circuits in bacteria to produce or respond to signaling molecules (Lou); Changes to eukaryotic genome organization to create a single chromosome yeast (X. Xue).
- **Ethics**. Considerations for responsible use and governance of gene manipulations in synthetic biology (W. Zhang) and in human genome editing applications (Y. Xue).

Professor Steven Higgs also briefly discussed a special use of CRISPR-Cas9 in the creation of a gene drive. Gene drives "are systems of biased inheritance in which the ability of a genetic element to pass from a parent to its offspring through sexual reproduction is enhanced" (NASEM 2016). The design of these systems includes a mechanism in which an edited gene can be copied to its homologous chromosome and will continue to spread as the organism reproduces (Esvelt et al. 2014). The advent of CRISPR-Cas9 genome editing enabled scientists to create a gene drive and the field has continued to progress rapidly, with gene drive modified mosquitos reported by late 2015 (Gantz et al., 2015). Scientists are exploring genetically modified and/or even gene drive modified insect vectors as one strategy for control of devastating insect-borne diseases. But if used in this way, modified insects ultimately would be released from the laboratory into an ecosystem. Special considerations arise from use of modified species in open field trials and potential deployment. Researchers will need to understand not only how a modification affects the target population, but also how it affects the broader ecological community. A number of reports have discussed scientific, ethical and social considerations, particularly around gene drives (for example, NASEM 2016), while funders and scientists are developing norms to guide responsible use (Emerson et al. 2017). Dr. Higgs highlighted these special considerations in his presentation on the use of insect vectors for infectious disease research.

References

CIOMS. 1993. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Council for International Organizations of Medical Sciences.

Doudna, J. A. and E. Charpentier. 2014. The new frontier of genome engineering with CRISPR-Cas9. *Science* 346(6213): 1077 and 1258096.

Emerson, C., S. James, K. Littler, and F. Randazza. 2017. Principles for gene drive research. *Science* 358(6367):1135-1136.

Esvelt, K. M., A. L. Smidler, F. Catteruccia, and G. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. *eLife* 3:e03401.

NASEM (National Academies of Sciences, Engineering, and Medicine). 2016. Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values. Washington DC: The National Academies Press

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002715

Gantz, V. M., N. Jasinskiene, O. Tatarenkova, A. Fazekas, V. M., Macias, E. Bier and A. A. James. 2015. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. *Proceedings of the National Academy of Sciences* 112(49):E6736-E6743.

NASEM 2017. Human Genome Editing: Science, Ethics, and Governance. Washington DC: The National Academies Press

People's Republic of China. 2017. Administrative Measures for the Safety of Biotechnology Research and Development Cell.

Shao, Yangyang et al. 2019. A single circular chromosome yeast. Cell Research, 29, 87-89. Available at: [HYPERLINK "https://www.nature.com/articles/s41422-018-0110-y" \l "Bib1"]. Accessed on 29 April 2019.

USG. 2012. United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern. Available at: [HYPERLINK "https://www.phe.gov/s3/dualuse/Documents/us-policy-durc-032812.pdf"]. Accessed on 26 April 2019.

USG. 2015. United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern. Available at: [HYPERLINK "https://www.phe.gov/s3/dualuse/documents/durc-policy.pdf"]. Accessed on 26 April 2019.

World Medical Association. 2013. Declaration of Helsinki. Available at: [HYPERLINK "https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/"]. Accessed on 26 April 2019.

****

Sessions and Presentations

Keynote addresses

- Oversight for Research on Viral Pathogens with Pandemic Potential – the Perspective from China
- Emerging Swine Coronaviruses and their Interspecies Transmission
- Vaccination in Poultry Eliminated Human Infections with H7N9 Virus in China

Comment [LJW3]: this was an especially important presentation. Maybe highlighted in the longer report.

Influenza

- Collaborating on Influenza Research from the U.S. perspective
- Human Infection with Zoonotic Influenza
- Interactions between Influenza Viral RNP Complex Proteins and Host Cellular Factors

African swine fever

- Current Situation and Control Strategy of African Swine Fever in China
- Characterization of African Swine Fever Virus Isolated from China

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002716

- ASFV Vaccine Status: Rapid Production of Recombinant ASFV for Live Attenuated Vaccines
- Genome-edited Pigs Protected From Classical Swine Fever Virus

Understanding and engineering viral pathogens with pandemic potential

- Advances in Understanding and Altering Pathogen Properties
- Cutting Edging New Biotechnology: Strategies and Tools for Engineering

Bioethics and responsible planning for pathogen research

- Biosafety and Bioethics in Medical Research
- Bioethical Considerations for the Conception and Design of pathogen Research and Approaches for Assessing Potential Risks and Benefits of Research
- Biosafety and Bioethics Considerations in Dual-Use Risks Management - China's Efforts and Future Works

Vector and host engineering: safety and security

- Biochemical Pathway of a Mosquito Innate Immunity, Melanization
- Best Practices in Safety and Security for Working with Arthropods that Serve as Pathogen Vectors, Including Responsible Research with Gene Drive Modified Vectors
- Vector Competence of Emerging Mosquito Borne Virus in China
- A Gut Commensal Bacterium Promotes Arbovirus Infection in Mosquitoes

Acute Flaccid Myelitis

- Review of what is currently known about the cause of Acute Flaccid Myelitis

Best practices in laboratory safety and security for pathogen research

- Institutional Review and Oversight for Research on Viral Pathogens with Pandemic Potential - a U.S. Perspective
- The Role of Leaders in Laboratory Safety: Culture and governance to steer toward behavior changes
- Overview of Laboratory Biosafety Management System in China

One Health in China

- Understanding how a One Health Approach is Shaping Research to Understand and Address Viral Pathogens in China

Chinese biosafety, biosecurity, and bioethics

- Development and Application of Laboratory Biosafety Equipment in China
- Kunming National Primate Research Center of High-Level Biosafety

Chinese perspectives on emerging infectious diseases

- DDX19, A novel Viral RNA Sensor, Regulates IFN Signaling upon Viral Infection
- Risks of MERS-cluster Coronaviruses in China
- Rational Design of Master Seed Virus to Improve the Safety and Effectiveness of Foot and Mouth Disease Vaccine
- Development of Inactivated EV71 Vaccine (Human Diploid Cell) and Pathogenic Study of EV71 Infection in Rhesus Macaques
- Zika Virus Neurotropism: the Bad and the Good

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002717

Special session (gene editing and synthetic biology)

- Large Gene Cluster and Regulatory Manipulation for Activating the Cryptic Natural Product Clusters in Streotomvces
- Creating a Functional Single-chromosome Yeast

China-U.S. Collaboration: Opportunities to Prevent Future Pandemics

American Participants

Ralph Baric, Professor
Department of Epidemiology, University of North Carolina, Chapel Hill

David Franz, Professor
USAMRIID (retired)

Douglas Gladue, Scientist
U.S. Department of Agriculture

Diane Griffin, Professor
Department of Molecular Microbiology and Immunology of Johns Hopkins Bloomberg School of Public Health

Stephen Higgs, Professor
Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University

Joseph Kanabrocki, Professor
Microbiology in the Biological Sciences Division of the University of Chicago

James Le Duc, Professor
Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston

David Relman, Professor
Department of Microbiology and Immunology, Stanford University School of Medicine

Linda Saif, Professor
Department of Veterinary Preventive Medicine, Food Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University

Pei-Yong Shi, Professor
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch

David Swayne, Center Director
Agricultural Research Service, United States Department of Agriculture

Katherine Bowman, Senior Program Officer
National Academy of Sciences

Benjamin Rusek, Senior Program Officer
National Academy of Sciences

Comment [MOU4]: I guess Doug and David S both sent talks?

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Chinese Participants

George F. Gao, Academician,

Director-General Chinese Center for Disease Control and Prevention

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002718

Zhigao Bu, Professor
Harbin Veterinary Research Institute, CAAS

Wen Dang, Doctor
Lanzhou Veterinary Research Institute, CAAS

Wuxiang Guan, Professor Wuhan Institute of Virology, CAS

Yunzhang Hu, Professor
Institute of Medical Biology, Chinese Academy of Medical Sciences

Mifang Liang, Professor
National Institute for Viral Disease Control and Prevention, China CDC

Chunbo Lou, Professor Institute of Microbiology, CAS

Hongsheng Ouyang, Professor
Jilin University

Chengfeng Qin, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Hualan Chen, Academician
Harbin Veterinary Research Institute, CAAS

Gong Cheng, Professor
Tsinghua University

Rui Gong, Professor
Wuhan Institute of Virology, CAS

Qian Han, Professor
Hainan University

Chengjun Li, Professor
Harbin Veterinary Research Institute, CAAS

Longding Liu, Professor
Institute of Medical Biology, Chinese Academy of Medical Sciences

Jiahai Lu, Professor
Sun Yat-sen University

Jiancheng Qi, Professor
National Biological Protection Engineering Center

Zhengli Shi, Professor
Wuhan Institute of Virology, CAS

Dayan Wang, Professor
Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College

Jianwei Wang, Professor
National Institute for Viral Disease Control and Prevention, China CDC

Changjiang Weng, Professor
Harbin Veterinary Research Institute, CAAS

Kongming Wu, Vice President
Chinese Academy of Agricultural Sciences

Xiaodong Wu, Professor
China Animal Health and Epidemiology Center

Xaoli Xue, Professor
Laboratory of Synthetic Biology, Shanghai Institute of Plant Physiology, CAS

Yang Xue, Associate Professor
Tianjin University

Ruifu Yang, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Comment [MOU5]: Wasn't there, was he. Did he send a presentation?

Formatted: Highlight

Formatted: Highlight

Zhiming Yuan, Professor
Wuhan Institute of Virology, CAS

Peijun Zhai, Professor
China National Accreditation Service for Conformity Assessment (CNAS)

Pingping Zhang, Doctor
Institute of Microbiology and Epidemiology
Academy of Military Medical Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002719

Tietao Zhang, Professor
International bureau, CAAS

Weiwen Zhang, Professor
Tianjin University

Chihong Zhao, Professor
National Institute for Viral Disease Control and Prevention, China CDC

Tongyan Zhao, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Yong Zhao, Doctor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Haixue Zheng, Professor
Lanzhou Veterinary Research Institute, CAAS

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002720

From: zlshi <zlshi@wh.iov.cn>
Sent: Sunday, June 9, 2019 8:59 PM
To: dyjin;tlying;Shi, Pei yong
Cc: Rong Lijun
Subject: Fw: SCBA session speakers

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all,

Would you please see the following email and register in the meeting.

Thanks and see you soon.

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Li, Linheng
Date: 2019-06-06 22:39
To: btsang@ohri.ca; bgao@mail.nih.gov; byang@sri.utoronto.ca; Yu, Ron; chgzou@ynu.edu.cn; clyang@genetics.ac.cn; cpeng@yorku.ca; Changqing.Ju@uth.tmc.edu; dann@coh.org; ld2567@cumc.columbia.edu; dewang@mcw.edu; dyu@mdanderson.org; dongwang@ucsd.edu; fxia@uams.edu; liuf@ioz.ac.cn; liuf@hotmail.com; gcheng@mednet.ucla.edu; gonghong.wei@oulu.fi; HLiang1@mdanderson.org; Hansen.He@uhnresearch.ca; hss.sun@utoronto.ca; yanghuanming@genomics.cn; huiz@bcm.edu; hulin@wakehealth.edu; Huiping.Zhou@vcuhealth.org; minglam@uw.edu; juh13@psu.edu; jxu@bcm.edu; jianping_jin@zju.edu.cn; jie.qiao@263.net; Jindan-yu@northwestern.edu; jchen@emory.edu; jsli@sibcb.ac.cn; jliu@mdanderson.org; jzhang@luc.edu; jchiang@neomed.edu; jhuang@zju.edu.cn; Ji@medicine.tamhsc.edu; klan@whu.edu.cn; XuK3@uthscsa.edu; llan1@mgh.harvard.edu; lijun@uic.edu; Lcheng2@jhmi.edu; Lcheng2@jhmi.edu; lsu@med.unc.edu; weilixin_smmu@163.com; qinlx@fudan.edu.cn; wmeng@bcm.edu; myou@neomed.edu; luominmin@nibs.ac.cn; homi@mail.nih.gov; psun@wakehealth.edu; perchen@163.com; pzhang@neomed.edu; qi.cao@northwestern.edu; rjzhou@whu.edu.cn; ren@brandeis.edu; rzhang27@Central.UH.EDU; sz2296@cumc.columbia.edu; ssun@mdanderson.org; shaomeng@umich.edu; gaoshaorong@tongji.edu.cn; Sheng.Zhang@uth.tmc.edu; chengs@mail.nih.gov; shc2034@med.cornell.edu; lantian012345@163.com; thchuang@nhri.org.tw; weizhang@uoguelph.ca; zongwx@pharmacy.rutgers.edu; weiwei.dang@bcm.edu; wxding@kumc.edu; wswei@pku.edu.cn; wh221@cinj.rutgers.edu; wwei2@bidmc.harvard.edu; xwwu@mdanderson.org; XJ.Wang@ucdenver.edu; Xiaobo.zhou@channing.harvard.edu; xyu@coh.org; xiaodong.cheng@uth.tmc.edu; xiaohwu@scripps.edu; xw3u@nih.gov; bianxiuwu@263.net; sean.li@childrens.harvard.edu; jzhang@cm.utexas.edu; Yang.Xia@uth.tmc.edu; liyi@bcm.edu; yisheng@yorku.ca; sunyi@umich.edu; yisun@zju.edu.cn; zhangyin@mail.nih.gov; yinghao@sibs.ac.cn; liy2@ccf.org; yongx@bcm.edu; liy2@mskcc.org; yfshi@suda.edu.cn; yuncail@lji.org; chris.lau@ucsf.edu; fengzh@cinj.rutgers.edu; zlshi@wh.iov.cn; lou.zhenkun@mayo.edu; shenzh@cinj.rutgers.edu; zp.feng@utoronto.ca; zdu@genetics.ac.cn
CC: 莫明和; Xu, Jianming; Li, Linheng
Subject: SCBA session speakers

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071643

Dear Cochairs,

The meeting local organizers received many e-mails asking about the traveling and lodging things. I was asked to
Send this note again to you as co-chairs and please do forward it to your session speakers to let them know how to handle
Registration, traveling and lodging things.

1. Please register (http://scba.medmeeting.org/8579?lang=en) and select speaker category, your registration fee is waived, However,
2. If you are a domestic speaker please pay your registration fee (http://scba.medmeeting.org) but the meeting will give you lecture fee.
3. You will be responsible for your own traveling including the airport-hotel transportation and reserving hotel room.

Thanks
We are looking forward to seeing you in Kunming.

Linheng

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071644

Academician ??,
Chinese Academy of Medical Sciences

RE: Proposed Chinese-U.S. dialogue meeting on the Challenges of Emerging Infections, Laboratory Safety & Global Health Security in Kunming, China

Dear Academician ??,

We are writing to formally request your permission and support to hold a China-U.S. dialogue on emerging infections, laboratory safety and global health security issues between the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) in China in 2019.

NASEM is an independent, non-governmental organization established 150 years ago by the U.S. government to provide objective advice to the government on matters of science and its applications.

Over the past several years, Dr. David Franz and Dr. James Le Duc have worked with NASEM staff and Chinese counterparts to organize a series of dialogue meetings between NASEM experts and Chinese experts designated by the Chinese Academy of Sciences, China Center for Disease Control, and the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. We are requesting your support of the next meeting because of the great expertise CAMS brings to these topics and because each of the other institutions has hosted a meeting; the meetings have been held in Beijing, Wuhan, Galveston, and most recently the Veterinary Institute in Harbin, China. Participants have included esteemed senior Chinese and American Scientists, such as George Gao, Linda Saif (NAS), and David Relman (NAM), and many others.

During the meeting in Harbin in January 2019, Dr Franz and Dr. Le Duc discussed holding a similar dialogue meeting with representatives of the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS)Topics that are proposed for discussion at the dialogue meeting include: medical countermeasure development, especially advanced development of vaccines, therapeutics and diagnostics; development and use of animal models of high-consequence diseases in biocontainment; host-pathogen interactions; the special challenges on the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnology in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector borne disease research.

We hope that you approve and will support this activity. China and the United States are world leaders in life science research and development and have large populations susceptible to emerging infections. Both of our countries operate large high-containment laboratories that are critical to responding to emerging infections. It is important to cooperate and discusses best practices and on these and other key areas of interest and concern for our two countries.

With your approval, NASEM and CAMS will establish an informal joint organizing committee to plan the workshop, invite workshop speakers and participants, and make workshop logistical arrangements. NASEM will pay the air, lodging and ancillary costs of all the American participants and might be able to contribute financial support meeting costs in China, if necessary. Communicating at NASEM's request, Pei-Yong Shi from the University of Texas, Galveston recently contacted Longding Liu to discuss the possibility of holding the meeting in Kunming before the end of the 2019 calendar year.

We look forward to your response regarding this proposal and your thoughts on the proposed workshop and to further discussions of the organization, content, and substance of this important dialogue meeting.

FOIA Confidential Treatment Requested by Univ of Texas System

Sincerely,

Diane E. Griffin
Vice President, NAS
…

Margaret Hamburg
Foreign secretary, NAM
…

NAS points of contact:

David R. Franz DVM, Ph.D.
Former Commander, USAMRIID
davidrfranz@gmail.com

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

Commented [LM1]: Not sure this helps here.

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong
Sent: Friday, June 21, 2019 3:25 PM
To: Rusek, Benjamin;LeDuc, James W.;David Franz
Cc: Lowenthal, Micah
Subject: RE: Kungmin update

Thanks, Ben
I have already emailed Dr. Qinhan Li for a phone call.
Cheers,
Pei-Yong

From: Rusek, Benjamin [mailto:BRusek@nas.edu]
Sent: Friday, June 21, 2019 2:49 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Kungmin update

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good to talk to you all today.

FYI Xuetao Cao, M.D., Ph.D., president, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China was elected a foreign member of NAM in 2017 https://nam.edu/national-academy-of-medicine-elects-80-new-members/

Qi Han Li, is listed as the Director, Kunming Institute of Medical Biology, Kunming, People's Republic of China (from 2013)

There was a Virology con in Kunming in 2017 http://www.imbcams.ac.cn/Item/17194.aspx. Lists De Yin Guo, George Fu Gao, and **Qi Han Li** as the meeting Chairmen.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, June 20, 2019 10:12 PM
To: David Franz <davidrfranz@gmail.com>
Cc: Shi, Pei yong <peshi@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Kungmin update

Thanks Pei Yong. Good to know that Zhiming is still willing to work with us.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007675

Sent from my iPhone

On Jun 20, 2019, at 6:31 PM, David Franz <davidrfranz@gmail.com> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Sounds good Pei-Yong. Thanks! Dave

Sent from my iPhone

On Jun 20, 2019, at 6:41 PM, Shi, Pei yong <peshi@utmb.edu> wrote:

Hi Ben, Dave, and Jim,

I talked with Longding and Zhiming. Here is the summary.

Longding was reluctant to go back to Kunming's leadership team for another trial. This is because their new Party Secretary (who makes the decision) is newly appointed from Beijing. So, I was not able to get the name from Longding whom the NAS letter should address to. We will discuss this further at our TC tomorrow.

Zhiming was very supportive to host the next meeting under CAS. The location could be Wuhan or any other cities in China. If we decide to work with Zhiming for the next meeting, NAS needs to send a letter to President of CAS (Dr. Chunli Bai), as we did for the Wuhan meeting in 2016.

I have not talked with George Gao yet and am planning to do so after our TC tomorrow.

Best, Pei-Yong

From: Rusek, Benjamin [mailto:BRusek@nas.edu]
Sent: Thursday, June 20, 2019 4:38 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; 'David Franz' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Kungmin update
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

I have attached a draft letter for Diane and Peggy for your review, Pei-yong, we will need to know who to send it to...

Re the call tomorrow, please call 1-888-537-7715 and enter participant code 12223052# at 1:00 PM ET.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007676

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, June 18, 2019 2:45 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'David Franz' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: Kungmin update

OK—added to my calendar. Please share call in information when available.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, June 18, 2019 12:52 PM
To: 'David Franz' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: RE: Kungmin update

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Pei-yong and I spoke on the phone, he is on vacation until Thursday. Lets plan to talk on Friday. How about 1 PM ET?

In the interim, I will write a draft letter and contact Peggy and Diane.

And yes I will leave the funding support offer out of the letter.

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: David Franz <davidrfranz@gmail.com>
Sent: Tuesday, June 18, 2019 1:49 PM
To: Shi, Pei yong <peshi@utmb.edu>
Cc: LeDuc, James W. <jwleduc@utmb.edu>; Rusek, Benjamin <BRusek@nas.edu>
Subject: Re: Kungmin update

If I don't make it on the call, the only thing I'm not comfortable with is offering them funding support. Whatever you guys decide is fine. I like Pei-Yong talking to Zhiming or George. Home tomorrow afternoon, dave

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007677

On Jun 18, 2019, at 4:18 PM, Shi, Pei yong <peshi@utmb.edu> wrote:

Hi all,

Longding's institution is very conservative. This has limited their growth. I'll be back to office on Thursday. We could have a TC on Thursday or Friday.

One suggestion is to talk to Zhiming and George for options. We could decide after our TC.

Best, Pei-Yong

From: LeDuc, James W.
Sent: Tuesday, June 18, 2019 9:11 AM
To: Shi, Pei yong; Rusek, Benjamin
Cc: Dave Franz
Subject: RE: Kungmin update

Thanks for the update Pei-Yong. This is very sad and frustrating, but certainly understandable from their perspective. We should probably have a brief teleconference to discuss options. I'm available all day.

Thanks, Jim

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Tuesday, June 18, 2019 7:04 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Kungmin update

Hi Ben, Dave, and Jim,

I just received a negative response from Longding that, due to the current China-US relationship, their institute has decided not to host our next meeting. I personally understand why they are changing their position. Let's talk about it through a TC or email.

Sorry about the negative development. Since Longding wrote to me in Chinese through WeChat. I am not forwarding it to you. However, I have asked him to email us about it in English.

Best regards,
Pei-Yong

On Jun 17, 2019 5:27 PM, "Rusek, Benjamin" <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007678

Hi Jim,

Here are my two cents. You might want to send the next draft to Katie Bowman (Bowman, Katherine KBowman@nas.edu)

Kind regards,

Ben

Benjamin Rusek

The U.S. National Academy of Sciences

1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Monday, June 17, 2019 6:10 PM
To: Dave Franz <davidrfranz@gmail.com>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Draft editorial

Thanks very much Dave. Received just fine and I will make the adjustments.

Jim

Sent from my iPhone

On Jun 17, 2019, at 2:48 PM, Dave Franz <davidrfranz@gmail.com> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007679

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Trying t send from Chromebook, with which I'm still a little unsure. Let me know if a marked up version comes through. d

James W. Le Duc, Ph.D.

Director

Galveston National Laboratory

University of Texas Medical Branch

Galveston, TX 77555-0610

(t) 409-266-6500

(f) 409-266-6810

(m) 409-789-2012

<Biosecurity in the age to synthetic biology June 16 2019.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007680

From: David Franz <davidrfranz@gmail.com>
Sent: Tuesday, July 16, 2019 2:31 PM
To: LeDuc, James W.
Cc: Rusek, Benjamin;Shi, Pei yong;Lowenthal, Micah
Subject: Re: Letter to CAS re dialogue meeting with in Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agree with Jim on that second point about timing. Dave

Sent from my iPhone

On Jul 16, 2019, at 3:20 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

> Hi Ben,
>
> Thanks for preparing the draft letter. I made a couple of minor edits on the attached for your consideration. Specifically, a suggestion that the next meeting be held in the "vicinity of Wuhan" as we may wish to go to a more leisure site since we have been in Wuhan a couple of times already. This was suggested by Zhiming I believe when he last spoke to Pei-Yong.
>
> The larger question is, Is now the right time to be asking to set up a formal MOU and standing committee for this initiative? Given the sour political environment and the fact that Kunming has already bowed out, I'm a little concerned that requesting to formalize things at this time may just provide the CAS with an excuse to bump up a decision to higher political levels and thereby delay a decision, or worse, result in a negative reply. I wonder if we should ask Zhiming or George Gao their opinion before finalizing the letter.
>
> Maybe we can have a quick conference call to discuss?
>
> Thanks, Jim
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Tuesday, July 16, 2019 1:40 PM
> **To:** LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
> **Cc:** Lowenthal, Micah <mlowenth@nas.edu>
> **Subject:** Letter to CAS re dialogue meeting with in Wuhan
> **Importance:** High
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> Hi Jim, Dave and Pei-yong,
>
> Here is the draft letter to seek approval to hold the next U.S. China bio dialogue meeting with NIV in Wuhan. The letter would be signed by Peggy Hamburg and Diane Griffin (and I will reach out to them in

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000001

a separate email) but I wanted to send it to you for final review first. I have been told by our leadership that Chunli Bai is no longer the president of CAS, Pei-yong could you ask Zhiming who this should go to after it gets signed?

Note that the letter also includes a request to formalize the dialogue (via memorandum of understanding and the appointment of a standing organizing committee) as a regular, ongoing activity between NASEM and CAS. It makes sense to do this now for several reasons. Was thinking that the standing committee could include Americans and the Chinese scientists/leaders we have been working with but happy to hear your thoughts on this.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Letter to CAS from Griffin and Hamburg v2-jwl.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000002

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, July 24, 2019 3:41 PM
To: LeDuc, James W.;Dave Franz (davidrfranz@gmail.com)
Cc: Lowenthal, Micah;Shi, Pei yong
Subject: Letter to CAS to hold next dialogue meeting in Wuhan
Attachments: Letter to CAS from Griffin and Hamburg for review.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dave and Jim,

Sorry for the delay, was out of town for other work last week, I have attached a note for Diane and Peggy along with a revised latter.

I wanted to make sure you are ok with the language in the letter and in the note before I send it to them for signature. I understand your rational for caution but would still like to try and formalize the relationship (reasons in the note) but toned down the sentence about it in the letter. Let me know what you think.

Kind regards,

Ben

***

Greetings Diane and Peggy,

I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we done before the 2017 meeting in Wuhan) to get approval for the meeting. Zhiming says that the president is still Bai Chunli but this may have changed recently.

More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the of Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.

The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal nothing that this dialogue meeting could be used to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this because it has taken many years to get to the point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group, we have now held several useful dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship, we are working with a committed group of Chinese scientists and leaders who recognize the importance of dialogue and communication that are tied formally to CAS (Zhiming, George Gao, others) who could serve on a Chinese organizing committee, the political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009090

formal sanction. I wrote the text so that the CAS leadership could decline this part of the request if they do not think it is the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009091

RE: Proposed Chinese-U.S. dialogue meeting on the Challenges of Emerging Infections, Laboratory Safety & Global Health Security in Wuhan, China

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to formally request your permission and support to hold the next in a series of China-U.S. meetings on emerging infections, laboratory safety, and global health security co-convened by the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Wuhan Institute of Virology, Chinese Academy of Sciences (CAS) in Wuhan, China in late 2019.

Over the past several years, Dr. David Franz and Dr. James Le Duc have worked with Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese officials to organize a series of meetings, a dialogue between experts designated by the CAS, China Center for Disease Control (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences and the NASEM. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the workshops. Meetings have been held in Beijing, Wuhan, Galveston, Texas and most recently the CAAS Veterinary Institute in Harbin, China. In addition to ourselves, participants have included esteemed senior Chinese and American Scientists, such as Gao Fu (CAS, CCDC, NAM), Yi Shi (CAS), Linda Saif (NAS), David Relman (NAM), Bu Zhigao, (CAAS), and many others.

During the meeting in Harbin in January 2019, Dr. Le Duc and Dr. Yuan discussed holding a second dialogue meeting in the vicinity of Wuhan. Topics that are proposed for discussion at the meeting include: medical countermeasure development, especially advanced development of vaccines, therapeutics, and diagnostics; development and use of animal models of high-consequence diseases in biocontainment; host-pathogen interactions; the special challenges associated with the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnologies in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector-borne disease research.

With your approval, NASEM and CAS will establish an informal joint organizing committee to plan the next dialogue meeting, invite workshop speakers and participants, and make workshop logistical arrangements. NASEM will pay the air, lodging, and ancillary costs of all the American participants and can contribute financial support for meeting costs in China, if necessary.

The meeting could also be used to formalize, via memorandum of understanding and the appointment of a standing organizing committee of Chinese and American experts, the China-U.S. dialogue on the challenges of emerging infections, laboratory safety, and global health security as a regular, ongoing activity between our two organizations.

China and the United States are world leaders in life science research and development, have large populations that may be susceptible to emerging infections, and are world leaders in public health and response to infectious disease. Both of our countries operate complex high biological containment laboratories that are critical to responding to outbreaks of especially dangerous pathogens. It is important to cooperate and discuss these and other key areas of interest and concern for our two countries and as the life sciences advance, continue to exchange best practices to ensure the safe and secure conduct of the life science enterprise going forward. We hope that you approve and will support this activity.

FOIA Confidential Treatment Requested by Univ of Texas System

We look forward to your thoughts on the organization, content, and substance of the dialogue meeting, your thoughts on the proposal to formalize the dialogue and any other issues that you and your colleagues wish to address.

Sincerely,

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM

…

…

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Wednesday, July 24, 2019 3:52 PM
To: Rusek, Benjamin;Dave Franz (davidrfranz@gmail.com)
Cc: Lowenthal, Micah;Shi, Pei yong
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan
Attachments: Letter to CAS from Griffin and Hamburg for review-jwl.docx

Thanks Ben. I made a couple of minor comments in the attached, but I think it's fine. RE the title of the standing committee, is "global health security" an acceptable phrase in this group?

Will you or Dave be attending Tom Inglesby's US-China meeting on synthetic biology in DC on Friday? I will be there and scheduled to speak in the morning session.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, July 24, 2019 3:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Letter to CAS to hold next dialogue meeting in Wuhan
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dave and Jim,

Sorry for the delay, was out of town for other work last week, I have attached a note for Diane and Peggy along with a revised latter.

I wanted to make sure you are ok with the language in the letter and in the note before I send it to them for signature. I understand your rational for caution but would still like to try and formalize the relationship (reasons in the note) but toned down the sentence about it in the letter. Let me know what you think.

Kind regards,

Ben

***

Greetings Diane and Peggy,

I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we done before the 2017 meeting in Wuhan) to get approval for the meeting. Zhiming says that the president is still Bai Chunli but this may have changed recently.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008750

More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the of Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.

The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal nothing that this dialogue meeting could be used to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this because it has taken many years to get to the point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group, we have now held several useful dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship, we are working with a committed group of Chinese scientists and leaders who recognize the importance of dialogue and communication that are tied formally to CAS (Zhiming, George Gao, others) who could serve on a Chinese organizing committee, the political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. I wrote the text so that the CAS leadership could decline this part of the request if they do not think it is the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008751

RE: Proposed Chinese-U.S. dialogue meeting on the Challenges of Emerging Infections, Laboratory Safety & Global Health Security in Wuhan, China

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to formally request your permission and support to hold the next in a series of China-U.S. meetings on emerging infections, laboratory safety, and global health security co-convened by the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Wuhan Institute of Virology, Chinese Academy of Sciences (CAS) in Wuhan, China in late 2019 or early 2020.

Over the past several years, Dr. David Franz and Dr. James Le Duc have worked with Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese officials to organize a series of meetings, a dialogue between experts designated by the CAS, China Center for Disease Control (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences and the NASEM. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the workshops. Meetings have been held in Beijing, Wuhan, Galveston, Texas and most recently the CAAS Veterinary Institute in Harbin, China. In addition to ourselves, participants have included esteemed senior Chinese and American Scientists, such as Gao Fu (CAS, CCDC, NAM), Yi Shi (CAS), Linda Saif (NAS), David Relman (NAM), Bu Zhigao, (CAAS), and many others.

During the meeting in Harbin in January 2019, Dr. Le Duc and Dr. Yuan discussed holding a second dialogue meeting in the vicinity of Wuhan. Topics that are proposed for discussion at the meeting include: medical countermeasure development, especially advanced development of vaccines, therapeutics, and diagnostics; development and use of animal models of high-consequence diseases in biocontainment; host-pathogen interactions; the special challenges associated with the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnologies in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector-borne disease research.

Commented [LJW1]: among others. May wish to cut down the laundry list of possible topics to maybe 3 key, overarching themes of broad international interest.

With your approval, NASEM and CAS will establish an informal joint organizing committee to plan the next dialogue meeting, invite workshop speakers and participants, and make workshop logistical arrangements. NASEM will pay the air, lodging, and ancillary costs of all the American participants and can contribute financial support for meeting costs in China, if necessary.

The meeting could also be used to formalize, via memorandum of understanding and the appointment of a standing organizing committee of Chinese and American experts, the China-U.S. dialogue on the challenges of emerging infections, laboratory safety, and global health security as a regular, ongoing activity between our two organizations.

China and the United States are world leaders in life science research and development, have large populations that may be susceptible to emerging infections, and are world leaders in public health and response to infectious disease. Both of our countries operate complex high biological containment laboratories that are critical to responding to outbreaks of especially dangerous pathogens. It is important to cooperate and discuss these and other key areas of interest and concern for our two countries and as the life sciences advance, continue to exchange best practices to ensure the safe and secure conduct of the life science enterprise going forward. We hope that you approve and will support this activity.

FOIA Confidential Treatment Requested by Univ of Texas System

We look forward to your thoughts on the organization, content, and substance of the dialogue meeting, your thoughts on the proposal to formalize the dialogue and any other issues that you and your colleagues wish to address.

Sincerely,

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM

...

...

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, July 24, 2019 5:30 PM
To: LeDuc, James W.
Cc: Dave Franz;Lowenthal, Micah;Shi, Pei yong
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim and Dave, thank you for the quick and useful comments and edits, I will take a final look and send the note and letter later tonight.

Ben

On Jul 24, 2019, at 6:18 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

> No problem in using my name if you think it would be helpful
>
> Sent from my iPhone
>
> On Jul 24, 2019, at 4:38 PM, Dave Franz <davidrfranz@gmail.com> wrote:
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> I will not attend Tom's meeting. Do we have a list of Chinese attendees?
>
> Oh, and Jim, I used your name in vein on a comment in the draft email to Diane and Peggy. Maybe it's not appropriate—and you can take Jim's name off Ben, if you think appropriate but Jim doesn't want to. I just thought it was worth mentioning to them that we are aware and thinking about the greater political climate. Dave
>
> On Jul 24, 2019, at 4:52 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:
>
> Thanks Ben. I made a couple of minor comments in the attached, but I think it's fine. RE the title of the standing committee, is "global health security" an acceptable phrase in this group?
>
> Will you or Dave be attending Tom Inglesby's US-China meeting on synthetic biology in DC on Friday? I will be there and scheduled to speak in the morning session.
>
> Thanks, Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007669

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, July 24, 2019 3:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Letter to CAS to hold next dialogue meeting in Wuhan
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dave and Jim,

Sorry for the delay, was out of town for other work last week, I have attached a note for Diane and Peggy along with a revised latter.

I wanted to make sure you are ok with the language in the letter and in the note before I send it to them for signature. I understand your rational for caution but would still like to try and formalize the relationship (reasons in the note) but toned down the sentence about it in the letter. Let me know what you think.

Kind regards,

Ben

***

Greetings Diane and Peggy,

I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we done before the 2017 meeting in Wuhan) to get approval for the meeting. Zhiming says that the president is still Bai Chunli but this may have changed recently.

More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the of Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.

The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal nothing that this dialogue meeting could be used to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this because it has

FOIA Confidential Treatment Requested by Univ of Texas System

taken many years to get to the point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group, we have now held several useful dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship, we are working with a committed group of Chinese scientists and leaders who recognize the importance of dialogue and communication that are tied formally to CAS (Zhiming, George Gao, others) who could serve on a Chinese organizing committee, the political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. I wrote the text so that the CAS leadership could decline this part of the request if they do not think it is the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Letter to CAS from Griffin and Hamburg for review-jwl.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007671

RE: Proposed Chinese-U.S. dialogue meeting on the Challenges of Emerging Infections, Laboratory Safety & Global Health Security in Wuhan, China

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to formally request your permission and support to hold the next in a series of China-U.S. meetings on emerging infections, laboratory safety, and global health security co-convened by the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Wuhan Institute of Virology, Chinese Academy of Sciences (CAS) in Wuhan, China in late 2019.

Over the past several years, Dr. David Franz and Dr. James Le Duc have worked with Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese officials to organize a series of meetings, now an informal dialogue, between experts designated by the CAS, China Center for Disease Control (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences and the NASEM. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the workshops. Meetings have been held in Beijing, Wuhan, Galveston, Texas and most recently the CAAS Veterinary Institute in Harbin, China. In addition to ourselves, participants have included esteemed senior Chinese and American Scientists, such as Gao Fu (CAS, CCDC, NAM), Yi Shi (CAS), Linda Saif (NAS), David Relman (NAM), Bu Zhigao, (CAAS), and many others.

During the meeting in Harbin in January 2019, Dr. Le Duc and Dr. Yuan discussed holding a second dialogue meeting in the vicinity of Wuhan. Topics that are proposed for discussion at the meeting include: the special challenges associated with the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnologies in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector-borne disease research.

With your approval, NASEM and CAS will establish an informal joint organizing committee to plan the next dialogue meeting, invite workshop speakers and participants, and make workshop logistical arrangements. NASEM will pay the air, lodging, and ancillary costs of all the American participants and can contribute financial support for meeting costs in China, if necessary.

This excellent series of meetings could also be used to formalize, via memorandum of understanding and the appointment of a standing organizing committee of Chinese and American experts as *The China-U.S. dialogue on the challenges of emerging infections, laboratory safety, and global health security* as a regular, ongoing activity between our two organizations.

China and the United States are world leaders in life science research and development, have large populations that may be susceptible to emerging infections, and are world leaders in public health and response to infectious disease. Both of our countries operate complex high biological containment laboratories that are critical to responding to outbreaks of especially dangerous pathogens. It is important to cooperate and discuss these and other key areas of interest and concern for our two countries and as the life sciences advance, continue to exchange best practices to ensure the safe and secure conduct of the enterprise going forward.

We look forward to your thoughts on the organization, content, and substance of the dialogue meeting, the proposal to formalize the dialogue and any other issues that you and your colleagues wish to address.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009000

Sincerely,

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM

…

…

Additional points of contact:
James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 5:47 PM
To: LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: Lowenthal, Micah
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?
Attachments: Letter to CAS re Wuhan from Griffin and Hamburg.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings Pei-yong,

I have attached the letter. Dave and Jim do you have any final thoughts/edits? If not it is ok from my perspective. Pei-yong is the plan for you to send this to Zhiming for review and then he will send to Chunli Bai? Of should this come from NASEM directly?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, July 25, 2019 5:47 PM
To: Hamburg, Margaret <MHamburg@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Diane and Peggy,

Thanks for your notes about the letter, we will send it with your electronic signatures (I think we have them on file but will get back to you if we don't). And yes timing will be tight.

Re Kunming and CAMs unwillingness to host, Pei-Yong (cced) may know more but our contact at Kunming noted that Dr. Qihan Li, General Director of the Kunming Institute, is reluctant to seek permission from their Party Secretary (who makes the decision) noting that he is newly appointed from Beijing. We may have more luck at a later time. We have had Kunming lab scientists at most of the dialogue meetings so they are not reluctant to participate, I expect that some will join the Wuhan meeting.

Kind regards,

Ben

Benjamin Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009183

From: Hamburg, Margaret <MHamburg@nas.edu>
Sent: Thursday, July 25, 2019 7:49 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

I agree with Diane that this looks fine. Lays out good case for collaboration.

I am puzzled by reluctance of Kunming Institute to approach CAMS about this. Do you understand why this might be?

Peggy

Sent from my iPhone

On Jul 25, 2019, at 6:54 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

> Ben - I think this is a good idea and the letter looks fine to me.
> Depending on the rapidity of the response, it may be tough to get something organized by the end of the year, but it's worth a try.
>
> Diane
>
> ---
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Wednesday, July 24, 2019 9:10:30 PM
> **To:** Diane Griffin; Hamburg, Margaret
> **Cc:** jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com); Shi, Pei yong (peshi@UTMB.EDU); Lowenthal, Micah; Boright, John
> **Subject:** Letter to CAS to hold next dialogue meeting in Wuhan?
>
> Greetings Diane and Peggy,
>
> I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we did before the 2017 meeting in Wuhan) to get approval for the meeting. (Zhiming says that the president is still Bai Chunli but this may have changed recently.)
>
> More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.
>
> The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal to use this meeting to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose

FOIA Confidential Treatment Requested by Univ of Texas System

this. It has taken many years to get to this point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group we have now held several useful, well attended dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship. We are working with a committed group of Chinese scientists and leaders that are tied formally to CAS (Zhiming, George Gao, others) who recognize the importance of dialogue and communication and who could serve on a Chinese organizing committee. In addition, the current political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. This climate only adds to the value of these technical dialogues and frank and open communication among expert colleagues from both sides. I should add that Jim and Dave did mention some concern about this being the right time to seek a formal agreement establishing a formal dialogue. Therefore, I have written the draft text so that the CAS leadership could decline this part of the request if they do not think it is appropriate or the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009185

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Proposed Chinese-U.S. dialogue meeting on the challenges of emerging infections, laboratory safety and global health security in Wuhan, China

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to formally request your permission and support to hold the next in a series of China-U.S. meetings on emerging infections, laboratory safety, and global health security co-convened by the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Wuhan Institute of Virology, Chinese Academy of Sciences (CAS) in Wuhan, China in late 2019 or early 2020.

Over the past several years, Dr. James Le Duc, Dr. David Franz and other representatives of NASEM have worked with Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese scientists to organize a series of meetings, now an informal dialogue, between experts designated by the CAS, China Center for Disease Control (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), the Chinese Academy of Medical Sciences and the NASEM. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the meetings. Meetings have been held in Beijing, Wuhan, Galveston, Texas and most recently the CAAS Veterinary Institute in Harbin, China. In addition to ourselves, participants have included esteemed senior Chinese and American Scientists, such as Gao Fu (CAS, CCDC, NAM), Yi Shi (CAS), Linda Saif (NAS), David Relman (NAM), Bu Zhigao, (CAAS), and many other experts.

During the meeting in Harbin in January 2019, Dr. Le Duc and Dr. Yuan discussed holding a second dialogue meeting in the vicinity of Wuhan. Topics that are proposed for discussion at the meeting include: the special challenges associated with the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnologies in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector-borne disease research.

With your approval, NASEM and CAS will establish an informal joint organizing committee to plan the next dialogue meeting, invite speakers and participants, and make logistical arrangements. NASEM will pay the air, lodging, and ancillary costs of all the American participants and can contribute financial support for meeting costs in China, if necessary.

This excellent series of meetings could also be used to formalize, via memorandum of understanding and the appointment of a standing organizing committee of Chinese and American experts *The China-U.S. Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security* as a regular, ongoing activity between our two organizations.

China and the United States are world leaders in life science research and development, have large populations that may be susceptible to emerging infections, and are world leaders in public health and response to infectious disease. Both of our countries operate complex high biological containment laboratories that are critical to responding to outbreaks of especially dangerous pathogens. It is important to cooperate and regularly discuss these and other key areas of interest and concern for our two countries and as the life sciences advance, continue to exchange best practices to ensure the safe and secure conduct of the enterprise going forward.

FOIA Confidential Treatment Requested by Univ of Texas System

We look forward to your thoughts on the organization, content, and substance of the dialogue meeting, the proposal to formalize dialogue and any other issues that you and your colleagues wish to address.

Sincerely,

Diane E. Griffin
Vice President, NAS



Margaret Hamburg
Foreign secretary, NAM



...

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong
Sent: Friday, July 26, 2019 6:34 PM
To: Rusek, Benjamin;LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)'
Cc: Lowenthal, Micah
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks, Ben
I just spoke to Zhiming. He does not need to be copied.
Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 6:18 PM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks, if that's the case it will come from John Boright on Monday. Should he cc Zhiming?

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, July 26, 2019 7:15 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Ben,

I'm fine with the letter. Zhiming told me he did not need to see the letter. So, you could send the letter to Chunli Bai now. I will inform Zhiming that the letter has been sent.

Have a great weekend!

Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008268

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 5:47 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings Pei-yong,

I have attached the letter. Dave and Jim do you have any final thoughts/edits? If not it is ok from my perspective. Pei-yong is the plan for you to send this to Zhiming for review and then he will send to Chunli Bai? Of should this come from NASEM directly?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, July 25, 2019 5:47 PM
To: Hamburg, Margaret <MHamburg@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Diane and Peggy,

Thanks for your notes about the letter, we will send it with your electronic signatures (I think we have them on file but will get back to you if we don't). And yes timing will be tight.

Re Kunming and CAMs unwillingness to host, Pei-Yong (cced) may know more but our contact at Kunming noted that Dr. Qihan Li, General Director of the Kunming Institute, is reluctant to seek permission from their Party Secretary (who makes the decision) noting that he is newly appointed from Beijing. We may have more luck at a later time. We have had Kunming lab scientists at most of the dialogue meetings so they are not reluctant to participate, I expect that some will join the Wuhan meeting.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008269

From: Hamburg, Margaret <MHamburg@nas.edu>
Sent: Thursday, July 25, 2019 7:49 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

I agree with Diane that this looks fine. Lays out good case for collaboration.

I am puzzled by reluctance of Kunming Institute to approach CAMS about this. Do you understand why this might be?

Peggy

Sent from my iPhone

On Jul 25, 2019, at 6:54 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

> Ben - I think this is a good idea and the letter looks fine to me.
> Depending on the rapidity of the response, it may be tough to get something organized by the end of the year, but it's worth a try.
>
> Diane
>
> ---
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Wednesday, July 24, 2019 9:10:30 PM
> **To:** Diane Griffin; Hamburg, Margaret
> **Cc:** jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com); Shi, Pei yong (peshi@UTMB.EDU); Lowenthal, Micah; Boright, John
> **Subject:** Letter to CAS to hold next dialogue meeting in Wuhan?
>
> Greetings Diane and Peggy,
>
> I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we did before the 2017 meeting in Wuhan) to get approval for the meeting. (Zhiming says that the president is still Bai Chunli but this may have changed recently.)
>
> More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.
>
> The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal to use this meeting to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this. It has taken many years to get to this point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group we have now held several useful, well attended dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship. We are working with a

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008270

committed group of Chinese scientists and leaders that are tied formally to CAS (Zhiming, George Gao, others) who recognize the importance of dialogue and communication and who could serve on a Chinese organizing committee. In addition, the current political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. This climate only adds to the value of these technical dialogues and frank and open communication among expert colleagues from both sides. I should add that Jim and Dave did mention some concern about this being the right time to seek a formal agreement establishing a formal dialogue. Therefore, I have written the draft text so that the CAS leadership could decline this part of the request if they do not think it is appropriate or the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008271

From: Shi, Pei yong
Sent: Monday, July 29, 2019 10:08 AM
To: Rusek, Benjamin;LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)'
Cc: Lowenthal, Micah
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks, Ben

I will let Zhiming know.

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, July 29, 2019 10:03 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The letter went out today.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, July 26, 2019 7:18 PM
To: 'Shi, Pei yong' <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks, if that's the case it will come from John Boright on Monday. Should he cc Zhiming?

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, July 26, 2019 7:15 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008264

Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Ben,

I'm fine with the letter. Zhiming told me he did not need to see the letter. So, you could send the letter to Chunli Bai now. I will inform Zhiming that the letter has been sent.

Have a great weekend!

Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 5:47 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings Pei-yong,

I have attached the letter. Dave and Jim do you have any final thoughts/edits? If not it is ok from my perspective. Pei-yong is the plan for you to send this to Zhiming for review and then he will send to Chunli Bai? Of should this come from NASEM directly?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, July 25, 2019 5:47 PM
To: Hamburg, Margaret <MHamburg@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Diane and Peggy,

Thanks for your notes about the letter, we will send it with your electronic signatures (I think we have them on file but will get back to you if we don't). And yes timing will be tight.

Re Kunming and CAMs unwillingness to host, Pei-Yong (cced) may know more but our contact at Kunming noted that Dr. Qihan Li, General Director of the Kunming Institute, is reluctant to seek permission from their Party Secretary (who

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008265

makes the decision) noting that he is newly appointed from Beijing. We may have more luck at a later time. We have had Kunming lab scientists at most of the dialogue meetings so they are not reluctant to participate, I expect that some will join the Wuhan meeting.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hamburg, Margaret <MHamburg@nas.edu>
Sent: Thursday, July 25, 2019 7:49 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

I agree with Diane that this looks fine. Lays out good case for collaboration.

I am puzzled by reluctance of Kunming Institute to approach CAMS about this. Do you understand why this might be?

Peggy

Sent from my iPhone

On Jul 25, 2019, at 6:54 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

> Ben - I think this is a good idea and the letter looks fine to me.
> Depending on the rapidity of the response, it may be tough to get something organized by the end of the year, but it's worth a try.
>
> Diane
>
> ---
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Wednesday, July 24, 2019 9:10:30 PM
> **To:** Diane Griffin; Hamburg, Margaret
> **Cc:** jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com); Shi, Pei yong (peshi@UTMB.EDU); Lowenthal, Micah; Boright, John
> **Subject:** Letter to CAS to hold next dialogue meeting in Wuhan?
>
> Greetings Diane and Peggy,
>
> I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we did before the 2017 meeting in Wuhan) to get approval for the meeting. (Zhiming says that the president is still Bai Chunli but this may have changed recently.)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008266

More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.

The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal to use this meeting to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this. It has taken many years to get to this point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group we have now held several useful, well attended dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship. We are working with a committed group of Chinese scientists and leaders that are tied formally to CAS (Zhiming, George Gao, others) who recognize the importance of dialogue and communication and who could serve on a Chinese organizing committee. In addition, the current political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. This climate only adds to the value of these technical dialogues and frank and open communication among expert colleagues from both sides. I should add that Jim and Dave did mention some concern about this being the right time to seek a formal agreement establishing a formal dialogue. Therefore, I have written the draft text so that the CAS leadership could decline this part of the request if they do not think it is appropriate or the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008267

From: LeDuc, James W.
Sent: Monday, July 29, 2019 10:20 AM
To: Rusek, Benjamin;Shi, Pei yong;'Dave Franz (davidrfranz@gmail.com)'
Cc: Lowenthal, Micah
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Great, thanks. Perhaps we should consider hosting the next meeting here in the USA rather than revisiting Wuhan? The visa challenges may make that impossible, but something to consider.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, July 29, 2019 10:03 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The letter went out today.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, July 26, 2019 7:18 PM
To: 'Shi, Pei yong' <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks, if that's the case it will come from John Boright on Monday. Should he cc Zhiming?

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, July 26, 2019 7:15 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008877

Hi Ben,

I'm fine with the letter. Zhiming told me he did not need to see the letter. So, you could send the letter to Chunli Bai now. I will inform Zhiming that the letter has been sent.

Have a great weekend!

Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 5:47 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings Pei-yong,

I have attached the letter. Dave and Jim do you have any final thoughts/edits? If not it is ok from my perspective. Pei-yong is the plan for you to send this to Zhiming for review and then he will send to Chunli Bai? Of should this come from NASEM directly?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, July 25, 2019 5:47 PM
To: Hamburg, Margaret <MHamburg@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Diane and Peggy,

Thanks for your notes about the letter, we will send it with your electronic signatures (I think we have them on file but will get back to you if we don't). And yes timing will be tight.

Re Kunming and CAMs unwillingness to host, Pei-Yong (cced) may know more but our contact at Kunming noted that Dr. Qihan Li, General Director of the Kunming Institute, is reluctant to seek permission from their Party Secretary (who makes the decision) noting that he is newly appointed from Beijing. We may have more luck at a later time. We have had Kunming lab scientists at most of the dialogue meetings so they are not reluctant to participate, I expect that some will join the Wuhan meeting.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008878

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hamburg, Margaret <MHamburg@nas.edu>
Sent: Thursday, July 25, 2019 7:49 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

I agree with Diane that this looks fine. Lays out good case for collaboration.

I am puzzled by reluctance of Kunming Institute to approach CAMS about this. Do you understand why this might be?

Peggy

Sent from my iPhone

On Jul 25, 2019, at 6:54 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

> Ben - I think this is a good idea and the letter looks fine to me.
> Depending on the rapidity of the response, it may be tough to get something organized by the end of the year, but it's worth a try.
>
> Diane
>
> ---
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Wednesday, July 24, 2019 9:10:30 PM
> **To:** Diane Griffin; Hamburg, Margaret
> **Cc:** jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com); Shi, Pei yong (peshi@UTMB.EDU); Lowenthal, Micah; Boright, John
> **Subject:** Letter to CAS to hold next dialogue meeting in Wuhan?
>
> Greetings Diane and Peggy,
>
> I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we did before the 2017 meeting in Wuhan) to get approval for the meeting. (Zhiming says that the president is still Bai Chunli but this may have changed recently.)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008879

More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.

The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal to use this meeting to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this. It has taken many years to get to this point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group we have now held several useful, well attended dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship. We are working with a committed group of Chinese scientists and leaders that are tied formally to CAS (Zhiming, George Gao, others) who recognize the importance of dialogue and communication and who could serve on a Chinese organizing committee. In addition, the current political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. This climate only adds to the value of these technical dialogues and frank and open communication among expert colleagues from both sides. I should add that Jim and Dave did mention some concern about this being the right time to seek a formal agreement establishing a formal dialogue. Therefore, I have written the draft text so that the CAS leadership could decline this part of the request if they do not think it is appropriate or the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008880

From: LeDuc, James W.
Sent: Friday, August 2, 2019 9:07 AM
To: Dave Franz (davidrfranz@gmail.com)
Subject: FW: Follow up

See string below from Andrew Snyder-Beattie, new program officer for Open Philanthropy. I think we should engage with Dave Relman, Pei Yong and a few others (George Gao?) to come up with a strategy to suggest to them that builds on the NAS-CAS partnership. Perhaps this will come from our teleconference at the end of the month. Hopefully the letter from Ben will lead to a more formal agreement which could be foundational to continued efforts. We need to have science at the core of the strategy given that Ingleby's group is already well funded by OP for dialogues.

Jim

From: Andrew Snyder-Beattie <andrew@openphilanthropy.org>
Sent: Thursday, August 01, 2019 7:40 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Follow up

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim (if I may),

Thank you so much for reaching out, and apologies about the delay getting back to you. It was great meeting you in DC—I appreciated your contributions to the discussion and agree that continuing the dialogues could be very important.

Thank you as well for giving me an overview of the topics you're working on, this is great to see. My initial hunch is that these projects are not a good fit for Open Phil at this time, but we are still in the process of figuring out our strategy, which is still very much up in the air. I will certainly let you know if I end up needing more information as I learn more about the space and get a better sense of our strategy. Thank you again and hope to cross paths again soon!

All the best,
Andrew

On Mon, Jul 29, 2019 at 2:32 PM LeDuc, James W. <jwleduc@utmb.edu> wrote:

> Dear Andrew,
>
> It was a pleasure to meet you at the recent US-China dialogue on biosafety and biosecurity in the era of synthetic biology. I enjoyed to talks and discussions and I was pleased to see this dialogue continue in spite of the difficult relations now in place between our two countries. Clearly we need to maintain the strong collaborations that we have worked so hard to develop.

FOIA Confidential Treatment Requested by Univ of Texas System

I wanted to take a minute to list a few of the topics on which we are working to see if there is anything that might be of interest to you and Open Philanthropy. All the activities listed are focused on building global capacity in biosafety, biosecurity and the safe and secure operations of biocontainment laboratories.

- Training in biosafety, biosecurity and biocontainment facilities operations. For nearly a decade we enjoy DOD support for our National Biocontainment Training Center and during that time we provided more than 10,000 hands-on training opportunities to staff associated with biocontainment labs from around the world, often providing the training at their own facility. This included extensive collaborations with the BSL4 labs in China which are continuing today through scientific collaborations. See table pasted below

- Global proliferation of biocontainment laboratories. There are more than 50 BSL4 labs built, under construction or in advanced planning located around the world. There is a clear need to engage with the leadership of these new facilities to share best practices and sustain safe and secure operations. See our recent editorial attached from *Science* co-written with Zhiming Yuan from Wuhan. We have a second joint commentary that will appear soon focused on synthetic biology. There is a great opportunity to establish global best practices.

- Building on the partnerships that we have established with international collaborators (especially in China and Turkey), we feel that the best way to sustain best practices and promote transparency is to jointly conduct scientific research on relevant endemic pathogens of mutual interest. I envision such studies would be scientifically meritorious, conducted in true joint partnership with shared work, expenses and credit. We have begun such a model in collaborations with investigators in the Wuhan BSL4 and their side's expenses are being covered by the Chinese government. We need to identify a similar funding source for the USA, and further, we need to create a model program that can be replicated with other partnerships around the world.

- Working with the US National Academy of Sciences in partnership with the Chinese Academy of Sciences, we have hosted a series of joint meetings both here in the USA (one here at the GNL that Jaime attended) and at biocontainment labs in China. These discussions have resulted in official meeting reports and more importantly, valuable contacts and friendships. The most recent joint meeting was earlier this year in Harbin entitled: U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research. Continuation of this dialogue would likely be managed by our NAS directly.

Let me know if any of these are of interest to you and Open Philanthropy and we can provide you with as much detail as you would like. Similarly, if you have ideas as to how we might contribute to your successful tenure at OP, please let me know.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008857

Training Course/Module	May-Dec 2009	Jan-Dec 2010	Jan-Dec 2011	Jan-Dec 2012	Jan-Dec 2013	Jan-Dec 2014	Jan-Dec 2015	Jan-Mar 2016	Apr-Jul 2016	Total
BSL2 theoretical	107	144	251	160	133	165	158	19	68	1,205
BSL2 hands-on	64	76	92	117	102	134	219	13	36	853
ABSL2 theoretical	N/A	1	79	149	284	116	172	28	55	884
ABSL2 hands-on	N/A	1	40	76	105	116	148	30	40	556
BSL3 theoretical	45	119	100	135	86	125	48	29	33	720
BSL3 hands-on	45	101	94	76	57	49	71	20	35	548
BSL3 mentorship	36	41	24	18	14	26	15	4	6	184
Class III cabinet theoretical (New course)	N/A	N/A	N/A	N/A	N/A	2	N/A	N/A	N/A	2
Class III cabinet hands-on (New course)	N/A	N/A	N/A	N/A	N/A	2	N/A	N/A	N/A	2
ABSL3 theoretical	29	55	47	73	76	36	89	13	20	438
ABSL3 hands-on	29	50	46	37	53	29	34	13	12	303
ABSL3 mentorship	N/A	N/A	38	19	26	34	7			124
BSL4 Training, orientation and mentorship	9	28	59	47	41	59	26	4	2	275
ABSL4 program	N/A	N/A	N/A	N/A	N/A	18	22	0	14	54
Non-human primate theoretical	16	15	60	41	20	24	9	9	3	197
Non-human primate, hands-on	N/A	N/A	90	41	28	23	20	0	7	209
Non-human primate annual refresher	N/A	N/A	37	114	89	108	120	N/A	N/A	468
Animal handling certificates	N/A	N/A	22	75	39	27	16	9	8	196
Graduate Program	39	36	32	13	18	25	44	0	8	215
Introduction to Microbiology	18	0	6	4	0	0	0	1	N/A	29
Aerobiology	19	5	2	8	0	2	0	0	0	36
Autoclave	195	27	46	30	25	14	0	0	0	337
High Throughput Safety training	8	11	3	2	17	12	0			53
PAPR (respirator training)	N/A	10	49	52	78	82	28	12	16	327
ABSA/AfBSA courses*	84	175	87	207	181	137	184	18	80	1,153
Agent specific training	N/A	N/A	N/A	N/A	186	141	0	N/A	N/A	327
Specialized Biosafety course	N/A	N/A	N/A	N/A	N/A	71	113	N/A	N/A	184
Ebola response training/ Healthcare training	N/A	N/A	N/A	N/A	N/A	177	206	32	75	490
Total trained	**743**	**895**	**1,304**	**1,494**	**1,658**	**1,754**	**1491**	**254**	**518**	**10369**

With best wishes,

Jim

James W. Le Duc, Ph.D.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008858

Director

Galveston National Laboratory

University of Texas Medical Branch

Galveston, TX 77555-0610

(t) 409-266-6500

(f) 409-266-6810

(m) 409-789-2012

--
Andrew Snyder-Beattie
Program Officer, Biosecurity and Pandemic Preparedness
www.openphilanthropy.org

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008859

From: David Franz <davidrfranz@gmail.com>
Sent: Friday, August 2, 2019 10:46 AM
To: LeDuc, James W.
Subject: Re: Follow up

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agree, Maybe we'll have something back in response to the letter before Micah returns. Thanks, dave

David R. Franz
Gettysburg, PA
(240) 674-0797

On Aug 2, 2019, at 10:06 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

See string below from Andrew Snyder-Beattie, new program officer for Open Philanthropy. I think we should engage with Dave Relman, Pei Yong and a few others (George Gao?) to come up with a strategy to suggest to them that builds on the NAS-CAS partnership. Perhaps this will come from our teleconference at the end of the month. Hopefully the letter from Ben will lead to a more formal agreement which could be foundational to continued efforts. We need to have science at the core of the strategy given that Ingleby's group is already well funded by OP for dialogues.

Jim

From: Andrew Snyder-Beattie <andrew@openphilanthropy.org>
Sent: Thursday, August 01, 2019 7:40 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Follow up

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim (if I may),

Thank you so much for reaching out, and apologies about the delay getting back to you. It was great meeting you in DC—I appreciated your contributions to the discussion and agree that continuing the dialogues could be very important.

FOIA Confidential Treatment Requested by Univ of Texas System

Thank you as well for giving me an overview of the topics you're working on, this is great to see. My initial hunch is that these projects are not a good fit for Open Phil at this time, but we are still in the process of figuring out our strategy, which is still very much up in the air. I will certainly let you know if I end up needing more information as I learn more about the space and get a better sense of our strategy. Thank you again and hope to cross paths again soon!

All the best,
Andrew

On Mon, Jul 29, 2019 at 2:32 PM LeDuc, James W. <jwleduc@utmb.edu> wrote:

> Dear Andrew,
>
> It was a pleasure to meet you at the recent US-China dialogue on biosafety and biosecurity in the era of synthetic biology. I enjoyed to talks and discussions and I was pleased to see this dialogue continue in spite of the difficult relations now in place between our two countries. Clearly we need to maintain the strong collaborations that we have worked so hard to develop.
>
> I wanted to take a minute to list a few of the topics on which we are working to see if there is anything that might be of interest to you and Open Philanthropy. All the activities listed are focused on building global capacity in biosafety, biosecurity and the safe and secure operations of biocontainment laboratories.
>
> - Training in biosafety, biosecurity and biocontainment facilities operations. For nearly a decade we enjoy DOD support for our National Biocontainment Training Center and during that time we provided more than 10,000 hands-on training opportunities to staff associated with biocontainment labs from around the world, often providing the training at their own facility. This included extensive collaborations with the BSL4 labs in China which are continuing today through scientific collaborations. See table pasted below
>
> - Global proliferation of biocontainment laboratories. There are more than 50 BSL4 labs built, under construction or in advanced planning located around the world. There is a clear need to engage with the leadership of these new facilities to share best practices and sustain safe and secure operations. See our recent editorial attached from *Science* co-written with Zhiming Yuan from Wuhan. We have a second joint commentary that will appear soon focused on synthetic biology. There is a great opportunity to establish global best practices.
>
> - Building on the partnerships that we have established with international collaborators (especially in China and Turkey), we feel that the best way to sustain best practices and promote transparency is to jointly conduct scientific research on relevant endemic pathogens of mutual interest. I envision such studies would be scientifically meritorious, conducted in true joint partnership with shared work, expenses and credit. We have begun such a model in collaborations with investigators in the Wuhan BSL4 and their side's expenses are being covered by the Chinese government. We need to identify a similar funding source for the USA, and further, we need to create a model program that can be replicated with other partnerships around the world.
>
> - Working with the US National Academy of Sciences in partnership with the Chinese Academy of Sciences, we have hosted a series of joint meetings both here in the USA (one here

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008095

at the GNL that Jaime attended) and at biocontainment labs in China. These discussions have resulted in official meeting reports and more importantly, valuable contacts and friendships. The most recent joint meeting was earlier this year in Harbin entitled: U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research. Continuation of this dialogue would likely be managed by our NAS directly.

Let me know if any of these are of interest to you and Open Philanthropy and we can provide you with as much detail as you would like. Similarly, if you have ideas as to how we might contribute to your successful tenure at OP, please let me know.
<image001.png>

With best wishes,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

--
Andrew Snyder-Beattie
Program Officer, Biosecurity and Pandemic Preparedness
www.openphilanthropy.org

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008096

From: LeDuc, James W.
Sent: Thursday, August 22, 2019 1:07 PM
To: Rusek, Benjamin
Cc: Shi, Pei yong;Dave Franz (davidrfranz@gmail.com);Lowenthal, Micah
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks Pei-Yong. Good news that CAS remains supportive. We'll need to revisit schedule as it looks like holding the meeting this year is going to be problematic.

Glad you're going to Kunming. Let's chat before you leave.

Jim

Sent from my iPhone

On Aug 22, 2019, at 12:56 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

This is great news, thanks for the update.

On Aug 22, 2019, at 12:47 PM, Shi, Pei yong <peshi@utmb.edu> wrote:

Dear Ben, Dave, and Jim,

Zhiming updated me today that CAS is supportive of the next meeting, but it takes some time to go through the paperwork at CAS.

I plan to visit Kunming in the middle of October and will arrange a meeting with the director and their leadership team there.

I will keep you updated of any progress.

Best, Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, July 29, 2019 10:03 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The letter went out today.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008665

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, July 26, 2019 7:18 PM
To: 'Shi, Pei yong' <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Thanks, if that's the case it will come from John Boright on Monday. Should he cc Zhiming?

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, July 26, 2019 7:15 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Ben,

I'm fine with the letter. Zhiming told me he did not need to see the letter. So, you could send the letter to Chunli Bai now. I will inform Zhiming that the letter has been sent.

Have a great weekend!

Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, July 26, 2019 5:47 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings Pei-yong,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008666

I have attached the letter. Dave and Jim do you have any final thoughts/edits? If not it is ok from my perspective. Pei-yong is the plan for you to send this to Zhiming for review and then he will send to Chunli Bai? Of should this come from NASEM directly?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, July 25, 2019 5:47 PM
To: Hamburg, Margaret <MHamburg@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: RE: Letter to CAS to hold next dialogue meeting in Wuhan?

Hi Diane and Peggy,

Thanks for your notes about the letter, we will send it with your electronic signatures (I think we have them on file but will get back to you if we don't). And yes timing will be tight.

Re Kunming and CAMs unwillingness to host, Pei-Yong (cced) may know more but our contact at Kunming noted that Dr. Qihan Li, General Director of the Kunming Institute, is reluctant to seek permission from their Party Secretary (who makes the decision) noting that he is newly appointed from Beijing. We may have more luck at a later time. We have had Kunming lab scientists at most of the dialogue meetings so they are not reluctant to participate, I expect that some will join the Wuhan meeting.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hamburg, Margaret <MHamburg@nas.edu>
Sent: Thursday, July 25, 2019 7:49 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>
Subject: Re: Letter to CAS to hold next dialogue meeting in Wuhan?

I agree with Diane that this looks fine. Lays out good case for collaboration.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008667

I am puzzled by reluctance of Kunming Institute to approach CAMS about this. Do you understand why this might be?

Peggy

Sent from my iPhone

On Jul 25, 2019, at 6:54 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

> Ben - I think this is a good idea and the letter looks fine to me. Depending on the rapidity of the response, it may be tough to get something organized by the end of the year, but it's worth a try.
>
> Diane
>
> ---
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Wednesday, July 24, 2019 9:10:30 PM
> **To:** Diane Griffin; Hamburg, Margaret
> **Cc:** jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com); Shi, Pei yong (peshi@UTMB.EDU); Lowenthal, Micah; Boright, John
> **Subject:** Letter to CAS to hold next dialogue meeting in Wuhan?
>
> Greetings Diane and Peggy,
>
> I have attached a letter detailing a request to hold a dialogue meeting in Wuhan, China between NASEM and the Chinese Academy of Science (CAS) in cooperation with the Wuhan National Institute of Virology (NIV) of the CAS. Yuan Zhiming, Professor and Deputy Director of the NIV, is very supportive but has let us know that we need to send a formal letter to the President of CAS (as we did before the 2017 meeting in Wuhan) to get approval for the meeting. (Zhiming says that the president is still Bai Chunli but this may have changed recently.)
>
> More broadly (as Diane knows) we had hoped to hold a dialogue meeting with the Kunming Institute of Medical Sciences, Chinese Academy of Medical Sciences (CAMS) but the Kunming Institute leadership is unwilling to seek approval from CAMS to hold a bilateral with NASEM at this time.
>
> The letter includes details about the recent dialogue meetings and outlines the topics we plan to address at the next dialogue meeting. It also includes a proposal to use this meeting to formalize the dialogue as a regular, ongoing activity between NASEM and CAS. I think it's the right time to propose this. It has taken many years to get to this point, after a long period of struggling unsuccessfully to organize meetings between CISAC and the Chinese Biological Scientists Group we have now held several useful, well attended dialogue meetings between NASEM and CAS (with CCDC, CAAS and other institutions involved) and could use those to justify a more formal relationship. We are working with a committed group of Chinese scientists and leaders that are tied formally to CAS (Zhiming, George Gao, others) who recognize the importance of dialogue and communication and who could serve on a Chinese

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008668

organizing committee. In addition, the current political relationship between the U.S. and China has started to affect ad hoc activities like these as well as the willingness of American scientists to travel to China and of Chinese scientists to travel to the U.S. without more formal sanction. This climate only adds to the value of these technical dialogues and frank and open communication among expert colleagues from both sides. I should add that Jim and Dave did mention some concern about this being the right time to seek a formal agreement establishing a formal dialogue. Therefore, I have written the draft text so that the CAS leadership could decline this part of the request if they do not think it is appropriate or the right time to do this.

We look forward to hearing your thoughts on the letter, the meeting and the proposal to formalize the dialogue under NASEM and CAS.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008669

From: 王延轶/Yan-Yi Wang <wangyy@wh.iov.cn>
Sent: Wednesday, October 9, 2019 3:20 AM
To: Shi, Pei yong
Cc: 陈新文; Yuan Zhiming; Bo Zhang
Subject: Re: Wuhan visit from Oct 19 to 21

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all,

I would like to invite all of you to a dinner on the 20th. Please let me know if the time is OK.

Best wishes,

Yanyi

> -----原始邮件-----
> 发件人: "Shi, Pei yong" <peshi@UTMB.EDU>
> 发送时间: 2019-10-05 21:10:55 (星期六)
> 收件人: "陈新文" <chenxw@wh.iov.cn>
> 抄送: "'Yanyi Wang'" <wangyy@wh.iov.cn>, "Yuan Zhiming" <yzm@wh.iov.cn>, "Bo Zhang" <zhangbo@wh.iov.cn>
> 主题: Wuhan visit from Oct 19 to 21
>
> Dear Xinwen,
>
> It was great talking to you yesterday. I look forward to discussing the exciting TBEV project. Please feel free to send me the slides to prepare for the discussion.
>
> Ping and I will arrive in Wuhan at 1:35 pm on October 19. The flight number is China Eastern Airline Flight MU2494. We plan to leave Wuhan on October 21. We look forward to seeing you and the colleagues at WIV!
>
> Best wishes from Galveston!
> Pei-Yong
>
>

--
王延轶

Yan-Yi Wang, Ph.D.

Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126315

Wuhan Institute of Virology

Chinese Academy of Sciences

TEL: 86-27-87198095

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126316

From: Xie, Xuping [xuxie@UTMB.EDU]
Sent: 10/16/2019 12:06:56 PM
To: 周缘 [zhouyuan@wh.iov.cn]; Shi, Pei yong [peshi@UTMB.EDU]; Zhang, Xianwen [zhxianwe@UTMB.EDU]
CC: 陈新文 [chenxw@wh.iov.cn]
Subject: RE: RE: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Hi Yuan,

We are not the member of the ASM. Based on the linker for the payment, it appears Pei-Yong is also not the member of ASM. I would like to wait for Pei-Yong's confirmation.

Best,


Xuping

From: 周缘 <zhouyuan@wh.iov.cn>
Sent: Tuesday, October 15, 2019 10:01 PM
To: Xie, Xuping <xuxie@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; Zhang, Xianwen <zhxianwe@UTMB.EDU>
Cc: 陈新文 <chenxw@wh.iov.cn>
Subject: Re: RE: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all ,How are you?

I need a writer's member name (should be a email) and password on ASM, because members can discount the page fee. I'm not one of the authors,so I can't get a discount even if I pay the membership fee. It's a little expensive(3300 dollars),Please see the picture below.



Your Publication Fees

Fee	Quantity	Unit Price	Total Cost
APC Charges	1	$3,300.00	$3,300.00

Subtotal before optional charges and taxes: $3,300.00

t at the email address in the help information by clicking here .

Yuan

--
周缘
中国科学院武汉病毒研究所
肝炎病毒分子生物学学科组，武汉市武昌区小洪山中区44号

Wuhan Institute of Virology, Chinese Academy of Sciences（WIV,CAS）
44 Xiao Hong Shan, Wuhan,430071, P.R.China
Email: zhouyuan@wh.iov.cn
Phone: 86-27-87197575

-----原始邮件-----
发件人:"Xie, Xuping" <xuxie@UTMB.EDU>
发送时间:2019-10-15 22:04:06 (星期二)
收件人: "周缘" <zhouyuan@wh.iov.cn>
抄送: "Zhang, Xianwen" <zhxianwe@UTMB.EDU>, "Shi, Pei yong" <peshi@UTMB.EDU>
主题: RE: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Dear Yuan,

Thanks. Please let us know if we can assist.

Best,

Xuping

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Tuesday, October 15, 2019 8:59 AM
To: 周缘 <zhouyuan@wh.iov.cn>
Cc: Xie, Xuping <xuxie@UTMB.EDU>; Zhang, Xianwen <zhxianwe@UTMB.EDU>
Subject: RE: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Thanks, Yuan

Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System

From: 周缘 <zhouyuan@wh.iov.cn>
Sent: Tuesday, October 15, 2019 1:52 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Prof.Pei-yong,

I'll deal with it as soon as possible!

Yuan
--
周缘
中国科学院武汉病毒研究所
肝炎病毒分子生物学学科组，武汉市武昌区小洪山中区44号

Wuhan Institute of Virology, Chinese Academy of Sciences（WIV,CAS）
44 Xiao Hong Shan, Wuhan,430071, P.R.China
Email: zhouyuan@wh.iov.cn
Phone: 86-27-87197575

-----原始邮件-----
发件人:"Shi, Pei yong" <peshi@UTMB.EDU>
发送时间:2019-10-14 20:00:19 (星期一)
收件人: "周缘" <zhouyuan@wh.iov.cn>
抄送:
主题: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Dear Yuan,

Please see the forwarded the email. Thanks so much for taking care of it.

Best regards,

Pei-Yong

From: asm.authorservicessupport@cenveo.com <asm.authorservicessupport@cenveo.com>
Sent: Monday, October 14, 2019 4:00 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: asm.authorservicessupport@cenveo.com
Subject: Payment for your upcoming article in mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Pei-Yong Shi,

Your article, Zika virus NS2A-mediated virion assembly (Manuscript # mBio02375-19), is scheduled to be published in issue 6 of mBio.

To facilitate prompt publication of your article, please use this link to the Author Services system to do any of the following:

- Pay publication fees
- Pay additional fees (Open Access, supplemental materials, etc.)
- Order reprints or eprints

https://authorservices.cadmus.com/Shibboleth.sso/Login?entityID=https://login.asm.org/idp/shibboleth&target=/DRIPShopperWeb%2Foffer.do%3FarticleID%3D3087836%26emailAddress%3Dpeshi%40utmb.edu

You may pay by credit card, or purchase order. Doing so will create a printable invoice that you can include with your payment, or submit to your funding institution as a pro-forma invoice. The invoice you create will contain information about payment by credit card, bank wire, or check. You must use this system to create an accurate invoice for payment.

ASM Members receive substantial discounts on publication fees and when ordering reprints and eprints. If you are a current ASM member, these discounts are applied automatically when you log in. If you are just now joining or renewing, we must first receive your payment for the membership discounts to be available.

To join or renew your ASM membership, go to: www.asm.org/join.

If you experience problems with your fees or with the Author Services website, please email ASM.AuthorServicesSupport@cenveo.com.

Thank you,

ASM Reprint/Billing Account Manager.

****

From: 周缘 [zhouyuan@wh.iov.cn]
Sent: 10/19/2019 10:43:04 PM
To: Shi, Pei yong [peshi@UTMB.EDU]; chenxw [chenxw@wh.iov.cn]
CC: Xie, Xuping [xuxie@UTMB.EDU]; Zhang, Xianwen [zhxianwe@UTMB.EDU]
Subject: about the publishingfee of mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all ;

I have already paid the membership fee of $90 , and saved the publishing fee for $900 ! (happy!haha...) I completed the payment of thepublishing.There were some problems logging into the U.S. website those days ,so delayed some time.

By the way,I have changed the invoice information (organization) of publishing fees. But I can't find the invoice about the membership fee. I need to change the organization.

--

周缘
中国科学院武汉病毒研究所
肝炎病毒分子生物学学科组，武汉市武昌区小洪山中区44号

Wuhan Institute of Virology, Chinese Academy of Sciences（WIV,CAS）
44 Xiao Hong Shan, Wuhan,430071, P.R.China
Email: zhouyuan@wh.iov.cn
Phone: 86-27-87197575

-----原始邮件-----
发件人:"Shi, Pei yong" <peshi@UTMB.EDU>
发送时间:2019-10-15 21:59:05 (星期二)
收件人: "周缘" <zhouyuan@wh.iov.cn>
抄送: "Xie, Xuping" <xuxie@UTMB.EDU>, "Zhang, Xianwen" <zhxianwe@UTMB.EDU>
主题: RE: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Thanks, Yuan

Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System

From: 周缘 <zhouyuan@wh.iov.cn>
Sent: Tuesday, October 15, 2019 1:52 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Prof.Pei-yong,

I'll deal with it as soon as possible!

Yuan
--
周缘
中国科学院武汉病毒研究所
肝炎病毒分子生物学学科组，武汉市武昌区小洪山中区44号

Wuhan Institute of Virology, Chinese Academy of Sciences（WIV,CAS）
44 Xiao Hong Shan, Wuhan,430071, P.R.China
Email: zhouyuan@wh.iov.cn
Phone: 86-27-87197575

-----原始邮件-----
发件人:"Shi, Pei yong" <peshi@UTMB.EDU>
发送时间:2019-10-14 20:00:19 (星期一)
收件人: "周缘" <zhouyuan@wh.iov.cn>

抄送:

主题: RE: Payment for your upcoming article in mBio , ms. mBio02375-19

Dear Yuan,

Please see the forwarded the email. Thanks so much for taking care of it.

Best regards,

Pei-Yong

From: asm.authorservicessupport@cenveo.com <asm.authorservicessupport@cenveo.com>
Sent: Monday, October 14, 2019 4:00 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: asm.authorservicessupport@cenveo.com
Subject: Payment for your upcoming article in mBio , ms. mBio02375-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Pei-Yong Shi,

Your article, Zika virus NS2A-mediated virion assembly (Manuscript # mBio02375-19), is scheduled to be published in issue 6 of mBio.

To facilitate prompt publication of your article, please use this link to the Author Services system to do any of the following:

- Pay publication fees
- Pay additional fees (Open Access, supplemental materials, etc.)
- Order reprints or eprints

https://authorservices.cadmus.com/Shibboleth.sso/Login?entityID=https://login.asm.org/idp/shibboleth&target=/DRIPShopperWeb%2Foffer.do%3FarticleID%3D3087836%26emailAddress%3Dpeshi%40utmb.edu

You may pay by credit card, or purchase order. Doing so will create a printable invoice that you can include with your payment, or submit to your funding institution as a pro-forma invoice. The invoice you create will contain information about payment by credit card, bank wire, or check. You must use this system to create an accurate invoice for payment.

ASM Members receive substantial discounts on publication fees and when ordering reprints and eprints. If you are a current ASM member, these discounts are applied automatically when you log in. If you are just now joining or renewing, we must first receive your payment for the membership discounts to be available.

To join or renew your ASM membership, go to: www.asm.org/join.

If you experience problems with your fees or with the Author Services website, please email ASM.AuthorServicesSupport@cenveo.com.

Thank you,

ASM Reprint/Billing Account Manager.

****

From: LeDuc, James W.
Sent: Friday, October 25, 2019 4:49 PM
To: Dave Franz (davidrfranz@gmail.com);Shi, Pei yong;Benjamin Rusek (BRusek@nas.edu)
Subject: NAM new members

Newly elected international members:

George Fu Gao, D.V.M., D.Phil., director-general, Chinese Center for Disease Control & Prevention (China CDC); and director and professor, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. For his contributions to the study of pathogen infection, interspecies transmission, and pathogen-host interaction, and revealing the origin and mechanisms of important pathogens including avian influenza, MERS-CoV, and Zika and Ebola virus.

I guess this is different from his previous recognition.

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008895

From: Shi, Pei yong [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=8906C46397AE48488FCC55537DC5D6D3-SHI, PEI YO]
Sent: 10/27/2019 5:43:44 PM
To: Rusek, Benjamin [BRusek@nas.edu]; David Franz [davidrfranz@gmail.com]; LeDuc, James W. [jwleduc@UTMB.EDU]
Subject: RE: Have a great trip to China!

Hi Ben, Dave, and Jim,

I'm on my way back to Galveston. The trip to China was packed with events and fun.

Oct. 14-17: Conference on "Plants for personalized medicine and aging" in Kunming. The conference focused on the development of Chinese traditional medicine for cancer, chronic disease, and infectious disease. Besides presentations from local and international speakers, the conference also organized hospital visits to discuss with physicians about Chinese medicine as well as field trips to Chinese medicine plantation.

Oct. 18: Visit to "Institute of Medical Biology, Chinese Academy of Medical Sciences" in Kunming. Besides giving a seminar, I had meetings with Qi-Han Li (Director-general), Yan-Chun Che (Head of Research Management), Long-Ding Liu (Group Leader of Vaccine Development), and other PIs. Here are a few take home messages. (i) Their P4 was under final certification in the week of Oct. 20. George Gao, Zhiming Yuan, and other experts were at their institute for the certification. (ii) The Institute mainly focuses on vaccine development and commercialization, with full capability from early development, GMP scale up to product manufacture. This is somewhat like Zhigao Bu' s institute in Harbin. (iii) The institute is scheduled to change its leadership next year. (iv) Compared with CAS, Chinese Academy of Medical Sciences is quite conservative and closely follows the instructions from Beijing Central Government. Points (ii) to (iv) explained why they were hesitant to host the US-China joint meeting. After the leadership transition next year, we may still re-engage them for future US-China joint meetings.

In addition, I brought up the possibility to collaborate on using tree threw as a model for viral pathogen studies. They were supportive and asked us to send brief proposals.

Oct. 19-20: Visit to "Wuhan Institute of Virology." I had meetings with Zhiming Yun, Yanyi Wang (new Director General of the institute), and Xinwen Chen (previous Director General of the institute). The leadership team remained enthusiastic and fully supportive of the next US-China joint meeting. Zhiming said that, due to the current US-China relationship, although CAS had already approved the joint meeting, a special extra step was being processed for the final approval. Zhiming was very optimistic about receiving the final approval soon. He proposed to have the meeting early next year in Huang Gang, a city next to Wuhan (about one hour drive from Wuhan airport).

Oct. 24: Visit to "Nanjing Medical University." I gave a seminar and discussed potential collaborations between UTMB and their institute on research and training. I was also honored to be a visiting professor at Nanjing Medical University.

Oct. 25: Visit to "Southeast University" in Nanjing. I gave a seminar and discussed potential collaborations.

Oct. 26: Visit to "Nanjing Normal University" where I attended college from 1985-1989. We had 30th anniversary college reunion.

I will follow up with Zhiming about the joint meeting again next week. Please let me know if we need a TC to discuss more details.

Best regards,
Pei-Yong

-----Original Message-----
From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, October 25, 2019 11:20 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: Have a great trip to China!

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

Hope your trip is going well. Any update from visit to Wuhan?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

-----Original Message-----
From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, October 11, 2019 10:26 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Have a great trip to China!

Thanks, Ben
Will do.
Best, Pei-Yong
-
-----Original Message-----
From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, October 11, 2019 9:05 PM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Have a great trip to China!

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Pei-Yong,

Sorry about the delay. Good luck in Kunming and Wuhan. If you need any NAS branded info about our planned meeting let me know and I will email. Tell Zhiming I said hi and that I hope he is doing well.

Ben

> On Oct 11, 2019, at 9:38 PM, Shi, Pei yong <peshi@utmb.edu> wrote:
>
> Hi Ben,
>
> Thanks for the email.
>
> My flight got delayed because of the weather in Dallas this morning. They switched me to a very early flight tomorrow morning. So, I'm staying at a hotel near the airport.
>
> The meetings in Wuhan and Kunming have been well planned. Besides Zhiming, I will meet the new director Yanyi Wang (an immunologist) and the previous director Xinwen Chen (who attended the UTMB meeting). In Kunming, I will meet director Qihan Li and give a seminar at his Institute of Medical Biology, Chinese Academy of Medical Sciences. There are other institutions I will visit in Kunming and Nanjing. I will brief you when the trip unfolds.
>
> Have a great weekend!
>
> Pei-Yong
>
> -----Original Message-----
> From: Rusek, Benjamin <BRusek@nas.edu>
> Sent: Friday, October 11, 2019 6:28 PM
> To: Shi, Pei yong <peshi@UTMB.EDU>
> Subject: Have a great trip to China!
>
> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
>
> Hope all goes well. Safe travels.
>
> Ben

From: LeDuc, James W.
Sent: Sunday, October 27, 2019 8:03 PM
To: Shi, Pei yong
Cc: Rusek, Benjamin;David Franz
Subject: Re: Have a great trip to China!

Thanks Pei-Yong. Sounds like a very exciting and productive trip. We can discuss this week if you're in the office. Thanks. Jim

Sent from my iPhone

> On Oct 27, 2019, at 5:43 PM, Shi, Pei yong <peshi@utmb.edu> wrote:
>
> Hi Ben, Dave, and Jim,
>
> I'm on my way back to Galveston. The trip to China was packed with events and fun.
>
> Oct. 14-17: Conference on "Plants for personalized medicine and aging" in Kunming. The conference focused on the development of Chinese traditional medicine for cancer, chronic disease, and infectious disease. Besides presentations from local and international speakers, the conference also organized hospital visits to discuss with physicians about Chinese medicine as well as field trips to Chinese medicine plantation.
>
> Oct. 18: Visit to "Institute of Medical Biology, Chinese Academy of Medical Sciences" in Kunming. Besides giving a seminar, I had meetings with Qi-Han Li (Director-general), Yan-Chun Che (Head of Research Management), Long-Ding Liu (Group Leader of Vaccine Development), and other PIs. Here are a few take home messages. (i) Their P4 was under final certification in the week of Oct. 20. George Gao, Zhiming Yuan, and other experts were at their institute for the certification. (ii) The Institute mainly focuses on vaccine development and commercialization, with full capability from early development, GMP scale up to product manufacture. This is somewhat like Zhigao Bu's institute in Harbin. (iii) The institute is scheduled to change its leadership next year. (iv) Compared with CAS, Chinese Academy of Medical Sciences is quite conservative and closely follows the instructions from Beijing Central Government. Points (ii) to (iv) explained why they were hesitant to host the US-China joint meeting. After the leadership transition next year, we may still re-engage them for future US-China joint meetings.
>
> In addition, I brought up the possibility to collaborate on using tree threw as a model for viral pathogen studies. They were supportive and asked us to send brief proposals.
>
> Oct. 19-20: Visit to "Wuhan Institute of Virology." I had meetings with Zhiming Yun, Yanyi Wang (new Director General of the institute), and Xinwen Chen (previous Director General of the institute). The leadership team remained enthusiastic and fully supportive of the next US-China joint meeting. Zhiming said that, due to the current US-China relationship, although CAS had already approved the joint meeting, a special extra step was being processed for the final approval. Zhiming was very optimistic about receiving the final approval soon. He proposed to have the meeting early next year in Huang Gang, a city next to Wuhan (about one hour drive from Wuhan airport).
>
> Oct. 24: Visit to "Nanjing Medical University." I gave a seminar and discussed potential collaborations between UTMB and their institute on research and training. I was also honored to be a visiting professor at Nanjing Medical University.
>
> Oct. 25: Visit to "Southeast University" in Nanjing. I gave a seminar and discussed potential collaborations.
>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002721

> Oct. 26: Visit to "Nanjing Normal University" where I attended college from 1985-1989. We had 30th anniversary college reunion.
>
> I will follow up with Zhiming about the joint meeting again next week. Please let me know if we need a TC to discuss more details.
>
> Best regards,
> Pei-Yong
>
> -----Original Message-----
> From: Rusek, Benjamin <BRusek@nas.edu>
> Sent: Friday, October 25, 2019 11:20 AM
> To: Shi, Pei yong <peshi@UTMB.EDU>
> Subject: RE: Have a great trip to China!
>
> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
>
> Hi Pei-yong,
>
> Hope your trip is going well. Any update from visit to Wuhan?
>
> Kind regards,
>
> Ben
>
> Benjamin Rusek
> The U.S. National Academy of Sciences
> 1-202-334-3975
>
> -----Original Message-----
> From: Shi, Pei yong <peshi@UTMB.EDU>
> Sent: Friday, October 11, 2019 10:26 PM
> To: Rusek, Benjamin <BRusek@nas.edu>
> Subject: RE: Have a great trip to China!
>
> Thanks, Ben
> Will do.
> Best, Pei-Yong
> -
> -----Original Message-----
> From: Rusek, Benjamin <BRusek@nas.edu>
> Sent: Friday, October 11, 2019 9:05 PM
> To: Shi, Pei yong <peshi@UTMB.EDU>
> Subject: Re: Have a great trip to China!
>
> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
>
> Thanks Pei-Yong,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002722

>
> Sorry about the delay. Good luck in Kunming and Wuhan. If you need any NAS branded info about our planned meeting let me know and I will email. Tell Zhiming I said hi and that I hope he is doing well.
>
> Ben
>
>> On Oct 11, 2019, at 9:38 PM, Shi, Pei yong <peshi@utmb.edu> wrote:
>>
>> Hi Ben,
>>
>> Thanks for the email.
>>
>> My flight got delayed because of the weather in Dallas this morning. They switched me to a very early flight tomorrow morning. So, I'm staying at a hotel near the airport.
>>
>> The meetings in Wuhan and Kunming have been well planned. Besides Zhiming, I will meet the new director Yanyi Wang (an immunologist) and the previous director Xinwen Chen (who attended the UTMB meeting). In Kunming, I will meet director Qihan Li and give a seminar at his Institute of Medical Biology, Chinese Academy of Medical Sciences. There are other institutions I will visit in Kunming and Nanjing. I will brief you when the trip unfolds.
>>
>> Have a great weekend!
>>
>> Pei-Yong
>>
>> -----Original Message-----
>> From: Rusek, Benjamin <BRusek@nas.edu>
>> Sent: Friday, October 11, 2019 6:28 PM
>> To: Shi, Pei yong <peshi@UTMB.EDU>
>> Subject: Have a great trip to China!
>>
>> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>>
>>
>> Hope all goes well. Safe travels.
>>
>> Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002723

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, October 30, 2019 1:38 PM
To: Shi, Pei yong;David Franz;LeDuc, James W.
Cc: Lowenthal, Micah
Subject: RE: Have a great trip to China!
Attachments: Letter to CAS re Wuhan from Griffin and Hamburg.docx; Draft long summary of Harbin Meeting.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the summary for the end of the long Harbin workshop report. I also attached the letter we sent to CAS via Zhiming.

***

THEMES, SUMMARY AND NEXT STEPS

Several themes emerged during the workshop. The first was a focus on the importance of pursuing an integrated, One Health-based approach to understanding the causes and addressing the effects of animal and human diseases. Some of the issues raised included the short-term intended and unintended effects of recent disease control strategies, as well as a need for collaboration amongst experts and across regions on medical, ecological and ecosystems science to ensure human and animal health.

The second was a growing appreciation for the widespread use of gene-editing tools, particularly those based on the CRISPR-Cas9 system, that are being integrated into many new research efforts. New gene editing techniques to cut, edit, activate and repress genes with greater accuracy and at much lower costs go well beyond longstanding methods of selective breeding of hosts and pathogens and allow researchers to quickly explore changes not readily achieved in the past. Although the benefits to society are potentially enormous, there is the potential for malevolent application or for the technology to contribute to dangerous "bioerror," that is, for researchers to inadvertently create a modified organism that has an unintended disastrous impact. Many of the technical talks including those on vaccine development, vector engineering, host engineering, and synthetic biology included details on the researchers' use of gene editing tools and techniques. During the presentations the importance of gene editing to facilitate genetic modifications were highlighted but participants also discussed how they assessed risks and untended consequence of using the tools and best practices to ensure the appropriate and safe use of this technology in the future. See box on Gene Editing below.

A third theme was the importance of establishing and maintaining strong institutional cultures and norms to support the safe and responsible conduct of science. The sessions included several discussions on possible collaborations between Chinese and American scientists and institutions on the responsible conduct of science and other ways to ensure that gene editing techniques are used safely and ethically across the life science enterprise in the future.

Throughout the workshop and during tours of the HVRI security and training centers, experts also shared information to ensure the safe and secure operation of high containment biological laboratories. **Topics discussed included combating emerging infectious diseases in livestock, safely doing research on insect vectors in high biological containment, inactivation/decontamination procedures for African swine fever virus, improving the public health response to disease outbreaks, training and vetting high containment laboratory workers, and the safe and sustainable operation of high containment laboratories.**

NAS has helped to shape the international dialogue on the risks and the multitude of challenges associated with planning for, building, sustaining, and safely and securely running high containment laboratories. Before the meeting the directors of the Galveston National Laboratory (of the University of Texas Medical Branch) and the Wuhan Institute of Virology (of the Chinese Academy of Sciences) jointly published an editorial in Science that calls for the creation of a global network to bring together the leaders of institutes that operate laboratories at the highest biological safety level, BSL-4, to ensure the safe, secure and sustainable operation of these facilities. The final session of the meeting included a discussion on the concept led by the authors of the editorial. During the discussion the director of China's Centers for Disease Control and the leadership of the Chinese institutes that

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051429

operate China's three BSL-4 labs indicated that they support the idea and will work with NAS to develop and create a network. Although there's a tremendous network of BL-3 labs in the U.S., in China and around the world, the group agreed to limit the network to the BL-4 community. Many BSL-4 labs are being constructed around the world, and not all of them are in the most robust economies, if there is a problem or accident in any one lab other labs will suffer. Some of the people that are building these laboratories have government support to build the building but don't have a good idea of what they're going to work on after construction ends and they don't necessarily have the understanding of the incredible cost of keeping the doors open. Operating BSL-4 facilities can be used to show potential operators how to work under BSL-4 conditions. NAS and CAS will work together to planning an international meeting of laboratory leaders to take place later in 2019.

The group also discussed future bilateral meetings. Going forward the groups should continue to think in terms of real partnership, with 50-50 joint funding, joint personal involvement by partners and joint sharing of credit. While safety and security are core issues that we need to continue to discuss, it's really important now that we focus on scientific collaboration and what we can we do together that is going to be of joint interest and beneficial to both China and the U.S. and to our society in general. The meetings should continue to reflect the interests of China and not be a paternalistic relationship, but a true partnership. The next bilateral meeting will likely take place in Kunming, China at the Kunming National Primate Research Center, another Chinese institute that operates a BSL-4 laboratory, later in 2019, it is too difficult to meet in the U.S. due to visa constraints.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

-----Original Message-----
From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, October 27, 2019 6:44 PM
To: Rusek, Benjamin <BRusek@nas.edu>; David Franz <davidrfranz@gmail.com>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: RE: Have a great trip to China!

Hi Ben, Dave, and Jim,

I'm on my way back to Galveston. The trip to China was packed with events and fun.

Oct. 14-17: Conference on "Plants for personalized medicine and aging" in Kunming. The conference focused on the development of Chinese traditional medicine for cancer, chronic disease, and infectious disease. Besides presentations from local and international speakers, the conference also organized hospital visits to discuss with physicians about Chinese medicine as well as field trips to Chinese medicine plantation.

Oct. 18: Visit to "Institute of Medical Biology, Chinese Academy of Medical Sciences" in Kunming. Besides giving a seminar, I had meetings with Qi-Han Li (Director-general), Yan-Chun Che (Head of Research Management), Long-Ding Liu (Group Leader of Vaccine Development), and other PIs. Here are a few take home messages. (i) Their P4 was under final certification in the week of Oct. 20. George Gao, Zhiming Yuan, and other experts were at their institute for the certification. (ii) The Institute mainly focuses on vaccine development and commercialization, with full capability from early development, GMP scale up to product manufacture. This is somewhat like Zhigao Bu's institute in Harbin. (iii) The institute is scheduled to change its leadership next year. (iv) Compared with CAS, Chinese Academy of Medical Sciences is quite conservative and closely follows the instructions from Beijing Central Government. Points (ii) to (iv) explained why they were hesitant to host the US-China joint meeting. After the leadership transition next year, we may still re-engage them for future US-China joint meetings.

In addition, I brought up the possibility to collaborate on using tree threw as a model for viral pathogen studies. They were supportive and asked us to send brief proposals.

Oct. 19-20: Visit to "Wuhan Institute of Virology." I had meetings with Zhiming Yun, Yanyi Wang (new Director General of the institute), and Xinwen Chen (previous Director General of the institute). The leadership team remained enthusiastic and fully supportive of the next US-China joint meeting. Zhiming said that, due to the current US-China relationship, although CAS had already approved the joint meeting, a special extra step was being processed for the final approval. Zhiming was very optimistic about receiving the final approval soon. He proposed to have the meeting early next year in Huang Gang, a city next to Wuhan (about one hour drive from Wuhan airport).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051430

Oct. 24: Visit to "Nanjing Medical University." I gave a seminar and discussed potential collaborations between UTMB and their institute on research and training. I was also honored to be a visiting professor at Nanjing Medical University.

Oct. 25: Visit to "Southeast University" in Nanjing. I gave a seminar and discussed potential collaborations.

Oct. 26: Visit to "Nanjing Normal University" where I attended college from 1985-1989. We had 30th anniversary college reunion.

I will follow up with Zhiming about the joint meeting again next week. Please let me know if we need a TC to discuss more details.

Best regards,
Pei-Yong

-----Original Message-----
From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, October 25, 2019 11:20 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: Have a great trip to China!

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

Hope your trip is going well. Any update from visit to Wuhan?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

-----Original Message-----
From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, October 11, 2019 10:26 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Have a great trip to China!

Thanks, Ben
Will do.
Best, Pei-Yong
-
-----Original Message-----
From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, October 11, 2019 9:05 PM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Have a great trip to China!

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Pei-Yong,

Sorry about the delay. Good luck in Kunming and Wuhan. If you need any NAS branded info about our planned meeting let me know and I will email. Tell Zhiming I said hi and that I hope he is doing well.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051431

Ben

> On Oct 11, 2019, at 9:38 PM, Shi, Pei yong <peshi@utmb.edu> wrote:
>
> Hi Ben,
>
> Thanks for the email.
>
> My flight got delayed because of the weather in Dallas this morning. They switched me to a very early flight tomorrow morning. So, I'm staying at a hotel near the airport.
>
> The meetings in Wuhan and Kunming have been well planned. Besides Zhiming, I will meet the new director Yanyi Wang (an immunologist) and the previous director Xinwen Chen (who attended the UTMB meeting). In Kunming, I will meet director Qihan Li and give a seminar at his Institute of Medical Biology, Chinese Academy of Medical Sciences. There are other institutions I will visit in Kunming and Nanjing. I will brief you when the trip unfolds.
>
> Have a great weekend!
>
> Pei-Yong
>
> -----Original Message-----
> From: Rusek, Benjamin <BRusek@nas.edu>
> Sent: Friday, October 11, 2019 6:28 PM
> To: Shi, Pei yong <peshi@UTMB.EDU>
> Subject: Have a great trip to China!
>
> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
>
> Hope all goes well. Safe travels.
>
> Ben

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Proposed Chinese-U.S. dialogue meeting on the challenges of emerging infections, laboratory safety and global health security in Wuhan, China

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to formally request your permission and support to hold the next in a series of China-U.S. meetings on emerging infections, laboratory safety, and global health security co-convened by the National Academies of Sciences, Engineering, and Medicine (NASEM) and the Wuhan Institute of Virology, Chinese Academy of Sciences (CAS) in Wuhan, China in late 2019 or early 2020.

Over the past several years, Dr. James Le Duc, Dr. David Franz and other representatives of NASEM have worked with Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese scientists to organize a series of meetings, now an informal dialogue, between experts designated by the CAS, China Center for Disease Control (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), the Chinese Academy of Medical Sciences and the NASEM. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the meetings. Meetings have been held in Beijing, Wuhan, Galveston, Texas and most recently the CAAS Veterinary Institute in Harbin, China. In addition to ourselves, participants have included esteemed senior Chinese and American Scientists, such as Gao Fu (CAS, CCDC, NAM), Yi Shi (CAS), Linda Saif (NAS), David Relman (NAM), Bu Zhigao, (CAAS), and many other experts.

During the meeting in Harbin in January 2019, Dr. Le Duc and Dr. Yuan discussed holding a second dialogue meeting in the vicinity of Wuhan. Topics that are proposed for discussion at the meeting include: the special challenges associated with the conduct of regulated studies in biocontainment; response to disease outbreaks; risk assessment of gene editing and other advanced biotechnologies in pathogen research; appropriate institutional oversight of biosafety and biosecurity training and facilities operations; and vector-borne disease research.

With your approval, NASEM and CAS will establish an informal joint organizing committee to plan the next dialogue meeting, invite speakers and participants, and make logistical arrangements. NASEM will pay the air, lodging, and ancillary costs of all the American participants and can contribute financial support for meeting costs in China, if necessary.

This excellent series of meetings could also be used to formalize, via memorandum of understanding and the appointment of a standing organizing committee of Chinese and American experts *The China-U.S. Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security* as a regular, ongoing activity between our two organizations.

China and the United States are world leaders in life science research and development, have large populations that may be susceptible to emerging infections, and are world leaders in public health and response to infectious disease. Both of our countries operate complex high biological containment laboratories that are critical to responding to outbreaks of especially dangerous pathogens. It is important to cooperate and regularly discuss these and other key areas of interest and concern for our two countries and as the life sciences advance, continue to exchange best practices to ensure the safe and secure conduct of the enterprise going forward.

FOIA Confidential Treatment Requested by Univ of Texas System

We look forward to your thoughts on the organization, content, and substance of the dialogue meeting, the proposal to formalize dialogue and any other issues that you and your colleagues wish to address.

Sincerely,

Diane E. Griffin
Vice President, NAS



Margaret Hamburg
Foreign secretary, NAM



...

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research

Harbin Veterinary Research Institute | Chinese Academy of Agricultural Sciences

January 8-10, 2019
Harbin, China



OVERVIEW

To address the interconnected life science challenges associated with combating infectious diseases and further enhance cooperation between China and the United States in the areas of global health, biosafety, and biosecurity, the U.S. National Academy of Sciences (NAS), and the Chinese Academy of Agricultural Sciences (CAAS) in partnership with representatives from other Chinese institutions held the fourth *U.S. China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security* in tandem with a *Workshop on Responsible Conduct in the Use of Gene Editing in Pathogen Research* on January 8-10, 2019 at the CAAS Harbin Veterinary Research Institute (HVRI) in Harbin, China. HVRI is one of three institutes in China that operate a Biological Safety Level-4 (BSL-4) laboratory.

The meeting, ultimately titled *U.S. China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research* was the latest in a series designed to share information on research relevant to combating emerging diseases of concern to the U.S. and China, promote common understanding of high biological containment laboratory safety, security and responsible research risk management, and build relationships among members of the U.S. and Chinese research communities who conduct infectious disease research. The special focus on research that uses gene-editing technology gave the opportunity to

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051435

participants to discuss ways to create norms and reduce risks when using these tools for research

Several themes emerged during the workshop. The first was the importance of pursuing an integrated, One Health-based approach to understanding the causes and addressing the effects of animal and human diseases. The second was a growing appreciation for the widespread use of gene-editing tools, particularly those based on the CRISPR-Cas9 system, as part of many recent research and development efforts. These tools have been used to facilitate a number of the genetic modifications described during meeting presentations (see Box 1 at the end of this document). The final theme running through several presentations and discussions was the importance of establishing and maintaining institutional cultures that support safe and responsible conduct of science. Appropriate scientific community cultures and norms form part of the foundation necessary for achieving success in high-containment infectious disease research. Many of the sessions, summarized further below, provided the opportunity to highlight this area.

INTRODUCTION

On January 8-10, 2019 approximately 45 scientists from the U.S. and China gathered at the Harbin Veterinary Research Institute for a meeting hosted by the Chinese Academy of Agricultural Sciences, Chinese Academy of Sciences, and U.S. National Academy of Sciences. The meeting was the latest in a series of dialogues aimed at sharing information on relevant research conducted in the partner countries, promoting common understanding of high containment laboratory safety and responsible risk management, and building relationships among members of the U.S. and Chinese research communities who conduct infectious disease research.

The following sections summarize the presentations made during the 2.5 day meeting. The agenda and participant list for the meeting is available at the end of this document.

WELCOME AND OPENING REMARKS

The workshop was opened by **Dr. Zhigao Bu**, director of the Harbin Veterinary research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS), who chaired the session of remarks from convening organizations. Dr. Bu welcomed participants to the 4th US - China dialogue on emerging infections, biosafety, and biosecurity. He looked forward to the opportunity to exchange ideas and to promote collaboration and cooperation, and expressed his thanks to the members of the organizing committee for their hard work in preparing the program.

Next, Dr**. Kongming Wu**, Vice president of CAAS, welcomed participants to Harbin and expressed his hope that the dialogue and workshop will make important contributions to the prevention and countering of emerging infectious diseases, along with the promotion of bioethics, biosafety, biosecurity, and laboratory safety. China and the U.S. share many common

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051436

interests in addressing these challenges. Through this meeting and the ongoing dialogue, China and the US are working together to build a shared community that supports public health security in accordance with principles of One Health, an approach that integrates human, animal, and environmental health concerns. Dr. Wu noted that international cooperation has become ever more important in addressing issues in disease research and promoting innovation. CAAS is ready to support fruitful collaborations with the U.S. and with partners around the world, and he wished the workshop success in its discussions.

Benjamin Rusek from the U.S. NAS welcomed the participants on behalf of the U.S. National Academy of Sciences. He noted that the purpose of the meeting is to improve scientific and technical cooperation to address public health threats of mutual concern and interest to China and the U.S., discuss ways to ensure the safe and secure conduct of life science research and high containment biological laboratories, and to build bridges between Chinese and American scientist and institutions. The meeting was designed to especially focus on ways to reduce risk and create norms for research on pathogens using in gene editing technology. Although the benefits of using gene editing technology are potentially enormous, there is the potential for malevolent application or for the technology to contribute to dangerous bio error. He thanked the CAAS for has assembling an excellent group of scientists and experts to Harbin and noted that the scientists from the U.S. Department of Agriculture would not be able to attend due to the U.S. Government shut down but that other members of the U.S. delegation would give their presentations on their behalf. He encouraged everyone to participate and read and use the discussion questions listed on the agenda during every session.

The final welcome address was provided by **Dr. Diane Griffin** from the Johns Hopkins University Bloomberg School of Public Health and Vice President of the U.S. National Academy of Sciences. She emphasized that, as the 4th dialogue of this series, these meetings have played an important role in bringing together scientists interested in addressing the challenges of emerging infectious diseases. Given the global implications of disease outbreaks, the ability to discuss such issues and to stimulate collaboration among scientists is vital. As the meeting moved into its primary scientific sessions, Dr. Griffin also encouraged participants to ask questions and to engage in active discussions over the course of the multi-day meeting.

KEYNOTE ADDRESSES

Keynote presentations were provided by **Dr. George F. Gao**, Academician and Director-General, Chinese Center for Disease Control and Prevention, **Dr. Linda Saif**, Distinguished University Professor, Ohio State University, and **Dr. Hualan Chen**, Academician of the Harbin Veterinary Research Institute.

Dr. Gao provided an overview of China's preparedness for outbreaks of pandemic diseases, particularly influenza, and a look to the future for disease control. He noted that China plays an important role in global public health, but is a relative newcomer to this area. A key approach to disease preparedness and response, emphasized by Dr. Gao and in multiple talks over the course of the meeting is the concept of One Health, in which the veterinary and agricultural

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051437

sciences, as well as human health communities, are collectively engaged to address disease issues.

Influenza remains one of the most serious infectious agent of concern to the China CDC for potential disease pandemics. The 1918 pandemic caused by H1N1, for example, is believed to have originated in China and caused over 40 million deaths worldwide. Pandemics occurred in 1957 (H2N2), 1968 (H3N2) and 2009 (again caused by H1N1, this time emerging in Mexico). Influenza strains can spread rapidly via migrating birds, and as a result, China has focused on developing its disease control capacity, including initiating influenza surveillance systems in the 1950s and joining the World Health Organisation (WHO)'s global surveillance network in the 1980s. Dr. Gao noted that the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS) resulted in further investment and capacity building to support public health, including in laboratory diagnostics and efforts to develop various vaccines, as well as ongoing strong communication with international networks such as WHO and the World Organisation for Animal Health (OIE). In 2010, China collected 200,000-400,000 samples and conducted antigenic analysis on approximately 20,000 viral strains. He pointed to remaining challenges in political commitment and public awareness, including the need for effective risk communication around infectious diseases such as influenza, as well as improved data and sample sharing between animal and human health research communities.

Dr. Saif focused her remarks on coronaviruses, a diverse family of RNA viruses that have four main subtypes (alpha, beta, delta, and gamma) along with a broad host range. The high polymerase error rate and high recombination frequencies in coronaviruses leads to the generation of significant viral diversity and contributes to the emergence of new strains that can have altered tissue tropism, changes in virulence, and ability to infect new hosts. Coronaviruses primarily cause enteric and respiratory infections in mammals and birds, and a number of events have occurred in which viral strains have moved from animal species to humans.

Dr. Saif's presentation emphasized the potential for interspecies transmission of emerging swine coronaviruses. She described aspects of the research conducted by her group on the receptors involved in viral entry into host cells and on genome changes that affect viral properties. For example, the porcine delta coronavirus can infect human cells in culture via the aminopeptidase N (APN) receptor, indicating that there may be possible human susceptibility to this virus. Recently, swine acute diarrheal syndrome was identified in China and may represent a recombination between a bat alpha coronavirus and an unknown beta coronavirus. Her research has also investigated the role of co-infections in disease susceptibility and severity (for example, co-infections with other respiratory pathogens and coronaviruses SARS or MERS). However, many questions remain to be addressed in understanding these and other emerging coronaviruses. There are bird, bat, ruminant, and rodent reservoirs for coronaviruses. Needs include a better understanding of how these viruses circulate among different species and the roles played by the high-density congregation of multiple species and of migratory birds in the process of viral adaptation to new species and the establishment of new reservoirs. Gaining an

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051438

increased knowledge of how particular mutations affect virulence and tropism will also be important to underpin the future development of vaccines and improved response strategies.

Dr. Chen's presentation concentrated on the control of influenza outbreaks caused by strains H5N1 (which first emerged in 1996) and H7N9 (which first emerged in 2013). A number of studies were subsequently undertaken to understand the genetic basis for H5N1 viral properties, such as host range, virulence, and transmission, and to use this information as the basis for developing both inactivated virus and recombinant vaccine platforms for use in poultry. Over 230 billion doses of the poultry vaccines have since been used in China as well as in other countries to support poultry disease control and to help prevent spread of H5N1 to humans.

More recently, extensive efforts in H7N9 disease control have been undertaken in China. Following its 2013 emergence, concerns included whether H7N9 can evolve to become highly pathogenic in poultry and whether it could become human-to-human transmissible as suggested by ferret studies. Dr. Chen's research included studies of mutations in viral HA and PB2 proteins that affect virulence in different species. These genetic mutations detected in chickens affected lethality and transmissibility in ferrets and mice, suggesting potential risks for humans. As a result, China conducted large-scale H7N9 surveillance. During 2017, highly pathogenic H7N9 caused a severe outbreak in chickens and a new (5^{th}) wave of infections in humans with 766 cases reported. Dr. Chen and her group drew on the vaccine platforms developed for controlling H5N1 as a basis for developing avian H7N9 and bivalent H5/H7 vaccines, after which a vaccination campaign was undertaken in chickens. Post vaccination surveillance revealed decreased rates of H7N9 isolation and the vaccination appears to have successfully helped prevent a 6^{th} wave of human infection. These examples illustrate the importance of addressing animal health and of using animal vaccination campaigns to help prevent human disease.

Discussion
The discussion addressed questions on conducting environmental surveillance and the challenges of going from genetic sequence to information on structure and function. It was noted that what can be accomplished depends on available resources, although the Global Virome Project (http://www.globalviromeproject.org/) was pointed out as a valuable example of an international effort. Scientific dialogue, as well as the need to improve data and sample sharing was also discussed, and Dr. Gao highlighted China's productive collaboration with Africa CDC

INFLUENZA
The following sessions of the meeting – on influenza and swine fever – were aimed at promoting further understanding of two serious infectious diseases of concern to both China and the U.S.

Dr. Ralph Baric from the University of North Carolina, Chapel Hill delivered the presentation on behalf of **Dr. David Swayne** from the Agricultural Research Service of the U.S Department of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051439

Agriculture, since Dr. Swayne was unable to participate in the meeting. Reservoirs for avian influenza exit in wild aquatic fowl such as ducks, and can spill over to domestic poultry such as chickens through exposure and adaptation. China and the US are the top two global producers of poultry, and have common interests in controlling disease outbreaks. A number of control strategies have been employed to stamp out outbreaks, including diagnostics and surveillance to identify infected poultry, culling to eliminate infected birds, biosecurity measures aimed at preventing movement of strains between farms and infection of naïve farms, and education about responsibilities to prevent and respond to the disease. But a number of questions remain. These include "How do low pathogenicity avian influenza (LPAI) viruses move from wild waterfowl reservoir to domestic agricultural systems? Can we "predict", based on environmental/management conditions at wild bird-agricultural interface and surveillance data, and intervene to prevent such LPAI virus transfers? Can we better understand & intervene to prevent LP → HP viruses in terrestrial poultry? How do we improve AI eradication within agricultural systems?"

In 2017, highly pathogenic avian influenza (HPAI) was detected in the US. Studies showed that insertion of nucleotides from chicken 28S rRNA in the HA cleavage site in the virus genome was a marker of the emergence of HPAI. Further phylogenetic analysis was undertaken to explore common ancestors and virus introduction events across several states. The results showed that low pathogenic avian influenza (LPAI) strains had been circulating in US poultry farms for several months prior to the HPAI emergence.

Dr. Swayne also provided an example of the global spread of highly pathogenic avian influenza H5N8 in 2014. The virus spread and evolved during the wildfowl breeding season in areas such as Siberia, then moved into Europe and the US along the Pacific coast flyway. Viral reassortment with North American avian influenza strains led to outbreaks in 2014-2015. The example shows how strains can spread around the world and evolve in combination with circulating regional strains. Enhanced surveillance along major flyways and in poultry agricultural systems will be critical to better understand the movement of avian influenza viruses and likely outbreaks, which provide a major incentive for countries to collaborate on disease control. Global networks such as the World Organization for Animal Health and Food and Agricultural Organization Animal Influenza Network (OFFLU) are very important in this context.

Dr. Dayan Wang of the National Institute for Viral Disease Control and Prevention of China CDC discussed additional efforts by China to study and control avian influenza outbreaks. China established its national influenza center (CNIC) in 1957 in the wake of the "Asian flu" and has more recently expanded the national influenza surveillance network so that it now includes over 400 network laboratories and multiple sentinel hospitals covering the major cities of the country. Influenza H5N6 is a current concern because of a high positive rate in poultry along with sporadic human cases.

Dr. Wang's presentation highlighted additional examples of research on H7N9 and H1N1. She noted differences in characteristics of human infections between these viruses – with older

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051440

people, for example, seeming to be more susceptible to infection with H7N9 and an apparent 2:1 male to female infection ratio whose reasons remain unknown, compared to H5N1 that seemed to infect younger adults. Her research on H7N9 has explored genetic variants, receptor binding capacity, tissue tropism, transmissibility in various animal species, and phylogenetic analysis of outbreak strains. Similarly, her laboratory has conducted research on the pathogenicity, tropism, and other viral properties associated with two genotypes of a European (EA) variant of H1N1, in which 12 cases of human infection have been identified since 2010. These two genotypes have similar tropism but show differences in virulence, although there is no clear evidence yet for human-to-human transmission. These ongoing studies will help to clarify the genetic basis for properties of avian influenza viruses and inform additional future research. Dr. Wang also noted that her institute has launched a new journal of Biosafety and Health sponsored by the Chinese Medical Association, and that this may be a publication of interest to the workshop.

Dr. Chengjun Li, a professor at HVRI, delivered the final presentation in this session. He highlighted the virus life cycle and key proteins encoded by the influenza virus genome, as well as host factors that interact with the virus at various stages of the infection process.

For example, the influenza ribonucleoprotein (RNP) complex is a critical functional unit required for viral transcription and replication. The host enzyme phospholipid scamblase 1 (PLSCR1) interacts with both the viral nucleoprotein (NP) and the host protein importin alpha. PLSCR1 interactions impede the interaction of importin alpha with importin beta, which are involved in the import pathway of the virus into the host cell nucleus, inhibiting this process. A second host factor investigated by Dr. Li, the enzyme PIAS1, also interacts with proteins in the import complex. PIAS1 interferes with assembly of the viral RNP complex and inhibits viral polymerase activity. Generation of heterozygous PIAS1 knock out mice results in enhanced pathogenicity as measured by titer and post-infection mortality. Finally, Dr. Li reported on mutations in the H7N9 polymerase that are key determinants of the adaptation of avian influenza virus to mammals. He reported that a mutation in the influenza PB2 protein at position 627 from glutamic acid (E) to lysine (K) was often acquired by avian H7N9 during replication in mammals. Different avian influenza viruses appear to differ in their capacity to acquire this mutation. Research is continuing to investigate mechanisms for this mutation along with other polymerase mutations and interactions with host factors as part of efforts to better understand the biology of the disease.

Discussion

Differences in the ability to control outbreaks of H5N6 versus H7N9 were discussed, including the role of host immune factors and the question of whether the viruses can escape from the inhibition provided by the host immune response. Strategies to control influenza outbreaks were also discussed, including the use of vaccination in chickens compared to culling. Culling has been commonly employed as a strategy in the US. Participants from China indicated that active animal surveillance programs identified influenza virus continuing to circulate even with culling, leading to the decision to undertake vaccination. It was noted that mass vaccination

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051441

campaigns can place new selection constraints on a virus, and it will be valuable to continue disease surveillance and research to understand the effects over time.

SWINE FEVER

The first three presentations in the session focused on African swine fever. The final presentation discussed advances in generating transgenic pig hosts for resistance to classical swine fever.

Dr. Xiaoxu Fan delivered the first presentation on control of African swine fever in China on behalf of **Dr. Xiaodong Wu**, professor at the China Animal Health and Epidemiology Center, as Dr. Wu was unable to attend the meeting. Although Africa Swine Fever (AFS) does not produce disease in humans, it produces virtually 100% mortality in infected animals with no available treatment or vaccine. Endemic in some African countries, AFS has spread globally; it is a notifiable disease by the World Organisation for Animal Health (OIE). China has a large pork industry and the country has undertaken efforts to prevent and control the spread of the virus as well as to develop diagnostics and vaccines. However, the clinical signs of AFS can be similar to classical swine fever and to several other swine diseases, which complicates surveillance and early response. By early 2019, cases of AFS had been reported in 19 provinces.

A number of possible transmission routes to domestic pigs are possible, including from wild boars and imported poultry. The Chinese government released technical guidelines for AFS in 2015 and a contingency plan in 2017. After an outbreak in August 2018, over 30 new disease-related policies were enacted. Efforts to prevent and control outbreaks include the deployment of field working groups, culling of over 600,000 pigs, and an awareness campaign for farmers, veterinarians, and the public. The government has also increased incentives for reporting, such as by increasing compensation. Two factors were identified as key in outbreak transmission – swill feeding and movement of live pigs and pig products. Banning swill feeding, reducing long distance/cross-province movement of animals, and cracking down on animal smuggling through customs have been important parts of control strategies. Other policies require slaughterhouses to run ASF tests on pig products before sale, cracking down on practices such as illegal slaughtering, and strengthening efforts such as confirmation testing to combat cases in domestic pigs and wild boar. Strong multisector collaboration will be needed to address ASF, including international collaboration on prevention and control strategies with partners such as the UN Food and Agriculture Organization (FAO), OIE, and other countries.

Dr. Zhigao Bu of HVRI provided additional information on the genetic analysis and properties of African Swine Fever. AFS is a large double-stranded DNA virus whose host is domestic pigs and wild boars. AFS is the number one killer of pigs, with approximately 58,000 cases in 22 countries in 2018. Because China has over 50% of the pigs on hand and pigs to market worldwide, this disease is of significant concern. Dr. Bu discussed an outbreak at several sites in Heilongjiang province in 2018, and reported phylogenetic comparison of the strains with those from other AFS outbreaks. In addition, researchers at HVRI successfully isolated the virus and conducted infection tests in pigs in high containment laboratory facilities to study properties such as

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051442

incubation time, viremia/titers, virus shedding, and time to death. As expected, the AFS strain was highly lethal.

Dr. Bu noted reports of two deletion mutations - delta CD2V and delta DP148R – that might attenuate the virus and could be candidates in the development of vaccines. However, results suggest that the mechanisms of pathogenicity are complicated and the mutant strains did not necessarily result in attenuated virulence plus protection against ASF challenge in pigs.

Dr. Pei-Yong Shi of the University of Texas Medical Branch, Galveston delivered the final presentation on African Swine Fever. He presented on behalf of **Dr. Douglas Gladue** of the U.S. Department of Agriculture's Plum Island Animal Disease Center, who was unable to attend. As noted in the prior presentation, the immune mechanisms associated with protection from African Swine Fever have not yet been identified, no commercial vaccine is available, and the mechanisms of protection associated with experimental vaccines are not well understood.

Dr. Gladue's research includes strategies to more efficiently develop and purify recombinant ASF virus as part of the development of live attenuated viral vaccines. Current processes can take up to two years. Dr. Gladue's group incorporated a fluorescent reporter gene to improve identification of the recombinant plasmid and used CRISPR/Cas9 editing to delete the locus 8DR. The protein encoded by this locus is involved in viral rosette formation and the deletion enabled them to quantify the extent to which use of CRISPR/Cas9 increased the rate of obtaining desired genetic changes. Dr. Gladue reported that combining the florescent marker and 8DR deletion enabled them to achieve significant increases in the efficiency and speed of generating, identifying and purifying recombinant virus, which could thus be produced in 3-4 months instead of years. These results demonstrates the possibilities enabled by using gene editing to engineer AFS. Finally, Dr. Gladue provided information on the use of live attenuated viral vaccines to combat the current AFS outbreak strain. Multiple deletion mutations have been created and studied, including delta 9GL, delta MFG, the double mutant delta 9GL/MFG, delta UK and the double mutant delta 9GL/delta UK, and delta CD2 for both viral attenuation and the ability to induce protection when administered as a live vaccine. However, alternatives will need to continue to be explored along with further collaborations to combine the advantages of various platforms.

The last presentation in the session was provided by **Dr. Hongsheng Ouyang**, a professor at Jilin University, who focused on the generation of genome-edited pigs as part of efforts to understand and control classical swine fever virus. Dr. Ouyang's research makes use of the tools enable by CRISPR/Cas 9 to edit genes. There are currently two main methods for generating genome edited pigs – direct microinjection of Cas9 mRNA and single guide (sg)RNA into zygotes and somatic cell nuclear transfer. Edited embryos are then implanted into surrogate pigs, resulting in the birth of edited piglets.

Dr. Ouyang focused on efforts to design and screen a short hairpin RNA (shRNA) that, when expressed in the pig genome, would act to target and silence the infecting virus. A plasmid containing the sequence that would produce this shRNA along with the CRISPR/Cas9 machinery

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051443

was introduced into the nucleus of a pig cell via electroporation, followed by somatic cell nuclear transfer and the generation of edited piglets whose cells produce the designed interfering RNA molecule. The aim was to generated edited pigs that would be resistant to classical swine fever. Challenge experiments were conducted in which both wild type and edited pigs were exposed to a swine fever-infected pig. During swine fever infection, the transgenic pigs exhibited greater antiviral responses than the wild type, unedited pigs. Dr. Ouyang also investigated whether mutations or deletions in the LamR receptor, which is the cellular receptor for classical swine fever, could result in pigs resistant to swine fever infection. The generation of transgenic pigs and initial tests in cell culture showed some resistance but more remains to be investigated.

Discussion

Questions were directed to the issue of what needs to be done to prepare for and control African Swine Fever. To date, there have been limited studies on T cell responses and neutralizing antibody titers are not closely correlated with protection, indicating that significant work remains to understand the biology and immunology of ASF infection. The need to implement traditional control strategies was noted, while research toward vaccine development continues. For example, swill feeding and long distance pig transportation have been factors in prior outbreaks, leading to changes to policies and practices.

UNDERSTANDING AND ENGINEERING VIRAL PATHOGENS WITH PANDEMIC POTENTIAL

The remainder of Day 1 focused on science and responsibility in studying pathogens with pandemic potential. The sessions included a discussion of challenges and opportunities in altering pathogen properties as part of research into understanding and combating disease, as well as the responsible planning and conduct of such research so that it can be conducted safety and securely.

Dr. Ralph Baric, a professor at the University of North Carolina Chapel Hill and an expert in coronaviruses, provided an overview of the selection and design of pathogen properties, along with information gaps and barriers. He noted the rapid pace of advance and decreasing cost of nucleic acid synthesis; the first coronavirus to be synthesized cost roughly $42,000, a price that would now be $6,000. The largest genome currently synthesized is a 520kb mycobacterium, indicating that it is now possible to synthesize the genomes of most RNA and DNA viruses. In addition, high fidelity sequences are available for many viruses, rendering it possible to synthesize viral genomes and recover viable virus for many strains.

Studies to alter pathogen properties of viruses can use several approaches, including selection pressure to drive evolution toward a phenotype as well as deliberate design. Potential opportunities might include building chimeric viruses with altered structures for the receptor for viral entry, or those that incorporate changes to other virulence determinants or that modulate host-pathogen interactions. Dr. Baric noted the example of adding the spike protein

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051444

from a mouse coronavirus to a bat coronavirus, which can produce a strain that is more virulent in mice. But he cautioned that a combination of techniques, including selection pressure from passaging in mice, is generally needed to generate virulent strains in a host and reminded the audience of the law of unintended consequences and the possibility of surprise.

Dr. Baric also noted that predictive modeling of protein interfaces and the use of such models for structure-guided virus design has recently improved, providing advancing capabilities for affecting host-virus interactions and altering antigenic properties. Similarly, he noted that the "shopping list" of virulence determinants continues to grow as more is learned about host-virus interfaces and how they evolve as viruses move through different species. As examples of both potential opportunities and ongoing barriers to effective engineering of viral properties, Dr. Baric referenced studies to develop a self-replicating alphavirus containing HIV sequences for use as an HIV vaccine, an approach that was abandoned when the virus was too pathogenic in mice. He also noted the barrier provided by a glycosylation site that makes it relatively easy to create mouse-adapted SARS strains but not mouse-adapted MERS. And the use of newer tools such as CRISPR/Cas-based gene editing to create a mouse model by introducing the human virus binding receptor domain into the mouse. On the other hand, creating a virus that is super-adapted to a particular host can actually result in an attenuation of virulence, if the virus interacts overly strongly with a cellular receptor. This shows the complexity of deliberate design as well as a potential sweet spot for pathogenicity. Other challenges to deliberate design include the fact that a large number of virus-host protein interactions occur, and changing one can have unexpected effects across the interaction networks as virus-host interactions are usually a "highly coordinated co-evolved process." Viral packaging constraints, the effects of host genetic variation on disease severity, and other factors all add to the complexity and confound the utility of predictive design models.

The second presentation in the session was delivered by **Dr. Weiwen Zhang**, professor at Tianjin University, who spoke about cutting-edge biotechnology, the potential for rapid changes in science and technology capabilities to outpace ethical and regulatory measures, and the need for appropriate governance. He provided the example of recent synthesis and preparation of horsepox virus from starting genetic sequence as illustrative of what could now be achieved at relatively low cost with fairly standard technical approaches. Past oversight has been based primarily on physical control of materials such as viral strains, but access to information such as gene sequences is of increasing importance. Many countries have made significant investments in synthetic biology R&D – in China, for example, a national key program for 2018-2011 will support 50-60 projects of $3-4M each. But achieving the right balance of research innovation and governance to prevent ethical, security, or other misuses of biotechnology is challenging and it can be difficult to separate positive uses from potential misuses (a "dual use dilemma"). A number of reports and continuing global dialogues address ethics and safety associated with new technologies such as synthetic biology and genome editing, and consider related aspects such as laboratory precautions and development of strategies that could mitigate harmful effects (for example, to reverse genetic changes). Following debate, the 2016 Human Genome Project-Write (HGP-W) has become Genome Write (not just human) and the project established an international bioethics and biosafety working group. The international genetically

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051445

engineered machines (iGEM) competition for students has also focused increasingly on ensuring biosafety, biosecurity, and risk management of projects undertaken by iGEM teams.

China has undertaken a number of efforts to promote and support responsible research and governance. For example, the synthetic biology society of China formed an ethics committee in 2018. The Ministry of Science and Technology has also established an ethical and regulatory framework for synthetic biology with goals of (1) establishing norms for research and market access and making government regulatory policy recommendations; (2) proposing effective safety management norms and implementation methods; (3) establishing public channels of communication and public participation; and (4) developing intellectual property mechanisms relevant to synthetic biology. Tianjin University established programs on ethics associated with new biotechnology in 2018. China and Pakistan have also put forward a proposal to the Biological Weapons Convention on a code of conduct for biological scientists. Dr. Zhang noted that identification and management of potential dual use issues should occur early in a relevant research project as well as various stages throughout the research life cycle stages, with responsibilities by multiple stakeholders; existing regulatory policies and laws are also frequently under discussion. These conversations within the scientific and government communities are ongoing.

A separate discussion session was not held following these talks; see the panel discussion "Science and Ethics in Research with Pathogens with Pandemic Potential," below

BIOETHICS AND RESPONSIBLE PLANNING FOR PATHOGEN RESEARCH

Dr. Zhiming Yuan, professor at the Wuhan Institute of Virology, discussed the value of learning from outbreaks such as SARS and Ebola and the role of the network of global high containment laboratories in efforts to improve global health security and strengthen public health systems. The BSL-4 laboratory at Wuhan, which announced its operation in early 2018, is part of this overall system. Prior to operation, significant time was spent on design and validation of the laboratory, which successfully received accreditation by China National Accreditation Service (CNAS). Projects being undertaken at the laboratory include on Crimean-Congo hemorrhagic fever virus and Nipah virus, along with synthetic biology studies manipulating proteins from Ebola and Nipah viruses. The facility also provides services in virus preservation, diagnostics, animal model development, education, and training.

Dr. Yuan echoed comments made by prior presenters emphasizing the role of governance for dual use research of concern (for example, the use of use of biotechnology to alter host responses to pathogens). He noted the existence of Chinese laws such as Article 331 Criminal Law of the People's Republic of China, relevant regulations and guidelines, and foundational ethical principles such as non-malfeasance, and stated that "ethics is a necessary supplement to the law" in preventing misuse. As part of the responsible planning and conduct of pathogen research, both national and institutional ethics review committees are commonly established. Dr. Yuan noted, however, that many bioethical committees still have a limited focus, such as on the protection of human subjects in biomedical research. Biorisk extends beyond this narrow

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051446

focus. It is a multi-stakeholder issue and there are a number of questions to consider when assessing benefits versus risks of a research effort. Biorisk management thus exists at an intersection that draws on biosafety, biosecurity, policy, ethics, society, economics, and science, animal and human health. Key players who need to be involved in these discussions include scientists, publishers, funders, accreditation bodies, and others while biorisk management occurs at multiple stages of a project from conception, preparations, application, and implementation to publication. He supported the need to establish a code of conduct for scientists and the importance of establishing a global network of biosafety laboratories to enable sharing of best practices, collaboration, and information exchange.

Dr. David Relman, a professor at the Stanford School of Medicine, continued the discussion of benefits and risks in pathogen research. He noted the imperative to understand and anticipate emerging infectious diseases in order to prepare for, prevent, and respond to them, along with the growing technical capabilities in the biosciences.

Dr. Relman highlighted the importance of the critical combination of pathogenicity and transmissibility, which affect the harm something can do and the means by which it can be disseminated. He also noted the need to understand things that have arisen in nature compared to things that have been created by human design. Dr. Relman suggested that the scientific community can learn from the global virome project, which is expanding viral discovery and generating large amounts of sequence information. The project will provide a more complete understanding of biodiversity and may inform diagnostics and therapeutics development. For example, analysis of the data collected may identify new pathogens or help to predict potential virulence factors. But in an era in which most viruses can be synthesized from a genetic sequence, the discovery new viruses and elucidation of their properties may present both biosafety and biosecurity concerns. As scientific and technical capabilities continue to expand, Dr. Relman emphasized the power and responsibility of the individual, along with recognition that the decisions investigators make about the research they undertake can have consequences. It is very difficult to quantify risks and benefits or to gain agreement on what should be done, but he suggested that a focus of assessment and decision-making should be the purpose of the work and end state product, not the means or process by which it is achieved. Dr. Relman noted that scientists routinely make decisions on experiments to undertake, or not to conduct, for all sorts of scientific and economic reasons. This type of calculus should be going on with regard to security as well. He supports transparency, the use of experimental design choices aimed at minimizing risks, and establishing research norms. There are roles in these efforts not only for individual researchers but also professional organizations, academia, and industry; national leadership; and international organizations. Finally, he noted that no matter how much we prepare some failures will occur. We need to be prepared to respond to such situations, emphasizing complementary strategies for risk reduction.

Finally, **Dr. Yang Xue**, Associate Professor at Tianjin University, highlighted the announcement in late 2018 of CRISPR-edited human babies and the resulting scientific and social criticism. Both international ethical frameworks and national regulations are relevant to the

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051447

considerations of biosecurity management and the encouragement of a culture of responsibility in life sciences. In the first case, documents such as the Declaration of Helsinki from the World Medical Association (2013) and International ethical guidelines for biomedical research involving human subjects (CIOMS 1993) support respect for individual welfare. There are also a number of relevant policies, regulations, and guidelines in China that could apply to the human genome editing situation. These include Ethical Guiding Principles for the Research on Human Embryonic Stem Cells (2003), Interim Measures for the Administration of Human Genetic Resources (2012), the Ethical Review of Biomedical Research Involving People (2016), and others. Institutions involved in biomedical research should set up ethics committees and file information with the practicing registration authority. In addition, they should follow Administrative Measures for the Safety of Biotechnology Research and Development Cell such as abiding "laws and administrative regulations, respect social ethics, and not harm…" (2017). Dr. Xue also presented the draft model code of conduct proposed by China and Pakistan to the Biological Weapons Convention. Finally, Dr. Xue shared some thoughts on pressures and factors that may have affected the project to create CRISPR edited babies, including publicity achieved by Dr. Junjiu Huang of Sun Yat-Sen University in 2015 for his use of genome editing for thalassemia in non-viable, non-implanted embryos. Rapid development and regulatory systems that have not necessarily kept pace with capabilities may also play roles.

A separate discussion session was not held following these talks; see the panel discussion "Science and Ethics in Research with Pathogens with Pandemic Potential," below

SCIENCE AND ETHICS IN RESEARCH WITH PATHOGENS WITH PANDEMINC POTENIAL (PANEL DISCUSSION)

The panel and meeting participants discussed the importance of institutional and scientific community cultures, along with research oversight systems, in promoting safe and ethical research.

Speakers and participants indicated that the research community has a number of responsibilities in this regard, including an awareness of potential risks and careful experimental planning. Research with pathogens can have unintended consequences because living systems are complex and unanticipated results can arise from experimental changes. There have been examples in which pathogenicity has been accidentally enhanced though experiments, thus it is important for researchers to recognize that they may not fully understand the systems they are changing, to reflect on potential risks during the experimental design stage, and to manage for the possibility of risks though use of appropriate containment levels.

Panelists and participants also discussed the role of researcher motivations and community norms for responsible conduct of research. It was suggested that researchers are often motivated by scientific curiosity, a quest for knowledge, and a desire to help others through their research, as well as a desire for respect and recognition from their scientific contributions. But it was also noted that researchers can be under pressure to produce results and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051448

publications, and may also be motivated by financial interests and a desire for fame and influence. One participant suggested that the scientific community has not had enough discussion about how the varying motivations, incentives, and disincentives for researchers influence the ethical, safe, secure, and responsible practice of science. Other participants agreed and suggested that researchers need to keep in mind not only scientific aims but also the broader objectives of the research and the ethical and regulatory context for their experiments.

It was suggested that research laboratories and the scientific community need to continue to foster cultures that recognize that unintended results can occur from experiments, that promote the need to think through how to respond when unintended findings arise, and that provide community and peer pressure to behave within expected norms of ethics, biosafety, and biosecurity. A number of panelists and participants suggested an important role for education and training for scientists in these issues. One participant also noted that relevant education and training will need to reach beyond students from traditional life sciences disciplines to include those with engineering, computational sciences, or other backgrounds who are increasingly involved in biotechnology projects.

In addition, speakers and participants discussed the importance of institutional oversight systems for research. It was suggested that one important question for the scientific community and research institutions remains how to go about deciding what experiments to conduct and not to conduct. Through review boards, research institutions have important oversight roles as part of this process. It was suggested that institutions need to have review meetings and debates so that the institution is able to consider relevant experiments, such as those involving pathogens. In addition, review boards need to have the expertise to ask detailed questions on proposed protocols. And it was noted that there need to be strict consequences for researchers who breach the institutional policies. Finally, several participants noted the need for balanced oversight systems and regulations that will enable the conduct of appropriate experiments and research projects while preventing or minimizing misuse. It was suggested that responsible research infrastructures and cultures are already well-established in certain settings, but that there is an important role for continuing to further develop and foster these systems in other settings.

Finally, the panelists and participants briefly considered the DIY bio community and the question of what experiments could be conducted with basic scientific knowledge outside of traditional laboratory settings. For example the potential to synthesize fentanyl was raised. On the other hand, it was noted that research with pathogens still remains largely within more advanced laboratories. In general, however, it was suggested that as biological technologies become more and more accessible, there will be a continued need for outreach on review procedures around which experiments are conducted and under what conditions, as well as the broad promotion of norms of biosafety and biosecurity.

VECTOR AND HOST ENGINEERING: SAFETY AND SECURITY

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051449

The second day of the conference opened with a session on research in vector and host engineering. **Dr. Qian Han**, professor at Hainan University, provided the first presentation. He discussed the mosquito innate immune system, referred to as melanization, a process that is also involved in wound healing and cuticle formation in addition to response to infection. Dr. Han presented the conversion pathway of the key substrate tyrosine to melanin, which includes enzymes prophenoloxidase (PPO) and dopachrome conversion enzymes (DCE). Mosquitos have "mosquito specific" PPO genes that catalyze tyrosine reactions, along with other, typical insect PPOs. DCE converts dopachrome to 5,6 dihydroxyindole (DHI), a molecule with high antibacterial activity. The enzyme arylalkylamine N-acetyltransferase (aaNAT) is also involved in melatonin synthesis and perhaps other functions; similar to PPO mosquitos have a greater number of aaNAT and aaNAT-like enzymes than other insects. The substrate specificity for mosquito-type aaNAT remains unknown and the laboratory is continuing to study this area.

Dr. Han's lab has used CRISPR/Cas9 genome editing tools to generate Aedes aegypti mosquitos with nucleotide deletions leading to knock out of DCE activity. They have also generated knock out aaNAT1 mosquitos. The laboratory is interested in studying whether the editing affects the mosquito's immune response to viral infection and are looking for collaborators in this area, as they do not have the facilities for viral infection studies.

Dr. Stephen Higgs, professor in the College of Veterinary Medicine at Kansas State University provided an overview of best practices in safely and security when conducting laboratory experiments with insect vectors. He provided an extensive list of reference papers on the topics of his talk (that was provided to HVRI after the meeting).

A number of excellent references are available on the design of laboratory insectories (including a recent paper from 2007) and the arthropod containment guidelines (2003). Insectories at BSL-3, for example, need to include practical safety and security features such as airflow specifications, secure access, signage, self-closing doors, prevention of two doors being open at same time, and screens to prevent insect escapes. Other references address experimental best practices and protocols for studies using insect vectors of disease (such as a 2006 guide). For example, an artificial blood meal chamber on top of insect cages can now be used to better simulate warm blood feedings. A number of resources are also available on practices in dissecting mosquitos, quantifying virus titer, collecting saliva, and conducting analysis, among other topics.

As projects involving transformed insect vectors potentially move out of the laboratory environment and into controlled field release trials, additional considerations become important. Dr. Higgs noted 2002, 2008, and 2014 guidance discussing planning for controlled trials, including trial design and cage placement, the types of data that should be collected, and the importance of community engagement. Since the emergence of CRISPR/Cas9 genome editing, progress in engineering various insect species has been rapid; by 2018 a gene edited mosquito for reduced malaria competence had been created. Editing to create gene drive modified vectors presents special circumstances (see Box 1) and a 2017 publication discusses

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051450

operating procedures for gene drive research. Finally, he noted that a revised version of the key 2003 arthropod containment guidelines will be published in 2019 to include the latest context of technical advances. A special issues of the journal *Vector Borne and Zoonotic Diseases* will also be released in early 2019 and may be of interest to the workshop.

Dr. Tongyan Zhao from the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences discussed vector competence for mosquito borne viruses including Dengue, West Nile, Western Equine Encephalitis, and Zika. Dengue has become a particular issue in the tropical forest border area of the Yunnan province, and the laboratory was interested in investigating whether the mosquito species Culex pipiens quinquefasciatus could serve as a vector (along with known vectors Aedes albopictus and Aedes aegypti). Blood feeding experiments revealed a virus binding protein in the midgut of Aedes species that was not identified in Culex. They also found that Dengue virus could survive in dipausing Aedes albopictus eggs, a strategy to survive overwintering. As a result, they have not found evidence to suggest that Culex is a vector for Dengue.

Similarly, the laboratory has investigated whether Culex species are potential vectors for West Nile Virus, WEE virus, and Zika virus through blood feeding and transmission studies. Culex tritaeniorhynchus, found widely in China, showed the highest vector competence for Dengue among the Culex species studies. Aedes species are also vectors for this disease. All mosquito species tested were susceptible to infection with WEE virus, including Culex tritaeniorhynchus, which is also an efficient transmission vector for Japanese Equine Encephalitis. For Zika, Aedes aegypti showed higher infection rates in salivary glands, midgut and ovary than Ae. albopictus and Cx. pipiens quinquefasciatus, though species such as Cx. pipiens quinquefasciatus can also transmit Zika to baby mice. This information on which mosquito species can be infected and transmit particular viral diseases will be valuable in informing the development of control strategies.

Finally, **Dr. Gong Cheng**, a professor at Tsinghua University, discussed arbovirus infection in Aedes and Culex mosquitos. During a typical arbovirus lifecycle, virus in host blood enters the mosquito gut environment, which has an abundant community of commensal bacteria. Dr. Cheng's laboratory thus investigated whether and how mosquito gut microorganisms affect viral replication. Use of antibiotics to eliminate gut bacteria in Ae. Aegypti led to reduced Dengue virus replication, while oral reintroduction of the isolated cultivatable bacterial species identified the bacteria Serratia marcescens as facilitating infection. The laboratory identified a secreted protein peptidase, named M60 Viral Enhancin, as key to the mechanism of action. Introducing this protein into the gut of antibiotic-treated mosquitos enhances infection with Dengue virus as well as other arboviruses such as Zika. Engineering the bacteria to knock out the enhancin protein abolished this infection-enhancing effect.

Dr. Cheng reported that the enhancin protein was first identified in baculoviruses, where it digests mucin polysaccharides and enables virus to more easily reach gut epithelial cells. It appears that the S. marcescens enhancin functions in a similar way. Both elimination of gut mucins and oral introduction of S. marcescens in field-derived mosquitos enhances viral

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051451

infection. S. marcescens has been identified in the gut of field caught mosquitos, and gaining further knowledge of this and other mechanisms that promote arbovirus infection in mosquitos is valuable for future public health and disease control research.

Discussion

During discussion a question was asked on the generation of transgenic insects in which the melanin enzymes were knocked out. It was noted that the survival rates were low, and there was a suggestion that pathways involving melanin enzymes are also involved in eggshell formation. A question was also asked on whether other gastrointestinal commensal bacteria that Serratia affect viral infection. It was noted that a number of bacteria in addition to Serratia encode an enhancing protein, or components in host blood such as microRNA might affect replication; a number of different avenues are being studied. The issue of managing ticks under biocontainment was raised and it was noted that ticks are more difficult to work with than insects such as mosquitoes because of their longer lifecycles and existence of few artificial feeding systems to aid in replacing the need to feed on animals. The emphasis in biocontainment is on preventing ticks, particularly larval ticks, from escaping. Finally, the release of gene drive modified organisms was discussed. The regulatory process for releasing gene drive modified organisms can be quite complicated, as approvals may need to be sought not only from the country of release but also from adjacent countries. There have been efforts to develop guidelines, but with the likely near-term releases of gene drive modified mosquitoes it is very important to continue to develop agreement around internationally recognized guidelines, norms and standards.

UPDATE ON ACCUTE FLACCID MYELITIS

The next session provided an update on a topic that has been receiving significant recent attention in US because of an ongoing outbreak – the disease acute flaccid myelitis. **Dr. Diane Griffin**, a professor at the Johns Hopkins University Bloomberg School of Public Health, reviewed what is known about the etiology of this disease, which is primarily identified in children and can cause rapid onset of paralysis with incomplete recovery. Gray matter spinal cord lesions are observed on MRI, particularly in the cervical area and upper extremity, though effects in the lower regions are seen as well. A prodromal febrile illness is also a common feature prior to onset of the weakness. Developing a definition that distinguishes acute flaccid myelitis from alternative diagnoses such as transverse myelitis and spinal cord ischemia has been important and a revised "restricted" definition was published in 2018. Disease outbreaks appear to have biennial periodicity with case peaks in the summer and fall of 2012, 2014, 2016, and 2018. Cases have occurred across the US as well as in ~20 countries.

Scientists and clinicians are still exploring the cause of this disease and extensive culturing and sequencing of samples from patients have been undertaken. No consistent cause has yet emerged. Although the illness presents similarly to Polio, it is not cause by poliovirus. The leading hypothesis so far centers on enterovirus EV-D68, which was first detected in California in 1962 as a cause of respiratory illness. Declared a "reemerging pathogen of disease concern,"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051452

there are some indications that EV-D68 has acquired mutations that make it more neurovirulent than the virus observed in early isolates. Should the two year pattern continue, the medical community might expect another outbreak in 2020. It will be important to continue to study and understand this disease, and to consider whether a vaccine should be developed.

Discussion

The question was raised on the existence of animal models for investigating acute flaccid myelitis. It was noted that a mouse model exists, involving inoculation of baby mice with the virus. However, more work needs to be done in developing mouse models to better understand viral pathogenesis and the roles of the acquired mutations in affecting disease characteristics.

BEST PRACTICES IN LABORATORY SAFETY AND SECURITY FOR PATHOGEN RESEARCH

Dr. Joseph Kanabrocki, a professor of microbiology and associate vice president for research safety at the University of Chicago, opened the session. He emphasized that having a scientific understanding of the research being conducted is important for appropriate oversight and encouraged institutions to employ scientists in roles such as his. In his view, this expertise is important in helping establish a positive institutional culture and the right balance of oversight.

Dr. Kanabrocki provided a brief review of the US policy landscape in biosafety and biosecurity. The BMBL and NIH guidelines for recombinant and synthetic nucleic acid long provided two core documents on laboratory safety. Concerns surrounding access to certain pathogens led to the creation of Select Agent policies in the 1990s. Since 2012, the US has also enacted policies for federal and institutional oversight of "dual use research of concern" (DURC). Debate over "gain of function" experiments with influenza H5N1 resulted in a funding pause on a subset of research projects. Subsequent scientific and government discussions eventually led to new policy guidance on "Potential Pandemic Pathogen Care and Oversight (P3CO)." Implementation of this guidance by the Department of Health and Human Services, the primary U.S. agency that would be involved in relevant studies, resulted in a framework that includes agency review, reporting, and risk management processes for projects that make use of the 15 agents and toxins currently designated "potentially pandemic pathogens."

Dr. Kanabrocki turned to how the University of Chicago has enacted these policies as a major research-conducting institution, providing an example of how an institution can undertake responsible safety and security oversight of its activities. In response to the US policies, the University created a DURC task force with members from its existing two institutional biosafety committees (IBCs). Task force members include investigators and biosafety and biosecurity experts, as well as those in university administration, providing valuable cross representation. Significantly, the university expanded its screening to include projects beyond the list of 15 mandated P3CO agents and toxins. Investigators complete online questions on the nature of their research and may have further conversations with the DURC task force based on their answers. As part of its institutional management of DURC research, the task force also provides

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051453

risk management recommendations in areas such as the design and conduct of projects, often in consultation with the US government funding agency. Reviews for DURC are conducted at the grant proposal and manuscript preparation stages and on an annual basis for those projects determined to have DURC components. These reviews focus on the potential for the research to yield information that could be misused to cause threats to public health and safety or to national security, as well as the benefits of the research. How to communicate the results of studies identified as DURC is one area in which it is important to be careful and considerate. For example, it is important in public communication to convey the beneficial reasons why the research was undertaken as well as the biosafety and biosecurity measures that were followed; certain information may also need to be redacted in light of security concerns.

In addition, Dr. Kanabrocki noted that the University requires all investigators working with the pathogens and toxins designated as Select Agents (a longer list than the 15 P3CO pathogens) to adhere to an ethical Code of Conduct that is signed annually and discussed during annual interviews. The code expects investigators to report mishaps including "near misses." The university is also considering requiring reporting of unanticipated laboratory results. The University has developed an iPhone/Android app for easily reporting incidents and quickly responding to them. These, along with other factors, have been important in establishing an institutional culture in which investigators can seek out DURC and biosafety advice in a collaborative fashion and that contribute to early identification and mitigation of any potential concerns.

Dr. David Franz, the retired former commander of the US Army Medical Research Institute of Infectious Diseases (USAMRIID) provided his perspective on the role of leaders in promoting laboratory safety. He emphasized the importance of building safety into the system and of the leader communicating that safety is a priority. The scientific community has both a tradition and an important responsibility of self-governance. In the US, however, various incidents associated with laboratory accidents or carelessness, as well as concerns over potential misuse, have been followed by new guidelines or regulations that attempt to prevent such incidents from occurring. Thus, "a malevolent or thoughtless act by an individual or small group can slow the entire enterprise."

For the leader of an institution, safety is one of many responsibilities. As a result, Dr. Franz emphasized that, in his experience, leaders need to rely on the skills of a competent biosafety professional to help scientists problem-solve when needed and to empower them to do their work well. This culture of trust and support among the leader, the biosafety professional, and the researchers is critical. An organization's culture should make people feel comfortable asking questions and seeking help when needed, while not being overly punitive. A research system needs to strike the right balance among safety and security, scientific progress, and regulatory control. Dr. Franz suggested that creating such cultures might play a role in strengthening regulatory authorities' view that the scientific community is behaving responsibly and help to reduce potential bureaucratic overreach.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051454

Dr. Franz concluded by sharing how leaders can build this culture of trust at their institution by leading with science. Leaders also need to be technically competent to be able to understand what people are doing.

Finally, **Dr. Peijun Zhai**, a professor from the China National Accreditation Service for Conformity Assessment (CNAS), provided an overview of biosafety laboratory management and accreditation in China. He began by briefly reviewing biosafety regulations. These include "Biosafety regulation on pathogenic microorganism laboratories," which were first published in 2004 and have been subsequently revised. Under Article #20, these regulations include that BSL 3 and BSL 4 laboratories will be accredited by an authorized body. Article 37 of "Regulation on certification and accreditation" provides that the accreditation body will be designated by the accreditation regulatory department of State Council.[1] In China, CNAS plays this laboratory accreditation role. Dr. Zhai noted that this system is different that the US, in which there are many accreditation bodies.

There are a number of additional Chinese regulations relevant to biosafety laboratories, such as "Law on the Prevention and Control of Infectious Disease," "Law on Evaluation of Environmental Effects," "Law on Sanitation & Quarantine on Country Board," and others. Dr. Zhai noted that there are categories of laboratory accreditation, including for testing laboratories, calibration laboratories, medical laboratories, proficiency testing laboratories, and producers of reference materials, as well as for biosafety level laboratories. For some of these types of laboratories, ISO, IEC or other international standards exist. The accreditation standard CNAS follows for BSL laboratories is based on China national standards GB19489-2008 and GB50346-2011, and follows the CNAS guidance documents CNAS-RL05 (rules for accreditation of laboratory biosafety) and CNAS-CL05 (further criteria and guidance documents). The general process of BSL accreditation is in accordance with the standard ISO/IEC17011n and includes an application from the laboratory, audit and on site assessment process, approval, and the granting of a certificate. Periodic surveillance and reassessment is also required. For BSL 4 (P4) laboratories, surveillance is conducted every 12 months, with reassessment for accreditation taking place every 5 years. Dr. Zhai concluded by emphasizing, "accreditation is playing an important role in normalizing laboratory management and evaluating laboratory competence."

Discussion

The discussion addressed the challenges of balancing potentially competing interests in achieving scientific results as well as ensuring safety and security. The important roles of laboratory management, biosafety professionals, scientists, and students and trainees were all noted. The importance of creating an interactive and integrated culture was highlighted, in which safety should not be seen as impeding the best science – these reinforce each other as part of responsible science.

ONE HEALTH IN CHINA

[1] https://wwwnc.cdc.gov/eid/article/25/5/18-0220_article

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051455

The utility of a One Health concept in addressing disease was a theme underlying a number of presentations and discussions during the meeting. **Dr. Harish Menghwar** provided an overview of the role of One Health in the Guangdong province of China on behalf of **Dr. Jiahai Liu**, a professor at Sun Yat-sen University, who was unable to attend.

The Guangdong province has a subtropical climate, diverse wildlife and livestock populations, is on migratory bird flyways, hosts a number of disease vector species, and has a food culture that consumes an array of animal products. Dr. Menghwar provided examples of recent outbreaks. For example, the source for SARS in 2002 was contact among infected bats and uninfected civets in markets while outbreaks of H7N9 are closely linked to markets with live poultry. Brucellosis, which causes disease in cattle, goats and sheep is considered endemic in the province. Guangdong is also the province most affected by Dengue virus, with all four subtypes identified in samples. The geographic range of Dengue has increased in recent years, and Guangdong has served as a hot spot enabling disease spread to other areas. Control strategies, such as closure of poultry markets in the case of H7N9, have had only temporary effects with cases reemerging when markets reopen. As a result, there is a general need to identify additional interventions and means of control for disease outbreaks. Dr. Menghwar emphasized the need for a multidisciplinary approach to the challenge of emerging infectious diseases. This approach will need to incorporate medical, ecological and ecosystem health, and animal health experts, to be cross-sectoral, and to occur across regional interfaces. Active surveillance of human – animal – environment interfaces and exposures will be important. Such an integrated approach can help to better identify causes and achieve reductions in transmission of diseases.

CHINESE BIOSAFETY, BIOSECURITY, AND BIOETHICS

The final two presentations on day 2 highlighted additional efforts by Chinese researchers and institutions to address laboratory safety issues.

Dr. Jiancheng Qi, a professor at the National Biological Protection Engineering Center, provided the first presentation. China has released a number of biosafety standards and has developed laboratory and research equipment to support the conduct of experiments in accordance with such safety guidelines. This includes personal protective equipment (PPE), related equipment such as masks, isolators, and biosafety cabinets, and decontamination and waste treatment equipment. They have also developed mobile laboratories, including a vehicle-mounted BLS 3 laboratory. Dr. Qi noted that the design and successful commissioning of BSL 4 laboratories such as the one at the Harbin Veterinary Research Institute reflects China's independent ability to provide for the highest biosafety level research. China is also assuming a global role in facilitating the safe conduct of research in partner countries. For example, equipment such as class II biosafety cabinets have been provided to laboratories in Sierra Leone and to a Sino-Kazakhstan laboratory, while the equipment for high temperature alkaline hydrolysis has been provided to Cuba for use in its vaccine laboratories. A mobile laboratory also was deployed in Africa during the Ebola outbreak.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051456

Dr. Yunzhang Hu, a professor at the Institute of Medical Biology in Kunming, further discussed the development of high containment laboratory capacity in China. He noted that China's 2006-2020 national plan on prevention and control for important infectious diseases included pillars on the development of new drugs and vaccines and on an emergency response system. High containment laboratory infrastructure is critical to these research and development efforts. China has established three BSL 4 (P4) laboratories - in Wuhan, Harbin, and Kunming. The laboratories at the Institute of Virology in Wuhan and at the Harbin Veterinary Research Institute are operational, while the "Kunming National Primate Research Center of High Level Biosafety" at the Institute of Medical Biology is proceeding through the process. It just received its certificate from the China National Accreditation Service (CNAS), the designated laboratory accreditation body. The facility will include laboratories at BSL (P) 2, 3, and 4. The P4 laboratory will include 7 principle investigators and 4 functional departments, including departments of biosafety management and of training.

Dr. Hu shared information on plans for the P4 laboratory once it is operational. It is intended that the laboratory will support national emergency response capacity for emerging infectious diseases. It will provide a platform for vaccine research and development, which is a traditional focus of the Institute; the new P4 capacity will enable the Institute to combine high containment research with the vaccine platform components. The desire is for the facilities to provide an efficient pipeline that includes virus isolation, animal model testing, studies to understand pathogenesis, and development of rapid detection methods. These will feed into downstream vaccine processes such as evaluations of safety and efficacy, clinical trials, new drug certification, and GMP production and marketing. The facility will also serve as pathogen seed bank and information center for important infectious diseases. Finally, the facility can be a regional resource and support opportunities through China's One Belt One Road efforts. As the high containment laboratory completes its final processes and becomes operational, Dr. Hu emphasized that ensuring a culture of biosafety will be very important to their success.

Discussion

During discussion, a question was asked on the process for developing the new vaccines at the Kunming Institute. It was indicated that basic research directed toward vaccine development is done within the Chinese Academy of Medical Sciences or in collaboration with others, depending on the particular diseases, and that the researchers are working only with rhesus monkeys, not in other types of primates. A question was also asked about emergency management. It was noted that China CDC has primary responsible for emergency response and management, and technicians from the Institute can accompany China CDC into the field as needed.

CHINESE PERSPECTIVES ON EMERGING INFECTIOUS DISEASES

The last day of the meeting provided an opportunity to learn more about innovative research on infectious diseases being conducted by laboratories in China.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051457

Dr. Changjiang Weng, professor at HVRI, discussed the inflammatory response in host cells resulting from entry of RNA viruses. A protein complex in host cells (the inflammasome) binds to viral genomic RNA and activates downstream enzymes leading to the production of the cytokine Il-1 beta. Dr. Weng's laboratory explored in more detail the interaction of RNA from porcine reproductive and respiratory syndrome virus (PRRSV) with the protein NLRP3 as part of the inflammasome complex. His group identified a helicase protein called DDX19A that binds to both components. In addition, the laboratory studied whether DDX19 could regulate production of the immune system cytokine interferon (IFN). In this case, experiments showed that DDX19 disrupts phosphorylation of the cellular protein IRF3 and blocks its interaction with another protein as part of the IFN signaling pathway. Thus, DDX19 leads to suppression of IFN while DDX19 knockdown experiments lead to enhanced IFN production. In future directions, the laboratory will study additional cellular inflammasome complexes affecting production of inflammatory cytokines in response to RNA virus infection.

Dr. Zhengli Shi, a professor at the Wuhan Institute of Virology, provided information on Middle East respiratory syndrome (MERS)-related coronavirus and cases in China. MERS emerged in recent years in the Arabian Peninsula, though it may have been circulating in its natural reservoirs for some time. It shares a number of genomic similarities with SARS virus, including the importance of the viral spike protein that binds to cellular receptors as part of viral entry. For MERS, the human cellular receptor to which the spike binds is DPP4.

There are multiple MERS-related coronaviruses, including strains in clades A and B that cause human infection, camel MERS viruses, and bat MERS-related coronaviruses including the related bat coronavirus HKU4. Dr. Shi's laboratory explored diversity in the MERS spike binding domain for its role in interspecies infection ability. A recombinant MERS containing the spike binding domain from HKU4 could replicate in human cells. Many strains of MERS-related coronaviruses are prevalent in multiple bat host species in China. The potential for interspecies transmission highlights the need for long-term surveillance of this group of viruses.

Dr. Wen Dang of the Lanzhou Veterinary Research Institute provided a presentation on foot and mouth disease (FMD) vaccine development. He delivered the presentation on behalf of **Dr. Haixue Zheng**, a professor at the Lanzhou Institute, who was unable to participate. FMD is a highly infectious virus that affects cloven-hoofed animals such as pigs and cattle. Current FMD vaccines have low efficacy and outbreaks can have significant economic cost; in addition to vaccination, current control strategies include quarantine and slaughter of animals. An improved FMD vaccine that can provide rapid and long lasting protection has been needed.

Dr. Dang discussed the Lanzhou laboratory's efforts to design attenuated seed viruses for use in FMD vaccine production. They explored the effects of a number of deletions in regions of the virus including 3A and PK, and in particular the effects of 43-nucleotide and 86-nucleotide deletions to create strains rO-DPKs43 and rO-DPKs86. These showed decreased pathogenicity when tested in cattle, but not in pigs. Studies of a mutation in region VPI found decreased pathogenicity in swine, so the laboratory tested a strain that included both PKS and VP1 mutations. They also examined the effects of a mutation in VP3 that may increase the host

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051458

immune response to FMD, resulting in earlier response and higher antibody titers in pigs. These efforts led to the design of various master seed stocks and cell lines for FMD vaccine production. The Institute has produced bivalent (O and A serotypes) and trivalent vaccines (O, A, Asia 1 types) against FMD. Dr. Dang indicated that FMD vaccine safety and efficacy have been improving and outbreaks of FMD in China have been declining, with China currently free of type Asia 1 and aiming to be free of type A by 2020.

Dr. Longding Liu from the Institute of Medical Biology of the Chinese Academy of Medical Sciences discussed enterovirus 71 (EV71), which causes outbreaks of hand, foot and mouth disease (HFMD) worldwide. The disease primarily causes lesions on skin and oral mucosa although serious side effects such as encephalitis can occur in some cases. As part of efforts to understand the biology of this virus and to develop a vaccine, a neonatal rhesus monkey model has been developed.

Dr. Liu's laboratory created a fluorescently labeled EV71 virus. During early stages of infection, the virus appeared in tracheal and bronchial epithelial cells, was subsequently identified in pulmonary lymph nodes, and by later stages could be identified around blood vessels of the olivary nucleus of the brainstem. Studies indicate that EV71 may have the ability to degrade cell junction proteins to increase penetration into the brain. There is also a suggestion that the subset of dendritic cells positive for CD141 are involved in transferring the virus from areas such as lymph nodes to the endothelial cells of the blood brain barrier. EV71 appears to proliferate in astrocytes rather than in neurons. The Institute subsequently created a viral vaccine seed stock that underwent human clinical trials and demonstrated protection in children. Market approval was obtained and Dr. Liu reported decreased mortality in China from HFMD.

Dr. Chengfeng Qin from the Institute of Microbiology and Epidemiology at the Academy of Military Medical Sciences provided the final presentation in this session, which focused on Zika virus. Zika is a flavivirus related to Dengue, West Nile, and yellow fever. It was first isolated from the Zika forest in Uganda around 1950. Since 2007, there have been infections in over 80 countries. Recent outbreaks have highlighted concern over cases of microcephaly, and direct injection of Zika virus into mouse brain can lead to reduced cerebral size, enlarged ventricles, and thinner cortex in infected mice. Zika virus replicates in the ventricular zone and infects neural progenitor cells but not differentiated glial cells and neurons. Analysis of Zika strains, particularly mutation S139N that first appeared in 2013 and subsequently spread in the Americas, shows enhanced neurovirulence compared to older strains.

Using this knowledge, Dr. Qin's laboratory has explored whether Zika virus could have application in the treatment of the cancer glioblastoma, which is an aggressive and hard to treat tumor that can show chemo- and radiotherapy resistance and recurrence. The laboratory created a live attenuated Zika virus vaccine strain, ZIKA-LAV. Testing in mice has shown promise including extended glioblastoma survival time. Studies tracking the virus in mice show it localized to mouse brain. These results suggest that it may be possible to develop this approach

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051459

further and to combine it with chemo and radiotherapy as part of efforts to provide glioblastoma treatment options.

Discussion

During discussion, a question was asked about disease surveillance in camels for MERS. It was indicated that MERS CoV was not detected in camels in China, but that Chinese camels are a different species from dromedary camels. With regard to the EV71 vaccine, the question was asked about testing for possible interference with other vaccines on the immunization schedule. It was answered that yes, testing to understand any possible effects in relation to the current schedule of childhood vaccines in required as part of the licensing process. A question was asked about the number of strains against which the FMD vaccine cross protects. It was noted that China's primary focus is on addressing the type A strain, and cross protection has not yet been investigated against other global strain types. Finally, a question was asked on the structural biology of S139. It was noted that a mutation can affect the interaction of S139 with a receptor on neuronal progenitor cells and affect viral replication, but research is still ongoing to explore this question.

SPECIAL SESSION (SYNTHETIC BIOLOGY)

The last session of the workshop covered two areas of progress in synthetic biology. **Dr. Chunbo Lou**, a professor at the Institute of Microbiology of the Chinese Academy of Sciences, first provided the first presentation. Methods enabling the manipulation of large nucleic acid fragments (over 30kb) are of assistance in the construction of gene circuits and organisms using synthetic biology. This scale of manipulation, for example, overlaps with a number of natural product gene clusters (10-150kb) and viruses (5-200kb). Dr. Lou's laboratory has focused on a method called Cas 9-assisted targeting of chromosome segments (CATCH). The positive rate of obtaining recombinant plasmid obtained through their process of RNA-guided Cas9 cleavage depends on the insert size; for a 50kb fragment, for example, the positive rate is roughly 60%. Dr. Lou also reported simultaneous editing to insert promoters or make other changes to five target locations in a gene cluster, with a 10% success rate.

Based on these tools, the laboratory is aiming to manipulate components of gene clusters in bacteria to affect transcription, translation, and/or cell-cell communication by turning on or off gene expression. They have designed components including a promotor, a chimeric transcription factor, and DNA binding site with the aim of eventually using these as part of a biosensor. Quorum sensing is a type of cell-cell communication in which changes in gene expression are affected by signaling molecules released and detected in response to cell density. The laboratory undertook de novo design of signaling molecules to turn on and off the gene for, made alterations to HSL molecules, and undertook directed evolution to generate significantly greater sensitivity than the natural system. They hope to combine multiple signaling molecules in three- and four- signal cellular communication systems in future efforts to design and control bacterial sensors. Such sensors can be engineered to make the bacteria

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051460

produce or recognize something, with the details dependent on the specific applications selected.

The second presentation also addressed fundamental research in synthetic biology and was provided by **Dr. Xiaoli Xue**, a professor in the Laboratory of Synthetic Biology at the Shanghai Institute of Plant Biology. Her research focused on eukaryotic chromosome evolution and the question of whether the number of chromosomes in eukaryotic cells can be changed, using yeast as an example organism. By fusing the 16 chromosomes found in budding yeast, her laboratory sought to generate a viable, single chromosome organism. She reported using CRISPR-Cas9 editing and homologous recombination to delete the extra yeast chromosome centromeres and telomeres and to ligate the chromosomes in pairwise fashion. There was also concern not to affect the expression of genes nearby these altered regions. Ultimately, a single chromosome yeast strain SY14 was created.

Fusing the wild type yeast chromosomes into a single, large chromosome resulted in drastic changes to the 3-D structure of the genome, from distinct chromosomes to a twisted globular configuration. Although wild type inter-chromosomal interactions were lost, local chromatin interactions appeared to be similar in the SY14 strain. The laboratory identified only 28 differentially expressed genes. The yeast was able to grow and showed similar overall morphology to wild type, although competition experiments showed that SY14's growth was slower. The creation of SY14 was recently published; Dr. Xue noted that the laboratory of Dr. Jef Boeke at New York University published a paper in the same journal issue reporting creation of a two-chromosome yeast, although the two groups used different approaches in their efforts.

Finally, Dr. Xue reported on further experiments to fuse the ends of the large single chromosome to create a yeast circular chromosome. This effort resulted in the creation of strain SY15. SY15 cells grew slower than SY14, showed a higher number of abnormal cell shapes, and were unable to produce viable spores. However, they did not exhibit the telomerase-dependent cellular senescence that wild type and SY14 strains did. She wondered whether efforts to understand circular eukaryotic chromosomes such as the SY15 might ultimately help to understand rare human ring chromosome syndromes.

Discussion

The question was asked about potential applications associated with the single chromosome yeast strain and the ongoing synthetic quorum sensing research. That the single chromosome yeast strain has been provided so far to over 30 research groups who have requested it, and it was noted further information on applications may arise. With regard to the quorum sensing system, the researchers hope to further develop their synthetic system in the future by exploring the ability to build a system similar to a multicellular organelle.

THEMES, SUMMARY AND NEXT STEPS

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051461

Several themes emerged during the workshop. The first was a focus on the importance of pursuing an integrated, One Health-based approach to understanding the causes and addressing the effects of animal and human diseases. Some of the issues raised included the short-term intended and unintended effects of recent disease control strategies, as well as a need for collaboration amongst experts and across regions on medical, ecological and ecosystems science to ensure human and animal health.

The second was a growing appreciation for the widespread use of gene-editing tools, particularly those based on the CRISPR-Cas9 system, that are being integrated into many new research efforts. New gene editing techniques to cut, edit, activate and repress genes with greater accuracy and at much lower costs go well beyond longstanding methods of selective breeding of hosts and pathogens and allow researchers to quickly explore changes not readily achieved in the past. Although the benefits to society are potentially enormous, there is the potential for malevolent application or for the technology to contribute to dangerous "bioerror," that is, for researchers to inadvertently create a modified organism that has an unintended disastrous impact. Many of the technical talks including those on vaccine development, vector engineering, host engineering, and synthetic biology included details on the researchers' use of gene editing tools and techniques. During the presentations the importance of gene editing to facilitate genetic modifications were highlighted but participants also discussed how they assessed risks and untended consequence of using the tools and best practices to ensure the appropriate and safe use of this technology in the future. See box on Gene Editing below.

A third theme was the importance of establishing and maintaining strong institutional cultures and norms to support the safe and responsible conduct of science. The sessions included several discussions on possible collaborations between Chinese and American scientists and institutions on the responsible conduct of science and other ways to ensure that gene editing techniques are used safely and ethically across the life science enterprise in the future.[2]

Throughout the workshop and during tours of the HVRI security and training centers, experts also shared information to ensure the safe and secure operation of high containment biological laboratories. Topics discussed included combating emerging infectious diseases in livestock, safely doing research on insect vectors in high biological containment, inactivation/decontamination procedures for African swine fever virus, improving the public health response to disease outbreaks, training and vetting high containment laboratory workers, and the safe and sustainable operation of high containment laboratories.

[2] Although the meeting agenda was not designed to focus on human gene editing, the research project led by He Jiankui, formally an associate professor in the Department of Biology of the Southern University of Science and Technology in Shenzhen, China that lead to the birth of two children with edited DNA was universally condemned by the meeting participants.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051462

NAS has helped to shape the international dialogue on the risks and the multitude of challenges associated with planning for, building, sustaining, and safely and securely running high containment laboratories. Before the meeting the directors of the Galveston National Laboratory (of the University of Texas Medical Branch) and the Wuhan Institute of Virology (of the Chinese Academy of Sciences) jointly published an editorial in Science that calls for the creation of a global network to bring together the leaders of institutes that operate laboratories at the highest biological safety level, BSL-4, to ensure the safe, secure and sustainable operation of these facilities. The final session of the meeting included a discussion on the concept led by the authors of the editorial. During the discussion the director of China's Centers for Disease Control and the leadership of the Chinese institutes that operate China's three BSL-4 labs indicated that they support the idea and will work with NAS to develop and create a network. Although there's a tremendous network of BL-3 labs in the U.S., in China and around the world, the group agreed to limit the network to the BL-4 community. Many BSL-4 labs are being constructed around the world, and not all of them are in the most robust economies, if there is a problem or accident in any one lab other labs will suffer. Some of the people that are building these laboratories have government support to build the building but don't have a good idea of what they're going to work on after construction ends and they don't necessarily have the understanding of the incredible cost of keeping the doors open. Operating BSL-4 facilities can be used to show potential operators how to work under BSL-4 conditions. NAS and CAS will work together to planning an international meeting of laboratory leaders to take place later in 2019.

The group also discussed future bilateral meetings. Going forward the groups should continue to think in terms of real partnership, with 50-50 joint funding, joint personal involvement by partners and joint sharing of credit. While safety and security are core issues that we need to continue to discuss, it's really important now that we focus on scientific collaboration and what we can we do together that is going to be of joint interest and beneficial to both China and the U.S. and to our society in general. The meetings should continue to reflect the interests of China and not be a paternalistic relationship, but a true partnership. The next bilateral meeting will likely take place in Kunming, China at the Kunming National Primate Research Center, another Chinese institute that operates a BSL-4 laboratory, later in 2019, it is too difficult to meet in the U.S. due to visa constraints.

****

BOX 1
GENE EDITING

Gene editing involves altering the DNA of a cell or organism. Modifications can include deletions, insertions, or other changes to the genetic code, generally carried out to change characteristics of a gene's expression. A particular edit might aim to "knock out" the gene and render it non-functional. Alternatively, precise changes to the nucleic acid sequence may be

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051463

made to affect properties of the protein that results from the gene's transcription and translation. Edits are carried out for a number of other purposes, as well.

Researchers have been making alterations to nucleic acid sequences for many years, but tools developed since approximately 2012 – particularly the CRISPR-Cas9 editing system – have significantly increased the flexibility, efficiency, accuracy, speed, and ease (including lower cost) of making these changes. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas9 (CRISPR-associated protein 9) were discovered in bacteria, where they form part of an immune mechanism for responding to infection. The basic system has since been adapted and repurposed as a key research tool and the use of gene editing is now widespread in research laboratories (Doudna and Charpentier 2014). A designed guide RNA sequence aligns with and binds to a target DNA sequence in the genome. The Cas9 protein then makes a double strand DNA cut. This cut can be repaired in various ways, including end joining or filling in with a donor DNA template to lead to sequence alterations.

Approximately a third of the presentations during the workshop referred to CRISPR and Cas9-based gene editing tools in some fashion. The key areas discussed during the workshop included (see presentation summaries for more detail):

- **Vaccine development efforts**. Use of gene editing to generate an attenuated version of a double-stranded DNA virus (Gladue)
- **Vector engineering**. Use in generating a mosquito that lacks an immune system associated enzyme (Han)
- **Host engineering**. Introduction of a human receptor domain into the mouse to create a model for viral infection (Baric); Creation of a pig designed to be resistant to a viral disease of interest (Ouyang)
- **Synthetic biology**. Design of gene circuits in bacteria to produce or respond to signaling molecules (Lou); Changes to eukaryotic genome organization to create a single chromosome yeast (X. Xue).
- **Ethics**. Considerations for responsible use and governance of gene manipulations in synthetic biology (W. Zhang) and in human genome editing applications (Y. Xue).

Professor Steven Higgs also briefly discussed a special use of CRISPR-Cas9 in the creation of a gene drive. Gene drives "are systems of biased inheritance in which the ability of a genetic element to pass from a parent to its offspring through sexual reproduction is enhanced" (NASEM 2016). The design of these systems includes a mechanism in which an edited gene can be copied to its homologous chromosome and will continue to spread as the organism reproduces (Esvelt et al. 2014). The advent of CRISPR-Cas9 genome editing enabled scientists to create a gene drive and the field has continued to progress rapidly, with gene drive modified mosquitos reported by late 2015 (Gantz et al., 2015). Scientists are exploring genetically modified and/or even gene drive modified insect vectors as one strategy for control of devastating insect-borne diseases. But if used in this way, modified insects ultimately would be released from the laboratory into an ecosystem. Special considerations arise from use of modified species in open field trials and potential deployment. Researchers will need to

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051464

understand not only how a modification affects the target population, but also how it affects the broader ecological community. A number of reports have discussed scientific, ethical and social considerations, particularly around gene drives (for example, NASEM 2016), while funders and scientists are developing norms to guide responsible use (Emerson et al. 2017). Dr. Higgs highlighted these special considerations in his presentation on the use of insect vectors for infectious disease research.

References

CIOMS. 1993. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Council for International Organizations of Medical Sciences.

Doudna, J. A. and E. Charpentier. 2014. The new frontier of genome engineering with CRISPR-Cas9. *Science* 346(6213): 1077 and 1258096.

Emerson, C., S. James, K. Littler, and F. Randazza. 2017. Principles for gene drive research. *Science* 358(6367):1135-1136.

Esvelt, K. M., A. L. Smidler, F. Catteruccia, and G. Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. *eLife* 3:e03401.

NASEM (National Academies of Sciences, Engineering, and Medicine). 2016. Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values. Washington DC: The National Academies Press

Gantz, V. M., N. Jasinskiene, O. Tatarenkova, A. Fazekas, V. M., Macias, E. Bier and A. A. James. 2015. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. *Proceedings of the National Academy of Sciences* 112(49):E6736-E6743.

NASEM 2017. Human Genome Editing: Science, Ethics, and Governance. Washington DC: The National Academies Press

People's Republic of China. 2017. Administrative Measures for the Safety of Biotechnology Research and Development Cell.

Shao, Yangyang et al. 2019. A single circular chromosome yeast. Cell Research, 29, 87-89. Available at: https://www.nature.com/articles/s41422-018-0110-y#Bib1. Accessed on 29 April 2019.

USG. 2012. United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern. Available at: https://www.phe.gov/s3/dualuse/Documents/us-policy-durc-032812.pdf. Accessed on 26 April 2019.

USG. 2015. United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern. Available at: https://www.phe.gov/s3/dualuse/documents/durc-policy.pdf. Accessed on 26 April 2019.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051465

World Medical Association. 2013. Declaration of Helsinki. Available at: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/. Accessed on 26 April 2019.

****

Sessions and Presentations

Keynote addresses

- Oversight for Research on Viral Pathogens with Pandemic Potential – the Perspective from China
- Emerging Swine Coronaviruses and their Interspecies Transmission
- Vaccination in Poultry Eliminated Human Infections with H7N9 Virus in China

Influenza

- Collaborating on Influenza Research from the U.S. perspective
- Human Infection with Zoonotic Influenza
- Interactions between Influenza Viral RNP Complex Proteins and Host Cellular Factors

African swine fever

- Current Situation and Control Strategy of African Swine Fever in China
- Characterization of African Swine Fever Virus Isolated from China
- ASFV Vaccine Status: Rapid Production of Recombinant ASFV for Live Attenuated Vaccines
- Genome-edited Pigs Protected From Classical Swine Fever Virus

Understanding and engineering viral pathogens with pandemic potential

- Advances in Understanding and Altering Pathogen Properties
- Cutting Edging New Biotechnology: Strategies and Tools for Engineering

Bioethics and responsible planning for pathogen research

- Biosafety and Bioethics in Medical Research
- Bioethical Considerations for the Conception and Design of pathogen Research and Approaches for Assessing Potential Risks and Benefits of Research
- Biosafety and Bioethics Considerations in Dual-Use Risks Management - China's Efforts and Future Works

Vector and host engineering: safety and security

- Biochemical Pathway of a Mosquito Innate Immunity, Melanization
- Best Practices in Safety and Security for Working with Arthropods that Serve as Pathogen Vectors, Including Responsible Research with Gene Drive Modified Vectors
- Vector Competence of Emerging Mosquito Borne Virus in China
- A Gut Commensal Bacterium Promotes Arbovirus Infection in Mosquitoes

Acute Flaccid Myelitis

- Review of what is currently known about the cause of Acute Flaccid Myelitis

Best practices in laboratory safety and security for pathogen research

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051466

- Institutional Review and Oversight for Research on Viral Pathogens with Pandemic Potential - a U.S. Perspective
- The Role of Leaders in Laboratory Safety: Culture and governance to steer toward behavior changes
- Overview of Laboratory Biosafety Management System in China

One Health in China

- Understanding how a One Health Approach is Shaping Research to Understand and Address Viral Pathogens in China

Chinese biosafety, biosecurity, and bioethics

- Development and Application of Laboratory Biosafety Equipment in China
- Kunming National Primate Research Center of High-Level Biosafety

Chinese perspectives on emerging infectious diseases

- DDX19, A novel Viral RNA Sensor, Regulates IFN Signaling upon Viral Infection
- Risks of MERS-cluster Coronaviruses in China
- Rational Design of Master Seed Virus to Improve the Safety and Effectiveness of Foot and Mouth Disease Vaccine
- Development of Inactivated EV71 Vaccine (Human Diploid Cell) and Pathogenic Study of EV71 Infection in Rhesus Macaques
- Zika Virus Neurotropism: the Bad and the Good

Special session (gene editing and synthetic biology)

- Large Gene Cluster and Regulatory Manipulation for Activating the Cryptic Natural Product Clusters in Streotomvces
- Creating a Functional Single-chromosome Yeast

China-U.S. Collaboration: Opportunities to Prevent Future Pandemics

American Participants

Ralph Baric, Professor
Department of Epidemiology, University of North Carolina, Chapel Hill

David Franz, Professor
USAMRIID (retired)

Douglas Gladue, Scientist
U.S. Department of Agriculture

Diane Griffin, Professor
Department of Molecular Microbiology and Immunology of Johns Hopkins Bloomberg School of Public Health

Stephen Higgs, Professor
Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University

Joseph Kanabrocki, Professor
Microbiology in the Biological Sciences Division of the University of Chicago

James Le Duc, Professor
Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston

David Relman, Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051467

Department of Microbiology and Immunology, Stanford University School of Medicine

Linda Saif, Professor
Department of Veterinary Preventive Medicine, Food Animal Health Research Program, Ohio Agricultural Research and Development Center, The Ohio State University

Pei-Yong Shi, Professor
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch

David Swayne, Center Director
Agricultural Research Service, United States Department of Agriculture

Katherine Bowman, Senior Program Officer
National Academy of Sciences

Benjamin Rusek, Senior Program Officer
National Academy of Sciences

Chinese Participants

George F. Gao, Academician,
Director-General Chinese Center for Disease Control and Prevention

Zhigao Bu, Professor
Harbin Veterinary Research Institute, CAAS

Wen Dang, Doctor
Lanzhou Veterinary Research Institute, CAAS

Wuxiang Guan, Professor Wuhan Institute of Virology, CAS
Yunzhang Hu, Professor
Institute of Medical Biology, Chinese Academy of Medical Sciences

Mifang Liang, Professor
National Institute for Viral Disease Control and Prevention, China CDC
Chunbo Lou, Professor Institute of Microbiology, CAS

Hongsheng Ouyang, Professor
Jilin University
Chengfeng Qin, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Hualan Chen, Academician
Harbin Veterinary Research Institute, CAAS

Gong Cheng, Professor
Tsinghua University

Rui Gong, Professor
Wuhan Institute of Virology, CAS

Qian Han, Professor
Hainan University

Chengjun Li, Professor
Harbin Veterinary Research Institute, CAAS

Longding Liu, Professor
Institute of Medical Biology, Chinese Academy of Medical Sciences

Jiahai Lu, Professor
Sun Yat-sen University

Jiancheng Qi, Professor
National Biological Protection Engineering Center

Zhengli Shi, Professor
Wuhan Institute of Virology, CAS

Dayan Wang, Professor
Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College

Jianwei Wang, Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051468

National Institute for Viral Disease Control and Prevention, China CDC

Changjiang Weng, Professor
Harbin Veterinary Research Institute, CAAS

Kongming Wu, Vice President
Chinese Academy of Agricultural Sciences

Xiaodong Wu, Professor
China Animal Health and Epidemiology Center

Xaoli Xue, Professor
Laboratory of Synthetic Biology, Shanghai Institute of Plant Physiology, CAS

Yang Xue, Associate Professor
Tianjin University

Ruifu Yang, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Zhiming Yuan, Professor
Wuhan Institute of Virology, CAS

Peijun Zhai, Professor
China National Accreditation Service for Conformity Assessment (CNAS)

Pingping Zhang, Doctor
Institute of Microbiology and Epidemiology Academy of Military Medical Sciences

Tietao Zhang, Professor
International bureau, CAAS

Weiwen Zhang, Professor
Tianjin University

Chihong Zhao, Professor
National Institute for Viral Disease Control and Prevention, China CDC

Tongyan Zhao, Professor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Yong Zhao, Doctor
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

Haixue Zheng, Professor
Lanzhou Veterinary Research Institute, CAAS

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051469

FOIA Confidential Treatment Requested by Univ of Texas System

第五届中美新发传染病、实验室安全与全球卫生安全挑战

研讨会会议方案（讨论稿）

（2020 年 5 月 13-14 日，中国湖北黄冈）

为进一步加强中美两国相关领域研究人员的学术交流和合作，中美第五届新发传染病、实验室安全与全球卫生安全挑战研讨会将于 2020 年 5 月 13-14 日在湖北黄冈召开。会议将重点围绕全球公共卫生安全、非洲猪瘟病毒防控研究、合成生物学和生物安全实验室运行管理等问题展开研讨。通过汇集中美两国在相关领域的杰出科技成果报告，反映相关研究最新进展，及时沟通和了解全球卫生安全领域出现的新情况、新问题，发挥中美合作与联合攻关的优势，更好地应对新发突发传染病疫情，保障实验室安全和全球卫生安全，为中美两国乃至人类健康事业做出贡献。

主办单位：　中国科学院、美国科学院

承办单位：　中国科学院生物安全大科学研究中心

会议主席：　袁志明（中国科学院武汉病毒研究所，研究员）

美方，待定

会议组委会：　高　福（中国科学院微生物研究所，院士）

王延轶（中国科学院武汉病毒研究所，所长）

龚　鹏（中国科学院武汉病毒研究所，副所长）

石正丽（中国科学院武汉病毒研究所，研究员）

美方，待定

美方，待定

美方，待定

会议地点：　湖北省黄冈市

会议形式：　大会报告、小组讨论

会议语言：　英语

会议议题：

1. 新发传染病和全球公共卫生安全
   Emerging Infectious Diseases and Global Health Security
2. 非洲猪瘟防控研究的现实与挑战
   Reality and Challenges of The Prevention and Control of African Swine Fever
3. 基因编辑和合成生物学

FOIA Confidential Treatment Requested by Univ of Texas System

Gene Editing and Synthetic Biology

4. 生物安全实验室的管理和运行

Management and Operation of Biosafety Laboratory

拟邀嘉宾（美方）

Diane E. Griffin（美国科学院，副院长/院士）

Linda Saif （美国俄亥俄州立大学，院士）

David Relman（美国斯坦福大学，院士）

James W. Le Duc（美国德克萨斯大学加尔维斯顿国家实验室，教授）

Thomas Ksiazek（美国德克萨斯大学加尔维斯顿国家实验室，教授）

David R. Franz（美国陆军传染病医学研究所，教授）

Benjamin J. Rusek（美国科学院，高级项目官员）

Shi Peiyong（美国德克萨斯大学，教授）

David Swayne（美国农业部东南家禽研究实验室，主任）

拟邀嘉宾（中方）

高　福（中国疾病预防控制中心，中国科学院院士）

徐建国（中国疾病预防控制中心传染病预防控制所，中国工程院院士）

步志高（中国农业科学院哈尔滨兽医研究所，研究员）

胡云章（中国医学科学院医学生物学研究所，研究员）

秦成峰（中国军事科学院军事医学研究院，教授）

程　功（清华大学，研究员）

陆家海（中山大学，教授）

张卫文（天津大学，教授）

待　定（中南财经政法大学）

武桂珍（中国疾病预防控制中心病毒病预防控制所，研究员）

梁米芳（中国疾病预防控制中心病毒病预防控制所，研究员）

张先恩（中国科学院生物物理研究所，研究员）

唐　宏（中国科学院上海巴斯德研究所，研究员）

刘文军（中国科学院微生物研究所，研究员）

郑永唐（中国科学院昆明动物研究所，研究员）

石正丽（中国科学院武汉病毒研究所，研究员）

胡志红（中国科学院武汉病毒研究所，研究员）

龚　睿（中国科学院武汉病毒研究所，研究员）

袁志明（中国科学院武汉病毒研究所，研究员）

待　定（中国科学院国际合作局）

FOIA Confidential Treatment Requested by Univ of Texas System

会议日程（报告主题待定）：

Date	Time	Agenda
Tuesday 12nd May	14:00-21:00	Registration Address: Island International Hotel Huanggang No.8 Xingang 2nd Road, Huangzhou District, Huanggang
	19:00-21:00	Dinner
Wednesday 13rd May	09:00-10:00	Welcome and opening remarks *Chair – **Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* China: **Yanyi Wang** (Director General/Principle Investigator, Wuhan Institute of Virology, CAS) U.S.: Diane E. Griffin(*Proposed*,Academician, National Academy of Sciences) To be confirmed
	10:00-10:30	Tea break and group photo
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair – **Peiyong Shi** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**George F. Gao** (Academician, Institute of Microbiology, CAS)
	10:50-11:10	**Linda Saif** (Academician, Ohio State University)
	11:10-11:30	**Zhengli Shi** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:30-11:50	**James Le Duc** (Professor, Galveston National Laboratory)
	11:50-14:00	Lunch
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair –**Zhiming Yuan** (Proposed, Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**Jianguo Xu** (Academician, National Institute for Communicable Disease Control and Prevention, China CDC)
	14:20-14:40	**Peiyong Shi** (Professor, University of Texas)
	14:40-15:00	**Yunzhang Hu** (Principle Investigator, Institute of Medical Biology, CAMS)
	15:00-15:30	**Gong Cheng** (Professor, Tsinghua University)
	15:30-15:50	**Rui Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)

FOIA Confidential Treatment Requested by Univ of Texas System

	15:50-16:10	Tea break
	16:10-16:30	**Chengfeng Qin** (Professor, The Academy of Military Medical Sciences)
	16:30-16:50	**David Swayne** (Director, USDA Southeast Poultry Research Laboratory)
	16:50-17:10	**Jiahai Lu** (Professor, Sun Yat-sen University)
	17:10-17:30	**Hong Tang** (Director General/Principle Investigator, Institut Pasteur Shanghai, CAS)
	17:30-17:50	**Peng Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)
	17:50-19:00	Dinner
Thursday 14th May	**Session 2: Reality and Challenges of The Prevention and Control of African Swine Fever** *Chair –**Peng Gong** (Proposed, Deputy Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	08:30-08:50	**Diane E. Griffin** (Academician, National Academy of Sciences)
	08:50-09:10	**Xian'en Zhang** (Principle Investigator, Institute of Biophysics, CAS)
	09:10-09:30	**Zhigao Bu** (Director General/Principle Investigator, Harbin Veterinary Research Institute, CAAS)
	09:30-09:50	**Guizhen Wu** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	09:50-10:10	**Yanyi Wang** *(Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*
	10:10-10:30	Tea break
	Session 3: Gene Editing and Synthetic Biology *Chair –**James Le Duc** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**Mifang Liang** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	10:50-11:10	**Thomas Ksiazek** (Professor, Galveston National Laboratory)
	11:10-11:20	**Weiwen Zhang** (Professor, Tianjin University)
	11:20-11:40	**Zhihong Hu** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:40-12:00	To be confirmed (Zhongnan University of Economics and Law)
	12:00-14:00	Lunch
	Session 4 : Management and Operation of Biosafety Laboratory *Chair –**Yanyi Wang** (Proposed, Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**David Relman** (Academician, Stanford University)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051364

	14:20-14:40	**Wenjun Liu** (Principle Investigator, Institute of Microbiology, CAS)
	14:40-15:00	**Yongtang Zheng** (Principle Investigator, Kunming Institute of Zoology, CAS)
	15:00-15:20	**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:20-15:50	Tea break
	15:50-16:50	Round Table Discussion *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–**James Le Duc** (Professor, Galveston National Laboratory)*
	16:50-17:30	Conclusions *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–To be confirmed* - Conclusions from the meeting and discussion on possible roles of CAS and NAS to enhance cooperation between the U.S. and China on Emerging Infections, Laboratory Safety and Global Health Security - Concluding remarks
	17:30-19:00	Dinner
Friday 15th May		Leave

FOIA Confidential Treatment Requested by Univ of Texas System

第五届中美新发传染病、实验室安全与全球卫生安全挑战

研讨会会议方案（讨论稿）

（2020 年 5 月 13-14 日，中国湖北黄冈）

为进一步加强中美两国相关领域研究人员的学术交流和合作，中美第五届新发传染病、实验室安全与全球卫生安全挑战研讨会将于 2020 年 5 月 13-14 日在湖北黄冈召开。会议将重点围绕全球公共卫生安全、非洲猪瘟病毒防控研究、合成生物学和生物安全实验室运行管理等问题展开研讨。通过汇集中美两国在相关领域的杰出科技成果报告，反映相关研究最新进展，及时沟通和了解全球卫生安全领域出现的新情况、新问题，发挥中美合作与联合攻关的优势，更好地应对新发突发传染病疫情，保障实验室安全和全球卫生安全，为中美两国乃至人类健康事业做出贡献。

主办单位：　中国科学院、美国科学院

承办单位：　中国科学院生物安全大科学研究中心

会议主席：　袁志明（中国科学院武汉病毒研究所，研究员）

美方，待定

会议组委会：　高　福（中国科学院微生物研究所，院士）

王延轶（中国科学院武汉病毒研究所，所长）

龚　鹏（中国科学院武汉病毒研究所，副所长）

石正丽（中国科学院武汉病毒研究所，研究员）

美方，待定

美方，待定

美方，待定

会议地点：　湖北省黄冈市

会议形式：　大会报告、小组讨论

会议语言：　英语

会议议题：

1. 新发传染病和全球公共卫生安全
   Emerging Infectious Diseases and Global Health Security
2. 非洲猪瘟防控研究的现实与挑战
   Reality and Challenges of The Prevention and Control of African Swine Fever
3. 基因编辑和合成生物学

FOIA Confidential Treatment Requested by Univ of Texas System

Gene Editing and Synthetic Biology

4. 生物安全实验室的管理和运行

Management and Operation of Biosafety Laboratory

拟邀嘉宾（美方）

Diane E. Griffin（美国科学院，副院长/院士）

Linda Saif （美国俄亥俄州立大学，院士）

David Relman（美国斯坦福大学，院士）

James W. Le Duc（美国德克萨斯大学加尔维斯顿国家实验室，教授）

Thomas Ksiazek（美国德克萨斯大学加尔维斯顿国家实验室，教授）

David R. Franz（美国陆军传染病医学研究所，教授）

Benjamin J. Rusek（美国科学院，高级项目官员）

Shi Peiyong（美国德克萨斯大学，教授）

David Swayne（美国农业部东南家禽研究实验室，主任）

拟邀嘉宾（中方）

高　福（中国疾病预防控制中心，中国科学院院士）

徐建国（中国疾病预防控制中心传染病预防控制所，中国工程院院士）

步志高（中国农业科学院哈尔滨兽医研究所，研究员）

胡云章（中国医学科学院医学生物学研究所，研究员）

秦成峰（中国军事科学院军事医学研究院，教授）

程　功（清华大学，研究员）

陆家海（中山大学，教授）

张卫文（天津大学，教授）

待　定（中南财经政法大学）

武桂珍（中国疾病预防控制中心病毒病预防控制所，研究员）

梁米芳（中国疾病预防控制中心病毒病预防控制所，研究员）

张先恩（中国科学院生物物理研究所，研究员）

唐　宏（中国科学院上海巴斯德研究所，研究员）

刘文军（中国科学院微生物研究所，研究员）

郑永唐（中国科学院昆明动物研究所，研究员）

石正丽（中国科学院武汉病毒研究所，研究员）

胡志红（中国科学院武汉病毒研究所，研究员）

龚　睿（中国科学院武汉病毒研究所，研究员）

袁志明（中国科学院武汉病毒研究所，研究员）

待　定（中国科学院国际合作局）

FOIA Confidential Treatment Requested by Univ of Texas System

会议日程（报告主题待定）：

Date	Time	Agenda
Tuesday 12nd May	14:00-21:00	Registration Address: Island International Hotel Huanggang No.8 Xingang 2nd Road, Huangzhou District, Huanggang
	19:00-21:00	Dinner
Wednesday 13rd May	09:00-10:00	Welcome and opening remarks *Chair – **Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* China: **Yanyi Wang** (Director General/Principle Investigator, Wuhan Institute of Virology, CAS) U.S.: Diane E. Griffin(*Proposed*,Academician, National Academy of Sciences) To be confirmed
	10:00-10:30	Tea break and group photo
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair – **Peiyong Shi** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**George F. Gao** (Academician, Institute of Microbiology, CAS)
	10:50-11:10	**Linda Saif** (Academician, Ohio State University)
	11:10-11:30	**Zhengli Shi** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:30-11:50	**James Le Duc** (Professor, Galveston National Laboratory)
	11:50-14:00	Lunch
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair –**Zhiming Yuan** (Proposed, Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**Jianguo Xu** (Academician, National Institute for Communicable Disease Control and Prevention, China CDC)
	14:20-14:40	**Peiyong Shi** (Professor, University of Texas)
	14:40-15:00	**Yunzhang Hu** (Principle Investigator, Institute of Medical Biology, CAMS)
	15:00-15:30	**Gong Cheng** (Professor, Tsinghua University)
	15:30-15:50	**Rui Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051810

	15:50-16:10	Tea break
	16:10-16:30	**Chengfeng Qin** (Professor, The Academy of Military Medical Sciences)
	16:30-16:50	**David Swayne** (Director, USDA Southeast Poultry Research Laboratory)
	16:50-17:10	**Jiahai Lu** (Professor, Sun Yat-sen University)
	17:10-17:30	**Hong Tang** (Director General/Principle Investigator, Institut Pasteur Shanghai, CAS)
	17:30-17:50	**Peng Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)
	17:50-19:00	Dinner
Thursday 14th May	**Session 2: Reality and Challenges of The Prevention and Control of African Swine Fever** *Chair –**Peng Gong** (Proposed, Deputy Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	08:30-08:50	**Diane E. Griffin** (Academician, National Academy of Sciences)
	08:50-09:10	**Xian'en Zhang** (Principle Investigator, Institute of Biophysics, CAS)
	09:10-09:30	**Zhigao Bu** (Director General/Principle Investigator, Harbin Veterinary Research Institute, CAAS)
	09:30-09:50	**Guizhen Wu** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	09:50-10:10	**Yanyi Wang** *(Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*
	10:10-10:30	Tea break
	Session 3: Gene Editing and Synthetic Biology *Chair –**James Le Duc** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**Mifang Liang** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	10:50-11:10	**Thomas Ksiazek** (Professor, Galveston National Laboratory)
	11:10-11:20	**Weiwen Zhang** (Professor, Tianjin University)
	11:20-11:40	**Zhihong Hu** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:40-12:00	To be confirmed (Zhongnan University of Economics and Law)
	12:00-14:00	Lunch
	Session 4 : Management and Operation of Biosafety Laboratory *Chair –**Yanyi Wang** (Proposed, Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**David Relman** (Academician, Stanford University)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051811

	14:20-14:40	**Wenjun Liu** (Principle Investigator, Institute of Microbiology, CAS)
	14:40-15:00	**Yongtang Zheng** (Principle Investigator, Kunming Institute of Zoology, CAS)
	15:00-15:20	**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:20-15:50	Tea break
	15:50-16:50	Round Table Discussion *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–**James Le Duc** (Professor, Galveston National Laboratory)*
	16:50-17:30	Conclusions *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–To be confirmed* - Conclusions from the meeting and discussion on possible roles of CAS and NAS to enhance cooperation between the U.S. and China on Emerging Infections, Laboratory Safety and Global Health Security - Concluding remarks
	17:30-19:00	Dinner
Friday 15th May		Leave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051812

第五届中美新发传染病、实验室安全与全球卫生安全挑战

研讨会会议方案（讨论稿）

（2020 年 5 月 13-14 日，中国湖北黄冈）

为进一步加强中美两国相关领域研究人员的学术交流和合作，中美第五届新发传染病、实验室安全与全球卫生安全挑战研讨会将于 2020 年 5 月 13-14 日在湖北黄冈召开。会议将重点围绕全球公共卫生安全、非洲猪瘟病毒防控研究、合成生物学和生物安全实验室运行管理等问题展开研讨。通过汇集中美两国在相关领域的杰出科技成果报告，反映相关研究最新进展，及时沟通和了解全球卫生安全领域出现的新情况、新问题，发挥中美合作与联合攻关的优势，更好地应对新发突发传染病疫情，保障实验室安全和全球卫生安全，为中美两国乃至人类健康事业做出贡献。

主办单位：　中国科学院、美国科学院

承办单位：　中国科学院生物安全大科学研究中心

会议主席：　袁志明（中国科学院武汉病毒研究所，研究员）

美方，待定

会议组委会：　高　福（中国科学院微生物研究所，院士）

王延轶（中国科学院武汉病毒研究所，所长）

龚　鹏（中国科学院武汉病毒研究所，副所长）

石正丽（中国科学院武汉病毒研究所，研究员）

美方，待定

美方，待定

美方，待定

会议地点：　湖北省黄冈市

会议形式：　大会报告、小组讨论

会议语言：　英语

会议议题：

1. 新发传染病和全球公共卫生安全
   Emerging Infectious Diseases and Global Health Security
2. 非洲猪瘟防控研究的现实与挑战
   Reality and Challenges of The Prevention and Control of African Swine Fever
3. 基因编辑和合成生物学

FOIA Confidential Treatment Requested by Univ of Texas System

Gene Editing and Synthetic Biology

4. 生物安全实验室的管理和运行

Management and Operation of Biosafety Laboratory

拟邀嘉宾（美方）

Diane E. Griffin（美国科学院，副院长/院士）

Linda Saif （美国俄亥俄州立大学，院士）

David Relman（美国斯坦福大学，院士）

James W. Le Duc（美国德克萨斯大学加尔维斯顿国家实验室，教授）

Thomas Ksiazek（美国德克萨斯大学加尔维斯顿国家实验室，教授）

David R. Franz（美国陆军传染病医学研究所，教授）

Benjamin J. Rusek（美国科学院，高级项目官员）

Shi Peiyong（美国德克萨斯大学，教授）

David Swayne（美国农业部东南家禽研究实验室，主任）

拟邀嘉宾（中方）

高　福（中国疾病预防控制中心，中国科学院院士）

徐建国（中国疾病预防控制中心传染病预防控制所，中国工程院院士）

步志高（中国农业科学院哈尔滨兽医研究所，研究员）

胡云章（中国医学科学院医学生物学研究所，研究员）

秦成峰（中国军事科学院军事医学研究院，教授）

程　功（清华大学，研究员）

陆家海（中山大学，教授）

张卫文（天津大学，教授）

待　定（中南财经政法大学）

武桂珍（中国疾病预防控制中心病毒病预防控制所，研究员）

梁米芳（中国疾病预防控制中心病毒病预防控制所，研究员）

张先恩（中国科学院生物物理研究所，研究员）

唐　宏（中国科学院上海巴斯德研究所，研究员）

刘文军（中国科学院微生物研究所，研究员）

郑永唐（中国科学院昆明动物研究所，研究员）

石正丽（中国科学院武汉病毒研究所，研究员）

胡志红（中国科学院武汉病毒研究所，研究员）

龚　睿（中国科学院武汉病毒研究所，研究员）

袁志明（中国科学院武汉病毒研究所，研究员）

待　定（中国科学院国际合作局）

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071521

会议日程（报告主题待定）：

Date	Time	Agenda
Tuesday 12nd May	14:00-21:00	Registration Address: Island International Hotel Huanggang No.8 Xingang 2nd Road, Huangzhou District, Huanggang
	19:00-21:00	Dinner
Wednesday 13rd May	09:00-10:00	Welcome and opening remarks *Chair – **Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* China: **Yanyi Wang** (Director General/Principle Investigator, Wuhan Institute of Virology, CAS) U.S.: Diane E. Griffin(*Proposed*,Academician, National Academy of Sciences) To be confirmed
	10:00-10:30	Tea break and group photo
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair – **Peiyong Shi** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**George F. Gao** (Academician, Institute of Microbiology, CAS)
	10:50-11:10	**Linda Saif** (Academician, Ohio State University)
	11:10-11:30	**Zhengli Shi** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:30-11:50	**James Le Duc** (Professor, Galveston National Laboratory)
	11:50-14:00	Lunch
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair –**Zhiming Yuan** (Proposed, Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**Jianguo Xu** (Academician, National Institute for Communicable Disease Control and Prevention, China CDC)
	14:20-14:40	**Peiyong Shi** (Professor, University of Texas)
	14:40-15:00	**Yunzhang Hu** (Principle Investigator, Institute of Medical Biology, CAMS)
	15:00-15:30	**Gong Cheng** (Professor, Tsinghua University)
	15:30-15:50	**Rui Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071522

	15:50-16:10	Tea break
	16:10-16:30	**Chengfeng Qin** (Professor, The Academy of Military Medical Sciences)
	16:30-16:50	**David Swayne** (Director, USDA Southeast Poultry Research Laboratory)
	16:50-17:10	**Jiahai Lu** (Professor, Sun Yat-sen University)
	17:10-17:30	**Hong Tang** (Director General/Principle Investigator, Institut Pasteur Shanghai, CAS)
	17:30-17:50	**Peng Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)
	17:50-19:00	Dinner
Thursday 14th May	**Session 2: Reality and Challenges of The Prevention and Control of African Swine Fever** *Chair –**Peng Gong** (Proposed, Deputy Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	08:30-08:50	**Diane E. Griffin** (Academician, National Academy of Sciences)
	08:50-09:10	**Xian'en Zhang** (Principle Investigator, Institute of Biophysics, CAS)
	09:10-09:30	**Zhigao Bu** (Director General/Principle Investigator, Harbin Veterinary Research Institute, CAAS)
	09:30-09:50	**Guizhen Wu** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	09:50-10:10	**Yanyi Wang** *(Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*
	10:10-10:30	Tea break
	Session 3: Gene Editing and Synthetic Biology *Chair –**James Le Duc** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**Mifang Liang** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	10:50-11:10	**Thomas Ksiazek** (Professor, Galveston National Laboratory)
	11:10-11:20	**Weiwen Zhang** (Professor, Tianjin University)
	11:20-11:40	**Zhihong Hu** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:40-12:00	To be confirmed (Zhongnan University of Economics and Law)
	12:00-14:00	Lunch
	Session 4 : Management and Operation of Biosafety Laboratory *Chair –**Yanyi Wang** (Proposed, Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**David Relman** (Academician, Stanford University)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071523

	14:20-14:40	**Wenjun Liu** (Principle Investigator, Institute of Microbiology, CAS)
	14:40-15:00	**Yongtang Zheng** (Principle Investigator, Kunming Institute of Zoology, CAS)
	15:00-15:20	**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:20-15:50	Tea break
	15:50-16:50	Round Table Discussion *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–**James Le Duc** (Professor, Galveston National Laboratory)*
	16:50-17:30	Conclusions *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–To be confirmed* - Conclusions from the meeting and discussion on possible roles of CAS and NAS to enhance cooperation between the U.S. and China on Emerging Infections, Laboratory Safety and Global Health Security - Concluding remarks
	17:30-19:00	Dinner
Friday 15th May		Leave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071524

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, November 20, 2019 10:42 AM
To: Shi, Pei yong;LeDuc, James W.
Cc: Dave Franz (davidrfranz@gmail.com);Lowenthal, Micah
Subject: RE: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119
Attachments: Wuhan 2020 draft program Chinese and English.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong, Dave and Jim,

Pei-yong, sounds like good news! Thanks for continuing to work this.

I used Google translate to quickly translate the email text and the Chinese portions of the proposed program agenda (attached). It's essentially an initial modification of the program agenda from the last meeting we held in Wuhan. Yes it would be good to do this sooner than May of 2020. I am available to talk this afternoon or tomorrow late afternoon.

Ben

***

Challenges - Conference Program (Discussion Draft)

Dear Professor,

Hello!

After discussion, we further revised the meeting plan of the 5th China-US Symposium on Newly Communicable Infectious Diseases, Laboratory Safety and Global Health Security Challenges. Please see the attachment for your review. After the topic of the meeting is finalized, we will send an invitation to the expert and confirm the subject of the report.

please know this, thanks!

Chen teasing
Wuhan Institute of Virology, Chinese Academy of Sciences
Research Planning Office 027-87197115
Mobile: 18963869921

***

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002693

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Wednesday, November 20, 2019 10:01 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: RE: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Hi Ben, Dave, and Jim,

Here are two highlights about Zhiming's meeting proposal.

1. The meeting will continue to focus on emerging infectious diseases, laboratory operation and safety, synthetic biology in infectious diseases, and control of African swine fever virus.
2. Although the proposed date is on May 13-14, Zhiming agrees to change it to an earlier time.

Jim and I would like to invite an expert on tree shrew animal model from Kunming to present at the upcoming meeting. UTMB is initiating a collaboration with the Institute of Medical Biology on using tree shrew as new models for viral infections.

Let's have a TC to discuss when you have time.

Best, Pei-Yong

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Tuesday, November 19, 2019 8:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: Re: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Thanks, Jim
I just communicated with Zhiming again. He still hasn't received the final approval, but is very optimistic about receiving it soon. I will keep my fingers on him.
Best, Pei-Yong

Get Outlook for Android

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, November 19, 2019 8:37:23 PM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: Re: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Good news. Let's get a translation so we can understand the details.

Thanks very much for pushing this through.

Jim

Sent from my iPhone

> On Nov 19, 2019, at 8:24 PM, Shi, Pei yong <peshi@utmb.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002694

Hi Ben, Dave, and Jim,
After several rounds of follow up with Zhiming, I have just received their meeting proposal. This proposal has been included for their approval process in China. We could discuss, modify, and give them our feedbacks.
Best wishes,
Pei-Yong

Get Outlook for Android

From: chendd@wh.iov.cn <chendd@wh.iov.cn>
Sent: Tuesday, November 19, 2019 3:42:02 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: 袁志明 <yzm@wh.iov.cn>; 张子超 <zhangzc@wh.iov.cn>; zhangyh <zhangyh@wh.iov.cn>
Subject: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

尊敬的史教授，

您好！

经讨论，我们进一步修订了第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会的会议方案，见附件，敬请您收阅。待会议主题确定后，我们将向专家发布邀请函，并与其确认报告主题。

请知悉，谢谢！

陈逗逗
中国科学院武汉病毒研究所
科研计划处 027-87197115
手机：18963986921
chendd@wh.iov.cn

发件人： chendd@wh.iov.cn
发送时间： 2019-10-29 09:05
收件人： peshi
抄送： 袁志明; 张子超
主题： 敬请查收：第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（稿）

尊敬的史教授，

您好！

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002695

敬请查收《第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（稿）》，谢谢您！

祝好！

陈逗逗
中国科学院武汉病毒研究所
科研计划处 027-87197115
手机：18963986921
chendd@wh.iov.cn

<第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002696

第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会会议方案（讨论稿）

（2020 年 5 月 13-14 日，中国湖北黄冈）

为进一步加强中美两国相关领域研究人员的学术交流和合作，中美第五届新发传染病、实验室安全与全球卫生安全挑战研讨会将于 2020 年 5 月 13-14 日在湖北黄冈召开。会议将重点围绕全球公共卫生安全、非洲猪瘟病毒防控研究、合成生物学和生物安全实验室运行管理等问题展开研讨。通过汇集中美两国在相关领域的杰出科技成果报告，反映相关研究最新进展，及时沟通和了解全球卫生安全领域出现的新情况、新问题，发挥中美合作与联合攻关的优势，更好地应对新发突发传染病疫情，保障实验室安全和全球卫生安全，为中美两国乃至人类健康事业做出贡献。

Deleted: ¶

Formatted: Centered, Indent: First line: 0"

The 5th China-US New Infectious Disease, Laboratory Safety and Global Health Security Challenge Seminar meeting plan (discussion draft)

(May 13-14, 2020, Huanggang, Hubei, China)

To further strengthen the academic exchanges and cooperation between researchers in related fields in China and the United States, the 5th China-US Symposium on New Infectious Diseases, Laboratory Safety and Global Health Security Challenge will be held in Huanggang, Hubei, on May 13-14, 2020. Held. The conference will focus on issues such as global public health security, African hog virus prevention and control research, synthetic biology and biosafety laboratory operation management. By bringing together the outstanding scientific and technological achievements reports of China and the United States in related fields, reflecting the latest developments in relevant research, timely communicating and understanding the new situations and new problems in the field of global health and safety, and giving full play to the advantages of Sino-US cooperation and joint research, better Responding to new outbreaks of infectious diseases, ensuring laboratory safety and global health security, and contributing to the cause of China and the United States and even human health.

Deleted: ¶

主办单位： 中国科学院、美国科学院

承办单位： 中国科学院生物安全大科学研究中心

会议主席： 袁志明（中国科学院武汉病毒研究所，研究员）

FOIA Confidential Treatment Requested by Univ of Texas System

美方，待定

会议组委会：高　福（中国科学院微生物研究所，院士）

王延轶（中国科学院武汉病毒研究所，所长）

龚　鹏（中国科学院武汉病毒研究所，副所长）

石正丽（中国科学院武汉病毒研究所，研究员）

美方，待定

美方，待定

美方，待定

会议地点：湖北省黄冈市

会议形式：大会报告、小组讨论

会议语言：英语

Organizer: Chinese Academy of Sciences, American Academy of Sciences

Organizer: Center for Biosafety Science, Chinese Academy of Sciences

Chairman of the meeting: Yuan Zhiming (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Conference Organizing Committee: US, to be determined

Gao Fu (Academician, Institute of Microbiology, Chinese Academy of Sciences)

Wang Yanxi (Director, Wuhan Institute of Virology, Chinese Academy of Sciences)

Gong Peng (Deputy Director, Wuhan Institute of Virology, Chinese Academy of Sciences)

Shi Zhengli (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

US, to be determined

US, to be determined

US, to be determined

Venue: Huanggang City, Hubei Province

Form of meeting: Conference report, group discussion

Conference language: English

会议议题：

1. 新发传染病和全球公共卫生安全
   Emerging Infectious Diseases and Global Health Security
2. 非洲猪瘟防控研究的现实与挑战
   Reality and Challenges of The Prevention and Control of African Swine Fever
3. 基因编辑和合成生物学
   Gene Editing and Synthetic Biology
4. 生物安全实验室的管理和运行

FOIA Confidential Treatment Requested by Univ of Texas System

Management and Operation of Biosafety Laboratory

拟邀嘉宾（美方）

Diane E. Griffin（美国科学院，副院长/院士）
Linda Saif （美国俄亥俄州立大学，院士）
David Relman（美国斯坦福大学，院士）
James W. Le Duc（美国德克萨斯大学加尔维斯顿国家实验室，教授）
Thomas Ksiazek（美国德克萨斯大学加尔维斯顿国家实验室，教授）
David R. Franz（美国陆军传染病医学研究所，教授）
Benjamin J. Rusek（美国科学院，高级项目官员）
Shi Peiyong（美国德克萨斯大学，教授）
David Swayne（美国农业部东南家禽研究实验室，主任）

拟邀嘉宾（中方）

高　福（中国疾病预防控制中心，中国科学院院士）
徐建国（中国疾病预防控制中心传染病预防控制所，中国工程院院士）
步志高（中国农业科学院哈尔滨兽医研究所，研究员）
胡云章（中国医学科学院医学生物学研究所，研究员）
秦成峰（中国军事科学院军事医学研究院，教授）
程　功（清华大学，研究员）
陆家海（中山大学，教授）
张卫文（天津大学，教授）
待　定（中南财经政法大学）
武桂珍（中国疾病预防控制中心病毒病预防控制所，研究员）
梁米芳（中国疾病预防控制中心病毒病预防控制所，研究员）
张先恩（中国科学院生物物理研究所，研究员）
唐　宏（中国科学院上海巴斯德研究所，研究员）
刘文军（中国科学院微生物研究所，研究员）
郑永唐（中国科学院昆明动物研究所，研究员）
石正丽（中国科学院武汉病毒研究所，研究员）
胡志红（中国科学院武汉病毒研究所，研究员）
龚　睿（中国科学院武汉病毒研究所，研究员）
袁志明（中国科学院武汉病毒研究所，研究员）
待　定（中国科学院国际合作局）

Gao Fu (Chinese Center for Disease Control and Prevention, Chinese Academy of Sciences)
Xu Jianguo (Infectious Disease Prevention and Control Institute, Chinese Center for Disease

FOIA Confidential Treatment Requested by Univ of Texas System

Control and Prevention, Academician of Chinese Academy of Engineering)

Bu Zhigao (Researcher, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences)

Hu Yunzhang (Researcher, Institute of Medical Biology, Chinese Academy of Medical Sciences)

Qin Chengfeng (Professor, Academy of Military Medical Sciences, Chinese Academy of Military Sciences)

Cheng Gong (Tsinghua University, Researcher)

Lu Jiahai (Zhongshan University, Professor)

Zhang Weiwen (Tianjin University, Professor)

To be determined (Zhongnan University of Economics and Law)

Wu Guizhen (Researcher, Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention)

Liang Mifang (Researcher, Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention)

Zhang Xianen (Researcher, Institute of Biophysics, Chinese Academy of Sciences)

Tang Hong (Researcher, Shanghai Pasteur Institute, Chinese Academy of Sciences)

Liu Wenjun (Researcher, Institute of Microbiology, Chinese Academy of Sciences)

Zheng Yongtang (Researcher, Kunming Institute of Zoology, Chinese Academy of Sciences)

Shi Zhengli (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Hu Zhihong (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Gong Rui (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Yuan Zhiming (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

To be determined (International Cooperation Bureau of the Chinese Academy of Sciences)

Deleted: ¶

会议日程（报告主题待定）：

Meeting schedule (report topic to be determined):

Date	Time	Agenda
Tuesday 12nd May	14:00-21:00	Registration Address: Island International Hotel Huanggang No.8 Xingang 2nd Road, Huangzhou District, Huanggang
	19:00-21:00	Dinner
Wednesday	09:00-10:00	Welcome and opening remarks

FOIA Confidential Treatment Requested by Univ of Texas System

13rd May		*Chair – **Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* China: **Yanyi Wang** (Director General/Principle Investigator, Wuhan Institute of Virology, CAS) U.S.: Diane E. Griffin(*Proposed*,Academician, National Academy of Sciences) To be confirmed
	10:00-10:30	Tea break and group photo
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair – **Peiyong Shi** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**George F. Gao** (Academician, Institute of Microbiology, CAS)
	10:50-11:10	**Linda Saif** (Academician, Ohio State University)
	11:10-11:30	**Zhengli Shi** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:30-11:50	**James Le Duc** (Professor, Galveston National Laboratory)
	11:50-14:00	Lunch
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair –**Zhiming Yuan** (Proposed, Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**Jianguo Xu** (Academician, National Institute for Communicable Disease Control and Prevention, China CDC)
	14:20-14:40	**Peiyong Shi** (Professor, University of Texas)
	14:40-15:00	**Yunzhang Hu** (Principle Investigator, Institute of Medical Biology, CAMS)
	15:00-15:30	**Gong Cheng** (Professor, Tsinghua University)
	15:30-15:50	**Rui Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:50-16:10	Tea break
	16:10-16:30	**Chengfeng Qin** (Professor, The Academy of Military Medical Sciences)
	16:30-16:50	**David Swayne** (Director, USDA Southeast Poultry Research Laboratory)
	16:50-17:10	**Jiahai Lu** (Professor, Sun Yat-sen University)
	17:10-17:30	**Hong Tang** (Director General/Principle Investigator, Institut Pasteur Shanghai, CAS)
	17:30-17:50	**Peng Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)

FOIA Confidential Treatment Requested by Univ of Texas System

	17:50-19:00	Dinner
Thursday 14th May	**Session 2: Reality and Challenges of The Prevention and Control of African Swine Fever** *Chair –**Peng Gong** (Proposed, Deputy Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	08:30-08:50	**Diane E. Griffin** (Academician, National Academy of Sciences)
	08:50-09:10	**Xian'en Zhang** (Principle Investigator, Institute of Biophysics, CAS)
	09:10-09:30	**Zhigao Bu** (Director General/Principle Investigator, Harbin Veterinary Research Institute, CAAS)
	09:30-09:50	**Guizhen Wu** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	09:50-10:10	**Yanyi Wang** *(Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*
	10:10-10:30	Tea break
	Session 3: Gene Editing and Synthetic Biology *Chair –**James Le Duc** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**Mifang Liang** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	10:50-11:10	**Thomas Ksiazek** (Professor, Galveston National Laboratory)
	11:10-11:20	**Weiwen Zhang** (Professor, Tianjin University)
	11:20-11:40	**Zhihong Hu** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:40-12:00	To be confirmed (Zhongnan University of Economics and Law)
	12:00-14:00	Lunch
	Session 4 : Management and Operation of Biosafety Laboratory *Chair –**Yanyi Wang** (Proposed, Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**David Relman** (Academician, Stanford University)
	14:20-14:40	**Wenjun Liu** (Principle Investigator, Institute of Microbiology, CAS)
	14:40-15:00	**Yongtang Zheng** (Principle Investigator, Kunming Institute of Zoology, CAS)
	15:00-15:20	**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:20-15:50	Tea break
	15:50-16:50	Round Table Discussion *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–**James Le Duc** (Professor, Galveston National Laboratory)*

FOIA Confidential Treatment Requested by Univ of Texas System

Friday 15th May	16:50-17:30	Conclusions *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–To be confirmed* - Conclusions from the meeting and discussion on possible roles of CAS and NAS to enhance cooperation between the U.S. and China on Emerging Infections, Laboratory Safety and Global Health Security - Concluding remarks
	17:30-19:00	Dinner Leave

FOIA Confidential Treatment Requested by Univ of Texas System

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, November 28, 2019 9:58 AM
To: zhengzhiming4
@gmail.com;haitguo@iupui.edu;tzhou@mail.nih.gov;GCheng@mednet.ucla.edu;liangy
@umn.edu;rli@vcu.edu;wjma@ksu.edu;xjmeng@vt.edu;Zhijian.Chen@UTSouthwester
n.edu;mluo@gsu.edu;zhangyj@umd.edu;xzhu1
@umd.edu;jqiu@kumc.edu;lijun@uic.edu;fengwei.bai@usm.edu;andyu@iupui.edu;rea
chxw@vt.edu;gluo@uab.edu;ldu@nybc.org;hxu@tulane.edu;liu_fy@berkeley.edu;shita
o.li@okstate.edu;Shan.lu@umassmed.edu;Hu, Haitao;wenzheho@temple.edu;Qfeng4
@central.uh.edu;tang@bio.fsu.edu;feng.li@sdstate.edu;ruilu@lsu.edu;sxiang2
@unl.edu;qiyi.tang@howard.edu;dingsw@ucr.edu;guohua@missouri.edu;bling@tulan
e.edu;junwang@pharmacy.arizona.edu;lifang@umn.edu;wang518@umd.edu;gaos8
@upmc.edu;pewang@uchc.edu;xiangy@uthscsa.edu;fzhu@bio.fsu.edu;chen.liang@mc
gill.ca;lyuan@vt.edu;fgao@duke.edu;wangjw28@163.com;xfyu1
@zju.edu.cn;bzhao@partners.org;jianw@musc.edu;zyang@ksu.edu;yu.cong@nih.gov;
weiming.yuan@usc.edu;Zongdi.feng@nationwidechildrens.org;juh13
@psu.edu;hengx@missouri.edu;lsu@med.unc.edu;ywu8
@gmu.edu;jwu@whu.edu.cn;tshuo@uic.edu;Shibojiang@fudan.edu.cn;sjiang@nybc.or
g;pinwang@usc.edu;rzhao@som.umaryland.edu;shuylong@mail.sysu.edu.cn;xuefeng.li
u@georgetown.edu;yuxingli@som.umaryland.edu;shixia.wang@umassmed.edu;yhe@i
pbcams.ac.cn;Pinghui.feng@usc.edu;ju-
tao.guo@bblumberg.org;lin.liu@okstate.edu;hua.zhu@rutgers.edu;Jinhong.chang@bb
lumberg.org;jianzhu1012@gmail.com;ronghai@ucr.edu;jun.zhu@nih.gov;jliu4
@uams.edu;xiangpeng.kong@med.nyu.edu;haoquanwu@outlook.com;Wenjun.liu@de
fence.gov.au;Liang.shan@wustl.edu;hliao@duke.edu;yuan2
@upenn.edu;zxing@umn.edu;hongmin.li@health.ny.gov;pzheng@ihv.umaryland.edu;y
aliu@ihv.umaryland.edu;jxw103@case.edu;xiangguo.qiu@canada.ca;Feng
Shao;zlshi@wh.iov.cn;klan@whu.edu.cn;zengmsh@mail.sysu.edu.cn;Nan Yan;Zhang,
Rong;liliwang@upenn.edu;Linheng Li;kli1
@uthsc.edu;tsx@case.edu;ssun@mdanderson.org;ysang@tnstate.edu;Liu, Shan-
Lu;wu@crystal.harvard.edu;Sun.Jie@mayo.edu;peijun@strubi.ox.ac.uk;jiayu@coh.org;b
chen@crystal.harvard.edu;Wen, Haitao;Qu, Feng;Hezhao.Ji@umanitoba.ca;Li,
Zihai;zhengyo@msu.edu;zhanglinqi@tsinghua.edu.cn;wxiao@temple.edu;Whu@templ
e.edu;RSun@mednet.ucla.edu;Guangping.Gao@umassmed.edu;PZheng@ihv.umarylan
d.edu;GMSWANG@nus.edu.sg;Shi, Pei yong;yaliu@ihv.umaryland.edu;ziying-
yan@uiowa.edu;lqiao@luc.edu;yong.xiong@yale.edu;Wang,
Qiuhong;shuping_tong_md@brown.edu;pinghuif@usc.edu;gaof@im.ac.cn
Subject: Happy Thanksgiving and meeting next year, June 12-13, 2020
Attachments: Meeting report_ACVA_SCBA-virology_Kunming.pdf; Junming_1.JPG; Kunming_2.JPG; Kunming_3.JPG; Kunming_4.JPG

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067338

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu

THE OHIO STATE UNIVERSITY

Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067339

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, November 28, 2019 9:58 AM
To: zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Shan.lu@umassmed.edu; Hu, Haitao; wenzheho@temple.edu; Qfeng4 @central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2 @unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518 @umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@ 163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; shixia.wang@umassmed.edu; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; Liu, Shan-Lu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Guangping.Gao@umassmed.edu; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; Shi, Pei yong; yaliu@ihv.umaryland.edu; ziying-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qiuhong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn
Subject: Happy Thanksgiving and meeting next year, June 12-13, 2020
Attachments: Meeting report_ACVA_SCBA-virology_Kunming.pdf; Junming_1.JPG; Kunming_2.JPG; Kunming_3.JPG; Kunming_4.JPG

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear friends and colleagues,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125922

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu

THE OHIO STATE UNIVERSITY

Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125923

From: Jiang, Wei <jianw@musc.edu>
Sent: Thursday, November 28, 2019 11:14 AM
To: Liu, Shan-Lu;zhengzhiming4
@gmail.com;haitguo@iupui.edu;tzhou@mail.nih.gov;GCheng@mednet.ucla.edu;liangy
@umn.edu;rli@vcu.edu;wjma@ksu.edu;xjmeng@vt.edu;Zhijian.Chen@UTSouthwester
n.edu;mluo@gsu.edu;zhangyj@umd.edu;xzhu1
@umd.edu;jqiu@kumc.edu;lijun@uic.edu;fengwei.bai@usm.edu;andyu@iupui.edu;rea
chxw@vt.edu;gluo@uab.edu;ldu@nybc.org;hxu@tulane.edu;liu_fy@berkeley.edu;shita
o.li@okstate.edu;Shan.lu@umassmed.edu;Hu, Haitao;wenzheho@temple.edu;Qfeng4
@central.uh.edu;tang@bio.fsu.edu;feng.li@sdstate.edu;ruilu@lsu.edu;sxiang2
@unl.edu;qiyi.tang@howard.edu;dingsw@ucr.edu;guohua@missouri.edu;bling@tulan
e.edu;junwang@pharmacy.arizona.edu;lifang@umn.edu;wang518@umd.edu;gaos8
@upmc.edu;pewang@uchc.edu;xiangy@uthscsa.edu;fzhu@bio.fsu.edu;chen.liang@mc
gill.ca;lyuan@vt.edu;fgao@duke.edu;wangjw28@163.com;xfyu1
@zju.edu.cn;bzhao@partners.org;zyang@ksu.edu;yu.cong@nih.gov;weiming.yuan@us
c.edu;Zongdi.feng@nationwidechildrens.org;juh13
@psu.edu;hengx@missouri.edu;lsu@med.unc.edu;ywu8
@gmu.edu;jwu@whu.edu.cn;tshuo@uic.edu;Shibojiang@fudan.edu.cn;sjiang@nybc.or
g;pinwang@usc.edu;rzhao@som.umaryland.edu;shuylong@mail.sysu.edu.cn;xuefeng.li
u@georgetown.edu;yuxingli@som.umaryland.edu;shixia.wang@umassmed.edu;yhe@i
pbcams.ac.cn;Pinghui.feng@usc.edu;ju-
tao.guo@bblumberg.org;lin.liu@okstate.edu;hua.zhu@rutgers.edu;Jinhong.chang@bb
lumberg.org;jianzhu1012@gmail.com;ronghai@ucr.edu;jun.zhu@nih.gov;jliu4
@uams.edu;xiangpeng.kong@med.nyu.edu;haoquanwu@outlook.com;Wenjun.liu@de
fence.gov.au;Liang.shan@wustl.edu;hliao@duke.edu;yuan2
@upenn.edu;zxing@umn.edu;hongmin.li@health.ny.gov;pzheng@ihv.umaryland.edu;y
aliu@ihv.umaryland.edu;jxw103@case.edu;xiangguo.qiu@canada.ca;Feng
Shao;zlshi@wh.iov.cn;klan@whu.edu.cn;zengmsh@mail.sysu.edu.cn;Nan Yan;Zhang,
Rong;liliwang@upenn.edu;Linheng Li;kli1
@uthsc.edu;tsx@case.edu;ssun@mdanderson.org;ysang@tnstate.edu;wu@crystal.harv
ard.edu;Sun.Jie@mayo.edu;peijun@strubi.ox.ac.uk;jiayu@coh.org;bchen@crystal.harva
rd.edu;Wen, Haitao;Qu, Feng;Hezhao.Ji@umanitoba.ca;Li,
Zihai;zhengyo@msu.edu;zhanglinqi@tsinghua.edu.cn;wxiao@temple.edu;Whu@templ
e.edu;RSun@mednet.ucla.edu;Guangping.Gao@umassmed.edu;pzheng@ihv.umarylan
d.edu;GMSWANG@nus.edu.sg;Shi, Pei yong;yaliu@ihv.umaryland.edu;ziying-
yan@uiowa.edu;lqiao@luc.edu;yong.xiong@yale.edu;Wang,
Qiuhong;shuping_tong_md@brown.edu;pinghuif@usc.edu;gaof@im.ac.cn
Subject: Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you for sharing the information, this was a fantastic meeting, I did enjoy it at Kunming!

Wei Jiang, M.D. & M.S
Associate Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067405

Department of Microbiology and Immunology
Division of Infectious Diseases, Department of Medicine
Medical University of South Carolina
173 Ashley Ave. BSB208D
Charleston, SC 29425
Lab phone 843-876-2457
jianw@musc.edu

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, November 28, 2019 10:57 AM
To: zhengzhiming4@gmail.com <zhengzhiming4@gmail.com>; haitguo@iupui.edu <haitguo@iupui.edu>; tzhou@mail.nih.gov <tzhou@mail.nih.gov>; GCheng@mednet.ucla.edu <GCheng@mednet.ucla.edu>; liangy@umn.edu <liangy@umn.edu>; rli@vcu.edu <rli@vcu.edu>; wjma@ksu.edu <wjma@ksu.edu>; xjmeng@vt.edu <xjmeng@vt.edu>; Zhijian.Chen@UTSouthwestern.edu <Zhijian.Chen@UTSouthwestern.edu>; mluo@gsu.edu <mluo@gsu.edu>; zhangyj@umd.edu <zhangyj@umd.edu>; xzhu1@umd.edu <xzhu1@umd.edu>; jqiu@kumc.edu <jqiu@kumc.edu>; lijun@uic.edu <lijun@uic.edu>; fengwei.bai@usm.edu <fengwei.bai@usm.edu>; andyu@iupui.edu <andyu@iupui.edu>; reachxw@vt.edu <reachxw@vt.edu>; gluo@uab.edu <gluo@uab.edu>; ldu@nybc.org <ldu@nybc.org>; hxu@tulane.edu <hxu@tulane.edu>; liu_fy@berkeley.edu <liu_fy@berkeley.edu>; shitao.li@okstate.edu <shitao.li@okstate.edu>; Shan.lu@umassmed.edu <Shan.lu@umassmed.edu>; haihu@UTMB.edu <haihu@UTMB.edu>; wenzheho@temple.edu <wenzheho@temple.edu>; Qfeng4@central.uh.edu <Qfeng4@central.uh.edu>; tang@bio.fsu.edu <tang@bio.fsu.edu>; feng.li@sdstate.edu <feng.li@sdstate.edu>; ruilu@lsu.edu <ruilu@lsu.edu>; sxiang2@unl.edu <sxiang2@unl.edu>; qiyi.tang@howard.edu <qiyi.tang@howard.edu>; dingsw@ucr.edu <dingsw@ucr.edu>; guohua@missouri.edu <guohua@missouri.edu>; bling@tulane.edu <bling@tulane.edu>; junwang@pharmacy.arizona.edu <junwang@pharmacy.arizona.edu>; lifang@umn.edu <lifang@umn.edu>; wang518@umd.edu <wang518@umd.edu>; gaos8@upmc.edu <gaos8@upmc.edu>; pewang@uchc.edu <pewang@uchc.edu>; xiangy@uthscsa.edu <xiangy@uthscsa.edu>; fzhu@bio.fsu.edu <fzhu@bio.fsu.edu>; chen.liang@mcgill.ca <chen.liang@mcgill.ca>; lyuan@vt.edu <lyuan@vt.edu>; fgao@duke.edu <fgao@duke.edu>; wangjw28@163.com <wangjw28@163.com>; xfyu1@zju.edu.cn <xfyu1@zju.edu.cn>; bzhao@partners.org <bzhao@partners.org>; Jiang, Wei <jianw@musc.edu>; zyang@ksu.edu <zyang@ksu.edu>; yu.cong@nih.gov <yu.cong@nih.gov>; weiming.yuan@usc.edu <weiming.yuan@usc.edu>; Zongdi.feng@nationwidechildrens.org <Zongdi.feng@nationwidechildrens.org>; juh13@psu.edu <juh13@psu.edu>; hengx@missouri.edu <hengx@missouri.edu>; lsu@med.unc.edu <lsu@med.unc.edu>; ywu8@gmu.edu <ywu8@gmu.edu>; jwu@whu.edu.cn <jwu@whu.edu.cn>; tshuo@uic.edu <tshuo@uic.edu>; Shibojiang@fudan.edu.cn <Shibojiang@fudan.edu.cn>; sjiang@nybc.org <sjiang@nybc.org>; pinwang@usc.edu <pinwang@usc.edu>; rzhao@som.umaryland.edu <rzhao@som.umaryland.edu>; shuylong@mail.sysu.edu.cn <shuylong@mail.sysu.edu.cn>; xuefeng.liu@georgetown.edu <xuefeng.liu@georgetown.edu>; yuxingli@som.umaryland.edu <yuxingli@som.umaryland.edu>; shixia.wang@umassmed.edu <shixia.wang@umassmed.edu>; yhe@ipbcams.ac.cn <yhe@ipbcams.ac.cn>; Pinghui.feng@usc.edu <Pinghui.feng@usc.edu>; ju-tao.guo@bblumberg.org <ju-tao.guo@bblumberg.org>; lin.liu@okstate.edu <lin.liu@okstate.edu>; hua.zhu@rutgers.edu <hua.zhu@rutgers.edu>; Jinhong.chang@bblumberg.org <Jinhong.chang@bblumberg.org>; jianzhu1012@gmail.com <jianzhu1012@gmail.com>; ronghai@ucr.edu <ronghai@ucr.edu>; jun.zhu@nih.gov <jun.zhu@nih.gov>; jliu4@uams.edu <jliu4@uams.edu>; xiangpeng.kong@med.nyu.edu <xiangpeng.kong@med.nyu.edu>; haoquanwu@outlook.com <haoquanwu@outlook.com>; Wenjun.liu@defence.gov.au <Wenjun.liu@defence.gov.au>; Liang.shan@wustl.edu <Liang.shan@wustl.edu>; hliao@duke.edu <hliao@duke.edu>; yuan2@upenn.edu <yuan2@upenn.edu>; zxing@umn.edu <zxing@umn.edu>; hongmin.li@health.ny.gov <hongmin.li@health.ny.gov>; pzheng@ihv.umaryland.edu <pzheng@ihv.umaryland.edu>; yaliu@ihv.umaryland.edu <yaliu@ihv.umaryland.edu>; jxw103@case.edu <jxw103@case.edu>; xiangguo.qiu@canada.ca <xiangguo.qiu@canada.ca>; Feng Shao <shaofeng@nibs.ac.cn>; zlshi@wh.iov.cn <zlshi@wh.iov.cn>; klan@whu.edu.cn <klan@whu.edu.cn>; zengmsh@mail.sysu.edu.cn <zengmsh@mail.sysu.edu.cn>; Nan Yan <Nan.Yan@UTSouthwestern.edu>; Zhang, Rong <rongzhang@wustl.edu>; liliwang@upenn.edu <liliwang@upenn.edu>; Linheng Li <LIL@stowers.org>; kli1@uthsc.edu <kli1@uthsc.edu>; tsx@case.edu <tsx@case.edu>; ssun@mdanderson.org <ssun@mdanderson.org>; ysang@tnstate.edu <ysang@tnstate.edu>; Liu, Shan-Lu <liu.6244@osu.edu>; wu@crystal.harvard.edu <wu@crystal.harvard.edu>; Sun.Jie@mayo.edu <Sun.Jie@mayo.edu>; peijun@strubi.ox.ac.uk <peijun@strubi.ox.ac.uk>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067406

jiayu@coh.org <jiayu@coh.org>; bchen@crystal.harvard.edu <bchen@crystal.harvard.edu>; Wen, Haitao <Haitao.Wen@osumc.edu>; Qu, Feng <qu.28@osu.edu>; Hezhao.Ji@umanitoba.ca <Hezhao.Ji@umanitoba.ca>; Li, Zihai <zihai@musc.edu>; zhengyo@msu.edu <zhengyo@msu.edu>; zhanglinqi@tsinghua.edu.cn <zhanglinqi@tsinghua.edu.cn>; wxiao@temple.edu <wxiao@temple.edu>; Whu@temple.edu <Whu@temple.edu>; RSun@mednet.ucla.edu <RSun@mednet.ucla.edu>; Guangping.Gao@umassmed.edu <Guangping.Gao@umassmed.edu>; PZheng@ihv.umaryland.edu <PZheng@ihv.umaryland.edu>; GMSWANG@nus.edu.sg <GMSWANG@nus.edu.sg>; peshi@UTMB.EDU <peshi@UTMB.EDU>; yaliu@ihv.umaryland.edu <yaliu@ihv.umaryland.edu>; ziying-yan@uiowa.edu <ziying-yan@uiowa.edu>; lqiao@luc.edu <lqiao@luc.edu>; yong.xiong@yale.edu <yong.xiong@yale.edu>; Wang, Qiuhong <wang.655@osu.edu>; shuping_tong_md@brown.edu <shuping_tong_md@brown.edu>; pinghuif@usc.edu <pinghuif@usc.edu>; gaof@im.ac.cn <gaof@im.ac.cn>
Subject: Happy Thanksgiving and meeting next year, June 12-13, 2020

CAUTION: External

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu

THE OHIO STATE UNIVERSITY

Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067407

From: Jiang, Wei <jianw@musc.edu>
Sent: Thursday, November 28, 2019 11:14 AM
To: Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Shan.lu@umassmed.edu; Hu, Haitao; wenzheho@temple.edu; Qfeng4 @central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2 @unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518 @umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@ 163.com; xfyu1@zju.edu.cn; bzhao@partners.org; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; shixia.wang@umassmed.edu; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Guangping.Gao@umassmed.edu; pzheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; Shi, Pei yong; yaliu@ihv.umaryland.edu; ziying-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qiuhong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn
Subject: Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you for sharing the information, this was a fantastic meeting, I did enjoy it at Kunming!

Wei Jiang, M.D. & M.S

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125884

Associate Professor
Department of Microbiology and Immunology
Division of Infectious Diseases, Department of Medicine
Medical University of South Carolina
173 Ashley Ave. BSB208D
Charleston, SC 29425
Lab phone 843-876-2457
jianw@musc.edu

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Thursday, November 28, 2019 10:57 AM
To: zhengzhiming4@gmail.com <zhengzhiming4@gmail.com>; haitguo@iupui.edu <haitguo@iupui.edu>; tzhou@mail.nih.gov <tzhou@mail.nih.gov>; GCheng@mednet.ucla.edu <GCheng@mednet.ucla.edu>; liangy@umn.edu <liangy@umn.edu>; rli@vcu.edu <rli@vcu.edu>; wjma@ksu.edu <wjma@ksu.edu>; xjmeng@vt.edu <xjmeng@vt.edu>; Zhijian.Chen@UTSouthwestern.edu <Zhijian.Chen@UTSouthwestern.edu>; mluo@gsu.edu <mluo@gsu.edu>; zhangyj@umd.edu <zhangyj@umd.edu>; xzhu1@umd.edu <xzhu1@umd.edu>; jqiu@kumc.edu <jqiu@kumc.edu>; lijun@uic.edu <lijun@uic.edu>; fengwei.bai@usm.edu <fengwei.bai@usm.edu>; andyu@iupui.edu <andyu@iupui.edu>; reachxw@vt.edu <reachxw@vt.edu>; gluo@uab.edu <gluo@uab.edu>; ldu@nybc.org <ldu@nybc.org>; hxu@tulane.edu <hxu@tulane.edu>; liu_fy@berkeley.edu <liu_fy@berkeley.edu>; shitao.li@okstate.edu <shitao.li@okstate.edu>; Shan.lu@umassmed.edu <Shan.lu@umassmed.edu>; haihu@UTMB.edu <haihu@UTMB.edu>; wenzheho@temple.edu <wenzheho@temple.edu>; Qfeng4@central.uh.edu <Qfeng4@central.uh.edu>; tang@bio.fsu.edu <tang@bio.fsu.edu>; feng.li@sdstate.edu <feng.li@sdstate.edu>; ruilu@lsu.edu <ruilu@lsu.edu>; sxiang2@unl.edu <sxiang2@unl.edu>; qiyi.tang@howard.edu <qiyi.tang@howard.edu>; dingsw@ucr.edu <dingsw@ucr.edu>; guohua@missouri.edu <guohua@missouri.edu>; bling@tulane.edu <bling@tulane.edu>; junwang@pharmacy.arizona.edu <junwang@pharmacy.arizona.edu>; lifang@umn.edu <lifang@umn.edu>; wang518@umd.edu <wang518@umd.edu>; gaos8@upmc.edu <gaos8@upmc.edu>; pewang@uchc.edu <pewang@uchc.edu>; xiangy@uthscsa.edu <xiangy@uthscsa.edu>; fzhu@bio.fsu.edu <fzhu@bio.fsu.edu>; chen.liang@mcgill.ca <chen.liang@mcgill.ca>; lyuan@vt.edu <lyuan@vt.edu>; fgao@duke.edu <fgao@duke.edu>; wangjw28@163.com <wangjw28@163.com>; xfyu1@zju.edu.cn <xfyu1@zju.edu.cn>; bzhao@partners.org <bzhao@partners.org>; Jiang, Wei <jianw@musc.edu>; zyang@ksu.edu <zyang@ksu.edu>; yu.cong@nih.gov <yu.cong@nih.gov>; weiming.yuan@usc.edu <weiming.yuan@usc.edu>; Zongdi.feng@nationwidechildrens.org <Zongdi.feng@nationwidechildrens.org>; juh13@psu.edu <juh13@psu.edu>; hengx@missouri.edu <hengx@missouri.edu>; lsu@med.unc.edu <lsu@med.unc.edu>; ywu8@gmu.edu <ywu8@gmu.edu>; jwu@whu.edu.cn <jwu@whu.edu.cn>; tshuo@uic.edu <tshuo@uic.edu>; Shibojiang@fudan.edu.cn <Shibojiang@fudan.edu.cn>; sjiang@nybc.org <sjiang@nybc.org>; pinwang@usc.edu <pinwang@usc.edu>; rzhao@som.umaryland.edu <rzhao@som.umaryland.edu>; shuylong@mail.sysu.edu.cn <shuylong@mail.sysu.edu.cn>; xuefeng.liu@georgetown.edu <xuefeng.liu@georgetown.edu>; yuxingli@som.umaryland.edu <yuxingli@som.umaryland.edu>; shixia.wang@umassmed.edu <shixia.wang@umassmed.edu>; yhe@ipbcams.ac.cn <yhe@ipbcams.ac.cn>; Pinghui.feng@usc.edu <Pinghui.feng@usc.edu>; ju-tao.guo@bblumberg.org <ju-tao.guo@bblumberg.org>; lin.liu@okstate.edu <lin.liu@okstate.edu>; hua.zhu@rutgers.edu <hua.zhu@rutgers.edu>; Jinhong.chang@bblumberg.org <Jinhong.chang@bblumberg.org>; jianzhu1012@gmail.com <jianzhu1012@gmail.com>; ronghai@ucr.edu <ronghai@ucr.edu>; jun.zhu@nih.gov <jun.zhu@nih.gov>; jliu4@uams.edu <jliu4@uams.edu>; xiangpeng.kong@med.nyu.edu <xiangpeng.kong@med.nyu.edu>; haoquanwu@outlook.com <haoquanwu@outlook.com>; Wenjun.liu@defence.gov.au <Wenjun.liu@defence.gov.au>; Liang.shan@wustl.edu <Liang.shan@wustl.edu>; hliao@duke.edu <hliao@duke.edu>; yuan2@upenn.edu <yuan2@upenn.edu>; zxing@umn.edu <zxing@umn.edu>; hongmin.li@health.ny.gov <hongmin.li@health.ny.gov>; pzheng@ihv.umaryland.edu <pzheng@ihv.umaryland.edu>; yaliu@ihv.umaryland.edu <yaliu@ihv.umaryland.edu>; jxw103@case.edu <jxw103@case.edu>; xiangguo.qiu@canada.ca <xiangguo.qiu@canada.ca>; Feng Shao <shaofeng@nibs.ac.cn>; zlshi@wh.iov.cn <zlshi@wh.iov.cn>; klan@whu.edu.cn <klan@whu.edu.cn>; zengmsh@mail.sysu.edu.cn <zengmsh@mail.sysu.edu.cn>; Nan Yan <Nan.Yan@UTSouthwestern.edu>; Zhang, Rong <rongzhang@wustl.edu>; liliwang@upenn.edu <liliwang@upenn.edu>; Linheng Li <LIL@stowers.org>; kli1@uthsc.edu <kli1@uthsc.edu>; tsx@case.edu <tsx@case.edu>; ssun@mdanderson.org <ssun@mdanderson.org>; ysang@tnstate.edu <ysang@tnstate.edu>; Liu, Shan-Lu <liu.6244@osu.edu>; wu@crystal.harvard.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125885

<wu@crystal.harvard.edu>; Sun.Jie@mayo.edu <Sun.Jie@mayo.edu>; peijun@strubi.ox.ac.uk <peijun@strubi.ox.ac.uk>; jiayu@coh.org <jiayu@coh.org>; bchen@crystal.harvard.edu <bchen@crystal.harvard.edu>; Wen, Haitao <Haitao.Wen@osumc.edu>; Qu, Feng <qu.28@osu.edu>; Hezhao.Ji@umanitoba.ca <Hezhao.Ji@umanitoba.ca>; Li, Zihai <zihai@musc.edu>; zhengyo@msu.edu <zhengyo@msu.edu>; zhanglinqi@tsinghua.edu.cn <zhanglinqi@tsinghua.edu.cn>; wxiao@temple.edu <wxiao@temple.edu>; Whu@temple.edu <Whu@temple.edu>; RSun@mednet.ucla.edu <RSun@mednet.ucla.edu>; Guangping.Gao@umassmed.edu <Guangping.Gao@umassmed.edu>; PZheng@ihv.umaryland.edu <PZheng@ihv.umaryland.edu>; GMSWANG@nus.edu.sg <GMSWANG@nus.edu.sg>; peshi@UTMB.EDU <peshi@UTMB.EDU>; yaliu@ihv.umaryland.edu <yaliu@ihv.umaryland.edu>; ziying-yan@uiowa.edu <ziying-yan@uiowa.edu>; lqiao@luc.edu <lqiao@luc.edu>; yong.xiong@yale.edu <yong.xiong@yale.edu>; Wang, Qiuhong <wang.655@osu.edu>; shuping_tong_md@brown.edu <shuping_tong_md@brown.edu>; pinghuif@usc.edu <pinghuif@usc.edu>; gaof@im.ac.cn <gaof@im.ac.cn>
Subject: Happy Thanksgiving and meeting next year, June 12-13, 2020

CAUTION: External

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

Shan-Lu

THE OHIO STATE UNIVERSITY

Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125886

From: Sun, Jie, Ph.D. <Sun.Jie@mayo.edu>
Sent: Thursday, November 28, 2019 11:37 AM
To: Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Shan.lu@umassmed.edu; Hu, Haitao; wenzheho@temple.edu; Qfeng4 @central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2 @unl.edu; qiyi.tang@howard.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518 @umd.edu; gaos8@upmc.edu; pewang@uchc.edu; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@ 163.com; xfyu1@zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; shixia.wang@umassmed.edu; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Guangping.Gao@umassmed.edu; PZheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; Shi, Pei yong; yaliu@ihv.umaryland.edu; ziying-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qiuhong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn
Subject: Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for sharing. Happy Thanksgiving to everyone!

Best wishes,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125895

Jie

Jie Sun, Ph.D.
Associate Professor
Department of Medicine
Department of Immunology
Mayo Clinic
Stabile 8-26
200 1st St SW
Rochester, MN 55905
Tel: 507-284-9503
Email: Sun.Jie@mayo.edu
http://www.mayo.edu/research/faculty/sun-jie-ph-d/bio-20348662

From: "Liu, Shan-Lu" <liu.6244@osu.edu>
Date: Thursday, November 28, 2019 at 10:54 AM
To: "zhengzhiming4@gmail.com" <zhengzhiming4@gmail.com>, "haitguo@iupui.edu" <haitguo@iupui.edu>, "tzhou@mail.nih.gov" <tzhou@mail.nih.gov>, "GCheng@mednet.ucla.edu" <GCheng@mednet.ucla.edu>, "liangy@umn.edu" <liangy@umn.edu>, "rli@vcu.edu" <rli@vcu.edu>, "wjma@ksu.edu" <wjma@ksu.edu>, "xjmeng@vt.edu" <xjmeng@vt.edu>, "Zhijian.Chen@UTSouthwestern.edu" <Zhijian.Chen@UTSouthwestern.edu>, "mluo@gsu.edu" <mluo@gsu.edu>, "zhangyj@umd.edu" <zhangyj@umd.edu>, "xzhu1@umd.edu" <xzhu1@umd.edu>, "jqiu@kumc.edu" <jqiu@kumc.edu>, "lijun@uic.edu" <lijun@uic.edu>, "fengwei.bai@usm.edu" <fengwei.bai@usm.edu>, "andyu@iupui.edu" <andyu@iupui.edu>, "reachxw@vt.edu" <reachxw@vt.edu>, "gluo@uab.edu" <gluo@uab.edu>, "ldu@nybc.org" <ldu@nybc.org>, "hxu@tulane.edu" <hxu@tulane.edu>, "liu_fy@berkeley.edu" <liu_fy@berkeley.edu>, "shitao.li@okstate.edu" <shitao.li@okstate.edu>, "Shan.lu@umassmed.edu" <Shan.lu@umassmed.edu>, "haihu@UTMB.edu" <haihu@UTMB.edu>, "wenzheho@temple.edu" <wenzheho@temple.edu>, "Qfeng4@central.uh.edu" <Qfeng4@central.uh.edu>, "tang@bio.fsu.edu" <tang@bio.fsu.edu>, "feng.li@sdstate.edu" <feng.li@sdstate.edu>, "ruilu@lsu.edu" <ruilu@lsu.edu>, "sxiang2@unl.edu" <sxiang2@unl.edu>, "qiyi.tang@howard.edu" <qiyi.tang@howard.edu>, "dingsw@ucr.edu" <dingsw@ucr.edu>, "guohua@missouri.edu" <guohua@missouri.edu>, "bling@tulane.edu" <bling@tulane.edu>, "junwang@pharmacy.arizona.edu" <junwang@pharmacy.arizona.edu>, "lifang@umn.edu" <lifang@umn.edu>, "wang518@umd.edu" <wang518@umd.edu>, "gaos8@upmc.edu" <gaos8@upmc.edu>, "pewang@uchc.edu" <pewang@uchc.edu>, "xiangy@uthscsa.edu" <xiangy@uthscsa.edu>, "fzhu@bio.fsu.edu" <fzhu@bio.fsu.edu>, "chen.liang@mcgill.ca" <chen.liang@mcgill.ca>, "lyuan@vt.edu" <lyuan@vt.edu>, "fgao@duke.edu" <fgao@duke.edu>, "wangjw28@163.com" <wangjw28@163.com>, "xfyu1@zju.edu.cn" <xfyu1@zju.edu.cn>, "bzhao@partners.org" <bzhao@partners.org>, "jianw@musc.edu" <jianw@musc.edu>, "zyang@ksu.edu" <zyang@ksu.edu>, "yu.cong@nih.gov" <yu.cong@nih.gov>, "weiming.yuan@usc.edu" <weiming.yuan@usc.edu>, "Zongdi.feng@nationwidechildrens.org" <Zongdi.feng@nationwidechildrens.org>, "juh13@psu.edu" <juh13@psu.edu>, "hengx@missouri.edu" <hengx@missouri.edu>, "lsu@med.unc.edu" <lsu@med.unc.edu>, "ywu8@gmu.edu" <ywu8@gmu.edu>, "jwu@whu.edu.cn" <jwu@whu.edu.cn>, "tshuo@uic.edu" <tshuo@uic.edu>, "Shibojiang@fudan.edu.cn" <Shibojiang@fudan.edu.cn>, "sjiang@nybc.org" <sjiang@nybc.org>, "pinwang@usc.edu" <pinwang@usc.edu>, "rzhao@som.umaryland.edu" <rzhao@som.umaryland.edu>, "shuylong@mail.sysu.edu.cn" <shuylong@mail.sysu.edu.cn>, "xuefeng.liu@georgetown.edu" <xuefeng.liu@georgetown.edu>, "yuxingli@som.umaryland.edu" <yuxingli@som.umaryland.edu>, "shixia.wang@umassmed.edu" <shixia.wang@umassmed.edu>, "yhe@ipbcams.ac.cn" <yhe@ipbcams.ac.cn>, "Pinghui.feng@usc.edu"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125896

<Pinghui.feng@usc.edu>, "ju-tao.guo@bblumberg.org" <ju-tao.guo@bblumberg.org>, "lin.liu@okstate.edu" <lin.liu@okstate.edu>, "hua.zhu@rutgers.edu" <hua.zhu@rutgers.edu>, "Jinhong.chang@bblumberg.org" <Jinhong.chang@bblumberg.org>, "jianzhu1012@gmail.com" <jianzhu1012@gmail.com>, "ronghai@ucr.edu" <ronghai@ucr.edu>, "jun.zhu@nih.gov" <jun.zhu@nih.gov>, "jliu4@uams.edu" <jliu4@uams.edu>, "xiangpeng.kong@med.nyu.edu" <xiangpeng.kong@med.nyu.edu>, "haoquanwu@outlook.com" <haoquanwu@outlook.com>, "Wenjun.liu@defence.gov.au" <Wenjun.liu@defence.gov.au>, "Liang.shan@wustl.edu" <Liang.shan@wustl.edu>, "hliao@duke.edu" <hliao@duke.edu>, "yuan2@upenn.edu" <yuan2@upenn.edu>, "zxing@umn.edu" <zxing@umn.edu>, "hongmin.li@health.ny.gov" <hongmin.li@health.ny.gov>, "pzheng@ihv.umaryland.edu" <pzheng@ihv.umaryland.edu>, "yaliu@ihv.umaryland.edu" <yaliu@ihv.umaryland.edu>, "jxw103@case.edu" <jxw103@case.edu>, "xiangguo.qiu@canada.ca" <xiangguo.qiu@canada.ca>, Feng Shao <shaofeng@nibs.ac.cn>, "zlshi@wh.iov.cn" <zlshi@wh.iov.cn>, "klan@whu.edu.cn" <klan@whu.edu.cn>, "zengmsh@mail.sysu.edu.cn" <zengmsh@mail.sysu.edu.cn>, Nan Yan <Nan.Yan@UTSouthwestern.edu>, "Zhang, Rong" <rongzhang@wustl.edu>, "liliwang@upenn.edu" <liliwang@upenn.edu>, Linheng Li <LIL@stowers.org>, "kli1@uthsc.edu" <kli1@uthsc.edu>, "tsx@case.edu" <tsx@case.edu>, "ssun@mdanderson.org" <ssun@mdanderson.org>, "ysang@tnstate.edu" <ysang@tnstate.edu>, "Liu, Shan-Lu" <liu.6244@osu.edu>, "wu@crystal.harvard.edu" <wu@crystal.harvard.edu>, "Sun, Jie, Ph.D." <Sun.Jie@mayo.edu>, "peijun@strubi.ox.ac.uk" <peijun@strubi.ox.ac.uk>, "jiayu@coh.org" <jiayu@coh.org>, "bchen@crystal.harvard.edu" <bchen@crystal.harvard.edu>, "Wen, Haitao" <Haitao.Wen@osumc.edu>, "Qu, Feng" <qu.28@osu.edu>, "Hezhao.Ji@umanitoba.ca" <Hezhao.Ji@umanitoba.ca>, "Li, Zihai" <zihai@musc.edu>, "zhengyo@msu.edu" <zhengyo@msu.edu>, "zhanglinqi@tsinghua.edu.cn" <zhanglinqi@tsinghua.edu.cn>, "wxiao@temple.edu" <wxiao@temple.edu>, "Whu@temple.edu" <Whu@temple.edu>, "RSun@mednet.ucla.edu" <RSun@mednet.ucla.edu>, "Guangping.Gao@umassmed.edu" <Guangping.Gao@umassmed.edu>, "PZheng@ihv.umaryland.edu" <PZheng@ihv.umaryland.edu>, "GMSWANG@nus.edu.sg" <GMSWANG@nus.edu.sg>, "peshi@UTMB.EDU" <peshi@UTMB.EDU>, "yaliu@ihv.umaryland.edu" <yaliu@ihv.umaryland.edu>, "ziying-yan@uiowa.edu" <ziying-yan@uiowa.edu>, "lqiao@luc.edu" <lqiao@luc.edu>, "yong.xiong@yale.edu" <yong.xiong@yale.edu>, "Wang, Qiuhong" <wang.655@osu.edu>, "shuping_tong_md@brown.edu" <shuping_tong_md@brown.edu>, "pinghuif@usc.edu" <pinghuif@usc.edu>, "gaof@im.ac.cn" <gaof@im.ac.cn>
Subject: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125897

All best wishes, and happy holidays!

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125898

From: Sun, Jie, Ph.D. <Sun.Jie@mayo.edu>
Sent: Thursday, November 28, 2019 11:37 AM
To: Liu, Shan-Lu;zhengzhiming4@gmail.com;haitguo@iupui.edu;tzhou@mail.nih.gov;GCheng@mednet.ucla.edu;liangy@umn.edu;rli@vcu.edu;wjma@ksu.edu;xjmeng@vt.edu;Zhijian.Chen@UTSouthwestern.edu;mluo@gsu.edu;zhangyj@umd.edu;xzhu1@umd.edu;jqiu@kumc.edu;lijun@uic.edu;fengwei.bai@usm.edu;andyu@iupui.edu;reachxw@vt.edu;gluo@uab.edu;ldu@nybc.org;hxu@tulane.edu;liu_fy@berkeley.edu;shitao.li@okstate.edu;Shan.lu@umassmed.edu;Hu, Haitao;wenzheho@temple.edu;Qfeng4@central.uh.edu;tang@bio.fsu.edu;feng.li@sdstate.edu;ruilu@lsu.edu;sxiang2@unl.edu;qiyi.tang@howard.edu;dingsw@ucr.edu;guohua@missouri.edu;bling@tulane.edu;junwang@pharmacy.arizona.edu;lifang@umn.edu;wang518@umd.edu;gaos8@upmc.edu;pewang@uchc.edu;xiangy@uthscsa.edu;fzhu@bio.fsu.edu;chen.liang@mcgill.ca;lyuan@vt.edu;fgao@duke.edu;wangjw28@163.com;xfyu1@zju.edu.cn;bzhao@partners.org;jianw@musc.edu;zyang@ksu.edu;yu.cong@nih.gov;weiming.yuan@usc.edu;Zongdi.feng@nationwidechildrens.org;juh13@psu.edu;hengx@missouri.edu;lsu@med.unc.edu;ywu8@gmu.edu;jwu@whu.edu.cn;tshuo@uic.edu;Shibojiang@fudan.edu.cn;sjiang@nybc.org;pinwang@usc.edu;rzhao@som.umaryland.edu;shuylong@mail.sysu.edu.cn;xuefeng.liu@georgetown.edu;yuxingli@som.umaryland.edu;shixia.wang@umassmed.edu;yhe@ipbcams.ac.cn;Pinghui.feng@usc.edu;ju-tao.guo@bblumberg.org;lin.liu@okstate.edu;hua.zhu@rutgers.edu;Jinhong.chang@bblumberg.org;jianzhu1012@gmail.com;ronghai@ucr.edu;jun.zhu@nih.gov;jliu4@uams.edu;xiangpeng.kong@med.nyu.edu;haoquanwu@outlook.com;Wenjun.liu@defence.gov.au;Liang.shan@wustl.edu;hliao@duke.edu;yuan2@upenn.edu;zxing@umn.edu;hongmin.li@health.ny.gov;pzheng@ihv.umaryland.edu;yaliu@ihv.umaryland.edu;jxw103@case.edu;xiangguo.qiu@canada.ca;Feng Shao;zlshi@wh.iov.cn;klan@whu.edu.cn;zengmsh@mail.sysu.edu.cn;Nan Yan;Zhang, Rong;liliwang@upenn.edu;Linheng Li;kli1@uthsc.edu;tsx@case.edu;ssun@mdanderson.org;ysang@tnstate.edu;wu@crystal.harvard.edu;peijun@strubi.ox.ac.uk;jiayu@coh.org;bchen@crystal.harvard.edu;Wen, Haitao;Qu, Feng;Hezhao.Ji@umanitoba.ca;Li, Zihai;zhengyo@msu.edu;zhanglinqi@tsinghua.edu.cn;wxiao@temple.edu;Whu@temple.edu;RSun@mednet.ucla.edu;Guangping.Gao@umassmed.edu;PZheng@ihv.umaryland.edu;GMSWANG@nus.edu.sg;Shi, Pei yong;yaliu@ihv.umaryland.edu;ziying-yan@uiowa.edu;lqiao@luc.edu;yong.xiong@yale.edu;Wang, Qiuhong;shuping_tong_md@brown.edu;pinghuif@usc.edu;gaof@im.ac.cn
Subject: Re: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for sharing. Happy Thanksgiving to everyone!

Best wishes,

Jie

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067401

Jie Sun, Ph.D.
Associate Professor
Department of Medicine
Department of Immunology
Mayo Clinic
Stabile 8-26
200 1st St SW
Rochester, MN 55905
Tel: 507-284-9503
Email: Sun.Jie@mayo.edu
http://www.mayo.edu/research/faculty/sun-jie-ph-d/bio-20348662

From: "Liu, Shan-Lu" <liu.6244@osu.edu>
Date: Thursday, November 28, 2019 at 10:54 AM
To: "zhengzhiming4@gmail.com" <zhengzhiming4@gmail.com>, "haitguo@iupui.edu" <haitguo@iupui.edu>, "tzhou@mail.nih.gov" <tzhou@mail.nih.gov>, "GCheng@mednet.ucla.edu" <GCheng@mednet.ucla.edu>, "liangy@umn.edu" <liangy@umn.edu>, "rli@vcu.edu" <rli@vcu.edu>, "wjma@ksu.edu" <wjma@ksu.edu>, "xjmeng@vt.edu" <xjmeng@vt.edu>, "Zhijian.Chen@UTSouthwestern.edu" <Zhijian.Chen@UTSouthwestern.edu>, "mluo@gsu.edu" <mluo@gsu.edu>, "zhangyj@umd.edu" <zhangyj@umd.edu>, "xzhu1@umd.edu" <xzhu1@umd.edu>, "jqiu@kumc.edu" <jqiu@kumc.edu>, "lijun@uic.edu" <lijun@uic.edu>, "fengwei.bai@usm.edu" <fengwei.bai@usm.edu>, "andyu@iupui.edu" <andyu@iupui.edu>, "reachxw@vt.edu" <reachxw@vt.edu>, "gluo@uab.edu" <gluo@uab.edu>, "ldu@nybc.org" <ldu@nybc.org>, "hxu@tulane.edu" <hxu@tulane.edu>, "liu_fy@berkeley.edu" <liu_fy@berkeley.edu>, "shitao.li@okstate.edu" <shitao.li@okstate.edu>, "Shan.lu@umassmed.edu" <Shan.lu@umassmed.edu>, "haihu@UTMB.edu" <haihu@UTMB.edu>, "wenzheho@temple.edu" <wenzheho@temple.edu>, "Qfeng4@central.uh.edu" <Qfeng4@central.uh.edu>, "tang@bio.fsu.edu" <tang@bio.fsu.edu>, "feng.li@sdstate.edu" <feng.li@sdstate.edu>, "ruilu@lsu.edu" <ruilu@lsu.edu>, "sxiang2@unl.edu" <sxiang2@unl.edu>, "qiyi.tang@howard.edu" <qiyi.tang@howard.edu>, "dingsw@ucr.edu" <dingsw@ucr.edu>, "guohua@missouri.edu" <guohua@missouri.edu>, "bling@tulane.edu" <bling@tulane.edu>, "junwang@pharmacy.arizona.edu" <junwang@pharmacy.arizona.edu>, "lifang@umn.edu" <lifang@umn.edu>, "wang518@umd.edu" <wang518@umd.edu>, "gaos8@upmc.edu" <gaos8@upmc.edu>, "pewang@uchc.edu" <pewang@uchc.edu>, "xiangy@uthscsa.edu" <xiangy@uthscsa.edu>, "fzhu@bio.fsu.edu" <fzhu@bio.fsu.edu>, "chen.liang@mcgill.ca" <chen.liang@mcgill.ca>, "lyuan@vt.edu" <lyuan@vt.edu>, "fgao@duke.edu" <fgao@duke.edu>, "wangjw28@163.com" <wangjw28@163.com>, "xfyu1@zju.edu.cn" <xfyu1@zju.edu.cn>, "bzhao@partners.org" <bzhao@partners.org>, "jianw@musc.edu" <jianw@musc.edu>, "zyang@ksu.edu" <zyang@ksu.edu>, "yu.cong@nih.gov" <yu.cong@nih.gov>, "weiming.yuan@usc.edu" <weiming.yuan@usc.edu>, "Zongdi.feng@nationwidechildrens.org" <Zongdi.feng@nationwidechildrens.org>, "juh13@psu.edu" <juh13@psu.edu>, "hengx@missouri.edu" <hengx@missouri.edu>, "lsu@med.unc.edu" <lsu@med.unc.edu>, "ywu8@gmu.edu" <ywu8@gmu.edu>, "jwu@whu.edu.cn" <jwu@whu.edu.cn>, "tshuo@uic.edu" <tshuo@uic.edu>, "Shibojiang@fudan.edu.cn" <Shibojiang@fudan.edu.cn>, "sjiang@nybc.org" <sjiang@nybc.org>, "pinwang@usc.edu" <pinwang@usc.edu>, "rzhao@som.umaryland.edu" <rzhao@som.umaryland.edu>, "shuylong@mail.sysu.edu.cn" <shuylong@mail.sysu.edu.cn>, "xuefeng.liu@georgetown.edu" <xuefeng.liu@georgetown.edu>, "yuxingli@som.umaryland.edu" <yuxingli@som.umaryland.edu>, "shixia.wang@umassmed.edu" <shixia.wang@umassmed.edu>, "yhe@ipbcams.ac.cn" <yhe@ipbcams.ac.cn>, "Pinghui.feng@usc.edu" <Pinghui.feng@usc.edu>, "ju-tao.guo@bblumberg.org" <ju-tao.guo@bblumberg.org>, "lin.liu@okstate.edu"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067402

<lin.liu@okstate.edu>, "hua.zhu@rutgers.edu" <hua.zhu@rutgers.edu>, "Jinhong.chang@bblumberg.org" <Jinhong.chang@bblumberg.org>, "jianzhu1012@gmail.com" <jianzhu1012@gmail.com>, "ronghai@ucr.edu" <ronghai@ucr.edu>, "jun.zhu@nih.gov" <jun.zhu@nih.gov>, "jliu4@uams.edu" <jliu4@uams.edu>, "xiangpeng.kong@med.nyu.edu" <xiangpeng.kong@med.nyu.edu>, "haoquanwu@outlook.com" <haoquanwu@outlook.com>, "Wenjun.liu@defence.gov.au" <Wenjun.liu@defence.gov.au>, "Liang.shan@wustl.edu" <Liang.shan@wustl.edu>, "hliao@duke.edu" <hliao@duke.edu>, "yuan2@upenn.edu" <yuan2@upenn.edu>, "zxing@umn.edu" <zxing@umn.edu>, "hongmin.li@health.ny.gov" <hongmin.li@health.ny.gov>, "pzheng@ihv.umaryland.edu" <pzheng@ihv.umaryland.edu>, "yaliu@ihv.umaryland.edu" <yaliu@ihv.umaryland.edu>, "jxw103@case.edu" <jxw103@case.edu>, "xiangguo.qiu@canada.ca" <xiangguo.qiu@canada.ca>, Feng Shao <shaofeng@nibs.ac.cn>, "zlshi@wh.iov.cn" <zlshi@wh.iov.cn>, "klan@whu.edu.cn" <klan@whu.edu.cn>, "zengmsh@mail.sysu.edu.cn" <zengmsh@mail.sysu.edu.cn>, Nan Yan <Nan.Yan@UTSouthwestern.edu>, "Zhang, Rong" <rongzhang@wustl.edu>, "liliwang@upenn.edu" <liliwang@upenn.edu>, Linheng Li <LIL@stowers.org>, "kli1@uthsc.edu" <kli1@uthsc.edu>, "tsx@case.edu" <tsx@case.edu>, "ssun@mdanderson.org" <ssun@mdanderson.org>, "ysang@tnstate.edu" <ysang@tnstate.edu>, "Liu, Shan-Lu" <liu.6244@osu.edu>, "wu@crystal.harvard.edu" <wu@crystal.harvard.edu>, "Sun, Jie, Ph.D." <Sun.Jie@mayo.edu>, "peijun@strubi.ox.ac.uk" <peijun@strubi.ox.ac.uk>, "jiayu@coh.org" <jiayu@coh.org>, "bchen@crystal.harvard.edu" <bchen@crystal.harvard.edu>, "Wen, Haitao" <Haitao.Wen@osumc.edu>, "Qu, Feng" <qu.28@osu.edu>, "Hezhao.Ji@umanitoba.ca" <Hezhao.Ji@umanitoba.ca>, "Li, Zihai" <zihai@musc.edu>, "zhengyo@msu.edu" <zhengyo@msu.edu>, "zhanglinqi@tsinghua.edu.cn" <zhanglinqi@tsinghua.edu.cn>, "wxiao@temple.edu" <wxiao@temple.edu>, "Whu@temple.edu" <Whu@temple.edu>, "RSun@mednet.ucla.edu" <RSun@mednet.ucla.edu>, "Guangping.Gao@umassmed.edu" <Guangping.Gao@umassmed.edu>, "PZheng@ihv.umaryland.edu" <PZheng@ihv.umaryland.edu>, "GMSWANG@nus.edu.sg" <GMSWANG@nus.edu.sg>, "peshi@UTMB.EDU" <peshi@UTMB.EDU>, "yaliu@ihv.umaryland.edu" <yaliu@ihv.umaryland.edu>, "ziying-yan@uiowa.edu" <ziying-yan@uiowa.edu>, "lqiao@luc.edu" <lqiao@luc.edu>, "yong.xiong@yale.edu" <yong.xiong@yale.edu>, "Wang, Qiuhong" <wang.655@osu.edu>, "shuping_tong_md@brown.edu" <shuping_tong_md@brown.edu>, "pinghuif@usc.edu" <pinghuif@usc.edu>, "gaof@im.ac.cn" <gaof@im.ac.cn>
Subject: [EXTERNAL] Happy Thanksgiving and meeting next year, June 12-13, 2020

Dear friends and colleagues,

I wish you all a great Thanksgiving holiday!

A few updates:

1. We will have our first scientific meeting on June 12-13, 2020, right before the ASV annual meeting (June 13-17) in Fort Collins, Colorado State University. Organizing and scientific committees will be formed soon.
2. I am excited to share that Dr. Xiang-Jin (XJ) Meng of Virginia Tech, a distinguished virology and a member of the US National Academy of Science, will be the keynote speaker of this meeting. Details will follow.
3. In addition to scientific programs, we will also hold an election; a new leadership team will be elected to serve our community for the next two years.
4. Attached please find a brief report of our Kunming meeting, along with a few photos.

Please let me know if you have comments and suggestions.

All best wishes, and happy holidays!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067403

Shan-Lu



Shan-Lu Liu, M.D., Ph.D.
Professor
Co-Director, Viruses and Emerging Pathogens Program
Infectious Diseases Institute
Center for Retrovirus Research
Departments of Veterinary Biosciences, Microbial Infection and Immunity, and Microbiology
The Ohio State University
1900 Coffey Rd, Room 480 VMAB
Columbus, Ohio 43210
Phone: (614) 292-8690
Fax: (614) 292-6473
Email: liu.6244@osu.edu; shan-lu.liu@osumc.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067404

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, December 20, 2019 2:26 PM
To: Shi, Pei yong;LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)'
Cc: Lowenthal, Micah
Subject: Topics for China bio meeting
Attachments: Wuhan 2020 draft program Chinese and English.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

As promised, here is the agenda we received from Zhiming. They propose:

Session 1: Emerging Infectious Diseases and Global Health Security
Session 2: Reality and Challenges of the Prevention and Control of African Swine Fever
Session 3: Gene Editing and Synthetic Biology
Session 4: Management and Operation of Biosafety Laboratory

On the phone you proposed to add talks on:
1) The Brucella outbreak (in Longzhou?)
2) Crimean-Congo Hemorrhagic Fever final clearance
3) Tree shrew animal model (highlighting the work done at the Kunming lab).
4) and a session about the future of the U.S. China partnership and future collaboration (maybe as an invitation only final session).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, November 20, 2019 11:42 AM
To: 'Shi, Pei yong' <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119
Importance: High

Hi Pei-yong, Dave and Jim,

Pei-yong, sounds like good news! Thanks for continuing to work this.

I used Google translate to quickly translate the email text and the Chinese portions of the proposed program agenda (attached). It's essentially an initial modification of the program agenda from the last meeting we held in Wuhan. Yes it would be good to do this sooner than May of 2020. I am available to talk this afternoon or tomorrow late afternoon.

FOIA Confidential Treatment Requested by Univ of Texas System

Ben

***

Challenges - Conference Program (Discussion Draft)

Dear Professor,

Hello!

After discussion, we further revised the meeting plan of the 5th China-US Symposium on Newly Communicable Infectious Diseases, Laboratory Safety and Global Health Security Challenges. Please see the attachment for your review. After the topic of the meeting is finalized, we will send an invitation to the expert and confirm the subject of the report.

please know this, thanks!

Chen teasing
Wuhan Institute of Virology, Chinese Academy of Sciences
Research Planning Office 027-87197115
Mobile: 18963869921

***

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Wednesday, November 20, 2019 10:01 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: RE: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Hi Ben, Dave, and Jim,

Here are two highlights about Zhiming's meeting proposal.

1. The meeting will continue to focus on emerging infectious diseases, laboratory operation and safety, synthetic biology in infectious diseases, and control of African swine fever virus.
2. Although the proposed date is on May 13-14, Zhiming agrees to change it to an earlier time.

Jim and I would like to invite an expert on tree shrew animal model from Kunming to present at the upcoming meeting. UTMB is initiating a collaboration with the Institute of Medical Biology on using tree shrew as new models for viral infections.

Let's have a TC to discuss when you have time.

Best, Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Tuesday, November 19, 2019 8:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: Re: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Thanks, Jim
I just communicated with Zhiming again. He still hasn't received the final approval, but is very optimistic about receiving it soon. I will keep my fingers on him.
Best, Pei-Yong

Get Outlook for Android

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, November 19, 2019 8:37:23 PM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: Re: 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

Good news. Let's get a translation so we can understand the details.

Thanks very much for pushing this through.

Jim

Sent from my iPhone

> On Nov 19, 2019, at 8:24 PM, Shi, Pei yong <peshi@utmb.edu> wrote:
>
> Hi Ben, Dave, and Jim,
> After several rounds of follow up with Zhiming, I have just received their meeting proposal. This proposal has been included for their approval process in China. We could discuss, modify, and give them our feedbacks.
> Best wishes,
> Pei-Yong
>
> Get Outlook for Android
>
> ---
>
> **From:** chendd@wh.iov.cn <chendd@wh.iov.cn>
> **Sent:** Tuesday, November 19, 2019 3:42:02 AM
> **To:** Shi, Pei yong <peshi@UTMB.EDU>
> **Cc:** 袁志明 <yzm@wh.iov.cn>; 张子超 <zhangzc@wh.iov.cn>; zhangyh <zhangyh@wh.iov.cn>
> **Subject:** 第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002684

尊敬的史教授，

您好！

经讨论，我们进一步修订了第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会的会议方案，见附件，敬请您收阅。待会议主题确定后，我们将向专家发布邀请函，并与其确认报告主题。

请知悉，谢谢！

陈逗逗
中国科学院武汉病毒研究所
科研计划处 027-87197115
手机：18963986921
chendd@wh.iov.cn

发件人： chendd@wh.iov.cn
发送时间： 2019-10-29 09:05
收件人： peshi
抄送： 袁志明; 张子超
主题： 敬请查收：第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（稿）

尊敬的史教授，

您好！

敬请查收《第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（稿）》，谢谢您！

祝好！

陈逗逗
中国科学院武汉病毒研究所
科研计划处 027-87197115
手机：18963986921
chendd@wh.iov.cn

<第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会-会议方案（讨论稿）20191119.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002685

第五届中美新发传染病、实验室安全与全球卫生安全挑战研讨会会议方案（讨论稿）

（2020 年 5 月 13-14 日，中国湖北黄冈）

为进一步加强中美两国相关领域研究人员的学术交流和合作，中美第五届新发传染病、实验室安全与全球卫生安全挑战研讨会将于 2020 年 5 月 13-14 日在湖北黄冈召开。会议将重点围绕全球公共卫生安全、非洲猪瘟病毒防控研究、合成生物学和生物安全实验室运行管理等问题展开研讨。通过汇集中美两国在相关领域的杰出科技成果报告，反映相关研究最新进展，及时沟通和了解全球卫生安全领域出现的新情况、新问题，发挥中美合作与联合攻关的优势，更好地应对新发突发传染病疫情，保障实验室安全和全球卫生安全，为中美两国乃至人类健康事业做出贡献。

Deleted: ¶

Formatted: Centered, Indent: First line: 0"

The 5th China-US New Infectious Disease, Laboratory Safety and Global Health Security Challenge Seminar meeting plan (discussion draft)

(May 13-14, 2020, Huanggang, Hubei, China)

To further strengthen the academic exchanges and cooperation between researchers in related fields in China and the United States, the 5th China-US Symposium on New Infectious Diseases, Laboratory Safety and Global Health Security Challenge will be held in Huanggang, Hubei, on May 13-14, 2020. Held. The conference will focus on issues such as global public health security, African hog virus prevention and control research, synthetic biology and biosafety laboratory operation management. By bringing together the outstanding scientific and technological achievements reports of China and the United States in related fields, reflecting the latest developments in relevant research, timely communicating and understanding the new situations and new problems in the field of global health and safety, and giving full play to the advantages of Sino-US cooperation and joint research, better Responding to new outbreaks of infectious diseases, ensuring laboratory safety and global health security, and contributing to the cause of China and the United States and even human health.

Deleted: ¶

主办单位： 中国科学院、美国科学院

承办单位： 中国科学院生物安全大科学研究中心

会议主席： 袁志明（中国科学院武汉病毒研究所，研究员）

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002686

美方，待定

会议组委会：高　福（中国科学院微生物研究所，院士）

王延轶（中国科学院武汉病毒研究所，所长）

龚　鹏（中国科学院武汉病毒研究所，副所长）

石正丽（中国科学院武汉病毒研究所，研究员）

美方，待定

美方，待定

美方，待定

会议地点：湖北省黄冈市

会议形式：大会报告、小组讨论

会议语言：英语

Organizer: Chinese Academy of Sciences, American Academy of Sciences

Organizer: Center for Biosafety Science, Chinese Academy of Sciences

Chairman of the meeting: Yuan Zhiming (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Conference Organizing Committee: US, to be determined

Gao Fu (Academician, Institute of Microbiology, Chinese Academy of Sciences)

Wang Yanxi (Director, Wuhan Institute of Virology, Chinese Academy of Sciences)

Gong Peng (Deputy Director, Wuhan Institute of Virology, Chinese Academy of Sciences)

Shi Zhengli (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

US, to be determined

US, to be determined

US, to be determined

Venue: Huanggang City, Hubei Province

Form of meeting: Conference report, group discussion

Conference language: English

会议议题：

1. 新发传染病和全球公共卫生安全
   Emerging Infectious Diseases and Global Health Security
2. 非洲猪瘟防控研究的现实与挑战
   Reality and Challenges of The Prevention and Control of African Swine Fever
3. 基因编辑和合成生物学
   Gene Editing and Synthetic Biology
4. 生物安全实验室的管理和运行

FOIA Confidential Treatment Requested by Univ of Texas System

Management and Operation of Biosafety Laboratory

拟邀嘉宾（美方）

Diane E. Griffin（美国科学院，副院长/院士）
Linda Saif （美国俄亥俄州立大学，院士）
David Relman（美国斯坦福大学，院士）
James W. Le Duc（美国德克萨斯大学加尔维斯顿国家实验室，教授）
Thomas Ksiazek（美国德克萨斯大学加尔维斯顿国家实验室，教授）
David R. Franz（美国陆军传染病医学研究所，教授）
Benjamin J. Rusek（美国科学院，高级项目官员）
Shi Peiyong（美国德克萨斯大学，教授）
David Swayne（美国农业部东南家禽研究实验室，主任）

拟邀嘉宾（中方）

高　福（中国疾病预防控制中心，中国科学院院士）
徐建国（中国疾病预防控制中心传染病预防控制所，中国工程院院士）
步志高（中国农业科学院哈尔滨兽医研究所，研究员）
胡云章（中国医学科学院医学生物学研究所，研究员）
秦成峰（中国军事科学院军事医学研究院，教授）
程　功（清华大学，研究员）
陆家海（中山大学，教授）
张卫文（天津大学，教授）
待　定（中南财经政法大学）
武桂珍（中国疾病预防控制中心病毒病预防控制所，研究员）
梁米芳（中国疾病预防控制中心病毒病预防控制所，研究员）
张先恩（中国科学院生物物理研究所，研究员）
唐　宏（中国科学院上海巴斯德研究所，研究员）
刘文军（中国科学院微生物研究所，研究员）
郑永唐（中国科学院昆明动物研究所，研究员）
石正丽（中国科学院武汉病毒研究所，研究员）
胡志红（中国科学院武汉病毒研究所，研究员）
龚　睿（中国科学院武汉病毒研究所，研究员）
袁志明（中国科学院武汉病毒研究所，研究员）
待　定（中国科学院国际合作局）

Gao Fu (Chinese Center for Disease Control and Prevention, Chinese Academy of Sciences)
Xu Jianguo (Infectious Disease Prevention and Control Institute, Chinese Center for Disease

FOIA Confidential Treatment Requested by Univ of Texas System

Control and Prevention, Academician of Chinese Academy of Engineering)

Bu Zhigao (Researcher, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences)

Hu Yunzhang (Researcher, Institute of Medical Biology, Chinese Academy of Medical Sciences)

Qin Chengfeng (Professor, Academy of Military Medical Sciences, Chinese Academy of Military Sciences)

Cheng Gong (Tsinghua University, Researcher)

Lu Jiahai (Zhongshan University, Professor)

Zhang Weiwen (Tianjin University, Professor)

To be determined (Zhongnan University of Economics and Law)

Wu Guizhen (Researcher, Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention)

Liang Mifang (Researcher, Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention)

Zhang Xianen (Researcher, Institute of Biophysics, Chinese Academy of Sciences)

Tang Hong (Researcher, Shanghai Pasteur Institute, Chinese Academy of Sciences)

Liu Wenjun (Researcher, Institute of Microbiology, Chinese Academy of Sciences)

Zheng Yongtang (Researcher, Kunming Institute of Zoology, Chinese Academy of Sciences)

Shi Zhengli (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Hu Zhihong (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Gong Rui (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

Yuan Zhiming (Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences)

To be determined (International Cooperation Bureau of the Chinese Academy of Sciences)

Deleted: ¶

会议日程（报告主题待定）：

Meeting schedule (report topic to be determined):

Date	Time	Agenda
Tuesday 12nd May	14:00-21:00	Registration Address: Island International Hotel Huanggang No.8 Xingang 2nd Road, Huangzhou District, Huanggang
	19:00-21:00	Dinner
Wednesday	09:00-10:00	Welcome and opening remarks

FOIA Confidential Treatment Requested by Univ of Texas System

13rd May		*Chair – **Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* China: **Yanyi Wang** (Director General/Principle Investigator, Wuhan Institute of Virology, CAS) U.S.: Diane E. Griffin(*Proposed*,Academician, National Academy of Sciences) To be confirmed
	10:00-10:30	Tea break and group photo
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair – **Peiyong Shi** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**George F. Gao** (Academician, Institute of Microbiology, CAS)
	10:50-11:10	**Linda Saif** (Academician, Ohio State University)
	11:10-11:30	**Zhengli Shi** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:30-11:50	**James Le Duc** (Professor, Galveston National Laboratory)
	11:50-14:00	Lunch
	Session 1: Emerging Infectious Diseases and Global Health Security *Chair –**Zhiming Yuan** (Proposed, Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**Jianguo Xu** (Academician, National Institute for Communicable Disease Control and Prevention, China CDC)
	14:20-14:40	**Peiyong Shi** (Professor, University of Texas)
	14:40-15:00	**Yunzhang Hu** (Principle Investigator, Institute of Medical Biology, CAMS)
	15:00-15:30	**Gong Cheng** (Professor, Tsinghua University)
	15:30-15:50	**Rui Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:50-16:10	Tea break
	16:10-16:30	**Chengfeng Qin** (Professor, The Academy of Military Medical Sciences)
	16:30-16:50	**David Swayne** (Director, USDA Southeast Poultry Research Laboratory)
	16:50-17:10	**Jiahai Lu** (Professor, Sun Yat-sen University)
	17:10-17:30	**Hong Tang** (Director General/Principle Investigator, Institut Pasteur Shanghai, CAS)
	17:30-17:50	**Peng Gong** (Principle Investigator, Wuhan Institute of Virology, CAS)

FOIA Confidential Treatment Requested by Univ of Texas System

	17:50-19:00	Dinner
Thursday 14th May	**Session 2: Reality and Challenges of The Prevention and Control of African Swine Fever** *Chair –**Peng Gong** (Proposed, Deputy Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	08:30-08:50	**Diane E. Griffin** (Academician, National Academy of Sciences)
	08:50-09:10	**Xian'en Zhang** (Principle Investigator, Institute of Biophysics, CAS)
	09:10-09:30	**Zhigao Bu** (Director General/Principle Investigator, Harbin Veterinary Research Institute, CAAS)
	09:30-09:50	**Guizhen Wu** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	09:50-10:10	**Yanyi Wang** *(Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*
	10:10-10:30	Tea break
	Session 3: Gene Editing and Synthetic Biology *Chair –**James Le Duc** (Proposed, Professor, University of Texas)*	
	10:30-10:50	**Mifang Liang** (Principle Investigator, National Institute for Viral Disease Control and Prevention, China CDC)
	10:50-11:10	**Thomas Ksiazek** (Professor, Galveston National Laboratory)
	11:10-11:20	**Weiwen Zhang** (Professor, Tianjin University)
	11:20-11:40	**Zhihong Hu** (Principle Investigator, Wuhan Institute of Virology, CAS)
	11:40-12:00	To be confirmed (Zhongnan University of Economics and Law)
	12:00-14:00	Lunch
	Session 4 : Management and Operation of Biosafety Laboratory *Chair –**Yanyi Wang** (Proposed, Director General/Principle Investigator, Wuhan Institute of Virology, CAS)*	
	14:00-14:20	**David Relman** (Academician, Stanford University)
	14:20-14:40	**Wenjun Liu** (Principle Investigator, Institute of Microbiology, CAS)
	14:40-15:00	**Yongtang Zheng** (Principle Investigator, Kunming Institute of Zoology, CAS)
	15:00-15:20	**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)
	15:20-15:50	Tea break
	15:50-16:50	Round Table Discussion *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–**James Le Duc** (Professor, Galveston National Laboratory)*

FOIA Confidential Treatment Requested by Univ of Texas System

Friday 15th May	16:50-17:30	Conclusions *Chair –**Zhiming Yuan** (Principle Investigator, Wuhan Institute of Virology, CAS)* *–To be confirmed* - Conclusions from the meeting and discussion on possible roles of CAS and NAS to enhance cooperation between the U.S. and China on Emerging Infections, Laboratory Safety and Global Health Security - Concluding remarks
	17:30-19:00	Dinner Leave

From: Liu, Shan-Lu <liu.6244@osu.edu>
Sent: Sunday, December 29, 2019 8:56 AM
To: zhengzhiming4
@gmail.com;haitguo@iupui.edu;tzhou@mail.nih.gov;GCheng@mednet.ucla.edu;liangy
@umn.edu;rli@vcu.edu;wjma@ksu.edu;xjmeng@vt.edu;Zhijian.Chen@UTSouthwester
n.edu;mluo@gsu.edu;zhangyj@umd.edu;xzhu1
@umd.edu;jqiu@kumc.edu;lijun@uic.edu;fengwei.bai@usm.edu;andyu@iupui.edu;rea
chxw@vt.edu;gluo@uab.edu;ldu@nybc.org;hxu@tulane.edu;liu_fy@berkeley.edu;shita
o.li@okstate.edu;Shan.lu@umassmed.edu;Hu, Haitao;wenzheho@temple.edu;Qfeng4
@central.uh.edu;tang@bio.fsu.edu;feng.li@sdstate.edu;ruilu@lsu.edu;sxiang2
@unl.edu;qiyi.tang@howard.edu;dingsw@ucr.edu;guohua@missouri.edu;bling@tulan
e.edu;junwang@pharmacy.arizona.edu;lifang@umn.edu;wang518@umd.edu;gaos8
@upmc.edu;pewang@uchc.edu;xiangy@uthscsa.edu;fzhu@bio.fsu.edu;chen.liang@mc
gill.ca;lyuan@vt.edu;fgao@duke.edu;wangjw28@163.com;xfyu1
@zju.edu.cn;bzhao@partners.org;jianw@musc.edu;zyang@ksu.edu;yu.cong@nih.gov;
weiming.yuan@usc.edu;Zongdi.feng@nationwidechildrens.org;juh13
@psu.edu;hengx@missouri.edu;lsu@med.unc.edu;ywu8
@gmu.edu;jwu@whu.edu.cn;tshuo@uic.edu;Shibojiang@fudan.edu.cn;sjiang@nybc.or
g;pinwang@usc.edu;rzhao@som.umaryland.edu;shuylong@mail.sysu.edu.cn;xuefeng.li
u@georgetown.edu;yuxingli@som.umaryland.edu;shixia.wang@umassmed.edu;yhe@i
pbcams.ac.cn;Pinghui.feng@usc.edu;ju-
tao.guo@bblumberg.org;lin.liu@okstate.edu;hua.zhu@rutgers.edu;Jinhong.chang@bb
lumberg.org;jianzhu1012@gmail.com;ronghai@ucr.edu;jun.zhu@nih.gov;jliu4
@uams.edu;xiangpeng.kong@med.nyu.edu;haoquanwu@outlook.com;Wenjun.liu@de
fence.gov.au;Liang.shan@wustl.edu;hliao@duke.edu;yuan2
@upenn.edu;zxing@umn.edu;hongmin.li@health.ny.gov;pzheng@ihv.umaryland.edu;y
aliu@ihv.umaryland.edu;jxw103@case.edu;xiangguo.qiu@canada.ca;Feng
Shao;zlshi@wh.iov.cn;klan@whu.edu.cn;zengmsh@mail.sysu.edu.cn;Nan Yan;Zhang,
Rong;liliwang@upenn.edu;Linheng Li;kli1
@uthsc.edu;tsx@case.edu;ssun@mdanderson.org;ysang@tnstate.edu;Liu, Shan-
Lu;wu@crystal.harvard.edu;Sun.Jie@mayo.edu;peijun@strubi.ox.ac.uk;jiayu@coh.org;b
chen@crystal.harvard.edu;Wen, Haitao;Qu, Feng;Hezhao.Ji@umanitoba.ca;Li,
Zihai;zhengyo@msu.edu;zhanglinqi@tsinghua.edu.cn;wxiao@temple.edu;Whu@templ
e.edu;RSun@mednet.ucla.edu;Guangping.Gao@umassmed.edu;PZheng@ihv.umarylan
d.edu;GMSWANG@nus.edu.sg;Shi, Pei yong;yaliu@ihv.umaryland.edu;ziying-
yan@uiowa.edu;lqiao@luc.edu;yong.xiong@yale.edu;Wang,
Qiuhong;shuping_tong_md@brown.edu;pinghuif@usc.edu;gaof@im.ac.cn;zihai@musc
.edu;zqin@uams.edu;guodeyin@www.sysu.edu.cn
Subject: ACVA/SCBA-Virology Division: 2019 Year in Review
Attachments: ACVASCBA-Virology 2019 year in review.pdf

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Colleagues and Friends:

Happy new year! I wish you all a healthy and productive 2020!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067368

I would like to share the below summary on our major activities in 2019.

ACVA/SCBA-Virology Division: 2019 Year in Review (chronologically)

1. Continuous and focused discussion on the Science letter "Racial Profiling Harms Science" (original title "Racial Profiling Harms American Science and Innovation").

2. Seven Chinese or Chinese American scientists, including 5 members of ACVA/SCBA-Virology Division, elected to the American Academy of Microbiology (AAM) - Genhong Cheng（程根宏）, Pinghui Feng （冯平辉）, Guangping Gao (高光坪）, Jake T Liang （連展阳）, Zhengli Shi （石正丽）, Yumei Wen (闻玉梅), Richard Zhao （赵玉琪）.

3. Themed discussion on the universal influenza vaccine, vectored ImmunoProphylaxis, and attenuated influenza vaccine.

4. Themed discussion of Open Access journal publishing.

5. Debate and discussion on the definition of "racial profiling": Chinese translations, differences between "racial profiling" and "racial discrimination", and differences in Chinese translations: " 种族标签，种族偏见，种族歧视".

6. Themed discussion on virus-host evolutionary arms races: HIV and others.

7. Ultimate publication of the Science letter on March 21, 2019 (online) – sagas and stories behind the scenes.

8. Responses to the Science letter and media reports – "The Scientist", "知识分子", and others.

9. Discussion and responses to US institution's statements, Emory/MD Anderson faculty firing, and NIH's foreign influences and FBI investigations.

10. Establishment of the ACVA/SCBA-Virology Division website (https://sites.google.com/view/scba-virology/home), as well as collection and distribution of membership list (https://sites.google.com/view/scba-virology/members).

11. Dr. George F. Gao elected to the US National Academy of Sciences as International Member (formerly called Foreign Associate).

12. Dr. Zongdi Feng (冯枞棣) won the 2019 ASV's Ann Palmenberg Junior Investigator's award.

13. ACVA/SCBA-Virology participation in the 17th SCBA International Symposium, Kunming, July 24-28, 2019, and scientific workshop and social gathering at the 2nd ACVA/SCBA-virology meeting in Kunming, July 28, 2019.

14. Response and discussion on the role of $\alpha 4\beta 7$ antibody in the control of HIV/SIV infection: 3 Science papers with all negative results - what has gone wrong and what is next?

15. Dr. Feng Shao won the 2019 Future Scientific Prize in Biological Sciences: congratulations and discussions on the scientific evaluation systems in China – ideas and solutions.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067369

16. Three members among the 2019 Journal of Virology top 25 reviewers: Drs. Dongdi Feng (冯枞棣), Bin He (何斌), and Dong-Yan Jin (金冬雁); note that Dr. Bin He is PhD advisor of Dr. Feng, and both have been on the list multiple times, including 2018 (Drs. Ju-tao Guo and Jianming Hu were among the 2018's JVI top 25 reviewers)

17. Response and discussion about the 2019 Lasker award for the discovery of T and B development.

18. Overwhelming responses to Dr. Xuetao Cao's publication issues raised by Pubpeer.com, and heated discussion on scientific misconduct in general.

19. Heated discussion on publishing in CNS (Cell, Nature and Science), selection of conference speakers, and scientific community networking.

20. Themed discussion on self-plagiarism and direct feedback from Editor in Chiefs of Journal of Virology (Roz Sandri-Goldin), Journal of Immunology (Gene Oltz), Viruses (Eric Freed), Emerging Microbes and Infections (Shan Lu), etc.

21. Themed discussion on publications of structural biology studies in CNS - a scientific favor or true advance in biology?

22. Themed discussion on US patents and institution royalties - why are they different?

23. Themed discussion on viral entry: definition of viral receptors – requirements and pitfalls.

Shan-Lu Liu, MD, PhD
President of ACVA/SCBA-Virology
The Ohio State University

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_067370

From: Shi, Pei yong
Sent: Wednesday, January 8, 2020 10:01 AM
To: Rusek, Benjamin;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com)
Subject: RE: China virus: Specter of new illness emerging from Wuhan raises alarms across Asia - The Washington Post

Thanks, Ben

This could be added to our joint meeting agenda. I hope they/we have identified the pathogen by then. I know Wuhan Institute of Virology and some of the speakers from our previous joint meetings are playing a key role in investigating it. Of course, George Gao should know the current status.

Happy New Year!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, January 8, 2020 9:29 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: China virus: Specter of new illness emerging from Wuhan raises alarms across Asia - The Washington Post

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

https://www.washingtonpost.com/world/asia_pacific/specter-of-possible-new-virus-emerging-from-central-china-raises-alarms-across-asia/2020/01/08/3d33046c-312f-11ea-971b-43bec3ff9860_story.html

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071550

From: LeDuc, James W.
Sent: Tuesday, January 21, 2020 4:34 PM
To: Benjamin Rusek (BRusek@nas.edu);Dave Franz (davidrfranz@gmail.com);Yuan Zhiming;George F GAO;Mifang Liang;Shi, Pei yong
Subject: Op Ed in Houston Chronicle
Attachments: Chinese Response to New Virus_Le Duc 21Jan revised.docx

Ben, Dave, Zhiming, George, Mifang and Pei-Yong

The attached, slightly modified to include mention of the new case in Washington State, is scheduled to appear in Wednesday 22 Jan's Houston Chronicle. Note mention of the NASEM/CAS collaborations.

Just FYI,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051126

Chinese Response to New Virus: Good News/Bad News

By James W. Le Duc

Fast action and open communications by China is helping the world prepare for another potentially devastating infectious disease outbreak. While the situation is rapidly evolving, there is good news that may not make the headlines. Many will recall the dark days in the spring of 2003 when Asia and the world were threatened by the appearance of a new virus disease, Severe Acute Respiratory Syndrome, or SARS, which first appeared in southern China and quickly spread to other countries around the world, ultimately causing over 8000 cases with nearly 10% of those ending in death. SARS was caused by a novel coronavirus then unknown to medical science. There was no known cure, no diagnostic tests and little understanding of where it came from or how it was spread, although person-to-person transmission was obvious as health care workers treating the first cases were themselves among the early victims. Initially, China was reluctant to share information or alert the international community of the magnitude of the epidemic, leading to international criticism and a dangerous global health situation. Fortunately, China reversed its position, opened to collaborations with the WHO, U.S. and others, and the epidemic was eventually controlled.

Today, with another novel coronavirus discovered in China, the start is very different. In quick measure, Chinese health officials recognized that a new disease had emerged, quickly isolated patients, and instituted an impressive set of interventions in attempts to limit disease spread and characterize the new pathogen. Importantly, they have been transparent in sharing their findings with the world, thus allowing other nations to take precautions and be on the lookout for the new disease. Already, the genome of the new virus was sequenced and posted for easy access by international experts, allowing rapid exploration of possible treatments, development of diagnostics and epidemiological investigations.

China's ability to respond quickly and efficiently to this new threat is the result of nearly two decades of investments and collaborations to improve public health in China. The Chinese Centers for Disease Control incorporates many of the strengths of our own CDC, but is designed to meet the needs of a 1.4 billion plus population. In addition, China has invested in building a robust scientific capacity and partnered with containment laboratories such as ours to incorporate best practices when studying dangerous pathogens.

FOIA Confidential Treatment Requested by Univ of Texas System

The current outbreak demonstrates a welcome openness to health information sharing with the global community. To diagnose an outbreak early requires astute healthcare providers able to recognize when something new or unusual is occurring; however, clinical recognition alone is meaningless if there is no capacity to investigate cases or characterize the disease-causing agent.

For the last few years, our National Academy of Science, Engineering and Medicine has worked with the Chinese Academy of Sciences to build relationships and share information on emerging diseases and advancements in vaccines and treatments. In Galveston, we welcomed leading Chinese health officials to collaborate on biocontainment facility design, biosafety training and laboratory operations. This dialogue, along with U.S.-based educational opportunities for Chinese students, benefit us all.

China's response to the new coronavirus demonstrates their investments in physical laboratories and scientific collaborations over the past decade are paying dividends, not only to China, but the entire world. Control of a new disease efficiently transmitted person-to-person is nearly impossible as we witnessed during the 2009 novel influenza pandemic and much must still be done together during this quickly evolving situation.

The outbreak is still in the early stages, but it is now clear that the new virus may be transmitted person-to-person, although the efficiency of such transmission remains in question. A few hundred patients have been identified, deaths occurred and the disease has spread from the epicenter in Wuhan to major cities in China and other Asian countries. Our CDC is now screening travelers arriving from Wuhan at U.S. airports, and the WHO is set to consider a global emergency response. With millions about to travel for the Chinese New Year, avoiding a global catastrophe must be the current goal.

The good news is that, at a time when US-China relations are being tested on many fronts, relations within the public health and scientific research arenas remain open and positive, which lays a solid foundation for curtailing this latest threat.

James Le Duc, PhD, is the Director of the Galveston National Laboratory at the University of Texas Medical Branch and a professor in UTMB's Department of Microbiology and Immunology.

705 words in body

From: 袁志明 <yzm@wh.iov.cn>
Sent: Wednesday, January 22, 2020 6:30 AM
To: LeDuc, James W.
Cc: Benjamin Rusek (BRusek@nas.edu);Dave Franz (davidrfranz@gmail.com);George F GAO;Mifang Liang;Shi, Pei yong
Subject: Re: Op Ed in Houston Chronicle

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim,
Thanks for your information and your positive attitute to Chinese public health response system and the practice. We are still work hard the on the novel coronovirus and hope to get the help from your team.

Regards

Zhiming

-----原始邮件-----

发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>

发送时间:2020-01-22 06:33:54 (星期三)

收件人: "Benjamin Rusek (BRusek@nas.edu)" <BRusek@nas.edu>, "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Yuan Zhiming" <yzm@wh.iov.cn>, "George F GAO" <gaof@im.ac.cn>, "Mifang Liang" <mifangl@hotmail.com>, "Shi, Pei yong" <peshi@UTMB.EDU>

抄送:

主题: Op Ed in Houston Chronicle

Ben, Dave, Zhiming, George, Mifang and Pei-Yong

The attached, slightly modified to include mention of the new case in Washington State, is scheduled to appear in Wednesday 22 Jan's Houston Chronicle. Note mention of the NASEM/CAS collaborations.

Just FYI,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009098

From: LeDuc, James W.
Sent: Wednesday, January 22, 2020 9:29 AM
To: 袁志明
Cc: Benjamin Rusek (BRusek@nas.edu);Dave Franz (davidrfranz@gmail.com);George F GAO;Mifang Liang;Shi, Pei yong
Subject: Re: Op Ed in Houston Chronicle

Thanks Zhiming. You are in a very challenging position and doing a great job. I would however recommend that you organize and quickly implement a way to share reference isolates. With cases occurring outside China, others will soon have their own isolates and China will have lost the opportunity for leadership. And if scientific publications start appearing from Chinese investigators without the world having independent access to a strain, China will likely be heavily criticized.

Keep up the good work

Jim

Sent from my iPhone

On Jan 22, 2020, at 6:30 AM, 袁志明 <yzm@wh.iov.cn> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim,
Thanks for your information and your positive attitute to Chinese public health response system and the practice. We are still work hard the on the novel coronovirus and hope to get the help from your team.

Regards

Zhiming

-----原始邮件-----

发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>

发送时间:2020-01-22 06:33:54 (星期三)

收件人: "Benjamin Rusek (BRusek@nas.edu)" <BRusek@nas.edu>, "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Yuan Zhiming" <yzm@wh.iov.cn>, "George F GAO" <gaof@im.ac.cn>, "Mifang Liang" <mifangl@hotmail.com>, "Shi, Pei yong" <peshi@UTMB.EDU>

抄送:

主题: Op Ed in Houston Chronicle

Ben, Dave, Zhiming, George, Mifang and Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008819

The attached, slightly modified to include mention of the new case in Washington State, is scheduled to appear in Wednesday 22 Jan's Houston Chronicle. Note mention of the NASEM/CAS collaborations.

Just FYI,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008820

From: Yuan Zhiming <yzm@wh.iov.cn>
Sent: Thursday, January 23, 2020 8:03 PM
To: Shi, Pei yong;LeDuc, James W.
Cc: brusek;David Franz;George F GAO;mifangl
Subject: 回复: RE: Op Ed in Houston Chronicle

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all,
Thanks for your suggestion and I do agree with you. I will try my best to promote the sharing of strain and experience betweet us and let you know later.

Regards

Zhiming

==========
Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480
==========

From: Shi, Pei yong
Date: 2020-01-22 23:56
To: LeDuc, James W.; 袁志明
CC: Benjamin Rusek (BRusek@nas.edu); Dave Franz (davidrfranz@gmail.com); George F GAO; Mifang Liang
Subject: RE: Op Ed in Houston Chronicle
I totally agree with Jim. The timing is critical here.

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, January 22, 2020 9:29 AM
To: 袁志明 <yzm@wh.iov.cn>
Cc: Benjamin Rusek (BRusek@nas.edu) <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; George F GAO <gaof@im.ac.cn>; Mifang Liang <mifangl@hotmail.com>; Shi,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007702

Pei yong <peshi@UTMB.EDU>
Subject: Re: Op Ed in Houston Chronicle

Thanks Zhiming. You are in a very challenging position and doing a great job. I would however recommend that you organize and quickly implement a way to share reference isolates. With cases occurring outside China, others will soon have their own isolates and China will have lost the opportunity for leadership. And if scientific publications start appearing from Chinese investigators without the world having independent access to a strain, China will likely be heavily criticized.

Keep up the good work

Jim
Sent from my iPhone

On Jan 22, 2020, at 6:30 AM, 袁志明 <yzm@wh.iov.cn> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim,
Thanks for your information and your positive attitute to Chinese public health response system and the practice. We are still work hard the on the novel coronovirus and hope to get the help from your team.

Regards

Zhiming

-----原始邮件-----

发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>

发送时间:2020-01-22 06:33:54 (星期三)

收件人: "Benjamin Rusek (BRusek@nas.edu)" <BRusek@nas.edu>, "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Yuan Zhiming" <yzm@wh.iov.cn>, "George F GAO" <gaof@im.ac.cn>, "Mifang Liang" <mifangl@hotmail.com>, "Shi, Pei yong" <peshi@UTMB.EDU>

抄送:

主题: Op Ed in Houston Chronicle

Ben, Dave, Zhiming, George, Mifang and Pei-Yong

The attached, slightly modified to include mention of the new case in Washington State, is scheduled to appear in Wednesday 22 Jan's Houston Chronicle. Note mention of the NASEM/CAS collaborations.

Just FYI,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007703

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007704

From: LeDuc, James W. [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=937DF08E29C4439E88A04BABFFB162AD-JWLEDUC]
Sent: 1/23/2020 9:20:12 PM
To: Yuan Zhiming [yzm@wh.iov.cn]
CC: Shi, Pei yong [peshi@UTMB.EDU]; brusek [BRusek@nas.edu]; David Franz [davidrfranz@gmail.com]; George F GAO [gaof@im.ac.cn]; mifangl [mifangl@hotmail.com]
Subject: Re: Op Ed in Houston Chronicle

Wonderful news. This is the right decision at the right time. Let me know if we can help.

Keep up the great work! Jim

Sent from my iPhone

On Jan 23, 2020, at 9:03 PM, Yuan Zhiming <yzm@wh.iov.cn> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear all,
Thanks for your suggestion and I do agree with you. I will try my best to promote the sharing of strain and experience betweet us and let you know later.

Regards

Zhiming

==========
Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480
==========

From: Shi, Pei yong
Date: 2020-01-22 23:56
To: LeDuc, James W.; 袁志明
CC: Benjamin Rusek (BRusek@nas.edu); Dave Franz (davidrfranz@gmail.com); George F GAO; Mifang Liang
Subject: RE: Op Ed in Houston Chronicle
I totally agree with Jim. The timing is critical here.

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, January 22, 2020 9:29 AM
To: 袁志明 <yzm@wh.iov.cn>
Cc: Benjamin Rusek (BRusek@nas.edu) <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; George F GAO <gaof@im.ac.cn>; Mifang Liang <mifangl@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Op Ed in Houston Chronicle

Thanks Zhiming. You are in a very challenging position and doing a great job. I would however recommend that you organize and quickly implement a way to share reference isolates. With cases occurring outside China, others will soon have their own isolates and China will have lost the opportunity for leadership. And if scientific publications start appearing from Chinese investigators without the world having independent access to a strain, China will likely be heavily criticized.

Keep up the good work

Jim
Sent from my iPhone

On Jan 22, 2020, at 6:30 AM, 袁志明 <yzm@wh.iov.cn> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim,
Thanks for your information and your positive attitute to Chinese public health response system and the practice. We are still work hard the on the novel coronovirus and hope to get the help from your team.

Regards

Zhiming

-----原始邮件-----
发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>
发送时间:2020-01-22 06:33:54 (星期三)
收件人: "Benjamin Rusek (BRusek@nas.edu)" <BRusek@nas.edu>, "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Yuan Zhiming" <yzm@wh.iov.cn>, "George F GAO" <gaof@im.ac.cn>, "Mifang Liang" <mifangl@hotmail.com>, "Shi, Pei yong" <peshi@UTMB.EDU>
抄送:
主题: Op Ed in Houston Chronicle

Ben, Dave, Zhiming, George, Mifang and Pei-Yong

The attached, slightly modified to include mention of the new case in Washington State, is scheduled to appear in Wednesday 22 Jan's Houston Chronicle. Note mention of the NASEM/CAS collaborations.

Just FYI,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, January 26, 2020 12:48 AM
To: LeDuc, James W.
Cc: Diane Griffin;Margaret Hamburg;Dave Franz;Shi, Pei yong;Raimer, Ben G.;Ksiazek, Thomas G.;Niesel, David W.;Urban, Randall J.;Weaver, Scott;Lowenthal, Micah;Boright, John;JohnHildebrand
Subject: Re: NCoV isolate
Attachments: Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx; ATT00001.htm

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003182

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Sharing of isolates of the 2019 Novel Coronavirus

Dr. Gao Fu
Director-General,
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to urge the Chinese Center for Disease Control and Prevention and the Chinese Academy of Sciences (CAS), either together or in coordination, to share isolates of the **2019 Novel Coronavirus (2019 nCoV) with experts in other countries for collaborative analysis and furtherance of public health.** We are still relatively early in the outbreak and China has taken important steps to identify and contain the outbreak and to share sequence data to study the strain, but the global scientific community remains hampered by the lack of access to an isolate of the new virus. China has the opportunity to show global leadership in response to such cases, but the window for doing so is closing rapidly.

As you know, over the past several years, we along with Dr. James Le Duc, Dr. David Franz, and other representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you, Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese scientists to organize a series of meetings, now an informal dialogue among experts designated by NASEM, the Chinese Academy of Sciences (CAS), the China Center for Disease Control and Prevention (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), the Chinese Academy of Medical Sciences. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the meetings. Meetings have been held in Beijing, Wuhan, Galveston, Texas, and the CAAS Veterinary Institute in Harbin, China, and we plan to hold the next meeting near Wuhan in the spring, if circumstances allow.
Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate us to work together to help address this situation.


The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

We hope that you will embrace this approach and that China will not miss this opportunity for leadership.

Sincerely,

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM





...

FOIA Confidential Treatment Requested by Univ of Texas System

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

Ben, Diane, Peggy
I'm sure you have been following the emergence of the new Coronavirus in China and beyond with concern. While much is being done to prepare nations for possible cases, the global scientific community remains hampered by the lack of access to an isolate of the new virus. Sequences data has been provided, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.

With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address this growing threat.

We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importance of harnessing the world's scientific capacity to help address this emerging threat.

Can we urgently draft an official letter for Diane or Peggy's signature?

Thanks for your consideration and help.

Jim

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Sharing of isolates of the 2019 Novel Coronavirus

Dr. Gao Fu
Director-General,
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

We are writing to urge the Chinese Center for Disease Control and Prevention and the Chinese Academy of Sciences (CAS), either together or in coordination, to share isolates of the **2019 Novel Coronavirus (2019 nCoV) with experts in other countries for collaborative analysis and furtherance of public health.** We are still relatively early in the outbreak and China has taken important steps to identify and contain the outbreak and to share sequence data to study the strain, but the global scientific community remains hampered by the lack of access to an isolate of the new virus. China has the opportunity to show global leadership in response to such cases, but the window for doing so is closing rapidly.

As you know, over the past several years, we along with Dr. James Le Duc, Dr. David Franz, and other representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you, Dr. Yuan Zhiming, Professor and Deputy Director, Wuhan Institute of Virology, CAS, and other Chinese scientists to organize a series of meetings, now an informal dialogue among experts designated by NASEM, the Chinese Academy of Sciences (CAS), the China Center for Disease Control and Prevention (CCDC), the Chinese Academy of Agricultural Sciences (CAAS), the Chinese Academy of Medical Sciences. These dialogue meetings have been designed to allow scientists from China and the United States to share research findings, best practices, and lessons learned and to create collaborative partnerships in areas identified during the meetings. Meetings have been held in Beijing, Wuhan, Galveston, Texas, and the CAAS Veterinary Institute in Harbin, China, and we plan to hold the next meeting near Wuhan in the spring, if circumstances allow.
Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate us to work together to help address this situation.


The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

We hope that you will embrace this approach and that China will not miss this opportunity for leadership.

Sincerely,

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM





...

FOIA Confidential Treatment Requested by Univ of Texas System

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=8906C46397AE48488FCC55537DC5D6D3-SHI, PEI YO]
Sent: 1/26/2020 9:10:42 AM
To: LeDuc, James W. [jwleduc@UTMB.EDU]; Rusek, Benjamin [BRusek@nas.edu]
CC: Diane Griffin [dgriffi6@jhmi.edu]; Margaret Hamburg [MargaretAHamburg@aol.com]; Dave Franz [davidrfranz@gmail.com]; Raimer, Ben G. [bgraimer@UTMB.EDU]; Ksiazek, Thomas G. [tgksiaze@UTMB.EDU]; Niesel, David W. [dniesel@UTMB.EDU]; Urban, Randall J. [rurban@UTMB.EDU]; Weaver, Scott [sweaver@UTMB.EDU]; Lowenthal, Micah [mlowenth@nas.edu]; Boright, John [JBoright@nas.edu]; JohnHildebrand [jhildebr@email.arizona.edu]
Subject: RE: NCoV isolate
Attachments: Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 26 2020.docx

Hi Ben,

Please see my edits of the letter. I just spoke to Zhiming. I agree with Jim that we should not mention Zhiming's name in this letter.

Please send it to George Gao and President Bai.

Thanks.

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Sunday, January 26, 2020 8:26 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Margaret Hamburg <MargaretAHamburg@aol.com>; Dave Franz <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

I think the letter is fine although I'm concerned about calling out Zhiming by name. I welcome others thoughts if this might call undue attention to him personally

Thanks for your rapid response. Suggest sending asap.

Jim

Sent from my iPhone

On Jan 26, 2020, at 12:49 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

> On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> Ben, Diane, Peggy
> I'm sure you have been following the emergence of the new Coronavirus in China and beyond with concern. While much is being done to prepare nations for possible cases, the global scientific community remains hampered by the lack of access to an isolate of the new virus. Sequences data has been provided, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.
>
> With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address this growing threat.
>
> We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importance of harnessing the world's scientific capacity to help address this emerging threat.
>
> Can we urgently draft an official letter for Diane or Peggy's signature?
>
> Thanks for your consideration and help.
>
> Jim
>
> Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Sunday, January 26, 2020 10:21 AM
To: LeDuc, James W.
Cc: Ksiazek, Thomas G.;Rusek, Benjamin;Diane Griffin;Dave Franz;Shi, Pei yong;Raimer, Ben G.;Niesel, David W.;Urban, Randall J.;Weaver, Scott;Boright, John;JohnHildebrand;Peggy Hamburg;Turekian, Vaughan
Subject: RE: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,
Thanks, and yes.
With the approval from Diane, Peggy, and John Hildebrand, and this endorsement by you (Jim), Dave, and Pei-Yong on the general text, Ben and I will do some minor editing to correct typos, grammar, and formatting according to Diane and Peggy's preferences. Peggy is also going to consult Victor Dzau. Further e-mails may be to a reduced distribution.
Because Ben and I are on travel and don't have access to some of our old e-mails or addresses, could you send the address you have for George Gao?
Thanks to all.
Micah

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Sunday, January 26, 2020 11:10 AM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>; Peggy Hamburg <peggy@hbfam.net>
Subject: Re: NCoV isolate

BEI is Biodefense and emerging infections research resources repository.

Don't you think the the letter should originate from NASEM rather than from UTMB?

Thanks. Jim

Sent from my iPhone

> On Jan 26, 2020, at 9:29 AM, Lowenthal, Micah <mlowenth@nas.edu> wrote:
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> All,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003163

I'm modifying the thread slightly to include Peggy's preferred address and some of the e-mails that she may have missed. Note that both Diane Griffin and John Hildebrand have weighed in in favor of the idea to send such a letter.
Also, sorry to be ignorant, but what is a BEI partner?
Micah

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:25 AM
To: Dave Franz <davidrfranz@gmail.com>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Thanks, Tom and Dave

Hi Ben,
I have included Tom's suggestion. Please use this version.

Best,
Pei-Yong

-----Original Message-----
From: Dave Franz <davidrfranz@gmail.com>
Sent: Sunday, January 26, 2020 10:19 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: James W. LeDuc <jwleduc@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Tom Ksiazek <tgksiaze@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Scott C. "Curtis" Weaver <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

Concur with Jim and Pei Yong's thoughts/edits. Dave

From: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:18 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Margaret Hamburg <MargaretAHamburg@aol.com>; Dave Franz <davidrfranz@gmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003164

In this paragraph

The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Should probably be modified

The University of Texas Medical Branch has volunteered to serve as home to the virus in its capacity as the World Reference Center for Emerging Viruses and Arboviruses and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Tom Ksiazek

Sent from a portable device

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:11 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Margaret Hamburg <MargaretAHamburg@aol.com>; Dave Franz <davidrfranz@gmail.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Hi Ben,

Please see my edits of the letter. I just spoke to Zhiming. I agree with Jim that we should not mention Zhiming's name in this letter.

Please send it to George Gao and President Bai.

Thanks.

- Pei-Yong

On Jan 26, 2020, at 00:49, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003165

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

> On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> Ben, Diane, Peggy
> I'm sure you have been following the emergence of the new Coronavirus in China and beyond with concern. While much is being done to prepare nations for possible cases, the global scientific community remains hampered by the lack of access to an isolate of the new virus. Sequences data has been provided, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.
>
> With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address this growing threat.
>
> We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importance of harnessing the world's scientific capacity to help address this emerging threat.
>
> Can we urgently draft an official letter for Diane or Peggy's signature?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003166

Thanks for your consideration and help.

Jim

Sent from my iPhone

<Edited letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 26 2020.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003167

From: LeDuc, James W.
Sent: Monday, January 27, 2020 9:17 AM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com);Shi, Pei yong
Subject: RE: NCoV isolate

This is a perfect example of the exceptional value of having the dialogue with China that you and the NAS have pioneered. I hope that we can leverage this experience into some sustained funding to keep the relationship vibrant.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:59 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Very happy to help, sounds like with this change it's ready to go. Diane will likely send it out soon.

Ben

On Jan 27, 2020, at 8:23 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

I think Peggy's suggested change is appropriate and otherwise it's ready to go. There are other efforts underway to get the isolates as well, so hopefully we'll get this done soon.

Thanks for your help in moving this along! Enjoy India.

Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 7:53 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Peggy Hamburg <peggy@hbfam.net>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim could you take a final look?

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010194

On Jan 27, 2020, at 7:09 PM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Do we think that it is ready?

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:02 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

And when this is ready Diane should send it to Bai Chunli [using clbai@cas.cn, JH-cao@cashq.ac.cn, sunhui@cashq.ac.cn] and Gao Fu [using gaof@im.ac.cn]

Probably want to cc Peggy and Jim and maybe John Hildebrand and John Boright

Kind regards,

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Monday, January 27, 2020 6:27 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>
Subject: FW: NCoV isolate

Jim,
Connecting you back to the discussion here. See below.
Micah

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, January 27, 2020 5:01 AM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: Re: NCoV isolate

Jim,

FOIA Confidential Treatment Requested by Univ of Texas System

Any thoughts on my question below. I am fine with letter as is, but does Iswem like situation has evolved a bit but still crucial to encourage Chinese to share isolates.

Peggy
Sent from my iPhone

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, January 27, 2020 7:06 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: Re: NCoV isolate

Micah, Peggy, Jim et al - I think that the letter is fine to send. I agree that the situation is changing, but it is still going to be important to compare the viruses that emerge in other countries with Chinese isolates over time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

> On Jan 27, 2020, at 2:10 AM, Lowenthal, Micah <mlowenth@nas.edu> wrote:
>
> Peggy,
> Perhaps I closed down discussion too early. Please feel free to reopen with Jim Le Duc. You can include others, but I would focus on the people you want to hear from.
> Also, we might want to note the MOU signed between UTMB and Chinese virology research organizations as the rationale for promoting UTMB as the partner. But that's up to you and Diane to decide.
>
> Micah
>
> > On Jan 27, 2020, at 9:20 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
> >
> > Hello. I think it is a strong letter. However, has the argument shifted somewhat? Given that cases are occurring in many places now the opportunity to gather isolates does not depend on Chinese, however the ability to get full understanding of the virus and it's evolution would be greatly advanced by expanded sharing of isolates.
> >
> > Peggy

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010196

Sent from my iPhone

On Jan 26, 2020, at 9:29 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Hi Diane and Peggy,

Here is a clean copy for your review, we are working to get you the correct email addresses and email routing for Gao Fu and Bai Chunli.

Micah notes that at the top of the letter, we say that work is hampered by the lack of an *isolate*. Lower down, we refer to sharing *isolates*. Should this be consistently plural?

Kind regards,

Ben

From: Rusek, Benjamin
Sent: Sunday, January 26, 2020 11:30 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Here is a version with these changes and a few other small edits.

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Sunday, January 26, 2020 9:08 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Ben,
We'll have to do some minor editing on the letter to correct typos from our original draft (replace focused in with focused on, near the end), to make it read a little better ("China has taken important lead to identify" just isn't good English), and some formatting according to Diane and Peggy's preferences. I would suggest unbolding the text and possibly formatting it more like a regular letter with return address, but that decision is up those who sign it.
Micah

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010197

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:25 AM
To: Dave Franz <davidrfranz@gmail.com>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Thanks, Tom and Dave

Hi Ben,
I have included Tom's suggestion. Please use this version.

Best,
Pei-Yong

From: Dave Franz <davidrfranz@gmail.com>
Sent: Sunday, January 26, 2020 9:21 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Benjamin Rusek <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

…and think Tom's point strengthens the letter as well. dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010198

On Jan 26, 2020, at 9:17 AM, Ksiazek, Thomas G. <tgksiaze@UTMB.EDU> wrote:

In this paragraph

The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Should probably be modified

The University of Texas Medical Branch has volunteered to serve as home to the virus in its capacity as the World Reference Center for Emerging Viruses and Arboviruses and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Tom Ksiazek

Sent from a portable device

On Jan 26, 2020, at 00:49, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010199

not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010200

Ben, Diane, Peggy I'm sure you have been following the emergence of the new Coronavirus in China and beyond with concern. While much is being done to prepare nations for possible cases, the global scientific community remains hampered by the lack of access to an isolate of the new virus. Sequences data has been provide

FOIA Confidential Treatment Requested by Univ of Texas System

d, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.

With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010202

point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010203

this growing threat.

We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importa

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010204

nce of harness ing the world's scientifi c capacit y to help address this emergi ng threat.

Can we urgentl y draft an official letter for Diane or Peggy's signatu re?

Thanks for your conside ration and help.

Jim

Sent from my iPhone

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 27 2020.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010205

From: LeDuc, James W.
Sent: Monday, January 27, 2020 9:17 AM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Shi, Pei yong
Subject: RE: NCoV isolate

This is a perfect example of the exceptional value of having the dialogue with China that you and the NAS have pioneered. I hope that we can leverage this experience into some sustained funding to keep the relationship vibrant.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:59 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Very happy to help, sounds like with this change it's ready to go. Diane will likely send it out soon.

Ben

> On Jan 27, 2020, at 8:23 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> I think Peggy's suggested change is appropriate and otherwise it's ready to go. There are other efforts underway to get the isolates as well, so hopefully we'll get this done soon.
>
> Thanks for your help in moving this along! Enjoy India.
>
> Jim
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Monday, January 27, 2020 7:53 AM
> **To:** Diane Griffin <dgriffi6@jhmi.edu>
> **Cc:** Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Peggy Hamburg <peggy@hbfam.net>
> **Subject:** Re: NCoV isolate
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> Jim could you take a final look?
>
> Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124840

On Jan 27, 2020, at 7:09 PM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Do we think that it is ready?

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:02 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

And when this is ready Diane should send it to Bai Chunli [using clbai@cas.cn, JH-cao@cashq.ac.cn, sunhui@cashq.ac.cn] and Gao Fu [using gaof@im.ac.cn]

Probably want to cc Peggy and Jim and maybe John Hildebrand and John Boright

Kind regards,

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Monday, January 27, 2020 6:27 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>
Subject: FW: NCoV isolate

Jim,
Connecting you back to the discussion here. See below.
Micah

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, January 27, 2020 5:01 AM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: Re: NCoV isolate

Jim,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124841

Any thoughts on my question below. I am fine with letter as is, but does Iswem like situation has evolved a bit but still crucial to encourage Chinese to share isolates.

Peggy
Sent from my iPhone

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, January 27, 2020 7:06 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: Re: NCoV isolate

Micah, Peggy, Jim et al - I think that the letter is fine to send. I agree that the situation is changing, but it is still going to be important to compare the viruses that emerge in other countries with Chinese isolates over time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

> On Jan 27, 2020, at 2:10 AM, Lowenthal, Micah <mlowenth@nas.edu> wrote:
>
> Peggy,
> Perhaps I closed down discussion too early. Please feel free to reopen with Jim Le Duc. You can include others, but I would focus on the people you want to hear from.
> Also, we might want to note the MOU signed between UTMB and Chinese virology research organizations as the rationale for promoting UTMB as the partner. But that's up to you and Diane to decide.
>
> Micah
>
> > On Jan 27, 2020, at 9:20 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
> >
> > Hello. I think it is a strong letter. However, has the argument shifted somewhat? Given that cases are occurring in many places now the opportunity to gather isolates does not depend on Chinese, however the ability to get full understanding of the virus and it's evolution would be greatly advanced by expanded sharing of isolates.
> >
> > Peggy

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124842

Sent from my iPhone

On Jan 26, 2020, at 9:29 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Hi Diane and Peggy,

Here is a clean copy for your review, we are working to get you the correct email addresses and email routing for Gao Fu and Bai Chunli.

Micah notes that at the top of the letter, we say that work is hampered by the lack of an *isolate*. Lower down, we refer to sharing *isolates*. Should this be consistently plural?

Kind regards,

Ben

From: Rusek, Benjamin
Sent: Sunday, January 26, 2020 11:30 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Here is a version with these changes and a few other small edits.

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Sunday, January 26, 2020 9:08 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Ben,
We'll have to do some minor editing on the letter to correct typos from our original draft (replace focused in with focused on, near the end), to make it read a little better ("China has taken important lead to identify" just isn't good English), and some formatting according to Diane and Peggy's preferences. I would suggest unbolding the text and possibly formatting it more like a regular letter with return address, but that decision is up those who sign it.
Micah

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124843

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:25 AM
To: Dave Franz <davidrfranz@gmail.com>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Thanks, Tom and Dave

Hi Ben,
I have included Tom's suggestion. Please use this version.

Best,
Pei-Yong

From: Dave Franz <davidrfranz@gmail.com>
Sent: Sunday, January 26, 2020 9:21 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Benjamin Rusek <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

…and think Tom's point strengthens the letter as well. dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124844

On Jan 26, 2020, at 9:17 AM, Ksiazek, Thomas G. <tgksiaze@UTMB.EDU> wrote:

In this paragraph

The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Should probably be modified

The University of Texas Medical Branch has volunteered to serve as home to the virus in its capacity as the World Reference Center for Emerging Viruses and Arboviruses and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Tom Ksiazek

Sent from a portable device

On Jan 26, 2020, at 00:49, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124845

not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124846

Ben, Diane, Peggy I'm sure you have been following the emergence of the new Coronavirus in China and beyond with concern. While much is being done to prepare nations for possible cases, the global scientific community remains hampered by the lack of access to an isolate of the new virus. Sequences data has been provide

FOIA Confidential Treatment Requested by Univ of Texas System

d, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.

With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124848

point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124849

this growing threat.

We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importa

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124850

nce of harnessing the world's scientific capacity to help address this emerging threat.

Can we urgently draft an official letter for Diane or Peggy's signature?

Thanks for your consideration and help.

Jim

Sent from my iPhone

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 27 2020.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124851

From: LeDuc, James W.
Sent: Monday, January 27, 2020 9:17 AM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Shi, Pei yong
Subject: RE: NCoV isolate

This is a perfect example of the exceptional value of having the dialogue with China that you and the NAS have pioneered. I hope that we can leverage this experience into some sustained funding to keep the relationship vibrant.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:59 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Very happy to help, sounds like with this change it's ready to go. Diane will likely send it out soon.

Ben

On Jan 27, 2020, at 8:23 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

I think Peggy's suggested change is appropriate and otherwise it's ready to go. There are other efforts underway to get the isolates as well, so hopefully we'll get this done soon.

Thanks for your help in moving this along! Enjoy India.

Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 7:53 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Peggy Hamburg <peggy@hbfam.net>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim could you take a final look?

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126300

On Jan 27, 2020, at 7:09 PM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Do we think that it is ready?

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:02 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

And when this is ready Diane should send it to Bai Chunli [using clbai@cas.cn, JH-cao@cashq.ac.cn, sunhui@cashq.ac.cn] and Gao Fu [using gaof@im.ac.cn]

Probably want to cc Peggy and Jim and maybe John Hildebrand and John Boright

Kind regards,

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Monday, January 27, 2020 6:27 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>
Subject: FW: NCoV isolate

Jim,
Connecting you back to the discussion here. See below.
Micah

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, January 27, 2020 5:01 AM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: Re: NCoV isolate

Jim,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126301

Any thoughts on my question below. I am fine with letter as is, but does Iswem like situation has evolved a bit but still crucial to encourage Chinese to share isolates.

Peggy
Sent from my iPhone

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, January 27, 2020 7:06 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: Re: NCoV isolate

Micah, Peggy, Jim et al - I think that the letter is fine to send. I agree that the situation is changing, but it is still going to be important to compare the viruses that emerge in other countries with Chinese isolates over time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

> On Jan 27, 2020, at 2:10 AM, Lowenthal, Micah <mlowenth@nas.edu> wrote:
>
> Peggy,
> Perhaps I closed down discussion too early. Please feel free to reopen with Jim Le Duc. You can include others, but I would focus on the people you want to hear from.
> Also, we might want to note the MOU signed between UTMB and Chinese virology research organizations as the rationale for promoting UTMB as the partner. But that's up to you and Diane to decide.
>
> Micah
>
> > On Jan 27, 2020, at 9:20 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
> >
> > Hello. I think it is a strong letter. However, has the argument shifted somewhat? Given that cases are occurring in many places now the opportunity to gather isolates does not depend on Chinese, however the ability to get full understanding of the virus and it's evolution would be greatly advanced by expanded sharing of isolates.
> >
> > Peggy

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126302

Sent from my iPhone

On Jan 26, 2020, at 9:29 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Hi Diane and Peggy,

Here is a clean copy for your review, we are working to get you the correct email addresses and email routing for Gao Fu and Bai Chunli.

Micah notes that at the top of the letter, we say that work is hampered by the lack of an *isolate*. Lower down, we refer to sharing *isolates*. Should this be consistently plural?

Kind regards,

Ben

From: Rusek, Benjamin
Sent: Sunday, January 26, 2020 11:30 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Here is a version with these changes and a few other small edits.

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Sunday, January 26, 2020 9:08 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Ben,
We'll have to do some minor editing on the letter to correct typos from our original draft (replace focused in with focused on, near the end), to make it read a little better ("China has taken important lead to identify" just isn't good English), and some formatting according to Diane and Peggy's preferences. I would suggest unbolding the text and possibly formatting it more like a regular letter with return address, but that decision is up those who sign it.
Micah

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126303

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:25 AM
To: Dave Franz <davidrfranz@gmail.com>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Thanks, Tom and Dave

Hi Ben,
I have included Tom's suggestion. Please use this version.

Best,
Pei-Yong

From: Dave Franz <davidrfranz@gmail.com>
Sent: Sunday, January 26, 2020 9:21 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Benjamin Rusek <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

…and think Tom's point strengthens the letter as well. dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126304

On Jan 26, 2020, at 9:17 AM, Ksiazek, Thomas G. <tgksiaze@UTMB.EDU> wrote:

In this paragraph

The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Should probably be modified

The University of Texas Medical Branch has volunteered to serve as home to the virus in its capacity as the World Reference Center for Emerging Viruses and Arboviruses and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Tom Ksiazek

Sent from a portable device

On Jan 26, 2020, at 00:49, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126305

not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126306

Ben,
Diane,
Peggy
I'm
sure
you
have
been
followi
ng the
emerge
nce of
the
new
Corona
virus in
China
and
beyond
with
concern
. While
much is
being
done to
prepare
nations
for
possibl
e cases,
the
global
scientifi
c
commu
nity
remains
hamper
ed by
the lack
of
access
to an
isolate
of the
new
virus. S
equenc
es data
has
been
provide

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126307

d, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.

With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126308

point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126309

this growing threat.

We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importa

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126310

nce of harness ing the world's scientifi c capacit y to help address this emergi ng threat.

Can we urgentl y draft an official letter for Diane or Peggy's signatu re?

Thanks for your conside ration and help.

Jim

Sent from my iPhone

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 27 2020.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126311

From: LeDuc, James W.
Sent: Monday, January 27, 2020 9:17 AM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com);Shi, Pei yong
Subject: RE: NCoV isolate

This is a perfect example of the exceptional value of having the dialogue with China that you and the NAS have pioneered. I hope that we can leverage this experience into some sustained funding to keep the relationship vibrant.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:59 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Very happy to help, sounds like with this change it's ready to go. Diane will likely send it out soon.

Ben

> On Jan 27, 2020, at 8:23 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> I think Peggy's suggested change is appropriate and otherwise it's ready to go. There are other efforts underway to get the isolates as well, so hopefully we'll get this done soon.
>
> Thanks for your help in moving this along! Enjoy India.
>
> Jim
>
> **From:** Rusek, Benjamin <BRusek@nas.edu>
> **Sent:** Monday, January 27, 2020 7:53 AM
> **To:** Diane Griffin <dgriffi6@jhmi.edu>
> **Cc:** Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Peggy Hamburg <peggy@hbfam.net>
> **Subject:** Re: NCoV isolate
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> Jim could you take a final look?
>
> Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051409

On Jan 27, 2020, at 7:09 PM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Do we think that it is ready?

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, January 27, 2020 8:02 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

And when this is ready Diane should send it to Bai Chunli [using clbai@cas.cn, JH-cao@cashq.ac.cn, sunhui@cashq.ac.cn] and Gao Fu [using gaof@im.ac.cn]

Probably want to cc Peggy and Jim and maybe John Hildebrand and John Boright

Kind regards,

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Monday, January 27, 2020 6:27 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>
Subject: FW: NCoV isolate

Jim,
Connecting you back to the discussion here. See below.
Micah

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, January 27, 2020 5:01 AM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: Re: NCoV isolate

Jim,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051410

Any thoughts on my question below. I am fine with letter as is, but does Iswem like situation has evolved a bit but still crucial to encourage Chinese to share isolates.

Peggy
Sent from my iPhone

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, January 27, 2020 7:06 AM
To: Lowenthal, Micah <mlowenth@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: Re: NCoV isolate

Micah, Peggy, Jim et al - I think that the letter is fine to send. I agree that the situation is changing, but it is still going to be important to compare the viruses that emerge in other countries with Chinese isolates over time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

> On Jan 27, 2020, at 2:10 AM, Lowenthal, Micah <mlowenth@nas.edu> wrote:
>
> Peggy,
> Perhaps I closed down discussion too early. Please feel free to reopen with Jim Le Duc. You can include others, but I would focus on the people you want to hear from.
> Also, we might want to note the MOU signed between UTMB and Chinese virology research organizations as the rationale for promoting UTMB as the partner. But that's up to you and Diane to decide.
>
> Micah
>
> > On Jan 27, 2020, at 9:20 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
> >
> > Hello. I think it is a strong letter. However, has the argument shifted somewhat? Given that cases are occurring in many places now the opportunity to gather isolates does not depend on Chinese, however the ability to get full understanding of the virus and it's evolution would be greatly advanced by expanded sharing of isolates.
> >
> > Peggy

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051411

Sent from my iPhone

On Jan 26, 2020, at 9:29 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Hi Diane and Peggy,

Here is a clean copy for your review, we are working to get you the correct email addresses and email routing for Gao Fu and Bai Chunli.

Micah notes that at the top of the letter, we say that work is hampered by the lack of an *isolate*. Lower down, we refer to sharing *isolates*. Should this be consistently plural?

Kind regards,

Ben

From: Rusek, Benjamin
Sent: Sunday, January 26, 2020 11:30 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Here is a version with these changes and a few other small edits.

Ben

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Sunday, January 26, 2020 9:08 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Diane Griffin (dgriffi6@jhmi.edu) <dgriffi6@jhmi.edu>
Subject: RE: NCoV isolate

Ben,
We'll have to do some minor editing on the letter to correct typos from our original draft (replace focused in with focused on, near the end), to make it read a little better ("China has taken important lead to identify" just isn't good English), and some formatting according to Diane and Peggy's preferences. I would suggest unbolding the text and possibly formatting it more like a regular letter with return address, but that decision is up those who sign it.
Micah

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051412

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Sunday, January 26, 2020 10:25 AM
To: Dave Franz <davidrfranz@gmail.com>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; Boright, John <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: RE: NCoV isolate

Thanks, Tom and Dave

Hi Ben,
I have included Tom's suggestion. Please use this version.

Best,
Pei-Yong

From: Dave Franz <davidrfranz@gmail.com>
Sent: Sunday, January 26, 2020 9:21 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Cc: Benjamin Rusek <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <MargaretAHamburg@aol.com>; Shi, Pei yong <peshi@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; Niesel, David W. <dniesel@UTMB.EDU>; Urban, Randall J. <rurban@UTMB.EDU>; Weaver, Scott <sweaver@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>
Subject: Re: NCoV isolate

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

…and think Tom's point strengthens the letter as well. dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051413

On Jan 26, 2020, at 9:17 AM, Ksiazek, Thomas G. <tgksiaze@UTMB.EDU> wrote:

In this paragraph

The University of Texas Medical Branch has volunteered to serve as both home to the virus reference center and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Should probably be modified

The University of Texas Medical Branch has volunteered to serve as home to the virus in its capacity as the World Reference Center for Emerging Viruses and Arboviruses and as a BEI partner to assist China in distribution of any isolates you wish to share. NASEM would be willing to facilitate another arrangement if you wish.

Tom Ksiazek

Sent from a portable device

On Jan 26, 2020, at 00:49, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051414

not click links or open attachments unless you recognize the sender and know the content is safe.

Great idea Jim,

Since this is urgent Micah and I have drafted text of a letter (that includes text explaining the dialogue) that could be sent to CCDC and CAS. Feel free to modify.

Have also looped in John Boright, the executive director of the NAS and John Hildebrand, the NAS foreign secretary. Peggy might want to include Victor Dzau in the next email.

FYI Micah and I are in India right now and will be online for the 12 hours or so.

Kind regards,

Ben

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg.docx>

On Jan 26, 2020, at 7:56 AM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051415

Ben,
Diane,
Peggy
I'm
sure
you
have
been
followi
ng the
emerge
nce of
the
new
Corona
virus in
China
and
beyond
with
concern
. While
much is
being
done to
prepare
nations
for
possibl
e cases,
the
global
scientifi
c
commu
nity
remains
hamper
ed by
the lack
of
access
to an
isolate
of the
new
virus. S
equenc
es data
has
been
provide

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051416

d, but despite repeated inquiries isolates have not been made available although Chinese front line scientists appear to be eager to share.

With this background, may I suggest that we explore an Academy to Academy request to share the isolates? Within a very few days this will likely be a moot

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051417

point given that cases are now occurring outside China and isolation attempts are underway. The window for Chinese global leadership is rapidly closing. Our dialogue over the past several years has focused in the very situation we now face and it seems appropriate for the academies to work together to help address

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051418

this growing threat.

We have volunteered to use UTMB's stature as both home to the virus reference center and as a BEI partner to assist the Chinese in distribution of any isolates they wish to share. Repeating this offer more formally by the NASEM to CAS may help the Chinese government appreciate the global importa

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051419

nce of harness ing the world's scientifi c capacit y to help address this emergi ng threat.

Can we urgentl y draft an official letter for Diane or Peggy's signatu re?

Thanks for your conside ration and help.

Jim

Sent from my iPhone

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 27 2020.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051420

From: df@wh.iov.cn
Sent: Monday, January 27, 2020 9:46 AM
To: Shi, Pei yong;zlshi
Cc: LeDuc, James W.;Ksiazek, Thomas G.;Lawal, Adeola
Subject: Re: RE: Request for new coronavirus isolates

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Request letter received.

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-27 21:54
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; Ksiazek, Thomas G.; Lawal, Adeola
Subject: RE: Request for new coronavirus isolates

Dear Fei and Zhengli,

Thanks you for the rapid response to our request. Please see the attached request letter. As indicated in the letter, this collaboration will use the viral isolate to test vaccine, therapeutics, and viral pathogenesis.

I'm copying our Technology Transfer Office to send you the MAT for signatures.

Hi Ade,
Would you please email UTMB's MTA for this request to Professor Fei Deng (df@wh.iov.cn)?

Sender: Professor Fei Deng, Wuhan Institute of Virology, Chinese Academy of Sciences, China
Receiver: Pei-Yong Shi and James LeDuc, UTMB
Reagent: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Scope of work: UTMB scientists will use the viral isolate to test vaccine, therapeutics, and viral pathogenesis

Since this is an urgent matter, please help with the process as soon as possible.

Thanks!

Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057533

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 1:33 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: Request for new coronavirus isolates

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
Nice to hear from you.

Yes we glad to share the virus isolate with UTMB for research collaborate. I suggest you send a formal request letter to our institute. And a MTA is needed, you can use your UTMB MTA and fill the information, and I suggest you to discuss with Prof.Zhengli for the detail research content for collaboration. Our strain is nCoV-2019 (IVCAS 6.7512).
You can send your documents to me, I will try to get export permittion for this.

With best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-27 02:58
To: df@wh.iov.cn; zlshi@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.
Subject: Request for new coronavirus isolates
Dear Zhengli and Fei,

Happy Chinese New Year and congratulations for your amazing work on the new coronavirus!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057534

We are writing to see if you are willing to collaborate with UTMB on studying the nCoV through sharing the viral isolates. We understand that, since many labs are currently isolating the viruses through imported cases, the window of leadership for Chinese scientists is closing rapidly. We greatly appreciate your rapid response to this request.

Best regards from Galveston,
Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057535

MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement ("**Agreement**") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("**UTMB**"), a health institution of The University of Texas System ("System"), an agency of the State of Texas, located at 301 University Blvd., Galveston, TX 77555-0926, and Wuhan Institute of Virology Chinese Academy of Sciences Wuhan, China ("**Provider**") located at _____.

From the laboratory of Professor Fei Deng, Ph.D., Professor Zhengli Shi, Ph.D., ("**Provider Scientists**"), Provider agrees to provide UTMB with certain materials for the purpose stated herein under the following conditions:

1. **Material and Research.** The Materials covered by this Agreement are as follows: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), ("**Material**"). The Material shall be used by UTMB in research ("**Research**"), as defined in **Attachment A**, and the Research will be conducted by UTMB under the supervision of, Pei-Yong Shi, Ph.D. and Dr. James LeDuc, ("**UTMB Scientists**").
2. **Use of Material.** This Material is made available for internal research use only in laboratory animals or in vitro experiments. The Material is considered proprietary to Provider and Provider shall be free, in its sole discretion, to distribute the Material to others and to use it for its own purposes. Except as provided for by this Agreement, UTMB shall not distribute, transfer, or release the Material to any person or entity other than laboratory personnel under UTMB Scientist's direct supervision, unless written permission is obtained from Provider. UTMB agrees that all of its UTMB Scientist(s) involved in the Research will have read the terms and conditions of this Agreement and abide by the terms and conditions of this Agreement.
3. **Rights.** The Material shall not be used by UTMB for any products or processes for any purpose other than performing the Research hereunder. .
4. **Confidentiality**. All Material and information relating to the Material that is disclosed by Provider to UTMB shall be considered to be confidential, subject to Section 5. Publication of this Agreement. UTMB will use reasonable efforts to prevent the disclosure of Provider's confidential information to third parties for a period of three (3) years from receipt, provided that UTMB's obligation shall not apply to information that:
   a) is already in the UTMB's possession at the time of disclosure;
   b) is or later becomes part of the public domain through no fault of the UTMB;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_066548

c) is received from a third party having no obligations of confidentiality to UTMB;
d) is independently developed by the UTMB; or
e) is required by law or regulation to be disclosed.

In the event that information is required to be disclosed pursuant to subsection (e), UTMB shall notify the UTMB, in order to allow UTMB to assert whatever exclusions or exemptions may be available to it under such law or regulation.

5. **Publication.** UTMB will inform Provider of results of Research, in confidence, related to the Material by providing Provider with a draft manuscript describing such results. If UTMB's Scientist desires to publish or present such Research results, then, not less than forty-five (45) days prior to submission to a third-party, UTMB will provide Provider with a copy of any manuscript or abstract disclosing such Research results for the purpose of protecting the Material and intellectual property of Provider that might be disclosed by such publication. In any such publication or presentation of Research results, UTMB agrees to acknowledge Provider scientist as provider of the Material.
6. **Intellectual Property.** Inventorship of any invention will be determined based on U.S. patent law. Ownership shall follow inventorship.
7. **Warranty.** The Material is experimental in nature and it is provided "AS IS" WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR SAFETY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. UTMB MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT.
8. **Liability.** Provider shall indemnify and hold harmless UTMB, System, their Regents, officers, agents and employees, from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against them arising out of the Provider's use of the results generated by UTMB's activities to be carried out pursuant to this Agreement excluding claims, loss, or damage that arise from the negligence or willful malfeasance of any Regent, officer, agent or employee of UTMB or System.
9. **Compliance.** UTMB will use the Material in compliance with all laws, governmental regulations and guidelines applicable to the Material. Moreover, if the Material is used in the United States, then UTMB will comply with current United States NIH guidelines.
10. **Export Control.** UTMB further agrees that if the U.S. export laws are or become applicable, it will not export any Materials received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_066549

unless UTMB has obtained prior written authorization from the appropriate authority responsible for such matters.

11. **Assignment.** This Agreement is not assignable, whether by operation of law or otherwise, without the prior written consent of Provider.
12. **Publicity.** Except as stated herein, neither party shall use the name of the other without express written consent, subject to Section 5. Publication of this Agreement.
13. **Term and Termination.** This Agreement shall be effective as of the date of the last signature and terminate one (1) year from that date. Upon termination, UTMB will immediately destroy all the Material then in its possession.

UNIVERSITY OF TEXAS MEDICAL BRANCH	**WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES**
_____	_____
Carolee A. King, JD Senior Vice President and General Counsel Date: _____	Name of Authorized Signatory Title: Date: _____
Read and understood:	Read and understood:
_____ Signature of UTMB Scientist	_____ Signature of Provider Scientist
Read and understood:	
_____ Signature of UTMB Scientist	

FOIA Confidential Treatment Requested by Univ of Texas System

Attachment A – Scope of Research

We are studying the new coronavirus through sharing the viral isolate (strain IVCAS 6.7512). Our goal is to use the viral isolate for testing vaccine, therapeutics, and viral pathogenesis. UTMB scientists will use the viral isolate to test vaccine, therapeutics, and viral pathogenesis.

FOIA Confidential Treatment Requested by Univ of Texas System

MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement ("**Agreement**") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("**UTMB**"), a health institution of The University of Texas System ("System"), an agency of the State of Texas, located at 301 University Blvd., Galveston, TX 77555-0926, and Wuhan Institute of Virology Chinese Academy of Sciences Wuhan, China ("**Provider**") located at [redacted].

From the laboratory of Professor Fei Deng, Ph.D., Professor Zhengli Shi, Ph.D., ("**Provider Scientists**"), Provider agrees to provide UTMB with certain materials for the purpose stated herein under the following conditions:

1. **Material and Research.** The Materials covered by this Agreement are as follows: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), ("**Material**"). The Material shall be used by UTMB in research ("**Research**"), as defined in **Attachment A**, and the Research will be conducted by UTMB under the supervision of, Pei-Yong Shi, Ph.D. and Dr. James LeDuc, ("**UTMB Scientists**").
2. **Use of Material.** This Material is made available for internal research use only in laboratory animals or in vitro experiments. The Material is considered proprietary to Provider and Provider shall be free, in its sole discretion, to distribute the Material to others and to use it for its own purposes. Except as provided for by this Agreement, UTMB shall not distribute, transfer, or release the Material to any person or entity other than laboratory personnel under UTMB Scientist's direct supervision, unless written permission is obtained from Provider. UTMB agrees that all of its UTMB Scientist(s) involved in the Research will have read the terms and conditions of this Agreement and abide by the terms and conditions of this Agreement.
3. **Rights.** The Material shall not be used by UTMB for any products or processes for any purpose other than performing the Research hereunder. .
4. **Confidentiality**. All Material and information relating to the Material that is disclosed by Provider to UTMB shall be considered to be confidential, subject to Section 5. Publication of this Agreement. UTMB will use reasonable efforts to prevent the disclosure of Provider's confidential information to third parties for a period of three (3) years from receipt, provided that UTMB's obligation shall not apply to information that:
   a) is already in the UTMB's possession at the time of disclosure;
   b) is or later becomes part of the public domain through no fault of the UTMB;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051405

c) is received from a third party having no obligations of confidentiality to UTMB;
d) is independently developed by the UTMB; or
e) is required by law or regulation to be disclosed.

In the event that information is required to be disclosed pursuant to subsection (e), UTMB shall notify the UTMB, in order to allow UTMB to assert whatever exclusions or exemptions may be available to it under such law or regulation.

5. **Publication.** UTMB will inform Provider of results of Research, in confidence, related to the Material by providing Provider with a draft manuscript describing such results. If UTMB's Scientist desires to publish or present such Research results, then, not less than forty-five (45) days prior to submission to a third-party, UTMB will provide Provider with a copy of any manuscript or abstract disclosing such Research results for the purpose of protecting the Material and intellectual property of Provider that might be disclosed by such publication. In any such publication or presentation of Research results, UTMB agrees to acknowledge Provider scientist as provider of the Material.
6. **Intellectual Property.** Inventorship of any invention will be determined based on U.S. patent law. Ownership shall follow inventorship.
7. **Warranty.** The Material is experimental in nature and it is provided "AS IS" WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR SAFETY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. UTMB MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT.
8. **Liability.** Provider shall indemnify and hold harmless UTMB, System, their Regents, officers, agents and employees, from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against them arising out of the Provider's use of the results generated by UTMB's activities to be carried out pursuant to this Agreement excluding claims, loss, or damage that arise from the negligence or willful malfeasance of any Regent, officer, agent or employee of UTMB or System.
9. **Compliance.** UTMB will use the Material in compliance with all laws, governmental regulations and guidelines applicable to the Material. Moreover, if the Material is used in the United States, then UTMB will comply with current United States NIH guidelines.
10. **Export Control.** UTMB further agrees that if the U.S. export laws are or become applicable, it will not export any Materials received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless UTMB

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051406

has obtained prior written authorization from the appropriate authority responsible for such matters.

11. **Assignment.** This Agreement is not assignable, whether by operation of law or otherwise, without the prior written consent of Provider.
12. **Publicity.** Except as stated herein, neither party shall use the name of the other without express written consent, subject to Section 5. Publication of this Agreement.
13. **Term and Termination.** This Agreement shall be effective as of the date of the last signature and terminate one (1) year from that date. Upon termination, UTMB will immediately destroy all the Material then in its possession.

UNIVERSITY OF TEXAS MEDICAL BRANCH	**WUHAN INSTITUTE OF VIROLOGY CHINESE ACADEMY OF SCIENCES**
_____	_____
Carolee A. King, JD Senior Vice President and General Counsel Date: _____	Name of Authorized Signatory Title: Date: _____
Read and understood:	Read and understood:
_____ Signature of UTMB Scientist	_____ Signature of Provider Scientist
Read and understood:	
_____ Signature of UTMB Scientist	

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051407

Attachment A – Scope of Research

We are studying the new coronavirus through sharing the viral isolate (strain IVCAS 6.7512). Our goal is to use the viral isolate for testing vaccine, therapeutics, and viral pathogenesis. UTMB scientists will use the viral isolate to test vaccine, therapeutics, and viral pathogenesis.

`

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051408

From: df@wh.iov.cn
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola;Shi, Pei yong;LeDuc, James W.
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057657

From: Shi, Pei yong
Sent: Tuesday, January 28, 2020 7:42 AM
To: df@wh.iov.cn;Lawal, Adeola;LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei
Best regards,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057647

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057648

From: df@wh.iov.cn
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057655

I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057656

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.;Ksiazek, Thomas G.
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057531

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057532

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Wednesday, January 29, 2020 9:22 PM
To: LeDuc, James W.;David Franz;Rusek, Benjamin
Subject: Fwd: Letter to President Bai with regard to nCov isolate sharing

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim, Dave,
Good news!
So sorry for the email mixup.
Best from Bangalore,
Micah

Begin forwarded message:

From: Diane Griffin <dgriffi6@jhmi.edu>
Date: January 30, 2020 at 3:12:14 AM GMT+5:30
To: George GAO <gaof@im.ac.cn>, "Boright, John" <JBoright@nas.edu>
Cc: "jh-cao@cashq.ac.cn" <jh-cao@cashq.ac.cn>, "clbai@cas.cn" <clbai@cas.cn>, "sunhui@cashq.ac.cn" <sunhui@cashq.ac.cn>, "Lowenthal, Micah" <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, "jwleduc@nas.edu" <jwleduc@nas.edu>, JohnHildebrand <jhildebr@email.arizona.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "Hamburg, Margaret" <MHamburg@nas.edu>
Subject: Re: Letter to President Bai with regard to nCov isolate sharing

Thanks George - fantastic news!

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: George GAO <gaof@im.ac.cn>
Sent: Wednesday, January 29, 2020 2:39 PM
To: Boright, John <JBoright@nas.edu>
Cc: jh-cao@cashq.ac.cn <jh-cao@cashq.ac.cn>; clbai@cas.cn <clbai@cas.cn>; sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>; Lowenthal, Micah <mlowenth@nas.edu>; Peggy Hamburg <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>; jwleduc@nas.edu <jwleduc@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>; Rusek,

FOIA Confidential Treatment Requested by Univ of Texas System

Benjamin <BRusek@nas.edu>; Hamburg, Margaret <MHamburg@nas.edu>
Subject: Re: Letter to President Bai with regard to nCov isolate sharing

We are happy to share and President Bai will write you soon.

发自我的iPhone

在 2020年1月29日， 02:50， Boright, John <JBoright@nas.edu> 写道：

Dear Colleagues,

Please find a letter to President Bai Chunli and Dr. Gao Fu, with regard to an urgent request.

John Boright
On behalf of Diane Griffin and Margaret Hamburg
<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 28 2020.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008279

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Wednesday, January 29, 2020 9:23 PM
To: LeDuc, James W.;David Franz;Shi, Pei yong;Rusek, Benjamin
Subject: Fwd: Letter to President Bai with regard to nCov isolate sharing

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Micah

Begin forwarded message:

From: "Hamburg, Margaret" <MHamburg@nas.edu>
Date: January 30, 2020 at 2:11:31 AM GMT+5:30
To: George GAO <gaof@im.ac.cn>
Cc: "Boright, John" <JBoright@nas.edu>, "jh-cao@cashq.ac.cn" <jh-cao@cashq.ac.cn>, "clbai@cas.cn" <clbai@cas.cn>, "sunhui@cashq.ac.cn" <sunhui@cashq.ac.cn>, "Lowenthal, Micah" <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, "Diane Griffin (dgriffi6@jhmi.edu)" <dgriffi6@jhmi.edu>, "jwleduc@nas.edu" <jwleduc@nas.edu>, JohnHildebrand <jhildebr@email.arizona.edu>, "Rusek, Benjamin" <BRusek@nas.edu>
Subject: Re: Letter to President Bai with regard to nCov isolate sharing

George, thanks for your amazingly rapid and constructive response, especially during these challenging times! This is very good news. We look forward to collaborating with you and your colleagues.

All best,
Margaret (Peggy) Hamburg

Sent from my iPhone

> On Jan 29, 2020, at 2:41 PM, George GAO <gaof@im.ac.cn> wrote:
>
> We are happy to share and President Bai will write you soon.
>
> 发自我的iPhone
>
> > 在 2020年1月29日，02:50，Boright, John <JBoright@nas.edu> 写道：
> >
> > Dear Colleagues,

FOIA Confidential Treatment Requested by Univ of Texas System

Please find a letter to President Bai Chunli and Dr. Gao Fu, with regard to an urgent request.

John Boright
On behalf of Diane Griffin and Margaret Hamburg
<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 28 2020.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008277

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, January 30, 2020 3:48 PM
To: LeDuc, James W.
Subject: Re: A good example of the value of engagement.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

One possibility would be to make a couple of ppts to add to the slide set we will use to market the BTRP study which Jerry Keusch and I just finalized and sent to internal NAS editorial review. We just had a conf call re. where to take it on the hill. d

David R. Franz
Gettysburg, PA
(240) 674-0797

On Jan 30, 2020, at 3:30 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

We need to leverage this situation to gain sustained support for our dialogue with China. Not sure where to look but the time is right!

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, January 30, 2020 2:24 PM
To: Boright, John <JBoright@nas.edu>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; mhamburg@nas.edu; Peggy Hamburg <margaretahamburg@aol.com>
Subject: A good example of the value of engagement.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for facilitating John! So glad we heard from George. I was in a situation yesterday that allowed me to compare the ability to communicate with our Russian ID colleagues with our much greater options in China...when we face common health challenges. The last 13 years of engagement with Chinese colleagues——which Peggy and Jim will recall began slowly and with small steps in '07 with the CBSG—-have expanded to make quite a positive difference. And the lack of similar continued engagement in Russia has taken its toll. Thanks again, dave

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124613

On Jan 28, 2020, at 1:59 PM, Boright, John <JBoright@nas.edu> wrote:

Jim,

I sent this at the request of Micah, when Dianne had not been online for a couple days. I got a "undeliverable" message re your address.

And Dave, I did not see you on it.

Dianne, I hope this is ok with you.

Best,
John

From: Boright, John
Sent: Tuesday, January 28, 2020 1:50 PM
To: 'jh-cao@cashq.ac.cn'; clbai@cas.cn; 'gaof@im.ac.cn'; sunhui@cashq.ac.cn
Cc: Lowenthal, Micah; Boright, John; 'Peggy Hamburg'; Diane Griffin (dgriffi6@jhmi.edu); 'jwleduc@nas.edu'; JohnHildebrand; Rusek, Benjamin; Hamburg, Margaret
Subject: Letter to President Bai with regard to nCov isolate sharing

Dear Colleagues,

Please find a letter to President Bai Chunli and Dr. Gao Fu, with regard to an urgent request.

John Boright
On behalf of Diane Griffin and Margaret Hamburg

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 28 2020.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124614

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, January 30, 2020 3:48 PM
To: LeDuc, James W.
Subject: Re: A good example of the value of engagement.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

One possibility would be to make a couple of ppts to add to the slide set we will use to market the BTRP study which Jerry Keusch and I just finalized and sent to internal NAS editorial review. We just had a conf call re. where to take it on the hill. d

David R. Franz
Gettysburg, PA
(240) 674-0797

On Jan 30, 2020, at 3:30 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

We need to leverage this situation to gain sustained support for our dialogue with China. Not sure where to look but the time is right!

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, January 30, 2020 2:24 PM
To: Boright, John <JBoright@nas.edu>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Micah Lowenthal <mlowenth@nas.edu>; mhamburg@nas.edu; Peggy Hamburg <margaretahamburg@aol.com>
Subject: A good example of the value of engagement.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for facilitating John! So glad we heard from George. I was in a situation yesterday that allowed me to compare the ability to communicate with our Russian ID colleagues with our much greater options in China...when we face common health challenges. The last 13 years of engagement with Chinese colleagues——which Peggy and Jim will recall began slowly and with small steps in '07 with the CBSG—-have expanded to make quite a positive difference. And the lack of similar continued engagement in Russia has taken its toll. Thanks again, dave

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010173

On Jan 28, 2020, at 1:59 PM, Boright, John <JBoright@nas.edu> wrote:

Jim,

I sent this at the request of Micah, when Dianne had not been online for a couple days. I got a "undeliverable" message re your address.

And Dave, I did not see you on it.

Dianne, I hope this is ok with you.

Best,
John

From: Boright, John
Sent: Tuesday, January 28, 2020 1:50 PM
To: 'jh-cao@cashq.ac.cn'; clbai@cas.cn; 'gaof@im.ac.cn'; sunhui@cashq.ac.cn
Cc: Lowenthal, Micah; Boright, John; 'Peggy Hamburg'; Diane Griffin (dgriffi6@jhmi.edu); 'jwleduc@nas.edu'; JohnHildebrand; Rusek, Benjamin; Hamburg, Margaret
Subject: Letter to President Bai with regard to nCov isolate sharing

Dear Colleagues,

Please find a letter to President Bai Chunli and Dr. Gao Fu, with regard to an urgent request.

John Boright
On behalf of Diane Griffin and Margaret Hamburg

<Letter to CCDC CAS re nCoV isolate sharing Griffin and Hamburg Jan 28 2020.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010174

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:21 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.;Ksiazek, Thomas G.;Yuan Zhiming;石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Hi Fei,

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058530

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058531

Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:21 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Hi Fei,

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124632

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124633

Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124634

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:21 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.;Ksiazek, Thomas G.;Yuan Zhiming;石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Hi Fei,

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008532

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008533

Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System

From: df@wh.iov.cn
Sent: Sunday, February 2, 2020 7:44 AM
To: Shi, Pei yong
Cc: LeDuc, James W.;Ksiazek, Thomas G.;yzm;zlshi
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
I contact with the General Administration of Customs in Beijing everyday, they don't reply me until today. But I'm preparing all documents for application when the custom system is open for me to upload the application.
Hope I can get progress.
Thank you for concering it.

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-02 21:20
To: df@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Hi Fei,

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008529

University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Thanks, Fei
Best regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008530

• Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008531

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:49 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.; Ksiazek, Thomas G.; yzm; zlshi
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Dear Fei,
Thanks so much for your unwavering effort. We look forward to further progress.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Sunday, February 2, 2020 7:44 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; yzm <yzm@wh.iov.cn>; zlshi <zlshi@wh.iov.cn>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
I contact with the General Administration of Customs in Beijing everyday, they don't reply me until today. But I'm preparing all documents for application when the custom system is open for me to upload the application.
Hope I can get progress.
Thank you for concering it.

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-02 21:20
To: df@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Hi Fei,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126394

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126395

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei
Best regards,

• Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126396

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126397

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:49 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.;Ksiazek, Thomas G.;yzm;zlshi
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Dear Fei,
Thanks so much for your unwavering effort. We look forward to further progress.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Sunday, February 2, 2020 7:44 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; yzm <yzm@wh.iov.cn>; zlshi <zlshi@wh.iov.cn>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
I contact with the General Administration of Customs in Beijing everyday, they don't reply me until today. But I'm preparing all documents for application when the custom system is open for me to upload the application.
Hope I can get progress.
Thank you for concering it.

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-02 21:20
To: df@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Hi Fei,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058526

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058527

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei
Best regards,

• Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058528

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_058529

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:49 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.; Ksiazek, Thomas G.; yzm; zlshi
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Dear Fei,
Thanks so much for your unwavering effort. We look forward to further progress.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Sunday, February 2, 2020 7:44 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; yzm <yzm@wh.iov.cn>; zlshi <zlshi@wh.iov.cn>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
I contact with the General Administration of Customs in Beijing everyday, they don't reply me until today. But I'm preparing all documents for application when the custom system is open for me to upload the application.
Hope I can get progress.
Thank you for concering it.

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-02 21:20
To: df@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Hi Fei,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124635

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124636

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei
Best regards,

• Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124637

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124638

From: Shi, Pei yong
Sent: Sunday, February 2, 2020 7:49 AM
To: df@wh.iov.cn
Cc: LeDuc, James W.;Ksiazek, Thomas G.;yzm;zlshi
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Dear Fei,
Thanks so much for your unwavering effort. We look forward to further progress.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Sunday, February 2, 2020 7:44 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; yzm <yzm@wh.iov.cn>; zlshi <zlshi@wh.iov.cn>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Prof.Peiyong,
I contact with the General Administration of Customs in Beijing everyday, they don't reply me until today. But I'm preparing all documents for application when the custom system is open for me to upload the application.
Hope I can get progress.
Thank you for concering it.

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-02 21:20
To: df@wh.iov.cn
CC: LeDuc, James W.; Ksiazek, Thomas G.; Yuan Zhiming; 石正丽
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)
Hi Fei,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003580

Any update on the isolate shipment? Since this is a public health emergency, I hope the approval will be dealt with urgency. Isolate sharing will definitely expedite countermeasure development.

Please let us know if there is anyone or any regulatory agency we should contact to speed up the process.

Thank you and all our best wishes!

Pei-Yong

Pei-Yong Shi, Ph.D.
I.H. Kempner Professor of Human Genetics
Vice Chair for Innovation and Commercialization
Department of Biochemistry & Molecular Biology
University of Texas Medical Branch
Galveston, Texas 77555
Phone: 409-772-6370
Email: peshi@utmb.edu

From: Shi, Pei yong
Sent: Wednesday, January 29, 2020 6:51 AM
To: df@wh.iov.cn
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei

Please let us know if there is anything we could facilitate the process. We greatly appreciate your effort.

All our best wishes from Galveston!

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003581

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-01-28 21:41
To: df@wh.iov.cn; Lawal, Adeola; LeDuc, James W.
Subject: RE: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Thanks, Fei
Best regards,

• Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Monday, January 27, 2020 11:17 PM
To: Lawal, Adeola <adlawal@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

MTA received.
I submit it to institute committe and try to sign it ASAP.
I will contact custom for export procedure.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Lawal, Adeola
Date: 2020-01-28 06:51
To: df@wh.iov.cn; Shi, Pei yong; LeDuc, James W.
Subject: FW: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003582

Please see attached MTA in support of our request to receive the following materials: New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512), from your institute. We look forward to getting this MTA in place.

Best wishes,

Ade Lawal, JD
Associate Legal Officer
UTMB Office of Technology Transfer
409.772.0369

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_003583

From: LeDuc, James W.
Sent: Tuesday, February 4, 2020 8:51 AM
To: Diane Griffin; Peggy Hamburg
Cc: Benjamin Rusek; Micah Lowenthal; John Boright; John Hildebrand; Shi, Pei yong; Dave Franz (davidrfranz@gmail.com); Benjamin Rusek (BRusek@nas.edu); Micah Lowenthal (mlowenth@NAS.EDU)
Subject: RE: sharing of isolates of 2019nCoV

This is indeed good news! Thank you all for your help and support.

Concurrent with the NAS-CAS communications, we have been dealing directly with the Wuhan Institute of Virology and as of last week they were in the process of seeking government approval to share the virus (see note pasted below). Hopefully this will be settled soon and we can arrange shipment.

We will keep you posted.

Thanks again, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126341

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, February 04, 2020 7:51 AM
To: Peggy Hamburg <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Benjamin Rusek <BRusek@nas.edu>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; John Hildebrand <jhildebr@email.arizona.edu>
Subject: Re: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agreed!

Sent from my iPhone

> On Feb 4, 2020, at 5:33 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
>
> Hello. This is good news....and seemed to be a most surprisingly straightforward process. Let's see how the next steps go.
>
> Jim, keep u up to date on how this all unfolds. Hopefully some good work can proceed swiftly.
>
> All best,
> Peggy
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "president-office@cas.cn" <president-office@cas.cn>
> > **Date:** February 3, 2020 at 11:20:56 PM EST
> > **To:** dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
> > **Cc:** mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
> > **Subject: sharing of isolates of 2019nCoV**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126342

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126343

From: LeDuc, James W.
Sent: Tuesday, February 4, 2020 8:51 AM
To: Diane Griffin;Peggy Hamburg
Cc: Benjamin Rusek;Micah Lowenthal;John Boright;John Hildebrand;Shi, Pei yong;Dave Franz (davidrfranz@gmail.com);Benjamin Rusek (BRusek@nas.edu);Micah Lowenthal (mlowenth@NAS.EDU)
Subject: RE: sharing of isolates of 2019nCoV

This is indeed good news! Thank you all for your help and support.

Concurrent with the NAS-CAS communications, we have been dealing directly with the Wuhan Institute of Virology and as of last week they were in the process of seeking government approval to share the virus (see note pasted below). Hopefully this will be settled soon and we can arrange shipment.

We will keep you posted.

Thanks again, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051135

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, February 04, 2020 7:51 AM
To: Peggy Hamburg <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Benjamin Rusek <BRusek@nas.edu>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; John Hildebrand <jhildebr@email.arizona.edu>
Subject: Re: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agreed!

Sent from my iPhone

> On Feb 4, 2020, at 5:33 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
>
> Hello. This is good news....and seemed to be a most surprisingly straightforward process. Let's see how the next steps go.
>
> Jim, keep u up to date on how this all unfolds. Hopefully some good work can proceed swiftly.
>
> All best,
> Peggy
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "president-office@cas.cn" <president-office@cas.cn>
> > **Date:** February 3, 2020 at 11:20:56 PM EST
> > **To:** dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
> > **Cc:** mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
> > **Subject: sharing of isolates of 2019nCoV**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051136

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051137

From: LeDuc, James W.
Sent: Tuesday, February 4, 2020 8:51 AM
To: Diane Griffin; Peggy Hamburg
Cc: Benjamin Rusek; Micah Lowenthal; John Boright; John Hildebrand; Shi, Pei yong; Dave Franz (davidrfranz@gmail.com); Benjamin Rusek (BRusek@nas.edu); Micah Lowenthal (mlowenth@NAS.EDU)
Subject: RE: sharing of isolates of 2019nCoV

This is indeed good news! Thank you all for your help and support.

Concurrent with the NAS-CAS communications, we have been dealing directly with the Wuhan Institute of Virology and as of last week they were in the process of seeking government approval to share the virus (see note pasted below). Hopefully this will be settled soon and we can arrange shipment.

We will keep you posted.

Thanks again, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124791

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, February 04, 2020 7:51 AM
To: Peggy Hamburg <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Benjamin Rusek <BRusek@nas.edu>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; John Hildebrand <jhildebr@email.arizona.edu>
Subject: Re: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agreed!

Sent from my iPhone

> On Feb 4, 2020, at 5:33 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
>
> Hello. This is good news....and seemed to be a most surprisingly straightforward process. Let's see how the next steps go.
>
> Jim, keep u up to date on how this all unfolds. Hopefully some good work can proceed swiftly.
>
> All best,
> Peggy
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "president-office@cas.cn" <president-office@cas.cn>
> > **Date:** February 3, 2020 at 11:20:56 PM EST
> > **To:** dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
> > **Cc:** mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
> > **Subject: sharing of isolates of 2019nCoV**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124792

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124793

From: LeDuc, James W.
Sent: Tuesday, February 4, 2020 8:51 AM
To: Diane Griffin;Peggy Hamburg
Cc: Benjamin Rusek;Micah Lowenthal;John Boright;John Hildebrand;Shi, Pei yong;Dave Franz (davidrfranz@gmail.com);Benjamin Rusek (BRusek@nas.edu);Micah Lowenthal (mlowenth@NAS.EDU)
Subject: RE: sharing of isolates of 2019nCoV

This is indeed good news! Thank you all for your help and support.

Concurrent with the NAS-CAS communications, we have been dealing directly with the Wuhan Institute of Virology and as of last week they were in the process of seeking government approval to share the virus (see note pasted below). Hopefully this will be settled soon and we can arrange shipment.

We will keep you posted.

Thanks again, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, January 29, 2020 4:30 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: RE: MTA to receive New coronavirus 2019 isolate: nCoV-2019 (IVCAS 6.7512)

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I contacted with Wuhan custom, then they send our application message to the General Administration of Customs in Beijing. Today I asked them the progress, they said they should ask for the General Office of the State Council. So please wait for the fedback with me.

Best wishes,
Fei

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008832

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, February 04, 2020 7:51 AM
To: Peggy Hamburg <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Benjamin Rusek <BRusek@nas.edu>; Micah Lowenthal <mlowenth@nas.edu>; John Boright <JBoright@nas.edu>; John Hildebrand <jhildebr@email.arizona.edu>
Subject: Re: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Agreed!

Sent from my iPhone

> On Feb 4, 2020, at 5:33 AM, Peggy Hamburg <peggy@hbfam.net> wrote:
>
> Hello. This is good news....and seemed to be a most surprisingly straightforward process. Let's see how the next steps go.
>
> Jim, keep u up to date on how this all unfolds. Hopefully some good work can proceed swiftly.
>
> All best,
> Peggy
>
> Sent from my iPhone
>
> Begin forwarded message:
>
> > **From:** "president-office@cas.cn" <president-office@cas.cn>
> > **Date:** February 3, 2020 at 11:20:56 PM EST
> > **To:** dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
> > **Cc:** mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
> > **Subject: sharing of isolates of 2019nCoV**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008833

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008834

Investigation into the possibility that the nCoV was the result of a release from the Wuhan Institute of Virology (main campus or new BSL3/BSL4 facilities).

The questions below deal with the period 1 October 2019 to the present:

Where is coronavirus research conducted?

What level of biocontainment?

How many different laboratories actually handle live virus?

Where are coronavirus stocks stored?

Is there an inventory record of each isolate of each coronavirus kept? If so, are there any discrepancies between the record and actual current inventory number (i.e., is there evidence to suggest that virus stocks may have been stolen or used without proper record?)

Physical Security

Is there controlled access to the laboratories and freezers where coronavirus stocks are held? (Locked doors; card-key access; biometric readers; others?) Were any breaches in security noted/access to the facility by unauthorized individuals?

Is the laboratory constantly monitored by security personnel (24/7)? If not, you could briefly summarize your physical security program during the period in question.

Is there any evidence to suggest a mechanical failure in biocontainment during the time in question?

-were biological safety cabinets used and appropriately certified?

-Exhaust air filtration systems working correctly?

-Autoclaves and waste stream disinfection systems working properly?

-Animal husbandry and management?

-Waste stream integrity (think of FMD leak in UK a few years ago)

Virus Stocks (You may wish to explain that many novel coronaviruses are known only from their sequence and are not able to replicate in culture)

When was the nCoV first handled in your laboratory?

What was the source of that virus? (patient specimen or field collected animal or other?)

During the period in question, what other coronaviruses (that replicate in culture) are stored/handled in your laboratories?

What are the coronaviruses in your possession that are most closely related to nCoV based on genetic sequences and are able to replicate in culture?

Is anyone on your team conducting gain of function studies, recombination studies or any other studies that may have resulted in the creation of the nCoV?

Personnel

How many people have access to the coronavirus stocks and laboratory?

Senior investigators? Junior investigators? Technical support staff? Post-docs? Students? Animal handlers? Janitors and other cleaning staff? Building support personnel? Others?

Is there any evidence to suggest that a disgruntled employee may have had access to the coronavirus stocks? (Recently fired or reprimanded individual(s), for example.)

Does the Institute have an occupational health clinic where employees and students can go to seek medical care? If so, was there any indication of unusual illness similar to that seen for nCoV among Institute staff? If yes, when were cases first seen relative to the nCoV outbreak.

Does a serum bank exist for staff and students working on infectious agents? If yes, could a current serum and the most recent banked sera be serologically tested for antibody to nCoV in an effort to document seroconversion? (If positive, this would not be able to differentiate between community acquired and occupational acquired infection, but absence of evidence of infection would be helpful in ruling out the lab as a source of infection.)

Have any of individuals working at the Wuhan Institute of Virology (main campus or BSL4 campus) been infected with the nCoV? Family members of employees?

If yes, when was the date of onset of illness for the first case recognized? (How does this date compare with the progress of the epidemic; that is, was this among the first cases recognized or later after the outbreak was well underway? How does this compare to the first recognition of nCoV in the greater Wuhan community?)

Where the individuals infected involved in coronavirus research?

Geography

(These questions deal with any association between the physical location of the lab(s) and the districts in Wuhan where the illness was first seen. The assumption is that someone suffering an occupational exposure would go to their local hospital for treatment.)

Where and when were the first Wuhan (or Hubei Province) residents infected with the nCoV first identified (hospital or clinic name/date of earliest cases)?

Do staff members of the Institute reside in the district serviced by this (these) hospital/clinic (s)?

Were any Institute staff members seen for clinical illness at this/these hospital (s) during the time in question?

Do staff members of the Wuhan Institute of Virology frequent the sea food/live market first associated with the nCoV outbreak?

Did any staff member visit the market in the weeks prior to it being closed?

If so, how many staff frequent the market? How often would they visit the market during the period of interest? Have any become infected with nCoV?

From: Shi, Pei yong
Sent: Wednesday, February 12, 2020 7:10 AM
To: df@wh.iov.cn; zlshi
Cc: LeDuc, James W.; yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: RE: sharing of isolates of 2019nCoV

Thanks, Fei
Although US CDC has already shared the virus isolate with a number of US institutions (including UTMB) last week, it is still important to successfully transfer and share the isolate(s) from China.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 12, 2020 3:34 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: RE: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

No prompt reply from the Custom until today. President Bai is trying to push it in Beijing. Please wait for a while.

With best

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-05 20:41
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: FW: sharing of isolates of 2019nCoV
Hi Fei,
Thanks for the update. We look forward to further progress.
Best,

- Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126531

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 5, 2020 5:57 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: FW: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for your information.
We are trying to discuss this with the General Administration of Customs in Beijing directly.
I will keep on contacting with you.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-04 22:52
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; Yuan Zhiming; wangyy@wh.iov.cn; Ksiazek, Thomas G.
Subject: FW: sharing of isolates of 2019nCoV
Dear Fei and Zhengli,

Please see the response from President Bai. Zhiming and Yanyi were copied on the original email. Let us know anything we could help to facilitate the isolate transfer.

Best regards,

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, February 4, 2020 8:39 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: sharing of isolates of 2019nCoV

From: "president-office@cas.cn" <president-office@cas.cn>
Date: February 3, 2020 at 11:20:56 PM EST
To: dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126532

Cc: mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>

Subject: sharing of isolates of 2019nCoV

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126533

From: Shi, Pei yong
Sent: Wednesday, February 12, 2020 7:10 AM
To: df@wh.iov.cn;zlshi
Cc: LeDuc, James W.;yzm;wangyy;Ksiazek, Thomas G.
Subject: RE: RE: sharing of isolates of 2019nCoV

Thanks, Fei
Although US CDC has already shared the virus isolate with a number of US institutions (including UTMB) last week, it is still important to successfully transfer and share the isolate(s) from China.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 12, 2020 3:34 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: RE: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

No prompt reply from the Custom until today. President Bai is trying to push it in Beijing. Please wait for a while.

With best

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-05 20:41
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: FW: sharing of isolates of 2019nCoV
Hi Fei,
Thanks for the update. We look forward to further progress.
Best,

- Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051800

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 5, 2020 5:57 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: FW: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for your information.
We are trying to discuss this with the General Administration of Customs in Beijing directly.
I will keep on contacting with you.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-04 22:52
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; Yuan Zhiming; wangyy@wh.iov.cn; Ksiazek, Thomas G.
Subject: FW: sharing of isolates of 2019nCoV
Dear Fei and Zhengli,

Please see the response from President Bai. Zhiming and Yanyi were copied on the original email. Let us know anything we could help to facilitate the isolate transfer.

Best regards,

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, February 4, 2020 8:39 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: sharing of isolates of 2019nCoV

From: "president-office@cas.cn" <president-office@cas.cn>
Date: February 3, 2020 at 11:20:56 PM EST
To: dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051801

Cc: mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>

Subject: sharing of isolates of 2019nCoV

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051802

From: LeDuc, James W. [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=937DF08E29C4439E88A04BABFFB162AD-JWLEDUC]
Sent: 2/12/2020 8:41:52 AM
To: Shi, Pei yong [peshi@UTMB.EDU]; df@wh.iov.cn; zlshi [zlshi@wh.iov.cn]
CC: yzm [yzm@wh.iov.cn]; wangyy [wangyy@wh.iov.cn]; Ksiazek, Thomas G. [tgksiaze@UTMB.EDU]
Subject: RE: RE: sharing of isolates of 2019nCoV

I strongly agree. We need to show international scientific collaborations at this time of potentially global crisis.

Thank you Fei for your continued efforts.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Wednesday, February 12, 2020 7:10 AM
To: df@wh.iov.cn; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: sharing of isolates of 2019nCoV

Thanks, Fei
Although US CDC has already shared the virus isolate with a number of US institutions (including UTMB) last week, it is still important to successfully transfer and share the isolate(s) from China.
Best,
- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 12, 2020 3:34 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: RE: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

No prompt reply from the Custom until today. President Bai is trying to push it in Beijing. Please wait for a while.

With best

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-05 20:41
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: FW: sharing of isolates of 2019nCoV

Hi Fei,

Thanks for the update. We look forward to further progress.

Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 5, 2020 5:57 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: FW: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for your information.

We are trying to discuss this with the General Administration of Customs in Beijing directly.

I will keep on contacting with you.

Best wishes,

Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-04 22:52
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; Yuan Zhiming; wangyy@wh.iov.cn; Ksiazek, Thomas G.
Subject: FW: sharing of isolates of 2019nCoV

Dear Fei and Zhengli,

Please see the response from President Bai. Zhiming and Yanyi were copied on the original email. Let us know anything we could help to facilitate the isolate transfer.

Best regards,

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, February 4, 2020 8:39 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: sharing of isolates of 2019nCoV

From: "president-office@cas.cn" <president-office@cas.cn>
Date: February 3, 2020 at 11:20:56 PM EST
To: dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
Cc: mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
Subject: sharing of isolates of 2019nCoV

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Wednesday, February 12, 2020 8:42 AM
To: Shi, Pei yong; df@wh.iov.cn; zlshi
Cc: yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: RE: sharing of isolates of 2019nCoV

I strongly agree. We need to show international scientific collaborations at this time of potentially global crisis.

Thank you Fei for your continued efforts.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Wednesday, February 12, 2020 7:10 AM
To: df@wh.iov.cn; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: RE: RE: sharing of isolates of 2019nCoV

Thanks, Fei
Although US CDC has already shared the virus isolate with a number of US institutions (including UTMB) last week, it is still important to successfully transfer and share the isolate(s) from China.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 12, 2020 3:34 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: RE: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124852

No prompt reply from the Custom until today. President Bai is trying to push it in Beijing. Please wait for a while.

With best

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong
Date: 2020-02-05 20:41
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; yzm; wangyy; Ksiazek, Thomas G.
Subject: RE: FW: sharing of isolates of 2019nCoV

Hi Fei,
Thanks for the update. We look forward to further progress.
Best,

- Pei-Yong

From: df@wh.iov.cn <df@wh.iov.cn>
Sent: Wednesday, February 5, 2020 5:57 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; zlshi <zlshi@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; yzm <yzm@wh.iov.cn>; wangyy <wangyy@wh.iov.cn>; Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Subject: Re: FW: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks for your information.
We are trying to discuss this with the General Administration of Customs in Beijing directly.
I will keep on contacting with you.

Best wishes,
Fei

Dr. Fei Deng
Virus Resource and Bioinformation Center,
Wuhan Institute of Virology, Chinese Academy of Sciences.
Tel/Fax:0086-27-87198465
Email: df@wh.iov.cn

From: Shi, Pei yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124853

Date: 2020-02-04 22:52
To: df@wh.iov.cn; zlshi
CC: LeDuc, James W.; Yuan Zhiming; wangyy@wh.iov.cn; Ksiazek, Thomas G.
Subject: FW: sharing of isolates of 2019nCoV

Dear Fei and Zhengli,

Please see the response from President Bai. Zhiming and Yanyi were copied on the original email. Let us know anything we could help to facilitate the isolate transfer.

Best regards,

• Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, February 4, 2020 8:39 AM
To: Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: sharing of isolates of 2019nCoV

From: "president-office@cas.cn" <president-office@cas.cn>
Date: February 3, 2020 at 11:20:56 PM EST
To: dgriffi6 <dgriffi6@jhmi.edu>, MHamburg <MHamburg@nas.edu>
Cc: mlowenth <mlowenth@nas.edu>, Peggy Hamburg <peggy@hbfam.net>, jwleduc <jwleduc@nas.edu>, jhilderbr <jhilderbr@arizona.edu>, BRsek <BRsek@nas.edu>, jboright <jboright@nas.edu>, clbai <clbai@cas.cn>, zhangyp <zhangyp@cashq.ac.cn>, gaof <gaof@im.ac.cn>, jh-cao <jh-cao@cashq.ac.cn>, liyin <liyin@cashq.ac.cn>, sunhui <sunhui@cashq.ac.cn>, wangyy <wangyy@wh.iov.cn>, yzm <yzm@wh.iov.cn>
Subject: sharing of isolates of 2019nCoV

Diane E. Griffin, Vice President, NAS,
Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124854

other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124855

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, February 13, 2020 2:35 PM
To: LeDuc, James W.
Cc: Dave Franz (davidrfranz@gmail.com)
Subject: FW: sharing of isolates of 2019nCoV

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FYI
Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Wednesday, February 12, 2020 9:09 PM
To: president-office <president-office@cas.cn>
Cc: Hamburg, Margaret <MHamburg@nas.edu>; dgriffi6 <dgriffi6@jhmi.edu>; Lowenthal, Micah <mlowenth@nas.edu>; jwleduc <jwleduc@nas.edu>; JohnHildebrand <jhildebr@email.arizona.edu>; Rusek, Benjamin <BRusek@nas.edu>; Boright, John <JBoright@nas.edu>; clbai <clbai@cas.cn>; George_Gao（高福）_Fu <gaof@im.ac.cn>; zhangyp <zhangyp@cashq.ac.cn>; jh-cao <jh-cao@cashq.ac.cn>; liyin <liyin@cashq.ac.cn>; Sunhui@cashq.ac.cn; wangyy <wangyy@wh.iov.cn>; yzm <yzm@wh.iov.cn>
Subject: Re: sharing of isolates of 2019nCoV

Dear President Bai,

Thank you very much for following up with this additional information. We are disappointed, of course, but understand the value of sharing within the context of the WHO framework. Such viral isolate sharing is a crucial aspect of the international collaboration needed to combat this devastating outbreak, as well as to address future threats.

We look forward to working with you on efforts to contain this virus and continue to offer our assistance as needed.

With best regards,

Diane E. Griffin, Vice President, NAS
Margaret Hamburg, Foreign Secretary, NAM

Sent from my iPhone

> On Feb 9, 2020, at 10:18 PM, president-office <president-office@cas.cn> wrote:
>
> Dear Prof. Griffin and Prof. Hamburg,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124655

We have just been advised that the National Health Commission of China (NHC), the Chinese governmental agency for health, will take the lead in coordinating discussions and collaborations with the World Health Organization (WHO) for the sharing of 2019nCov isolates under WHO framework. As you may undertand, in addition to the U.S., many other countries have also made requests on isolates sharing from China.

CAS is still much interested in working with the international community on the specifics for isolates sharing under the guidance of NHC. It is our sincere hope that, with joint international efforts, the spread of the virus will be contained soon.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
President
The Alliance of International Science Organiztions (ANSO)

From: Hamburg, Margaret
Date: 2020-02-06 23:02
To: president-office@cas.cn
CC: dgriffi6; Lowenthal, Micah; peggy; jwleduc; JohnHildebrand; Rusek, Benjamin; Boright, John; clbai; gaof; zhangyp; jh-cao; liyin; sunhui; wangyy; yzm
Subject: Re: sharing of isolates of 2019nCoV

Dear Professor Bai,

Thank you so much for your very prompt and constructive response. We are deeply grateful for your willingness to help facilitate this important scientific collaboration. The health of the public will benefit in both our countries and around the globe.

We also want to extend our deepest sympathy to you and your country at this difficult time. Needless to say, we are eager to work closely with you to advance efforts to contain the spread of this virus.

With thanks and best regards,
I
Diane E. Griffin, Vice President, NAS
Margaret Hamburg, Foreign Secretary, NAM

Sent from my iPhone

> On Feb 3, 2020, at 11:32 PM, "president-office@cas.cn" <president-office@cas.cn> wrote:
>
> Diane E. Griffin, Vice President, NAS,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124656

Margaret Hamburg, Foreign Secretary, NAM

Dear Prof. Griffin and Prof. Hamburg,

Thank you for your concerns on the recent outbreak of the 2019 novo-coronavirus epidemic. Upon receiving your letter dated January 28, my colleagues have discussed with Dr. George Fu Gao and other experts and we are willing to share isolates of the 2019 nCoV with the international community. We believe this is critical to engaging joint international efforts to contain the spread of the virus.

The National Biosafety Laboratory Wuhan of the Chinese Academy of Sciences is prepared and willing to work with The University of Texas Medical Branch and other international research institutions on the specifics for the sharing and distribution of the isolates. We are in the process of getting it ready.

I look forward to hearing your further advice on this matter.

With best regards,

Chunli Bai

Chunli Bai
President
Chinese Academy of Sciences
The Alliance of International Science Organizations (ANSO)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124657

The NASEM U.S. China dialogue on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security

Dr. Zhengli Shi's presentations on corona viruses and the ongoing outbreak of COVID-19

Over the past five years representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with the Chinese Academy of Sciences (CAS), Chinese Center for Disease Control and Prevention (CCDC) and other Chinese life science and public health organizations to organize a series of dialogue meetings on infectious disease research, combating emerging infections, life science collaboration and data sharing, and high containment biological laboratory management. The dialogue meetings, hosted by institutes in China and the United States, have been well attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences.[1] The meetings have enabled scientists from China and the United States to exchange research findings on diseases of mutual concern to China and the United States, best practices and lessons learned for managing and operating high containment biological laboratories, and to establish new collaborative research and institutional partnerships.

Each meeting included sessions on corona viruses, with experts from China and the U.S.[2] presenting research findings. One of the Chinese participants **Dr. Zhengli Shi**,[3] a Chinese virologist. Her research focuses on SADS, MERS, and SARS and similar strains of these corona viruses and the study of interspecies as well as animal-to-human transmission originating in camels, bats, mice, swine, and other animals. Dr. Shi has also built one of the world's largest databases of bat-related viruses. In 2005, she and Dr. Cui Jie found that the SARS virus likely originated in bats, a finding which has implications for the emergence of SARS-like coronaviruses or related viruses (Li et al., 2005). Recently Dr. Shi led a study with several other scientists on antiviral agents to combat the COVID-19 and found that remdesivir and chloroquine are highly effective in the control of the virus in vitro. They recommended that the compounds be assessed in human patients suffering from COVID-19, and clinical trials of remdesivir, led by the American pharmaceutical company Gilead (Grady, 2020).

The following memo summarizes the presentations Dr. Shi's gave at the NASEM U.S. China dialogue meetings from 2015 to 2019.

First China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security (September 2015, Beijing, China)

Presentation Title: **Bat coronaviruses associated with human diseases**

Dr. Shi presented research on a bat-transmissible coronavirus and spoke about the evolution and pathogenesis of diverse SARS-like coronavirus (SL CoV) in bats. She explained that her research team found diverse types of SARs-like coronaviruses in bats in China. She explained that rhinolophid bats carry genetically diverse SL-CoVs, some of which are direct ancestor of SARS-CoV and have the potential to cause direct interspecies transmission to humans, and bats are likely natural reservoirs of MERS-CoV or an ancestral MERS-like CoV. **She warned that**

[1] Key NASEM participants: Dr. Diane Griffin, Dr. Margaret Hamburg, Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi. Key Chinese participants: Dr. Fu Gao (Director-General, Chinese Center for Disease Control and Prevention), Dr. Chunli Bai (President, Academician, Chinese Academy of Sciences), Dr. Zhiming Yuan (director of the Wuhan National Biosafety Laboratory of the Chinese Academy of Sciences), and Dr. Zhigao Bu (Director of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences).

[2] Dr. Linda Saif (Professor, The Ohio State University) and Dr. Ralph Baric (Professor Department of Epidemiology, University of North Carolina, Chapel Hill).

[3] Dr. Shi is director of the Center for Emerging Infectious Diseases at the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS). She holds a PhD from Montepellier II University, masters degrees from the WIV, and a bachelors from Wuhan University.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051206

disease outbreak resulting from spillover of bat coronaviruses will continue to occur in the future due to human activity increasingly overlapping the habitats of bats. Therefore, she said, it is necessary to maintain a long-term coronavirus surveillance in bats as well as in other wildlife and livestock animals and that laboratory-based studies (receptor specificity, pathogenesis and animal infection) will help to conduct better risk assessment and to reveal the potential intermediate hosts.

Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (May 2017, Wuhan, China)

Presentation Title: **Pathogenicity analysis of bat SARS-like coronaviruses**

Dr. Shi spoke about her continuing research on the evolution and pathogenesis of bat SARS-like coronavirus (SL CoV) and **said that bat SL CoV could be the next pandemic**. Her current research focus is on the pathogenesis of SL CoV in transgenic mice, noting that the virus replicates very well in mice and human tissue. The virus can easily enter human cells but said that in the animal model the virus has less pathogenesis; this is good news. **Her research shows that some bat SL CoVs have potential interspecies transmission to other animals and humans.** She added that continued surveillance of bat SL-CoV, as well as the examination of human behavior risk for infection and serological survey are needed.

Third U.S. China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (January 2018, Galveston, Texas, USA)

Presentation Title: **Coronaviruses associated with human and animal diseases in China -From SARS to SADS**

Dr. Shi discussed SARS and SADS coronaviruses and their different hosts, the animal origin of SARS, the natural host, the possible intermediate host (likely the civit cat) and the end host. She said that her team is still searching for the distributor of the SARS coronavirus and **discussed what to do if SARS spills over to humans again, a key concern for China, including measures such as the use of antibodies to neutralize infections.** She discussed swine acute diarrhea syndrome (SADS) noting that bats are the natural reservoirs of a divers set of coronaviruses, some bat coronavirus have potential for spilling to humans and this would be a problem because many coronaviruses have a high fatality rate in humans. She once again recommended surveillance and pathogenesis studies of bat coronaviruses. **She added that early diagnosis methods, treatment, and prevention should be prepared in advance for future emerging infectious diseases caused by bat coronaviruses.**

Fourth U.S.-China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and meeting on ***Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research*** (2019, Harbin, China)

Presentation Title: **Risks of MERS-cluster coronaviruses in China**

Dr. Shi provided information on MERS-related coronavirus and cases in China. MERS shares a number of genomic similarities with SARS virus, including the importance of the viral spike protein that binds to cellular receptors as part of viral entry. For MERS, the human cellular receptor to which the spike binds is DPP4. There are multiple MERS-related coronaviruses, including strains in clades A and B that cause human infection, camel MERS-related coronaviruses, including strains in clades A and B that cause human infection, camel MERS viruses, and bat MERS-related coronaviruses including the related bat coronavirus HKU4. Dr. Shi's laboratory explored diversity in the MERS spike binding domain for its roles in interspecies infection ability. A recombinant MERS containing the spike binding domain from HKU4 could replicate in human cells. **She noted that many strains of MERS-**

Commented [NAS1]: What did she say?

Commented [NAS2R1]: Translated Powerpoint notes, slide 19: Chimeric viruses expressing the S protein of the bat SARS-like coronavirus SHC014 strain can effectively replicate in human airway epithelial cells and infected mouse lungs, achieving replication levels comparable to SARS-CoV. HAE, human airway epithelial cells

Audio: file 'GNL Day 2 afternoon 1' at 53:00.
What can we do? 1:05:00 – somewhat unclear but maybe you can make clear what she said:
We can use antibodies to neutralize the infections, as we found in SHC014. "Ralph said we can use mice to confirm the result" and says "Thanks to Prof Ralph Baric in North Carolina Univeristy" in the powerpoint, as I understand they used some specialized lab equipment he has there.

Also consider adding: She said at that time there were 6 humans who had tested positive for the coronavirus, based on the study of individuals who live around bat caves.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051207

related coronaviruses are prevalent in multiple bat host species in China and said that the potential for interspecies transmission highlights the need for long-term surveillance of this group of viruses.

***

CDC on COVID-19 Origin

"The SARS-CoV-2 virus is a betacoronavirus, like MERS-CoV and SARS-CoV, both of which have their origins in bats. The sequences from U.S. patients are similar to the one that China initially posted, suggesting a likely single, recent emergence of this virus from an animal reservoir. Early on, many of the patients in the COVID-19 outbreak in Wuhan, China had some link to a large seafood and live animal market, suggesting animal-to-person spread. Later, a growing number of patients reportedly did not have exposure to animal markets, indicating person-to-person spread. Person-to-person spread has been reported outside China, including in the United States and other countries. Chinese officials report that sustained person-to-person spread in the community is occurring in China. In addition, other destinations have apparent community spread, meaning some people have been infected who are not sure how or where they became infected. (CDC, 2020)."

References (Zhengli Shi in bold)

Azhar, E. I., S. A. El-Kafrawy, S. A. Farraj, A. M. Hassan, M. S. Al-Saeed, A. M. Hashem, and T. A. Madani. 2014. Evidence for camel-to-human transmission of mers coronavirus. *New England Journal of Medicine* 370(26):2499-2505.

Briese, T., N. Mishra, K. Jain, I. S. Zalmout, O. J. Jabado, W. B. Karesh, P. Daszak, O. B. Mohammed, A. N. Alagaili, and W. I. Lipkin. 2014. Middle east respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in saudi arabia. *mBio* 5(3):e01146-01114.

CDC. 2020. *Coronavirus disease 2019 (covid-19) situation summary*. https://www.cdc.gov/coronavirus/2019-ncov/summary.html (accessed.

Drexler, J. F., F. Gloza-Rausch, J. Glende, V. M. Corman, D. Muth, M. Goettsche, A. Seebens, M. Niedrig, S. Pfefferle, S. Yordanov, L. Zhelyazkov, U. Hermanns, P. Vallo, A. Lukashev, M. A. Muller, H. Deng, G. Herrler, and C. Drosten. 2010. Genomic characterization of severe acute respiratory syndrome-related coronavirus in european bats and classification of coronaviruses based on partial rna-dependent rna polymerase gene sequences. *J Virol* 84(21):11336-11349.

Ge, X.-Y., J.-L. Li, X.-L. Yang, A. A. Chmura, G. Zhu, J. H. Epstein, J. K. Mazet, B. Hu, W. Zhang, C. Peng, Y.-J. Zhang, C.-M. Luo, B. Tan, N. Wang, Y. Zhu, G. Crameri, S.-Y. Zhang, L.-F. Wang, P. Daszak, and **Z.-L. Shi.** 2013. Isolation and characterization of a bat sars-like coronavirus that uses the ace2 receptor. *Nature* 503(7477):535-538.

Grady, D. 2020. China begins testing an antiviral drug in coronavirus patients. *The New York Times*, February 6, 2020.

Guan, Y., B. Zheng, Y. He, X. Liu, Z. Zhuang, C. Cheung, S. Luo, P. Li, L. Zhang, and Y. Guan. 2003. Isolation and characterization of viruses related to the sars coronavirus from animals in southern china. *Science* 302(5643):276-278.

Hu, B., L.-P. Zeng, X.-L. Yang, X.-Y. Ge, W. Zhang, B. Li, J.-Z. Xie, X.-R. Shen, Y.-Z. Zhang, N. Wang, D.-S. Luo, X.-S. Zheng, M.-N. Wang, P. Daszak, L.-F. Wang, J. Cui, and **Z.-L. Shi.** 2017. Discovery of a rich gene pool of bat sars-related coronaviruses provides new insights into the origin of sars coronavirus. *PLoS pathogens* 13(11):e1006698-e1006698.

Lau, S. K. P., P. C. Y. Woo, K. S. M. Li, Y. Huang, H.-W. Tsoi, B. H. L. Wong, S. S. Y. Wong, S.-Y. Leung, K.-H. Chan, and K.-Y. Yuen. 2005. Severe acute respiratory syndrome coronavirus-like virus in chinese horseshoe

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051208

bats. *Proceedings of the National Academy of Sciences of the United States of America* 102(39):14040-14045.

Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, J. Zhang, J. McEachern, H. Field, P. Daszak, B. T. Eaton, S. Zhang, and L. F. Wang. 2005. Bats are natural reservoirs of sars-like coronaviruses. *Science* 310(5748):676-679.

Li, H., E. Mendelsohn, C. Zong, W. Zhang, E. Hagan, N. Wang, S. Li, H. Yan, H. Huang, G. Zhu, N. Ross, A. Chmura, P. Terry, M. Fielder, M. Miller, **Z. Shi**, and P. Daszak. 2019. Human-animal interactions and bat coronavirus spillover potential among rural residents in southern china. *Biosafety and Health* 1.

Loo, Y.-M., D. M. Owen, K. Li, A. K. Erickson, C. L. Johnson, P. M. Fish, D. S. Carney, T. Wang, H. Ishida, M. Yoneyama, T. Fujita, T. Saito, W. M. Lee, C. H. Hagedorn, D. T.-Y. Lau, S. A. Weinman, S. M. Lemon, and M. Gale. 2006. Viral and therapeutic control of ifn-β promoter stimulator 1 during hepatitis c virus infection. *Proceedings of the National Academy of Sciences* 103(15):6001-6006.

Menachery, V. D., B. L. Yount Jr, K. Debbink, S. Agnihothram, L. E. Gralinski, J. A. Plante, R. L. Graham, T. Scobey, X.-Y. Ge, and E. F. Donaldson. 2015. A sars-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nature medicine* 21(12):1508.

Ren, W., X. Qu, W. Li, Z. Han, M. Yu, P. Zhou, S. Y. Zhang, L. F. Wang, H. Deng, and **Z. Shi.** 2008. Difference in receptor usage between severe acute respiratory syndrome (sars) coronavirus and sars-like coronavirus of bat origin. *J Virol* 82(4):1899-1907.

Tong, S., C. Conrardy, S. Ruone, I. V. Kuzmin, X. Guo, Y. Tao, M. Niezgoda, L. Haynes, B. Agwanda, R. F. Breiman, L. J. Anderson, and C. E. Rupprecht. 2009. Detection of novel sars-like and other coronaviruses in bats from kenya. *Emerging infectious diseases* 15(3):482-485.

Wang, Q., J. Qi, Y. Yuan, Y. Xuan, P. Han, Y. Wan, W. Ji, Y. Li, Y. Wu, J. Wang, A. Iwamoto, P. C. Woo, K. Y. Yuen, J. Yan, G. Lu, and G. F. Gao. 2014. Bat origins of mers-cov supported by bat coronavirus hku4 usage of human receptor cd26. *Cell Host Microbe* 16(3):328-337.

WHO. 2017. *Middle east respiratory syndrome coronavirus mers-cov*. https://www.who.int/csr/don/archive/disease/mers-cov/en/ (accessed.

Wu, Z., L. Yang, X. Ren, J. Zhang, F. Yang, S. Zhang, and Q. Jin. 2015. Orf8-related genetic evidence for chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus. *The Journal of Infectious Diseases* 213(4):579-583.

Yang, X.-L., B. Hu, B. Wang, M.-N. Wang, Q. Zhang, W. Zhang, L.-J. Wu, X.-Y. Ge, Y.-Z. Zhang, P. Daszak, L.-F. Wang, and **Z.-L. Shi.** 2016. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. *Journal of Virology* 90(6):3253-3256.

Yuan, J., C.-C. Hon, Y. Li, D. Wang, G. Xu, H. Zhang, P. Zhou, L. L. M. Poon, T. T.-Y. Lam, F. C.-C. Leung, and **Z. Shi.** 2010. Intraspecies diversity of sars-like coronaviruses in rhinolophus sinicus and its implications for the origin of sars coronaviruses in humans. *Journal of General Virology* 91(4):1058-1062.

Zaki, A. M., S. van Boheemen, T. M. Bestebroer, A. D. M. E. Osterhaus, and R. A. M. Fouchier. 2012. Isolation of a novel coronavirus from a man with pneumonia in saudi arabia. *New England Journal of Medicine* 367(19):1814-1820.

Zeng, L.-P., X.-Y. Ge, C. Peng, W. Tai, S. Jiang, L. Du, and **Z.-L. Shi**. 2017. Cross-neutralization of sars coronavirus-specific antibodies against bat sars-like coronaviruses. *Science China Life Sciences* 60(12):1399-1402.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051209

From: LeDuc, James W.
Sent: Sunday, March 8, 2020 8:05 AM
To: Shi, Pei yong
Subject: Fwd: Vox article

Let's discuss Monday.

Sent from my iPhone

Begin forwarded message:

> **From:** Yuan Zhiming <yzm@wh.iov.cn>
> **Date:** March 8, 2020 at 12:10:31 AM CST
> **To:** "LeDuc, James W." <jwleduc@UTMB.EDU>
> **Subject: 回复: Vox article**

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim,

Nice to hear from you and hope everything goes well with you and your colleagues. As you could know, we have been experienced hard time during the epidemic, fighting the virus and fighting the rumors. We are in the hurricane center of rumors, however we still do as sechulled. Thanks for your positive and pertinen remarks to our lab and our works and I am sure some people will understand finally what we have done the preparation of new emerging diseases. What is why we are here.

In these days, I am thinking about the possilbe long-term negative effects of the rumor on the necessarity,role, functioning of high level biosafety labor. Whethere the novel coronavirus is related to the lab or not, I am sure it is not, some administratives and pubulic might regard the lab as a dangerour place, and finally limit its operation. Which will surely confllict with the mission of the platform, and finally impact the global health security. We construct the lab for fighting the disease, we have stick management for preventing the pathogens from lab. we accumulate the knoweldge and develope the technology for preparing the now pathogens, that is what we do.

I do not know, it is suitable or not to write a paper to tell the scientific community and public why we need the P4, how to manage the P4, and what we can do for new emerging diseases.

Anyway, thanks for your courage and support.

Regards

Zhiming

FOIA Confidential Treatment Requested by Univ of Texas System

==========

Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480

==========

From: LeDuc, James W.
Date: 2020-03-05 22:50
To: Yuan Zhiming; zlshi
CC: Shi, Pei yong
Subject: Vox article

Dear Zhiming and Zhengli,

I hope you are both well during this very difficult time.

The link below is to an article just published that may be of interest to you.

With all good wishes for your personal health and safety as we all work together to control the new virus.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: Eliza Barclay <eliza.barclay@vox.com>
Sent: Wednesday, March 04, 2020 8:49 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim,
The story went up today. Thanks so much for your help with it, and let me know if you see any inaccuracies to fix or updates I should make.
Very best, and hope to stay in touch,

FOIA Confidential Treatment Requested by Univ of Texas System

Eliza
https://www.vox.com/2020/3/4/21156607/how-did-the-coronavirus-get-started-china-wuhan-lab

On Fri, Feb 28, 2020 at 3:06 PM Eliza Barclay <eliza.barclay@vox.com> wrote:

> Sure, will do.
>
> On Feb 28, 2020, at 12:16 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> Better to call after about 4 pm CT. We're kinda busy…
>
> Thanks, Jim
>
> **From:** Eliza Barclay <eliza.barclay@vox.com>
> **Sent:** Friday, February 28, 2020 1:07 PM
> **To:** LeDuc, James W. <jwleduc@UTMB.EDU>
> **Cc:** Keusch, Gerald T <keusch@bu.edu>
> **Subject:** Re: Wuhan
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> Thanks for the connection, Jerry.
> And thanks so much for the quick response, Jim. I will give you a call in about an hour.
> Best,
> Eliza
>
> On Fri, Feb 28, 2020 at 10:50 AM LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> > Hi Jerry,
> >
> > Thanks for the introduction and happy to meet you, Eliza. I'm happy to chat about this issue at your convenience. My direct office line is [redacted]
> >
> > Thanks, Jim
> >
> > James W. Le Duc, Ph.D.
> > Director
> > Galveston National Laboratory
> > University of Texas Medical Branch
> > Galveston, TX 77555-0610
> > (t) 409-266-6500
> > (f) 409-266-6810
> > (m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System

From: Keusch, Gerald T <keusch@bu.edu>
Sent: Friday, February 28, 2020 11:48 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Eliza Barclay <eliza.barclay@vox.com>
Subject: Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim,

I was talking to Eliza Barclay from Vox (copied above) who was referred to me by our friend Peter Daszak. Eliza is working on a story to address the various conspiracy theories being bandied about on the origin of the Covid19 virus. One of the issues, of course, was the Wuhan laboratory as a source – whether accidental or deliberate – and the questions being raised about it biosecurity and biosafety protocols. I said that I was absolutely confident that they had proper protocols and trained people in place, in part because I am was aware that GNL had connections with that lab, had trained many of their staff, and that you have been there.

Eliza will follow up and if you have the time she would like to talk with you. She is trying to gather the scientific argument and be able to translate it for a general audience to be able to distinguish between evidence and conspiracy.

Hope all is well.

Jerry

Gerald T. Keusch, M.D.
Professor of Medicine and International Health
Boston University School of Medicine
Associate Director, National Emerging Infectious Diseases Laboratories
620 Albany Street
Boston, MA 02118

--
Eliza Barclay • Science Editor


<~WRD363.jpg>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000932

Follow Vox on Twitter • Instagram • Facebook

--

Eliza Barclay • Science Editor



Follow Vox on Twitter • Instagram • Facebook

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000933

From: LeDuc, James W.
Sent: Friday, March 20, 2020 2:40 PM
To: Yuan Zhiming
Cc: Shi, Pei yong
Subject: RE: 回复: Vox article

Dear Zhiming,

Thank you for your kinds words and your heroic efforts to control the epidemic in Wuhan. Your success is an inspiration to all of us as we work to halt transmission here in the USA and in other countries. We are just at the start of the explosion of cases in our region and we expect that over the next few weeks we will see very high numbers of cases requiring hospitalization and ICU support. We are preparing as best we can, but as you know well the challenges will be substantial.

Pei Yong and his team continue to make remarkable progress on different aspects of study and it would be excellent if we could identify areas for collaborations.

With all good wishes,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: Yuan Zhiming <yzm@wh.iov.cn>
Sent: Friday, March 20, 2020 1:33 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: 回复: Vox article

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim，
I am sincerely hope everything goes well with you and your family!
The 2019 novel coronavirus (SARS-CoV-2) outbreak is a major challenge for global public health security. Infection with SARS-CoV-2 has been associated with serious acute respiratory distress syndrome with large number of patients' hospitalization and relatively high mortality. We had a very hard time in combating the

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051371

infection in Wuhan, the epicenter of the COVID-19 in China, and now we can see the situation goes in good direction, with no reported confirmed case, no reported suspected case in last two days here.
My colleagues and I, have been working on characterization of pathogens, antiviral screen, vaccine development, animal modeling since the early January this year, and some progresses have been made. I hope our understanding of the virus and the technology could be valuable in the global fighting to the virus.
As I can see from the media, the virus is spreading in your country, and more people are infected during the last days, and the situation worries me a lot. I am confident that we could finally curb the spreading of the virus with our joint effort, and our life will return back to the normal soon. I do not know what I can do in the special moment and I hope you could protect you and your family.
Best regards

Zhiming

==========
Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480
==========

From: LeDuc, James W.
Date: 2020-03-05 22:50
To: Yuan Zhiming; zlshi
CC: Shi, Pei yong
Subject: Vox article

Dear Zhiming and Zhengli,

I hope you are both well during this very difficult time.

The link below is to an article just published that may be of interest to you.

With all good wishes for your personal health and safety as we all work together to control the new virus.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051372

From: Eliza Barclay <eliza.barclay@vox.com>
Sent: Wednesday, March 04, 2020 8:49 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim,
The story went up today. Thanks so much for your help with it, and let me know if you see any inaccuracies to fix or updates I should make.
Very best, and hope to stay in touch,
Eliza
https://www.vox.com/2020/3/4/21156607/how-did-the-coronavirus-get-started-china-wuhan-lab

On Fri, Feb 28, 2020 at 3:06 PM Eliza Barclay <eliza.barclay@vox.com> wrote:

> Sure, will do.
>
> On Feb 28, 2020, at 12:16 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> Better to call after about 4 pm CT. We're kinda busy...
>
> Thanks, Jim
>
> **From:** Eliza Barclay <eliza.barclay@vox.com>
> **Sent:** Friday, February 28, 2020 1:07 PM
> **To:** LeDuc, James W. <jwleduc@UTMB.EDU>
> **Cc:** Keusch, Gerald T <keusch@bu.edu>
> **Subject:** Re: Wuhan
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> Thanks for the connection, Jerry.
> And thanks so much for the quick response, Jim. I will give you a call in about an hour.
> Best,
> Eliza
>
> On Fri, Feb 28, 2020 at 10:50 AM LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> > Hi Jerry,
> >
> > Thanks for the introduction and happy to meet you, Eliza. I'm happy to chat about this issue at your convenience. My direct office line is [redacted]
> >
> > Thanks, Jim

FOIA Confidential Treatment Requested by Univ of Texas System

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

From: Keusch, Gerald T <keusch@bu.edu>
Sent: Friday, February 28, 2020 11:48 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Eliza Barclay <eliza.barclay@vox.com>
Subject: Wuhan

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim,

I was talking to Eliza Barclay from Vox (copied above) who was referred to me by our friend Peter Daszak. Eliza is working on a story to address the various conspiracy theories being bandied about on the origin of the Covid19 virus. One of the issues, of course, was the Wuhan laboratory as a source – whether accidental or deliberate – and the questions being raised about it biosecurity and biosafety protocols. I said that I was absolutely confident that they had proper protocols and trained people in place, in part because I am was aware that GNL had connections with that lab, had trained many of their staff, and that you have been there.

Eliza will follow up and if you have the time she would like to talk with you. She is trying to gather the scientific argument and be able to translate it for a general audience to be able to distinguish between evidence and conspiracy.

Hope all is well.

Jerry

Gerald T. Keusch, M.D.
Professor of Medicine and International Health
Boston University School of Medicine
Associate Director, National Emerging Infectious Diseases Laboratories
620 Albany Street
Boston, MA 02118


FOIA Confidential Treatment Requested by Univ of Texas System

--
Eliza Barclay • Science Editor

<~WRD363.jpg>

Follow Vox on Twitter • Instagram • Facebook

--
Eliza Barclay • Science Editor



Follow Vox on Twitter • Instagram • Facebook

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051375

From: LeDuc, James W. [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=937DF08E29C4439E88A04BABFFB162AD-JWLEDUC]
Sent: 4/10/2020 1:03:20 PM
To: Dave Franz [davidrfranz@gmail.com]
Subject: RE: Potential topics for discussion with Russian colleagues.

Thanks Dave. I don't know what to make of Rita's lack of engagement with us, especially if she is calling for an ID work group meeting in less than 2 weeks.

If we have a dialogue with the Russians, I think we should focus on the current COVID-19 pandemic and raise a few serious scientific issues such as a strategy for vaccine development and production for a global need. I think that there is a lot we do not know about immunity to this virus and we need to be very careful as we design and test vaccines. We need to address the question of re-infection/re-occurrence of illness. Is this an artifact of PCR testing or represent a real issue.

Also, basic public health questions about how effective—or not—certain interventions have been and how sustainable they are. Contact tracing is the current big challenge and the question about individual rights to privacy versus society need to interrupt transmission in the context of cell phone GPS tracking and other modern tools that have been used in other parts of the world.

There is also emerging information on genetic variability of the virus and what the impact might be on transmission and disease.

Pasted below is a string of email between Phil Russell and me following his viewing of the video we discussed yesterday. Read from the bottom up. This is not going away—and it probably shouldn't.

Happy Easter,

Jim

I admire your desire to avoid an adversarial situation but the seem to be impossible with the Chinese communists.

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
To: pkrussell@aol.com <pkrussell@aol.com>
Sent: Fri, Apr 10, 2020 9:11 am
Subject: RE: Very scary. You must watch this

I agree that it is certainly possible that a lab accident was the source of the epidemic and I also agree that we can't trust the Chinese government. I sent a rather detailed plan to investigate the possibility that the lab might have been the source of the outbreak to Zhiming Yuan early in the event, but never heard back from him. It's good that folks are pressing the issue, but we need to strike a balance such that we are not in an adversarial situation. That's why we have focused on the NAS-CAS linkage as an appropriate forum.

From: pkrussell@aol.com <pkrussell@aol.com>
Sent: Friday, April 10, 2020 9:51 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Very scary. You must watch this

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,

I have no doubt that Zheng Li Shi is a brilliant scientist and very charming. That does not rule out the possibility that one of the many bat coronaviruses isolated in the Wuhan lab infected a technician who walked out the door. No need for engineering the virus.
The flimsiness of the epidemiology pointing to the wet market, the absence of bats in the market, the failure to identify an intermediate animal host, the extraordinary measures taken by the Chinese government, including persecution and probable killing of two brave physicians, to cover up the outbreak, the steps taken to silence the laboratory personnel,. the change in leadership of the lab, all point to the lab as the source of the outbreak.

This reminds me of the efforts by Matt Messelson and many colleagues to coverup up the Sverdeslosk anthrax outbreak. They succeeded for many years aided and abetted by many in academia until Ken Alibek defected and the truth came out.

I bought the wet market story for months but now am very skeptical of anything information coming from the Chinese government.

Phil

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
To: pkrussell@aol.com <pkrussell@aol.com>
Sent: Thu, Apr 9, 2020 4:06 pm
Subject: RE: Very scary. You must watch this
Yes, I just received the link this morning from Doug Watts. I don't believe that the virus originated from the lab in Wuhan and I think the attached paper makes a strong argument that it came from nature, a conclusion with which I concur.

We have been working with Zheng Li Shi through a dialogue established between the US National Academy of Sciences and the Chinese Academy of Sciences. Dr Shi has presented at each of these meetings starting with the first in Beijing in 2015, and her message has consistently been that these bat coronaviruses hold the ability to infect humans through the hACE2 receptor. She's a very talented scientist and a charming person. Our meetings have included Ralph Baric and Linda Saif, two of the premier coronavirologist in the US and the discussions have always been open and frank. See attached summary prepared by NAS at the end of February, 2020 as the pandemic was unfolding. **PLEASE DO NOT FORWARD.**

I can't argue with the comments against the Chinese communist party. It's too bad that the global pandemic is being conflated with the challenges the world faces from the Chinese communist party. They are both important issues, but I'm not convinced that they are linked.

Hope you and Connie are staying well through all this,

Jim

From: pkrussell@aol.com <pkrussell@aol.com>
Sent: Thursday, April 09, 2020 4:33 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Fwd: Very scary. You must watch this

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,

This is gaining credibity. What do you think?

Phil

From: Dave Franz <davidrfranz@gmail.com>
Sent: Friday, April 10, 2020 12:39 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Fwd: Potential topics for discussion with Russian colleagues.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim, This is what I sent Rita. Neither she nor Micah have acknowledged it, so I'm just going to leave it at that. See the blue type at the bottom. This is what Rita sent our to the nuc CISACers plus me. Matt Bunn, in one of his responses suggested that I put something together, thus this list. I was trying to stay away from a focused discussion on their response to the pandemic…but maybe that was being too cautious. As I said, if we forward it to 'expert' in CISAC, it would probably change significantly. …but not a peep from anyone except Dick Garwin who wrote me and then asked me to call him this morning, which I did. He didn't say anything about this, but just wanted to know what I had going on these days and what I thought a bout a couple of things. d

P.S. Note at the bottom Rita has proposed an ID meeting for 4/22; you know as much as I do about that. If we were going to do that, I would think we might start putting a list of participants together.

Begin forwarded message:

From: Dave Franz <davidrfranz@gmail.com>
Subject: Potential topics for discussion with Russian colleagues.
Date: April 8, 2020 at 5:55:26 PM EDT
To: Rita Guenther <RGuenther@nas.edu>
Cc: "Bunn, Matthew" <Matthew_Bunn@hks.harvard.edu>, James Timbie <jptimbie@gmail.com>, Linton Brooks <linton.brooks@cox.net>, Jill Hruby <jillhruby@gmail.com>, Robert Latiff <rlatiff@nd.edu>, Richard Mies <miesrw@verizon.net>, "Richard L. Garwin" <rlg2@us.ibm.com>, Raymond Jeanloz <jeanloz@berkeley.edu>, Steve Fetter <sfetter@umd.edu>, Micah Lowenthal <mlowenth@nas.edu>, "Cervenka, Nicole" <NCervenka@nas.edu>, Rose Gottemoeller <gottemoeller@stanford.edu>

Colleagues, Matt suggested I draft something from the bio subgroup.

I don't know how much involvement CISAC leadership is seeking from the 'bio'… or "Infectious Disease" Working Group. Each of us is officially, or unofficially in my case, spending a lot of time on the pandemic. Because they are probably nearly overwhelmed with work, we may not get a lot of time from the other four or five members of the bio subpanel just now, but I'm happy to coordinate a short paper with a list of suggested topics for collaboration if Rita and Micah are interested. I've taken a first cut at some bullets below, but the list might change significantly if I run it by the real experts.

Russia, as of yesterday, has reported about 40% as many 'tests' as the US and about 2% as many cases. My sense would be to start with a few rather generic, yet relevant, topics that don't get into the fine details of their response to or reporting of COVID19 pandemic. Some potential examples:

- Observations from the current COVID19 pandemic relevant to planning and preparations for a future highly contiguous and virulent influenza pandemic
- The effect of climate change on vector-borne infectious disease
- Timely recognition and public health response to emerging diseases

- Antimicrobial resistance
- Laboratory safety, security, regulation and progress in infectious disease research
- Human and Animal Health relationships. Zoonotic disease and the "One Health" concept.
- The Biotech Revolution: Safety, security and progress
- Managing the Health Impacts of natural disasters

I welcome thoughts of comments from anyone…and, Rita, let me know if you want me to continue down this or another track.

Stay well all, dave

Proposed Working Groups:
New START and arms control
Cyber Security
Space Security
Infectious Disease
China and Strategic Stability

Proposed Schedule of Virtual Meetings ('plenary' and 'working group' meetings):
4/15: Beyond New START (non-strategic weapons, verification, monitoring, trade-offs, etc.) – Plenary Meeting
4/22: Infectious Disease – Working Group Meeting
4/29: Cyber – Plenary Meeting
5/6: Possible Working Group Meeting (this date falls over the Russian May Holidays, so this may not be feasible for most Russians)
5/13: Space – Plenary Meeting
5/20: Possible Working Group Meeting
5/27: Strategic Stability and Arms Control – Plenary Meeting
6/3: Possible Working Group Meeting
6/10: China and Strategic Stability – Plenary Meeting
(FYI: The IMEMO Primakov Readings, a major conference which includes arms control issues, is scheduled for June 15-17)

<Bunn Further Reactions to Sergei Rogov paper RG comments.docx>

David R. Franz
Gettysburg, PA
240-674-0797

David R. Franz
Gettysburg, PA
240-674-0797

From: Dave Franz <davidrfranz@gmail.com>
Sent: Friday, April 10, 2020 1:18 PM
To: LeDuc, James W.
Subject: Re: Potential topics for discussion with Russian colleagues.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim, You are probably right and it's certainly worth a try. I was probably trying to hard to assure they were willing to start a discussion. Sergey (from several years ago now) had me a little gun-shy about what we should try. … my sense is that they aren't reporting cases accurately so, similar to china, scientists might be muzzled regarding this pandemic right now. I will write Rita, copy Micah and ask about the 22nd.

BTW, I've been pretty close to Phil's interpretation thus far. If someone credible would write something that happened before the Lancet paper's 1 Dec 'index case' I would breathe a sigh of relief for Zhengli.

Will let you know what Micah and Rita have to say. Thanks, dave

On Apr 10, 2020, at 2:03 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

Thanks Dave. I don't know what to make of Rita's lack of engagement with us, especially if she is calling for an ID work group meeting in less than 2 weeks.

If we have a dialogue with the Russians, I think we should focus on the current COVID-19 pandemic and raise a few serious scientific issues such as a strategy for vaccine development and production for a global need. I think that there is a lot we do not know about immunity to this virus and we need to be very careful as we design and test vaccines. We need to address the question of re-infection/re-occurrence of illness. Is this an artifact of PCR testing or represent a real issue.

Also, basic public health questions about how effective—or not—certain interventions have been and how sustainable they are. Contact tracing is the current big challenge and the question about individual rights to privacy versus society need to interrupt transmission in the context of cell phone GPS tracking and other modern tools that have been used in other parts of the world.

There is also emerging information on genetic variability of the virus and what the impact might be on transmission and disease.

Pasted below is a string of email between Phil Russell and me following his viewing of the video we discussed yesterday. Read from the bottom up. This is not going away—and it probably shouldn't.

Happy Easter,

Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009228

I admire your desire to avoid an adversarial situation but the seem to be impossible with the Chinese communists.

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
To: pkrussell@aol.com <pkrussell@aol.com>
Sent: Fri, Apr 10, 2020 9:11 am
Subject: RE: Very scary. You must watch this

I agree that it is certainly possible that a lab accident was the source of the epidemic and I also agree that we can't trust the Chinese government. I sent a rather detailed plan to investigate the possibility that the lab might have been the source of the outbreak to Zhiming Yuan early in the event, but never heard back from him. It's good that folks are pressing the issue, but we need to strike a balance such that we are not in an adversarial situation. That's why we have focused on the NAS-CAS linkage as an appropriate forum.

From: pkrussell@aol.com <pkrussell@aol.com>
Sent: Friday, April 10, 2020 9:51 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Very scary. You must watch this

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,

I have no doubt that Zheng Li Shi is a brilliant scientist and very charming. That does not rule out the possibility that one of the many bat coronaviruses isolated in the Wuhan lab infected a technician who walked out the door. No need for engineering the virus.
The flimsiness of the epidemiology pointing to the wet market, the absence of bats in the market, the failure to identify an intermediate animal host, the extraordinary measures taken by the Chinese government, including persecution and probable killing of two brave physicians, to cover up the outbreak, the steps taken to silence the laboratory personnel,. the change in leadership of the lab, all point to the lab as the source of the outbreak.

This reminds me of the efforts by Matt Messelson and many colleagues to coverup up the Sverdeslosk anthrax outbreak. They succeeded for many years aided and abetted by many in academia until Ken Alibek defected and the truth came out.

I bought the wet market story for months but now am very skeptical of anything information coming from the Chinese government.

Phil

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
To: pkrussell@aol.com <pkrussell@aol.com>
Sent: Thu, Apr 9, 2020 4:06 pm
Subject: RE: Very scary. You must watch this
Yes, I just received the link this morning from Doug Watts. I don't believe that the virus originated from the lab in Wuhan and I think the attached paper makes a strong argument that it came from nature, a conclusion with which I concur.

We have been working with Zheng Li Shi through a dialogue established between the US National Academy of Sciences and the Chinese Academy of Sciences. Dr Shi has presented at

FOIA Confidential Treatment Requested by Univ of Texas System

each of these meetings starting with the first in Beijing in 2015, and her message has consistently been that these bat coronaviruses hold the ability to infect humans through the hACE2 receptor. She's a very talented scientist and a charming person. Our meetings have included Ralph Baric and Linda Saif, two of the premier coronavirologist in the US and the discussions have always been open and frank. See attached summary prepared by NAS at the end of February, 2020 as the pandemic was unfolding. **PLEASE DO NOT FORWARD.**

I can't argue with the comments against the Chinese communist party. It's too bad that the global pandemic is being conflated with the challenges the world faces from the Chinese communist party. They are both important issues, but I'm not convinced that they are linked.

Hope you and Connie are staying well through all this,

Jim

From: pkrussell@aol.com <pkrussell@aol.com>
Sent: Thursday, April 09, 2020 4:33 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Fwd: Very scary. You must watch this

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,

This is gaining credibity. What do you think?

Phil

From: Dave Franz <davidrfranz@gmail.com>
Sent: Friday, April 10, 2020 12:39 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Fwd: Potential topics for discussion with Russian colleagues.

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim, This is what I sent Rita. Neither she nor Micah have acknowledged it, so I'm just going to leave it at that. See the blue type at the bottom. This is what Rita sent our to the nuc CISACers plus me. Matt Bunn, in one of his responses suggested that I put something together, thus this list. I was trying to stay away from a focused discussion on their response to the pandemic…but maybe that was being too cautious. As I said, if we forward it to 'expert' in CISAC, it would probably change significantly. …but not a peep from anyone except Dick Garwin who wrote me and then asked me to call him this morning, which I did. He didn't say anything about this, but just wanted to know what I had going on these days and what I thought a bout a couple of things. d

P.S. Note at the bottom Rita has proposed an ID meeting for 4/22; you know as much as I do about that. If we were going to do that, I would think we might start putting a list of participants together.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009230

Begin forwarded message:

From: Dave Franz <davidrfranz@gmail.com>
Subject: Potential topics for discussion with Russian colleagues.
Date: April 8, 2020 at 5:55:26 PM EDT
To: Rita Guenther <RGuenther@nas.edu>
Cc: "Bunn, Matthew" <Matthew_Bunn@hks.harvard.edu>, James Timbie <jptimbie@gmail.com>, Linton Brooks <linton.brooks@cox.net>, Jill Hruby <jillhruby@gmail.com>, Robert Latiff <rlatiff@nd.edu>, Richard Mies <miesrw@verizon.net>, "Richard L. Garwin" <rlg2@us.ibm.com>, Raymond Jeanloz <jeanloz@berkeley.edu>, Steve Fetter <sfetter@umd.edu>, Micah Lowenthal <mlowenth@nas.edu>, "Cervenka, Nicole" <NCervenka@nas.edu>, Rose Gottemoeller <gottemoeller@stanford.edu>

Colleagues, Matt suggested I draft something from the bio subgroup.

I don't know how much involvement CISAC leadership is seeking from the 'bio'… or "Infectious Disease" Working Group. Each of us is officially, or unofficially in my case, spending a lot of time on the pandemic. Because they are probably nearly overwhelmed with work, we may not get a lot of time from the other four or five members of the bio subpanel just now, but I'm happy to coordinate a short paper with a list of suggested topics for collaboration if Rita and Micah are interested. I've taken a first cut at some bullets below, but the list might change significantly if I run it by the real experts.
Russia, as of yesterday, has reported about 40% as many 'tests' as the US and about 2% as many cases. My sense would be to start with a few rather generic, yet relevant, topics that don't get into the fine details of their response to or reporting of COVID19 pandemic. Some potential examples:
- Observations from the current COVID19 pandemic relevant to planning and preparations for a future highly contiguous and virulent influenza pandemic
- The effect of climate change on vector-borne infectious disease
- Timely recognition and public health response to emerging diseases
- Antimicrobial resistance
- Laboratory safety, security, regulation and progress in infectious disease research
- Human and Animal Health relationships. Zoonotic disease and the "One Health" concept.
- The Biotech Revolution: Safety, security and progress
- Managing the Health Impacts of natural disasters

I welcome thoughts of comments from anyone…and, Rita, let me know if you want me to continue down this or another track.

Stay well all, dave

> Proposed Working Groups:
> New START and arms control

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009231

Cyber Security
Space Security
Infectious Disease
China and Strategic Stability

Proposed Schedule of Virtual Meetings ('plenary' and 'working group' meetings):
4/15: Beyond New START (non-strategic weapons, verification, monitoring, trade-offs, etc.) – Plenary Meeting
4/22: Infectious Disease – Working Group Meeting
4/29: Cyber – Plenary Meeting
5/6: Possible Working Group Meeting (this date falls over the Russian May Holidays, so this may not be feasible for most Russians)
5/13: Space – Plenary Meeting
5/20: Possible Working Group Meeting
5/27: Strategic Stability and Arms Control – Plenary Meeting
6/3: Possible Working Group Meeting
6/10: China and Strategic Stability – Plenary Meeting
(FYI: The IMEMO Primakov Readings, a major conference which includes arms control issues, is scheduled for June 15-17)

<Bunn Further Reactions to Sergei Rogov paper RG comments.docx>

David R. Franz
Gettysburg, PA
240-674-0797

David R. Franz
Gettysburg, PA
240-674-0797

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009232

Investigation into the possibility that the nCoV was the result of a release from the Wuhan Institute of Virology (main campus or new BSL3/BSL4 facilities).

The questions below deal with the period 1 October 2019 to the present:

Where is coronavirus research conducted?

What level of biocontainment?

How many different laboratories actually handle live virus?

Where are coronavirus stocks stored?

Is there an inventory record of each isolate of each coronavirus kept? If so, are there any discrepancies between the record and actual current inventory number (i.e., is there evidence to suggest that virus stocks may have been stolen or used without proper record?)

Physical Security

Is there controlled access to the laboratories and freezers where coronavirus stocks are held? (Locked doors; card-key access; biometric readers; others?) Were any breaches in security noted/access to the facility by unauthorized individuals?

Is the laboratory constantly monitored by security personnel (24/7)? If not, you could briefly summarize your physical security program during the period in question.

Is there any evidence to suggest a mechanical failure in biocontainment during the time in question?

-were biological safety cabinets used and appropriately certified?

-Exhaust air filtration systems working correctly?

-Autoclaves and waste stream disinfection systems working properly?

-Animal husbandry and management?

-Waste stream integrity (think of FMD leak in UK a few years ago)

Virus Stocks (You may wish to explain that many novel coronaviruses are known only from their sequence and are not able to replicate in culture)

When was the nCoV first handled in your laboratory?

What was the source of that virus? (patient specimen or field collected animal or other?)

During the period in question, what other coronaviruses (that replicate in culture) are stored/handled in your laboratories?

What are the coronaviruses in your possession that are most closely related to nCoV based on genetic sequences and are able to replicate in culture?

Is anyone on your team conducting gain of function studies, recombination studies or any other studies that may have resulted in the creation of the nCoV?

Personnel

How many people have access to the coronavirus stocks and laboratory?

Senior investigators? Junior investigators? Technical support staff? Post-docs? Students? Animal handlers? Janitors and other cleaning staff? Building support personnel? Others?

Is there any evidence to suggest that a disgruntled employee may have had access to the coronavirus stocks? (Recently fired or reprimanded individual(s), for example.)

Does the Institute have an occupational health clinic where employees and students can go to seek medical care? If so, was there any indication of unusual illness similar to that seen for nCoV among Institute staff? If yes, when were cases first seen relative to the nCoV outbreak.

Does a serum bank exist for staff and students working on infectious agents? If yes, could a current serum and the most recent banked sera be serologically tested for antibody to nCoV in an effort to document seroconversion? (If positive, this would not be able to differentiate between community acquired and occupational acquired infection, but absence of evidence of infection would be helpful in ruling out the lab as a source of infection.)

Have any of individuals working at the Wuhan Institute of Virology (main campus or BSL4 campus) been infected with the nCoV? Family members of employees?

If yes, when was the date of onset of illness for the first case recognized? (How does this date compare with the progress of the epidemic; that is, was this among the first cases recognized or later after the outbreak was well underway? How does this compare to the first recognition of nCoV in the greater Wuhan community?)

Where the individuals infected involved in coronavirus research?

Geography

(These questions deal with any association between the physical location of the lab(s) and the districts in Wuhan where the illness was first seen. The assumption is that someone suffering an occupational exposure would go to their local hospital for treatment.)

Where and when were the first Wuhan (or Hubei Province) residents infected with the nCoV first identified (hospital or clinic name/date of earliest cases)?

Do staff members of the Institute reside in the district serviced by this (these) hospital/clinic (s)?

Were any Institute staff members seen for clinical illness at this/these hospital (s) during the time in question?

Do staff members of the Wuhan Institute of Virology frequent the sea food/live market first associated with the nCoV outbreak?

Did any staff member visit the market in the weeks prior to it being closed?

If so, how many staff frequent the market? How often would they visit the market during the period of interest? Have any become infected with nCoV?


From: LeDuc, James W.
Sent: Tuesday, April 14, 2020 8:53 AM
To: Shi, Pei yong;Dave Franz (davidrfranz@gmail.com);Benjamin Rusek (BRusek@nas.edu)
Subject: FW: wsj

Just FYI

From: James T. AREDDY <james.areddy@wsj.com>
Sent: Tuesday, April 14, 2020 8:01 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: wsj

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim
Hi. We spoke several weeks ago when I did a story for The Wall Street Journal about BSL-4 labs. Since then the Washington Post has had two stories suggesting fears in USA that there could have been an accident in Wuhan. I'm curious to know what you think about these reports?
(FWIW. I, along with a number of American reporters, have been kicked out of China so I'm now working for WSJ in the U.S.)



Editorial-Opinion

State Department cables warned of safety issues at Wuhan **lab** studying bat coronaviruses

Josh Rogin

By Josh **Rogin**

1480 words
14 April 2020
Washington Post.com
WPCOM
English
Copyright 2020, The Washington Post Co. All Rights Reserved.

Two years before the novel coronavirus pandemic upended the world, U.S. Embassy officials visited a Chinese research facility in the city of Wuhan several times and sent two official warnings back to Washington about inadequate safety at the **lab**, which was conducting risky studies on coronaviruses from bats. The cables have fueled discussions inside the U.S. government about whether this or another Wuhan **lab** was the source of the virus — even though conclusive proof has yet to emerge.

FOIA Confidential Treatment Requested by Univ of Texas System

In January 2018, the U.S. Embassy in Beijing took the unusual step of repeatedly sending U.S. science diplomats to the Wuhan Institute of Virology (WIV), which had in 2015 become China's first laboratory to achieve the highest level of international bioresearch safety (known as BSL-4). WIV issued a news release in English about the last of these visits, which occurred on March 27, 2018. The U.S. delegation was led by Jamison Fouss, the consul general in Wuhan, and Rick Switzer, the embassy's counselor of environment, science, technology and health. Last week, WIV erased that statement from its website, though it remains archived on the Internet.

What the U.S. officials learned during their visits concerned them so much that they dispatched two diplomatic cables categorized as Sensitive But Unclassified back to Washington. The cables warned about safety and management weaknesses at the WIV lab and proposed more attention and help. The first cable, which I obtained, also warns that the lab's work on bat coronaviruses and their potential human transmission represented a risk of a new SARS-like pandemic.

"During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory," states the Jan. 19, 2018, cable, which was drafted by two officials from the embassy's environment, science and health sections who met with the WIV scientists. (The State Department declined to comment on this and other details of the story.) The Chinese researchers at WIV were receiving assistance from the Galveston National Laboratory at the University of Texas Medical Branch and other U.S. organizations, but the Chinese requested additional help. The cables argued that the United States should give the Wuhan lab further support, mainly because its research on bat coronaviruses was important but also dangerous.

As the cable noted, the U.S. visitors met with Shi Zhengli, the head of the research project, who had been publishing studies related to bat coronaviruses for many years. In November 2017, just before the U.S. officials' visit, Shi's team had published research showing that horseshoe bats they had collected from a cave in Yunnan province were very likely from the same bat population that spawned the SARS coronavirus in 2003.

"Most importantly," the cable states, "the researchers also showed that various SARS-like coronaviruses can interact with ACE2, the human receptor identified for SARS-coronavirus. This finding strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like diseases. From a public health perspective, this makes the continued surveillance of SARS-like coronaviruses in bats and study of the animal-human interface critical to future emerging coronavirus outbreak prediction and prevention."

The research was designed to prevent the next SARS-like pandemic by anticipating how it might emerge. But even in 2015, other scientists questioned whether Shi's team was taking unnecessary risks. In October 2014, the U.S. government had imposed a moratorium on funding of any research that makes a virus more deadly or contagious, known as "gain-of-function" experiments.

As many have pointed out, there is no evidence that the virus now plaguing the world was engineered; scientists largely agree it came from animals. But that is not the same as saying it didn't come from the lab, which spent years testing bat coronaviruses in animals, said Xiao

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000951

Qiang, a research scientist at the School of Information at the University of California at Berkeley.

"The cable tells us that there have long been concerns about the possibility of the threat to public health that came from this lab's research, if it was not being adequately conducted and protected," he said.

There are similar concerns about the nearby Wuhan Center for Disease Control and Prevention lab, which operates at biosecurity level 2, a level significantly less secure than the level-4 standard claimed by the Wuhan Insititute of Virology lab, Xiao said. That's important because the Chinese government still refuses to answer basic questions about the origin of the novel coronavirus while suppressing any attempts to examine whether either lab was involved.

Sources familiar with the cables said they were meant to sound an alarm about the grave safety concerns at the WIV lab, especially regarding its work with bat coronaviruses. The embassy officials were calling for more U.S. attention to this lab and more support for it, to help it fix its problems.

"The cable was a warning shot," one U.S. official said. "They were begging people to pay attention to what was going on."

No extra assistance to the labs was provided by the U.S. government in response to these cables. The cables began to circulate again inside the administration over the past two months as officials debated whether the lab could be the origin of the pandemic and what the implications would be for the U.S. pandemic response and relations with China.

Inside the Trump administration, many national security officials have long suspected either the WIV or the Wuhan Center for Disease Control and Prevention lab was the source of the novel coronavirus outbreak. According to the New York Times, the intelligence community has provided no evidence to confirm this. But one senior administration official told me that the cables provide one more piece of evidence to support the possibility that the pandemic is the result of a lab accident in Wuhan.

"The idea that is was just a totally natural occurrence is circumstantial. The evidence it leaked from the lab is circumstantial. Right now, the ledger on the side of it leaking from the lab is packed with bullet points and there's almost nothing on the other side," the official said.

As my colleague David Ignatius noted, the Chinese government's original story — that the virus emerged from a seafood market in Wuhan — is shaky. Research by Chinese experts published in the Lancet in January showed the first known patient, identified on Dec. 1, had no connection to the market, nor did more than one-third of the cases in the first large cluster. Also, the market didn't sell bats.

Shi and other WIV researchers have categorically denied this lab was the origin for the novel coronavirus. On Feb. 3, her team was the first to publicly report the virus known as 2019-nCoV was a bat-derived coronavirus.

The Chinese government, meanwhile, has put a total lockdown on information related to the virus origins. Beijing has yet to provide U.S. experts with samples of the novel coronavirus collected from the earliest cases. The Shanghai lab that published the novel coronavirus genome on Jan. 11 was quickly shut down by authorities for "rectification." Several of the doctors and journalists who reported on the spread early on have disappeared.

On Feb. 14, Chinese President Xi Jinping called for a new biosecurity law to be accelerated. On Wednesday, CNN reported the Chinese government has placed severe restrictions

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000952

requiring approval before any research institution publishes anything on the origin of the novel coronavirus.

The origin story is not just about blame. It's crucial to understanding how the novel coronavirus pandemic started because that informs how to prevent the next one. The Chinese government must be transparent and answer the questions about the Wuhan labs because they are vital to our scientific understanding of the virus, said Xiao.

We don't know whether the novel coronavirus originated in the Wuhan **lab**, but the cable pointed to the danger there and increases the impetus to find out, he said.

"I don't think it's a conspiracy theory. I think it's a legitimate question that needs to be investigated and answered," he said. "To understand exactly how this originated is critical knowledge for preventing this from happening in the future."

James T. Areddy

The Wall Street Journal
+86 1370 1700 594

james.areddy@wsj.com
james.areddy@shng-news.com (中文)
jamesareddy@yahoo.com
@jamestareddy
WeChat/Signal/Telegram/Facetime/WhatsApp

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_000953


From: LeDuc, James W.
Sent: Tuesday, April 14, 2020 8:53 AM
To: Shi, Pei yong;Dave Franz (davidrfranz@gmail.com);Benjamin Rusek (BRusek@nas.edu)
Subject: FW: wsj

Just FYI

From: James T. AREDDY <james.areddy@wsj.com>
Sent: Tuesday, April 14, 2020 8:01 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: wsj

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim
Hi. We spoke several weeks ago when I did a story for The Wall Street Journal about BSL-4 labs. Since then the Washington Post has had two stories suggesting fears in USA that there could have been an accident in Wuhan. I'm curious to know what you think about these reports?
(FWIW. I, along with a number of American reporters, have been kicked out of China so I'm now working for WSJ in the U.S.)



Editorial-Opinion

State Department cables warned of safety issues at Wuhan **lab** studying bat coronaviruses

Josh Rogin

By Josh **Rogin**

1480 words
14 April 2020
Washington Post.com
WPCOM
English
Copyright 2020, The Washington Post Co. All Rights Reserved.

Two years before the novel coronavirus pandemic upended the world, U.S. Embassy officials visited a Chinese research facility in the city of Wuhan several times and sent two official warnings back to Washington about inadequate safety at the **lab**, which was conducting risky studies on coronaviruses from bats. The cables have fueled discussions inside the U.S. government about whether this or another Wuhan **lab** was the source of the virus — even though conclusive proof has yet to emerge.

FOIA Confidential Treatment Requested by Univ of Texas System

In January 2018, the U.S. Embassy in Beijing took the unusual step of repeatedly sending U.S. science diplomats to the Wuhan Institute of Virology (WIV), which had in 2015 become China's first laboratory to achieve the highest level of international bioresearch safety (known as BSL-4). WIV issued a news release in English about the last of these visits, which occurred on March 27, 2018. The U.S. delegation was led by Jamison Fouss, the consul general in Wuhan, and Rick Switzer, the embassy's counselor of environment, science, technology and health. Last week, WIV erased that statement from its website, though it remains archived on the Internet.

What the U.S. officials learned during their visits concerned them so much that they dispatched two diplomatic cables categorized as Sensitive But Unclassified back to Washington. The cables warned about safety and management weaknesses at the WIV lab and proposed more attention and help. The first cable, which I obtained, also warns that the lab's work on bat coronaviruses and their potential human transmission represented a risk of a new SARS-like pandemic.

"During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory," states the Jan. 19, 2018, cable, which was drafted by two officials from the embassy's environment, science and health sections who met with the WIV scientists. (The State Department declined to comment on this and other details of the story.) The Chinese researchers at WIV were receiving assistance from the Galveston National Laboratory at the University of Texas Medical Branch and other U.S. organizations, but the Chinese requested additional help. The cables argued that the United States should give the Wuhan lab further support, mainly because its research on bat coronaviruses was important but also dangerous.

As the cable noted, the U.S. visitors met with Shi Zhengli, the head of the research project, who had been publishing studies related to bat coronaviruses for many years. In November 2017, just before the U.S. officials' visit, Shi's team had published research showing that horseshoe bats they had collected from a cave in Yunnan province were very likely from the same bat population that spawned the SARS coronavirus in 2003.

"Most importantly," the cable states, "the researchers also showed that various SARS-like coronaviruses can interact with ACE2, the human receptor identified for SARS-coronavirus. This finding strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like diseases. From a public health perspective, this makes the continued surveillance of SARS-like coronaviruses in bats and study of the animal-human interface critical to future emerging coronavirus outbreak prediction and prevention."

The research was designed to prevent the next SARS-like pandemic by anticipating how it might emerge. But even in 2015, other scientists questioned whether Shi's team was taking unnecessary risks. In October 2014, the U.S. government had imposed a moratorium on funding of any research that makes a virus more deadly or contagious, known as "gain-of-function" experiments.

As many have pointed out, there is no evidence that the virus now plaguing the world was engineered; scientists largely agree it came from animals. But that is not the same as saying it didn't come from the lab, which spent years testing bat coronaviruses in animals, said Xiao

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012238

Qiang, a research scientist at the School of Information at the University of California at Berkeley.

"The cable tells us that there have long been concerns about the possibility of the threat to public health that came from this lab's research, if it was not being adequately conducted and protected," he said.

There are similar concerns about the nearby Wuhan Center for Disease Control and Prevention lab, which operates at biosecurity level 2, a level significantly less secure than the level-4 standard claimed by the Wuhan Insititute of Virology lab, Xiao said. That's important because the Chinese government still refuses to answer basic questions about the origin of the novel coronavirus while suppressing any attempts to examine whether either lab was involved.

Sources familiar with the cables said they were meant to sound an alarm about the grave safety concerns at the WIV lab, especially regarding its work with bat coronaviruses. The embassy officials were calling for more U.S. attention to this lab and more support for it, to help it fix its problems.

"The cable was a warning shot," one U.S. official said. "They were begging people to pay attention to what was going on."

No extra assistance to the labs was provided by the U.S. government in response to these cables. The cables began to circulate again inside the administration over the past two months as officials debated whether the lab could be the origin of the pandemic and what the implications would be for the U.S. pandemic response and relations with China.

Inside the Trump administration, many national security officials have long suspected either the WIV or the Wuhan Center for Disease Control and Prevention lab was the source of the novel coronavirus outbreak. According to the New York Times, the intelligence community has provided no evidence to confirm this. But one senior administration official told me that the cables provide one more piece of evidence to support the possibility that the pandemic is the result of a lab accident in Wuhan.

"The idea that is was just a totally natural occurrence is circumstantial. The evidence it leaked from the lab is circumstantial. Right now, the ledger on the side of it leaking from the lab is packed with bullet points and there's almost nothing on the other side," the official said.

As my colleague David Ignatius noted, the Chinese government's original story — that the virus emerged from a seafood market in Wuhan — is shaky. Research by Chinese experts published in the Lancet in January showed the first known patient, identified on Dec. 1, had no connection to the market, nor did more than one-third of the cases in the first large cluster. Also, the market didn't sell bats.

Shi and other WIV researchers have categorically denied this lab was the origin for the novel coronavirus. On Feb. 3, her team was the first to publicly report the virus known as 2019-nCoV was a bat-derived coronavirus.

The Chinese government, meanwhile, has put a total lockdown on information related to the virus origins. Beijing has yet to provide U.S. experts with samples of the novel coronavirus collected from the earliest cases. The Shanghai lab that published the novel coronavirus genome on Jan. 11 was quickly shut down by authorities for "rectification." Several of the doctors and journalists who reported on the spread early on have disappeared.

On Feb. 14, Chinese President Xi Jinping called for a new biosecurity law to be accelerated. On Wednesday, CNN reported the Chinese government has placed severe restrictions

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012239

requiring approval before any research institution publishes anything on the origin of the novel coronavirus.

The origin story is not just about blame. It's crucial to understanding how the novel coronavirus pandemic started because that informs how to prevent the next one. The Chinese government must be transparent and answer the questions about the Wuhan labs because they are vital to our scientific understanding of the virus, said Xiao.

We don't know whether the novel coronavirus originated in the Wuhan lab, but the cable pointed to the danger there and increases the impetus to find out, he said.

"I don't think it's a conspiracy theory. I think it's a legitimate question that needs to be investigated and answered," he said. "To understand exactly how this originated is critical knowledge for preventing this from happening in the future."

James T. Areddy

The Wall Street Journal
+86 1370 1700 594

james.areddy@wsj.com
james.areddy@shng-news.com (中文)
jamesareddy@yahoo.com
@jamestareddy
WeChat/Signal/Telegram/Facetime/WhatsApp

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012240

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Wednesday, April 15, 2020 8:57 AM
To: LeDuc, James W.;Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com)
Subject: RE: Shi

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I'm tied up until probably 2pm EDT. Let me give this a little more thought and suggest an approach.
Micah

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 15, 2020 9:28 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Subject: RE: Shi

Given all the attention to Dr Shi and the Wuhan lab, I think it would benefit our efforts to have some publically available links that shows our sustained engagement. Can we at least post the agenda and titles of the dialogue? Or are the reports to our sponsors available publically? We created a unique science-based exchange that is very relevant today; we just need to find a way to share what we have accomplished. Added Dave for his perspective/comments.

Let me know if you want to discuss. I'm free from about 10:30 am CT--or at least less busy!

Thanks, Jim

-----Original Message-----
From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 14, 2020 10:07 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Shi

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim,

They are not posted on the web, we can't post them on the NAS website because they are reports from the dialogue and do not undergo review. The Wuhan meeting reports were on the WIV website for a while and I had links to those but the links were removed sometime in the last year or so.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001657

Micah do you have thoughts? I wrote the memo about Dr. Shi's statements at the dialogue meetings to show that she has been warning about a coronavirus pandemic for years but the statements and the document would most certainly be taken out of context if posted on the web.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

-----Original Message-----
From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, April 14, 2020 9:39 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Subject: Shi

Ben, are the abstracts or agendas from our NAS-CAS dialogue available on the academy website? Given today's story it would be good to have them accessible to show that Dr Shi had been warning about the possibility of a novel coronavirus for some time. Please send me the link if available.

Thanks. Jim

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001658

From: LeDuc, James W.
Sent: Wednesday, April 15, 2020 1:26 PM
To: Ksiazek, Thomas G.;Murphy, Frederick A.
Cc: 'Tesh, Robert (rbtesh22@gmail.com)';Dave Franz (davidrfranz@gmail.com)
Subject: RE: Wuhan

Hi Fred,

I agree with Tom's assessments (of course!) and would add that through the US National Academy of Science working in partnership with the Chinese Academy of Sciences, we have maintained a dialogue on emerging infectious diseases, biosafety and biosecurity. Dave Franz and I are very active in the group, as has been Diane Griffin. We have held joint meetings about annually since 2015 in both China (Wuhan, Harbin, Beijing) and in the US, including here at the GNL. During these discussions we have always had a session on coronaviruses and Zheng-Li Shi has participated in each meeting during which she has shared her most recent findings. The US side has been represented by Ralph Baric and Linda Saif, both solid, serious scientists. Even during the first meeting in 2015, Dr Shi was discussing bat-associated coronaviruses that likely held the ability to infect humans. I have no information on the lab conditions under which she conducted her experiments, although it was not at BSL4 since that lab only opened officially in 2017 or so.

Second, you may recall the training center that we established at UTMB with earmark funding from Kay Bailey Hutchinson that ran until 2016. Using funds from that program and later my funding, we offered training in both biosafety and biocontainment lab operations to participants from around the world, including from the new lab in Wuhan. In addition, we supported two Chinese post-docs who went through the complete training program and gained independent access to work in our BSL4. Both have returned to Wuhan and have been involved in standing up the new lab and designing their biosafety training program. We continue to maintain contact with these scientist and are implementing joint research projects.

The first I learned about the State Department reports of safety concerns from the Wuhan lab was in the Washington Post article. While we usually had some level of dialogue with folks in the embassy as we arranged our joint meetings, I do not recall the individuals mentioned in the article and I don't recall anyone from the embassy expressing concern about the safety of the lab in Wuhan. The comments that they discovered bat coronaviruses likely capable of infecting humans has been known for quite some time.

Stay safe!

Jim

From: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Sent: Wednesday, April 15, 2020 12:33 PM
To: Murphy, Frederick A. <famurphy@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: 'Tesh, Robert (rbtesh22@gmail.com)' <rbtesh22@gmail.com>
Subject: RE: Wuhan

Fred,

As you know there have been no end to the stories on the origin of the virus. The paper by Andersen et al pretty much puts an end to the stories that the virus was cooked up in the lab. Other scenarios are that they had the virus and that it

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002568

escaped from the lab, another I have not seen mentioned is that someone got infected in the field and they were patient 0. I don't know, but don't think they were working with live bats, don't think they would have been doing this in the BSL4. From Pei-Yong's discussions with the "bat lady", Dr. Shi, I don't believe that they had this virus in the lab before this started. One thing that a lot of people don't appreciate is that most of the viruses identified in bats have not been able to be grown…there are a few exceptions; but most that you see in publications are done by PCR and NGS sequencing.

The Chinese central government has clamped down on investigations and work on the origin of the virus, some might interpret that as part of a cover up. However, after SARS and the small lab escape they had, they pretty much shut down SARS work in China, maybe that was part of a cover up, but most folks don't believe it was.

I'm a lot more worried about the US status as a leader in world public health and science than Chinamen hiding behind every tree. Not that there isn't some level of industrial espionage occurring, but we're killing ourselves in terms of how we're seen by others.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC and Garry RF. 2020. **The proximal origin of SARS-CoV-2**. Nat Med 26(4): 450-452.

https://www.ncbi.nlm.nih.gov/pubmed/32284615
https://www.nature.com/articles/s41591-020-0820-9.pdf

From: Murphy, Frederick A.
Sent: 15 April, 2020 11:03
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: 'Tesh, Robert (rbtesh22@gmail.com)' <rbtesh22@gmail.com>
Subject: Wuhan

Tom, Jim,

I know you are very busy, but I could use your advice re the WP article that the CoV came from the Wuhan lab. Although I am in lockdown, of course, emails from good friends here are asking about the WP article and the conspiracy theory website that has carried the same/similar article.

These friends are Jon and Emily Reynolds – Jon F-105 pilot shot down over Hanoi, 7 years in the Hilton with John McCain, later PhD (Duke), rose to O7, he and his wife spent years in US Embassy in Beijing, Air Attaché, having spent two years in Taipei learning Chinese (! Emily still takes advanced Chinese lessons) – Jon also served in Secretary of the Air Force as #2. Reasonable folk, Republicans, but we don't talk politics. They really know and care about China, but I think they are easily led toward some of the conspiracy theory stuff. Led by Emily, they are really into this story and ready to believe the stuff about the source of the virus. I need some advice / fodder to deal with this, as the stuff spreads around here – several retired ambassadors live here (stuffy, arrogant types). Does GNL / UTMB have public statements on all this? Counterpoints?

https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002569

Here is my annotation on the WP Opinion Piece:

<< File: State Dept problems China containment labs WP 14Apr highlight annotate.docx >>

\Fred

Frederick A. Murphy
8300 Burdette Road Unit B661
Bethesda, MD 20817
(Cell) 409 739 3332
(Tel) 301 968 4798
(Email) famurphy@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Wednesday, April 15, 2020 1:26 PM
To: Ksiazek, Thomas G.;Murphy, Frederick A.
Cc: 'Tesh, Robert (rbtesh22@gmail.com)';Dave Franz (davidrfranz@gmail.com)
Subject: RE: Wuhan

Fred,

I agree with Tom's assessments (of course!) and would add that through the US National Academy of Sciences (NAS) working in partnership with the Chinese Academy of Sciences, we have maintained a dialogue on emerging infectious diseases, biosafety and biosecurity. Dave Franz and I are very active in the group, as has been Diane Griffin [Johns Hopkins School of Medicine, and vice president, National Academy of Medicine, NAS]. We have held joint meetings about annually since 2015 in both China (Wuhan, Harbin, Beijing) and in the US, including here at the Galveston National Laboratory (GNL). During these discussions we have always had a session on coronaviruses and Zheng-Li Shi has participated in each meeting during which she has shared her most recent findings. The US side has been represented by Ralph Baric and Linda Saif, both worl-class coronavirus authorities. Even in the first meeting in 2015, Dr Shi discussed bat-associated coronaviruses that likely had the potential ability to infect humans. I have no information on the lab conditions under which she conducted her experiments at that time, although it was not at BSL4 since the BSL4 lab only opened officially in 2017 or so..

Second, you may recall the training center that we established at UTMB with earmark funding from Senator Kay Bailey Hutchinson that ran until 2016. Using funds from that program and later my funding, we offered training in both biosafety and biocontainment lab operations to participants from around the world, including from the new lab in Wuhan. In addition, we supported two Chinese post-docs who went through the complete training program and gained independent access to work in our BSL4. Both have returned to Wuhan and have been involved in standing up the new lab and designing their biosafety training program. We continue to maintain contact with these scientist and are implementing joint research projects.

The first I learned about the State Department reports of safety concerns from the Wuhan lab was in the Washington Post article. While we usually had some level of dialogue with folks in the embassy as we arranged our joint meetings, I do not recall the individuals mentioned in the article and I don't recall anyone from the embassy expressing concern about the safety of the lab in Wuhan. The comments that the Chinese discovered bat coronaviruses likely capable of infecting humans has been known for quite some time.

Stay safe!

Jim

James Le Duc, PhD
Director, Galveston National Laboratory
Professor, Department of Microbiology and Immunology
John Sealy Distinguished Chair in Tropical and Emerging Virology
University of Texas Medical Branch
Galveston, TX 77554

From: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012962

Sent: Wednesday, April 15, 2020 12:33 PM
To: Murphy, Frederick A. <famurphy@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: 'Tesh, Robert (rbtesh22@gmail.com)' <rbtesh22@gmail.com>
Subject: RE: Wuhan

Fred,

As you know there have been no end to the stories on the origin of the virus. The paper by Andersen et al pretty much puts an end to the stories that the virus was cooked up in the lab. Other scenarios are that they had the virus and that it escaped from the lab, another I have not seen mentioned is that someone got infected in the field and they were patient 0. I don't know, but don't think they were working with live bats, don't think they would have been doing this in the BSL4. From Pei-Yong's discussions with the "bat lady", Dr. Shi, I don't believe that they had this virus in the lab before this started. One thing that a lot of people don't appreciate is that most of the viruses identified in bats have not been able to be grown…there are a few exceptions; but most that you see in publications are done by PCR and NGS sequencing.

The Chinese central government has clamped down on investigations and work on the origin of the virus, some might interpret that as part of a cover up. However, after SARS and the small lab escape they had, they pretty much shut down SARS work in China, maybe that was part of a cover up, but most folks don't believe it was.

I'm a lot more worried about the US status as a leader in world public health and science than Chinamen hiding behind every tree. Not that there isn't some level of industrial espionage occurring, but we're killing ourselves in terms of how we're seen by others.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC and Garry RF. 2020. **The proximal origin of SARS-CoV-2**. Nat Med 26(4): 450-452.

https://www.ncbi.nlm.nih.gov/pubmed/32284615
https://www.nature.com/articles/s41591-020-0820-9.pdf

From: Murphy, Frederick A.
Sent: 15 April, 2020 11:03
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>
Cc: 'Tesh, Robert (rbtesh22@gmail.com)' <rbtesh22@gmail.com>
Subject: Wuhan

Tom, Jim,

I know you are very busy, but I could use your advice re the WP article that the CoV came from the Wuhan lab. Although I am in lockdown, of course, emails from good friends here are asking about the WP article and the conspiracy theory website that has carried the same/similar article.

These friends are Jon and Emily Reynolds – Jon F-105 pilot shot down over Hanoi, 7 years in the Hilton with John McCain, later PhD (Duke), rose to O7, he and his wife spent years in US Embassy in Beijing, Air Attaché, having spent two years in Taipei learning Chinese (! Emily still takes advanced Chinese lessons) – Jon also served in Secretary of the Air Force as #2.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012963

Reasonable folk, Republicans, but we don't talk politics. They really know and care about China, but I think they are easily led toward some of the conspiracy theory stuff. Led by Emily, they are really into this story and ready to believe the stuff about the source of the virus. I need some advice / fodder to deal with this, as the stuff spreads around here -- several retired ambassadors live here (stuffy, arrogant types). Does GNL / UTMB have public statements on all this? Counterpoints?

https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/

Here is my annotation on the WP Opinion Piece:
<< File: State Dept problems China containment labs WP 14Apr highlight annotate.docx >>
\Fred

Frederick A. Murphy
8300 Burdette Road Unit B661
Bethesda, MD 20817
(Cell) 409 739 3332
(Tel) 301 968 4798
(Email) famurphy@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 16, 2020 10:39 PM
To: Dave Franz (davidrfranz@gmail.com);LeDuc, James W.;Shi, Pei yong
Cc: Sharples, Fran;Lowenthal, Micah
Subject: Draft letter proposing virtual China bio dialogue
Attachments: Draft Letter to CCDC CAS re virtural dialgoue Griffin and Hamburg April 16 2020 v2.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Dave, Jim and Pei-yong,

We have drafted the attached letter proposing the virtual China bio dialogue. Fran and Katie helped come up with the questions under the five topics. Please review those carefully.

After your review we will send it to Peggy and Diane for review and comments. Staff will also need to coordinate with the NASEM Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats (maybe via Julie Pavlin). And coordinate or at least inform whomever has arranged for George Gao to speak at the NASEM annual meeting on the 25th.

Thanks in advance for you attention. If this goes out I hope that the reply to the proposal is positive but I think there is merit to proposing even if the response is negative.

PS I see a lot of support for cooperation in this op/ed by the Chinese Ambassador to U.S., we could cite it in the letter or as part of the email that goes with the letter: https://www.nytimes.com/2020/04/05/opinion/coronavirus-china-us.html. Also were you aware of this website: https://covid19.21wecan.com/

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009260

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Virtual Dialogue Meeting April 16, 2020

Dr. Gao Fu
Director-General,
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen after unprecedented efforts to control its cases, China now knows more about dealing with COVID-19 than any other country and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research, combating emerging infections, collaboration and data sharing, and laboratory management. The dialogue meetings have been well attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings, best practices, and lessons learned, and to establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we now face.

Chinese scientist now have unique knowledge about responding to and mitigating COVID-19, so they are in a position to help American scientists better understand and combat the outbreak in the United States. We hope that a meeting between our scientists can address (1) The biology of COVID-19 (2) Managing COVID-19 in patients (3) Limiting the spread of COVID-19 (4) Drug and vaccine development (5) Preventing and managing future epidemics and pandemics. A list detailing questions related to these five topics is appended to the end of this letter.

NASEM is willing to facilitate and host a virtual discussion using Zoom video conference software or another mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory leaders who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal and if the participants feel it would be useful, a follow on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world combat and recover from this terrible pandemic.

Sincerely,

FOIA Confidential Treatment Requested by Univ of Texas System

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment?
   - Have there been accurate measurements of incubation period? What factors are responsible for the variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point the virus is most infectious?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, etc.?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community made progress in understanding the routes of exposure to SARS-CoV-2 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in wild or livestock animal species or interventions to reduce contact between humans and wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?

FOIA Confidential Treatment Requested by Univ of Texas System

- Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?

5. **Preventing and managing future epidemics and pandemics**
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?

From: LeDuc, James W.
Sent: Friday, April 17, 2020 8:48 AM
To: Rusek, Benjamin;Dave Franz (davidrfranz@gmail.com);Shi, Pei yong
Cc: Sharples, Fran;Lowenthal, Micah
Subject: RE: Draft letter proposing virtual China bio dialogue
Attachments: Draft Letter to CCDC CAS re virtural dialgoue Griffin and Hamburg April 16 2020 v2-jwl.docx

Nicely done. Please see attached with some comments and suggestions. I think it's important to highlight our discussions on biosafety and biosecurity training and facilities operations as very practical contributions from the dialogue. I note that there is no discussion on the origin of the virus, which is probably wise at this stage.

Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 16, 2020 10:39 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; LeDuc, James W. <jwleduc@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Sharples, Fran <FSharples@nas.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Draft letter proposing virtual China bio dialogue
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Dave, Jim and Pei-yong,

We have drafted the attached letter proposing the virtual China bio dialogue. Fran and Katie helped come up with the questions under the five topics. Please review those carefully.

After your review we will send it to Peggy and Diane for review and comments. Staff will also need to coordinate with the NASEM Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats (maybe via Julie Pavlin). And coordinate or at least inform whomever has arranged for George Gao to speak at the NASEM annual meeting on the 25th.

Thanks in advance for you attention. If this goes out I hope that the reply to the proposal is positive but I think there is merit to proposing even if the response is negative.

PS I see a lot of support for cooperation in this op/ed by the Chinese Ambassador to U.S., we could cite it in the letter or as part of the email that goes with the letter: https://www.nytimes.com/2020/04/05/opinion/coronavirus-china-us.html. Also were you aware of this website: https://covid19.21wecan.com/

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009251

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009252

The National Academies of
SCIENCES · ENGINEERING · MEDICINE

RE: Virtual Dialogue Meeting April 16, 2020

Dr. Gao Fu
Director-General,
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President, Academician
Chinese Academy of Sciences

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen after unprecedented efforts to control its cases, China now knows more about dealing with COVID-19 than any other country and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research, combating emerging infections, collaboration and data sharing, and laboratory management. The dialogue meetings have been well attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings, share best practices in biosafety, biosecurity, and biocontainment laboratory operations, reflect on lessons learned, and to establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we now face.

Formatted: Highlight
Deleted: and

Chinese scientist now have unique knowledge about responding to and mitigating COVID-19, so they are in a position to help American scientists better understand and combat the outbreak in the United States. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list detailing questions related to these five topics is appended to the end of this letter.

NASEM is willing to facilitate and host a virtual discussion using Zoom video conference software or another mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal and if the participants feel it would be useful, a follow on meeting could be held later in the month.

Deleted: leaders

Deleted: ,

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world combat and recover from this terrible pandemic.

Sincerely,

FOIA Confidential Treatment Requested by Univ of Texas System

Diane E. Griffin
Vice President, NAS

Margaret Hamburg
Foreign secretary, NAM

...

Additional points of contact:

James Le Duc Ph.D.
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment? Transmissibility, Clinical course of disease
   - Have there been accurate measurements of incubation period? What factors are responsible for the variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point the virus is most infectious? The degree of virus shedding among pre-symptomatic, asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community made progress in understanding the routes of exposure to SARS-CoV-2 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**

Formatted: Highlight

Formatted: Highlight

Deleted: etc.

Commented [LJW1]: Cats have been shown to become infected and able to transmit the virus in work done in Harbin lab and also by Dr Shi I think.

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

FOIA Confidential Treatment Requested by Univ of Texas System

- Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
- Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
- What is China's experience in using immune plasma or other antibody-based therapies to the treatment of COVID patients or prevention of onward spread of disease.

5. **Preventing and managing future epidemics and pandemics**
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries?

Also consider lessons learned in returning society and the economy to "normal". Recommended steps to be taken in anticipation of a full peak of transmission. Measurement of immune response, binding assays versus neutralization tests, use of antibody assays in diagnosis of acute disease and as an indicator of protection.

Formatted: Highlight
Formatted: Font:
Formatted: Highlight
Formatted: Font:
Formatted: No bullets or numbering
Formatted: Highlight

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong
Sent: Friday, April 17, 2020 1:43 PM
To: LeDuc, James W.;Sharples, Fran;Rusek, Benjamin;'Dave Franz'
Cc: Lowenthal, Micah
Subject: RE: Draft letter proposing virtual China bio dialogue

Thanks, Jim
When I spoke to Zhengli Shi this morning, she suggested someone at higher level will be more effective. She did mention Tony Fauci.

- Pei-Yong

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Friday, April 17, 2020 1:40 PM
To: Sharples, Fran <FSharples@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Draft letter proposing virtual China bio dialogue

Pei-Yong, thoughts?

From: Sharples, Fran <FSharples@nas.edu>
Sent: Friday, April 17, 2020 1:37 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; Rusek, Benjamin <BRusek@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Draft letter proposing virtual China bio dialogue

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I would think Diane and Peggy fit that description.

Fran Sharples, PhD
Board on Life Sciences
National Academy of Sciences

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Friday, April 17, 2020 2:28 PM
To: Shi, Pei yong; Rusek, Benjamin; 'Dave Franz'
Cc: Sharples, Fran; Lowenthal, Micah
Subject: RE: Draft letter proposing virtual China bio dialogue

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009233

We may wish to have the most senior person possible from the NASEM to sign the letter given the sensitivity of the situation.

Jim

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, April 17, 2020 12:17 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Sharples, Fran <FSharples@nas.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Draft letter proposing virtual China bio dialogue

Hi Ben and all,
The letter looks good!
Zhengli Shi called me this morning. As a scientist, she looks forward to this type of communication/conference.
Cheers, Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 17, 2020 12:13 PM
To: 'Dave Franz' <davidrfranz@gmail.com>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>; Sharples, Fran <FSharples@nas.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Draft letter proposing virtual China bio dialogue
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thank you Dave and Jim, I have attached a revised draft. Jim I tried to work your points at the end into the bulleted list. **Bullet 1 under point 2 and bullet 4 under point 3 could use some attention.**

Pei-yong do you have thoughts before this goes to Peggy and Diane for review?

Also I asked Fran to take a look at the Chinese portal https://covid19.21wecan.com/ in case some of the questions we are asking have already been answered.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Dave Franz <davidrfranz@gmail.com>
Sent: Friday, April 17, 2020 10:33 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: James W. LeDuc <jwleduc@UTMB.EDU>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>; Sharples, Fran <FSharples@nas.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Draft letter proposing virtual China bio dialogue
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009234

I think it looks good Ben and Fran. Just a couple of comments for consideration:

Non-technical: Be consistent in the acronyms for the academies (CAMS left out)
Last line of penultimate paragraph of letter body ("follow-on")

Technical: Part 1. Third bullet—Could say, "Has it been determined at what point in the course of infections the patient is most infectious."

Part 3. Third bullet—We refer to diagnostics here. Might say, "….testing for viral infection and antibody response adequate?" Might want to mention in a bullet, maybe right after that one talking about testing, "Have your scientists arrived at an explanation regarding the pathogenesis (?) leading to apparent recrudescence of disease in previously positive, then negative patients?" (Someone can wordsmith that better.)

Use what's useful, dave

On Apr 16, 2020, at 11:38 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

<Draft Letter to CCDC CAS re virtural dialgoue Griffin and Hamburg April 16 2020 v2.docx>

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009235

From: Yuan Zhiming <yzm@wh.iov.cn>
Sent: Saturday, April 18, 2020 9:56 PM
To: LeDuc, James W.;zlshi
Cc: Shi, Pei yong
Subject: 回复: RE: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Jim ,

Thanks for your informaiton. I really appreciate your help and your action, we need to let some people understand well the the mission of high-level biosafey lab. what we do, and how we do inside. We all know that the labs were built not for causing epidmic, but for proventing the epidemic, and the labs are managed according to interantional guildline and national accquirement, Wuhan's lab is among the others.

I will contact Zhengli to see what she can do for your report.

Regards

Zhiming

==========
Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480
==========

From: LeDuc, James W.
Date: 2020-04-19 00:44
To: 石正丽
CC: Shi, Pei yong; Yuan Zhiming
Subject: RE: Fwd: Rubio
Dear Zhengli,

Thank you for your response. I understand completely and I certainly do not wish to compromise you personally or your research activities. Given our long history of collaborations between the GNL and the

FOIA Confidential Treatment Requested by Univ of Texas System

WIV, I have been approached repeatedly for details on our work. Attached is a draft summary that I will be providing to the leadership of our University of Texas system and likely to Congressional committees that are being formed now. Please review carefully and make any changes that you would like. I want this to be as accurate as possible and I certainly do not want to misrepresent any of your valuable contributions. I need to submit this on Monday, 20 April, so your prompt reply would be very much appreciated. I have copied Zhiming for his comments as well.

With best wishes,

Jim

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 9:20 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your email and consideration our communication.

Due to the complicated situation, I don't think it's a right time to communicate by the call.

What I can tell you is that this virus is not a leaky from our lab or any other labs.It's a shame to make this scientific question so complicated.

I hope to talk with you whenever the COVID-19 is over and world is calme and believe in the science.

Best regards,
Zhengli,

-----原始邮件-----
发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>
发送时间:2020-04-17 11:06:38 (星期五)
收件人: "zengli Shi" <zlshi@wh.iov.cn>
抄送:
主题: Fwd: Rubio

Hi Zheng-Li. I hope you are well as surviving all the COVID19 drama. I wonder if you would have time

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008556

for a phone call sometime soon. Let me know a good number and time and I'll call. The email below is relevant.

I will certainly understand if you are not available but Pei-Yong keeps encouraging me to call.

With all good wishes.

Jim.

My office line is [redacted] or cell is [redacted] if it's easier for you to call me.

Sent from my iPhone

Begin forwarded message:

From: David Franz <davidrfranz@gmail.com>
Date: April 16, 2020 at 8:04:55 PM CDT
To: "LeDuc, James W." <jwleduc@UTMB.EDU>
Subject: Rubio
WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I heard from someone in government this evening that Senator Rubio is starting to push for AN investigation regarding Wuhan lab. Just found it on the web at Forbes by Kenneth Repoza. Title of article is "eight senators call for investigation into coronavirus origins"

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System

From: 石正丽 [zlshi@wh.iov.cn]
Sent: 4/18/2020 11:30:09 PM
To: Yuan Zhiming [yzm@wh.iov.cn]
CC: LeDuc, James W. [jwleduc@UTMB.EDU]; Shi, Pei yong [peshi@UTMB.EDU]
Subject: Re: 回复: RE: Fwd: Rubio
Attachments: 2016 Menachery-PNAS-SARS-like WIV1-CoV poised for human emergence.pdf; 2013 Ge XY Nature-Isolation and characterization of a bat SARS-like coronavirus.pdf; 2016-Yang XL-JVI-WIV16.pdf; 2017-Hu Ben- ppat-Discovery of A Rich Gene Pool of Bat SARS-related Coronaviruses.pdf

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,
Thank you for your clarifying.
I've added some detailed information for your reference. I'm also sending you some papers published for your reference.

Best regards,
Zhengli,

-----原始邮件-----
发件人:"Yuan Zhiming" <yzm@wh.iov.cn>
发送时间:2020-04-19 10:55:33 (星期日)
收件人: "James LeDuc" <jwleduc@UTMB.EDU>, zlshi <zlshi@wh.iov.cn>
抄送: "Shi Peiyong" <peshi@UTMB.EDU>
主题: 回复: RE: Fwd: Rubio

Dear Jim,

Thanks for your informaiton. I really appreciate your help and your action, we need to let some people understand well the the mission of high-level biosafey lab. what we do, and how we do inside. We all know that the labs were built not for causing epidmic, but for proventing the epidemic, and the labs are managed according to interantional guildline and national accquirement, Wuhan's lab is among the others.

I will contact Zhengli to see what she can do for your report.

Regards

Zhiming

Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480

==========

From: LeDuc, James W.
Date: 2020-04-19 00:44
To: 石正丽
CC: Shi, Pei yong; Yuan Zhiming
Subject: RE: Fwd: Rubio
Dear Zhengli,

Thank you for your response. I understand completely and I certainly do not wish to compromise you personally or your research activities. Given our long history of collaborations between the GNL and the WIV, I have been approached repeatedly for details on our work. Attached is a draft summary that I will be providing to the leadership of our University of Texas system and likely to Congressional committees that are being formed now. Please review carefully and make any changes that you would like. I want this to be as accurate as possible and I certainly do not want to misrepresent any of your valuable contributions. I need to submit this on Monday, 20 April, so your prompt reply would be very much appreciated. I have copied Zhiming for his comments as well.

With best wishes,

Jim

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 9:20 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your email and consideration our communication.

Due to the complicated situation, I don't think it's a right time to communicate by the call.

What I can tell you is that this virus is not a leaky from our lab or any other labs.It's a shame to make this scientific question so complicated.

I hope to talk with you whenever the COVID-19 is over and world is calme and believe in the science.

Best regards,
Zhengli,

-----原始邮件-----
发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>
发送时间:2020-04-17 11:06:38 (星期五)
收件人: "zengli Shi" <zlshi@wh.iov.cn>
抄送:

主题: Fwd: Rubio

Hi Zheng-Li. I hope you are well as surviving all the COVID19 drama. I wonder if you would have time for a phone call sometime soon. Let me know a good number and time and I'll call. The email below is relevant.

I will certainly understand if you are not available but Pei-Yong keeps encouraging me to call.

With all good wishes.

Jim.

My office line is [redacted] or cell is [redacted] if it's easier for you to call me.

Sent from my iPhone

Begin forwarded message:

From: David Franz <davidrfranz@gmail.com>
Date: April 16, 2020 at 8:04:55 PM CDT
To: "LeDuc, James W." <jwleduc@UTMB.EDU>
Subject: Rubio
WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I heard from someone in government this evening that Senator Rubio is starting to push for AN investigation regarding Wuhan lab. Just found it on the web at Forbes by Kenneth Repoza. Title of article is "eight senators call for investigation into coronavirus origins"

Sent from my iPhone

From: calisher@cybersafe.net
Sent: Sunday, April 19, 2020 11:39 AM
To: Ksiazek, Thomas G.;Holubar, Connie J.;'Erdman Dean';Murphy, Frederick A.;LeDuc, James W.;'Denison Mark';Shi, Pei yong;'Rollin Pierre';'Tesh Robert';Tseng, Chien-Te K.;Menachery, Vineet;'Folks Thomas';'Nichol Stuart';'Spiropoulou Christina (CDC/CCID/NCZVED)';'Franz David'
Subject: RE: Director of maximum-security Wuhan lab denies being source of coronavirus

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The photo looks fake.

I do not see how anyone could definitively state that the virus could not possibly have come from that lab. An incidental/accidental error infecting a lab worker who subsequently and asymptomatically shed virus could have occurred. I'm not suggesting that it did occur, only that it is possible.

Charlie


From: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>
Sent: Sunday, April 19, 2020 12:34 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Erdman Dean <derdman05@gmail.com>; Murphy, Frederick A. <famurphy@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Denison Mark <mark.denison@vanderbilt.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Rollin Pierre <pierrerollin2019@gmail.com>; Tesh Robert <rbtesh22@gmail.com>; Tseng, Chien-Te K. <sktseng@UTMB.EDU>; Menachery, Vineet <vimenach@UTMB.EDU>; Folks Thomas <Virusdoctom@aol.com>; Calisher Charles <calisher@cybersafe.net>; Nichol Stuart <stn1@CDC.GOV>; Spiropoulou Christina (CDC/CCID/NCZVED) <ccs8@cdc.gov>; Franz David <davidrfranz@gmail.com>
Subject: Director of maximum-security Wuhan lab denies being source of coronavirus

https://www.washingtonpost.com/world/2020/04/19/coronavirus-latest-news/?p9w22b2p=b2p22p9w00098&tid=a_classic-iphone&no_nav=true#link-RTFRG73KVJAFXKAH6FQC7XQZ3M

1:19 a.m.

Director of maximum-security Wuhan lab denies being source of coronavirus

FOIA Confidential Treatment Requested by Univ of Texas System



This photo taken on February 23, 2017 shows Chinese virologist Shi Zhengli inside the P4 laboratory in Wuhan, capital of China's Hubei province. (Johannes Eisele/Afp Via Getty Images)

The director of the research unit at the Wuhan Institute of Virology, in the Chinese city at the center of the coronavirus outbreak, has rejected the "conspiracy theory" that the virus originated in his lab. In his first public remarks since the world became aware of the virus in January, Yuan Zhiming said that it was "impossible" that the virus began in his lab.

"As people who carry out viral studies, we clearly know what kind of research is going on at the institute and how the institute manages viruses and samples," he told CGTN, the Chinese state broadcaster's international arm. "As we said early on, there is no way this virus came from us. We have a strict regulatory regimen and we have a code of conduct for research, so we are confident of that."

Yuan heads the top-security-level P4 lab at the Wuhan institute, which 2018 become the first lab in Asia equipped to handle "Class 4" pathogens like Ebola.

Washington Post columnist Josh Rogin last week wrote that American officials were expressing concerns about inadequate safety at the lab as far back as January 2018.

Shi Zhengli, a scientist at the institute known for her work on viruses that stem from bats, as this new coronavirus is thought too, also initially wondered if it had escaped from the lab.

If coronaviruses were the culprit, "could they have come from our lab?" she recalled thinking in an interview with Scientific American. (She concluded it had not.)

Conspiracy theories about the virus's origins have been rife, and have moved into official spheres. After President Trump repeatedly called the coronavirus the "Chinese virus," Foreign Ministry spokesman Zhao Lijian suggested that the pathogen could have been planted in Wuhan by American soldiers who attended the World Military Games, held in the city last October.

Tom Ksiazek

Sent from a portable device

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009727

Sent: 4/19/2020 12:53:20 PM
To: 石正丽 [zlshi@wh.iov.cn]; Yuan Zhiming [yzm@wh.iov.cn]
CC: Shi, Pei yong [peshi@UTMB.EDU]
Subject: RE: 回复: RE: Fwd: Rubio

Thank you Zhengli and Zhiming for your comments and the reference publications. I did not receive the document I sent for your review so if you made comments on that, please resend. I'm afraid that this discussion will continue for some time regarding where early coronavirus work was being done, the role, if any, of the Wuhan CDC in research on bat-associated coronaviruses, and exactly when scientists at WIV first became aware of the new coronavirus and had possession of specimens in the WIV and

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 11:30 PM
To: Yuan Zhiming <yzm@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: 回复: RE: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your clarifying.

I've added some detailed information for your reference. I'm also sending you some papers published for your reference.

Best regards,

Zhengli,

-----原始邮件-----

发件人:"Yuan Zhiming" <yzm@wh.iov.cn>

发送时间:2020-04-19 10:55:33 (星期日)

收件人: "James LeDuc" <jwleduc@UTMB.EDU>, zlshi <zlshi@wh.iov.cn>

抄送: "Shi Peiyong" <peshi@UTMB.EDU>

主题: 回复: RE: Fwd: Rubio

Dear Jim,

Thanks for your informaiton. I really appreciate your help and your action, we need to let some people understand well the the mission of high-level biosafey lab. what we do, and how we do inside. We all know that the labs were built not for causing epidmic, but for proventing the epidemic, and the labs are managed according to interantional guildline and national accquirement, Wuhan's lab is among the others.

I will contact Zhengli to see what she can do for your report.

Regards

Zhiming

Yuan Zhiming, Ph. D.
Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan 430071, China
Tel: 86-27-87198195(O)
86-27-87197242(L)
Fax: 86-27-87199480

From: LeDuc, James W.
Date: 2020-04-19 00:44
To: 石正丽
CC: Shi, Pei yong; Yuan Zhiming
Subject: RE: Fwd: Rubio
Dear Zhengli,

Thank you for your response. I understand completely and I certainly do not wish to compromise you personally or your research activities. Given our long history of collaborations between the GNL and the WIV, I have been approached repeatedly for details on our work. Attached is a draft summary that I will be providing to the leadership of our University of Texas system and likely to Congressional committees that are being formed now. Please review carefully and make any changes that you would like. I want this to be as accurate as possible and I certainly do not want to misrepresent any of your valuable contributions. I need to submit this on Monday, 20 April, so your prompt reply would be very much appreciated. I have copied Zhiming for his comments as well.

With best wishes,

Jim

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 9:20 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your email and consideration our communication.

Due to the complicated situation, I don't think it's a right time to communicate by the call.

What I can tell you is that this virus is not a leaky from our lab or any other labs.It's a shame to make this scientific question so complicated.

I hope to talk with you whenever the COVID-19 is over and world is calme and believe in the science.

Best regards,
Zhengli,

-----原始邮件-----
发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>
发送时间:2020-04-17 11:06:38 (星期五)
收件人: "zengli Shi" <zlshi@wh.iov.cn>
抄送:
主题: Fwd: Rubio

Hi Zheng-Li. I hope you are well as surviving all the COVID19 drama. I wonder if you would have time for a phone call sometime soon. Let me know a good number and time and I'll call. The email below is relevant.

I will certainly understand if you are not available but Pei-Yong keeps encouraging me to call.

With all good wishes.

Jim.

My office line is [redacted] or cell is [redacted] if it's easier for you to call me.

Sent from my iPhone

Begin forwarded message:

From: David Franz <davidrfranz@gmail.com>
Date: April 16, 2020 at 8:04:55 PM CDT
To: "LeDuc, James W." <jwleduc@UTMB.EDU>
Subject: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I heard from someone in government this evening that Senator Rubio is starting to push for AN investigation regarding Wuhan lab. Just found it on the web at Forbes by Kenneth Repoza. Title of article is "eight senators call for investigation into coronavirus origins"

Sent from my iPhone

From: 石正丽 [zlshi@wh.iov.cn]
Sent: 4/19/2020 6:13:32 PM
To: LeDuc, James W. [jwleduc@UTMB.EDU]
CC: Yuan Zhiming [yzm@wh.iov.cn]; Shi, Pei yong [peshi@UTMB.EDU]
Subject: Re: RE: 回复: RE: Fwd: Rubio
Attachments: a nCoV and WIV-drf2-zl.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Sorry, I forgot the reviewed document.

-----原始邮件-----
发件人:"LeDuc, James W." <jwleduc@UTMB.EDU>
发送时间:2020-04-20 01:55:34 (星期一)
收件人: "石正丽" <zlshi@wh.iov.cn>, "Yuan Zhiming" <yzm@wh.iov.cn>
抄送: "Shi, Pei yong" <peshi@UTMB.EDU>
主题: RE: 回复: RE: Fwd: Rubio

Thank you Zhengli and Zhiming for your comments and the reference publications. I did not receive the document I sent for your review so if you made comments on that, please resend. I'm afraid that this discussion will continue for some time regarding where early coronavirus work was being done, the role, if any, of the Wuhan CDC in research on bat-associated coronaviruses, and exactly when scientists at WIV first became aware of the new coronavirus and had possession of specimens in the WIV and where was that work done (level of biocontainment). Next week will be busy…

Best wishes, Jim

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 11:30 PM
To: Yuan Zhiming <yzm@wh.iov.cn>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: 回复: RE: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your clarifying.

I've added some detailed information for your reference. I'm also sending you some papers published for your reference.

Best regards,

Zhengli,

-----原始邮件-----

发件人:"Yuan Zhiming" <yzm@wh.iov.cn>

发送时间:2020-04-19 10:55:33 (星期日)

收件人: "James LeDuc" <jwleduc@UTMB.EDU>, zlshi <zlshi@wh.iov.cn>

抄送: "Shi Peiyong" <peshi@UTMB.EDU>

主题: 回复: RE: Fwd: Rubio

Dear Jim,

Thanks for your informaiton. I really appreciate your help and your action, we need to let some people understand well the the mission of high-level biosafey lab. what we do, and how we do inside. We all know that the labs were built not for causing epidmic, but for proventing the epidemic, and the labs are managed according to interantional guildline and national accquirement, Wuhan's lab is among the others.

I will contact Zhengli to see what she can do for your report.

Regards

Zhiming

==========

Yuan Zhiming, Ph. D.

Professor of Wuhan Institute of Virology

President of Wuhan Branch

Chinese Academy of Sciences

Wuhan 430071, China

Tel: 86-27-87198195(O)

86-27-87197242(L)

Fax: 86-27-87199480

==========

From: LeDuc, James W.

Date: 2020-04-19 00:44

To: 石正丽

CC: Shi, Pei yong; Yuan Zhiming

Subject: RE: Fwd: Rubio

Dear Zhengli,

Thank you for your response. I understand completely and I certainly do not wish to compromise you personally or your research activities. Given our long history of collaborations between the GNL and the WIV, I have been approached repeatedly for details on our work. Attached is a draft summary that I will be providing to the leadership of our University of Texas system and likely to Congressional committees that are being formed now. Please review carefully and make any changes that you would like. I want this to be as accurate as possible and I certainly do not want to misrepresent any of your valuable contributions. I need to submit this on Monday, 20 April, so your prompt reply would be very much appreciated. I have copied Zhiming for his comments as well.

With best wishes,

Jim

From: 石正丽 <zlshi@wh.iov.cn>
Sent: Saturday, April 18, 2020 9:20 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: Fwd: Rubio

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear James,

Thank you for your email and consideration our communication.

Due to the complicated situation, I don't think it's a right time to communicate by the call.

What I can tell you is that this virus is not a leaky from our lab or any other labs.It's a shame to make this scientific question so complicated.

I hope to talk with you whenever the COVID-19 is over and world is calme and believe in the science.

Best regards,
Zhengli,

> -----原始邮件-----
> **发件人:**"LeDuc, James W." <jwleduc@UTMB.EDU>

发送时间:2020-04-17 11:06:38 (星期五)
收件人: "zengli Shi" <zlshi@wh.iov.cn>
抄送:
主题: Fwd: Rubio

Hi Zheng-Li. I hope you are well as surviving all the COVID19 drama. I wonder if you would have time for a phone call sometime soon. Let me know a good number and time and I'll call. The email below is relevant.

I will certainly understand if you are not available but Pei-Yong keeps encouraging me to call.

With all good wishes.

Jim.

My office line is [redacted] or cell is [redacted] if it's easier for you to call me.

Sent from my iPhone

Begin forwarded message:

> **From:** David Franz <davidrfranz@gmail.com>
> **Date:** April 16, 2020 at 8:04:55 PM CDT
> **To:** "LeDuc, James W." <jwleduc@UTMB.EDU>
> **Subject: Rubio**
>
> WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> I heard from someone in government this evening that Senator Rubio is starting to push for AN investigation regarding Wuhan lab. Just found it on the web at Forbes by Kenneth Repoza. Title of article is "eight senators call for investigation into coronavirus origins"
>
> Sent from my iPhone

Draft v5 April 21, 2020

U.S. - China Bilateral Dialogue on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security

Since 2015, the National Academies of Sciences, Engineering, and Medicine (NASEM) has organized a series of meetings on the challenges of emerging infections, laboratory safety, and global health security with the Chinese Academy of Sciences (CAS), Chinese Center for Disease Control and Prevention (CCDC), and other Chinese life science and public health organizations. Academy members and other top-flight American researchers in human and animal virology and immunology participated, including current and former directors of BSL-4 laboratories, former CDC, and former uniform military biodefense experts. They have met with China's BSL-4 laboratory directors and researchers, among others. The topics discussed included infectious-disease research; the challenges of combating emerging infections; life-science collaboration and research-data sharing; high-containment biological laboratory management, safety and security; and responsible conduct in the use of gene editing in viral infectious disease research.

The meetings enabled scientists from the United States and China to discuss research findings on diseases of mutual concern to China and the United States, to share best practices and lessons learned for managing and operating high containment biological laboratories, and to establish new collaborative research and institutional partnerships. NASEM promotes international scientific collaboration to address important issues for the United States and the world. These activities lead to better practices and increased transparency. Connecting scientists in China and the United States allows those working to combat emerging infectious disease to identify and implement the best management, safety, and security standards in their laboratories, and to create research collaboration and training partnerships to improve laboratory safety and security.

Ben Rusek, Senior Program Officer, PGA

Commented [RB1]: Maybe delete this part

Commented [RB2]: Raymond recommended that we delete the list of meetings but he wanted to hear your thoughts…

Deleted: ***First) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security*** (September 2015, Beijing, China)¶
¶
(Second) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (May 2017, Wuhan, China)¶
¶
(Third) U.S.-China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (January 2018, Galveston, Texas, USA)¶
¶
(Fourth) China-U.S. Dialogue on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and workshop on ***Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research*** (January 2019, Harbin, China)¶

Deleted: ¶

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010281

From: LeDuc, James W.
Sent: Tuesday, April 21, 2020 5:10 PM
To: Rusek, Benjamin;David Franz
Cc: 'Raymond JEANLOZ';Lowenthal, Micah
Subject: RE: NASEM China Bio discussion
Attachments: U.S. China dialogue meetings v5-jwl.docx; Media Statement_UTMB and WIV-4-20-20.docx

Attached has some suggestions. Looks fine to me.

I had an hour plus telecon with the House Foreign Affairs subcommittee on Oversight & Investigations to discuss the Washington Post article about the possible leak from WIV and the State Department inspection and cable. 5-6 participants from their side and all engaged. I provided them with the attached summary before the meeting and we had a good discussion about our relationship. The NASEM-CAS ties were of interest to them and they seemed to appreciate our efforts at engagement. As much detail as you can provide on the posting will be useful I suspect.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 3:04 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim and Dave,

Here is the latest draft of the website text for your review.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Raymond JEANLOZ <jeanloz@berkeley.edu>
Sent: Monday, April 20, 2020 4:38 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; David Franz <davidrfranz@gmail.com>
Subject: Re: NASEM China Bio discussion

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002548

I made a new copy of the transcript of the NPR interview -- attached.

Raymond

On Mon, Apr 20, 2020 at 8:46 AM Lowenthal, Micah <mlowenth@nas.edu> wrote:

> Hi there,
>
> Micah Lowenthal is inviting you to a scheduled Zoom meeting.
>
> Join from PC, Mac, Linux, iOS or Android:
> https://nasem.zoom.us/j/95438044518?pwd=Nm9Ha2V3dXpJeS9oREpMenY0WFJEZz09
> Password: 042020
>
> Would you like to test your Zoom connection? Please click on the link below.
> https://nasem.zoom.us/test
>
> NOTICE: The Zoom service allows audio and any materials exchanged or viewed during the session to be recorded and shared. Please be aware that by participating in this activity, you consent to your voice, likeness, and any materials you provide, being recorded for use and dissemination, without payment of any compensation for such use, in any language, format, or media now known or later devised, and you release the National Academies of Sciences, Engineering, and Medicine from any and all claims, liability, or damages arising from any such use. The Academies will proceed in reliance upon such consent and release. If you do not consent to the foregoing, please do not join the session.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002549

Draft v5 April 21, 2020

U.S. - China Bilateral Dialogue on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security

Since 2015, the National Academies of Sciences, Engineering, and Medicine (NASEM) has organized a series of meetings on the challenges of emerging infections, laboratory safety, and global health security with the Chinese Academy of Sciences (CAS), Chinese Center for Disease Control and Prevention (CCDC), and other Chinese life science and public health organizations. Academy members and other top-flight American researchers in human and animal virology and immunology participated, including current and former directors of BSL-4 laboratories, former CDC, and former uniform military biodefense experts. They have met with China's BSL-4 laboratory directors and researchers from top universities and research centers across China. The topics discussed included basic and applied research on infectious diseases; the challenges of combating emerging infections; life-science collaboration and research-data sharing; high-containment biological laboratory management, safety and security; and responsible conduct in the use of gene editing in infectious disease research.

The meetings enabled scientists from the United States and China to discuss research findings on diseases of mutual concern to China and the United States, to share best practices and lessons learned for managing and operating high containment biological laboratories, and to establish new collaborative research and institutional partnerships. NASEM promotes international scientific collaboration to address important issues for the United States and the world. These activities lead to better practices and increased transparency. Connecting scientists in China and the United States allows those working to combat emerging infectious disease to identify and implement the best management, safety, and security standards in their laboratories, and to create research collaboration and training partnerships to improve laboratory safety and security and to further basic and applied science on emerging infectious diseases.

(

Ben Rusek, Senior Program Officer, PGA

Commented [LJW1]: how many or list later the dates (yr)/sites.

Deleted: , among others

Deleted: -

Deleted: research

Deleted: viral

Commented [RB2]: Maybe delete this part

Commented [LJW3R2]: Yes, I don't think it adds much.

Commented [RB4]: Raymond recommended that we delete the list of meetings but he wanted to hear your thoughts…

Deleted: ***First) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security*** (September 2015, Beijing, China)¶
¶
(Second) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (May 2017, Wuhan, China)¶
¶
(Third) U.S.-China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (January 2018, Galveston, Texas, USA)¶
¶
(Fourth) China-U.S. Dialogue on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and workshop on ***Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research*** (January 2019, Harbin, China)¶

Deleted: ¶

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002550

utmb Health
Galveston National Laboratory

Galveston National Laboratory's Role with International Laboratories; Including Chinese Laboratories

Dr. James W. Le Duc, Director
20 April 20

Introduction

The Galveston National Laboratory (GNL) held its grand opening in November 2008. It is one of 14 laboratories based on university campuses in the U.S. that belong to the NIAID Biodefense Laboratory Network.

The GNL has been fully operational at all levels of biocontainment (Biological Safety Level-2, BSL3 and BSL4) since 2010. Our faculty members are involved in basic and translational research on emerging and re-emerging infectious diseases that require purpose-built containment facilities and specially-trained staff to handle these high consequence pathogens. We have been heavily involved in research and diagnostic testing on the new coronavirus since it was first recognized, and we have had longstanding research programs for both Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronaviruses.

The GNL Training Mission

The Galveston National Laboratory benefited greatly in building the GNL workforce through two projects funded through the Department of Defense (W81XWH-09-2-0053 and W81XWH-11-2-0148) that allowed us to establish the National Biocontainment Training Center at UTMB. This Center provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to our own staff and to international partners from around the world who had built or were building new biocontainment laboratories. Parenthetically, during a World Health Organization (WHO) sponsored meeting in December 2017, representatives from more than 50 BSL4 laboratories were present. Each of these laboratories was presumably being built to conduct research on especially dangerous pathogens such as Ebola virus, and the need for high quality training from experienced instructors was obvious.

The DoD funding for the National Biocontainment Training Center ended in 2016, and by that time, the GNL had provided training through more than 10,000 encounters for participants from about 70 different countries, as well as from universities, government agencies and industry personnel throughout the U.S. Training was provided in the training center and laboratories at UTMB as well as on-site at international locations where a greater number of personnel could be reached and we could provide a customized learning experience for trainees within their own familiar laboratory setting.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002551

We continue to provide training to our own staff and faculty, but without dedicated funding we are now unable to provide training for international partners.

Training Support for China

In 2013 the Galveston National Laboratory began to engage with the staff of the BSL4 laboratories under construction in China, which included the Wuhan Institute of Virology (WIV) laboratory located in the outskirts of Wuhan and affiliated with the Chinese Academy of Sciences. A second BSL4 laboratory remains under construction in Kunming and is associated with the Chinese Academy of Medical Sciences, and the third BSL4 laboratory is now fully operational in Harbin, where it serves the Chinese Academy of Agricultural Sciences.

In addition to providing short-term training experiences to staff from the WIV, the GNL also hosted two Chinese post-doctoral scientists, who completed the nearly year-long training needed to gain independent access to our BSL4 facilities. This includes mentored work at BSL3 and at least 100 hours of mentored training at BSL4. Both young scientists worked on cutting-edge scientific projects on Crimean Congo hemorrhagic fever virus in partnership with GNL faculty members, and their results were published in high-impact international scientific journals. Both have since returned to WIV in China, where they were instrumental in establishing their biosafety and biosecurity training program for the new BSL4 laboratory and where they continue their independent research in the new facility. Our faculty and staff maintain contact and continue to collaborate scientifically with these two scientists.

These training efforts had two primary goals: To ensure that all scientists working in biocontainment anywhere in the world are exposed to proven best practices in biosafety and biosecurity as well as in the safe and secure operations of these complex facilities; and second to engage in scientific collaborations. The director of the Wuhan BSL4 laboratory, Zhiming Yuan and I jointly published an editorial on the need for global collaboration among biocontainment laboratories in *Science* on 19 October 2018.

A second area of engagement has been an ongoing scientific dialogue facilitated by our U.S. National Academy of Sciences, Engineering and Medicine and the Chinese Academy of Sciences. Through this partnership, the Galveston National Lab has participated in joint meetings on emerging infectious diseases, biocontainment laboratory safety and security, and, more recently, gene editing. Meetings alternate between the US and China and have occurred about annually, with the first being held in Beijing in September 2015. The Galveston National Lab hosted one of the meetings in Galveston in January 2018.

Specific Coronavirus Discussions

Importantly, during each of these NASEM/CAS meetings, we have held a session on the coronaviruses with presentations by the foremost American leaders in this field. At each of these sessions, Dr. Zhengli Shi has presented her most recent work. During the September 2015 meeting, she described her studies of bat-associated coronaviruses and concluded that there was significant potential risk of transmission of some of these

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002552

viruses to humans. She is the research scientist who discovered the link between bats and the original SARS virus that caused disease world-wide in 2003. She has participated in each of our dialogues; in every session, she has been fully engaged, very open and transparent about her work, and eager to collaborate.

There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature given its high similarity to other known bat-associated coronaviruses. Dr Shi was among the first to identify the new virus, to determine its genetic sequence, and to share it publicly. She was also among the first to publish about the new virus in the international scientific literature.

The Wuhan Institute of Virology Lab

I have visited and toured the new BSL4 laboratory in Wuhan, prior to it starting operations in 2017. The facility was built in partnership with the French and it is modeled after the BSL4 laboratory in Lyon, France. It is of comparable quality and safety measures as any currently in operation in the US or Europe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002553

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 7:42 PM
To: LeDuc, James W.;David Franz
Cc: 'Raymond JEANLOZ';Lowenthal, Micah
Subject: RE: NASEM China Bio discussion
Attachments: U.S. China dialogue meetings v6.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim, sounds like your session with the House subcommittee went well and I am glad to that they are generally supportive of engagement. (I assume that the subcommittee has access to the two cables cited by the wapo.) I like the utmb statement as well.

Thanks for the edits. I have attached what I think is the final version of the China dialogue blurb for the NASEM website. Can still use the bulleted list we created last week when/if we talk about the dialogue with gov folks.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, April 21, 2020 6:10 PM
To: Rusek, Benjamin <BRusek@nas.edu>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion

Attached has some suggestions. Looks fine to me.

I had an hour plus telecon with the House Foreign Affairs subcommittee on Oversight & Investigations to discuss the Washington Post article about the possible leak from WIV and the State Department inspection and cable. 5-6 participants from their side and all engaged. I provided them with the attached summary before the meeting and we had a good discussion about our relationship. The NASEM-CAS ties were of interest to them and they seemed to appreciate our efforts at engagement. As much detail as you can provide on the posting will be useful I suspect.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 3:04 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001652

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim and Dave,

Here is the latest draft of the website text for your review.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Raymond JEANLOZ <jeanloz@berkeley.edu>
Sent: Monday, April 20, 2020 4:38 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; David Franz <davidrfranz@gmail.com>
Subject: Re: NASEM China Bio discussion

I made a new copy of the transcript of the NPR interview -- attached.

Raymond

On Mon, Apr 20, 2020 at 8:46 AM Lowenthal, Micah <mlowenth@nas.edu> wrote:

> Hi there,
>
> Micah Lowenthal is inviting you to a scheduled Zoom meeting.
>
> Join from PC, Mac, Linux, iOS or Android:
> https://nasem.zoom.us/j/95438044518?pwd=Nm9Ha2V3dXpJeS9oREpMenY0WFJEZz09
> Password: 042020
>
> Would you like to test your Zoom connection? Please click on the link below.
> https://nasem.zoom.us/test
>
> NOTICE: The Zoom service allows audio and any materials exchanged or viewed during the session to be recorded and shared. Please be aware that by participating in this activity, you consent to your voice, likeness, and any materials you provide, being recorded for use and dissemination, without payment of any compensation for such use, in any language, format, or media now known or later devised, and you release the National Academies of Sciences, Engineering, and Medicine from any and all claims, liability, or damages arising from any such use. The Academies will proceed in reliance upon such consent and release. If you do not consent to the foregoing, please do not join the session.

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Wednesday, April 22, 2020 8:52 AM
To: Rusek, Benjamin;David Franz
Cc: Raymond JEANLOZ;Lowenthal, Micah
Subject: RE: NASEM China Bio discussion

The House Committee had NOT seen the memo and quipped that the only one that had seen it was the reporter.

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 8:54 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: Raymond JEANLOZ <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: NASEM China Bio discussion

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Balanced article on Zhengli Shi by the WSJ reporter who contacted Jim
https://www.wsj.com/articles/chinas-bats-expert-says-her-wuhan-lab-wasnt-source-of-new-coronavirus-11587463204

On Apr 21, 2020, at 8:42 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Thanks Jim, sounds like your session with the House subcommittee went well and I am glad to that they are generally supportive of engagement. (I assume that the subcommittee has access to the two cables cited by the wapo.) I like the utmb statement as well.

Thanks for the edits. I have attached what I think is the final version of the China dialogue blurb for the NASEM website. Can still use the bulleted list we created last week when/if we talk about the dialogue with gov folks.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, April 21, 2020 6:10 PM
To: Rusek, Benjamin <BRusek@nas.edu>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion

Attached has some suggestions. Looks fine to me.

FOIA Confidential Treatment Requested by Univ of Texas System

I had an hour plus telecon with the House Foreign Affairs subcommittee on Oversight & Investigations to discuss the Washington Post article about the possible leak from WIV and the State Department inspection and cable. 5-6 participants from their side and all engaged. I provided them with the attached summary before the meeting and we had a good discussion about our relationship. The NASEM-CAS ties were of interest to them and they seemed to appreciate our efforts at engagement. As much detail as you can provide on the posting will be useful I suspect.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 3:04 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim and Dave,

Here is the latest draft of the website text for your review.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Raymond JEANLOZ <jeanloz@berkeley.edu>
Sent: Monday, April 20, 2020 4:38 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; David Franz <davidrfranz@gmail.com>
Subject: Re: NASEM China Bio discussion

I made a new copy of the transcript of the NPR interview -- attached.

Raymond

On Mon, Apr 20, 2020 at 8:46 AM Lowenthal, Micah <mlowenth@nas.edu> wrote:

> Hi there,
>
> Micah Lowenthal is inviting you to a scheduled Zoom meeting.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008875

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/95438044518?pwd=Nm9Ha2V3dXpJeS9oREpMenY0WFJEZz09
Password: 042020

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

NOTICE: The Zoom service allows audio and any materials exchanged or viewed during the session to be recorded and shared. Please be aware that by participating in this activity, you consent to your voice, likeness, and any materials you provide, being recorded for use and dissemination, without payment of any compensation for such use, in any language, format, or media now known or later devised, and you release the National Academies of Sciences, Engineering, and Medicine from any and all claims, liability, or damages arising from any such use. The Academies will proceed in reliance upon such consent and release. If you do not consent to the foregoing, please do not join the session.

<U.S. China dialogue meetings v6.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008876

From: David Franz <davidrfranz@gmail.com>
Sent: Wednesday, April 22, 2020 8:47 PM
To: LeDuc, James W.;Ksiazek, Thomas G.
Subject: Another story; More errors

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

There continue to be geographic and other errors in these stories and accusations

The Chinese lab at the center of the coronavirus controversy

Axios

Bethany Allen-Ebrahimian

China's highest-security virology center is at the center of debate, speculation and misinformation about how, where and when the novel coronavirus emerged.

Why it matters: Knowing the origin of the novel coronavirus is key to efforts to prevent future possible pandemics and will shape China's role in the post-pandemic world.

In the U.S., two similar-sounding theories link the Wuhan Institute of Virology and the origin of the coronavirus. One is very unlikely; the other is plausible but unverified.

Theory 1: The coronavirus was created as part of a Chinese bioweapons research program allegedly linked to the WIV.

- Virologists have determined this is highly unlikely. By looking at a virus' genetic material, it is possible to tell if it has been engineered in a lab. The coronavirus shows no such signs, as the World Health Organization also emphasized on April 21.
- Some U.S. officials previously showed interest in this theory, but the scientific evidence debunking it has been persuasive.
    - There is also growing scientific evidence the virus originated in a bat and spread to humans via an intermediary animal, which would make it less likely it came from a lab.

Theory 2: The novel coronavirus was being studied at the WIV, and a lab accident resulted in the virus' accidental transmission to an employee who then unknowingly spread the virus in the city after leaving the institute premises.

- This is plausible, but as yet there is no direct evidence to support it.

FOIA Confidential Treatment Requested by Univ of Texas System

- It isn't possible to tell from looking at the coronavirus' genetic sequence if it jumped from animal to human in a lab or in a wet market (or somewhere else). Confirmation would therefore have to come from contact tracing and related measures by Chinese authorities.
- This theory has gained significant traction within U.S. government circles.

Context: There is precedent in China — and other countries, including Singapore — where breaches in lab safety procedures resulted in disease outbreaks.

- In 2004, the coronavirus that causes SARS was accidentally leaked from a facility in Beijing, infecting nine people and killing one.
- **Yes, but:** That was a known pathogen studied in numerous labs around the world. The novel coronavirus that causes COVID-19 was previously unknown to the scientific community.

What they're saying: Yuan Zhiming, the director of the Wuhan National Biosafety Laboratory and vice director of the WIV, denied the novel coronavirus had any connection to the lab in an April 18 interview with Chinese state broadcaster CGTN.

- "There is no way this virus came from us," said Yuan. "People can't help but make associations, which I think is understandable. But it's bad when some are deliberately trying to mislead people."
- Shi Zhengli, a highly respected scientist who also works at the institute and who has long studied coronaviruses that come from bats, said in February that she could "guarantee on my life" that the novel coronavirus did not come from the lab, according to the Wall Street Journal.
- A version of the second theory, which claims that "patient zero" was an intern at the facility, has also made the rounds on the Chinese internet, prompting state news agency Xinhua to publish a Feb. 16 article stating that the person in question had never been infected.

Here are three key facts about the WIV:

1. It houses the Wuhan National Biosafety Laboratory, which is China's only Biosafety Level-4 (BSL-4) lab. That means it is the only facility in China permitted to handle the most dangerous known pathogens, including the Ebola and Lassa viruses.

- It is the first of several BSL-4 labs that China is planning to build.
- BSL-4 labs are rare and confer a degree of prestige on the countries that have them. Taiwan has two such labs; Japan's first BSL4 lab wasn't approved to handle top-tier pathogens until 2015.
- By comparison, the U.S. has about a half-dozen BSL4 labs, with several more planned.

2. The lab is located just under 9 miles from the wet market where some scientists say the outbreak may have originated.

- Its proximity to the first known cluster of cases at the Huanan market has fueled speculationthe lab could somehow be involved.

3. The WIV is home to the Chinese scientists who sequenced the complete novel coronavirus genome in early January and who are now working on a vaccine.

- Scientists affiliated with the institute have studied coronaviruses for years, but it's not the only lab in China where coronaviruses are studied.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008014

The bottom line: As China seeks to demonstrate scientific heft, a spillover event at China's most prestigious virology lab — and subsequent cover-up — would be "another nail in the coffin of Xi's personal reputation and the CCP's reputation on the global stage," Elizabeth Economy, director for Asia studies at the Council on Foreign Relations, said on a media call last week.

- "Globally, it would certainly be very harmful, Domestically, I think it would probably reinforce people's impressions who are already distrustful of the regime."

https://www.axios.com/wuhan-institute-of-virology-china-coronavirus-79ad2d32-9834-4099-8a94-5df501845e3d.html

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008015

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010276

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010277

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010278

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010269

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010270

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010271

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010272

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 23, 2020 8:22 AM
To: Lowenthal, Micah; Dave Franz; LeDuc, James W.; Shi, Pei yong; Sharples, Fran; Bowman, Katherine
Subject: Fwd: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Letter to CCDC CAS re virtual dialogue April 22 2020.pdf; ATT00001.htm

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FYI

Begin forwarded message:

From: NASPresident <naspresident@nas.edu>
Date: April 23, 2020 at 8:50:30 AM EDT
To: "jh-cao@cashq.ac.cn" <jh-cao@cashq.ac.cn>, "clbai@cas.cn" <clbai@cas.cn>, "gaof@im.ac.cn" <gaof@im.ac.cn>, "sunhui@cashq.ac.cn" <sunhui@cashq.ac.cn>
Cc: "McNutt, Marcia K." <MMcNutt@nas.edu>, "Dzau, Victor J." <VDzau@nas.edu>, "dgriffi6@jhmi.edu" <dgriffi6@jhmi.edu>, "peggy@hbfam.net" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "jwleduc@UTMB.EDU" <jwleduc@utmb.edu>
Subject: Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123801

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123802

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123803

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123804

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123805

From: LeDuc, James W.
Sent: Thursday, April 23, 2020 4:59 PM
To: Dave Franz
Subject: RE: And here is the HC story that posted Thursday afternoon

I spoke to Ellen several times when she was working on the big article about the early stages of the pandemic. She seems very nice and competent. Giver her my regards.

I don't know where Zhengli worked. I had some email exchange with her last weekend but she didn't volunteer much and declined a call. I think they are under pretty strict orders to keep quite.

From: Dave Franz <davidrfranz@gmail.com>
Sent: Thursday, April 23, 2020 4:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Pretty balanced from you. Do you know Ellen Nakashima from the Wash Post. Michael Callahan apparently gave her my name. I'll talk with her only on background , if it might be helpful and it would be comparable with what you say in the Houston Chronicle. Do we know if Zhengli worked BOTH on campus and in the BSL-4?

See below;

Hello, David,

I hope you are managing to stay safe and sane during these trying times.

Dr. Michael Callahan, whom I've been speaking to about various issues surrounding the USG response to the pandemic, suggested I reach out to you. I'm interested in sounding out experts in BSL-4 labs. Here's the issue. It's been pretty well established that Covid-19 wasn't bioengineered in a lab. But how plausible is the theory that the virus was ACCIDENTALLY released from the Wuhan Institute of Virology, where a great amount of research was being done on coronaviruses and bat viruses?

As you've seen, the USG had concerns about the biosafety of the lab. And we know from open sources that since 2017 the lab participated in about 35 studies, published in English-language journals, pertaining to coronaviruses or other viruses carried by bats (or in a couple of cases, looking at other vectors carrying the same viruses). Scientists collected bats and guano not only in China but in Singapore and Malaysia (at least), but most of the work was laboratory based, using bats or bat tissues, cells and live viruses.

None of the studies point to bad science. They just illustrate the fact that that the Wuhan lab was doing a truly extraordinary amount of work with live bats and bat viruses.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009777

I know Shi Zhengli has said the lab did no work on that virus strain before it was discovered. But is it possible that one of the other strains they were working on mutated there and got out? Is that a silly question?

What would the questions be that you would ask in order to determine that the virus was there and accidentally jumped, as opposed to originating somewhere else?

Would you be willing to speak to me about this? I'm not on deadline.

Thanks very much,
Ellen Nakashima
202-841-3655

On Apr 23, 2020, at 5:26 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle

A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009778

world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009779

Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009780

don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009781

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009782

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009783

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

> On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:
>
> I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.
>
> **From:** Reyes, Raul <rareyes@UTMB.EDU>
> **Sent:** Wednesday, April 22, 2020 9:11 PM
> **To:** Raimer, Ben G. <bgraimer@UTMB.EDU>
> **Cc:** LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
> **Subject:** GDN GNL/Wuhan story
>
> # Galveston bio lab explains connections to Wuhan
>
> - By JOHN WAYNE FERGUSON The Daily News
> - 33 min ago

FOIA Confidential Treatment Requested by Univ of Texas System

- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009785

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009786

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009787

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009788

originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
-

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009789

happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009790

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, April 23, 2020 5:01 PM
To: LeDuc, James W.
Subject: Re: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ok. Thanks! d
Sent from my iPhone

On Apr 23, 2020, at 5:59 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:

I spoke to Ellen several times when she was working on the big article about the early stages of the pandemic. She seems very nice and competent. Giver her my regards.

I don't know where Zhengli worked. I had some email exchange with her last weekend but she didn't volunteer much and declined a call. I think they are under pretty strict orders to keep quite.

From: Dave Franz <davidrfranz@gmail.com>
Sent: Thursday, April 23, 2020 4:41 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Pretty balanced from you. Do you know Ellen Nakashima from the Wash Post. Michael Callahan apparently gave her my name. I'll talk with her only on background , if it might be helpful and it would be comparable with what you say in the Houston Chronicle. Do we know if Zhengli worked BOTH on campus and in the BSL-4?

See below;

Hello, David,

I hope you are managing to stay safe and sane during these trying times.

Dr. Michael Callahan, whom I've been speaking to about various issues surrounding the USG response to the pandemic, suggested I reach out to you. I'm interested in sounding out experts in BSL-4 labs. Here's the issue. It's been pretty well established that Covid-19 wasn't bioengineered in a lab. But how plausible is the theory that the virus was ACCIDENTALLY released from the Wuhan Institute of Virology, where a great amount of research was being done on coronaviruses and bat viruses?

As you've seen, the USG had concerns about the biosafety of the lab. And we know from open sources that since 2017 the lab participated in about 35 studies, published in English-language journals, pertaining to coronaviruses or other viruses carried by bats (or in a couple of cases, looking at other vectors carrying the same viruses). Scientists collected bats and guano not only in China but in Singapore and Malaysia (at least), but most of the work was laboratory based, using bats or bat tissues, cells and live viruses.

None of the studies point to bad science. They just illustrate the fact that that the Wuhan lab was doing a truly extraordinary amount of work with live bats and bat viruses.

I know Shi Zhengli has said the lab did no work on that virus strain before it was discovered. But is it possible that one of the other strains they were working on mutated there and got out? Is that a silly question?

What would the questions be that you would ask in order to determine that the virus was there and accidentally jumped, as opposed to originating somewhere else?

Would you be willing to speak to me about this? I'm not on deadline.

Thanks very much,
Ellen Nakashima
202-841-3655

On Apr 23, 2020, at 5:26 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle
•
A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet

markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009673

appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

FOIA Confidential Treatment Requested by Univ of Texas System

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like

anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."
nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP
By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul
Sent from my iPhone8 Plus

On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:

I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 9:11 PM

To: Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: GDN GNL/Wuhan story

Galveston bio lab explains connections to Wuhan

- By JOHN WAYNE FERGUSON The Daily News
- 33 min ago

- 0
- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON
In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.
People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.
But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.
"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.
"But sometimes accidents happen," he said
LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.
LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.
LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said. Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009678

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:
Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System

Sent: 4/24/2020 2:00:26 PM
To: Rusek, Benjamin [BRusek@nas.edu]; LeDuc, James W. [jwleduc@UTMB.EDU]; Dave Franz (davidrfranz@gmail.com) [davidrfranz@gmail.com]; Raymond Jeanloz [jeanloz@berkeley.edu]; Lowenthal, Micah [mlowenth@nas.edu]
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is later this year might be

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.
http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle
•
A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was

FOIA Confidential Treatment Requested by Univ of Texas System

relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

FOIA Confidential Treatment Requested by Univ of Texas System

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

FOIA Confidential Treatment Requested by Univ of Texas System

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:

I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 9:11 PM
To: Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: GDN GNL/Wuhan story

Galveston bio lab explains connections to Wuhan

- By JOHN WAYNE FERGUSON The Daily News

- 33 min ago
- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_043803

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

FOIA Confidential Treatment Requested by Univ of Texas System

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

FOIA Confidential Treatment Requested by Univ of Texas System

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>

Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System

From: Shi, Pei yong
Sent: Friday, April 24, 2020 6:42 PM
To: Rusek, Benjamin;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Raymond Jeanloz;Lowenthal, Micah
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is that later this year might be possible. I think George Gao and Chunli Bai are the rights targets to discuss the feasibility.
Have a good weekend!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.
http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009857

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle

A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009858

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009859

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009860

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

> On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:
>
> I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.
>
> **From:** Reyes, Raul <rareyes@UTMB.EDU>
> **Sent:** Wednesday, April 22, 2020 9:11 PM
> **To:** Raimer, Ben G. <bgraimer@UTMB.EDU>
> **Cc:** LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
> **Subject:** GDN GNL/Wuhan story
>
> # Galveston bio lab explains connections to Wuhan

FOIA Confidential Treatment Requested by Univ of Texas System

- By JOHN WAYNE FERGUSON The Daily News
- 33 min ago

- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009862

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009863

Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009864

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009865

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009866

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:22 AM
To: Shi, Pei yong;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Raymond Jeanloz;Lowenthal, Micah
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

Did you get the impression that we would get a formal response from George Gao and Bai Chunli soon? The letter asks them to support a virtual meeting in May to discuss important and time sensitive questions/issues associated with Covid-19.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, April 24, 2020 7:42 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is that later this year might be possible. I think George Gao and Chunli Bai are the rights targets to discuss the feasibility.
Have a good weekend!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009846

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.
http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle

A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009847

Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009848

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009849

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009850

Sent from my iPhone8 Plus

On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:

I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 9:11 PM
To: Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: GDN GNL/Wuhan story

Galveston bio lab explains connections to Wuhan

- By JOHN WAYNE FERGUSON The Daily News
- 33 min ago

- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009851

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009852

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009853

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009854

nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009855

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009856

From: Shi, Pei yong
Sent: Monday, April 27, 2020 10:24 AM
To: Rusek, Benjamin;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Raymond Jeanloz;Lowenthal, Micah
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
Let me pin George today and let you know.
When did we send the letter to them?
Thanks!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:22 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

Did you get the impression that we would get a formal response from George Gao and Bai Chunli soon? The letter asks them to support a virtual meeting in May to discuss important and time sensitive questions/issues associated with Covid-19.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, April 24, 2020 7:42 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is that later this year might be possible. I think George Gao and Chunli Bai are the rights targets to discuss the feasibility.
Have a good weekend!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009621

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.
http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009622

A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009623

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009624

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009625

To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

> On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:
>
> I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.
>
> **From:** Reyes, Raul <rareyes@UTMB.EDU>
> **Sent:** Wednesday, April 22, 2020 9:11 PM
> **To:** Raimer, Ben G. <bgraimer@UTMB.EDU>
> **Cc:** LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
> **Subject:** GDN GNL/Wuhan story
>
> # Galveston bio lab explains connections to Wuhan
>
> - By JOHN WAYNE FERGUSON The Daily News
> - 33 min ago
>
> - 0
>
> - Facebook
> - Twitter
> - WhatsApp
> - SMS
> - Email
> - Save
>
> GALVESTON

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009626

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009627

fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009628

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009629

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009630

redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009631

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126325

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126326

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126327

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126328

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051130

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051131

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051132

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_051133

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:37 AM
To: Shi, Pei yong;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Raymond Jeanloz;Lowenthal, Micah
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong, it went out on April 23, 2020 at 8:50 AM ET, I just sent you the fw.

PS Good to see George speak at the NAS annual meeting on Saturday. FYI the session is archived here, George starts at about 47 min in: https://www.youtube.com/watch?v=wQaK2JS0Kc4&feature=emb_logo

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Monday, April 27, 2020 11:24 AM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
Let me pin George today and let you know.
When did we send the letter to them?
Thanks!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:22 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009610

Did you get the impression that we would get a formal response from George Gao and Bai Chunli soon? The letter asks them to support a virtual meeting in May to discuss important and time sensitive questions/issues associated with Covid-19.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, April 24, 2020 7:42 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is that later this year might be possible. I think George Gao and Chunli Bai are the rights targets to discuss the feasibility.
Have a good weekend!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.
http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009611

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle

A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009612

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009613

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009614

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

> On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:
>
> I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.
>
> **From:** Reyes, Raul <rareyes@UTMB.EDU>
> **Sent:** Wednesday, April 22, 2020 9:11 PM
> **To:** Raimer, Ben G. <bgraimer@UTMB.EDU>
> **Cc:** LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone,

FOIA Confidential Treatment Requested by Univ of Texas System

Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: GDN GNL/Wuhan story

Galveston bio lab explains connections to Wuhan

- By JOHN WAYNE FERGUSON The Daily News
- 33 min ago

- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009616

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009617

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009618

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009619

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009620

From: Shi, Pei yong
Sent: Monday, April 27, 2020 10:40 AM
To: Rusek, Benjamin;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Raymond Jeanloz;Lowenthal, Micah
Subject: RE: And here is the HC story that posted Thursday afternoon

Thanks, Ben
I attended Saturday's event. It was very successful.
Best, Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:37 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong, it went out on April 23, 2020 at 8:50 AM ET, I just sent you the fw.

PS Good to see George speak at the NAS annual meeting on Saturday. FYI the session is archived here, George starts at about 47 min in: https://www.youtube.com/watch?v=wQaK2JS0Kc4&feature=emb_logo

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Monday, April 27, 2020 11:24 AM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
Let me pin George today and let you know.
When did we send the letter to them?
Thanks!

- Pei-Yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009598

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, April 27, 2020 10:22 AM
To: Shi, Pei yong <peshi@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Pei-yong,

Did you get the impression that we would get a formal response from George Gao and Bai Chunli soon? The letter asks them to support a virtual meeting in May to discuss important and time sensitive questions/issues associated with Covid-19.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Shi, Pei yong <peshi@UTMB.EDU>
Sent: Friday, April 24, 2020 7:42 PM
To: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: And here is the HC story that posted Thursday afternoon

Hi Ben,
I discussed the virtual conference with Zhiming. His response is that later this year might be possible. I think George Gao and Chunli Bai are the rights targets to discuss the feasibility.
Have a good weekend!

- Pei-Yong

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, April 24, 2020 1:48 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: RE: And here is the HC story that posted Thursday afternoon

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Jim,

Pei-yong have you mentioned the virtual dialogue letter to Zhiming?

FYI George Gao is scheduled to be on a virtual panel with Toni Fauci at the NAS annual meeting tomorrow afternoon at 2 pm.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009599

http://www.nasonline.org/about-nas/events/annual-meeting/nas157/covid19-update.html

Anyone can listen in.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 23, 2020 5:27 PM
To: Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Rusek, Benjamin <BRusek@nas.edu>; Raymond Jeanloz <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: FW: And here is the HC story that posted Thursday afternoon

From the Houston Chronicle just posted.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Thursday, April 23, 2020 4:06 PM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: And here is the HC story that posted Thursday afternoon

UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research

By Nick Powell
Houston Chronicle

- A leading Texas scientist who visited a Chinese laboratory conducting coronavirus research acknowledged that while that facility made security a priority, it is possible that an accident could have led to the global virus outbreak.

James Le Duc, the director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB) in Galveston, has had a professional relationship with several Chinese biocontainment labs since 2013, including the Wuhan Institute of Virology laboratory, which studies some of the world's most lethal infectious diseases, including coronaviruses in bats.

The Wuhan laboratory's research has prompted speculation by Trump administration officials and others that it may have had a role in causing the coronavirus outbreak in China's Hubei Province, the virus's epicenter. Administration officials have also called on China to close its "wet markets," more widely viewed as the source of the COVID-19 outbreak linked to more than 183,000 deaths worldwide.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009600

Le Duc visited the Wuhan lab in 2017, shortly before it opened, and even hosted the lab's building engineers at the Galveston National Laboratory for a training program on building operations and maintenance while it was under construction. While Le Duc said he did not see anything during that visit to the lab that alarmed him or hinted at lax safety protocols, he acknowledged that even laboratories with the highest level of security are prone to accidents.

Related Stories

Diplomatic cables from 2018 obtained by The Washington Post warned about questionable safety and inadequate training at the lab and the risk potential of coronaviruses from bats being transmitted to humans and causing a pandemic similar to SARS in 2003.

"Accidents happen," Le Duc told the Houston Chronicle. "You do your best to prevent it, and you prepare for an eventuality if it should happen. So all I can say is (the Wuhan lab) was built comparable to ours, with a whole series of redundant safety measures in place. We did our best to share best practices so that they knew how to drive it and keep it safe. But it would be foolish to say there's no risk, because there's risk in everything."

Senior officials at the Wuhan lab have consistently denied any link between their facility and the coronavirus outbreak. Yuan Zhiming, a top scientist at the Wuhan facility, told Chinese state television recently, "There is absolutely no way that the virus originated from our institute."

Shi Zhengli, a virologist at the Wuhan lab and one of the world's leading researchers on bat coronaviruses, told Scientific American last month that she initially feared the virus could have originated at her facility, but was relieved that none of the genetic sequences taken from infected patients matched the viruses her team had sampled from bat caves.

"That really took a load off my mind," Shi said. "I had not slept a wink for days."

Yet the coronavirus research at the Wuhan lab so alarmed American science diplomats that they requested the United States provide further support beyond the assistance that the lab was getting from UTMB. In another cable, diplomats noted "the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory."

As part of a team at UTMB that helped train staff from the Wuhan lab, Le Duc was hesitant to ascribe blame or speculate on any specific cause of the coronavirus outbreak in Wuhan. He did, however, acknowledge China's relative lack of experience in establishing high-security biocontainment labs.

"I can say that this was a brand-new laboratory that was working at a level of biocontainment that they had not worked at in the past, so it's not surprising that they don't have a whole lot of people with experience in it," said Le Duc, who joined UTMB in 2006 from the Centers for Disease Control and Prevention. "I don't think that that means that they were any less appreciative of safety and security than anyone else."

UTMB's relationship with China dates back to 2013, when the medical branch opened discussions with three labs that were under construction, including the facility in Wuhan. Through the Galveston National Laboratory's federally-funded national training center, Le Duc led a team that provided individualized, hands-

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009601

on training in biosafety, biosecurity and biocontainment laboratory operations to international partners from around the world who had built or were building new biocontainment laboratories.

As part of this engagement with the Chinese, the Galveston National Laboratory hosted a team of engineers that was building the lab in Wuhan to train them specifically on maintenance and operations of biocontainment labs. The national laboratory also hosted two Chinese post-doctoral scientists from the Wuhan lab. They completed the nearly year-long training needed to gain independent access to the Galveston facility and collaborated with UTMB faculty on Crimean Congo hemorrhagic fever virus research.

UTMB did not provide the specific dates when the Chinese staffers came to Galveston, but Le Duc said they arrived in the years prior to the Wuhan facility opening in 2017. The medical branch also declined to release the names of the two Chinese scientists from the Wuhan lab, citing federal law that protects the privacy of student records.

"We wanted to make sure that we were engaged with (China) because they're a huge country, they've got tremendous intellectual power, and a lot of ongoing scientific collaborations," Le Duc said. "We just wanted to make sure that as they stood up their new biocontainment labs, that they were aware of our experiences and kind of open up a dialogue so that we could share best practices."

Le Duc spoke highly of Shi, a professional colleague whose research he admires. Both scientists attended annual meetings hosted by the Chinese Academy of Sciences and the U.S. National Academy of Sciences, where Le Duc listened to Shi warn of the dangers of coronaviruses jumping from animals to humans as far back as 2015. Shi's presentations at these meetings have not been made public.

While one of the 2018 diplomatic cables obtained by The Post warned of the public health risk of bat-associated coronaviruses, Le Duc said the dangers of these viruses have been common knowledge in the scientific community for years, in large part because of Shi's research.

"I've never seen the cable but it's kind of being implied that this is breaking news," he said. "Well, in the scientific community we had been talking about this for at least five years. It wasn't breaking news and it wasn't a surprise to the scientists that are working in this field."

He has kept in touch with Shi since the outbreak and is saddened her integrity has come into question. Le Duc said he believes Shi's account of when she was first notified of the first coronavirus infections and that the timeline of events suggests to him that the virus did not originate in the Wuhan lab.

"It's all speculation that the lab was involved and I think it's very appropriate that people look into this because that's where some of the work is done, but the timeline doesn't make sense," he said. "I'm not at all trying to defend her or the laboratory, and frankly I think the Chinese government has done themselves and the global community a big disservice by not being more transparent as to what's going on, but that's a whole different set of issues."

Federal officials had hoped UTMB's unique relationship with the Wuhan lab might led to an exchange that would help U.S. officials develop a diagnostic test for COVID-19, but Chinese officials nixed the idea in late January, The Post has reported.

Le Duc also dismissed conspiracy theories suggesting that the coronavirus was man-made in the Wuhan lab, saying it "almost certainly originated from nature" given its similarity to other known bat-associated

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009602

coronaviruses. But he conceded that working with infectious diseases, even in the most secure facilities, is inherently risky.

"We as scientists try and use the best practices," he said. "Nobody wants to get sick, nobody wants to take their work home with them. Like anything, it's a highly specialized field, there are tools and procedures that protect the individuals working in the field and we all try and use them."

nick.powell@chron.com

Nick Powell

Nick Powell covers Galveston and the Bay Area for the Houston Chronicle.

Past Articles from this Author:

- Galveston, Montgomery counties will not mandate face coverings
- UTMB scientist acknowledges safety risks at Chinese lab doing coronavirus research
- State parks reopen, giving Texans a much-needed break from cabin fever

NEWSLETTER

Coronavirus updates

Get breaking news alerts and a morning briefing with the latest on COVID-19 and other local news.

SIGN UP

By subscribing, you agree to our Terms of use and acknowledge that your information will be used as described in our Privacy Policy.

Most Popular

From: Reyes, Raul
Sent: Thursday, April 23, 2020 8:45 AM
To: Lidstone, Sheila <shlidsto@UTMB.EDU>
Cc: Raimer, Ben G. <bgraimer@UTMB.EDU>; LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Re: GDN GNL/Wuhan story

Good to hear Sheila.

Thank you.

Raul

Sent from my iPhone8 Plus

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009603

On Apr 23, 2020, at 8:41 AM, Lidstone, Sheila <shlidsto@utmb.edu> wrote:

I thought the story was very transparent and very well done. My husband brought the paper to me this morning and said "hey, there's a great story on the GNL on the front page today." He is not aware of our struggling with how best to handle this at all.

From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 9:11 PM
To: Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: GDN GNL/Wuhan story

Galveston bio lab explains connections to Wuhan

- By JOHN WAYNE FERGUSON The Daily News
- 33 min ago

- 0

- Facebook
- Twitter
- WhatsApp
- SMS
- Email
- Save

GALVESTON

In a biocontainment laboratory, there's always a risk of something going wrong, Dr. James LeDuc, director of the Galveston National Laboratory said.

People can unintentionally be stuck with a needle or bitten by an infected animal, causing a breach of even the most secure lab protocols.

But as a theory about a Chinese lab being the original source of the global coronavirus pandemic circulates at the highest level of the U.S. government, LeDuc was cautious about placing blame on the Wuhan Institute of Virology.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009604

"I certainly wouldn't say that there isn't a possibility for something to get released out of our laboratory or any other lab around the world," LeDuc said. "I can say there are redundant safety mechanisms in place both here, and certainly in Wuhan, that guard against that.

"But sometimes accidents happen," he said

LeDuc is a former U.S. Centers for Disease Control official who once led the office responsible for preventing deaths from viral disease.

LeDuc wasn't just speculating about the safety of the Wuhan lab. The Galveston National Lab at the University of Texas Medical Branch has a years-long relationship with the facility and its researchers.

LeDuc, who visited the Wuhan lab while it was under construction in 2017, said it is comparable in quality and safety to biosafety labs in the United State and Europe.

Questions about the role of the Wuhan lab have increased in recent days because of statements by President Donald Trump and other political leaders. A widely read column in The Washington Post also raised new questions about where the virus originated.

Wuhan, a city in eastern China, was the site of the first major outbreak of the coronavirus. Speculation about the lab as the source of the outbreak has been fueled by multiple factors, including its location and by the efforts of the Chinese government to tamp down on reporting about the virus outbreak.

Recent news about the Wuhan lab has included mentions of the Galveston National Laboratory and the medical branch's connection to the Chinese lab.

WHAT IS THE CONNECTION?

The Galveston lab has worked with China since 2013, when construction began on the Wuhan laboratory. Both the Galveston and Wuhan research facilities

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009605

operate Biosafety Level 4 laboratories, which are designed to safely contain the most lethal and infectious pathogens for research, LeDuc said.

While the Wuhan lab was under construction, the National Lab provided "short-term training experiences" to the staff, LeDuc said. The Galveston lab also hosted two Chinese post-doctoral students, who were trained to work safely in BSL-4 laboratories and who returned to China to work in the Wuhan lab, LeDuc said.

Those students started a biosafety and biocontainment training program for the Wuhan lab, LeDuc said.

The National Laboratory's role in training researchers from China isn't unusual. Between 2008 and 2016, the National Lab's National Biocontainment Training Center was funded the by U.S. Department of Defense to teach researchers from about 70 countries on laboratory safety techniques.

Defense department funding for the training center ended in 2016. Since then, the Galveston National Laboratory hasn't offered training to international researchers, LeDuc said.

QUESTIONS ABOUT TRAINING

Claims about a lack of training have been at the center of the latest news about the Wuhan lab's connection to the coronavirus outbreak.

On April 14, Washington Post opinion columnist Josh Rogin reported on U.S. State Department cables, written in 2018, that warned about safety management weaknesses at the Wuhan lab.

Rogin interviewed an unnamed U.S. official who called the cables a "warning shot" meant to bring more attention and support to the lab. The cables said the Wuhan lab had a shortage of trained technicians and researchers. Despite the cables, no extra U.S. assistance was given to the lab, Rogin said.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009606

In recent months, the cables have circulated among Trump administration officials as possible evidence the coronavirus was released in China as the result of a lab accident, Rogin said. On the same day as Rogin's column, Yahoo News published its own report about the Trump administration's speculation about the Wuhan Lab that emphasized there was no hard evidence for the connection.

The intelligence community "has not come down on any one theory," about the origins of the virus, the Yahoo story said.

LeDuc didn't know anything about the State Department cables, he said. He didn't think the comments about training were a direct reference to the Galveston National Laboratory or its programs, he said.

Rogin's report focuses on the concerns about Wuhan's BSL-4 lab. The Yahoo article and the CDC's own website note that coronavirus samples can be handled safely in laboratories with lower safety levels.

The Galveston National Laboratory received a sample of the coronavirus for research in February. Since then, researchers have worked with the virus in the medical branch's BSL-3 and BSL-4 laboratories, officials confirmed Tuesday.

After the Washington Post column was published, some conservative news organizations, including Fox News, reported about "increased confidence," again from unnamed U.S. officials about the Wuhan lab being the origin of the virus. On Saturday, Trump said China should face consequences if it was "knowingly responsible" for releasing the virus.

The director of the Wuhan lab on Tuesday denied any connection between the lab and the outbreak. Also on Tuesday, the World Health Organization said evidence shows the virus likely originated in animals and that it was not manipulated or constructed in a laboratory.

LeDuc had similar sentiments about the origins of the coronavirus.

"There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009607

nature, given its high similarity to other known bat-associated coronaviruses," LeDuc said.

John Wayne Ferguson: 409-683-5226; john.ferguson@galvnews.com or on Twitter @johnwferguson.

- Facebook
- Twitter
- WhatsApp
- SMS
- Email

Sent from my iPhone8 Plus

On Apr 22, 2020, at 5:36 PM, Raimer, Ben G. <bgraimer@utmb.edu> wrote:

Thank you Raul.

-----Original Message-----
From: Reyes, Raul <rareyes@UTMB.EDU>
Sent: Wednesday, April 22, 2020 4:00 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>; Lidstone, Sheila <shlidsto@UTMB.EDU>; Campbell, Stephen <stepcamp@UTMB.EDU>; Raimer, Ben G. <bgraimer@UTMB.EDU>
Cc: Koopmann, Kurt E. <kekoopma@UTMB.EDU>; Ramirez, Donna R. <d1ramire@UTMB.EDU>
Subject: Dr. Le Duc, HC and GDN

Good afternoon all.

Dr. Le Duc has spoken to the GDN and the HC in separate interviews.

In response to whether he thought that the virus could have escaped from a lab in Wuhan, Dr. Le Duc essentially said that we don't know. He pointed out all the safety redundancies that the lab there and the GNL have.

"You know there's always a risk of something going wrong." "Did that happen here? I have no idea."

Also, Dr. Le Duc was asked about the possibility of accidents by the Chronicle reporter "You do your best to prevent it. All I can say is that their lab was built with a bunch of safety redundancies...it would be foolish to say that there are no accidents.".

Both reporters asked about the State Department cables and Dr. Le Duc said that he hadn't seen the cables and could not speak to that specifically.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009608

Both reporters wanted to know about the training that we had provided and Dr. Le Duc provided some good explanations. He also stressed why we think that the training is important because we want everyone to be safe and no one wants to have an accident or get sick.

I will send copies of the stories once they are posted or published.

Thank you everyone,

Raul

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009609

中国科学院
CHINESE ACADEMY OF SCIENCES

地址：中国·北京三里河路52号
邮编：100864
Add: 52 Sanlihe Rd., Beijing, China
Postcode: 100864

April 28, 2020

Dr. Marcia McNutt
President
National Academy of Sciences

Dr. Victor Dzau
President
National Academy of Medicine

Dear Drs. McNutt and Dzau,

Thank you for your letter dated April 22. Please accept our deepest sympathies for the enormous suffering and loss of life in the United States. We appreciate the great efforts and leadership of NASEM during the unprecedented crisis.

The battle against COVID-19 has made us more aware that we are in a community with shared future. The pressing pandemic requires us to rise to the occasion and meet this challenge with solidarity and concerted efforts. Nevertheless, we also notice that the bilateral scientific exchange and cooperation between our two nations has been adversely affected by politics and biased arguments recently. As science academies, we should seek truth with evidence and fulfill our responsibilities of jointly addressing this international crisis in an open and collaborative manner.

We are pleased to accept your proposal to jointly organize a virtual dialogue meeting on mitigation of COVID-19 impact and prevention of future pandemics. Apart from scientists from CAS and CCDC, we also plan to bring some members of the Chinese Academy of Engineering into the dialogue. Dr. Fu Gao could serve as the lead coordinator from our end. We agree with the principle of not inviting high-level government officials or press to the videoconference, and not attributing remarks and discussion comments without permission of speakers. For your information, the health ministers from our two countries have recently agreed to hold a virtual dialogue to share expertise and experience on COVID-19 prevention and control in the coming weeks.

As China will have a national holiday during May 1-5, we propose that the first online dialogue be held in the week of May 10, preferably on May 12 or 13. Please let us know the lead coordinator from the US side, so that Dr. Gao will follow up with him/her on topics of mutual interest and corresponding speakers soon. My colleagues from CAS Bureau of International Cooperation will assist Dr. Gao on the specifics of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010037

the videoconference preparation. In the meantime, please feel free to let us know should you have any further concerns.

Sincerely,

Prof. Chunli Bai
President
Chinese Academy of Sciences

Prof. Fu Gao
Director
CCDC

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Lowenthal, Micah;'Frances Sharples'
Cc: Bowman, Katherine
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Letter to NASEM Presidents.pdf

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009956

Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident

发送时间： 2020-04-23 20:50:33

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'

抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'

主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System

中国科学院
CHINESE ACADEMY OF SCIENCES

地址：中国·北京三里河路52号
邮编：100864
Add: 52 Sanlihe Rd., Beijing, China
Postcode: 100864

April 28, 2020

Dr. Marcia McNutt
President
National Academy of Sciences

Dr. Victor Dzau
President
National Academy of Medicine

Dear Drs. McNutt and Dzau,

Thank you for your letter dated April 22. Please accept our deepest sympathies for the enormous suffering and loss of life in the United States. We appreciate the great efforts and leadership of NASEM during the unprecedented crisis.

The battle against COVID-19 has made us more aware that we are in a community with shared future. The pressing pandemic requires us to rise to the occasion and meet this challenge with solidarity and concerted efforts. Nevertheless, we also notice that the bilateral scientific exchange and cooperation between our two nations has been adversely affected by politics and biased arguments recently. As science academies, we should seek truth with evidence and fulfill our responsibilities of jointly addressing this international crisis in an open and collaborative manner.

We are pleased to accept your proposal to jointly organize a virtual dialogue meeting on mitigation of COVID-19 impact and prevention of future pandemics. Apart from scientists from CAS and CCDC, we also plan to bring some members of the Chinese Academy of Engineering into the dialogue. Dr. Fu Gao could serve as the lead coordinator from our end. We agree with the principle of not inviting high-level government officials or press to the videoconference, and not attributing remarks and discussion comments without permission of speakers. For your information, the health ministers from our two countries have recently agreed to hold a virtual dialogue to share expertise and experience on COVID-19 prevention and control in the coming weeks.

As China will have a national holiday during May 1-5, we propose that the first online dialogue be held in the week of May 10, preferably on May 12 or 13. Please let us know the lead coordinator from the US side, so that Dr. Gao will follow up with him/her on topics of mutual interest and corresponding speakers soon. My colleagues from CAS Bureau of International Cooperation will assist Dr. Gao on the specifics of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009958

the videoconference preparation. In the meantime, please feel free to let us know should you have any further concerns.

Sincerely,

Prof. Chunli Bai
President
Chinese Academy of Sciences

Prof. Fu Gao
Director
CCDC

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W.; Dave Franz (davidrfranz@gmail.com); Lowenthal, Micah; 'Frances Sharples'
Cc: Bowman, Katherine
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Letter to NASEM Presidents.pdf

Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124691

Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident

发送时间： 2020-04-23 20:50:33

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'

抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'

主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124692

中国科学院
CHINESE ACADEMY OF SCIENCES

地址：中国·北京三里河路52号
邮编：100864
Add: 52 Sanlihe Rd., Beijing, China
Postcode: 100864

April 28, 2020

Dr. Marcia McNutt
President
National Academy of Sciences

Dr. Victor Dzau
President
National Academy of Medicine

Dear Drs. McNutt and Dzau,

Thank you for your letter dated April 22. Please accept our deepest sympathies for the enormous suffering and loss of life in the United States. We appreciate the great efforts and leadership of NASEM during the unprecedented crisis.

The battle against COVID-19 has made us more aware that we are in a community with shared future. The pressing pandemic requires us to rise to the occasion and meet this challenge with solidarity and concerted efforts. Nevertheless, we also notice that the bilateral scientific exchange and cooperation between our two nations has been adversely affected by politics and biased arguments recently. As science academies, we should seek truth with evidence and fulfill our responsibilities of jointly addressing this international crisis in an open and collaborative manner.

We are pleased to accept your proposal to jointly organize a virtual dialogue meeting on mitigation of COVID-19 impact and prevention of future pandemics. Apart from scientists from CAS and CCDC, we also plan to bring some members of the Chinese Academy of Engineering into the dialogue. Dr. Fu Gao could serve as the lead coordinator from our end. We agree with the principle of not inviting high-level government officials or press to the videoconference, and not attributing remarks and discussion comments without permission of speakers. For your information, the health ministers from our two countries have recently agreed to hold a virtual dialogue to share expertise and experience on COVID-19 prevention and control in the coming weeks.

As China will have a national holiday during May 1-5, we propose that the first online dialogue be held in the week of May 10, preferably on May 12 or 13. Please let us know the lead coordinator from the US side, so that Dr. Gao will follow up with him/her on topics of mutual interest and corresponding speakers soon. My colleagues from CAS Bureau of International Cooperation will assist Dr. Gao on the specifics of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124693

the videoconference preparation. In the meantime, please feel free to let us know should you have any further concerns.

Sincerely,

Prof. Chunli Bai
President
Chinese Academy of Sciences

Prof. Fu Gao
Director
CCDC

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Wednesday, April 29, 2020 8:37 AM
To: Rusek, Benjamin;Dave Franz (davidrfranz@gmail.com);Lowenthal, Micah;'Frances Sharples';Shi, Pei yong
Cc: Bowman, Katherine
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057653

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_057654

From: LeDuc, James W.
Sent: Wednesday, April 29, 2020 8:37 AM
To: Rusek, Benjamin; Dave Franz (davidrfranz@gmail.com); Lowenthal, Micah; 'Frances Sharples'; Shi, Pei yong
Cc: Bowman, Katherine
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126281

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126282

From: LeDuc, James W.
Sent: Wednesday, April 29, 2020 8:37 AM
To: Rusek, Benjamin; Dave Franz (davidrfranz@gmail.com); Lowenthal, Micah; 'Frances Sharples'; Shi, Pei yong
Cc: Bowman, Katherine
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124801

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124802

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 9:14 AM
To: LeDuc, James W.; Dave Franz (davidrfranz@gmail.com); 'Diane Griffin'; Peggy Hamburg
Cc: Bowman, Katherine; Boright, John; 'Frances Sharples'; Shi, Pei yong; Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Letter to CCDC CAS re virtual dialogue April 22 2020.pdf; Letter to NASEM Presidents.pdf; Agenda draft v1 for Biology and Treatment of Covid-19.docx

Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124699

Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124700

Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident

发送时间： 2020-04-23 20:50:33

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'

抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'

主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124701

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124702

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124703

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124704

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124705

中国科学院
CHINESE ACADEMY OF SCIENCES

地址：中国·北京三里河路52号
邮编：100864
Add: 52 Sanlihe Rd., Beijing, China
Postcode: 100864

April 28, 2020

Dr. Marcia McNutt
President
National Academy of Sciences

Dr. Victor Dzau
President
National Academy of Medicine

Dear Drs. McNutt and Dzau,

Thank you for your letter dated April 22. Please accept our deepest sympathies for the enormous suffering and loss of life in the United States. We appreciate the great efforts and leadership of NASEM during the unprecedented crisis.

The battle against COVID-19 has made us more aware that we are in a community with shared future. The pressing pandemic requires us to rise to the occasion and meet this challenge with solidarity and concerted efforts. Nevertheless, we also notice that the bilateral scientific exchange and cooperation between our two nations has been adversely affected by politics and biased arguments recently. As science academies, we should seek truth with evidence and fulfill our responsibilities of jointly addressing this international crisis in an open and collaborative manner.

We are pleased to accept your proposal to jointly organize a virtual dialogue meeting on mitigation of COVID-19 impact and prevention of future pandemics. Apart from scientists from CAS and CCDC, we also plan to bring some members of the Chinese Academy of Engineering into the dialogue. Dr. Fu Gao could serve as the lead coordinator from our end. We agree with the principle of not inviting high-level government officials or press to the videoconference, and not attributing remarks and discussion comments without permission of speakers. For your information, the health ministers from our two countries have recently agreed to hold a virtual dialogue to share expertise and experience on COVID-19 prevention and control in the coming weeks.

As China will have a national holiday during May 1-5, we propose that the first online dialogue be held in the week of May 10, preferably on May 12 or 13. Please let us know the lead coordinator from the US side, so that Dr. Gao will follow up with him/her on topics of mutual interest and corresponding speakers soon. My colleagues from CAS Bureau of International Cooperation will assist Dr. Gao on the specifics of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124706

the videoconference preparation. In the meantime, please feel free to let us know should you have any further concerns.

Sincerely,

Prof. Chunli Bai
President
Chinese Academy of Sciences

Prof. Fu Gao
Director
CCDC

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 9:14 AM
To: LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);'Diane Griffin';Peggy Hamburg
Cc: Bowman, Katherine;Boright, John;'Frances Sharples';Shi, Pei yong;Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Letter to CCDC CAS re virtual dialogue April 22 2020.pdf; Letter to NASEM Presidents.pdf; Agenda draft v1 for Biology and Treatment of Covid-19.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010175

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29
SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010176

http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010177

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 22, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

Please accept our sympathies for the hardship and loss of life in China. We in the United States are now deep into our own suffering under the COVID-19 pandemic. As China begins to recover and reopen, China now has extensive experience dealing with COVID-19 and Chinese scientists have much to share as the rest of the world continues to battle the virus. We are writing to ask you, as leaders of the Chinese Center for Disease Control and Prevention (CCDC) and the Chinese Academy of Sciences (CAS) to approve and designate Chinese scientists to participate in a virtual dialogue meeting (video teleconference) to discuss mitigating the impact of COVID-19 and preventing future pandemics.

As you know, over the past five years, we along with Dr. James Le Duc, Dr. David Franz, Dr. Pei-Yong Shi, and several other representatives of the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with both of you and other Chinese scientists to organize a series of dialogue meetings on disease research; on combating emerging infections; on collaboration and data sharing; and on laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings. Our dialogue has focused on preparing for and mitigating the very situation we face with COVID-19.

Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the scientific community to better understand and combat the outbreak. We hope that a meeting between our scientists can address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A list of more detailed questions related to these five topics is appended to the end of this letter.

FOIA Confidential Treatment Requested by Univ of Texas System

NASEM is willing to facilitate and host a virtual dialogue discussion using Zoom video conference software or any other mutually acceptable medium. We hope that Chinese participants can include scientists and laboratory directors who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants would include Academy members and other top-flight American researchers, but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. After your approval we would like to hold the virtual meeting as early as possible. The first week of May would be ideal; and, if the participants feel it would be useful, a follow-on meeting could be held later in the month.

Thank you for your efforts and leadership during this remarkably difficult period. We hope that you will embrace this opportunity to assist the United States and the rest of the world to combat and recover from this pandemic.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

Diane Griffin
Vice President,
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010179

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010180

- What lessons has China learned about returning society and the economy to a "normal" state?
- What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
- What are the most fruitful areas of future scientific collaborations between our countries in this area?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010181

中国科学院
CHINESE ACADEMY OF SCIENCES

地址：中国·北京三里河路52号
邮编：100864
Add: 52 Sanlihe Rd., Beijing, China
Postcode: 100864

April 28, 2020

Dr. Marcia McNutt
President
National Academy of Sciences

Dr. Victor Dzau
President
National Academy of Medicine

Dear Drs. McNutt and Dzau,

Thank you for your letter dated April 22. Please accept our deepest sympathies for the enormous suffering and loss of life in the United States. We appreciate the great efforts and leadership of NASEM during the unprecedented crisis.

The battle against COVID-19 has made us more aware that we are in a community with shared future. The pressing pandemic requires us to rise to the occasion and meet this challenge with solidarity and concerted efforts. Nevertheless, we also notice that the bilateral scientific exchange and cooperation between our two nations has been adversely affected by politics and biased arguments recently. As science academies, we should seek truth with evidence and fulfill our responsibilities of jointly addressing this international crisis in an open and collaborative manner.

We are pleased to accept your proposal to jointly organize a virtual dialogue meeting on mitigation of COVID-19 impact and prevention of future pandemics. Apart from scientists from CAS and CCDC, we also plan to bring some members of the Chinese Academy of Engineering into the dialogue. Dr. Fu Gao could serve as the lead coordinator from our end. We agree with the principle of not inviting high-level government officials or press to the videoconference, and not attributing remarks and discussion comments without permission of speakers. For your information, the health ministers from our two countries have recently agreed to hold a virtual dialogue to share expertise and experience on COVID-19 prevention and control in the coming weeks.

As China will have a national holiday during May 1-5, we propose that the first online dialogue be held in the week of May 10, preferably on May 12 or 13. Please let us know the lead coordinator from the US side, so that Dr. Gao will follow up with him/her on topics of mutual interest and corresponding speakers soon. My colleagues from CAS Bureau of International Cooperation will assist Dr. Gao on the specifics of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010182

the videoconference preparation. In the meantime, please feel free to let us know should you have any further concerns.

Sincerely,

Prof. Chunli Bai
President
Chinese Academy of Sciences

Prof. Fu Gao
Director
CCDC

FOIA Confidential Treatment Requested by Univ of Texas System

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Wednesday, April 29, 2020 9:47 AM
To: Rusek, Benjamin;LeDuc, James W.;Dave Franz (davidrfranz@gmail.com);Peggy Hamburg
Cc: Bowman, Katherine;Boright, John;'Frances Sharples';Shi, Pei yong;Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010000

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010001

Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010002

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Wednesday, April 29, 2020 9:47 AM
To: Rusek, Benjamin; LeDuc, James W.; Dave Franz (davidrfranz@gmail.com); Peggy Hamburg
Cc: Bowman, Katherine; Boright, John; 'Frances Sharples'; Shi, Pei yong; Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126270

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126271

Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126272

From: Bowman, Katherine <KBowman@nas.edu>
Sent: Thursday, April 30, 2020 10:45 AM
To: Peggy Hamburg; Frances Sharples; Dave Franz; Diane Griffin; Rusek, Benjamin; LeDuc, James W.; Boright, John; Shi, Pei yong; Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

> On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:
>
> Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave
>
> > On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:
> >
> > Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123866

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123867

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123868

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123869

From: Bowman, Katherine <KBowman@nas.edu>
Sent: Thursday, April 30, 2020 10:45 AM
To: Peggy Hamburg;Frances Sharples;Dave Franz;Diane Griffin;Rusek, Benjamin;LeDuc, James W.;Boright, John;Shi, Pei yong;Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

> On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:
>
> Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave
>
> > On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:
> >
> > Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010073

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010074

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010075

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010076

From: Frances Sharples <fsharples_3@hotmail.com>
Sent: Thursday, April 30, 2020 1:38 PM
To: Bowman, Katherine;Peggy Hamburg;Dave Franz;Diane Griffin;Rusek, Benjamin;LeDuc, James W.;Boright, John;Shi, Pei yong;Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Peter Daszak has, in fact, been collecting corona viruses in China. Perhaps he should be on the call?

From: Bowman, Katherine <KBowman@nas.edu>
Sent: Thursday, April 30, 2020 11:44 AM
To: Peggy Hamburg <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010049

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010050

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010051

'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010052

From: Frances Sharples <fsharples_3@hotmail.com>
Sent: Thursday, April 30, 2020 1:38 PM
To: Bowman, Katherine; Peggy Hamburg; Dave Franz; Diane Griffin; Rusek, Benjamin; LeDuc, James W.; Boright, John; Shi, Pei yong; Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Peter Daszak has, in fact, been collecting corona viruses in China. Perhaps he should be on the call?

From: Bowman, Katherine <KBowman@nas.edu>
Sent: Thursday, April 30, 2020 11:44 AM
To: Peggy Hamburg <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123862

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123863

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123864

'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123865

From: LeDuc, James W.
Sent: Thursday, April 30, 2020 2:19 PM
To: Rusek, Benjamin; 'Peggy Hamburg'; Frances Sharples; Bowman, Katherine
Cc: Dave Franz; Diane Griffin; Boright, John; Shi, Pei yong; Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Oxley-2020-Large-Vessel Stroke as a Presenting.pdf

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123839

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123840

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123841

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123842

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123843

Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123844

http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123845

From: LeDuc, James W.
Sent: Thursday, April 30, 2020 2:19 PM
To: Rusek, Benjamin;'Peggy Hamburg';Frances Sharples;Bowman, Katherine
Cc: Dave Franz;Diane Griffin;Boright, John;Shi, Pei yong;Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Oxley-2020-Large-Vessel Stroke as a Presenting.pdf

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001845

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001846

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001847

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001848

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001849

Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001850

http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001851

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Thursday, April 30, 2020 4:53 PM
To: LeDuc, James W.; Rusek, Benjamin; 'Peggy Hamburg'; Frances Sharples; Bowman, Katherine
Cc: Dave Franz; Boright, John; Shi, Pei yong; Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

All - I think that Peter Daszak is a good idea. Also, the idea of a 2-day dialogue is attractive - lots of issues and will make things a little less rushed. I like the topics of control (what worked and didn't), how to go back to normal, evidence of late transmission, what do we know about Ab, did anyone with a previous Hx of SARS become infected/sick, unusual complications/virus replication outside the/ respiratory tract/autopsy data, etc? We have a lot to learn from their experience.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126273

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126274

- Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
- How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
- Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126275

<JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126276

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126277

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126278

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126279

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126280

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Thursday, April 30, 2020 4:53 PM
To: LeDuc, James W.;Rusek, Benjamin;'Peggy Hamburg';Frances Sharples;Bowman, Katherine
Cc: Dave Franz;Boright, John;Shi, Pei yong;Lowenthal, Micah
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

All - I think that Peter Daszak is a good idea. Also, the idea of a 2-day dialogue is attractive - lots of issues and will make things a little less rushed. I like the topics of control (what worked and didn't), how to go back to normal, evidence of late transmission, what do we know about Ab, did anyone with a previous Hx of SARS become infected/sick, unusual complications/virus replication outside the/ respiratory tract/autopsy data, etc? We have a lot to learn from their experience.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010003

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010004

- Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
- How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
- Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010005

<JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010006

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010007

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010008

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010009

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010010

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 30, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

We were very pleased to receive you letter dated April 28, 2020, agreeing to conduct virtual dialogue meetings on both mitigation of COVID-19 impacts and prevention of future pandemics. For these meetings, Dr. Diane Griffin will lead the U.S. participation and Mr. Ben Rusek will be the staff contact supporting Dr. Griffin to coordinate schedules, the medium (what software platform will be used), and correspondence on the agenda. Your proposal to hold the first meeting on May 12 or 13 will work for our group. We will leave it to Drs. Griffin and Gao and Mr. Rusek to work out the details.

We agree that our Academies should address this international crisis in an open and collaborative manner based on facts and science. This is a critically important role for scientists to fulfill at times of global threat and need. We look forward to working together for the benefit of our countries and the world.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 30, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

We were very pleased to receive you letter dated April 28, 2020, agreeing to conduct virtual dialogue meetings on both mitigation of COVID-19 impacts and prevention of future pandemics. For these meetings, Dr. Diane Griffin will lead the U.S. participation and Mr. Ben Rusek will be the staff contact supporting Dr. Griffin to coordinate schedules, the medium (what software platform will be used), and correspondence on the agenda. Your proposal to hold the first meeting on May 12 or 13 will work for our group. We will leave it to Drs. Griffin and Gao and Mr. Rusek to work out the details.

We agree that our Academies should address this international crisis in an open and collaborative manner based on facts and science. This is a critically important role for scientists to fulfill at times of global threat and need. We look forward to working together for the benefit of our countries and the world.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 30, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

We were very pleased to receive you letter dated April 28, 2020, agreeing to conduct virtual dialogue meetings on both mitigation of COVID-19 impacts and prevention of future pandemics. For these meetings, Dr. Diane Griffin will lead the U.S. participation and Mr. Ben Rusek will be the staff contact supporting Dr. Griffin to coordinate schedules, the medium (what software platform will be used), and correspondence on the agenda. Your proposal to hold the first meeting on May 12 or 13 will work for our group. We will leave it to Drs. Griffin and Gao and Mr. Rusek to work out the details.

We agree that our Academies should address this international crisis in an open and collaborative manner based on facts and science. This is a critically important role for scientists to fulfill at times of global threat and need. We look forward to working together for the benefit of our countries and the world.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

April 30, 2020

RE: Virtual Dialogue Meeting

Dr. Gao Fu
Director-General
Chinese Center for Disease Control and Prevention

Dr. Bai Chunli
President
Chinese Academy of Sciences

Dear Drs. Gao and Bai:

We were very pleased to receive you letter dated April 28, 2020, agreeing to conduct virtual dialogue meetings on both mitigation of COVID-19 impacts and prevention of future pandemics. For these meetings, Dr. Diane Griffin will lead the U.S. participation and Mr. Ben Rusek will be the staff contact supporting Dr. Griffin to coordinate schedules, the medium (what software platform will be used), and correspondence on the agenda. Your proposal to hold the first meeting on May 12 or 13 will work for our group. We will leave it to Drs. Griffin and Gao and Mr. Rusek to work out the details.

We agree that our Academies should address this international crisis in an open and collaborative manner based on facts and science. This is a critically important role for scientists to fulfill at times of global threat and need. We look forward to working together for the benefit of our countries and the world.

Sincerely,

Marcia McNutt
President
National Academy of Sciences

Victor Dzau
President
National Academy of Medicine

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 11:13 AM
To: LeDuc, James W.;Frances Sharples
Cc: Dave Franz;Diane Griffin;Shi, Pei yong;Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Agenda draft MAH edits Covid-19.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009987

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009988

- Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
- Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
- Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009989

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009990

W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009991

1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009992

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009993

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 11:13 AM
To: LeDuc, James W.; Frances Sharples
Cc: Dave Franz; Diane Griffin; Shi, Pei yong; Lowenthal, Micah
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Agenda draft MAH edits Covid-19.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126283

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126284

- Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
- Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
- Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126285

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126286

W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126287

1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126288

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_126289

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 4:19 PM
To: LeDuc, James W.;'Dave Franz';'Diane Griffin';'Peggy Hamburg'
Cc: Shi, Pei yong;Lowenthal, Micah;'Frances Sharples'
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Draft email from DG to GG re virtual dialogue.docx; Draft Covid-19 US-China dialogue agenda v3 ml fs br.docx; Draft invite letter re virtual dialogue May1 2020 v2.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi everyone,

Looping in Peggy. After the call today Fran, Micah and I revised the topic list. The list is now split into two in case we are able to hold two sessions on two back to back days as will be proposed. The shaded bullets are "secondary" questions. We also drafted a letter for George Gao (for Diane to send as an email once the topic list is final) and a draft letter to inform and invite additional American participants that I can send on behalf of the group. So far, in addition to everyone on this email the invite list I have is Linda Saif, David Relman, Ralph Baric, Peter Daszak, Stan Perman, as well as Harvey Feinberg and Victor Dzau. Should we invite others?

Please review the attached documents as soon as you can, would like to get the note out to George asap and the invite to the other Americans as soon as possible.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 1, 2020 12:13 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Frances Sharples <fsharples_3@hotmail.com>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007948

<fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007949

- Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
- What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
- Do "recovered" patients continue to shed infectious virus? If yes, for how long?
- After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007950

- What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638

FOIA Confidential Treatment Requested by Univ of Texas System

Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor

FOIA Confidential Treatment Requested by Univ of Texas System

sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007953

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007954

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

RE: Virtual Dialogue Meeting with Chinese experts fighting and studying COVID-19

I am writing to ask you to participate in a virtual bilateral dialogue meeting[1] between Chinese and American experts studying and fighting the COVID-19 pandemic.

As China begins to recover and reopen, China's scientists, doctors, and public health officials have extensive experience dealing with COVID-19 and have much to share as the rest of the world continues to battle the virus. Chinese scientists now have unique knowledge about responding to and mitigating COVID-19, so are in a position to help the American scientific and clinical communities to better understand and combat the pandemic.

The Presidents of NAS (Marcia McNutt) and NAM (Victor Dzau), along with the leadership of the CCDC and the CAS have agreed to designate American and Chinese experts to participate in an invitation only virtual dialogue meeting (video teleconference) to discuss what has been learned thus far from the pandemic, how to mitigate its impact , and preventing future pandemics. Diane Griffin, Vice President of the NAS and George Gao, Director of the CCDC will chair the dialogue. They have agreed to hold the meeting on May 11, 12 and/or 13. The meeting (two, 2 hour sessions on back to back days proposed) will likely take place during the evening/night hours of May 11 and May 12 for Americans and on the morning of May 12 and 13 for the Chinese. NASEM will facilitate the virtual dialogue discussion using Zoom video conference software or another mutually acceptable medium to be determined.

In general the dialogue meeting will address: (1) The biology of COVID-19; (2) Managing COVID-19 in patients; (3) Limiting the spread of COVID-19; (4) Drug and vaccine development; and (5) Preventing and managing future epidemics and pandemics. A draft agenda with more detailed subtopics/questions we expect to address is below this letter.

We expect that the Chinese participants will include scientists, laboratory directors, and medical officials who are leading the response as well as those who have participated in previous dialogue sessions. American meeting participants will include Academy members and other top-flight American researchers, some who are serving on the NASEM *Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats,* but not government officials or members of the press. Information and insights from the meeting that may promote improved response to the pandemic will be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker. If you are interested and agree to participate please let us know as soon as possible. The American participants plan to hold a preparatory discussion on the evening of May 7.

---

[1]Over the past five years, the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) lead by Dr. James Le Duc and several other representatives have worked with Chinese organizations and experts to organize a series of dialogue meetings on disease research; combating emerging infections; collaboration and data sharing; and laboratory management. The dialogue meetings have been attended by leading scientists from NASEM, the Chinese Center for Disease Control and Prevention (CCDC), the Chinese Academy of Sciences (CAS), the Chinese Academy of Agricultural Sciences, and the Chinese Academy of Medical Sciences. The meetings have enabled scientists from China and the United States to exchange research findings; share best practices in biosafety, biosecurity and biocontainment laboratory operations; reflect on lessons learned; and establish new collaborative partnerships in areas identified during the meetings.

FOIA Confidential Treatment Requested by Univ of Texas System

We hope that you will embrace this opportunity to discuss these issues and question with key Chinese experts and that this effort ultimately helps the world combat and recover from this terrible pandemic.

Sincerely,

Diane Griffin
Vice President
National Academy of Sciences

Margaret Hamburg
Foreign secretary
National Academy of Medicine

Additional points of contact:

James Le Duc
Director, Galveston National Laboratory
jwleduc@utmb.edu, 1.409.266.6500

Benjamin Rusek
Senior Program Officer, NASEM
brusek@nas.edu 1.202.334.3975

Appendix: Proposed topics for virtual dialogue meeting:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007960

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Friday, May 1, 2020 5:31 PM
To: Rusek, Benjamin;LeDuc, James W.;'Dave Franz';'Diane Griffin'
Cc: Shi, Pei yong;Lowenthal, Micah;'Frances Sharples'
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Terrific. This is all good news. I think you have a good mix of invitees on our side. If we add too many more it will be hard to have much of a dialogue. Will reflect on if we are missing someone or a category of person though.....

All best,
Peggy

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 5:18 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; 'Diane Griffin' <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi everyone,

Looping in Peggy. After the call today Fran, Micah and I revised the topic list. The list is now split into two in case we are able to hold two sessions on two back to back days as will be proposed. The shaded bullets are "secondary" questions. We also drafted a letter for George Gao (for Diane to send as an email once the topic list is final) and a draft letter to inform and invite additional American participants that I can send on behalf of the group. So far, in addition to everyone on this email the invite list I have is Linda Saif, David Relman, Ralph Baric, Peter Daszak, Stan Perman, as well as Harvey Feinberg and Victor Dzau. Should we invite others?

Please review the attached documents as soon as you can, would like to get the note out to George asap and the invite to the other Americans as soon as possible.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 1, 2020 12:13 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Frances Sharples <fsharples_3@hotmail.com>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007924

Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007925

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007926

- Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
- Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
- What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007927

SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007928

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007929

<fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007930

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax: +86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007931

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Saturday, May 2, 2020 7:28 AM
To: Peggy Hamburg;Rusek, Benjamin;LeDuc, James W.;'Dave Franz'
Cc: Shi, Pei yong;Lowenthal, Micah;'Frances Sharples'
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - I think that this looks fine.

A couple of name spelling edits for our invitees that you have probably already discovered: Perlman, Fineberg

Thanks for reworking the agenda. Let me know when ok to email to George.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Friday, May 1, 2020 6:31 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

Terrific. This is all good news. I think you have a good mix of invitees on our side. If we add too many more it will be hard to have much of a dialogue. Will reflect on if we are missing someone or a category of person though.....

All best,
Peggy

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 5:18 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; 'Diane Griffin'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007907

<dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi everyone,

Looping in Peggy. After the call today Fran, Micah and I revised the topic list. The list is now split into two in case we are able to hold two sessions on two back to back days as will be proposed. The shaded bullets are "secondary" questions. We also drafted a letter for George Gao (for Diane to send as an email once the topic list is final) and a draft letter to inform and invite additional American participants that I can send on behalf of the group. So far, in addition to everyone on this email the invite list I have is Linda Saif, David Relman, Ralph Baric, Peter Daszak, Stan Perman, as well as Harvey Feinberg and Victor Dzau. Should we invite others?

Please review the attached documents as soon as you can, would like to get the note out to George asap and the invite to the other Americans as soon as possible.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 1, 2020 12:13 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Frances Sharples <fsharples_3@hotmail.com>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007908

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007909

- How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
- What has been the Chinese experience with drug treatments for sick patients?
- Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
- Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
- How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
- Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007910

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007911

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007912

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**

2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)

3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007913

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007914

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007915

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 2, 2020 2:26 PM
To: 'Diane Griffin';Peggy Hamburg;LeDuc, James W.;'Dave Franz'
Cc: Shi, Pei yong;Lowenthal, Micah;'Frances Sharples'
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Diane and Peggy,

Do others have comments on the draft documents (specifically the topic list and email note) before Diane sends the email to George Gao?

Please let us know by 5 PM CT / 6PM ET today, would like to get the note out to George tonight so he has it his time Sunday morning.

I will start sending invitations to the Americans (using the letter, will cc this group) tonight as well. Diane, thanks for the spelling corrections.

PS Linda Saif said she could participate.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Saturday, May 2, 2020 8:28 AM
To: Peggy Hamburg <peggy@hbfam.net>; Rusek, Benjamin <BRusek@nas.edu>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

Ben - I think that this looks fine.

A couple of name spelling edits for our invitees that you have probably already discovered: Perlman, Fineberg

Thanks for reworking the agenda. Let me know when ok to email to George.

Diane

Diane E. Griffin, MD PhD

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007779

Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Friday, May 1, 2020 6:31 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

Terrific. This is all good news. I think you have a good mix of invitees on our side. If we add too many more it will be hard to have much of a dialogue. Will reflect on if we are missing someone or a category of person though.....

All best,
Peggy

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 5:18 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; 'Diane Griffin' <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi everyone,

Looping in Peggy. After the call today Fran, Micah and I revised the topic list. The list is now split into two in case we are able to hold two sessions on two back to back days as will be proposed. The shaded bullets are "secondary" questions. We also drafted a letter for George Gao (for Diane to send as an email once the topic list is final) and a draft letter to inform and invite additional American participants that I can send on behalf of the group. So far, in addition to everyone on this email the invite list I have is Linda Saif, David Relman, Ralph Baric, Peter Daszak, Stan Perlman, as well as Harvey Finberg and Victor Dzau. Should we invite others?

Please review the attached documents as soon as you can, would like to get the note out to George asap and the invite to the other Americans as soon as possible.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007780

From: Rusek, Benjamin
Sent: Friday, May 1, 2020 12:13 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Frances Sharples <fsharples_3@hotmail.com>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007781

<peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007782

- Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007783

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007784

615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007785

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007786

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007787

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Saturday, May 2, 2020 3:54 PM
To: Rusek, Benjamin;'Diane Griffin';LeDuc, James W.;'Dave Franz'
Cc: Shi, Pei yong;Lowenthal, Micah;'Frances Sharples'
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

looks good to me. thanks
Peggy

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 2, 2020 3:26 PM
To: 'Diane Griffin' <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Diane and Peggy,

Do others have comments on the draft documents (specifically the topic list and email note) before Diane sends the email to George Gao?

Please let us know by 5 PM CT / 6PM ET today, would like to get the note out to George tonight so he has it his time Sunday morning.

I will start sending invitations to the Americans (using the letter, will cc this group) tonight as well. Diane, thanks for the spelling corrections.

PS Linda Saif said she could participate.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Saturday, May 2, 2020 8:28 AM
To: Peggy Hamburg <peggy@hbfam.net>; Rusek, Benjamin <BRusek@nas.edu>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007758

<fsharples_3@hotmail.com>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

Ben - I think that this looks fine.

A couple of name spelling edits for our invitees that you have probably already discovered: Perlman, Fineberg

Thanks for reworking the agenda. Let me know when ok to email to George.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Friday, May 1, 2020 6:31 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

Terrific. This is all good news. I think you have a good mix of invitees on our side. If we add too many more it will be hard to have much of a dialogue. Will reflect on if we are missing someone or a category of person though.....

All best,
Peggy

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 1, 2020 5:18 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; 'Dave Franz' <davidrfranz@gmail.com>; 'Diane Griffin' <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: 'Shi, Pei yong' <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi everyone,

Looping in Peggy. After the call today Fran, Micah and I revised the topic list. The list is now split into two in case we are able to hold two sessions on two back to back days as will be proposed. The shaded bullets are "secondary" questions. We also drafted a letter for George Gao (for Diane to send as an email once the topic list is final) and a draft letter to inform and invite additional American participants that I can send on behalf of the group. So far, in addition to everyone

FOIA Confidential Treatment Requested by Univ of Texas System

on this email the invite list I have is Linda Saif, David Relman, Ralph Baric, Peter Daszak, Stan Perlman, as well as Harvey Finberg and Victor Dzau. Should we invite others?

Please review the attached documents as soon as you can, would like to get the note out to George asap and the invite to the other Americans as soon as possible.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 1, 2020 12:13 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Frances Sharples <fsharples_3@hotmail.com>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Thursday, April 30, 2020 3:19 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; Frances Sharples <fsharples_3@hotmail.com>; Bowman, Katherine <KBowman@nas.edu>
Cc: Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Thanks Ben and Fran for coordinating the organization of the meeting. I wonder if we should focus some of the discussion on our current US national status of trying to transition back to some semblance of "normal" activities (hopefully) on the downside of the epidemic curve. They instituted a wide range of interventions and they may have good ideas as to what was most effective and what was not. If you believe the press, it looks like they have been successful in their control efforts and perhaps we could learn from them. Some of these are highlighted below and are already mentioned in the working discussion draft agenda commented upon by Peggy.

Also, there is growing recognition of unique aspects of the clinical disease including clotting complications (see NEJM article attached) and possible neurologic involvement (note popular press story about physician suicide). I wonder if we should probe these topics with their clinicians?

I highlighted some topics below that I thought would be most relevant given the brief meeting time.

Do we envision formal presentations or will this be a timed, open discussion of selected topics, perhaps moderated by experts in that specific area from both countries? Also, what is the plan for audience participation and selection of panelists/speakers?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007760

I wonder if it would be possible to hold the meeting on two consecutive days/evenings with each following the 2 hr 15 min format already proposed? That might give both sides an opportunity to consider questions raised on day 1 more thoroughly and respond during the second meeting.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, April 30, 2020 11:46 AM
To: 'Peggy Hamburg' <peggy@hbfam.net>; Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Peggy, thanks for modifying Fran's draft agenda yesterday.

The letter from the presidents to CAS and CCDC proposed questions in 5 topics areas (including questions about vaccine development). Fran's draft agenda that you modified focuses on the first two topics. **Question to everyone: are there other critical questions in the list that you feel we should try to address during the proposed May 12/13 meeting?** Peggy's markup is attached and the original list from the letter is below:

Appendix: Proposed topics for virtual dialogue meeting:

1. **Understanding the biology of COVID-19**
   - What is the rate of evolutionary change in the virus and how quickly does it accumulate mutations? Have mutations impacted the efficacy of treatment, transmissibility or the clinical course of disease?
   - Have there been accurate measurements of incubation period? What factors are responsible for any variability in incubation period?
   - What magnitude of viral load is required to initiate infection? Has it been determined at what point in the course of infections the patient is most infectious? What is the degree of virus shedding among pre-symptomatic/asymptomatic individuals?
   - Do "recovered" patients continue to shed infectious virus? If yes, for how long?
   - After recovery, do patients have immunity? How strong is this immunity and is it likely to be permanent or might it eventually disappear?

2. **Managing COVID-19 in patients**
   - How is China measuring immune response; binding assays versus neutralization tests; use of antibody assays in diagnosis of acute disease and as an indicator of protection?
   - What has been the Chinese experience with drug treatments for sick patients?
   - Were effective non-pharmaceutical interventions (NPIs) for patient care identified?
   - Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?
   - How was the efficacy of either drugs or NPIs and best practices influenced by patient age, gender, general health condition, or other characteristics?
   - Were there any lessons learned from the pandemic that should be applied to future staffing and equipping of hospitals or other patient care facilities?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007761

3. **Limiting the spread of COVID-19**
   - What NPIs proved most effective in halting viral spread in China?
   - Were other best practices for containment used and proven to be effective?
   - Was available technology for testing for viral infection and antibody response adequate? If not, what other or new technologies would be helpful or even essential in the future?
   - Has the Chinese research community arrived at an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients?
   - Has the Chinese research community made progress in understanding the routes of exposure to COVID-19 in air, water, and from surfaces (both indoors and outdoors)?
   - Would practices such as increased surveillance for coronaviruses in pets, wild or livestock animal species or interventions to reduce contact between humans and pets, wild or livestock animal species have a role in limiting the spread of COVID-19 or in preparing for future pandemics?

4. **Drug and vaccine development**
   - Has the Chinese research community made progress in the development of effective drugs to treat COVID-19? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - Has the Chinese research community made progress in the development of COVID-19 vaccines? If yes, would China be willing to share this new knowledge as part of a U.S.-China scientific partnership?
   - What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID patients or prevention of onward spread of disease?

5. **Preventing and managing future epidemics and pandemics**
   - What steps should be taken in anticipation of a fall resurgence in transmission?
   - What lessons has China learned about returning society and the economy to a "normal" state?
   - What observations and determinations from the COVID-19 pandemic are most important for preventing, detecting, and managing future epidemics/pandemics? Based on the answers to 1-4, how can the lessons learned in dealing with COVID-19 so far be used to avert another pandemic?
   - What are the most fruitful areas of future scientific collaborations between our countries in this area?

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Thursday, April 30, 2020 12:07 PM
To: Bowman, Katherine <KBowman@nas.edu>
Cc: Frances Sharples <fsharples_3@hotmail.com>; Dave Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; James W. LeDuc <jwleduc@utmb.edu>; Boright, John <JBoright@nas.edu>; Shi, Pei yong <peshi@utmb.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting

It would clearly be desirable to develop vaccines with efficacy across Coronavirus strains How much to put into this dialogue is an open question still I think. At the moment vaccines are not on agenda at all but probably should be and this could be part of the discussion.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007762

Peggy

Sent from my iPhone

On Apr 30, 2020, at 11:45 AM, Bowman, Katherine <KBowman@nas.edu> wrote:

Wonderful news that a dialogue meeting will be able to take place! This may be far too futuristic given the many immediate needs with Covid-19, but I wanted to float the idea of an additional potential topic in case it could be of interest. It seems likely that scientists from research institutes in China will have had some of the most direct experience analyzing multiple strains of coronavirus – not only SARS and SARS-CoV-2, but also samples identified from animal surveillance. And that there are many other strains of coronaviruses out in the environment that could potentially cross over to humans in the future.

Will all that in mind, I wondered whether there might be a role for sharing information on whether it could be possible to develop vaccines that would provide protection against multiple coronavirus strains, and if so what targets or strategies might seem most promising to explore. If not for a May dialogue meeting, perhaps as an area you could consider exploring for future dialogue meetings in the upcoming year(s).

Best,
Katie

Katherine Bowman, Ph.D.
Board on Life Sciences
The National Academies of Sciences, Engineering, and Medicine
Washington, DC 20001
Phone: 202-334-2638
Email: kbowman@nas.edu

On Apr 29, 2020, at 10:51 AM, Dave Franz <davidrfranz@gmail.com> wrote:

Might the whole set of confusions and data limitations related to serologies and viral shedding be of interest as one of the topics…or is it just me? dave

On Apr 29, 2020, at 10:47 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I think 2-3h is about the max considering that for one of the groups it will be getting late (could we start at 8?). Therefore, 2 topics seems a reasonable plan.

Including Linda, David and Ralph if possible, would be good.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007763

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 10:14 AM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>
Cc: Bowman, Katherine <KBowman@nas.edu>; Boright, John <JBoright@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings,

Diane suggested that staff take the lead on writing a draft response to the attached letter that includes proposing a date and agenda in consultation with you, her, Dave and Peggy with Marcia and Victor sending the response back. I am looping Diane and Peggy into this thread.

I have attached a possible agenda for the call that Fran put together at my request. The agenda draft only covers the first 2 (Scientific Questions and Treatment for and Management of Patients) of the 5 areas listed at the end of the original letter (also attached) with the idea that we might be able to discuss the other topics in a second virtual meeting. A few initial questions to consider:

1) **Since holding one meeting might be all we are able to do what topics do you think are the most important to cover?**
2) **How long do you think the meeting should/can last?** (9 am or pm ET on the 12th or the 13th might be a good time to start it)
3) **What other Americans should be invited?** (I mentioned the meeting to Linda Saif but can reach out to David Relman, Ralph Baric and others at your direction…)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007764

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 29, 2020 9:37 AM
To: Rusek, Benjamin <BRusek@nas.edu>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>; Shi, Pei yong <peshi@UTMB.EDU>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Yes, very good news indeed. Who is organizing the meeting on our side?

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, April 29, 2020 8:21 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Frances Sharples' <fsharples_3@hotmail.com>
Cc: Bowman, Katherine <KBowman@nas.edu>
Subject: FW: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good news from CAS and CCDC.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007765

Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007766

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 2, 2020 7:08 PM
To: Lowenthal, Micah;Frances Sharples;Dave Franz;LeDuc, James W.;Shi, Pei yong
Subject: Fwd: Dialogue plans
Attachments: Draft Covid-19 US-China dialogue agenda.docx; ATT00001.htm; email letter from DG to GG re virtual dialogue.docx; ATT00002.htm

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Fyi

Begin forwarded message:

From: Diane Griffin <dgriffi6@jhmi.edu>
Date: May 2, 2020 at 8:06:04 PM EDT
To: "gaof@im.ac.cn" <gaof@im.ac.cn>
Cc: "jh-cao@cashq.ac.cn" <jh-cao@cashq.ac.cn>, "clbai@cas.cn" <clbai@cas.cn>, liyin <liyin@cashq.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@utmb.edu>, Peggy Hamburg <peggy@hbfam.net>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>
Subject: Dialogue plans

Dear George,

I'm looking forward to our dialogue tentatively planned for about 10 days from now. Attached find an explanatory letter proposing 2 sessions and draft list of topics.
I look forward to hearing your thoughts on how we can best use our time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010086

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 2, 2020 7:08 PM
To: Lowenthal, Micah; Frances Sharples; Dave Franz; LeDuc, James W.; Shi, Pei yong
Subject: Fwd: Dialogue plans
Attachments: Draft Covid-19 US-China dialogue agenda.docx; ATT00001.htm; email letter from DG to GG re virtual dialogue.docx; ATT00002.htm

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Fyi

Begin forwarded message:

From: Diane Griffin <dgriffi6@jhmi.edu>
Date: May 2, 2020 at 8:06:04 PM EDT
To: "gaof@im.ac.cn" <gaof@im.ac.cn>
Cc: "jh-cao@cashq.ac.cn" <jh-cao@cashq.ac.cn>, "clbai@cas.cn" <clbai@cas.cn>, liyin <liyin@cashq.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@utmb.edu>, Peggy Hamburg <peggy@hbfam.net>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>
Subject: Dialogue plans

Dear George,

I'm looking forward to our dialogue tentatively planned for about 10 days from now. Attached find an explanatory letter proposing 2 sessions and draft list of topics.
I look forward to hearing your thoughts on how we can best use our time.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_123808

Subject: NAS-CAS dialogue organizing meeting
Location: Zoom or Skype

Start: Thu 5/7/2020 7:00 PM
End: Thu 5/7/2020 8:00 PM

Recurrence: (none)

Organizer: LeDuc, James W.

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008985

From: Kuhn, Jens (NIH/NIAID) [C] <kuhnjens@niaid.nih.gov>
Sent: Thursday, May 7, 2020 8:05 PM
Cc: 'Valerian Dolja';Arvind Varsani (Arvind.Varsani@asu.edu);Yutin, Natalya (NIH/NLM/NCBI) [E];xy2012204717@163.com;ghzhou@scau.edu.cn;beatriz.navarro@ipsp.cnr.it;minutolm@unina.it;alioto@unina.it;francesco.diserio@ipsp.cnr.it;jorlan@ioc.fiocruz.br;guterres@ioc.fiocruz.br;reolivira@ioc.fiocruz.br;john.chamberlain@phe.gov.uk;roger.hewson@phe.gov.uk;elemos@ioc.fiocruz.br;tgoldstein@ucdavis.edu;Anthony, Simon J.;bhbird@ucdavis.edu;gbakimaaa2009@gmail.com;amarajambai@yahoo.com;hlw2124@cumc.columbia.edu;udo.hetzel@uzh.ch;teemu.smura@helsinki.fi;satu.hepojoki@helsinki.fi;jardim@ioc.fiocruz.br;davila@ioc.fiocruz.br;maa22@fayoum.edu.eg;Bob.Martin@ars.usda.gov;dibellop@oregonstate.edu;Karen.Keller@ars.usda.gov;ss501@msstate.edu;Zhengli Shi (zlshi@wh.iov.cn);yangxl;nbuzkan@ksu.edu.tr;michela.chiumenti@ipsp.cnr.it;sebastien.massart@ulg.ac.be;kamilsarpkaya@gmail.com;angelantonio.minafra@ipsp.cnr.it;drazizangel@gmail.com;arnfinn.okland@uib.no;Muhammad Zubair Shabbir;Mifang Liang;xuyu@utmb.edu;dexin li;strakova.p@centrum.cz;dufkoval@vri.cz;sirmarova@vri.cz;salat@vri.cz;bartonic@sci.muni.cz;Pfaff, Florian;Höper, Dirk;Bernd.Hoffmann@fli.de;Ulrich, Rainer Günter;Daniel Ruzek (ruzekd@paru.cas.cz);whsmilewh@163.com;liuyan06@caas.cn;liuwenwen98@163.com;caomengji@cric.cn;xfwang@ippcaas.cn;leonie.forth@fli.de;wangjw28@163.com;are.nylund@uib.no;zdsys@vip.sina.com;wuzq2009@ipbcams.ac.cn
Subject: Phylum Arch Virol VDN update article
Attachments: VDN Negarnaviricota 05072020.docx; Arch Virol VDN 2020 Negarnaviricota Author Information.xlsx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear All,

first and foremost, please DO NOT "reply to all"

Please find attached a first draft of an *Arch Virol* Virology Division News (VDN) article outlining the current (2020) taxonomic composition of phylum *Negarnaviricota*. This article basically continues the taxonomic updates we have written annually over the last years for the orders *Bunyavirales* and *Mononegavirales*, but now combines both of them into one article and additionally includes the other parts of the phylum taxonomy that have not seen regular/annual updates in print. As always, this article only shows official ICTV taxonomy at the taxon level (as per the last ratification in March 2020) and species composition and virus nomenclatures based on the most recent recommendations from the respective Study Groups. The purpose of the article is to serve as a one-stop citable article that connects ICTV taxon structure with viruses and their abbreviations; these update articles routinely are the best-cited and most-downloaded articles of the journal.

As previously, the author list consists of all current ICTV Study Group members and the respective ICTV Subcommittee Chairs to ensure everything is correct and endorsed as stated, and all authors of taxonomic

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070374

proposals that were submitted in 2019 and ratified in March of 2020. Please do not pay attention to whether you are in the To or in the CC line of this email (or whether your name is colored green or black in the article/Excel) – I separated authors only to be able to handle the large author list in a more efficient manner on my side.

Action Items:

1. **All:** please complete/correct your information in the attached Excel sheet and send back to me. Once/if you are OK with publication, please indicate so in the Excel file in the first column. Authors in black: I took your name and email information from the ICTV webpage. If you suggest changes, I will get the information updated on the webpage as well. In the future, please ensure that the webpage information is always up to date. Authors in green: please complete your names as much as possible (sometimes I only know about first initials etc.).

2. **Subcommittee Chairs:** please double-check whether all your Study Groups are adequately represented and Study Group composition is correct (taken from the ICTV webpage). I will contact you regarding emails that bounce after sending this email so you can sort that out 😊

3. **Study Group Chairs:** please double-check whether Study Group composition is correct (taken from the ICTV webpage). I will contact you regarding emails that bounce after sending this email so you can sort that out 😊

4. **All**: please ensure all taxonomic proposal authors are listed as authors.

5. **All:** please go through the article carefully and double-check against the proposals that you evaluated/handled/wrote and make any corrections with tracked changes and send back to me (ideally, consult within Study Groups and then send me merged Study Group corrections to reduce my email traffic).

   The general format of a species description in the article is:

   "Species *Xxx* was established for virus yyy (ABCV) first discovered by NGS in/first isolated from organism (*species name* Authority) in city, highest admin level, country (publication first describing the virus, publication first describing the full information needed for classification) (TaxoProp X)"

   ➔ I used "isolated" if I interpreted the virus to be in culture; "discovered by NGS" if I interpreted the virus to be discovered by any kind of sequencing. Please double check each entry relevant to you and extend where necessary (for instance, missing organism information when I just write "sandflies" or missing locations etc.). Please very carefully double-check the reference call-outs. Bob (Tesh) and ICTV *Phenuiviridae* Study Group: please very carefully go through the phlebovirus list and correct referencing throughout as you know best which papers/arbovirus catalogues etc. to cite for the first description of these viruses.

For your convenience, the tables already contain tracked changes that hopefully correctly outline the changes that were ratified this year compared to last year's official taxonomy of the phylum. I will dissolve those tracked changes for the next version.

- Guohui Zhou: I did not have email addresses for Biao Chen and Tong Zhang. Please forward this email to them and also let me know their contact email addresses

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070375

- Angelantonio Minafra: I did not have the email address for S. Karadağd. Please forward this email and also let me know the correct contact email address

Please don't crucify me for errors I made (I am sure there are many). I hope to get this all fixed, sorted out, and polished by end of next week.

Best,
Jens

Jens H. Kuhn, MD, PhD, PhD, MS
Virology Lead
Tunnell Government Services (TGS) – Contractor supporting:

National Institute of Allergy and Infectious Diseases (NIH/NIAID)
Division of Clinical Research (DCR)
Integrated Research Facility at Fort Detrick (IRF-Frederick)
B-8200 Research Plaza
Fort Detrick, Frederick, MD 21702, USA
Office: +1.301.631.7245
Fax: +1.301.631.7389
Email: kuhnjens@mail.nih.gov

FOR TUNNELL LIFE SCIENCES:
Follow us on Facebook and LinkedIn:

FOR TUNNELL GOVERNMENT SERVICES:
Follow us on LinkedIn:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070376

2020 TAXONOMIC UPDATE FOR PHYLUM *Negarnaviricota* (*Riboviria*: *Orthornavirae*), INCLUDING THE LARGE ORDERS *Bunyavirales* AND *Mononegavirales*

Jens H. Kuhn[I,I,II,IV,V,VI,IX,XI,XII,XIII,iv], **Scott Adkins**[V,XVI,XXIII], **Daniela Alioto**, **Sergey V. Alkhovskiy [Альховский Сергей Владимирович]**[XI,XVI], **Gaya Amarasinghe**[VI], **Simon J. Anthony**, **Tatjana Avšič-Županc**[XI], **María A. Ayllón**[X], **Justin Bahl**[XIV], **Anne Balkema-Buschmann**[XV], **Matthew J. Ballinger**[XVII], **Tomáš Bartonička**, **Christopher Basler**[VI], **Sina Bavari**[VI], **Martin Beer**[XVI], **Dennis A. Bente**[XI], **Éric Bergeron**[XI], **Brian Bird**, **Carol Blair**[XVI], **Kim R. Blasdell**[XX], **Steven Bradfute**[VIII], **Rachel Breyta**[XX], **Thomas Briese**[IV,XVIII], **Paul A. Brown**[XIX], **Ulla J. Buchholz**[XIX], **Michael J. Buchmeier**[I], **Alexander A. Bukreyev**[VI], **Felicity Burt**[XI], **N. Buzkan**, **Charles H. Calisher**[VIII,XVI], **M. J. Cao**, **Inmaculada Casas**[XIV], **John Chamberlain**, **Kartik Chandran**[VI], **Rémi N. Charrel**[I,XVIII], **Biao Chen**, **Michela Chiumenti**, **Il-Ryong Choi**[XXII], **J. Christopher S. Clegg**[I], **Ian Crozier**[VI], **John V. da Graça**[III], **Elena Dal Bó**[III], **Alberto M. R. Dávila**, **Xavier De Lamballerie**[XVIII], **Juan Carlos de la Torre**[I,V], **Rik de Swart**[XIX], **P. L. Di Bello**, **Ralf G. Dietzgen**[II,IX,XIII,XX], **Michele Digiaro**[VII], **Francesco Diserio**, **Valerian V. Dolja**, **Olga Dolnik**[VI], **Mike Drebot**[XVI], **J. Felix Drexler**[XIX], **Ralf Duerrwald**[IV], **Lucie Dufková**, **William G. Dundon**[XV], **W. Paul Duprex**[IX,XV,XIX], **John M. Dye**[VI], **Andrew J. Easton**[XV,XIX], **Hideki Ebihara [海老原秀喜]**[XVIII], **Toufic Elbeaino**[VII], **Koray Ergünay**[XI], **Jorlan Fernandes**, **Anthony R. Fooks**[XX], **Pierre B. H. Formenty**[VI], **Leonie Forth**, **Ron Fouchier**[XV], **Juliana Freitas-Astúa**[XX], **Selma Gago-Zachert**[III], **George Fú Gāo [高福]**[XVIII], **Maria Laura Garcia**[III], **Adolfo García-Sastre**[XIV], **Aura Garrison**[XI], **Aiah Gbakima**, **Tracey Goldstein**, **Jean-Paul J. Gonzalez**[I], **Anthony Griffiths**[VI], **Martin Groschup**[XVIII], **Jose Guerri**[III], **Stephan Günther**[I], **Alexandro Guterres**, **Anne-Lise Haenni**[XXII], **Roy Hall**[XVII], **John Hammond**[III], **M.**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070377

Hassan, **Jussi Hepojoki**[I], Satu Hepojoki, Udo Hetzel, **Roger Hewson**[VI,XI], Bernd Hoffmann, **Seiji Hongō [本郷誠治]**[XIV], Dirk Höper, **Masayuki Horie [堀江真行]**[IV], **Holly R. Hughes**[XVI], **Timothy H. Hyndman**[IV,XXI], Amara Jambai, Rodrigo Jardins, **Dàohóng Jiāng [姜道宏]**[II,IX,X,XIII], Q. Jin, **Gilda Jonson**[XXII], **Sandra Junglen**[V,XVII], S. Karadağd, K. E. Keller, **Boris Klempa**[VIII], **Jonas Klingström**[VIII], **Gary Kobinger**[VI], **Hideki Kondō [近藤秀樹]**[XX], **Eugene V. Koonin**[XII], **Mart Krupovic**[XII], **Gael Kurath**[XV,XX,XXI], **Ivan V. Kuzmin**[XX], **Lies Laenen**[VIII], **Bob Lamb**[XV], **Amy J. Lambert**[V,XVI,XXIII], **Stanley L. Langevin**[XVII], **Benhur Lee**[XV], Elba R. S. Lemos, **Eric M. Leroy**[VI], Dexin Li, **Jiànróng Lǐ [李建荣]**[XIX], Mifang Liang, W. W. Liu, Y. Liu, **Igor S. Lukashevich**[I], **Piet Maes**[V,VIII,IX], **William Marciel de Souza**[XVI], **Marco Marklewitz**[V,XVI], **Sergio Marshall**[XIV], **Giovanni P. Martelli**[VII], Robert R. Martin, **Shin-Yi L. Marzano**[X], Sebastien Massart, **John McCauley**[XIV], **Nicole Miehlke-Ehret**[VII], Angelantonio Minafra, Maria Minutolo, **Ali Mirazimi**[XI], **Pedro Moreno**[III], **Toshiyuki Morikawa**[III], **Hans-Peter Muehlbach**[VII], **Elke Mühlberger**[VI], **Rayapati Naidu**[XXIII], **Tomohide Natsuaki**[III], Beatriz Navarro, **Sergey V. Netesov [Нетёсов Сергей Викторович]**[VI], **Gabi Neumann**[XIV], **Norbert Nowotny**[IV], **Márcio R. T. Nunes**[XVI,XVIII], Are Nylund, Arnfinn Økland, Renata C. Oliveira, **Gustavo Palacios**[V,VI,XI,XVIII], **Bernadett Pályi**[VI], **Anna Papa [Άννα Παπά]**[XI], **Colin R. Parrish**[XIV], **Alex Pauvolid-Corrêa**[XVII], **Janusz T. Pawęska**[VI,IX], **Susan Payne**[IV], **Eduardo J. Peña**[III], **Daniel R. Pérez**[XIV], Florian Pfaff, **Sheli R. Radoshitzky**[I], Aziz-ul Rahman, P. L. Ramos-González, **Renato Resende**[XXIII], **Bertus K. Rima**[IX,XV], **Víctor Romanowski**[I], **Paul Rota**[XV], **Dennis Rubbenstroth**[IV,IX], **Jonathan A. Runstadler**[XIV], Daniel Růžek, Sead Sabanadzovic, Jiří Salát, **Amadou Alpha Sall**[XI], **Maria S. Salvato**[I], Kamil Sarpkaya, **Takahide Sasaya [笹谷孝英]**[V,XVIII,XXII], **Martin Schwemmle**[XIV], Muhammad Z. Shabbir, **Xiǎohóng Shí [石晓宏]**[XVI], Zhènglì Shí (石正丽), **Yukio Shirako**[XXII], **Peter Simmonds**[i], J.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070378

Širmarová, **Manuela Sironi[I]**, **Sophie Smither[VI]**, Teemu Smura, **Jin-won Song [송진원][VIII,XVIII]**, **Kirsten Spann[XIX]**, **Jessica R. Spengler[XI]**, **Mark D. Stenglein[I,IV]**, **David M. Stone[XX]**, Petra Straková, **Ayato Takada [高田礼人][VI]**, **Robert B. Tesh[XX]**, **Natalie J. Thornburg[XIX]**, **Keizō Tomonaga[IV]**, **Noël Tordo[XX]**, **Valeria Torok[III]**, **Jonathan S. Towner[VI]**, **Massimo Turina[XXIII]**, **Ioannis Tzanetakis[III]**, Rainer G. Ulrich, **Anne Maria Vaira[III]**, **Bernadette van den Hoogen[XIX]**, Arvind Varsani, **Nikos Vasilakis[II,XIII,XX]**, **Martin Verbeek[III]**, **H. Josef Vetten[III]**, **Victoria Wahl[VI]**, **Peter J. Walker[IX,XX,ii]**, H. Wang, J. Wang, **Línfā Wáng [王林发][XV]**, X. F. Wang, **Taiyun Wei[XXII]**, Heather Wells, **Anna E. Whitfield[XX,XXIII]**, **John V. Williams[XIX]**, **Yuri I. Wolf[XII]**, Z. Wu, Xin Yang, Xìnglóu Yáng (扬兴娄), Xue-Jie Yu, Natalya Yutin, **F. Murilo Zerbini[iii]**, Tong Zhang, **Yǒngzhèn Zhāng [张永振][V,VIII,IX]**, Guohui Zhou, **Xueping Zhou[XXII]**

[I]Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, USA. For all other author affiliations and for ORCIDs please consult the co-submitted Excel sheet

*Corresponding author: JHK: Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA; Phone: +1-301-631-7245; Fax: +1-301-631-7389; Email: kuhnjens@mail.nih.gov

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070379

The current members of the 2017–2020 International Committee on Taxonomy of Viruses (ICTV) [I]*Arenaviridae*, [II]*Artoviridae*, [III]*Aspiviridae*, [IV]*Bornaviridae*, [V]*Bunyavirales*, [VI]*Filoviridae*, [VII]*Fimoviridae*, [VIII]*Hantaviridae*, [IX]*Monjiviricetes*, [X]*Mymonaviridae*, [XI]*Nairoviridae*, [XII]*Negarnaviricota*, [XIII]*Nyamiviridae*, [XIV]*Orthomyxoviridae*, [XV]*Paramyxoviridae*, [XVI]*Peribunyaviridae*, [XVII]*Phasmaviridae*, [XVIII]*Phenuiviridae*, [XIX]*Pneumoviridae*, [XX]*Rhabdoviridae*, [XXI]*Sunviridae*, [XXII]*Tenuivirus*, and [XXIII]*Tospoviridae* Study Groups; [i]the current 2017–2020 ICTV Chair of the Fungal and Protist Viruses Subcommittee; [ii]the 2018–2020 ICTV Proposal Secretary; [iii]the 2017–2020 ICTV Chair of the Plant Viruses Subcommittee; and [iv]the 2017–2020 ICTV Chair of the Animal dsRNA and ssRNA- Viruses Subcommittee.

Keywords:

Arenaviridae; *Articulavirales*; *Artoviridae*; *Aspiviridae*; *Bornaviridae*; *Bunyavirales*; bunyavirus; *Filoviridae*; *Fimoviridae*; *Goujianvirales*; *Hantaviridae*; ICTV; International Committee on Taxonomy of Viruses; *Jingchuvirales*; megaclassification; megataxonomy; *Mononegavirales*; *Muvirales*; *Mymonaviridae*; *Nairoviridae*; *Negarnaviricota*; *Nyamiviridae*; *Orthomyxoviridae*; *Orthornavirae*; *Paramyxoviridae*; *Peribunyaviridae*; *Phasmaviridae*; *Phenuiviridae*; *Pneumoviridae*; *Rhabdoviridae*; *Riboviria*; *Serpentovirales*; *Sunviridae*; *Tenuivirus*; *Tospoviridae*; virus classification; virus nomenclature; virus taxonomy

ABSTRACT

In March 2020, following the annual International Committee on Taxonomy of Viruses (ICTV) taxon ratification vote, the phylum *Negarnaviricota* was amended and emended: 20 new genera and 160 new species were added, 2 genera and 4 species were deleted, 1 genus was moved, 10

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070380

species were moved and renamed, and 3 genera and 30 species were renamed. This article presents the updated taxonomy of *Negarnaviricota* as now accepted by the ICTV.

INTRODUCTION

Phylum *Negarnaviricota* was established in 2019 by the International Committee on Taxonomy of Viruses (ICTV) for negative-sense RNA viruses that can be connected evolutionary through their encoded RNA-directed RNA polymerase (RdRp) core domains. The phylum includes two subphyla, *Haploviricotina* and *Polyploviricotina*, for negative-sense RNA viruses that encode large (L) proteins with or without mRNA capping activity, respectively. The two subphyla include four classes (*Chunqiuviricetes*, *Milneviricetes*, *Monjivircetes*, and *Yunchangviricetes*) and two classes (*Ellioviricetes* and *Insthoviricetes*), respectively [56, 109, 135]. The vast majority of viruses that have been assigned to phylum *Negarnaviricota* belong to two orders: *Monjiviricetes/Mononegavirales* (established in 1991 [92] and amended/emended in 1995 [16], 1997 [93], 2000 [94], 2005 [95], 2011 [32], 2016 [2], 2017 [7], March 2018 [8], October 2018 [66], and 2019 [9]) and *Ellioviricetes/Bunyavirales* (established in 2017 and amended/emended in 2018 [64, 65] and 2019 [1]).

Here we present the changes that were proposed to the entire phylum *Negarnaviricota* via official ICTV taxonomic proposals (TaxoProps) in 2019 and that were accepted by the ICTV in March 2020. These changes are now part of the official ICTV taxonomy.

TAXONOMIC CHANGES ABOVE THE PHYLUM RANK

Until recently, *Negarnaviricota* was the only phylum included in realm *Riboviria* (established in 2019 [127]), and the only established phylum in general. In 2020, virus taxonomy was amended

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070381

to include *Negarnaviricota* in the new riboviriad kingdom *Orthornavirae* as one of five sister phyla [55] (TaxoProp 2019.006G.A.v1.Riboviria).

TAXONOMIC CHANGES AT THE SUBPHYLUM RANK

No changes were made.

TAXONOMIC CHANGES AT THE CLASS RANK

No changes were made.

TAXONOMIC CHANGES AT THE ORDER RANK

No changes were made.

Taxonomic changes in order *Goujianvirales* (*Haploviricotina*: *Yunchangviricetes*)

No changes were made.

Taxonomic changes in order *Jingchuvirales* (*Haploviricotina*: *Monjiviricetes*)

Family *Chuviridae*

One new species, *Taiyuan mivirus*, was added to genus *Mivirus* for Tàiyuán leafhopper virus (TYLeV) first discovered by next generation sequencing (NGS) in a leafhopper (*Psammotettix alienus* Dahlbom, 1850) sampled in Tàiyuán (太原), Shānxī Province (山西省), China [128] (TaxoProp 2019.018M.A.v2.1newsp_Taiyuan_mivirus).

Taxonomic changes in order *Mononegavirales* (*Haploviricotina*: *Monjiviricetes*)

Family *Artoviridae*

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070382

The family was expanded by one new genus, *Hexartovirus*, including one new species, *Caligid hexartovirus*, for Lepeophtheirus salmonis negative stranded RNA virus 1 (LsNSRV-1) first discovered by NGS in salmon lice (*Lepeophtheirus salmonis* Krøyer, 1837) sampled on the west coast of Norway [81]. Species *Barnacle peropuvirus* was moved from genus *Peropuvirus* into genus *Hexartovirus* and renamed *Barnacle hexartovirus* (TaxoProp 2019.021M.A.v1.1newgenus_Hexartovirus).

Family *Bornaviridae*

No changes were made.

Filoviridae

The family was expanded by one genus, *Dianlovirus*, including a single new species, *Mengla dianlovirus*, for Měnglà virus (MLAV) discovered by NGS in a *Rousettus* sp. bat sampled in Měnglà County (勐腊县), Yúnnán Province (云南省), China [144, 145] (TaxoProp 2019.011M.A.v1.Mengla_dianlovirus).

One new species, *Bombali ebolavirus*, was created in genus *Ebolavirus*, for Bombali virus (BOMV) first discovered by NGS in little free-tailed bats (*Chaerephon pumilus* Cretzschmar, 1826) and Angola free-tailed bats (*Mops condylurus* Andrew Smith, 1833) sampled in Bombali District, Northern Province, Sierra Leone [37] (TaxoProp 2019.007M.A.v2.Bombali_ebolavirus).

Family *Lispiviridae*

No changes were made.

Family *Mymonaviridae*

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070383

A new genus, *Hubramonas*, was established for two new species: *Hubei hubramonavirus* for Húběi rhabdo-like virus 4 (HbRLV-4) discovered by NGS in an arthropod mix collected in Húběi Province (湖北省), China [106] and *Lentinula hubramonavirus* for Lentinula edodes negative-strand RNA virus 1 (LeNSRV-1) detected by NGS in commercial shiitake mushrooms (*Lentinula edodes* (Berk.) Pegler (1976)) sampled in Japan [60] (TaxoProp 2019.001F.A.v1.Hubramonavirus_1gen).

Family *Nyamiviridae*

No changes were made.

Family *Paramyxoviridae*

The overlooked deletion of species *Bat mumps orthorubulavirus* and the overlooked renaming of species *Synodus paramyxovirus* to *Synodus synodonvirus* were corrected (TaxoProp 2019.016M.A.v1.Corrections).

The family was expanded by three new genera: genus *Cynoglossusvirus* for the already established species *Cynoglossus paramyxovirus* (now renamed *Cynoglossus cynoglossusvirus*); genus *Hoplichthysvirus* for the already established species *Hoplichthys paramyxovirus* (now renamed *Hoplichthys hoplichthysvirus*); and genus *Scoliodonvirus* for the already established species *Scoliodon paramyxovirus* (now renamed *Scoliodon scoliodonvirus*) (TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Aquaparamyxovirus* was expanded by one species, *Oncorhynchus aquaparamyxovirus*, for Pacific salmon paramyxovirus (PSPV) first isolated from Chinook salmon (*Oncorhynchus tshawytscha* Walbaum, 1792) in Oregon, USA [134]. Species *Salmon aquaparamyxovirus* was

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070384

renamed *Salmo aquaparamyxovirus* (TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Jeilongvirus* was expanded by one species, *Miniopteran jeilongvirus*, for "bat paramyxovirus isolate Bat-ParaV/B16-40" (here renamed Shaan virus [ShaV]) first isolated from a Schreibers's long-fingered bat (*Miniopterus schreibersii* Kuhl, 1817) feces sampled in Danyang County (단양군), North Chungcheong Province (충청북도), South Korea [79] (TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Orthoavulavirus* was expanded by two species, *Avian orthoavulavirus 21* and, erroneously, *Avian orthovulavirus 21*, for "avian paramyxovirus 17" (here renamed avian paramyxovirus 21 [APMV-21]) first isolated from bird feces collected in Seosan (서산시), South Chungcheong Province (충청남도), South Korea [48] (TaxoProps 2019.014M.A.v1.Avulavirus_1newsp and 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Orthorubulavirus* was expanded by one species, *Mammalian orthorubulavirus 6*, for Alston virus (AlsV) irst isolated from pteropodid bat urine sampled in Alstonville, New South Wales, Australia [49] (TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Pararubulavirus* was expanded by one species, *Hervey pararubulavirus*, for Hervey virus (HerV) first isolated from pteropodid bat urine sampled in Hervey Bay, New South Wales, Australia [11, 53]. (TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp).

Genus *Respirovirus* was expanded by one species, *Squirrel respirovirus*, for giant squirrel virus (GSqV) first isolated from a Sri Lankan giant squirrel (*Ratufa macroura* Pennant, 1769) sampled in a German zoo [35] (TaxoProp 2019.019M.A.v2.1newsp_Squirrel_respirovirus).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070385

Family *Pneumoviridae*

No changes were made.

Rhabdoviridae

Genus *Almendravirus* was expanded by one species, *Menghai almendravirus*, for Menghai rhabdovirus (MRV) first isolated from mosquitoes (*Aedes albopictus* Skuse, 1894) collected in Měnghǎi County (勐海县) in Yúnnán Province (云南省) [113] (TaxoProp 2019.033M.N.v1.Menghai_almendravirus_1sp).

Genus *Nucleorhabdovirus* was split into three genera, *Alphanucleorhabdovirus*, *Betanucleorhabdovirus*, and *Gammanucleorhabdovirus* (TaxoProp 2019.031M.Ac.v1.Nucleorhabdovirus_splitgen). Established species *Eggplant mottled dwarf nucleorhabdovirus*, *Maize Iranian mosaic nucleorhabdovirus*, *Maize mosaic nucleorhabdovirus*, *Potato yellow dwarf nucleorhabdovirus*, *Rice yellow stunt nucleorhabdovirus*, and *Taro vein chlorosis nucleorhabdovirus* were assigned to genus *Alphanucleorhabdovirus* and renamed *Eggplant mottled dwarf alphanucleorhabdovirus*, *Maize Iranian mosaic alphanucleorhabdovirus*, *Maize mosaic alphanucleorhabdovirus*, *Potato yellow dwarf alphanucleorhabdovirus*, *Rice yellow stunt alphanucleorhabdovirus*, and *Taro vein chlorosis alphanucleorhabdovirus*, respectively. Established species *Datura yellow vein nucleorhabdovirus*, *Sonchus yellow net nucleorhabdovirus*, and *Sowthistle yellow vein nucleorhabdovirus* were assigned to genus *Betanucleorhabdovirus* and renamed *Datura yellow vein betanucleorhabdovirus, Sonchus yellow net betanucleorhabdovirus*, and *Sowthistle yellow vein betanucleorhabdovirus*, respectively. Establishes species *Maize fine streak*

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070386

nucleorhabdovirus was assigned to genus *Gammanucleorhabdovirus* and renamed *Maize fine streak gammarhabdovirus* (TaxoProp 2019.031M.Ac.v1.Nucleorhabdovirus_splitgen).

Three new species were established in genus *Alphanucleorhabdovirus*:

- *Morogoro maize-associated alphanucleorhabdovirus* for Morogoro maize-associated virus (MMaV) first detected by NGS in maize (*Zea mays* L.) in Morogoro, Morogoro Region, Tanzania [97];
- *Physostegia chlorotic mottle alphanucleorhabdovirus* for Physostegia chlorotic mottle virus (PhCMoV) first isolated from lionhearts (*Physostegia* sp.) in Austria [76]; and
- *Wheat yellow striate alphanucleorhabdovirus* for wheat yellow striate virus (WYSV) first isolated from wheat (*Triticum aestivum* L.) in Hánchéng (韩城), Shǎnxī Province (陕西省), China [61] (TaxoProp 2019.031M.Ac.v1.Nucleorhabdovirus_splitgen).

Three new species were established in genus *Betanucleorhabdovirus*:

- *Alfalfa betanucleorhabdovirus* for alfalfa-associated nucleorhabdovirus (AaNV) first discovered by NGS in alfalfa (*Medicago sativa* L.) sampled in Stadl-Paura, Upper Austria, Austria [36];
- *Blackcurrant betanucleorhabdovirus* for blackcurrant-associated rhabdovirus (BCaRV) first discovered by NGS in blackcurrant (*Ribes nigrum* L.) sampled in Russia [137]; and
- *Trefoil betanucleorhabdovirus* for birds-foot trefoil-associated virus (BFTV) first discovered by NGS in bird´s-foot trefoil (*Lotus corniculatus* L.) sampled in the Qínlǐng Mountains (秦岭山), Shǎnxī Province (陕西省), China [26, 130] (TaxoProp 2019.031M.Ac.v1.Nucleorhabdovirus_splitgen).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070387

One new genus, *Arurhavirus*, was established to include four species:

- *Aruac arurhavirus* for Aruac virus (ARUV) first isolated from mosquitoes (*Trichoprosopon theobaldi* Lane and Cerqueira, 1942) collected in Melaju Forest, Trinidad, Trinidad and Tobago, British Empire [110, 126];
- *Inhangapi arurhavirus* for Inhangapi virus (INHV) first isolated from sandflies (*Lutzomyia flaviscutellata* Mangabeira, 1942) collected in Catu Forest, Belém, Pará State, Brazil, in 1969 [3, 126];
- *Santabarbara arurhavirus* for Santa Barbara virus (SBAV) first detected by NGS in sandflies collected in Santa Bárbara do Pará, Pará State, Brazil [unpublished]; and
- *Xiburema arurhavirus* for Xiburema virus (XIBV) first isolated from mosquitoes (*Sabethes intermedius* Lutz, 1904) sampled in Sena Madureira, Acre State, Brazil [51, 131] (2019.006M.A.v1.Arurhavirus_1gen4sp).

One new genus, *Barhavirus*, was established to include two new species: *Bahia barhavirus* for Bahia Grande virus (BGV) first isolated from mosquitoes (*Aedes*, *Culex*, *Anopheles*, *Psorophora* spp.) collected in Texas, Louisiana, New Mexico, and North Dakota, USA [52, 126] and *Muir barhavirus* for Muir Springs virus (MSV) first isolated from mosquitoes (*Aedes* sp.) collected in Fort Morgan, Colorado, USA [52, 126] (TaxoProp 2019.012M.A.v1.Rhabdoviridae_5gen8sp1reasp).

One new genus, *Lostrhavirus*, was established to include new species *Lonestar zarhavirus* [sic] for Lone Star tick rhabdovirus (LSTRV) first detected by NGS in ticks (*Amblyomma americanum* Linnaeus, 1758) collected in the USA [unpublished] (TaxoProp

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070388

2019.012M.A.v1.Rhabdoviridae_5gen8sp1reasp).

One new genus, *Mousrhavirus*, was established to include the previously established species *Moussa virus* (now renamed *Moussa mousrhavirus*) (TaxoProp 2019.012M.A.v1.Rhabdoviridae_5gen8sp1reasp).

One new genus, *Ohlsrhavirus*, was established to include five species:

- *Culex ohlsrhavirus* for Culex rhabdo-like virus (CRLV) first discovered by NGS in mosquitoes (*Culex quinquefasciatus* Say, 1823) collected near Perth, Western Australia, Australia [107];
- *Northcreek ohlsrhavirus* for North Creek virus (NORCV) first discovered by NGS in mosquitoes (*Culex sitiens* Wiedemann, 1828) collected in Ballina, New South Wales, Australia [23];
- *Ohlsdorf ohlsrhavirus* for Ohlsdorf virus (OHLDV) first discovered by NGS in mosquitoes (*Ochlerotatus cantans* Meigen, 1818) collected in Hamburg, Germany [105];
- *Riverside ohlsrhavirus* for riverside virus (RISV) first discovered by NGS in mosquitoes (*Ochlerotatus* sp.) collected in Gemenc, Gyékényes, and Drávaszabolcs, Hungary [98]; and
- *Tongilchon ohlsrhavirus* for Tongilchon virus 1 (TCHV-1) first detected in mosquitoes (*Culex bitaeniorhynchus* Giles, 1901) collected in Tongil-chon (통일 촌), Gyeonggi Privince (경기도), South Korea [39] (TaxoProp 2019.032M.N.v1.Ohlsrhavirus_1gen5sp).

One new genus, *Sawgrhavirus*, was established to include four new species:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070389

- *Connecticut sawgrhavirus* for Connecticut virus (CNTV) first isolated from ticks (*Ixodes dentatus* Marx, 1899) taken from an eastern cottontail (*Sylvilagus floridanus* J. A. Allen, 1890) captured in Lyme, Connecticut, USA [67, 126];
- *Island sawgrhavirus* for Long Island tick rhabdovirus (LITRV) first detected by NGS in ticks (*Amblyomma americanum* Linnaeus, 1758) collected on Long Island, New York, USA [119];
- *Minto sawgrhavirus* for New Minto virus (NMV) first isolated from ticks (*Haemaphysalis leporispalustris* Packard, 1869) sampled in New Minto, Alaska, USA [99, 126]; and
- *Sawgrass sawgrhavirus* for Sawgrass virus (SAWV) isolated from ticks (*Dermacentor variabilis* Say, 1821) sampled at Sawgrass Lake, Tampa Bay, Florida, USA [102, 126] (TaxoProp 2019.012M.A.v1.Rhabdoviridae_5gen8sp1reasp).

One new genus, *Sunrhavirus*, was established to accommodate six novel species:

- *Garba sunrhavirus* for Garba virus (GARV) first isolated from a malachite kingfisher (*Corythornis cristatus* Pallas, 1764) trapped in Bangui, Central African Republic [51, 126] ;
- *Harrison sunrhavirus* for Harrison Dam virus (HARDV) first isolated from common banded mosquitoes (*Culex annulirostris* Skuse, 1889) collected at Beatrice Hill, Northern Territory, Australia [71];
- *Kwatta sunrhavirus* for Kwatta virus (KWAV) first isolated from mosquitoes (*Culex* sp.) collected near Paramaribo, Suriname [25, 126];
- *Oakvale sunrhavirus* for Oak Vale virus (OVV) first isolated from mosquitoes (*Culex* sp.) sampled in Peachester, Queensland, Australia [77, 96];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070390

- *Sunguru sunrhavirus* for Sunguru virus (SUNV) first isolated from a domestic chicken (*Gallus gallus domesticus* Linnaeus, 1758) in Arua District, Northern Region, Uganda [58]; and
- *Walkabout sunrhavirus* for Walkabout Creek virus (WACV) first isolated from biting midges (*Culicoides austropalpalis* Lee & Reye, 1955) collected near Samford, Queensland, Australia [71] (2019.004M.A.v2.Sunrhavirus).

One new genus, *Zarhavirus*, was created for one new species, *Zahedan zarhavirus*, for Zahedan rhabdovirus (ZARV) first isolated from ticks (*Hyalomma anatolicum anatolicum* Koch, 1844) collected in Zâhedân (زاهدان), Sistan and Baluchestan Province (استان سیستان و بلوچستان), Iran [28] (TaxoProp 2019.012M.A.v1.Rhabdoviridae_5gen8sp1reasp).

One new species, *Taiwan bat lyssavirus*, was added to genus *Lyssavirus* for Taiwan bat lyssavirus (TWBLV) first isolated from a Japanese pipistrelle (*Pipistrellus abramus* Temminck, 1838) sampled in Taiwan [45] (TaxoProp 2019.001M.A.v1.Lyssavirus).

Genus *Cytorhabdovirus* was expanded by 12 species:

- *Cabbage cytorhabdovirus* for cabbage cytorhabdovirus 1 (CCyV-1) first discovered by NGS in cabbage (*Brassica oleracea* L.) sampled in the UK [89];
- *Maize-associated cytorhabdovirus* for maize-associated cytorhabdovirus (MaCV) first discovered by NGS in maize (*Zea mays* L.) collected in Lima, Peru [132];
- *Maize yellow striate cytorhabdovirus* for maize yellow striate virus (MYSV) first discovered by NGS in maize (*Zea mays* L.) and wheat (*Triticum aestivum* L.) collected in Sinsacate, Córdoba Province, Argentina [70];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070391

- *Papaya cytorhabdovirus* for papaya virus E (PpVE) first discovered by NGS in papaya (*Carica papaya* L.) sampled in Los Ríos Province, Ecuador [73];
- *Persimmon cytorhabdovirus* for persimmon virus A (PeVA) first discovered by NGS in Japanese persimmon (*Diospyros kaki* Thunb.) sampled in Japan [47];
- *Raspberry vein chlorosis cytorhabdovirus* for raspberry vein chlorosis virus (RVCV) first discovered by NGS in red raspberries (*Rubus idaeus* L.) sampled in Dundee, Scotland, UK [50];
- *Rice stripe mosaic cytorhabdovirus* for rice stripe mosaic virus (RSMV) first discovered by NGS in rice (*Oryza sativa* L.) sampled in Luódìng (罗定), Guǎngdōng Province (广东省), southern China [146];
- *Tomato yellow mottle-associated cytorhabdovirus* for tomato yellow mottle-associated virus (TYMaV) first discovered by NGS in tomato (*Solanum lycopersicum* L.) sampled in Chóngqìng (重庆), China [140];
- *Wuhan 4 insect cytorhabdovirus* for Wuhan insect virus 4 (WuIV-4) first discovered by NGS in mealy plum aphids (*Hyalopterus pruni* Geoffroy, 1762) sampled in Wǔhàn (武汉), Húběi Province (湖北省), China [59];
- *Wuhan 5 insect cytorhabdovirus* for Wuhan insect virus 5 (WuIV-5) first discovered by NGS in mealy plum aphids (*Hyalopterus pruni* Geoffroy, 1762) sampled in Wǔhàn (武汉), Húběi Province (湖北省), China [59];
- *Wuhan 6 insect cytorhabdovirus* for Wuhan insect virus 6 (WuIV-6) first discovered by NGS in mealy plum aphids (*Hyalopterus pruni* Geoffroy, 1762) sampled in Wǔhàn (武汉), Húběi Province (湖北省), China [59]; and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070392

- *Yerba mate chlorosis-associated cytorhabdovirus* for yerba mate chlorosis-associated virus (YmCaV) [12] first discovered by NGS in yerba mate (*Ilex paraguariensis* St. Hil.) sampled in Cerro Azul, Misiones Province, Argentina (TaxoProps 2019.002M.A.v3.Cytorhabdovirus and 2019.030M.A.v1.Cytorhabovirus_12newsp).

One new species, *Holmes hapavirus*, was added to genus *Hapavirus*, for Holmes Jungle virus (HOJV) first isolated from mosquitoes (*Culex annulirostris* Skuse, 1889) collected near Darwin, Northern Territory, Australia [38] (2019.003M.A.v3.Hapavirus).

Three new species were added to genus *Sripuvirus*:

- *Charleville sripuvirus* for Charleville virus (CHVV) first isolated from sandflies (*Phlebotomus* sp.) collected in Charleville, Queensland, Australia [29, 123];
- *Cuiaba sripuvirus* for Cuiaba virus (CUIV) isolated from a cane toad (*Bufo marinus* Linnaeus, 1758) captured in Pará State, Brazil [51, 123]; and
- *Hainan sripuvirus* for Hainan black-spectacled toad rhabdovirus (HnBSTRV) first detected by NGS in an Asian common toad (*Duttaphrynus melanostictus* Schneider, 1799) sampled in Hǎinán Provicne (海南省), China [108] (TaxoProp 2019.013M.A.v1.Sripuvirus_3newsp).

Sunviridae

No changes were made.

Xinmoviridae

No changes were made.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070393

Taxonomic changes in order *Muvirales* (*Haploviricotina*: *Chunqiuviricetes*)

No changes were made.

Taxonomic changes in order *Serpentovirales* (*Haploviricotina*: *Milneviricetes*)

No changes were made.

Taxonomic changes in order *Articulavirales* (*Polyploviricotina*: *Insthoviricetes*)

No changes were made.

Taxonomic changes in order *Bunyavirales* (*Polyploviricotina*: *Ellioviricetes*)

Family *Arenaviridae*

Genus *Hartmanivirus* was expanded by three species: *Muikkunen hartmanivirus* for Dante Muikkunen virus 1 (DaMV-1), *Schoolhouse hartmanivirus* for old schoolhouse viruses 1 and 2 (OScV-1/2), and *Zurich hartmanivirus* for veterinary pathology Zurich viruses 1 and 2 (VPZV-1), all first detected by NGS in captive boid snakes [44] (TaxoProp 2019.008M.A.v2.Hartmanivirus_3new sp).

Genus *Mammarenavirus* was expanded by four species:

- *Alxa mammarenavirus* for RtDs-AreV/IM2014 virus (here renamed Alxa virus [ALXV]) (TaxoProp 2019.020M.A.v2.1newsp_Alxa_mammarenavirus) first discovered by NGS in a Northern three-toed jerboa (*Dipus sagitta* Pallas, 1773) sampled in Alxa Left Banner (阿拉善左旗), Inner Mongolia Autonomous Region (内蒙古自治区), China [138, 139];
- *Chevrier mammarenavirus* for Lìjiāng virus (LIJV) first discovered by NGS in a Chevrier's

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070394

field mouse (*Apodemus chevrieri* Milne-Edwards, 1868) sampled around Lìjiāng (丽江), Yúnnán Province (云南省), China [unpublished] (TaxoProp 2019.009M.A.v2.Mammarenavirus_sp_LIJV);

- *Planalto mammarenavirus* for Aporé virus (APOV) first discovered by NGS in a pygmy rice rat/colilargo (*Oligoryzomys mattogrossae* Allen, 1916) sampled in Cassilândia, Mato Grosso do Sul State, Brazil (TaxoProp 2019.010M.A.v1.Mammarenavirus_sp_APOV) [34]; and
- *Xapuri mammarenavirus* for Xapuri virus (XAPV) first discovered by NGS in a pygmy rice rat/colilargo (*Oligoryzomys mattogrossae* Allen, 1916) sampled in Cassilândia, Mato Grosso do Sul State, Brazil [33] (TaxoProp 2019.005M.A.v1.Mammarenavirus_sp_XAPV).

Family *Cruliviridae*

No changes were made.

Famil *Fimoviridae*

Genus *Emaravirus* was expanded by two species: *Blackberry leaf mottle associated emaravirus* for blackberry leaf mottle-associated virus (BLMaV) first discovered in wild blackberries (*Rubus* spp.) in various US states (TaxoProp 2019.010P.A.v1.Emaravirus_1sp) [41] and *Pistacia emaravirus B* for pistacia virus B (PiVB) discovered by NGS in pistachio (*Pistacia vera* L.) sampled in Turkey [18] (TaxoProp 2019.011P.A.v1.Emaravirus_1sp).

Family *Hantaviridae*

Genus *Loanvirus* was expanded by one species, *Brno loanvirus*, for Brno virus (BRNV) first

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070395

discovered by NGS in a noctule (*Nyctalus noctule* Schreber, 1774) sampled in Brno, South Moravia Region (Jihomoravský kraj), Czech Republic [112] (TaxoProp 2019.017M.A.v3.1newsp_Brno_virus).

Family *Leishbuviridae*

No changes were made.

Family *Mypoviridae*

No changes were made.

Family *Nairoviridae*

No changes were made.

Family *Peribunyaviridae*

Genus *Pacuvirus* was expanded by two species: new species *Caimito pacuvirus* for Caimito virus (CAIV) first isolated from sandflies (*Nyssomyia ylephiletor* Fairchild & Hertig, 1952) sampled in El Aguacate, Chiriquí Province, Panama [46, 116] (TaxoProp 2019.022M.A.v2.2sp_Pacuvirus) and *Chilibre pacuvirus* (the former *Chilibre phlebovirus*, renamed and moved form genus *Phlebovirus*) (TaxoProps 2019.022M.A.v2.2sp_Pacuvirus and 2019.026M.A.v1.Phenuiviridae_4gen79sp).

Family *Phasmaviridae*

Genus *Inshuvirus* and included species *Insect inshuvirus* were abolished (TaxoProp 2019.028M.A.v2.Phasmaviridae_1newsp_abol1gen3sp).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070396

New species *Anopheles orthophasmavirus* was included in genus *Orthophasmavirus* for Anopheles triannulatus orthophasmavirus (AtOPV) first discovered by NGS in mosquitoes (*Anopheles triannulatus* Neiva and Pinto 1922) sampled in Santa Bárbara Farm, Amapá State, Brazil [103], but species *Nome phantom orthophasmavirus* and *Seattle orthophasmavirus* were abolished (TaxoProp 2019.028M.A.v2.Phasmaviridae_1newsp_abol1gen3sp).

Family *Phenuiviridae*

The previously free-floating genus *Coguvirus* was included in family *Phenuiviridae* (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp). One new species, *Coguvirus eburi*, was created in the genus for citrus virus A (CiVA) first discovered by NGS in a sweet orange tree in Italy [78] (2019.004P.A.v1.Coguvirus_1sp).

Genus *Banyangvirus* and included species *Huaiyangshan banyangvirus*, *Guertu bandavirus*, and *Heartland bandavirus* were renamed *Bandavirus*, *Dabie bandavirus*, *Guertu bandavirus*, and *Heartland bandavirus*, respectively (TaxoProps 2019.015M.A.v1.Bandavirus and 2019.026M.A.v1.Phenuiviridae_4gen79sp). Four new bandavirus species were added to the genus:

- *Bhanja bandavirus* for Bhanja virus (BHAV) first isolated from flat-inner-spurred haemaphysalids (*Haemaphysalis intermedia* Warburton & Nuttall, 1909) sampled in Orissa State, India [27, 104];
- *Hunter Island bandavirus* for Hunter Island virus (HUIV) first isolated from ticks (*Ixodes eudyptidis* Maskell, 1885) sampled on Albatross Island, Tasmania, Australia [129];
- *Kismaayo bandavirus* for Kismaayo virus (KISV; name corrected from the previously

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070397

circulating "Kismayo virus" and "Kisemayo virus") first isolated from yellow back ticks (*Rhipicephalus pulchellus* Gerstäcker, 1873) sampled in Kismaayo, Lower Juba (Jubbada Hoose) Region, Somalia [148]; and

- *Lone Star bandavirus* for Lone Star virus (LSV) first isolated from lone star ticks (*Amblyomma americanum* Linnaeus, 1758) sampled in Kentucky, USA [54, 114] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

Genus *Entovirus* was created for one new species, *Entoleuca entovirus*, for Entoleuca phenui-like virus 1 (EnPLV-1) first discovered by NGS in *Entoleuca* sp. fungi sampled in Málaga Province, Spain [124] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

Genus *Kabutovirus* and included species *Kabuto mountain kabutovirus* and *Huangpi kabutovirus* were renamed *Uukuvirus*, *Kabuto mountain uukuvirus*, and *Huangpi uukuvirus*, respectively. The established species *Uukuniemi phlebovirus* was moved into genus *Kabutovirus* and renamed *Uukuniemi uukuvirus*. 14 new species were established in genus *Uukuvirus*:

- *American dog uukuvirus* for American dog tick virus (ADAV) first detected by NGS in American dog ticks (*Dermacentor variabilis* Say, 1821) sampled in Heckscher State Park, New York, USA [120];
- *Dabieshan uukuvirus* for Dàbiéshān tick virus (DbsTV) first discovered by NGS in Asian longhorned ticks (*Haemaphysalis longicornis* Neumann, 1901) collected in the Dàbié Mountains (大别山), China [59];
- *Grand Arbaud uukuvirus* for Grand Arbaud virus (GAV) first isolated from ticks (*Argas reflexus* Fabricius, 1794) sampled in Bouches-du-Rhône Department, France [40, 85];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070398

- *Kaisodi uukuvirus* for Kaisodi virus (KASDV) first isolated from hard-bodied ticks (*Haemaphysalis spinigera* Neumann, 1897) sampled in Mysore State, India [14, 88, 143];
- *Lihan uukuvirus* for Lihan tick virus (LITV) first discovered by NGS in Asian blue ticks (*Rhipicephalus microplus* Canestrini, 1888) sampled in China [59];
- *Murre uukuvirus* for Murre virus (MURV) first isolated from common murres (*Uria aalge* Pontoppidan, 1763) sampled in Alaska, USA [85];
- *Pacific coast uukuvirus* for Pacific coast tick virus (PACTV) first discovered by NGS in Pacific coast ticks (*Dermacentor occidentalis* Marx, 1892) sampled in Mendocino County, California, USA [17];
- *Precarious Point* uukuvirus for Precarious Point virus (PPV) first isolated from seabird ticks (*Ixodes uriae* White, 1852) sampled on Macquarie Island, Tasmania, Australia [85, 111];
- *Rukutama uukuvirus* for Rukutama virus (RUKV) first isolated from seabird ticks (*Ixodes uriae* White, 1852) sampled on Tûlenij Island (Остров Тюлений), Sakhalin Oblast (Сахалинская область), Russia [63, 149];
- *Schmidt uukuvirus* for EgAn 1825-61 virus (here renamed Nile warbler virus (EGAV)) first isolated from a willow warbler (*Phylloscopus trochilus* Linnaeus, 1758) sampled in Nile Delta, Egypt [85];
- *Silverwater uukuvirus* for Silverwater virus (SILV) first isolated from rabbit ticks (*Haemaphysalis leporispalustris* Packard, 1869) sampled near Powassan, Ontario, Canada [69, 72];
- *Tacheng uukuvirus* for Tăchéng tick virus 2 (TcTV-2) first discovered by NGS in ticks

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070399

(*Dermacentor marginatus* Sulzer, 1776) in China [59];

- *Yongjia uukuvirus* for Yǒngjiā tick virus 1 (YjTV-1) first discovered by NGS in East Asian mountain haemaphysalids (*Haemaphysalis hystricis* Supino, 1897) in China [59]; and
- *Zaliv Terpeniya uukuvirus* for Zaliv Terpeniya virus (ZTV) first isolated from seabird ticks (*Ixodes uriae* White, 1852) on Tûlenij Island (Остров Тюлений), Sakhalin Oblast (Сахалинская область) and Commander Islands (Командорские острова), Kamchatka Krai (Камчатский край), RSFSR, USSR [62, 150] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

Genus *Ixovirus* was established for the three new species:

- *Blackleg ixovirus* for blacklegged tick phlebovirus 1 (BTPV-1) first discovered by NGS in deer ticks (*Ixodes scapularis* Say, 1821) sampled in Heckscher State Park, New York, USA [120];
- *Norway ixovirus* for Norway phlebovirus 1 (NIXV) first discovered by NGS in castor bean ticks (*Ixodes ricinus* Linnaeus, 1758) sampled in Norway [91]; and
- *Scapularis ixovirus* for blacklegged tick phlebovirus 3 (BTPV-3) first discovered by NGS in deer ticks (*Ixodes scapularis* Say, 1821) sampled in Heckscher State Park, New York, USA [120] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

Genus *Lentinuvirus* was created for one new species, *Lentinula lentinuvirus*, for Lentinula edodes negative-strand RNA virus 2 (LeNSRV-2) first discovered by NGS in shiitake (*Lentinula edodes* (Berk.) Pegler (1976)) sampled in Japan [60] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070400

In genus *Phlebovirus*, established species *Sandfly fever Naples phlebovirus* was renamed *Naples phlebovirus*. The genus was expanded by 53 new species (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp):

- *Adana phlebovirus* for Adana virus (ADAV) first isolated from *Phlebotomus* spp. sandflies sampled in Adana, Mediterranean Region, Turkey [4];
- *Aguacate phlebovirus* for Aguacate virus (AGUV) first isolated from *Lutzomyia* spp. sandflies sampled in El Aguacate, Chiriquí Province, Panama [82, 116];
- *Alcube phlebovirus* for Alcube virus (ACBV) first isolated from sandlfies (*Phlebotomus perniciosus* Newstead, 1911) sampled around Arrábida, Portugal [10];
- *Alenquer phlebovirus* for Alenquer virus (ALEV) first isolated from a human in Ramal das Pias, Alenquer, Brazil [83, 122];
- *Ambe phlebovirus* for Ambe virus (ABEV) first isolated from psychodid sandflies sampled near Altamira, Pará State, Brazil [80, 118];
- *Anhanga phlebovirus* for Anhangá virus (ANHV) first isolated from a Linnaeus's two-toed sloth (*Choloepus brasiliensis* Linnaeus, 1758) sampled in Castanhal Forest, Pará State, Brazil [80];
- *Arumowot phlebovirus* for Arumowot virus (AMTV) first isolated from moquitoes (*Culex antennatus* Becker, 1903) sampled on Sudan [13, 84]
- *Buenaventura phlebovirus* for Buenaventura virus (BUEV) first isolated in 1984 from *Lutzomyia* sp. sandflies sampled in Rio Raposo, Valle del Cauca, Colombia [87, 116];
- *Cacao phlebovirus* for Cacao virus (CACV) first isolated from sandflies (*Nyssomyia trapidoi* Fairchild & Hertig, 1952) sampled in El Aguacate, Chiriquí Province, Panama

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070401

[87, 116];

- *Campana phlebovirus* for Campana virus (CMAV) first isolated from phlebotomine sandflies sampled in El Aguacate, Chiriquí Province, Panama [87];
- *Chagres phlebovirus* for Chagres virus (CHGV) first isolated from humans sampled at Fort Sherman, Canal Zone, Panama [90];
- *Cocle phlebovirus* for Coclé virus (CCLV) ifirst solated from a human sampled in Penonomé, Coclé Province, Panama [87];
- *Dashli phlebovirus* for Dāshlī virus (DASV) first isolated from *Sergentomyia* sp. sandflies sampled in Dāshlīborun (داشلی‌برون), Golestān Province (استان گلستان), Iran [6];
- *Durania phlebovirus* for Durania virus (DRNV) first isolated from sandflies sampled in 1986 near Durania, North Santander Department, Colombia [82, 118];
- *Echarate phlebovirus* for Echarate virus (ECHV) first isolated from a human sampled in Cusco, Peru [83];
- *Gabek phlebovirus* for for Gabek forest virus (GFV) first isolated from a northeast African spiny mouse (*Acomys cahirinus* É. Geoffroy, 1803) sampled in Gabek forest, near Paloich, Sudan [86];
- *Gordil phlebovirus* for Gordil virus (GORV) first isolated from a typical lemniscomys (*Lemniscomys striatus* Linnaeus, 1758) sampled in Gordil, Vakaga Prefecture, Central African Republic [86];
- *Icoaraci phlebovirus* for Icoaraci virus (ICOV) first isolated from a water rat (*Nectomys* sp.) sampled in Belém, Pará State, Brazil [19, 141];
- *Itaituba phlebovirus* for Itaituba virus (ITAV) first isolated from a common opposum

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070402

(*Didelphis marsupialis marsupialis* Linnaeus, 1758) trapped at the Tapacurazinho stream, Itaituba, Pará State, Brazil [83, 122];

- *Itaporanga phlebovirus* for Itaporanga virus (ITPV) first isolated from a sentinel Swiss mouse collected in Itaporanga, São Paulo State, Brazil [46, 121];
- *Ixcanal phlebovirus* for Ixcanal virus (IXCV) first isolated from *Lutzomyia* sp. sandflies sampled in Aldea Ixcanal and Aldea Puerta, El Progreso Department, Guatemala [82, 118] ;
- *Karimabad phlebovirus* for Karimabad virus (KARV) first isolated from *Phlebotomus* sp. sandflies in Karīmābād (كريم اباد), Tehran Province (استان تهران), Iran [86];
- *La Gloria phlebovirus* for La Gloria virus (LAGV) first discovered by NGS in phlebotomine sandflies sampled in Panama Canal area, central Panama [68];
- *Lara phlebovirus* for GGP-2011a virus (here renamed Rio Claro virus [RICV]) first isolated from a sentinel hamster sampled in Venezuela [unpublished];
- *Leticia phlebovirus* for Leticia virus (LETV) first isolated from sandflies sampled in Leticia, Amazonas Department, Colombia [87];
- *Maldonado phlebovirus* for Maldonado virus (MLOV) first isolated from a human sampled in Puerto Maldonado, Madre de Dios Region, Peru [83];
- *Massilia phlebovirus* for Massilia virus (MASV) first isolated from sandflies (*Phlebotomus perniciosus* Newstead, 1911) sampled in Marseille and Nice, Provence-Alpes-Côte d'Azur and France [20, 86];
- *Medjerda phlebovirus* for Medjerda Valley virus (MVV) first isolated from phlebotomine sandflies, Utique close to Tunis,Tunisia [15];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070403

- *Mona Grita phlebovirus* for Mona Grita virus (MOGV) first discovered by NGS in sandflies (*Nyssomyia trapidoi* Fairchild & Hertig, 1952) sampled in Panama Canal area, central Panama [68];
- *Munguba phlebovirus* for Munguba virus (MUNV) first isolated from sandflies (*Nyssomyia umbratilis* Ward & Fraiha, 1977) sampled in Monte Dourado, Pará State, Brazil [80, 122];
- *Naples phlebovirus* for sandfly fever Naples virus (SFNV) first isolated from a human sampled in Naples (Napoli), Campania Region, Italy [86, 101];
- *Nique phlebovirus* for Nique virus (NIQV) first isolated from sandflies (*Lutzomyia panamensis* Shannon, 1926) sampled in Cerro Nique, Darién Province, Panama [83, 117];
- *Ntepes phlebovirus* for Ntepes virus (NTPV) first isolated from *Sergentomyia* sp. sandflies sampled in Marigat District, Baringo County, Kenya [115];
- *Odrenisrou phlebovirus* for Odrénisrou virus (ODRV) first isolated from mosquitoes (*Culex albiventris* Edwards, 1922) collected in the Taï Forest, Côte d'Ivoire [84];
- *Oriximina phlebovirus* for Oriximiná virus (ORXV) first isolated from *Lutzomyia* sp. sandflies sampled in Saracazinho, Pará State, Brazil [83, 122];
- *Pena Blanca phlebovirus* for Peña Blanca virus (PEBV) first discovered by NGS in phlebotomine sandflies sampled in Panama Canal area, central Panama [68];
- *Punique phlebovirus* for Punique virus (PUNV) first isolated from sandflies (*Phlebotomus perniciosus* Newstead, 1911 and *Phlebotomus longicuspis* Nitzulescu, 1930) sampled in Tunis, Tunisia [86];
- *Rio Grande phlebovirus* for Rio Grande virus (RGV) first isolated from a Southern Plains woodrat (*Neotoma micropus* Baird, 1855) sampled in Texas, USA [46];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070404

- *Saint Floris phlebovirus* for Saint-Floris virus (SAFV) first isolated from a gerbil sampled in Gordil, Vakaga Prefecture, Central African Republic [86];
- *Salanga phlebovirus* for Salanga virus (SLGV) first isolated from a Hinde's aethomys (*Aethomys hindei* Thomas, 1902) collected in Salanga, Ombella-M'Poko Prefecture, Central African Republic [51, 147];
- *Salobo phlabovirus* [sic] for Salobo virus (SLBOV) first isolated from a Guyenne spiny-rat (*Proechimys guyannensis* E. Geoffroy, 1803) in Pará State,Brazil [141];
- *Sicilian phlebovirus* for sandfly fever Sicilian virus (SFSV) first isolated from a human sampled in Palermo Region, Sicily region, Italy [101, 136];
- *Tapara phlebovirus* for Tapará virus (TPRV) first isolated from phlebotomine sandflies in Altamira, Pará State, Brazil [80];
- *Tehran phlebovirus* for Tehran virus (THEV) first isolated from sandflies (*Phlebotomus papatasi* Scopoli, 1786) sampled in Tehran, Iran [86];
- *Tico phebovirus* for Tico virus (TICV) discovered by NGS in sandflies sampled in Panama Canal area, central Panama [68];
- *Toros phlebovirus* for Toros virus (TORV) first discovered by NGS in sandflies sampled in Damyeri, Adana Province (Adana ili), Turkey [5];
- *Toscana phlebovirus* for Toscana virus (TOSV) first isolated from sandflies (*Phlebotomus perniciosus* Newstead, 1911) in Toscany, Italy [86, 125];
- *Tres Almendras phlebovirus* for Tres Almendra virus (TRAV) first discovered by NGS in sandflies (*Psychodopygus panamensis* Shannon, 1926) sampled in Panama Canal area, central Panama [68];

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070405

- *Turuna phlebovirus* for Turuna virus (TUAV) first isolated from *Lutzomyia* sp. sandflies sampled in Cachoeira Porteira, Pará State, Brazil [83, 122];
- *Uriurana phlebovirus* for Uriurana virus (URIV) first isolated from phlebotomine sandflies in Tucuruí, Pará State, Brazil [80];
- *Urucuri phlebovirus* for Urucuri virus (URUV) first isolated from a Guyenne spiny-rat (*Proechimys guyannensis* E. Geoffroy, 1803) in Utinga Forest, Belém, Pará State, Brazil [80, 122];
- *Viola phlebovirus* for viola virus (VIOV) first discovered by NGS in sandflies (*Lutzomyia longipalpis* Lutz & Neiva, 1912) sampled in Pirizal, Mato Grosso State, Brazil [24]; and
- *Zerdali phlebovirus* for Zerdali virus (ZERV) first discovered by NGS in sandflies sampled in Zerdali, Adana Province (Adana ili), Turkey [5].

Genus *Rubodvirus* was created for the two new species *Apple rubodvirus 1* and *2* to accommodate apple rubbery wood viruses 1 and (ARWV-1/2), respectively, first discovered using NGS in apple trees (*Malus* sp.) sampled in Germany and USA [100] (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

One new species, *Melon tenuivirus*, was added to genus *Tenuivirus* for melon chlorotic spot virus (MeCSV) first isolated from muskmelon (*Cucumis melo* L.) sampled in Provence-Alpes-Côte d'Azur Region, France [57].

Genus *Wubeivirus* was abolished and its two species, *Fly wubeivirus* and *Dipteran wubeivirus*, were moved into genus *Phasivirus* and renamed *Fly phasivirus* and *Dipteran phasivirus*, respectively (TaxoProp 2019.026M.A.v1.Phenuiviridae_4gen79sp).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070406

Family *Tospoviridae*

The overlooked adjustment of 12 tospovirid species names to correct non-Latinized binomials was implemented (TaxoProp 2019.016M.A.v1.Corrections).

Eight new species were created in genus *Orthotospovirus*:

- *Alstroemeria necrotic streak orthotospovirus* for Alstroemeria necrotic streak virus (ANSV) first isolated from ornamental crops (*Alstroemeria* sp.) sampled in Colombia [42];
- *Alstroemeria yellow spot orthotospovirus* for Alstroemeria yellow spot virus (AYSV) first isolated from ornamental crops (*Alstroemeria* sp.) sampled in the Netherlands [43];
- *Groundnut chlorotic fan spot orthotospovirus* for groundnut chlorotic fan-spot virus (GCFSV) first isolated from peanut (*Arachis hypogaea* L.) sampled in Taiwan [21];
- *Hippeastrum chlorotic ringspot orthotospovirus* for Hippeastrum chlorotic spot virus (HCRV) first isolated from amaryllis (*Hippeastrum* sp.) and spider lily (*Hymenocallis littoralis* (Jacq.) Salisb.) sampled in southwestern China [31, 142];
- *Mulberry vein banding associated orthotospovirus* for mulberry vein banding-associated virus (MVBaV) discovered first by NGS in mulberry (*Morus alba* L.) sampled in Guǎngxī Zhuàng Autonomous Region, China in 2011 [74, 75];
- *Pepper chlorotic spot orthotospovirus* for pepper chlorotic spot virus (PCSV) first isolated from sweet pepper (*Capsicum annuum* L.) in Taiwan [22];
- *Tomato yellow ring orthotospovirus* for tomato yellow ring virus (TYRV) first isolated from tomato (*Solanum lycopersicum* L.) in Iran [133]; and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070407

- *Tomato zonate spot orthotospovirus* for tomato zonate spot virus (TZSV) first isolated from tomato (*Solanum lycopersicum* L.) and chili pepper (*Capsicum annuum* L.) sampled in Yúnnán Province (云南省), China [30] (TaxoProp 2019.006P.A.v1.Orthotospovirus_8sp).

Wupedeviridae

No changes were made.

SUMMARY

A summary of the current, ICTV-accepted taxonomy of the phylum *Negarnaviricota* is presented in Table 1 (*Goujianvirales*), Table 2 (*Jingchuvirales*), Table 3 (*Mononegavirales*), Table 4 (*Muvirales*), Table 5 (*Serpentovirales*), Table 6 (*Articulavirales*), and Table 7 (*Bunyavirales*).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070408

Table 1. ICTV-accepted taxonomy of the order *Goujianvirales* (*Negarnaviricota*: *Haploviricotina*: *Yunchangviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	Species¶	Virus (Abbreviation)¶
Family *Yueviridae*		
Yuyuevirus	*Beihai yuyuevirus**	Běihǎi sesarmid crab virus 3 (BhSCV-3)
	Shahe yuyuevirus	Shāhé yuèvirus-like virus 1 (ShYLV-1)

*type species

¶Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070409

Table 2. ICTV-accepted taxonomy of the order *Jingchunvirales* (*Negarnaviricota*: *Haploviricotina*: *Monjiviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	Species¶	Virus (Abbreviation)¶
	Family *Chuviridae*	
Mivirus	*Argas mivirus*	Tǎchéng tick virus 4 (TcTV-4)
	*Barnacle mivirus**	Běihǎi barnacle virus 9 (BhBV-9)
	Beetle mivirus	Húběi coleoptera virus 3 (HbCV-3)
	Bole mivirus	Bólè tick virus 3 (BTV-3)
	Brunnich mivirus	Wēnlǐng crustacean virus 14 (WlCV-14)
	Changping mivirus	Chāngpíng tick virus 2 (CpTV-2)
	Charybdis mivirus	Wēnzhōu crab virus 3 (WzCV-3)
	Cockroach mivirus	Wǔchāng cockroach virus 3 (WcLFV-3)
	Crab mivirus	Wēnzhōu crab virus 2 (WzCV-2)
	Crustacean mivirus	Wēnlǐng crustacean virus 13 (WlCV-13)
	Dermacentor mivirus	Chāngpíng tick virus 3 (CpTV-3)
		Tǎchéng tick virus 5 (TcTV-5)
	Hermit mivirus	Běihǎi hermit crab virus 3 (BhHCV-3)
	Hippoboscid mivirus	Wǔhàn louse fly virus 7 (WhLFV-7)
	Hubei mivirus	Húběi chǔvirus-like virus 1 (HbCLV-1)
	Hubei odonate mivirus	Húběi chǔvirus-like virus 3 (HbCLV-3)
	Imjin mivirus	Imjin River virus 1 (IjRV-1)
	Lacewing mivirus	Shuāngào insect virus 5 (SgIV-5)
	Lishi mivirus	Líshí spider virus 1 (LsSV-1)
	Lonestar mivirus	lone star tick chǔvirus 1 (LSTCV-1)
	Louse fly mivirus	Wǔhàn louse fly virus 6 (WhLFV-6)
	Mosquito mivirus	Wǔhàn mosquito virus 8 (WhMV-8)
	Myriapod mivirus	Húběi myriapoda virus 8 (HbMV-8)
	Odonate mivirus	Húběi odonate virus 11 (HbOV-11)
	Sanxia mivirus	Sānxiá atyid shrimp virus 4 (SxASC-4)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070410

	Shayang mivirus	Shāyáng fly virus 1 (SyFV-1)
	Suffolk mivirus	Suffolk virus (SFKV)
	Taiyuan mivirus	Tàiyuán leafhopper virus (TYLeV)
	Wenling mivirus	Wēnlǐng crustacean virus 15 (WlCV-15)
	Wuhan mivirus	Wǔhàn tick virus 2 (WhTV-2)
	Xinzhou mivirus	Xīnzhōu nematode virus 5 (XzNV-5)

*type species

¶Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070411

Table 3. ICTV-accepted taxonomy of the order *Mononegavirales* (*Negarnaviricota*: *Haploviricotina*: *Monjiviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	Species¶	Virus (Abbreviation)¶
Family *Artoviridae*		
~~*Peropuvirus*~~*Hexartovirus*	*Barnacle ~~peropuvirus~~hexartovirus*	Běihaǐ barnacle virus 8 (BhBV-8)
	*Caligid hexartovirus**	Lepeophtheirus salmonis negative stranded RNA virus 1 (LsNSRV-1)
Peropuvirus	*Beihai peropuvirus*	Běihaǐ rhabdo-like virus 1 (BhRLV-1)
	Hubei peropuvirus	Húběi rhabdo-like virus 6 (HbRLV-6)
	Odonate peropuvirus	Húběi rhabdo-like virus 8 (HbRLV-8)
	Pillworm peropuvirus	Húběi rhabdo-like virus 5 (HbRLV-5)
	*Pteromalus puparum peropuvirus**	Pteromalus puparum negative-strand RNA virus 1 (PpNSRV-1)
	Woodlouse peropuvirus	Běihaǐ rhabdo-like virus 2 (BhRLV-2)
Family *Bornaviridae*		
Carbovirus	*Queensland carbovirus**	jungle carpet python virus (JCPV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070412

	Southwest carbovirus	southwest carpet python virus (SWCPV)
Cultervirus	*Sharpbelly cultervirus**	Wǔhàn sharpbelly bornavirus (WhSBV)
Orthobornavirus	*Elapid 1 orthobornavirus*	Loveridge's garter snake virus 1 (LGSV-1)
	*Mammalian 1 orthobornavirus**	Borna disease virus 1 (BoDV-1)
		Borna disease virus 2 (BoDV-2)
	Mammalian 2 orthobornavirus	variegated squirrel bornavirus 1 (VSBV-1)
	Passeriform 1 orthobornavirus	canary bornavirus 1 (CnBV-1)
		canary bornavirus 2 (CnBV-2)
		canary bornavirus 3 (CnBV-3)
	Passeriform 2 orthobornavirus	estrildid finch bornavirus 1 (EsBV-1)
	Psittaciform 1 orthobornavirus	parrot bornavirus 1 (PaBV-1)
		parrot bornavirus 2 (PaBV-2)
		parrot bornavirus 3 (PaBV-3)
		parrot bornavirus 4 (PaBV-4)
		parrot bornavirus 7 (PaBV-7)
	Psittaciform 2 orthobornavirus	parrot bornavirus 5 (PaBV-5)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070413

	Waterbird 1 orthobornavirus	aquatic bird bornavirus 1 (ABBV-1)
		aquatic bird bornavirus 2 (ABBV-2)
Family *Filoviridae*		
Cuevavirus	*Lloviu cuevavirus**	Lloviu virus (LLOV)
Dianlovirus	*Mengla dianlovirus**	Měnglà virus (MLAV)
Ebolavirus	*Bombali ebolavirus*	Bombali virus (BOMV)
	Bundibugyo ebolavirus	Bundibugyo virus (BDBV)
	Reston ebolavirus	Reston virus (RESTV)
	Sudan ebolavirus	Sudan virus (SUDV)
	Tai Forest ebolavirus	Taï Forest virus (TAFV)
	*Zaire ebolavirus**	Ebola virus (EBOV)
Marburgvirus	*Marburg marburgvirus**	Marburg virus (MARV)
		Ravn virus (RAVV)
Striavirus	*Xilang striavirus**	Xīlǎng virus (XILV)
Thamnovirus	*Huangjiao thamnovirus**	Huángjiāo virus (HUJV)
Family *Lispiviridae*		

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070414

Arlivirus	*Gerrid arlivirus*	Sānxiá water strider virus 4 (SxWSV-4)
	Hubei arlivirus	Húběi rhabdo-like virus 3 (HbRLV-3)
	*Lishi arlivirus**	Líshí spider virus 2 (LsSV-2)
	Odonate arlivirus	Húběi odonate virus 10 (HbOV-10)
	Tacheng arlivirus	Tǎchéng tick virus 6 (TcTV-6)
	Wuchang arlivirus	Wǔchāng romanomermis nematode virus 2 (WcRNV-2)
Family *Mymonaviridae*		
Hubramonavirus	*Hubei ~~sclerotii~~hubramonavirus**	Húběi rhabdo-like virus 4 (HbRLV-4)
	Lentinula hubramonavirus	Lentinula edodes negative-strand RNA virus 1 (LeNSRV-1)
Sclerotimonavirus	*Dadou sclerotimonavirus*	soybean leaf-associated negative-stranded RNA virus 3 (SLaNSRV-3)
	Drop sclerotimonavirus	Sclerotinia sclerotiorum negative-stranded RNA virus 2 (SsNSRV-2)
		Sclerotinia sclerotiorum negative-stranded

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070415

		RNA virus 4 (SsNSRV-4)
	Glycine sclerotimonavirus	Fusarium graminearum negative-stranded RNA virus 1 (FgNSRV-1)
		soybean leaf-associated negative-stranded RNA virus 1 (SLaNSRV-1)
	Hubei sclerotimonavirus[1]	
	Illinois sclerotimonavirus	soybean leaf-associated negative-stranded RNA virus 2 (SLaNSRV-2)
	Phyllosphere sclerotimonavirus	soybean leaf-associated negative-stranded RNA virus 4 (SLaNSRV-4)
	*Sclerotinia sclerotimonavirus**	Sclerotinia sclerotiorum negative-stranded RNA virus 1 (SsNSRV-1)
		Sclerotinia sclerotiorum negative-stranded RNA virus 3 (SsNSRV-3)
Family *Nyamiviridae*		
Berhavirus	*Beihai berhavirus*	Beĭhaĭ rhabdo-like virus 4 (BhRLV-4)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070416

	Echinoderm berhavirus	Běihǎi rhabdo-like virus 5 (BhRLV-5)
	*Sipunculid berhavirus**	Běihǎi rhabdo-like virus 3 (BhRLV-3)
Crustavirus	*Beihai crustavirus*	Běihǎi rhabdo-like virus 6 (BhRLV-6)
	Wenling crustavirus	Wēnlǐng crustacean virus 12 (WlCV-12)
	*Wenzhou crustavirus**	Wēnzhōu crab virus 1 (WzCV-1)
Nyavirus	*Midway nyavirus*	Midway virus (MIDWV)
	*Nyamanini nyavirus**	Nyamanini virus (NYMV)
	Sierra Nevada nyavirus	Sierra Nevada virus (SNVV)
Orinovirus	*Orinoco orinovirus**	Orinoco virus (ONCV)
Socyvirus	*Soybean cyst nematode socyvirus**	soybean cyst nematode virus 1 (SbCNV-1)
Tapwovirus	*Tapeworm tapwovirus**	Wēnzhōu tapeworm virus 1 (WzTWV-1)
Family *Paramyxoviridae*		
Subfamily *Avulavirinae*		
Metaavulavirus	*Avian metaavulavirus 2**	avian paramyxovirus 2 (APMV-2)
	Avian metaavulavirus 5	avian paramyxovirus 5 (APMV-5)
	Avian metaavulavirus 6	avian paramyxovirus 6 (APMV-6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070417

	Avian metaavulavirus 7	avian paramyxovirus 7 (APMV-7)
	Avian metaavulavirus 8	avian paramyxovirus 8 (APMV-8)
	Avian metaavulavirus 10	avian paramyxovirus 10 (APMV-10)
	Avian metaavulavirus 11	avian paramyxovirus 11 (APMV-11)
	Avian metaavulavirus 14	avian paramyxovirus 14 (APMV-14)
	Avian metaavulavirus 15	avian paramyxovirus 15 (APMV-15)
	Avian metaavulavirus 20	avian paramyxovirus 20 (APMV-20)
Orthoavulavirus	*Avian orthoavulavirus 1**	avian paramyxovirus 1 (APMV-1)[2]
	Avian orthoavulavirus 9	avian paramyxovirus 9 (APMV-9)
	Avian orthoavulavirus 12	avian paramyxovirus 12 (APMV-12)
	Avian orthoavulavirus 13	avian paramyxovirus 13 (APMV-13)
	Avian orthoavulavirus 16	avian paramyxovirus 16 (APMV-16)
	Avian orthoavulavirus 17	Antarctic penguin virus A (APV-A)
	Avian orthoavulavirus 18	Antarctic penguin virus B (APV-B)
	Avian orthoavulavirus 19	Antarctic penguin virus C (APV-C)
	Avian orthoavulavirus 21	avian paramyxovirus 21 (APMV-21)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070418

	Avian orthovulavirus 21[3]	
Paraavulavirus	*Avian paraavulavirus 3**	avian paramyxovirus 3 (APMV-3)
	Avian paraavulavirus 4	avian paramyxovirus 4 (APMV-4)
Subfamily *Metaparamyxovirinae*		
Synodonvirus	*Synodus ~~paramyxovirus~~synodonvirus**	Wēnlǐng triplecross lizardfish paramyxovirus (WTLPV)
Subfamily *Orthoparamyxovirinae*		
Aquaparamyxovirus	*Oncorhynchus aquaparamyxovirus*	Pacific salmon paramyxovirus (PSPV)
	*Salmo~~n~~ aquaparamyxovirus**	Atlantic salmon paramyxovirus (AsaPV)
Ferlavirus	*Reptilian ferlavirus**	fer-de-lance virus (FDLV)
Henipavirus	*Cedar henipavirus*	Cedar virus (CedV)
	Ghanaian bat henipavirus	Ghana virus (GhV)
	*Hendra henipavirus**	Hendra virus (HeV)
	Mojiang henipavirus	Mòjiāng virus (MojV)
	Nipah henipavirus	Nipah virus (NiV)
Jeilongvirus	*Beilong jeilongvirus**	Beilong virus (BeiV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070419

	Jun jeilongvirus	J virus (JV)
	Lophuromys jeilongvirus 1	Mount Mabu Lophuromys virus 1 (MMLV-1)
	Lophuromys jeilongvirus 2	Mount Mabu Lophuromys virus 2 (MMLV-2)
	Miniopteran jeilongvirus	Shaan virus (ShaV)
	Myodes jeilongvirus	Pohorje Myodes paramyxovirus 1 (PMPV-1)
	Tailam jeilongvirus	Tailam virus (TaiV)
Morbillivirus	*Canine morbillivirus*	canine distemper virus (CDV)
	Cetacean morbillivirus	cetacean morbillivirus (CeMV)
	Feline morbillivirus	feline morbillivirus (FeMV)
	*Measles morbillivirus**	measles virus (MeV)
	Phocine morbillivirus	phocine distemper virus (PDV)
	Rinderpest morbillivirus	rinderpest virus (RPV)
	Small ruminant morbillivirus	peste-des-petits-ruminants virus (PPRV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070420

Narmovirus	*Mossman narmovirus*	Mossman virus (MossV)
	Myodes narmovirus	bank vole virus 1 (BaV-1)
	*Nariva narmovirus**	Nariva virus (NarV)
	Tupaia narmovirus	Tupaia paramyxovirus (TupV)
Respirovirus	*Bovine respirovirus 3*	bovine parainfluenza virus 3 (BPIV-3)
	Caprine respirovirus 3	caprine parainfluenzavirus 3 (CPIV-3)
	Human respirovirus 1	human parainfluenza virus 1 (HPIV-1)
	Human respirovirus 3	human parainfluenza virus 3 (HPIV-3)
	*Murine respirovirus**	Sendai virus (SeV)
	Porcine respirovirus 1	porcine parainfluenza virus 1 (PPIV-1)
	Squirrel respirovirus	giant squirrel virus (GSqV)
Salemvirus	*Salem salemvirus**	Salem virus (SalV)
Subfamily *Rubulavirinae*		
	~~*Bat mumps orthorubulavirus*[3]~~	~~bat mumps virus (BMV)~~
Orthorubulavirus	*Human orthorubulavirus 2*	human parainfluenza virus 2 (HPIV-2)
	Human orthorubulavirus 4	human parainfluenza virus 4a (HPIV-4a)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070421

		human parainfluenza virus 4b (HPIV-4b)
	Mammalian orthorubulavirus 5	parainfluenza virus 5 (PIV-5)
	Mammalian orthorubulavirus 6	Alston virus (AlsV)
	Mapuera orthorubulavirus	Mapuera virus (MapV)
	*Mumps orthorubulavirus**	mumps virus (MuV)
	Porcine orthorubulavirus	La Piedad Michoacán Mexico virus (LPMV)
	Simian orthorubulavirus	simian virus 41 (SV-41)
Pararubulavirus	*Achimota pararubulavirus 1*	Achimota virus 1 (AchPV-1)
	Achimota pararubulavirus 2	Achimota virus 2 (AchPV-2)
	Hervey pararubulavirus	Hervey virus (HerV)
	*Menangle pararubulavirus**	Menangle virus (MenPV)
	Sosuga pararubulavirus	Sosuga virus (SOSV)
	Teviot pararubulavirus	Teviot virus (TevPV)
	Tioman pararubulavirus	Tioman virus (TioPV)
	Tuhoko pararubulavirus 1	Tuhoko virus 1 (ThkPV-1)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070422

	Tuhoko pararubulavirus 2	Tuhoko virus 2 (ThkPV-2)
	Tuhoko pararubulavirus 3	Tuhoko virus 3 (ThkPV-3)
Unassigned (to subfamilies)		
~~*Unassigned*~~*Cynoglossusvirus*	*Cynoglossus ~~paramyxovirus~~cynoglossusvirus**	Wēnlǐng tonguesole paramyxovirus (WTSPV)
~~*Unassigned*~~*Hoplichthysvirus*	*Hoplichthys ~~paramyxovirus~~hoplichthysvirus**	Wēnlǐng hoplichthys paramyxovirus (WHPV)
~~*Unassigned*~~*Scoliodonvirus*	*Scoliodon ~~paramyxovirus~~scoliodonvirus**	Wēnzhōu pacific spadenose shark paramyxovirus (WPSSPV)
Family *Pneumoviridae*		
Metapneumovirus	*Avian metapneumovirus**	avian metapneumovirus (AMPV)
	Human metapneumovirus	human metapneumovirus (HMPV)
Orthopneumovirus	*Bovine orthopneumovirus*	bovine respiratory syncytial virus (BRSV)
	*Human orthopneumovirus**	human respiratory syncytial virus (HRSV)
	Murine orthopneumovirus	murine pneumonia virus (MPV)
Family *Rhabdoviridae*		

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070423

Almendravirus	*Arboretum almendravirus*	Arboretum virus (ABTV)
	Balsa almendravirus	Balsa virus (BALV)
	Coot Bay almendravirus	Coot Bay virus (CBV)
	Menghai almendravirus	Menghai virus (MRV)
	*Puerto Almendras almendravirus**	Puerto Almendras virus (PTAMV)
	Rio Chico almendravirus	Rio Chico virus (RCHV)
Alphanemrhavirus	*Xingshan alphanemrhavirus**	Xingshan nematode virus 4 (XsNV-4)
	Xinzhou alphanemrhavirus	Xinzhou nematode virus 4 (XzNV-4)
Alphanucleorhabdovirus	*Eggplant mottled dwarf alphanucleorhabdovirus*	eggplant mottled dwarf virus (EMDV)
	Maize Iranian mosaic alphanucleorhabdovirus	maize Iranian mosaic virus (MIMV)
	Maize mosaic alphanucleorhabdovirus	maize mosaic virus (MMV)
	Morogoro maize-associated alphanucleorhabdovirus	Morogoro maize-associated virus (MMaV)
	Physostegia chlorotic mottle	Physostegia chlorotic mottle virus

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070424

	alphanucleorhabdovirus	(PhCMoV)
	*Potato yellow dwarf alphanucleorhabdovirus**	potato yellow dwarf virus (PYDV)
	Rice yellow stunt alphanucleorhabdovirus	rice yellow stunt virus (RYSV)
		rice transitory yellowing virus (RTYV)
	Taro vein chlorosis alphanucleorhabdovirus	taro vein chlorosis virus (TaVCV)
	Wheat yellow striate alphanucleorhabdovirus	wheat yellow striate virus (WYSV)
Arurhavirus	*Aruac arurhavirus**	Aruac virus (ARUV)
	Inhangapi arurhavirus	Inhangapi virus (INHV)
	Santabarbara arurhavirus	Santa Barbara virus (SBAV)
	Xiburema arurhavirus	Xiburema virus (XIBV)
Barhavirus	*Bahia barhavirus**	Bahia Grande virus (BGV)
	Muir barhavirus	Muir Springs virus (MSV)
Betanucleorhabdovirus	*Alfalfa betanucleorhabdovirus*	alfalfa-associated nucleorhabdovirus

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070425

		(AaNV)
	Blackcurrant betanucleorhabdovirus	blackcurrant-associated rhabdovirus (BCaRV)
	Datura yellow vein betanucleorhabdovirus	datura yellow vein virus (DYVV)
	*Sonchus yellow net betanucleorhabdovirus**	Sonchus yellow net virus (SYNV)
	Sowthistle yellow vein betanucleorhabdovirus	sowthistle yellow vein virus (SYVV)
	Trefoil betanucleorhabdovirus	birds-foot trefoil-associated virus (BFTV)
Caligrhavirus	*Caligus caligrhavirus*	Caligus rogercresseyi rhabdovirus (CRogRV)
	*Lepeophtheirus caligrhavirus**	Lepeophtheirus salmonis rhabdovirus 127 (LSalRV-127)
	Salmonlouse caligrhavirus	Lepeophtheirus salmonis rhabdovirus 9 (LSalRV-9)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070426

Curiovirus	*Curionopolis curiovirus**	Curionopolis virus (CURV)
	Iriri curiovirus	Iriri virus (IRIRV)
	Itacaiunas curiovirus	Itacaiunas virus (ITAV)
	Rochambeau curiovirus	Rochambeau virus (RBUV)
Cytorhabdovirus	*Alfalfa dwarf cytorhabdovirus*	alfalfa dwarf virus (ADV)
	Barley yellow striate mosaic cytorhabdovirus	barley yellow striate mosaic virus (BYSMV)
	Broccoli necrotic yellows cytorhabdovirus	broccoli necrotic yellows virus (BNYV)
	Cabbage cytorhabdovirus	cabbage cytorhabdovirus 1 (CCyV-1)
	Colocasia bobone disease-associated cytorhabdovirus	Colocasia bobone disease-associated virus (CBDaV)
	Festuca leaf streak cytorhabdovirus	Festuca leaf streak virus (FLSV)
	*Lettuce necrotic yellows cytorhabdovirus**	lettuce necrotic yellows virus (LNYV)
	Lettuce yellow mottle cytorhabdovirus	lettuce yellow mottle virus (LYMoV)
	Maize-associated cytorhabdovirus	maize-associated cytorhabdovirus (MaCV)
	Maize yellow striate cytorhabdovirus	maize yellow striate virus (MYSV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070427

	Northern cereal mosaic cytorhabdovirus	northern cereal mosaic virus (NCMV)
	Papaya cytorhabdovirus	papaya virus E (PpVE)
	Persimmon cytorhabdovirus	persimmon virus A (PeVA)
	Raspberry vein chlorosis cytorhabdovirus	raspberry vein chlorosis virus (RVCV)
	Rice stripe mosaic cytorhabdovirus	rice stripe mosaic virus (RSMV)
	Sonchus cytorhabdovirus 1	Sonchus virus (SonV)
	Strawberry crinkle cytorhabdovirus	strawberry crinkle virus (SCV)
	Tomato yellow mottle-associated cytorhabdovirus	tomato yellow mottle-associated virus (TYMaV)
	Wheat American striate mosaic cytorhabdovirus	wheat American striate mosaic virus (WASMV)
	Wuhan 4 insect cytorhabdovirus	Wuhan insect virus 4 (WuIV-4)
	Wuhan 5 insect cytorhabdovirus	Wuhan insect virus 5 (WuIV-5)
	Wuhan 6 insect cytorhabdovirus	Wuhan insect virus 6 (WuIV-6)
	Yerba mate chlorosis-associated cytorhabdovirus	yerba mate chlorosis-associated virus (YmCaV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070428

Dichorhavirus	*Citrus chlorotic spot dichorhavirus*	citrus chlorotic spot virus (CiCSV)
	Citrus leprosis N dichorhavirus	citrus leprosis virus N (CiLV-N)
	Clerodendrum chlorotic spot dichorhavirus	clerodendrum chlorotic spot virus (ClCSV)
	Coffee ringspot dichorhavirus	coffee ringspot virus (CoRSV)
	*Orchid fleck dichorhavirus**	orchid fleck virus (OFV)
Ephemerovirus	*Adelaide River ephemerovirus*	Adelaide River virus (ARV)
	Berrimah ephemerovirus	Berrimah virus (BRMV)
	*Bovine fever ephemerovirus**	bovine ephemeral fever virus (BEFV)
	Kimberley ephemerovirus	Kimberley virus (KIMV)
		Malakal virus (MALV)
	Koolpinyah ephemerovirus	Koolpinyah virus (KOOLV)
	Kotonkan ephemerovirus	kotonkan virus (KOTV)
	Obodhiang ephemerovirus	Obodhiang virus (OBOV)
	Yata ephemerovirus	Yata virus (YATV)
Gammanucleorhabdovirus	*Maize fine streak*	maize fine streak virus (MFSV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070429

	gammanucleorhabdovirus	
Hapavirus	*Flanders hapavirus**	Flanders virus (FLAV)
	Gray Lodge hapavirus	Gray Lodge virus (GLOV)
	Holmes hapavirus	Holmes Jungle virus (HOJV)
	Hart Park hapavirus	Hart Park virus (HPV)
	Joinjakaka hapavirus	Joinjakaka virus (JOIV)
	Kamese hapavirus	Kamese virus (KAMV)
	La Joya hapavirus	La Joya virus (LJV)
	Landjia hapavirus	Landjia virus (LANV = LJAV)
	Manitoba hapavirus	Manitoba virus (MANV = MNTBV)
	Marco hapavirus	Marco virus (MCOV)
	Mosqueiro hapavirus	Mosqueiro virus (MQOV)
	Mossuril hapavirus	Mossuril virus (MOSV)
	Ngaingan hapavirus	Ngaingan virus (NGAV)
	Ord River hapavirus	Ord River virus (ORV)
	Parry Creek hapavirus	Parry Creek virus (PCV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070430

	Wongabel hapavirus	Wongabel virus (WONV)
Ledantevirus	*Barur ledantevirus*	Barur virus (BARV)
	Fikirini ledantevirus	Fikirini virus (FKRV)
	Fukuoka ledantevirus	Fukuoka virus (FUKV)
	Kanyawara ledantevirus	Kanyawara virus (KYAV)
	Kern Canyon ledantevirus	Kern Canyon virus (KCV)
	Keuraliba ledantevirus	Keuraliba virus (KEUV)
	Kolente ledantevirus	Kolente virus (KOLEV)
	Kumasi ledantevirus	Kumasi rhabdovirus (KRV)
	*Le Dantec ledantevirus**	Le Dantec virus (LDV)
	Mount Elgon bat ledantevirus	Mount Elgon bat virus (MEBV)
	Nishimuro ledantevirus	Nishimuro virus (NISV)
	Nkolbisson ledantevirus	Nkolbisson virus (NKOV)
	Oita ledantevirus	Oita virus (OITAV)
	Vaprio ledantevirus	Vaprio virus (VAPV)
	Wuhan ledantevirus	Wuhan louse fly virus 5 (WLFV-5)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070431

	Yongjia ledantevirus	Yongjia tick virus 2 (YTV-2)
Lostrhavirus	*Lonestar zarhavirus**,[4]	Lone Star tick rhabdovirus (LITRV)
Lyssavirus	*Aravan lyssavirus*	Aravan virus (ARAV)
	Australian bat lyssavirus	Australian bat lyssavirus (ABLV)
	Bokeloh bat lyssavirus	Bokeloh bat lyssavirus (BBLV)
	Duvenhage lyssavirus	Duvenhage virus (DUVV)
	European bat 1 lyssavirus	European bat lyssavirus 1 (EBLV-1)
	European bat 2 lyssavirus	European bat lyssavirus 2 (EBLV-2)
	Gannoruwa bat lyssavirus	Gannoruwa bat lyssavirus (GBLV)
	Ikoma lyssavirus	Ikoma lyssavirus (IKOV)
	Irkut lyssavirus	Irkut virus (IRKV)
	Khujand lyssavirus	Khujand virus (KHUV)
	Lagos bat lyssavirus	Lagos bat virus (LBV)
	Lleida bat lyssavirus	Lleida bat lyssavirus (LLEBV)
	Mokola lyssavirus	Mokola virus (MOKV)
	*Rabies lyssavirus**	rabies virus (RABV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070432

	Shimoni bat lyssavirus	Shimoni bat virus (SHIBV)
	Taiwan bat lyssavirus	Taiwan bat lyssavirus (TWBLV)
	West Caucasian bat lyssavirus	West Caucasian bat virus (WCBV)
Mousrhavirus	*Moussa mousrhavirus**	Moussa virus (MOUV)
Novirhabdovirus	*Hirame novirhabdovirus*	hirame rhabdovirus (HIRRV = HIRV)
	Piscine novirhabdovirus	viral hemorrhagic septicemia virus (VHSV)
	*Salmonid novirhabdovirus**	infectious hematopoietic necrosis virus (IHNV)
	Snakehead novirhabdovirus	snakehead rhabdovirus (SHRV)
~~*Nucleorhabdovirus*~~	~~*Datura yellow vein nucleorhabdovirus*~~	~~datura yellow vein virus (DYVV)~~
	~~*Eggplant mottled dwarf nucleorhabdovirus*~~	~~eggplant mottled dwarf virus (EMDV)~~
	~~*Maize fine streak nucleorhabdovirus*~~	~~maize fine streak virus (MSFV)~~
	~~*Maize Iranian mosaic nucleorhabdovirus*~~	~~maize Iranian mosaic virus (MIMV)~~
	~~*Maize mosaic nucleorhabdovirus*~~	~~maize mosaic virus (MMV)~~
	~~*Potato yellow dwarf nucleorhabdovirus**~~	~~potato yellow dwarf virus (PYDV)~~

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070433

	~~*Rice yellow stunt nucleorhabdovirus*~~	~~rice yellow stunt virus (RYSV)~~
		~~rice transitory yellowing virus (RTYV)~~
	~~*Sonchus yellow net nucleorhabdovirus*~~	~~Sonchus yellow net virus (SYNV)~~
	~~*Sowthistle yellow vein nucleorhabdovirus*~~	~~sowthistle yellow vein virus (SYVV)~~
	~~*Taro vein chlorosis nucleorhabdovirus*~~	~~taro vein chlorosis virus (TaVCV)~~
Ohlsrhavirus	*Ohlsdorf ohlsrhavirus*	Ohlsdorf virus (OHLDV)
	Tongilchon ohlsrhavirus	Tongilchon virus 1 (TCHV-1)
	Riverside ohlsrhavirus	Riverside virus (RISV)
	Culex ohlsrharhavirus	Culex rhabdo-like virus (CRLV)
	Northcreek ohlsrhavirus	North Creek virus (NORCV)
Perhabdovirus	*Anguillid perhabdovirus*	eel virus European X (EVEX)
	*Perch perhabdovirus**	perch rhabdovirus (PRV)
	Sea trout perhabdovirus	lake trout rhabdovirus (LTRV)
Sawgrhavirus	*Connecticut sawgrhavirus*	Connecticut virus (CNTV)
	Island sawgrhavirus	Long Island tick rhabdovirus (LITRV)
	Minto sawgrhavirus	New Minto virus (NMV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070434

	*Sawgrass sawgrhavirus**	Sawgrass virus (SAWV)
Sigmavirus	*Drosophila affinis sigmavirus*	Drosophila affinis sigmavirus (DAffSV)
	Drosophila ananassae sigmavirus	Drosophila ananassae sigmavirus (DAnaSV)
	Drosophila immigrans sigmavirus	Drosophila immigrans sigmavirus (DImmSV)
	*Drosophila melanogaster sigmavirus**	Drosophila melanogaster sigmavirus (DMelSV)
	Drosophila obscura sigmavirus	Drosophila obscura sigmavirus (DObsSV)
	Drosophila tristis sigmavirus	Drosophila tristis sigmavirus (DTriSV)
	Muscina stabulans sigmavirus	Muscina stabulans sigmavirus (MStaSV)
Sprivivirus	*Carp sprivivirus**	spring viremia of carp virus (SVCV)
	Pike fry sprivivirus	grass carp rhabdovirus (GrCRV)
		pike fry rhabdovirus (PFRV)
		tench rhabdovirus (TenRV)
Sripuvirus	*Almpiwar sripuvirus*	Almpiwar virus (ALMV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070435

	Chaco sripuvirus	Chaco virus (CHOV)
	Charleville sripuvirus	Charleville virus (CHVV)
	Cuiaba sripuvirus	Cuiaba virus (CUIV)
	Hainan sripuvirus	Hainan black-spectacled toad rhabdovirus (HnBSTRV)
	*Niakha sripuvirus**	Niakha virus (NIAV)
	Sena Madureira sripuvirus	Sena Madureira virus (SMV)
	Sripur sripuvirus	Sripur virus (SRIV)
Sunrhavirus	*Garba sunrhavirus*	Garba virus (GARV)
	Harrison sunrhavirus	Harrison Dam virus (HARDV)
	Kwatta sunrhavirus	Kwatta virus (KWAV)
	Oakvale sunrhavirus	Oak Vale virus (OVV)
	*Sunguru sunrhavirus**	Sunguru virus (SUNV)
	Walkabout sunrhavirus	Walkabout Creek virus (WAKV)
Tibrovirus	*Bas Congo tibrovirus*	Bas-Congo virus (BASV)
	Beatrice Hill tibrovirus	Beatrice Hill virus (BHV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070436

	Coastal Plains tibrovirus	Coastal Plains virus (CPV)
	Ekpoma 1 tibrovirus	Ekpoma virus 1 (EKV-1)
	Ekpoma 2 tibrovirus	Ekpoma virus 2 (EKV-2)
	Sweetwater Branch tibrovirus	Sweetwater Branch virus (SWBV)
	*Tibrogargan tibrovirus**	Bivens Arm virus (BAV)
		Tibrogargan virus (TIBV)
Tupavirus	*Durham tupavirus**	Durham virus (DURV)
	Klamath tupavirus	Klamath virus (KLAV)
	Tupaia tupavirus	tupaia virus (TUPV)
Varicosavirus	*Lettuce big-vein associated varicosavirus**	lettuce big-vein associated virus (LBVaV)
Vesiculovirus	*Alagoas vesiculovirus*	vesicular stomatitis Alagoas virus (VSAV)
	American bat vesiculovirus	American bat vesiculovirus (ABVV)
	Carajas vesiculovirus	Carajas virus (CJSV)
	Chandipura vesiculovirus	Chandipura virus (CHPV)
	Cocal vesiculovirus	Cocal virus (COCV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070437

	*Indiana vesiculovirus**	vesicular stomatitis Indiana virus (VSIV)
	Isfahan vesiculovirus	Isfahan virus (ISFV)
	Jurona vesiculovirus	Jurona virus (JURV)
	Malpais Spring vesiculovirus	Malpais Spring virus (MSPV)
	Maraba vesiculovirus	Maraba virus (MARAV)
	Morreton vesiculovirus	Morreton virus (MORV)
	New Jersey vesiculovirus	vesicular stomatitis New Jersey virus (VSNJV)
	Perinet vesiculovirus	Perinet virus (PERV)
	Piry vesiculovirus	Piry virus (PIRYV)
	Radi vesiculovirus	Radi virus (RADV)
	Yug Bogdanovac vesiculovirus	Yug Bogdanovac virus (YBV)
Zarhavirus	*Zahedan zarhavirus**	Zahedan rhabdovirus (ZARV)
~~Unassigned~~	~~*Moussa virus Maize fine streak rhabdovirus**~~	~~Moussa virus (MOUV) maize fine streak virus (MFSV)~~
Family *Sunviridae*		

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070438

Sunshinevirus	*Reptile sunshinevirus 1**	Sunshine Coast virus (SunCV)
Family *Xinmoviridae*		
Anphevirus	*Bolahun anphevirus*	Bolahun virus (BLHV)
		Gambie virus (GAMV)
	Dipteran anphevirus	Húběi diptera virus 11 (HbDV-11)
	Drosophilid anphevirus	Drosophila unispina virus 1 (DuniV-1)
	Odonate anphevirus	Húběi rhabdo-like virus 7 (HbRLV-7)
	Orthopteran anphevirus	Húběi orthoptera virus 5 (HbOV-5)
	Shuangao anphevirus	Shuāngāo fly virus 2 (SgFV-2)
	*Xincheng anphevirus**	Xīnchéng mosquito virus (XcMV)

*type species

[1]Due to a formal classification mistake this species was not deleted. A proposal to delete this species name will be submitted prior to the next taxonomic proposal submission deadline. [2]Includes: Newcastle disease virus (NDV). [3]Due to a formal classification mistake, this species was incorrectly named *Avian orthovulavirus 21* in TaxoProp 2019.014M.A.v1.Avulavirus_1newsp but correctly named *Avian orthoavulavirus 21* in TaxoProp 2019.025M.A.v2.Paramyxoviridae_3gen5sp4rensp. Hence as of now, both species names are official. A proposal to abolish the species *Avian orthovulavirus 21* will be submitted prior to the next taxonomic proposal submission

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070439

deadline. [4]Due to a formal classification mistake this species was named *Lonestar zarhavirus* instead of *Lonestar lostrhavirus*. A proposal to correct this species name will be submitted prior to the next taxonomic proposal submission deadline.

[¶]Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070440

Table 4. ICTV-accepted taxonomy of the order *Muvirales* (*Negarnaviricota*: *Haploviricotina*: *Chunqiuviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	Species¶	Virus (Abbreviation)¶
Family *Qinviridae*		
Yingvirus	*Beihai yingvirus*	Běihǎi sesarmid crab virus 4 (BhSCV-4)
	Charybdis yingvirus	Wēnzhōu qínvirus-like virus 2 (WzQLV-2)
	Hubei yingvirus	Húběi qínvirus-like virus 1 (HbQLV-1)
	Sanxia yingvirus	Sānxiá qínvirus-like virus 1 (SxQLV-1)
	Shahe yingvirus	Shāhé qínvirus-like virus 1 (ShQLV-1)
	Wenzhou yingvirus	Wēnzhōu qínvirus-like virus 1 (WzQLV-1)
	*Wuhan yingvirus**	Wǔhàn insect virus 15 (WhIV-15)
	Xinzhou yingvirus	Xīnzhōu nematode virus 3 (XzNV-3)

*type species

¶Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070441

capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070442

Table 5. ICTV-accepted taxonomy of the order *Serpentovirales* (*Negarnaviricota*: *Haploviricotina*: *Milneviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	Species¶	Virus (Abbreviation)¶
Family *Aspiviridae*		
Ophiovirus	*Blueberry mosaic associated ophiovirus*	blueberry mosaic associated virus (BlMaV)
	*Citrus psorosis ophiovirus**	citrus psorosis virus (CPsV)
	Freesia sneak ophiovirus	freesia sneak virus (FreSV)
	Lettuce ring necrosis ophiovirus	lettuce ring necrosis virus (LRNV)
	Mirafiori lettuce big-vein ophiovirus	Mirafiori lettuce big-vein virus (MLBVV)
	Ranunculus white mottle ophiovirus	ranunculus white mottle virus (RWMV)
	Tulip mild mottle mosaic ophiovirus	tulip mild mottle mosaic virus (TMMMV)

*type species

¶Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070443

Table 6. ICTV-accepted taxonomy of the order *Articulavirales* (*Negarnaviricota*: *Polyploviricotina*: *Insthoviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	**Species¶**	**Virus (Abbreviation)¶**
Family *Amnoonviridae*		
Tilapinevirus	*Tilapia tilapinevirus**	tilapia lake virus (TiLV)
Family *Orthomyxoviridae*		
Alphainfluenzavirus	*Influenza A virus**	influenza A virus (FLUAV)
Betainfluenzavirus	*Influenza B virus**	influenza B virus (FLUBV)
Deltainfluenzavirus	*Influenza D virus**	influenza D virus (FLUDV)
Gammainfluenzavirus	*Influenza C virus**	influenza C virus (FLUCV)
Isavirus	*Salmon isavirus**	infectious salmon anemia virus (ISAV)
Quaranjavirus	*Johnston Atoll quaranjavirus*	Johnston Atoll virus (JAV)
	*Quaranfil quaranjavirus**	Quaranfil virus (QRFV)
Thogotovirus	*Dhori thogotovirus*	Dhori virus (DHOV)
	*Thogoto thogotovirus**	Thogoto virus (THOV)

*type species

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070444

¶Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070445

Table 7. ICTV-accepted taxonomy of the order *Bunyavirales* (*Negarnaviricota*: *Polyploviricotina*: *Ellioviricetes*) as of March 2020. Listed are all order members that are classified into species.

Genus	**Species¶**	**Virus (Abbreviation)¶**
Family *Arenaviridae*		
Antennavirus	*Hairy antennavirus*	Wēnlǐng frogfish arenavirus 2 (WlFAV-2)
	*Striated antennavirus**	Wēnlǐng frogfish arenavirus 1 (WlFAV-1)
Hartmanivirus	*Haartman hartmanivirus**	Haartman Institute snake virus 1 (HISV-1)
	Muikkunen hartmanivirus	Dante Muikkunen virus 1 (DaMV-1)
	Schoolhouse hartmanivirus	old schoolhouse virus 1 (OScV-1)
		old schoolhouse virus 2 (OScV-2)
	Zurich hartmanivirus	veterinary pathology Zurich virus 1 (VPZV-1)
		veterinary pathology Zurich virus 2 (VPZV-2)
Mammarenavirus	*Allpahuayo mammarenavirus*	Allpahuayo virus (ALLV)
	Alxa mammarenavirus	Alxa virus (ALXV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070446

	Argentinian mammarenavirus	Junín virus (JUNV)
	Bear Canyon mammarenavirus	Bear Canyon virus (BCNV)
	Brazilian mammarenavirus	Sabiá virus (SBAV)
	Cali mammarenavirus	Pichindé virus (PICHV)
	Chapare mammarenavirus	Chapare virus (CHAPV)
	Chevrier mammarenavirus	Lìjiāng virus (LIJV)
	Cupixi mammarenavirus	Cupixi virus (CUPXV)
	Flexal mammarenavirus	Flexal virus (FLEV)
	Gairo mammarenavirus	Gairo virus (GAIV)
	Guanarito mammarenavirus	Guanarito virus (GTOV)
	Ippy mammarenavirus	Ippy virus (IPPYV)
	Lassa mammarenavirus	Lassa virus (LASV)
	Latino mammarenavirus	Latino virus (LATV)
	Loei River mammarenavirus	Loei River virus (LORV)
	Lujo mammarenavirus	Lujo virus (LUJV)
	Luna mammarenavirus	Luli virus (LULV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070447

		Luna virus (LUAV)
	Lunk mammarenavirus	Lunk virus (LNKV)
	*Lymphocytic choriomeningitis mammarenavirus**	Dandenong virus (DANV)
		lymphocytic choriomeningitis virus (LCMV)
	Machupo mammarenavirus	Machupo virus (MACV)
	Mariental mammarenavirus	Mariental virus (MRLV)
	Merino Walk mammarenavirus	Merino Walk virus (MRWV)
	Mobala mammarenavirus	mobala virus (MOBV)
	Mopeia mammarenavirus	Mopeia virus (MPOV)
		Morogoro virus (MORV)
	Okahandja mammarenavirus	Okahandja virus (OKAV)
	Oliveros mammarenavirus	Oliveros virus (OLVV)
	Paraguayan mammarenavirus	Paraná virus (PRAV)
	Planalto mammarenavirus	Aporé virus (APOV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070448

	Pirital mammarenavirus	Pirital virus (PIRV)
	Ryukyu mammarenavirus	Ryukyu virus (RYKV)
	Serra do Navio mammarenavirus	Amaparí virus (AMAV)
	Solwezi mammarenavirus	Solwezi virus (SOLV)
	Souris mammarenavirus	souris virus (SOUV)
	Tacaribe mammarenavirus	Tacaribe virus (TCRV)
	Tamiami mammarenavirus	Tamiami virus (TMMV)
	Wenzhou mammarenavirus	Wēnzhōu virus (WENV)
	Whitewater Arroyo mammarenavirus	Big Brushy Tank virus (BBRTV)
		Catarina virus (CTNV)
		Skinner Tank virus (SKTV)
		Tonto Creek virus (TTCV)
		Whitewater Arroyo virus (WWAV)
	Xapuri mammarenavirus	Xapuri virus (XAPV)
Reptarenavirus	*California reptarenavirus*	CAS virus (CASV)
	Giessen reptarenavirus	University of Giessen virus 1 (UGV-1)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070449

		University of Giessen virus 2 (UGV-2)
		University of Giessen virus 3 (UGV-3)
	*Golden reptarenavirus**	Golden Gate virus (GOGV)
	Ordinary reptarenavirus	tavallinen suomalainen mies virus 2 (TSMV-2)
	Rotterdam reptarenavirus	ROUT virus (ROUTV)
		University of Helsinki virus 1 (UHV-1)
Family *Cruliviridae*		
Lincruvirus	*Crustacean lincruvirus**	Wēnlǐng crustacean virus 9 (WlCV-9)
Family *Fimoviridae*		
Emaravirus	*Actinidia chlorotic ringspot-associated emaravirus*	Actinidia chlorotic ringspot-associated virus (AcCRaV)
	Blackberry leaf mottle associated emaravirus	blackberry leaf mottle-associated virus (BLMaV)
	*European mountain ash ringspot-associated emaravirus**	European mountain ash ringspot-associated virus (EMARaV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070450

	Fig mosaic emaravirus	fig mosaic virus (FMV)
	High Plains wheat mosaic emaravirus	High Plains wheat mosaic virus (HPWMoV)
	Pigeonpea sterility mosaic emaravirus 1	pigeonpea sterility mosaic virus (PPSMV)
	Pigeonpea sterility mosaic emaravirus 2	pigeonpea sterility mosaic virus 2 (PPSMV-2)
	Pistacia emaravirus B	pistacia virus B (PiVB)
	Raspberry leaf blotch emaravirus	raspberry leaf blotch virus (RLBV)
	Redbud yellow ringspot-associated emaravirus	redbud yellow ringspot-associated virus (RYRaV)
	Rose rosette emaravirus	rose rosette virus (RRV)
Family *Hantaviridae*		
Subfamily *Actantavirinae*		
Actinovirus	*Batfish actinovirus**	Wēnlǐng minipizza batfish virus (WEMBV)
	Goosefish actinovirus	Wēnlǐng yellow goosefish virus (WEYGV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070451

	Spikefish actinovirus	Wēnlǐng red spikefish virus (WERSV)
Subfamily *Agantavirinae*		
Agnathovirus	*Hagfish agnathovirus**	Wēnlǐng hagfish virus (WEHV)
Subfamily *Mammantavirinae*		
Loanvirus	*Brno loanvirus*	Brno virus (BRNV)
	*Longquan loanvirus**	Lóngquán virus (LQUV)
Mobatvirus	*Laibin mobatvirus*	Láibīn virus (LAIV)
	*Nova mobatvirus**	Nova virus (NVAV)
	Quezon mobatvirus	Quezon virus (QZNV)
Orthohantavirus	*Andes orthohantavirus*	Andes virus (ANDV)
		Castelo dos Sonhos virus (CASV)
		Lechiguanas virus (LECV = LECHV)
		Orán virus (ORNV)
	Asama orthohantavirus	Asama virus (ASAV)
	Asikkala orthohantavirus	Asikkala virus (ASIV)
	Bayou orthohantavirus	bayou virus (BAYV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070452

		Catacamas virus (CATV)
	Black Creek Canal orthohantavirus	Black Creek Canal virus (BCCV)
	Bowe orthohantavirus	Bowé virus (BOWV)
	Bruges orthohantavirus	Bruges virus (BRGV)
	Cano Delgadito orthohantavirus	Caño Delgadito virus (CADV)
	Cao Bang orthohantavirus	Cao Bằng virus (CBNV)
		Liánghé virus (LHEV)
	Choclo orthohantavirus	Choclo virus (CHOV)
	Dabieshan orthohantavirus	Dàbiéshān virus (DBSV)
	Dobrava-Belgrade orthohantavirus	Dobrava virus (DOBV)
		Kurkino virus (KURV)
		Saaremaa virus (SAAV)
		Sochi virus (SOCV)
	El Moro Canyon orthohantavirus	Carrizal virus (CARV)
		El Moro Canyon virus (ELMCV)
		Huitzilac virus (HUIV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070453

	Fugong orthohantavirus	Fúgòng virus (FUGV)
	Fusong orthohantavirus	Fŭsōng virus (FUSV)
	*Hantaan orthohantavirus**	Amur virus (AMRV)
		Hantaan virus (HTNV)
		Soochong virus (SOOV)
	Jeju orthohantavirus	Jeju virus (JJUV)
	Kenkeme orthohantavirus	Kenkeme virus (KKMV)
	Khabarovsk orthohantavirus	Khabarovsk virus (KHAV)
		Topografov virus (TOPV)
	Laguna Negra orthohantavirus	Laguna Negra virus (LANV)
		Maripa virus (MARV)
		Riı́o Mamoré virus (RIOMV)
	Luxi orthohantavirus	Lúxī virus (LUXV)
	Maporal orthohantavirus	Maporal virus (MAPV)
	Montano orthohantavirus	Montaño virus (MTNV)
	Necocli orthohantavirus	Necoclí virus (NECV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070454

	Oxbow orthohantavirus	Oxbow virus (OXBV)
	Prospect Hill orthohantavirus	Prospect Hill virus (PHV)
	Puumala orthohantavirus	Hokkaido virus (HOKV)
		Muju virus (MUJV)
		Puumala virus (PUUV)
	Rockport orthohantavirus	Rockport virus (RKPV)
	Sangassou orthohantavirus	Sangassou virus (SANGV)
	Seewis orthohantavirus	Seewis virus (SWSV)
	Seoul orthohantavirus	gōu virus (GOUV)
		Seoul virus (SEOV)
	Sin Nombre orthohantavirus	New York virus (NYV)
		Sin Nombre virus (SNV)
	Thailand orthohantavirus	Anjozorobe virus (ANJZV)
		Serang virus (SERV)
		Thailand virus (THAIV)
	Tigray orthohantavirus	Tigray virus (TIGV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070455

	Tula orthohantavirus	Adler virus (ADLV)
		Tula virus (TULV)
	Yakeshi orthohantavirus	Yákèshí virus (YKSV)
Thottimvirus	*Imjin thottimvirus*	Imjin virus (MJNV)
	*Thottapalayam thottimvirus**	Thottapalayam virus (TPMV)
Subfamily *Repantavirinae*		
Reptillovirus	*Gecko reptillovirus**	Hǎinán oriental leaf-toed gecko virus (HOLGV)
Family *Leishbuviridae*		
Shilevirus	*Leptomonas shilevirus**	Leptomonas moramango virus (LEPMV)
Family *Mypoviridae*		
Hubavirus	*Myriapod hubavirus**	Húběi myriapoda virus 5 (HbMV-5)
Family *Nairoviridae*		
Orthonairovirus	*Artashat orthonairovirus*	Artashat virus (ARTSV)
	Chim orthonairovirus	Chim virus (CHIMV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070456

	Crimean-Congo hemorrhagic fever orthonairovirus	Crimean-Congo hemorrhagic fever virus (CCHFV)
	Dera Ghazi Khan orthonairovirus	Abu Hammad virus (AHV)
		Abu Mina virus (AMV)
		Dera Ghazi Khan virus (DGKV)
		Sapphire II virus (SAPV)
	*Dugbe orthonairovirus**	Dugbe virus (DUGV)
		kupe virus (KUPEV)
	Estero Real orthonairovirus	Estero Real virus (ERV)
	Hazara orthonairovirus	Hazara virus (HAZV)
		Tofla virus (TFLV)
	Hughes orthonairovirus	Caspiy virus (CASV)
		Farallon virus (FARV)
		Great Saltee virus (GRSV)
		Hughes virus (HUGV)
		Punta Salinas virus (PSV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070457

		Raza virus (RAZAV)
		Soldado virus (SOLV)
		Zirqa virus (ZIRV)
	Kasokero orthonairovirus	Kasokero virus (KASV = KASOV)
		Leopards Hill virus (LPHV)
		Yogue virus (YOGV)
	Keterah orthonairovirus	Gossas virus (GOSV)
		Issyk-kul virus (ISKV)
		Keterah virus (KTRV)
		Uzun-Agach virus (UZAV)
	Nairobi sheep disease orthonairovirus	Nairobi sheep disease virus (NSDV)
	Qalyub orthonairovirus	Bandia virus (BDAV)
		Geran virus (GERV)
		Qalyub virus (QYBV)
	Sakhalin orthonairovirus	Avalon virus (AVAV)
		Clo Mor virus (CMV = CLMV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070458

		Sakhalin virus (SAKV)
		Taggert virus (TAGV)
		Tillamook virus (TILLV)
	Tamdy orthonairovirus	Burana virus (BURV)
		Huángpí tick virus 1 (HpTV-1)
		Tăchéng tick virus 1 (TcTV-1)
		Tamdy virus (TAMV)
		Wēnzhōu tick virus (WzTV)
	Thiafora orthonairovirus	Erve virus (ERVEV)
		Thiafora virus (TFAV)
Shaspivirus	*Spider shaspivirus**	Shāyáng spider virus 1 (SySV-1)
Striwavirus	*Strider striwavirus**	Sānxiá water strider virus 1 (SxWSV-1)
Family *Peribunyaviridae*		
Herbevirus	*Herbert herbevirus**	Herbert virus (HEBV)
	Kibale herbevirus	Kibale virus (KIBV)
	Tai herbevirus	Taï virus (TAIV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070459

Orthobunyavirus	*Acara orthobunyavirus*	Acará virus (ACAV)
		Moriche virus (MORV)
	Aino orthobunyavirus	Aino virus (AINOV)
	Akabane orthobunyavirus	Akabane virus (AKAV)
		Tinaroo virus (TINV)
		Yaba-7 virus (Y7V)
	Alajuela orthobunyavirus	Alajuela virus (ALJV)
		San Juan virus (SJV)
	Anadyr orthobunyavirus	Anadyr virus (ANADV)
	Anhembi orthobunyavirus	Anhembi virus (AMBV)
	Anopheles A orthobunyavirus	Anopheles A virus (ANAV)
		Arumateua virus (ARTV = ARMTV)
		Caraipé virus (CPEV = CRPV)
		Las Maloyas virus (LMV)
		Lukuni virus (LUKV)
		Trombetas virus (TRMV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070460

		Tucuruí virus (TUCV = TUCRV)
	Anopheles B orthobunyavirus	Anopheles B virus (ANBV)
		Boracéia virus (BORV)
	Bakau orthobunyavirus	Bakau virus (BAKV)
		Ketapang virus (KETV)
		Nola virus (NOLAV)
		Tanjong Rabok virus (TRV)
		Telok Forest virus (TFV)
	Batai orthobunyavirus	Batai virus (BATV)
	Batama orthobunyavirus	Batama virus (BMAV)
	Bellavista orthobunyavirus	Bellavista virus (BELLV)
	Benevides orthobunyavirus	Benevides virus (BVSV = BENV)
	Bertioga orthobunyavirus	Bertioga virus (BERV)
		Cananéia virus (CNAV)
		Guaratuba virus (GTBV)
		Itimirim virus (ITIV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070461

		Mirim virus (MIRV)
	Bimiti orthobunyavirus	bimiti virus (BIMV)
	Birao orthobunyavirus	Birao virus (BIRV)
	Botambi orthobunyavirus	Botambi virus (BOTV)
	Bozo orthobunyavirus	Bozo virus (BOZOV)
	*Bunyamwera orthobunyavirus**	Bunyamwera virus (BUNV)
		Germiston virus (GERV)
		Lokern virus (LOKV)
		Mboké virus (MBOV)
		Ngari virus (NRIV)
		Northway virus (NORV)
		Santa Rosa virus (SARV)
		Shokwe virus (SHOV)
		Stanfield virus (STAV)
		Xingu virus (XINV)
	Bushbush orthobunyavirus	Benfica virus (BENV = BNFV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070462

		Bushbush virus (BSBV)
		Juan Díaz virus (JDV)
	Buttonwillow orthobunyavirus	Buttonwillow virus (BUTV)
	Bwamba orthobunyavirus	Bwamba virus (BWAV)
		Pongola virus (PGAV)
	Cache Valley orthobunyavirus	Cache Valley virus (CVV)
		Cholul virus (CHLV)
		Tlacotalpan virus (TLAV)
	Cachoeira Porteira orthobunyavirus	Cachoeira Porteira virus (CPOV)
	California encephalitis orthobunyavirus	California encephalitis virus (CEV)
		Morro Bay virus (MBV)
	Capim orthobunyavirus	Capim virus (CAPV)
	Caraparu orthobunyavirus	Apeú virus (APEUV)
		Bruconha virus (BRUV)
		Caraparú virus (CARV)
		El Huayo virus (EHUV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070463

		Itaya virus (ITYV)
		Ossa virus (OSSAV)
		Vinces virus (VINV)
	Cat Que orthobunyavirus	Cát Quế virus (CQV)
		Oya virus (OYAV)
	Catu orthobunyavirus	Catú virus (CATUV)
	Enseada orthobunyavirus	Enseada virus (ENSV)
	Faceys paddock orthobunyavirus	Facey's paddock virus (FPV)
	Fort Sherman orthobunyavirus	Fort Sherman virus (FSV)
	Gamboa orthobunyavirus	Brus Laguna virus (BLAV)
		Calchaquí virus (CQIV)
		Gamboa virus (GAMV)
		Pueblo Viejo virus (PVV)
		Soberanía virus (SOBV)
	Guajara orthobunyavirus	Guajará virus (GJAV)
	Guama orthobunyavirus	Ananindeua virus (ANUV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070464

		Guamá virus (GMAV)
		Mahogany Hammock virus (MHV)
		Moju virus (MOJUV)
	Guaroa orthobunyavirus	Guaroa virus (GROV)
	Iaco orthobunyavirus	Iaco virus (IACOV)
	Ilesha orthobunyavirus	Ilesha virus (ILEV)
	Ingwavuma orthobunyavirus	Ingwavuma virus (INGV)
	Jamestown Canyon orthobunyavirus	Inkoo virus (INKV)
		Jamestown Canyon virus (JCV)
		Jerry Slough virus (JSV)
		South River virus (SORV)
	Jatobal orthobunyavirus	Jatobal virus (JATV)
	Kaeng Khoi orthobunyavirus	Kaeng Khoi virus (KKV)
	Kairi orthobunyavirus	Kairi virus (KRIV)
	Keystone orthobunyavirus	Keystone virus (KEYV)
	Koongol orthobunyavirus	koongol virus (KOOV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070465

		wongal virus (WONV)
	La Crosse orthobunyavirus	La Crosse virus (LACV)
	Leanyer orthobunyavirus	Leanyer virus (LEAV)
	Lumbo orthbunyavirus	Lumbo virus (LUMV)
	Macaua orthobunyavirus	Macauã virus (MCAV)
	Madrid orthobunyavirus	Madrid virus (MADV)
	Maguari orthobunyavirus	Maguari virus (MAGV)
		Playas virus (PLAV)
	Main Drain orthobunyavirus	Main Drain virus (MDV)
	Manzanilla orthobunyavirus	Manzanilla virus (MANV)
		Inini virus (INIV)
	Marituba orthobunyavirus	Gumbo Limbo virus (GLV)
		Marituba virus (MTBV)
		Murutucú virus (MURV)
		Nepuyo virus (NEPV)
		Restan virus (RESV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070466

		Zungarococha virus (ZUNV)
	Melao orthobunyavirus	Melao virus (MELV)
	Mermet orthobunyavirus	Mermet virus (MERV)
	Minatitlan orthobunyavirus	Minatitlán virus (MNTV)
		Palestina virus (PLSV)
	MPoko orthobunyavirus	M'Poko virus (MPOV)
		Yaba-1 virus (Y1V)
	Nyando orthobunyavirus	Eretmapodites virus (ERETV)
		Mojuí dos Campos virus (MDCV)
		Nyando virus (NDV)
	Olifantsvlei orthobunyavirus	Bobia virus (BIAV)
		Dabakala virus (DABV)
		Olifantsvlei virus (OLIV)
		Oubi virus (OUBIV)
	Oriboca orthobunyavirus	Itaquí virus (ITQV)
		Oriboca virus (ORIV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070467

	Oropouche orthobunyavirus	Iquitos virus (IQTV)[d]
		Madre de Dios virus (MDDV)
		Oropouche virus (OROV)
		Perdões virus (PDEV)
		Pintupo virus (PINTV)
	Patois orthobunyavirus	Abras virus (ABRV)
		Babahoya virus (BABV)
		Pahayokee virus (PAHV)
		Patois virus (PATV)
		Shark River virus (SRV)
	Peaton orthobunyavirus	Peaton virus (PEAV)
	Potosi orthobunyavirus	Potosi virus (POTV)
	Sabo orthobunyavirus	Sabo virus (SABOV)
	San Angelo orthobunyavirus	San Angelo virus (SAV)
	Sango orthobunyavirus	Sango virus (SANV)
	Schmallenberg orthobunyavirus	Douglas virus (DOUV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070468

		Sathuperi virus (SATV)
		Schmallenberg virus (SBV)
		Shamonda virus (SHAV)
	Serra do Navio orthobunyavirus	Serra do Navio virus (SDNV)
	Shuni orthobunyavirus	Kaikalur virus (KAIV)
		-Shuni virus (SHUV)
	Simbu orthobunyavirus	Para virus (PARAV)
		Simbu virus (SIMV)
	Snowshoe hare orthobunyavirus	Khatanga virus (KHATV)[9]
		-snowshoe hare virus (SSHV)
	Sororoca orthobunyavirus	Sororoca virus (SORV)
	Tacaiuma orthobunyavirus	CoAr 1071 virus (CA1071V)
		CoAr 3627 virus (CA3626V)
		Tacaiuma virus (TCMV)
		Virgin River virus (VRV)
	Tahyna orthobunyavirus	Ťahyňa virus (TAHV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070469

	Tataguine orthobunyavirus	Tataguine virus (TATV)
	Tensaw orthobunyavirus	Tensaw virus (TENV)
	Tete orthobunyavirus	Bahig virus (BAHV)
		Matruh virus (MTRV)
		Tete virus (TETEV)
		Tsuruse virus (TSUV)
		Weldona virus (WELV)
	Thimiri orthobunyavirus	Thimiri virus (THIV)
	Timboteua orthobunyavirus	Timboteua virus (TBTV)
	Trivittatus orthobunyavirus	Achiote virus (ACHOV)
		Trivittatus virus (TVTV)
	Turlock orthobunyavirus	Lednice virus (LEDV)
		Turlock virus (TURV)
		Umbre virus (UMBV)
	Utinga orthobunyavirus	Utinga virus (UTIV)
	Witwatersrand orthobunyavirus	Witwatersrand virus (WITV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070470

	Wolkberg orthobunyavirus	Wolkberg virus (WBV)
	Wyeomyia orthobunyavirus	Rio Pracupi virus
		Taiassui virus (TAIAV)
		Tucunduba virus (TUCV)
		Wyeomyia virus (WYOV)
	Zegla orthobunyavirus	Zegla virus (ZEGV)
Pacuvirus	*Caimito pacuvirus*	Caimito virus (CAIV)
	Chilibre pacuvirus	Chilibre virus (CHIV)
	*Pacui pacuvirus**	Pacui virus (PACV)
	Rio Preto da Eva pacuvirus	Rio Preto da Eva virus (RPEV)
	Tapirape pacuvirus	Tapirapé virus (TAPV)
Shangavirus	*Insect shangavirus**	Shuāngào insect virus 1 (SgIV-1)
Family *Phasmaviridae*		
Feravirus	*Ferak feravirus**	Ferak virus (FRKV)
~~*Inshuvirus*~~	~~*Insect inshuvirus**~~	~~Shuāngào insect virus 2 (SgIV-2)~~
Jonvirus	*Jonchet jonvirus**	jonchet virus (JONV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070471

Orthophasmavirus	*Anopheles orthophasmavirus*	Anopheles triannulatus orthophasmavirus (AtOPV)
	Culex orthophasmavirus	Culex orthophasmavirus (CPLV)
	Ganda orthophasmavirus	Ganda orthophasmavirus (GBEEV)
	*Kigluaik phantom orthophasmavirus**	Kigluaik phantom virus (KIGV)
	~~*Nome phantom orthophasmavirus*~~	~~Nome phantom virus (NOMV)~~
	Odonate orthophasmavirus	Odonate orthophasmavirus (HbOV-8)
	Qingling orthophasmavirus	Qingling orthophasmavirus (HbOV-9)
	~~*Seattle orthophasmavirus*~~	~~Seattle orthophasmavirus (SEPV)~~
	Wuchang cockroach orthophasmavirus 1	Wǔchāng cockroach virus 1 (WcCV-1)
	Wuhan mosquito orthophasmavirus 1	Wǔhàn mosquito virus 1 (WhMV-1)
	Wuhan mosquito orthophasmavirus 2	Wǔhàn mosquito virus 2 (WhMV-2)
Sawastrivirus	*Sanxia sawastrivirus**	Sānxiá water strider virus 2 (SxWSV-2)
Wuhivirus	*Insect wuhivirus**	Wǔhàn insect virus 2 (WhIV-2)
Family *Phenuiviridae*		
Band~~yang~~virus	*Bhanja bandavirus*	Bhanja virus (BHAV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070472

	*Dabie bandavirus**	severe fever with thrombocytopenia syndrome virus (SFTSV)
	Guertu band~~y~~a~~ng~~virus	Guertu virus (GTV)
	Heartland band~~y~~a~~ng~~virus	Heartland virus (HRTV)
	Hunter Island bandavirus	Hunter Island virus (HUIV)
	Kismaayo bandavirus	Kismaayo virus (KISV)
	Lone Star bandavirus	Lone Star virus (LSV)
	~~*Huaiyangshan banyangvirus**~~	~~severe fever with thrombocytopenia syndrome virus (SFTSV)~~
Beidivirus	*Dipteran beidivirus**	Húběi diptera virus 3 (HbDV-3)
Coguvirus	*Citrus coguvirus**	citrus concave gum-associated virus (CCGaV)
	Coguvirus eburi	citrus virus A (CiV-A)
Entovirus	*Entoleuca entovirus**	Entoleuca phenui-like virus 1 (EnPLV-1)
Goukovirus	*Cumuto goukovirus*	Cumuto virus (CUMV)
	*Gouleako goukovirus**	Gouléako virus (GOLV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070473

	Yichang insect goukovirus	Yíchāng insect virus (YcIV)
Horwuvirus	*Horsefly horwuvirus**	Wǔhàn horsefly virus (WhHV)
Hudivirus	*Dipteran hudivirus**	Húběi diptera virus 4 (HbDV-4)
Hudovirus	*Lepidopteran hudovirus**	Húběi lepidoptera virus 1 (HbLV-1)
~~*Kabutovirus*~~	~~*Huangpi kabutovirus**~~	~~Huángpí tick virus 2 (HpTV-2)~~
	~~*Kabuto mountain kabutovirus*~~	~~Kabuto mountain virus (KAMV)~~
Ixovirus	*Blackleg ixovirus**	blacklegged tick phlebovirus- 1 (BTPV-1)
	Norway ixovirus	Norway phlebovirus 1 (NIXV)
	Scapularis ixovirus	blacklegged tick phlebovirus 3 (BTPV-3)
Laulavirus	*Laurel Lake laulavirus**	Laurel Lake virus (LLV)
Lentinuvirus	*Lentinula lentinuvirus**	Lentinula edodes negative-strand RNA virus 2 (LeNSRV-2)
Mobuvirus	*Mothra mobuvirus**	Mothra virus (MTHV)
Phasivirus	*Badu phasivirus**	Badu virus (BADUV)
	Dipteran phasivirus	Húběi diptera virus 5 (HbDV-5)
	Fly phasivirus	Wǔhàn fly virus 1 (WhFV-1)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070474

	Phasi Charoen-like phasivirus	Phasi Chaeron-like virus (PCLV)
	Wutai mosquito phasivirus	Wǔtái mosquito virus (WtMV)
Phlebovirus	*Adana phlebovirus*	Adana virus (ADAV)
	Aguacate phlebovirus	Aguacate virus (AGUV)
	Alcube phlebovirus	Alcube virus (ACBV)
	Alenquer phlebovirus	Alenquer virus (ALEV)
	Ambe phlebovirus	Ambe virus (ABEV)
	Anhanga phlebovirus	Anhangá virus (ANHV)
	Arumowot phlebovirus	Arumowot virus (AMTV)
	Buenaventura phlebovirus	Buenaventura virus (BUEV)
	Bujaru phlebovirus	Bujaru virus (BUJV)
	Cacao phlebovirus	Cacao virus (CACV)
		~~Munguba virus (MUNV)~~
		~~Alenquer virus (ALEV)~~
	Campana phlebovirus	Campana virus (CMAV)
	Candiru phlebovirus	Ariquemes virus (ARQV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070475

		Candirú virus (CDUV)
		~~Itaituba virus (ITAV)~~
		Jacundá virus (JCNV)
		~~Maldonado virus (MLOV)~~
		Morumbi virus (MR(M)BV)
		Mucura virus (MCRV/MRAV)
		~~Nique virus (NIQV)~~
		~~Oriximiná virus (ORXV)~~
		Serra Norte virus (SRNV)
		~~Turuna virus (TUAV)~~
	Chagres phlebovirus	Chagres virus (CHGV)
	Cocle phlebovirus	Coclé virus (CCLV)
	Dashli phlebovirus	Dāshlī virus (DASV)
	Durania phlebovirus	Durania virus (DRNV)
	~~*Chilibre phlebovirus*~~	~~Cacao virus (CACV)~~
		~~Chilibre virus (CHIV)~~

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070476

	~~*Frijoles phlebovirus*~~	~~Frijoles virus (FRIV)~~
		~~Joá virus (JOAV)~~
	Echarate phlebovirus	Echarate virus (ECHV)
	Gabek phlebovirus	Gabek forest virus (GFV)
	Gordil phlebovirus	Gordil virus (GORV)
	Icoaraci phlebovirus	Icoaraci virus (ICOV)
	Itaituba phlebovirus	Itaituba virus (ITAV)
	Itaporanga phlebovirus	Itaporanga virus (ITPV)
	Ixcanal phlebovirus	Ixcanal virus (IXCV)
	Karimabad phlebovirus	Karimabad virus (KARV)
	La Gloria phlebovirus	La Gloria virus (LAGV)
	Lara phlebovirus	Rio Claro virus (RICV)
	Leticia phlebovirus	Leticia virus (LTCV)
	Maldonado phlebovirus	Maldonado virus (MLOV)
	Mariquita phlebovirus	Mariquita virus (MRQV)
	Massilia phlebovirus	Massilia virus (MASV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070477

	Medjerda phlebovirus	Medjerda Valley virus (MVV)
	Mona Grita phlebovirus	Mona Grita virus (MOGV)
	Mukawa phlebovirus	Mukawa virus (MKWV)
	Munguba phlebovirus	Munguba virus (MUNV)
	Naples phlebovirus	Arrábida virus (ARRV)
		Balkan virus (BALKV)
		Fermo virus (FERV)
		Granada virus (GRV = GRAV)
		Saddaguia virus (SADV)
		sandfly fever Naples virus (SFNV)
	Nique phlebovirus	Nique virus (NIQV)
	Ntepes phlebovirus	Ntepes virus (NTPV)
	Odrenisrou phlebovirus	Odrénisrou virus (ODRV)
	Oriximina phlebovirus	Oriximiná virus (ORXV)
	Pena Blanca phlebovirus	Peña Blanca virus (PEBV)
	Punique phlebovirus	Punique virus (PUNV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070478

	Punta Toro phlebovirus	Buenaventura virus (BUEV)
		~~Campana virus (CMAV)~~
		Capira virus (CAPIV)
		~~Coclé virus (CCLV)~~
		~~Leticia virus (LTCV)~~
		Punta Toro virus (PTV)
	*Rift Valley fever phlebovirus**	Rift Valley fever virus (RVFV)
	Rio Grande phlebovirus	Rio Grande virus (RGV)
	Saint Floris phlebovirus	Saint-Floris virus (SAFV)
	Salanga phlebovirus	Salanga virus (SLGV)
		~~Adana virus (ADAV)~~
	Salehabad phlebovirus	Adria virus (ADRV)
		~~Alcube virus~~
		Arbia virus (ARBV)
		~~Arumowot virus (AMTV)~~
		Bregalaka virus (BREV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070479

		~~Medjerda Valley virus (MVV)~~
		~~Odrénisrou virus (ODRV)~~
		Olbia virus (OLBV)
		Salehabad virus (SALV)
		Zaba virus (ZABAV)
	Salobo phlabovirus[1]	Salobo virus (SLBOV)
	~~*Sandfly fever Naples phlebovirus*~~	~~Arrábida virus (ARRV)~~
		~~Balkan virus (BALKV)~~
		~~Fermo virus (FERV)~~
		~~Gordil virus (GORV)~~
		~~Granada virus (GRV = GRAV)~~
		~~Massilia virus (MASV)~~
		~~Punique virus (PUNV)~~
		~~Saddaguia virus (SADV)~~
		~~Saint-Floris virus (SAFV)~~
		~~sandfly fever Naples virus (SFNV)~~

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070480

		~~Tehran virus (THEV)~~
		~~Toscana virus (TOSV)~~
		~~Zerdali virus (ZERV)~~
	Sicilian phlebovirus	sandfly fever Sicilian virus (SFSV)
	Tapara phlebovirus	Tapará virus (TPRV)
	Tehran phlebovirus	Tehran virus (THEV)
	Tico phebovirus	Tico virus (TICV)
	Toros phlebovirus	Toros virus (TORV)
	Toscana phlebovirus	Toscana virus (TOSV)
	Tres Almendras phlebovirus	Tres Almendras virus (TRAV)
	Turuna phlebovirus	Turuna virus (TUAV)
	Uriurana phlebovirus	Uriurana virus (URIV)
	Urucuri phlebovirus	Urucuri virus (URUV)
	Viola phlebovirus	viola virus (VIOV)
	Zerdali phlebovirus	Zerdali virus (ZERV)
	~~*Uukuniemi phlebovirus*~~	~~Chizé virus (CHZV)~~

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070481

		~~EgAN 1825-61 virus (EGAV)~~
		~~Fin V 707 virus (FINV)~~
		~~Oceanside virus (OCV = OCEV)~~
		~~Pontevès virus (PTVV)~~
		~~St. Abbs Head virus (SAHV)~~
		~~Uukuniemi virus (UUKV)~~
		~~Zaliv Terpenyia virus (ZTV)~~
Pidchovirus	*Pidgey pidchovirus**	Pidgey virus (PGYV)
Rubodvirus	*Apple rubodvirus 1**	apple rubbery wood virus 1 (ARWV-1)
	Apple rubodvirus 2	apple rubbery wood virus 2 (ARWV-2)
Tenuivirus	*Echinochloa hoja blanca tenuivirus*	Echinochloa hoja blanca virus (EHBV)
	Iranian wheat stripe tenuivirus	Iranian wheat stripe virus (IWSV)
	Maize stripe tenuivirus	maize stripe virus (MStV = MSpV)
	Melon tenuivirus	melon chlorotic spot virus (MeCSV)
	Rice grassy stunt tenuivirus	rice grassy stunt virus (RGSV)
	Rice hoja blanca tenuivirus	rice hoja blanca virus (RHBV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070482

	*Rice stripe tenuivirus**	rice stripe virus (RSV = RStV)
	Urochloa hoja blanca tenuivirus	Urochloa hoja blanca virus (UHBV)
Uukuvirus	*American dog uukuvirus*	American dog tick virus (ADAV)
	Dabieshan uukuvirus	Dàbiéshān tick virus (DBSH)
	Grand Arbaud uukuvirus	Grand Arbaud virus (GAV)
	Huangpi uukuvirus	Huángpí tick virus 2 (HpTV-2)
	Kabuto mountain uukuvirus	Kabuto mountain virus (KAMV)
	Kaisodi uukuvirus	Kaisodi virus (KASDV)
	Lihan uukuvirus	Lihan tick virus (LITV)
	Manawa uukuvirus	Manawa virus (MWAV)
	Murre uukuvirus	Murre virus (MURV)
	Pacific coast uukuvirus	Pacific coast tick virus (PACV)
	Precarious Point uukuvirus	Precarious Point virus (PPV)
	Rukutama uukuvirus	Rukutama virus (RUKV)
	Schmid uukuvirus	Nile Warbler virus (EGAV)
	Silverwater uukuvirus	Silverwater virus (SILV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070483

	Tacheng uukuvirus	Tăchéng tick virus 2 (TCGV)
	*Uukuniemi uukuvirus**	Chizé virus (CHZV)
		Fin V 707 virus (FINV)
		Oceanside virus (OCV = OCEV)
		Pontevès virus (PTVV)
		St. Abbs Head virus (SAHV)
		Uukuniemi virus (UUKV)
	Yongjia uukuvirus	Yǒngjiā tick virus (YONV)
	Zaliv Terpeniya uukuvirus	Zaliv Terpen~~y~~iya virus (ZTV)
Wenrivirus	*Shrimp wenrivirus**	Wēnzhōu shrimp virus 1 (WzSV-1)
~~*Wubeivirus*~~	~~*Dipteran wubeivirus**~~	~~Húběi diptera virus 5 (HbDV-5)~~
	~~*Fly wubeivirus*~~	~~Wǔhàn fly virus 1 (WhFV-1)~~
Family *Tospoviridae*		
Orthotospovirus	*Alstroemeria necrotic streak orthotospovirus*	Alstroemeria necrotic streak virus (ANSV)
	Alstroemeria yellow spot orthotospovirus	Alstroemeria yellow spot virus (AYSV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070484

	Bean necrotic mosaic orthotospovirus	bean necrotic mosaic virus (BeNMV)
	Calla lily chlorotic spot orthotospovirus	calla lily chlorotic spot virus (CCSV)
	Capsicum chlorosis orthotospovirus	Capsicum chlorosis virus (CaCV)
	Chrysanthemum stem necrosis orthotospovirus	Chrysanthemum stem necrosis virus (CSNV)
	Groundnut bud necrosis orthotospovirus[‡]	groundnut bud necrosis virus (GBNV)
	Groundnut chlorotic fan spot orthotospovirus	groundnut chlorotic fan-spot virus (GCFSV)
	Groundnut ringspot orthotospovirus[‡]	groundnut ringspot virus (GRSV)
	Groundnut yellow spot orthotospovirus[‡]	groundnut yellow spot virus (GYSV)
	Hippeastrum chlorotic ringspot orthotospovirus	Hippeastrum chlorotic spot virus (HCRV)
	Impatiens necrotic spot orthotospovirus[‡]	impatiens necrotic spot virus (INSV)
	Iris yellow spot orthotospovirus[‡]	iris yellow spot virus (IYSV)
	Melon severe mosaic orthotospovirus	melon severe mosaic virus (MSMV)
	Melon yellow spot orthotospovirus	melon yellow spot virus (MYSV)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070485

	Mulberry vein banding associated orthotospovirus	mulberry vein banding-associated virus (MVBaV)
	Pepper chlorotic spot orthotospovirus	pepper chlorotic spot virus (PCSV)
	*Polygonum ringspot orthotospovirus*ǂ	Polygonum ringspot virus (PolRSV)
	Soybean vein necrosis orthotospovirus	soybean vein necrosis virus (SVNV)
	*Tomato chlorotic spot orthotospovirus*ǂ	tomato chlorotic spot virus (TCSV)
	*Tomato spotted wilt orthotospovirus**ǂ	tomato spotted wilt virus (TSWV)
	Tomato yellow ring orthotospovirus	tomato yellow ring virus (TYRV)
	Tomato zonate spot orthotospovirus	tomato zonate spot virus (TZSV)
	*Watermelon bud necrosis orhtotospovirus*ǂ	watermelon bud necrosis virus (WBNV)
	*Watermelon silver mottle orthotospovirus*ǂ	watermelon silver mottle virus (WSMoV)
	*Zucchini lethal chlorosis orthotospovirus*ǂ	zucchini lethal chlorosis virus (ZLCV)
Family *Wupedeviridae*		
Wumivirus	*Millipede wumivirus**	Wǔhàn millipede virus 2 (WhMV-2)
~~Unassigned~~		
~~*Coguvirus*~~	~~*Citrus coguvirus**~~	~~citrus concave gum-associated virus~~

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070486

		~~(CCGaV)~~

*type species

[1]Due to a formal classification mistake this species was named *Salobo phlabovirus* instead of *Salobo phlebovirus*. A proposal to correct the spelling of this species name will be submitted prior to the next taxonomic proposal submission deadline.

[¶]Note that viruses are real objects that are assigned to concepts that are called taxa. Species, genera, families, and orders are taxa. Taxon names are always italicized and always begin with a capital letter. Virus names, on the other hand, are not italicized and are not capitalized, except if the name or a name component is a proper noun. This column lists the virus names with their correct (lack of) capitalization. Lists of viruses within a given species are provisional at this point and will likely be amended in the near future.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070487

COMPLIANCE WITH ETHICAL STANDARDS

The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the US Department of the Army, the US Department of Defense, the US Department of Health and Human Services, the Department of Homeland Security (DHS) Science and Technology Directorate (S&T), or of the institutions and companies affiliated with the authors. In no event shall any of these entities have any responsibility or liability for any use, misuse, inability to use, or reliance upon the information contained herein. The US departments do not endorse any products or commercial services mentioned in this publication.

Funding

This work was supported in part through Laulima Government Solutions, LLC prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272201800013C. J.H.K. performed this work as employees of Tunnell Government Services (TGS), a subcontractor of Laulima Government Solutions, LLC under Contract No. HHSN272201800013C. This work was also supported in part with federal funds from the National Cancer Institute (NCI), National Institutes of Health (NIH), under Contract No. HHSN261200800001E to I.C., who was supported by the Clinical Monitoring Research Program Directorate, Frederick National Lab for Cancer Research, sponsored by NCI. This work was also funded in part by Contract No. HSHQDC-15-C-00064 awarded by the Department of Homeland Security (DHS) Science and Technology Directorate (S&T) for the management and operation of The National Biodefense Analysis and Countermeasures Center (NBACC), a federally funded research and development center operated by the Battelle National Biodefense Institute (V.W.);

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070488

and NIH contract HHSN272201000040I/HHSN27200004/D04 and grant R24AI120942 (N.V., R.B.T.).

Conflict of Interest

The authors declare no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070489

REFERENCES

1. Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, Bente DA, Beer M, Bergeron É, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Cháng C, Charrel RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, Dèng F, Di Serio F, Digiaro M, Drebot MA, Duàn X, Ebihara H, Elbeaino T, Ergünay K, Fulhorst CF, Garrison AR, Gāo GF, Gonzalez J-PJ, Groschup MH, Günther S, Haenni A-L, Hall RA, Hepojoki J, Hewson R, Hú Z, Hughes HR, Jonson MG, Junglen S, Klempa B, Klingström J, Kòu C, Laenen L, Lambert AJ, Langevin SA, Liu D, Lukashevich IS, Luò T, Lǔ C, Maes P, de Souza WM, Marklewitz M, Martelli GP, Matsuno K, Mielke-Ehret N, Minutolo M, Mirazimi A, Moming A, Mühlbach H-P, Naidu R, Navarro B, Nunes MRT, Palacios G, Papa A, Pauvolid-Corrêa A, Pawęska JT, Qiáo J, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Shěn S, Shí X, Shirako Y, Simmonds P, Sironi M, Song J-W, Spengler JR, Stenglein MD, Sū Z, Sūn S, Táng S, Turina M, Wáng B, Wáng C, Wáng H, Wáng J, Wèi T, Whitfield AE, Zerbini FM, Zhāng J, Zhāng L, Zhāng Y, Zhang Y-Z, Zhāng Y, Zhou X, Zhū L, Kuhn JH (2019) Taxonomy of the order *Bunyavirales*: update 2019. Arch Virol 164:1949-1965

2. Afonso CL, Amarasinghe GK, Bányai K, Bào Y, Basler CF, Bavari S, Bejerman N, Blasdell KR, Briand F-X, Briese T, Bukreyev A, Calisher CH, Chandran K, Chéng J, Clawson AN, Collins PL, Dietzgen RG, Dolnik O, Domier LL, Dürrwald R, Dye JM, Easton AJ, Ebihara H, Farkas SL, Freitas-Astúa J, Formenty P, Fouchier RA, Fù Y, Ghedin E, Goodin MM, Hewson R, Horie M, Hyndman TH, Jiāng D, Kitajima EW, Kobinger GP, Kondo H, Kurath G, Lamb RA, Lenardon S, Leroy EM, Li C-X, Lin X-D,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070490

Liú L, Longdon B, Marton S, Maisner A, Mühlberger E, Netesov SV, Nowotny N, Patterson JL, Payne SL, Paweska JT, Randall RE, Rima BK, Rota P, Rubbenstroth D, Schwemmle M, Shi M, Smither SJ, Stenglein MD, Stone DM, Takada A, Terregino C, Tesh RB, Tian J-H, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Verbeek M, Volchkov VE, Wahl-Jensen V, Walsh JA, Walker PJ, Wang D, Wang L-F, Wetzel T, Whitfield AE, Xiè JT, Yuen K-Y, Zhang Y-Z, Kuhn JH (2016) Taxonomy of the order *Mononegavirales*: update 2016. Arch Virol 161:2351-2360

3. Aitken TH, Woodall JP, De Andrade AHP, Bensabath G, Shope RE (1975) Pacui virus, phlebotomine flies, and small mammals in Brazil: an epidemiological study. Am J Trop Med Hyg 24:358-368

4. Alkan C, Alwassouf S, Piorkowski G, Bichaud L, Tezcan S, Dincer E, Ergunay K, Ozbel Y, Alten B, de Lamballerie X, Charrel RN (2015) Isolation, genetic characterization, and seroprevalence of Adana virus, a novel phlebovirus belonging to the Salehabad virus complex, in Turkey. J Virol 89:4080-4091

5. Alkan C, Erisoz Kasap O, Alten B, de Lamballerie X, Charrel RN (2016) Sandfly-Borne Phlebovirus Isolations from Turkey: New Insight into the *Sandfly fever Sicilian* and *Sandfly fever Naples* Species. PLoS neglected tropical diseases 10:e0004519

6. Alkan C, Moin Vaziri V, Ayhan N, Badakhshan M, Bichaud L, Rahbarian N, Javadian E-A, Alten B, de Lamballerie X, Charrel RN (2017) Isolation and sequencing of Dashli virus, a novel Sicilian-like virus in sandflies from Iran; genetic and phylogenetic evidence for the creation of one novel species within the *Phlebovirus* genus in the *Phenuiviridae* family. PLoS neglected tropical diseases 11:e0005978

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070491

7. Amarasinghe GK, Bào Y, Basler CF, Bavari S, Beer M, Bejerman N, Blasdell KR, Bochnowski A, Briese T, Bukreyev A, Calisher CH, Chandran K, Collins PL, Dietzgen RG, Dolnik O, Dürrwald R, Dye JM, Easton AJ, Ebihara H, Fang Q, Formenty P, Fouchier RAM, Ghedin E, Harding RM, Hewson R, Higgins CM, Hong J, Horie M, James AP, Jiāng D, Kobinger GP, Kondo H, Kurath G, Lamb RA, Lee B, Leroy EM, Li M, Maisner A, Mühlberger E, Netesov SV, Nowotny N, Patterson JL, Payne SL, Paweska JT, Pearson MN, Randall RE, Revill PA, Rima BK, Rota P, Rubbenstroth D, Schwemmle M, Smither SJ, Song Q, Stone DM, Takada A, Terregino C, Tesh RB, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Volchkov VE, Wahl-Jensen V, Walker PJ, Wang B, Wang D, Wang F, Wang L-F, Werren JH, Whitfield AE, Yan Z, Ye G, Kuhn JH (2017) Taxonomy of the order *Mononegavirales*: update 2017. Arch Virol 162:2493–2504

8. Amarasinghe GK, Ceballos NGA, Banyard AC, Basler CF, Bavari S, Bennett AJ, Blasdell KR, Briese T, Bukreyev A, Caì Y, Calisher CH, Lawson CC, Chandran K, Chapman CA, Chiu CY, Choi K-S, Collins PL, Dietzgen RG, Dolja VV, Dolnik O, Domier LL, Dürrwald R, Dye JM, Easton AJ, Ebihara H, Echevarría JE, Fooks AR, Formenty PBH, Fouchier RAM, Freuling CM, Ghedin E, Goldberg TL, Hewson R, Horie M, Hyndman TH, Jiāng D, Kityo R, Kobinger GP, Kondō H, Koonin EV, Krupovic M, Kurath G, Lamb RA, Lee B, Leroy EM, Maes P, Maisner A, Marston DA, Mor SK, Müller T, Mühlberger E, Ramírez VMN, Netesov SV, Ng TFF, Nowotny N, Palacios G, Patterson JL, Pawęska JT, Payne SL, Prieto K, Rima BK, Rota P, Rubbenstroth D, Schwemmle M, Siddell S, Smither SJ, Song Q, Song T, Stenglein MD, Stone DM, Takada A, Tesh RB, Thomazelli LM, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Vázquez-Morón S, Verdugo C, Volchkov VE, Wahl V, Walker PJ, Wang D, Wang L-F,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070492

Wellehan JFX, Wiley MR, Whitfield AE, Wolf YI, Yè G, Zhāng Y-Z, Kuhn JH (2018) Taxonomy of the order *Mononegavirales*: update 2018. Arch Virol 163:2283-2294

9. Amarasinghe GK, Ayllón MA, Bào Y, Basler CF, Bavari S, Blasdell KR, Briese T, Brown PA, Bukreyev A, Balkema-Buschmann A, Buchholz UJ, Chabi-Jesus C, Chandran K, Chiapponi C, Crozier I, de Swart RL, Dietzgen RG, Dolnik O, Drexler JF, Dürrwald R, Dundon WG, Duprex WP, Dye JM, Easton AJ, Fooks AR, Formenty PBH, Fouchier RAM, Freitas-Astúa J, Griffiths A, Hewson R, Horie M, Hyndman TH, Jiāng D, Kitajima EW, Kobinger GP, Kondō H, Kurath G, Kuzmin IV, Lamb RA, Lavazza A, Lee B, Lelli D, Leroy EM, Lǐ J, Maes P, Marzano S-YL, Moreno A, Mühlberger E, Netesov SV, Nowotny N, Nylund A, Økland AL, Palacios G, Pályi B, Pawęska JT, Payne SL, Prosperi A, Ramos-González PL, Rima BK, Rota P, Rubbenstroth D, Shī M, Simmonds P, Smither SJ, Sozzi E, Spann K, Stenglein MD, Stone DM, Takada A, Tesh RB, Tomonaga K, Tordo N, Towner JS, van den Hoogen B, Vasilakis N, Wahl V, Walker PJ, Wang L-F, Whitfield AE, Williams JV, Zerbini FM, Zhāng T, Zhang Y-Z, Kuhn JH (2019) Taxonomy of the order *Mononegavirales*: update 2019. Arch Virol 164:1967-1980

10. Amaro F, Zé-Zé L, Alves MJ, Börstler J, Clos J, Lorenzen S, Becker SC, Schmidt-Chanasit J, Cadar D (2015) Co-circulation of a novel phlebovirus and Massilia virus in sandflies, Portugal. Virol J 12:174

11. Barr J, Smith C, Smith I, de Jong C, Todd S, Melville D, Broos A, Crameri S, Haining J, Marsh G, Crameri G, Field H, Wang LF (2015) Isolation of multiple novel paramyxoviruses from pteropid bat urine. J Gen Virol 96:24-29

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070493

12. Bejerman N, de Breuil S, Debat H, Miretti M, Badaracco A, Nome C (2017) Molecular characterization of yerba mate chlorosis-associated virus, a putative cytorhabdovirus infecting yerba mate (*Ilex paraguariensis*). Arch Virol 162:2481-2484

13. Berge TO (1975) International Catalogue of Arboviruses Including Certain Other Viruses of Vertebrates. US Public Health Service publication no. (CDC) 75-8301, 2nd edn. Department of Health, Education and Welfare, Washington, DC, USA

14. Bhatt PN, Kulkarni KG, Boshell M. J, Rajagopalan PK, Patil AP, Goverdhan MK, Pavri KM (1966) Kaisodi virus, a new agent isolated from *Haemaphysalis spinigera* in Mysore State, South India. I. Isolation of strains. Am J Trop Med Hyg 15:958-960

15. Bichaud L, Dachraoui K, Alwassouf S, Alkan C, Mensi M, Piorkowski G, Sakhria S, Seston M, Fares W, De Lamballerie X, Zhioua E, Charrel RN (2016) Isolation, full genomic characterization and neutralization-based human seroprevalence of Medjerda Valley virus, a novel sandfly-borne phlebovirus belonging to the Salehabad virus complex in northern Tunisia. J Gen Virol 97:602-610

16. Bishop DHL, Pringle CR (1995) Order *Mononegavirales*. In: Murphy FA, Fauquet CM, Bishop DHL, Ghabrial SA, Jarvis AW, Martelli GP, Mayo MA, Summers MD (eds) Virus Taxonomy—Sixth Report of the International Committee on Taxonomy of Viruses/Archives of Virology Supplement 10. Springer-Verlag, Vienna, Austria, pp 265-267

17. Bouquet J, Melgar M, Swei A, Delwart E, Lane RS, Chiu CY (2017) Metagenomic-based surveillance of Pacific Coast tick *Dermacentor occidentalis* identifies two novel bunyaviruses and an emerging human ricksettsial pathogen. Sci Rep 7:12234

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070494

18. Buzkan N, Chiumenti M, Massart S, Sarpkaya K, Karadağ S, Minafra A (2019) A new emaravirus discovered in *Pistacia* from Turkey. Virus Res 263:159-163

19. Causey OR, Shope RE (1965) Icoaraci, a new virus related to Naples phlebotomus fever virus. Proc Soc Exp Biol Med 118:420-421

20. Charrel RN, Moureau G, Temmam S, Izri A, Marty P, Parola P, da Rosa AT, Tesh RB, de Lamballerie X (2009) Massilia virus, a novel *Phlebovirus* (*Bunyaviridae*) isolated from sandflies in the Mediterranean. Vector Borne Zoonotic Dis 9:519-530

21. Chen CC, Chiu RJ (1996) A tospovirus infecting peanut in Taiwan. Acta Hortic:57-67

22. Cheng Y-H, Zheng Y-X, Tai C-H, Yen J-H, Chen Y-K, Jan F-J (2014) Identification, characterisation and detection of a new tospovirus on sweet pepper. Ann Appl Biol 164:107-115

23. Coffey LL, Page BL, Greninger AL, Herring BL, Russell RC, Doggett SL, Haniotis J, Wang C, Deng X, Delwart EL (2014) Enhanced arbovirus surveillance with deep sequencing: identification of novel rhabdoviruses and bunyaviruses in Australian mosquitoes. Virology 448:146-158

24. de Carvalho MS, de Lara Pinto AZ, Pinheiro A, Rodrigues JSV, Melo FL, da Silva LA, Ribeiro BM, Dezengrini-Slhessarenko R (2018) Viola phlebovirus is a novel Phlebotomus fever serogroup member identified in *Lutzomyia* (*Lutzomyia*) *longipalpis* from Brazilian Pantanal. Parasites & vectors 11:405

25. De Haas RA, Jonkers AH, Heinemann DW (1966) Kwatta virus, a new agent isolated from *Culex* mosquitoes in Surinam. Am J Trop Med Hyg 15:954-957

26. Debat HJ, Bejerman N (2019) Novel bird's-foot trefoil RNA viruses provide insights into a clade of legume-associated enamoviruses and rhabdoviruses. Arch Virol 164:1419-1426

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070495

27. Dilcher M, Alves MJ, Finkeisen D, Hufert F, Weidmann M (2012) Genetic characterization of Bhanja virus and Palma virus, two tick-borne phleboviruses. Virus Genes 45:311-315

28. Dilcher M, Faye O, Faye O, Weber F, Koch A, Sadegh C, Weidmann M, Sall AA (2015) Zahedan rhabdovirus, a novel virus detected in ticks from Iran. Virol J 12:183

29. Doherty RL, Carley JG, Standfast HA, Dyce AL, Kay BH, Snowdon WA (1973) Isolation of arboviruses from mosquitoes, biting midges, sandflies and vertebrates collected in Queensland, 1969 and 1970. Trans R Soc Trop Med Hyg 67:536-543

30. Dong J-H, Cheng X-F, Yin YY, Fang Q, Ding M, Li T-T, Zhang L-Z, Su X-X, McBeath J-H, Zhang Z-K (2008) Characterization of tomato zonate spot virus, a new tospovirus in China. Arch Virol 153:855-864

31. Dong JH, Yin YY, Fang Q, McBeath JH, Zhang ZK (2013) A new tospovirus causing chlorotic ringspot on *Hippeastrum* sp. in China. Virus Genes 46:567-570

32. Easton AJ, Pringle CR (2011) Order *Mononegavirales*. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (eds) Virus Taxonomy—Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier/Academic Press, London, United Kingdom, pp 653-657

33. Fernandes J, Guterres A, de Oliveira RC, Chamberlain J, Lewandowski K, Teixeira BR, Coelho TA, Crisóstomo CF, Bonvicino CR, D'Andrea PS, Hewson R, de Lemos ERS (2018) Xapuri virus, a novel mammarenavirus: natural reassortment and increased diversity between New World viruses. Emerg Microbes Infect 7:120

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070496

34. Fernandes J, Guterres A, de Oliveira RC, Jardim R, Dávila AMR, Hewson R, de Lemos ERS (2019) Apore virus, a novel mammarenavirus (Bunyavirales: Arenaviridae) related to highly pathogenic virus from South America. Mem Inst Oswaldo Cruz 114:e180586

35. Forth LF, Konrath A, Klose K, Schlottau K, Hoffmann K, Ulrich RG, Höper D, Pohlmann A, Beer M (2018) A novel squirrel respirovirus with putative zoonotic potential. Viruses 10:373

36. Gaafar YZA, Richert-Pöggeler KR, Maaß C, Vetten H-J, Ziebell H (2019) Characterisation of a novel nucleorhabdovirus infecting alfalfa (*Medicago sativa*). Virol J 16:55

37. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, Belaganahalli MN, Wells HL, Dhanota JK, Liang E, Grodus M, Jangra RK, DeJesus VA, Lasso G, Smith BR, Jambai A, Kamara BO, Kamara S, Bangura W, Monagin C, Shapira S, Johnson CK, Saylors K, Rubin EM, Chandran K, Lipkin WI, Mazet JAK (2018) The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol 3:1084-1089

38. Gubala A, Walsh S, McAllister J, Weir R, Davis S, Melville L, Mitchell I, Bulach D, Gauci P, Skvortsov A, Boyle D (2017) Identification of very small open reading frames in the genomes of Holmes Jungle virus, Ord River virus, and Wongabel virus of the genus *Hapavirus*, family *Rhabdoviridae*. Evol Bioinform Online 13:1176934317713484

39. Hang J, Klein TA, Kim H-C, Yang Y, Jima DD, Richardson JH, Jarman RG (2016) Genome sequences of five arboviruses in field-captured mosquitoes in a unique rural environment of South Korea. Genome Announc 4:e01644-01615

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070497

40. Hannoun C, Corniou B, Rageau J (1970) Isolation in southern France and characterization of new tick-borne viruses related to Uukuniemi: Grand Arbaud and Ponteves. Acta Virol 14:167-170

41. Hassan M, Di Bello PL, Keller KE, Martin RR, Sabanadzovic S, Tzanetakis IE (2017) A new, widespread emaravirus discovered in blackberry. Virus Res 235:1-5

42. Hassani-Mehraban A, Botermans M, Verhoeven JTJ, Meekes E, Saaijer J, Peters D, Goldbach R, Kormelink R (2010) A distinct tospovirus causing necrotic streak on *Alstroemeria* sp. in Colombia. Arch Virol 155:423-428

43. Hassani-Mehraban A, Dullemans AM, Verhoeven JTJ, Roenhorst JW, Peters D, van der Vlugt RAA, Kormelink R (2019) Alstroemeria yellow spot virus (AYSV): a new orthotospovirus species within a growing Eurasian clade. Arch Virol 164:117-126

44. Hepojoki J, Hepojoki S, Smura T, Szirovicza L, Dervas E, Prahauser B, Nufer L, Schraner EM, Vapalahti O, Kipar A, Hetzel U (2018) Characterization of Haartman Institute snake virus-1 (HISV-1) and HISV-like viruses - the representatives of genus *Hartmanivirus*, family *Arenaviridae*. PLoS Pathog 14:e1007415

45. Hu S-C, Hsu C-L, Lee M-S, Tu Y-C, Chang J-C, Wu C-H, Lee S-H, Ting L-J, Tsai K-R, Cheng M-C, Tu W-J, Hsu W-C (2018) Lyssavirus in Japanese pipistrelle, Taiwan. Emerg Infect Dis 24:782-785

46. Hughes HR, Russell BJ, Lambert AJ (2020) Genetic characterization of Frijoles and Chilibre species complex viruses (genus *Phlebovirus*; family *Phenuiviridae*) and three unclassified New World hhleboviruses. Am J Trop Med Hyg 102:359-365

47. Ito T, Suzaki K, Nakano M (2013) Genetic characterization of novel putative rhabdovirus and dsRNA virus from Japanese persimmon. J Gen Virol 94:1917-1921

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070498

48. Jeong J, Kim Y, An I, Wang S-J, Kim Y, Lee H-J, Choi K-S, Im S-P, Min W, Oem J-K, Jheong W (2018) Complete genome sequence of a novel avian paramyxovirus isolated from wild birds in South Korea. Arch Virol 163:223-227

49. Johnson RI, Tachedjian M, Rowe B, Clayton BA, Layton R, Bergfeld J, Wang L-F, Marsh GA (2018) Alston virus, a novel paramyxovirus isolated from bats causes upper respiratory tract infection in experimentally challenged ferrets. Viruses 10:675

50. Jones S, McGavin W, MacFarlane S (2019) The complete sequences of two divergent variants of the rhabdovirus raspberry vein chlorosis virus and the design of improved primers for virus detection. Virus Res 265:162-165

51. Karabatsos N (1985) International catalogue of arboviruses including certain other viruses of vertebrates. American Society for Tropical Medicine and Hygiene, San Antonio, Texas, USA

52. Kerschner JH, Calisher CH, Vorndam AV, Francy DB (1986) Identification and characterization of Bahia Grande, Reed Ranch and Muir Springs viruses, related members of the family Rhabdoviridae with widespread distribution in the United States. J Gen Virol 67:1081-1089

53. Kohl C, Tachedjian M, Todd S, Monaghan P, Boyd V, Marsh GA, Crameri G, Field H, Kurth A, Smith I, Wang L-F (2018) Hervey virus:sStudy on co-circulation with henipaviruses in pteropid bats within their distribution range from Australia to Africa. PLoS One 13:e0191933

54. Kokernot RH, Calisher CH, Stannard LJ, Hayes J (1969) Arbovirus studies in the Ohio-Mississippi Basin, 1964-1967. VII. Lone Star virus, a hitherto unknown agent isolated from the tick *Amblyomma americanum* (Linn.). Am J Trop Med Hyg 18:789-795

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070499

55. Koonin EV, Dolja VV, Krupovic M, Arvind V, Wolf YI, Yutin N, Zerbini FM, Kuhn JH (2020) Global organization and proposed megataxonomy of the virus world. Microbiology and molecular biology reviews (Washington, DC) 84:e00061-00019

56. Kuhn JH, Wolf YI, Krupovic M, Zhang Y-Z, Maes P, Dolja VV, Koonin EV (2019) Classify viruses—the gain is worth the pain. Nature 566:318-320

57. Lecoq H, Wipf-Scheibel C, Verdin E, Desbiez C (2019) Characterization of the first tenuivirus naturally infecting dicotyledonous plants. Arch Virol 164:297-301

58. Ledermann JP, Zeidner N, Borland EM, Mutebi J-P, Lanciotti RS, Miller BR, Lutwama JJ, Tendo JM, Andama V, Powers AM (2014) Sunguru virus: a novel virus in the family *Rhabdoviridae* isolated from a chicken in north-western Uganda. J Gen Virol 95:1436-1443

59. Li C-X, Shi M, Tian J-H, Lin X-D, Kang Y-J, Chen L-J, Qin X-C, Xu J, Holmes EC, Zhang Y-Z (2015) Unprecedented genomic diversity of RNA viruses in arthropods reveals the ancestry of negative-sense RNA viruses. Elife 4::e05378

60. Lin Y-H, Fujita M, Chiba S, Hyodo K, Andika IB, Suzuki N, Kondo H (2019) Two novel fungal negative-strand RNA viruses related to mymonaviruses and phenuiviruses in the shiitake mushroom *(Lentinula edodes*). Virology 533:125-136

61. Liu Y, Du Z, Wang H, Zhang S, Cao M, Wang X (2018) Identification and characterization of wheat yellow striate virus, a novel leafhopper-transmitted nucleorhabdovirus infecting wheat. Front Microbiol 9:468

62. Lvov DK, Timopheeva AA, Gromashevski VL, Gostinshchikova GV, Veselovskaya OV, Chervonski VI, Fomina KB, Gromov AI, Pogrebenko AG, Zhezmer VY (1973) "Zaliv Terpeniya" virus, a new Uukuniemi group arbovirus isolated from Ixodes (Ceratixodes)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070500

putus Pick.-Camb. 1878 on Tyuleniy Island (Sakhalin region) and Commodore Islands (Kamchatsk region). Arch Gesamte Virusforsch 41:165-169

63. Lvov SD, Gromashevsky VL, Andreev VP, Skvortsova TM, Kondrashina NG, Morozova TN, Avershin AD, Aristova VA, Dmitriev GA, Kandaurov YK, Kuznetsov AA, Galkina IV, Yamnikova SS, Shchipanova MV (1990) Natural foci of arboviruses in far northern latitudes of Eurasia. In: Calisher CH (ed) Hemorrhagic fever with renal syndrome, tick- and mosquito-borne viruses Archives of Virology Supplementum 1. Springer, Vienna, Austria, pp 267-275

64. Maes P, Alkhovsky SV, Bào Y, Beer M, Birkhead M, Briese T, Buchmeier MJ, Calisher CH, Charrel RN, Choi IR, Clegg CS, Torre JCdl, Delwart E, DeRisi JL, Bello PLD, Serio FD, Digiaro M, Dolja VV, Drosten C, Druciarek TZ, Du J, Ebihara H, Elbeaino T, Gergerich RC, Gillis AN, Gonzalez J-PJ, Haenni A-L, Hepojoki J, Hetzel U, Hồ T, Hóng N, Jain RK, Vuren PJv, Jin Q, Jonson MG, Junglen S, Keller KE, Kemp A, Kipar A, Kondov NO, Koonin EV, Kormelink R, Korzyukov Y, Krupovic M, Lambert AJ, Laney AG, LeBreton M, Lukashevic IS, Marklewitz M, Markotter W, Martelli GP, Martin RR, Mielke-Ehret N, Mühlbach H-P, Navarro B, Ng TFF, Nunes MRT, Palacios G, Pawęska JT, Peters CJ, Plyusnin A, Radoshitzky SR, Romanowski V, Salmenperä P, Salvato MS, Sanfaçon H, Sasaya T, Schmaljohn C, Schneider BS, Shirako Y, Siddell S, Sironen TA, Stenglein MD, Storm N, Sudini H, Tesh RB, Tzanetakis IE, Uppala M, Vapalahti O, Vasilakis N, Walker PJ, Wáng G, Wáng L, Wáng Y, Wèi T, Wiley MR, Wolf YI, Wolfe ND, Wú Z, Xú W, Yang L, Yāng Z, Yeh S-D, Zhāng Y-Z, Zhèng Y, Zhou X, Zhū C, Zirkel F, Kuhn JH (2018) Taxonomy of the family *Arenaviridae* and the order *Bunyavirales*: update 2018. Arch Virol 163:2295-2310

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070501

65. Maes P, Adkins S, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, Bente DA, Beer M, Bergeron É, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Charrel1 RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, DeRisi JL, Digiaro M, Drebot M, Ebihara H, Elbeaino T, Ergünay K, Fulhorst CF, Garrison AR, Gāo GF, Gonzalez J-PJ, Groschup MH, Günther S, Haenni A-L, Hall RA, Hewson R, Hughes HR, Jain RK, Jonson MG, Junglen S, Klempa B, Klingström J, Kormelink R, Lambert AJ, Langevin SA, Lukashevich IS, Marklewitz M, Martelli GP, Mielke-Ehret N, Mirazimi A, Mühlbach H-P, Naidu R, Nunes MRT, Palacios G, Papa A, Pawęska JT, Peters CJ, Plyusnin A, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Schmaljohn C, Shí X, Shirako Y, Simmonds P, Sironi M, Song J-W, Spengler JR, Stenglein MD, Tesh RB, Turina M, Wèi T, Whitfield AE, Yeh S-D, Zerbini FM, Zhang Y-Z, Zhou X, Kuhn JH (2019) Taxonomy of the order *Bunyavirales*: second update 2018. Arch Virol 164:927-941

66. Maes P, Amarasinghe GK, Ayllón MA, Basler CF, Bavari S, Blasdell KR, Briese T, Brown PA, Bukreyev A, Balkema-Buschmann A, Buchholz UJ, Chandran K, Crozier I, de Swart RL, Dietzgen RG, Dolnik O, Domier LL, Drexler JF, Dürrwald R, Dundon WG, Duprex WP, Dye JM, Easton AJ, Fooks AR, Formenty PBH, Fouchier RAM, Freitas-Astúa J, Ghedin E, Griffiths A, Hewson R, Horie M, Hurwitz JL, Hyndman TH, Jiāng D, Kobinger GP, Kondō H, Kurath G, Kuzmin IV, Lamb RA, Lee B, Leroy EM, Lǐ J, Marzano S-YL, Mühlberger E, Netesov SV, Nowotny N, Palacios G, Pályi B, Pawęska JT, Payne SL, Rima BK, Rota P, Rubbenstroth D, Simmonds P, Smither SJ, Song Q, Song T, Spann K, Stenglein MD, Stone DM, Takada A, Tesh RB, Tomonaga K, Tordo N, Towner JS, van den Hoogen B, Vasilakis N, Wahl V, Walker PJ, Wang D, Wang L-F,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070502

Whitfield AE, Williams JV, Yè G, Zerbini FM, Zhang Y-Z, Kuhn JH (2019) Taxonomy of the order *Mononegavirales*: second update 2018. Arch Virol 164:1233–1244

67. Main AJ, Carey AB (1980) Connecticut virus: a new Sawgrass group virus from *Ixodes dentatus* (Acari: Ixodidae). J Med Entomol 17:473-476

68. Marklewitz M, Dutari LC, Paraskevopoulou S, Page RA, Loaiza JR, Junglen S (2019) Diverse novel phleboviruses in sandflies from the Panama Canal area, Central Panama. J Gen Virol 100:938-949

69. Matsuno K, Weisend C, Kajihara M, Matysiak C, Williamson BN, Simuunza M, Mweene AS, Takada A, Tesh RB, Ebihara H (2015) Comprehensive molecular detection of tick-borne phleboviruses leads to the retrospective identification of taxonomically unassigned bunyaviruses and the discovery of a novel member of the genus *Phlebovirus*. J Virol 89:594-604

70. Maurino F, Dumón AD, Llauger G, Alemandri V, de Haro LA, Mattio MF, Del Vas M, Laguna IG, Giménez Pecci MdlP (2018) Complete genome sequence of maize yellow striate virus, a new cytorhabdovirus infecting maize and wheat crops in Argentina. Arch Virol 163:291-295

71. McAllister J, Gauci PJ, Mitchell IR, Boyle DB, Bulach DM, Weir RP, Melville LF, Davis SS, Gubala AJ (2014) Genomic characterisation of Almpiwar virus, Harrison Dam virus and Walkabout Creek virus; three novel rhabdoviruses from northern Australia. Virol Rep 3-4:1-17

72. McLean DM, Larke RPB (1963) Powassan and Silverwater viruses: ecology of two Ontario arboviruses. Canadian Medical Association journal 88:182-185

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070503

73. Medina-Salguero AX, Cornejo-Franco JF, Grinstead S, Mollov D, Mowery JD, Flores F, Quito-Avila DF (2019) Sequencing, genome analysis and prevalence of a cytorhabdovirus discovered in *Carica papaya*. PLoS One 14:e0215798

74. Meng J, Liu P, Zhu L, Zou C, Li J, Chen B (2015) Complete genome sequence of mulberry vein banding associated virus, a new tospovirus infecting mulberry. PLoS One 10:e0136196

75. Meng JR, Liu PP, Zou CW, Wang ZQ, Liao YM, Cai JH, Qin BX, Chen BS (2013) First report of a *Tospovirus* in mulberry. Plant Dis 97:1001

76. Menzel W, Richert-Pöggeler KR, Winter S, Knierim D (2018) Characterization of a nucleorhabdovirus from *Physostegia*. Acta Hortic 1193:29-38

77. Muller MJ, Standfast HA (1986) Vectors of ephemeral fever group viruses. In: St George TD, Kay BH, Blok J (eds) Arbovirus research in Australia - Proceedings of the fourth symposium. CSIRO/QMIR, Brisbane, Australia, pp 295–300

78. Navarro B, Zicca S, Minutolo M, Saponari M, Alioto D, Di Serio F (2018) A negative-stranded RNA virus infecting citrus trees: the second member of a new genus within the order Bunyavirales. Front Microbiol 9:2340

79. Noh JY, Jeong DG, Yoon S-W, Kim JH, Choi YG, Kang S-Y, Kim HK (2018) Isolation and characterization of novel bat paramyxovirus B16-40 potentially belonging to the proposed genus *Shaanvirus*. Sci Rep 8:12533

80. Nunes-Neto JP, Souza WM, Acrani GO, Romeiro MF, Fumagalli M, Vieira LC, Medeiros DBdA, Lima JA, de Lima CPS, Cardoso JF, Figueiredo LTM, da Silva SPD, Tesh R, Nunes MRT, Vasconcelos PFdC (2017) Characterization of the Bujaru, frijoles and Tapara

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070504

antigenic complexes into the sandfly fever group and two unclassified phleboviruses from Brazil. J Gen Virol 98:585-594

81. Økland AL, Nylund A, Øvergård A-C, Skoge RH, Kongshaug H (2019) Genomic characterization, phylogenetic position and *in situ* localization of a novel putative mononegavirus in *Lepeophtheirus salmonis*. Arch Virol 164:675-689

82. Palacios G, da Rosa AT, Savji N, Sze W, Wick I, Guzman H, Hutchison S, Tesh R, Lipkin WI (2011) *Aguacate virus*, a new antigenic complex of the genus *Phlebovirus* (family *Bunyaviridae*). J Gen Virol 92:1445-1453

83. Palacios G, Tesh R, Travassos da Rosa A, Savji N, Sze W, Jain K, Serge R, Guzman H, Guevara C, Nunes MR, Nunes-Neto JP, Kochel T, Hutchison S, Vasconcelos PFC, Lipkin WI (2011) Characterization of the Candiru antigenic complex (*Bunyaviridae*: *Phlebovirus*), a highly diverse and reassorting group of viruses affecting humans in tropical America. J Virol 85:3811-3820

84. Palacios G, Savji N, Travassos da Rosa A, Desai A, Sanchez-Seco MP, Guzman H, Lipkin WI, Tesh R (2013) Characterization of the Salehabad virus species complex of the genus *Phlebovirus* (*Bunyaviridae*). J Gen Virol 94:837-842

85. Palacios G, Savji N, Travassos da Rosa A, Guzman H, Yu X, Desai A, Rosen GE, Hutchison S, Lipkin WI, Tesh R (2013) Characterization of the Uukuniemi virus group (*Phlebovirus*: *Bunyaviridae*): evidence for seven distinct species. J Virol 87:3187-3195

86. Palacios G, Tesh RB, Savji N, Travassos da Rosa APA, Guzman H, Bussetti AV, Desai A, Ladner J, Sanchez-Seco M, Lipkin WI (2014) Characterization of the Sandfly fever Naples species complex and description of a new Karimabad species complex (genus *Phlebovirus*, family *Bunyaviridae*). J Gen Virol 95:292-300

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070505

87. Palacios G, Wiley MR, Travassos da Rosa APA, Guzman H, Quiroz E, Savji N, Carrera J-P, Bussetti AV, Ladner JT, Ian Lipkin W, Tesh RB (2015) Characterization of the Punta Toro species complex (genus *Phlebovirus*, family *Bunyaviridae*). J Gen Virol 96:2079-2085

88. Pavri KM, Casals J (1966) Kaisodi virus, a new agent isolated from *Haemaphysalis spinigera* in Mysore state, South India. Am J Trop Med Hyg 15:961-963

89. Pecman A, Kutnjak D, Gutiérrez-Aguirre I, Adams I, Fox A, Boonham N, Ravnikar M (2017) Next generation sequencing for detection and discovery of plant viruses and viroids: comparison of two approaches. Front Microbiol 8:1998

90. Peralta PH, Shelokov A, Brody JA (1965) Chagres virus: a new human isolate from Panama. Am J Trop Med Hyg 14:146-151

91. Pettersson JH-O, Shi M, Bohlin J, Eldholm V, Brynildsrud OB, Paulsen KM, Andreassen Å, Holmes EC (2017) Characterizing the virome of *Ixodes ricinus* ticks from northern Europe. Sci Rep 7:10870

92. Pringle CR, Alexander DJ, Billeter MA, Collins PL, Kingsbury DW, Lipkind MA, Nagai Y, Orvell C, Rima B, Rott R, ter Meulen V (1991) The order *Mononegavirales*. Arch Virol 117:137-140

93. Pringle CR (1997) The order *Mononegavirales*—current status. Arch Virol 142:2321-2326

94. Pringle CR (2000) Order *Mononegavirales*. In: van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, Wickner RB (eds) Virus Taxonomy—Seventh Report of the International

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070506

Committee on Taxonomy of Viruses. Academic Press, San Diego, California, USA, pp 525-530

95. Pringle CR (2005) Order *Mononegavirales*. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds) Virus Taxonomy—Eighth Report of the International Committee on Taxonomy of Viruses. Elsevier/Academic Press, San Diego, California, USA, pp 609-614

96. Quan P-L, Williams DT, Johansen CA, Jain K, Petrosov A, Diviney SM, Tashmukhamedova A, Hutchison SK, Tesh RB, Mackenzie JS, Briese T, Lipkin WI (2011) Genetic characterization of K13965, a strain of Oak Vale virus from Western Australia. Virus Res 160:206-213

97. Read DA, Featherston J, Rees DJG, Thompson GD, Roberts R, Flett BC, Mashingaidze K, Pietersen G, Kiula B, Kullaya A, Mbega ER (2019) Molecular characterization of Morogoro maize-associated virus, a nucleorhabdovirus detected in maize (*Zea mays*) in Tanzania. Arch Virol 164:1711-1715

98. Reuter G, Boros A, Pál J, Kapusinszky B, Delwart E, Pankovics P (2016) Detection and genome analysis of a novel (dima)rhabdovirus (Riverside virus) from *Ochlerotatus* sp. mosquitoes in Central Europe. Infect Genet Evol 39:336-341

99. Ritter DG, Calisher CH, Muth DJ, Shope RE, Murphy FA, Whitfield SG (1978) New Minto virus: a new rhabdovirus from ticks in Alaska. Can J Microbiol 24:422-426

100. Rott ME, Kesanakurti P, Berwarth C, Rast H, Boyes I, Phelan J, Jelkmann W (2018) Discovery of negative-sense RNA viruses in trees infected with apple rubbery wood disease by next-generation sequencing. Plant Dis 102:1254-1263

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070507

101. Sabin AB (1951) Experimental studies on Phlebotomus (pappataci, sandfly) fever during World War II. Arch Gesamte Virusforsch 4:367-410

102. Sather GE, Lewis AL, Jennings W, Bond JO, Hammon WM (1970) Sawgrass virus: a newly described arbovirus in Florida. Am J Trop Med Hyg 19:319-326

103. Scarpassa VM, Debat HJ, Alencar RB, Saraiva JF, Calvo E, Arcà B, Ribeiro JMC (2019) An insight into the sialotranscriptome and virome of Amazonian anophelines. BMC Genomics 20:166

104. Shah KV, Work TH (1969) Bhanja virus: a new arbovirus from ticks *Haemaphysalis intermedia* Warburton and Nuttall, 1909, in Orissa, India. The Indian journal of medical research 57:793-798

105. Shahhosseini N, Lühken R, Jöst H, Jansen S, Börstler J, Rieger T, Krüger A, Yadouleton A, de Mendonça Campos R, Cirne-Santos CC, Ferreira DF, Garms R, Becker N, Tannich E, Cadar D, Schmidt-Chanasit J (2017) Detection and characterization of a novel rhabdovirus in *Aedes cantans* mosquitoes and evidence for a mosquito-associated new genus in the family *Rhabdoviridae*. Infect Genet Evol 55:260-268

106. Shi M, Lin XD, Tian JH, Chen LJ, Chen X, Li CX, Qin XC, Li J, Cao JP, Eden JS, Buchmann J, Wang W, Xu J, Holmes EC, Zhang YZ (2016) Redefining the invertebrate RNA virosphere. Nature 540:539-543

107. Shi M, Neville P, Nicholson J, Eden J-S, Imrie A, Holmes EC (2017) High-resolution metatranscriptomics reveals the ecological dynamics of mosquito-associated RNA viruses in western Australia. J Virol 91:e00680-00617

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070508

108. Shi M, Lin X-D, Chen X, Tian J-H, Chen L-J, Li K, Wang W, Eden J-S, Shen J-J, Liu L, Holmes EC, Zhang Y-Z (2018) The evolutionary history of vertebrate RNA viruses. Nature 556:197-202

109. Siddell SG, Walker PJ, Lefkowitz EJ, Mushegian AR, Adams MJ, Dutilh BE, Gorbalenya AE, Harrach Bz, Harrison RL, Junglen S, Knowles NJ, Kropinski AM, Krupovic M, Kuhn JH, Nibert M, Rubino L, Sabanadzovic S, Sanfaçon H, Simmonds P, Varsani A, Zerbini FM, Davison AJ (2019) Additional changes to taxonomy ratified in a special vote by the International Committee on Taxonomy of Viruses (October 2018). Arch Virol 164:943-946

110. Spence L, Anderson CR, Aitken THG, Downs WG (1966) Aruac virus, a new agent isolated from Trinidadian mosquitoes. Am J Trop Med Hyg 15:231-234

111. St George TD, Doherty RL, Carley JG, Filippich C, Brescia A, Casals J, Kemp DH, Brothers N (1985) The isolation of arboviruses including a new flavivirus and a new Bunyavirus from *Ixodes* (*Ceratixodes*) uriae (Ixodoidea: Ixodidae) collected at Macquarie Island, Australia, 1975-1979. Am J Trop Med Hyg 34:406-412

112. Straková P, Dufkova L, Širmarová J, Salát J, Bartonička T, Klempa B, Pfaff F, Höper D, Hoffmann B, Ulrich RG, Růžek D (2017) Novel hantavirus identified in European bat species *Nyctalus noctula*. Infect Genet Evol 48:127-130

113. Sun Q, Zhao Q, An X, Guo X, Zuo S, Zhang X, Pei G, Liu W, Cheng S, Wang Y, Shu P, Mi Z, Huang Y, Zhang Z, Tong Y, Zhou H, Zhang J (2017) Complete genome sequence of Menghai rhabdovirus, a novel mosquito-borne rhabdovirus from China. Arch Virol 162:1103-1106

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070509

114. Swei A, Russell BJ, Naccache SN, Kabre B, Veeraraghavan N, Pilgard MA, Johnson BJB, Chiu CY (2013) The genome sequence of Lone Star virus, a highly divergent bunyavirus found in the *Amblyomma americanum* tick. PLoS One 8:e62083

115. Tchouassi DP, Marklewitz M, Chepkorir E, Zirkel F, Agha SB, Tigoi CC, Koskei E, Drosten C, Borgemeister C, Torto B, Junglen S, Sang R (2019) Sand fly-associated phlebovirus with evidence of neutralizing antibodies in humans, Kenya. Emerg Infect Dis 25:681-690

116. Tesh RB, Chaniotis BN, Peralta PH, Johnson KM (1974) Ecology of viruses isolated from Panamanian phlebotomine sandflies. Am J Trop Med Hyg 23:258-269

117. Tesh RB (1975) Multiplication of Phlebotomus fever group arboviruses in mosquitos after intrathoracic inoculation. Journal of Medical Entomology 12:1-4

118. Tesh RB, Boshell J, Young DG, Morales A, De Carrasquilla CF, Corredor A, Modi GB, Travassos Da Rosa APA, McLean RG, De Rodriguez C, Gaitan MO (1989) Characterization of 5 new phleboviruses recently isolated from sand flies in tropical America. Am J Trop Med Hyg 40:529-533

119. Tokarz R, Sameroff S, Leon MS, Jain K, Lipkin WI (2014) Genome characterization of Long Island tick rhabdovirus, a new virus identified in *Amblyomma americanum* ticks. Virol J 11:26

120. Tokarz R, Williams SH, Sameroff S, Sanchez Leon M, Jain K, Lipkin WI (2014) Virome analysis of *Amblyomma americanum*, *Dermacentor variabilis*, and *Ixodes scapularis* ticks reveals novel highly divergent vertebrate and invertebrate viruses. J Virol 88:11480-11492

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070510

121. Trapp EE, Paes de Andrade AH, Shope RE (1965) Itaporanga, a newly reecognized arbovirus from Sao Paulo State, Brazil. Proc Soc Exp Biol Med 118:421-422

122. Travassos da Rosa APA, Tesh RB, Pinheiro FP, Travassos da Rosa JFS, Peterson NE (1983) Characterization of eight new phlebotomus fever serogroup arboviruses (Bunyaviridae: *Phlebovirus*) from the Amazon region of Brazil. Am J Trop Med Hyg 32:1164-1171

123. Vasilakis N, Tesh RB, Widen SG, Mirchandani D, Walker PJ (2019) Genomic characterisation of Cuiaba and Charleville viruses: arboviruses (family *Rhabdoviridae*, genus *Sripuvirus*) infecting reptiles and amphibians. Virus Genes 55:87-94

124. Velasco L, Arjona-Girona I, Cretazzo E, López-Herrera C (2019) Viromes in Xylariaceae fungi infecting avocado in Spain. Virology 532:11-21

125. Verani P, Ciufolini MG, Nicoletti L, Balducci M, Sabatinelli G, Coluzzi M, Paci P, Amaducci L (1982) Studi ecologici ed epidemiologici del virus Toscana, un arbovirus isolato da flebotomi. Ann Ist Super Sanita 18:397-399

126. Walker PJ, Firth C, Widen SG, Blasdell KR, Guzman H, Wood TG, Paradkar PN, Holmes EC, Tesh RB, Vasilakis N (2015) Evolution of genome size and complexity in the *Rhabdoviridae*. PLoS Pathog 11:e1004664

127. Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM, Dutilh BE, Harrach B, Harrison RL, Hendrickson RC, Junglen S, Knowles NJ, Kropinski AM, Krupovic M, Kuhn JH, Nibert M, Rubino L, Sabanadzovic S, Simmonds P (2019) Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2019). Arch Virol 164:2417-2429

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070511

128. Wang H, Liu Y, Liu W, Cao M, Wang X (2019) Sequence analysis and genomic organization of a novel chuvirus, Tàiyuán leafhopper virus. Arch Virol 164:617-620

129. Wang J, Selleck P, Yu M, Ha W, Rootes C, Gales R, Wise T, Crameri S, Chen H, Broz I, Hyatt A, Woods R, Meehan B, McCullough S, Wang L-F (2014) Novel phlebovirus with zoonotic potential isolated from ticks, Australia. Emerg Infect Dis 20:1040-1043

130. Wang Y, Hua W, Wang J, Hannoufa A, Xu Z, Wang Z (2013) Deep sequencing of *Lotus corniculatus* L. reveals key enzymes and potential transcription factors related to the flavonoid biosynthesis pathway. Mol Genet Genomics 288:131-139

131. Wanzeller ALM, Martins LC, Diniz Júnior JAP, de Almeida Medeiros DB, Cardoso JF, da Silva DEA, de Oliveira LF, de Vasconcelos JM, Nunes MRT, da S. G. Vianez Júnior JL, Vasconcelos PFC (2014) Xiburema virus, a hitherto undescribed virus within the family *Rhabdoviridae* isolated in the Brazilian Amazon Region. Genome Announc 2:e00454-00414

132. Willie K, Stewart LR (2017) Complete genome sequence of a new maize-associated cytorhabdovirus. Genome Announc 5:e00591-00517

133. Winter S, Koerbler M, Shahraeen N, Katul L, Lesemann D-E (2003) Characterization of a new tospovirus species infecting tomato in Iran. J Plant Dis Prot 110:74

134. Winton JR, Batts WN, Powers RL, Purcell MK (2019) Complete genome sequences of the index isolates of two genotypes of Pacific salmon paramyxovirus. Microbiol Resour Announc 8:e01521-01518

135. Wolf YI, Kazlauskas D, Iranzo J, Lucía-Sanz A, Kuhn JH, Krupovic M, Dolja VV, Koonin EV (2018) Origins and evolution of the global RNA virome. mBIO (Washington, DC) 9:e02329-02318

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070512

136. Woyessa AB, Omballa V, Wang D, Lambert A, Waiboci L, Ayele W, Ahmed A, Abera NA, Cao S, Ochieng M, Montgomery JM, Jima D, Fields B (2014) An outbreak of acute febrile illness caused by sandfly fever Sicilian virus in the Afar Region of Ethiopia, 2011. Am J Trop Med Hyg 91:1250-1253

137. Wu L-P, Yang T, Liu H-W, Postman J, Li R (2018) Molecular characterization of a novel rhabdovirus infecting blackcurrant identified by high-throughput sequencing. Arch Virol 163:1363-1366

138. Wu Z, Du J, Lu L, Yang L, Dong J, Sun L, Zhu Y, Liu Q, Jin Q (2018) Detection of Hantaviruses and Arenaviruzses [sic] in three-toed jerboas from the Inner Mongolia Autonomous Region, China. Emerg Microbes Infect 7:35

139. Wu Z, Lu L, Du J, Yang L, Ren X, Liu B, Jiang J, Yang J, Dong J, Sun L, Zhu Y, Li Y, Zheng D, Zhang C, Su H, Zheng Y, Zhou H, Zhu G, Li H, Chmura A, Yang F, Daszak P, Wang J, Liu Q, Jin Q (2018) Comparative analysis of rodent and small mammal viromes to better understand the wildlife origin of emerging infectious diseases. Microbiome 6:178

140. Xu C, Sun X, Taylor A, Jiao C, Xu Y, Cai X, Wang X, Ge C, Pan G, Wang Q, Fei Z, Wang Q (2017) Diversity, distribution, and evolution of tomato viruses in China uncovered by small RNA sequencing. J Virol 91:e00173-00117

141. Xu FL, Liu DY, Nunes MRT, Da Rosa A, Tesh RB, Xiao SY (2007) Antigenic and genetic relationships among rift valley fever virus and other selected members of the genus Phlebovirus (Bunyaviridae). Am J Trop Med Hyg 76:1194-1200

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070513

142. Xu Y, Lou S-G, Li XL, Zheng Y-X, Wang W-C, Liu Y-T (2013) The complete S RNA and M RNA nucleotide sequences of a hippeastrum chlorotic ringspot virus (HCRV) isolate from *Hymenocallis littoralis* (Jacq.) Salisb in China. Arch Virol 158:2597-2601

143. Yadav PD, Nyayanit DA, Shete AM, Jain S, Majumdar TP, Chaubal GY, Shil P, Kore PM, Mourya DT (2019) Complete genome sequencing of Kaisodi virus isolated from ticks in India belonging to *Phlebovirus* genus, family *Phenuiviridae*. Ticks and tick-borne diseases 10:23-33

144. Yang X-L, Zhang Y-Z, Jiang R-D, Guo H, Zhang W, Li B, Wang N, Wang L, Waruhiu C, Zhou J-H, Li S-Y, Daszak P, Wang L-F, Shi Z-L (2017) Genetically diverse filoviruses in *Rousettus* and *Eonycteris* spp. bats, China, 2009 and 2015. Emerg Infect Dis 23:482-486

145. Yang X-L, Tan CW, Anderson DE, Jiang R-D, Li B, Zhang W, Zhu Y, Lim XF, Zhou P, Liu X-L, Guan W, Zhang L, Li S-Y, Zhang Y-Z, Wang L-F, Shi Z-L (2019) Characterization of a filovirus (Měnglà virus) from *Rousettus* bats in China. Nat Microbiol 4:390-395

146. Yang X, Huang J, Liu C, Chen B, Zhang T, Zhou G (2016) Rice stripe mosaic virus, a novel cytorhabdovirus infecting rice via leafhopper transmission. Front Microbiol 7:2140

147. Zhao G, Krishnamurthy S, Cai Z, Popov VL, Travassos da Rosa AP, Guzman H, Cao S, Virgin HW, Tesh RB, Wang D (2013) Identification of novel viruses using VirusHunter - an automated data analysis pipeline. PLoS One 8:e78470

148. Бутенко АМ, Громашевский ВЛ, Львов ДК, Попов ВФ (1979) Вирус Кисемайо - представитель антигенной группы Бханджа. Вопр Вирусол:661-665

149. Львов ДК, Альховский СВ, Щелканов МЮ, Щетинин АМ, Дерябин ПГ, Аристова ВА, Гительман АК, Самохвалов ЕИ, Ботиков АГ (2014) Генетическая

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070514

характеристика вирусов Сахалин (SAKV - Sakhalin virus), Парамушир (PMRV - Paramushir virus) (*Bunyaviridae*, *Nairovirus*, группа Сахалин) и Рукутама (RUKV - Rukutama virus) (*Bunyaviridae*, *Phlebovirus*, группа Укуниеми), изолированных от облигатных паразитов колониальных морских птиц - клещей *Ixodes* (*Ceratixodes*) *uriae*, White 1852 и *I. signatus* Birulya, 1895 в бассейнах Охотского и Берингова морей. Вопр Вирусол 59:11-17

150. Львов ДК, Альховский СВ, Щелканов МЮ, Щетинин АМ, Дерябин ПГ, Гительман АК, Самохвалов ЕИ, Ботиков АГ (2014) Генетическая характеристика штаммов вируса Залив Терпения (ZTV - Zaliv Terpeniya virus) (*Bunyaviridae*, *Phlebovirus*, антигенный комплекс Укуниеми), изолированного в высоких широтах Северной Евразии из облигатных эктопаразитов чистиковых птиц (Alcidae Leach, 1820) - клещей *Ixodes* (*Ceratixodes*) *uriae* White, 1852 и от комаров *Culex modestus* Ficalbi, 1889 в субтропиках Закавказья. Вопр Вирусол 59:12-18

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070515

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Friday, May 8, 2020 1:31 PM
To: 'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007573

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007574

Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007575

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007576

From:	Rusek, Benjamin <BRusek@nas.edu>
Sent:	Friday, May 8, 2020 11:18 PM
To:	'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)'
Cc:	'Frances Sharples';Lowenthal, Micah;Bowman, Katherine;Shi, Pei yong
Subject:	RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Attachments:	Draft Covid-19 US-China dialogue agenda v2.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Diane,

Following up from the call, I assume that we want to ask Harvey Fineberg to give the proposed 5 min U.S. situation overview. Linda Saif has offered to shepherd answers to the CoV immunity questions. Who should we ask/task with taking on the responsibility for the other questions/issues? I attached a revised agenda.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007535

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007536

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007537

US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007538

1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007539

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Saturday, May 9, 2020 8:42 AM
To: Rusek, Benjamin;'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)'
Cc: 'Frances Sharples';Lowenthal, Micah;Bowman, Katherine;Shi, Pei yong
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Attachments: Draft Covid-19 US-China dialogue agenda v3.docx; Bios for Americans.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - Attached are my suggestions and some edits to the participants list.

1. I agree that we should ask Harvey to provide the US overview.
2. I rearranged the topics somewhat to group similar questions so we can assign one discussion leader to these "groups" e.g. clinical, treatment, immunity, epidemiology, etc.
3. I also thought that "future collaborations" should be last for each section.
4. I wasn't sure how much to assign to those new to this dialogue, but have options for involving everyone or restricting to fewer people.
5. I was most uncertain about the clinical section. We have several MDs (me, Relman, Dzau, Hamburg, Perlman, Fineberg), but I'm not sure any of us are seeing/caring for these patients. Suggestions appreciated.
6. I wasn't sure how much Victor wants to be involved vs "attending".

Suggestions/edits from the group on these issues or others are welcome.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 9, 2020 12:18 AM
To: Diane Griffin <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Bowman, Katherine <KBowman@nas.edu>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007527

Hi Diane,

Following up from the call, I assume that we want to ask Harvey Fineberg to give the proposed 5 min U.S. situation overview. Linda Saif has offered to shepherd answers to the CoV immunity questions. Who should we ask/task with taking on the responsibility for the other questions/issues? I attached a revised agenda.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007528

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007529

'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007530

'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007531

From: LeDuc, James W.
Sent: Saturday, May 9, 2020 10:36 AM
To: Diane Griffin;Rusek, Benjamin;'Peggy Hamburg';'Dave Franz (davidrfranz@gmail.com)'
Cc: 'Frances Sharples';Lowenthal, Micah;Bowman, Katherine;Shi, Pei yong
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Looks good to me.

Thanks, Jim

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Saturday, May 9, 2020 8:42 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Bowman, Katherine <KBowman@nas.edu>; Shi, Pei yong <peshi@UTMB.EDU>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - Attached are my suggestions and some edits to the participants list.

1. I agree that we should ask Harvey to provide the US overview.
2. I rearranged the topics somewhat to group similar questions so we can assign one discussion leader to these "groups" e.g. clinical, treatment, immunity, epidemiology, etc.
3. I also thought that "future collaborations" should be last for each section.
4. I wasn't sure how much to assign to those new to this dialogue, but have options for involving everyone or restricting to fewer people.
5. I was most uncertain about the clinical section. We have several MDs (me, Relman, Dzau, Hamburg, Perlman, Fineberg), but I'm not sure any of us are seeing/caring for these patients. Suggestions appreciated.
6. I wasn't sure how much Victor wants to be involved vs "attending".

Suggestions/edits from the group on these issues or others are welcome.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008862

410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 9, 2020 12:18 AM
To: Diane Griffin <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Bowman, Katherine <KBowman@nas.edu>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Hi Diane,

Following up from the call, I assume that we want to ask Harvey Fineberg to give the proposed 5 min U.S. situation overview. Linda Saif has offered to shepherd answers to the CoV immunity questions. Who should we ask/task with taking on the responsibility for the other questions/issues? I attached a revised agenda.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008863

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008864

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008865

Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008866

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Saturday, May 9, 2020 10:24 PM
To: 'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Attachments: Draft Covid-19 US-China dialogue agenda v3.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008077

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008078

5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008079

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008080

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008081

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Sunday, May 10, 2020 7:30 AM
To: Rusek, Benjamin
Cc: 'dgriffi6@jhmi.edu';'peggy@hbfam.net';JohnHildebrand;Boright, John;LeDuc, James W.;'gaof@im.ac.cn';liyin;tongting@cashq.ac.cn
Subject: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: Chinese Participants-0510.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Rusek,

Thank you for agreeing to accommodating the change of schedule and sharing with us the information of American participants. FYI, please find attached the list of the Chinese participants. Please note that some participants may only be available for one of the sessions. I am still waiting for the confirmation of Dr. Chen Wang, who might only be available on the 14th.

I don't see any problem of your using the feature of recording/transcription during the dialogue. We would be happy if you could share the notes with us.

We will do the test of connection with the zoom link you sent to us. See you tomorrow morning online.

Best wishes,

Sun Hui

-----原始邮件-----
发件人:"Rusek, Benjamin" <BRusek@nas.edu>
发送时间:2020-05-09 05:53:57 (星期六)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008067

收件人: "'孙辉'" <sunhui@cashq.ac.cn>
抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>
主题: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for your email. We are pleased to hear that your group will be able to participate for two sessions.

With regards to the exact timing, let's move the second session back 24 hours as you suggest. We can keep the first session scheduled for 9-11am on **May 12** (Beijing time) and then reschedule the second session for 9-11 am on **May 14** (Beijing Time).

Thank you for agreeing to conduct the call in English. One question: Zoom has a built in recording/transcription feature, does your group mind if we use this feature during the sessions? As noted in the letter "Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information…but remarks and discussion comments would not be attributed without permission of the speaker." The transcript would only be used for internal notes and we would be happy to share it with you.

I would be happy to test the connection with you at 9:00 AM on Monday, May 11 Beijing time (9:00 PM on Sunday, May 10 in Washington, DC). I will send you a Zoom link/meeting invitation for that test call after this email.

I have attached the list of American participants for your information, we look forward to seeing the list of Chinese participants.

Kind regards,

Ben

Benjamin Rusek

The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008068

1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Friday, May 8, 2020 8:58 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

I am writing to follow up on the virtual dialogue meeting next week on behalf of Dr. George Gao. The topical agenda sent by Dr. Griffin to Dr. Gao looks fine to us.

With regard to the timing of the dialogue, we could have two 2-hour sessions as you suggested. However, Dr. Gao has some other emergent commitment on May 13, so we would like to suggest the dialogues be rescheduled to 9-11am on May 11 and 12, or 9-11am on May 12 and 14, or 9-11am on May 12 and 15 (all Beijing Time). Please let us know which time slot you would prefer. We are sorry for any inconvenience this may cause you.

The dialogue could be in English, and we could use the zoom videoconference. We will test it 24 hours in advance following your guidance.

FYI, we have sent invitations to potential speakers on our side, hopefully we could finalize the list of speakers very soon. We will have no more than 13 speakers on each side as you suggested. Please share with us the name and title of participants from the US side when it becomes available, and we will do the same.

Best wishes,

SUN Hui(Mr.)

Director

Division of American and Oceanian Affairs

Bureau of International Cooperation

Chinese Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008069

-----原始邮件-----

发件人:NASPresident <naspresident@nas.edu>

发送时间:2020-05-01 21:42:08 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "McNutt, Marcia K." <MMcNutt@nas.edu>, "Dzau, Victor J." <VDzau@nas.edu>, "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'jh-cao@cashq.ac.cn'" <jh-cao@cashq.ac.cn>, "'clbai@cas.cn'" <clbai@cas.cn>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, NASPresident <naspresident@nas.edu>

主题: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Colleagues:

Please find the attached letter from Drs. McNutt and Dzau.

Best regards,

Anna

Anna Bashkirova

Assistant to the President

National Academy of Sciences

Office: 2101 Constitution Ave NW | Washington, DC 20418

Mailing address: 500 5th St NW, NAS 215 | Washington, DC 20001

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008070

(202) 334-2635 | abashkirova@nas.edu | www.nasonline.org

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008071

发件人： NASPresident

发送时间： 2020-04-23 20:50:33

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'

抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'

主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008072

Chinese Participants

Bin Cao: Dr. Bin Cao is a physician and professor at the China-Japan Friendship Hospital.

Zhu Chen: Dr. Zhu Chen is president of the Red Cross Society of China, CAS member. He was previously minister of the National Health Commission of China. (Only available on the 14th)

George F. Gao: Dr. George F. Gao is Director-General of CCDC, a professor at the CAS Institute of Microbiology, CAS member.

Dongfeng Gu: Dr. Dongfeng Gu is Vice President of Southern University of Science and Technology, CAS member.

Hualiang Jiang: Dr. Hualiang Jiang is a professor at the CAS Shanghai Institute of Materia Medica, CAS member.

Lanjuan Li: Dr. Lanjuan Li is a physician and professor in infectious diseases, a member of the Chinese Academy of Engineering, and she is currently director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. (Only available on the 12th)

Zhengli Shi: Dr. Zhengli Shi is a professor at CAS Wuhan Institute of Virology.

Wenjie Tan: Dr. Wenjie Tan is a professor at the National Institute of Viral Disease Control and Prevention, CCDC.

Chen Wang: Dr. Chen Wang is Vice President and a member of the Chinese Academy of Engineering, and President of the Chinese Academy of Medical Sciences. (To be confirmed)

Haiming Wei: Dr. Haiming Wei is a professor at the University of Science and Technology of China.

Zhiming Yuan: Dr. Zhiming Yuan is a professor at CAS Wuhan Institute of Virology, Director of Wuhan P4 lab.

Yongqing Zhang: Dr. Yongqing Zhang is Deputy Director General of CAS Bureau of Frontier sciences and Education, a Professor at CAS Institute of Genetics and Developmental Biology.

Guoping Zhao: Dr. Guoping Zhao is a professor at CAS Shanghai Institutes for Biological Sciences, CAS member.

Qi Zhou: Dr. Qi Zhou is Deputy Secretary-General of CAS, Director of CAS Institute of Zoology, CAS member.

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 11:15 AM
To: 'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Attachments: Chinese Participants-0510.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008060

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008061

<harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008062

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008063

Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008064

Chinese Participants

Bin Cao: Dr. Bin Cao is a physician and professor at the China-Japan Friendship Hospital.

Zhu Chen: Dr. Zhu Chen is president of the Red Cross Society of China, CAS member. He was previously minister of the National Health Commission of China. (Only available on the 14th)

George F. Gao: Dr. George F. Gao is Director-General of CCDC, a professor at the CAS Institute of Microbiology, CAS member.

Dongfeng Gu: Dr. Dongfeng Gu is Vice President of Southern University of Science and Technology, CAS member.

Hualiang Jiang: Dr. Hualiang Jiang is a professor at the CAS Shanghai Institute of Materia Medica, CAS member.

Lanjuan Li: Dr. Lanjuan Li is a physician and professor in infectious diseases, a member of the Chinese Academy of Engineering, and she is currently director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. (Only available on the 12th)

Zhengli Shi: Dr. Zhengli Shi is a professor at CAS Wuhan Institute of Virology.

Wenjie Tan: Dr. Wenjie Tan is a professor at the National Institute of Viral Disease Control and Prevention, CCDC.

Chen Wang: Dr. Chen Wang is Vice President and a member of the Chinese Academy of Engineering, and President of the Chinese Academy of Medical Sciences. (To be confirmed)

Haiming Wei: Dr. Haiming Wei is a professor at the University of Science and Technology of China.

Zhiming Yuan: Dr. Zhiming Yuan is a professor at CAS Wuhan Institute of Virology, Director of Wuhan P4 lab.

Yongqing Zhang: Dr. Yongqing Zhang is Deputy Director General of CAS Bureau of Frontier sciences and Education, a Professor at CAS Institute of Genetics and Developmental Biology.

Guoping Zhao: Dr. Guoping Zhao is a professor at CAS Shanghai Institutes for Biological Sciences, CAS member.

Qi Zhou: Dr. Qi Zhou is Deputy Secretary-General of CAS, Director of CAS Institute of Zoology, CAS member.

FOIA Confidential Treatment Requested by Univ of Texas System

From: LeDuc, James W.
Sent: Sunday, May 10, 2020 11:36 AM
To: Rusek, Benjamin
Cc: Diane Griffin;Dave Franz
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Excellent. Do we have sufficient front line clinicians on our side?

Jim

Sent from my iPhone

On May 10, 2020, at 11:15 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008837

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008838

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008839

1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008840

US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008841

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Chinese Participants-0510.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008842

From: David Franz <davidrfranz@gmail.com>
Sent: Sunday, May 10, 2020 11:51 AM
To: LeDuc, James W.
Cc: Rusek, Benjamin;Diane Griffin
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben and Diane,

A thought about introductions. If you were planning to have everyone introduced themselves very very briefly like we did the other night, it might be useful for one of you to call out the name and then have that person speak. As you know, if we are just asked introduce ourselves there is often confusion as to who goes next. A minor detail but it might save us a little time. Dave

Sent from my iPhone

> On May 10, 2020, at 12:36 PM, LeDuc, James W. <jwleduc@utmb.edu> wrote:
>
> Excellent. Do we have sufficient front line clinicians on our side?
>
> Jim
>
> Sent from my iPhone
>
> > On May 10, 2020, at 11:15 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:
> >
> > **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
> >
> > The list of Chinese participants is attached.
> >
> > Kind regards,
> >
> > Ben
> >
> > Benjamin Rusek
> > The U.S. National Academy of Sciences
> > 1-202-334-3975
> >
> > **From:** Rusek, Benjamin
> > **Sent:** Saturday, May 9, 2020 11:24 PM
> > **To:** 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System

'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008055

May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)

FOIA Confidential Treatment Requested by Univ of Texas System

2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008057

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008058

<antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Chinese Participants-0510.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008059

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 4:12 PM
To: LeDuc, James W.
Cc: Diane Griffin;Dave Franz;Sharples, Fran;Peggy Hamburg
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Do you know someone who could add additional clinical expertise? They would need to be available on very short notice.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Sunday, May 10, 2020 12:36 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Excellent. Do we have sufficient front line clinicians on our side?

Jim

Sent from my iPhone

> On May 10, 2020, at 11:15 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:
>
> **WARNING:** This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.
>
> The list of Chinese participants is attached.
>
> Kind regards,
>
> Ben
>
> Benjamin Rusek
> The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007932

1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007933

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007934

4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007935

The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007936

discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Chinese Participants-0510.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007937

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 11:06 PM
To: 'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007721

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007722

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007723

5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007724

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007725

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007726

From: Peter Daszak <daszak@ecohealthalliance.org>
Sent: Monday, May 11, 2020 12:00 AM
To: Rusek, Benjamin;'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';Alison Andre;'Jennifer Ryan';Bowman, Katherine
Subject: Re. List of Chinese participants - Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Well done on getting confirmation of this meeting from CAS, and a very impressive list of senior people who will attend. Having so many senior academicians, including Chen Zhu - a former VP of CAS and essentially former Minister for Health is particularly important and shows that they are taking this meeting extremely seriously.

I look forward to seeing some familiar faces on the calls and to two great sessions!

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street
New York, NY 10001
USA

Tel.: +1-212-380-4474
Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; Peter Daszak <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007712

'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007713

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007714

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007715

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007716

2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007717

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 8:04 AM
To: Rusek, Benjamin;LeDuc, James W.
Cc: Dave Franz;Sharples, Fran;Peggy Hamburg
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - I could ask Paul Auwaerter who is head of the clinical ID operations at JH - professor of medicine/infectious diseases, past president of the IDSA, a former postdoc in my lab.

Let me know if you want me to contact him.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 5:11 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>; Sharples, Fran <FSharples@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Do you know someone who could add additional clinical expertise? They would need to be available on very short notice.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Sunday, May 10, 2020 12:36 PM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008623

To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Excellent. Do we have sufficient front line clinicians on our side?

Jim

Sent from my iPhone

On May 10, 2020, at 11:15 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008624

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008625

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008626

<jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008627

https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Chinese Participants-0510.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008628

From: LeDuc, James W.
Sent: Monday, May 11, 2020 9:28 AM
To: Peggy Hamburg;Rusek, Benjamin
Cc: David Franz;Diane Griffin;Sharples, Fran
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

No problem. Thanks, Jim

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, May 11, 2020 9:06 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: David Franz <davidrfranz@gmail.com>; Diane Griffin <dgriffi6@jhmi.edu>; LeDuc, James W. <jwleduc@UTMB.EDU>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I think not necessary for this call. Perhaps at another time would be good to drill
More deeply into clinics experiences in echo country
Peggy

Sent from my iPhone

On May 11, 2020, at 10:03 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

I am fine either way, Jim also suggested a Dr. from UTBM but it sounds like the group does not think another participant is necessary.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: David Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 9:41 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Peggy Hamburg <peggy@hbfam.net>; Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Agree as well. dave

FOIA Confidential Treatment Requested by Univ of Texas System

Sent from my iPhone

On May 11, 2020, at 9:30 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Peggy - I think that you are correct and that an additional person is not really necessary.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Peggy Hamburg <peggy@hbfam.net>
Sent: Monday, May 11, 2020 9:25 AM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; Dave Franz <davidrfranz@gmail.com>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

I did ask David Relman if he is seeing patients but have not heard back. Will pin him again. To be honest, although I think I may have suggested bringing in someone with a clinical background, I am now wondering if it will just add to the clumsiness of the call....a lot of people and not a lot of time. Also, the context, format and language issueS add challenges. I suspect that we all have enough "exposure" to the clinical concerns to discuss even if not Doing clinical care.

Peggy

Sent from my iPhone

On May 11, 2020, at 9:04 AM, Diane Griffin <dgriffi6@jhmi.edu> wrote:

Ben - I could ask Paul Auwaerter who is head of the clinical ID operations at JH - professor of medicine/infectious diseases, past president of the IDSA, a former postdoc in my lab.

FOIA Confidential Treatment Requested by Univ of Texas System

Let me know if you want me to contact him.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Sunday, May 10, 2020 5:11 PM
To: 'LeDuc, James W.' <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>; Sharples, Fran <FSharples@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Do you know someone who could add additional clinical expertise? They would need to be available on very short notice.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Sunday, May 10, 2020 12:36 PM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Dave Franz <davidrfranz@gmail.com>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Excellent. Do we have sufficient front line clinicians on our side?

Jim

Sent from my iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008722

On May 10, 2020, at 11:15 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008723

delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008724

and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008725

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008726

(antoinette_baric@med.unc.edu)'
<antoinette_baric@med.unc.edu>; 'Alison Andre'
<andre@ecohealthalliance.org>; 'Jennifer Ryan'
<jennifer.ryan@moore.org>; Bowman, Katherine
<KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008727

Dial(for higher quality, dial a number based on your current location) :

US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)

Meeting ID: 934 1863 7725

Password: 662746

International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008728

the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

<Chinese Participants-0510.docx>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008729

From: LeDuc, James W.
Sent: Monday, May 11, 2020 10:47 AM
To: Diane Griffin;Rusek, Benjamin;'peggy@hbfam.net'
Cc: 'Dave Franz (davidrfranz@gmail.com)';Lowenthal, Micah;Sharples, Fran
Subject: Future collaborations

The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.

Thanks, Jim

Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.

1. Clinical Disease—Acute and Convalescence
    a. Long-term sequela seen in survivors, especially lung function, cardiac disease.
    b. Better definition of Pediatric Inflammatory Syndrome of COVID
    c. Neurologic complications??
    d. Psychiatric issues??
2. Pathogenesis and Treatment options
    a. Antiviral drug targets and development
    b. Monoclonal antibody therapies
    c. Immune modulators and management of inflammation
3. Prophylactics and Preventatives
    a. Passive antibody therapy
    b. Vaccine development
        i. Various techniques under development
        ii. Animal models
        iii. Clinical testing
        iv. Production capacity
        v. Ethics considerations

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008682

Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008683

1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008684

1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008685

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008686

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008687

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008688

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008689

From: Dave Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 10:51 AM
To: LeDuc, James W.
Cc: Diane Griffin;Benjamin Rusek;Peggy Hamburg;Micah Lowenthal;Fran Sharples
Subject: Re: Future collaborations

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I was thinking the same thing re. taking notes along the way to be prepared for the 'collaborations'. Good list.

What about something on understanding what 'recovery' and 'protection' means. Do you know, for example, if anyone has done viral isolations or animal challenges with with materials from 'recovered' patients with IgG who are still PCR positive?

On May 11, 2020, at 11:47 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.

Thanks, Jim

Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.

1. Clinical Disease—Acute and Convalescence
    a. Long-term sequela seen in survivors, especially lung function, cardiac disease.
    b. Better definition of Pediatric Inflammatory Syndrome of COVID
    c. Neurologic complications??
    d. Psychiatric issues??
2. Pathogenesis and Treatment options
    a. Antiviral drug targets and development
    b. Monoclonal antibody therapies
    c. Immune modulators and management of inflammation
3. Prophylactics and Preventatives
    a. Passive antibody therapy
    b. Vaccine development
        i. Various techniques under development
        ii. Animal models
        iii. Clinical testing
        iv. Production capacity
        v. Ethics considerations

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007475

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007476

Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link:
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007477

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007478

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007479

To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007480

Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or
Android: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007481

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007482

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 11:34 AM
To: 'Dave Franz';LeDuc, James W.
Cc: Diane Griffin;Peggy Hamburg;Lowenthal, Micah;Sharples, Fran
Subject: RE: Future collaborations

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim, thanks for putting this framework together in advaince, it looks good to me.

PS Peter Dazak and others on 60 mins last night
https://www.cbsnews.com/news/trump-administration-coronavirus-vaccine-researcher-covid-19-cure-60-minutes/

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Dave Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 11:51 AM
To: James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Future collaborations

I was thinking the same thing re. taking notes along the way to be prepared for the 'collaborations'. Good list.

What about something on understanding what 'recovery' and 'protection' means. Do you know, for example, if anyone has done viral isolations or animal challenges with with materials from 'recovered' patients with IgG who are still PCR positive?

On May 11, 2020, at 11:47 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.

Thanks, Jim

Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.

1. Clinical Disease—Acute and Convalescence
    a. Long-term sequela seen in survivors, especially lung function, cardiac disease.
    b. Better definition of Pediatric Inflammatory Syndrome of COVID
    c. Neurologic complications??
    d. Psychiatric issues??

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007466

2. Pathogenesis and Treatment options
    a. Antiviral drug targets and development
    b. Monoclonal antibody therapies
    c. Immune modulators and management of inflammation
3. Prophylactics and Preventatives
    a. Passive antibody therapy
    b. Vaccine development
        i. Various techniques under development
        ii. Animal models
        iii. Clinical testing
        iv. Production capacity
        v. Ethics considerations

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007467

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link:
Password: 613725

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007468

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007469

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007470

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007471

The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or
Android: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007472

US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007473

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007474

From: Sharples, Fran <FSharples@nas.edu>
Sent: Monday, May 11, 2020 12:35 PM
To: Rusek, Benjamin;'Dave Franz';LeDuc, James W.
Cc: Diane Griffin;Peggy Hamburg;Lowenthal, Micah
Subject: Re: Future collaborations

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Yes, and I am supposed to be writing these calls up, so I would very much appreciate it if all you good notetakers could share what you put together. It would help me immensely!

Best,
Fran

Fran Sharples, PhD
Board on Life Sciences
National Academy of Sciences

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:33 PM
To: 'Dave Franz'; James W. LeDuc
Cc: Diane Griffin; Peggy Hamburg; Lowenthal, Micah; Sharples, Fran
Subject: RE: Future collaborations

Hi Jim, thanks for putting this framework together in advaince, it looks good to me.

PS Peter Dazak and others on 60 mins last night
https://www.cbsnews.com/news/trump-administration-coronavirus-vaccine-researcher-covid-19-cure-60-minutes/

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Dave Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 11:51 AM
To: James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Future collaborations

I was thinking the same thing re. taking notes along the way to be prepared for the 'collaborations'. Good list.

What about something on understanding what 'recovery' and 'protection' means. Do you know, for example, if anyone has done viral isolations or animal challenges with with materials from 'recovered' patients with IgG who are still PCR positive?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008302

On May 11, 2020, at 11:47 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.

Thanks, Jim

Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.

1. Clinical Disease—Acute and Convalescence
    a. Long-term sequela seen in survivors, especially lung function, cardiac disease.
    b. Better definition of Pediatric Inflammatory Syndrome of COVID
    c. Neurologic complications??
    d. Psychiatric issues??
2. Pathogenesis and Treatment options
    a. Antiviral drug targets and development
    b. Monoclonal antibody therapies
    c. Immune modulators and management of inflammation
3. Prophylactics and Preventatives
    a. Passive antibody therapy
    b. Vaccine development
        i. Various techniques under development
        ii. Animal models
        iii. Clinical testing
        iv. Production capacity
        v. Ethics considerations

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008303

410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008304

To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link:
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008305

1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008306

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008307

4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008308

The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or
Android: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008309

discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008310

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 12:39 PM
To: Sharples, Fran;'Dave Franz';LeDuc, James W.
Cc: Diane Griffin;Peggy Hamburg;Lowenthal, Micah
Subject: RE: Future collaborations

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Thanks Fran.

FYI the CAS agreed to allow the use of the record/transcribe feature on Zoom (and would like a copy) but I am unsure how clear the transcript it produces will be.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Sharples, Fran <FSharples@nas.edu>
Sent: Monday, May 11, 2020 1:35 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>; James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Future collaborations

Yes, and I am supposed to be writing these calls up, so I would very much appreciate it if all you good notetakers could share what you put together. It would help me immensely!

Best,
Fran

Fran Sharples, PhD
Board on Life Sciences
National Academy of Sciences

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:33 PM
To: 'Dave Franz'; James W. LeDuc
Cc: Diane Griffin; Peggy Hamburg; Lowenthal, Micah; Sharples, Fran
Subject: RE: Future collaborations

Hi Jim, thanks for putting this framework together in advaince, it looks good to me.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008293

PS Peter Dazak and others on 60 mins last night
https://www.cbsnews.com/news/trump-administration-coronavirus-vaccine-researcher-covid-19-cure-60-minutes/

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Dave Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 11:51 AM
To: James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Future collaborations

I was thinking the same thing re. taking notes along the way to be prepared for the 'collaborations'. Good list.

What about something on understanding what 'recovery' and 'protection' means. Do you know, for example, if anyone has done viral isolations or animal challenges with with materials from 'recovered' patients with IgG who are still PCR positive?

> On May 11, 2020, at 11:47 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:
>
> The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.
>
> Thanks, Jim
>
> Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.
>
> 1. Clinical Disease—Acute and Convalescence
>   a. Long-term sequela seen in survivors, especially lung function, cardiac disease.
>   b. Better definition of Pediatric Inflammatory Syndrome of COVID
>   c. Neurologic complications??
>   d. Psychiatric issues??
> 2. Pathogenesis and Treatment options
>   a. Antiviral drug targets and development
>   b. Monoclonal antibody therapies
>   c. Immune modulators and management of inflammation
> 3. Prophylactics and Preventatives
>   a. Passive antibody therapy
>   b. Vaccine development
>   i. Various techniques under development
>   ii. Animal models
>   iii. Clinical testing
>   iv. Production capacity
>   v. Ethics considerations

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008294

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008295

Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link:
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008296

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008297

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008298

To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008299

Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or
Android: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008300

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008301

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 3:02 PM
To: Sharples, Fran;'Dave Franz';LeDuc, James W.
Cc: Diane Griffin;Peggy Hamburg;Lowenthal, Micah
Subject: RE: Future collaborations

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Re intros tonight, both sides will have the American and Chinese lists of participants. Maybe we could simply ask folks to very briefly introduce themselves in the order that they appear on their list?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 1:39 PM
To: Sharples, Fran <FSharples@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>; James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: Future collaborations

Thanks Fran.

FYI the CAS agreed to allow the use of the record/transcribe feature on Zoom (and would like a copy) but I am unsure how clear the transcript it produces will be.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Sharples, Fran <FSharples@nas.edu>
Sent: Monday, May 11, 2020 1:35 PM
To: Rusek, Benjamin <BRusek@nas.edu>; 'Dave Franz' <davidrfranz@gmail.com>; James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: Future collaborations

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008206

Yes, and I am supposed to be writing these calls up, so I would very much appreciate it if all you good notetakers could share what you put together. It would help me immensely!

Best,
Fran

Fran Sharples, PhD
Board on Life Sciences
National Academy of Sciences

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:33 PM
To: 'Dave Franz'; James W. LeDuc
Cc: Diane Griffin; Peggy Hamburg; Lowenthal, Micah; Sharples, Fran
Subject: RE: Future collaborations

Hi Jim, thanks for putting this framework together in advaince, it looks good to me.

PS Peter Dazak and others on 60 mins last night
https://www.cbsnews.com/news/trump-administration-coronavirus-vaccine-researcher-covid-19-cure-60-minutes/

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Dave Franz <davidrfranz@gmail.com>
Sent: Monday, May 11, 2020 11:51 AM
To: James W. LeDuc <jwleduc@UTMB.EDU>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Future collaborations

I was thinking the same thing re. taking notes along the way to be prepared for the 'collaborations'. Good list.

What about something on understanding what 'recovery' and 'protection' means. Do you know, for example, if anyone has done viral isolations or animal challenges with with materials from 'recovered' patients with IgG who are still PCR positive?

> On May 11, 2020, at 11:47 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:
>
> The last topic for both days is "Future Collaborations." I will take notes during the discussion to capture topics as they arise; however, we should probably have a back-up plan as well. Pasted below is a start based on general headings relevant to day 1. Please review, add/delete/share with others, etc. Or let me know if you think it's not needed.
>
> Thanks, Jim
>
> Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.
>
> 1. Clinical Disease—Acute and Convalescence
>   a. Long-term sequela seen in survivors, especially lung function, cardiac disease.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008207

    b. Better definition of Pediatric Inflammatory Syndrome of COVID
    c. Neurologic complications??
    d. Psychiatric issues??
2. Pathogenesis and Treatment options
    a. Antiviral drug targets and development
    b. Monoclonal antibody therapies
    c. Immune modulators and management of inflammation
3. Prophylactics and Preventatives
    a. Passive antibody therapy
    b. Vaccine development
        i. Various techniques under development
        ii. Animal models
        iii. Clinical testing
        iv. Production capacity
        v. Ethics considerations

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 11, 2020 10:31 AM
To: Rusek, Benjamin <BRusek@nas.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: LeDuc, James W. <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I don't think so other than to confirm that he plans to do it.

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 11, 2020 10:47 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>; Diane Griffin <dgriffi6@jhmi.edu>
Cc: 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

Peggy, thanks for sending the info and a note to Victor Dzau.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008208

Diane/Peggy, do we need to talk to Harvey Fineberg re his proposed 5 min U.S. situational overview?

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 10:00 AM
To: 'peggy@hbfam.net' <peggy@hbfam.net>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; jwleduc@UTMB.EDU; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>
Subject: FW: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call
Importance: High

Greetings Peggy,

Can you make sure that Victor Dzau has what he needs for the call tonight?

The Zoom link is below and the revised American agenda and participant lists are attached. Please let him know that we have asked the Chinese to lead the discussion, Americans are listed after each question to ensure that we get an answer to that question during the discussion. The Chinese have the version of the agenda without names listed after the questions.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008209

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link:
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008210

<KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008211

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008212

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or
Android: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008213

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008214

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

David R. Franz
Gettysburg, PA
240-674-0797

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008215

From: Rusek, Benjamin [BRusek@nas.edu]
Sent: 5/12/2020 3:10:07 PM
To: 'David A Relman' [relman@stanford.edu]; 'Baric, Ralph S' [rbaric@email.unc.edu]; 'Saif, Linda' [saif.2@osu.edu]; 'Perlman, Stanley' [stanley-perlman@uiowa.edu]; 'Peter Daszak' [daszak@ecohealthalliance.org]; 'Harvey V. Fineberg' [harvey.fineberg@moore.org]; 'Diane Griffin' [dgriffi6@jhmi.edu]; 'Peggy Hamburg' [peggy@hbfam.net]; LeDuc, James W. [jwleduc@UTMB.EDU]; 'Dave Franz (davidrfranz@gmail.com)' [davidrfranz@gmail.com]; Shi, Pei yong [peshi@UTMB.EDU]; Dzau, Victor J. [VDzau@nas.edu]
CC: 'Frances Sharples' [fsharples_3@hotmail.com]; Lowenthal, Micah [mlowenth@nas.edu]; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' [antoinette_baric@med.unc.edu]; 'Alison Andre' [andre@ecohealthalliance.org]; 'Jennifer Ryan' [jennifer.ryan@moore.org]; Bowman, Katherine [KBowman@nas.edu]; Hare, Hope [HHare@nas.edu]; Kanarek, Morgan [MKanarek@nas.edu]; Clark, David [DClark@nas.edu]
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Attachments: Topics for future collaborations between the NAS and CAS on COVID-draft 1.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RpdUlYVVZpT1pTZ1dHVFdKL1QyQT09
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C'

(antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C'

(antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>;

FOIA Confidential Treatment Requested by Univ of Texas System

'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

FOIA Confidential Treatment Requested by Univ of Texas System

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System

Topics for future collaborations between the NAS and CAS on COVID-19, Day 1.

1. Natural experiment underway in the USA as states implement various strategies of public health response to address COVID-19 and resume normal activities
2. Clinical Disease—Acute and Convalescence
    a. Early predictors of severe disease/cytokine storm
    b. Long-term sequela seen in survivors
    c. Better understanding/recognition of Pediatric Inflammatory Syndrome of COVID
3. Pathogenesis and Treatment options
    a. Antiviral drug targets and development (not really discussed but important for future dialogue)
    b. Monoclonal antibody therapies (anti-IL-6 monoclonal antibody treatment; "balance" with coagulation dysfunction)
    c. Clinical trial of chloroquine treatment (preliminary results shared)
4. Prophylactics and Preventatives
    a. Passive antibody therapy (raised question but not really discussed)
    b. Vaccine development
        i. Various techniques under development (not discussed)
        ii. Animal models (mentioned but details not shared)
        iii. Clinical testing (not discussed)
        iv. Production capacity (not discussed)
        v. Ethics considerations (not discussed)
    c. Isolation of contacts (Wuhan lock-down)
    d. Educational tools for communications with populations at risk

FOIA Confidential Treatment Requested by Univ of Texas System

From: sunhui@cashq.ac.cn
Sent: Wednesday, May 13, 2020 4:10 AM
To: Rusek, Benjamin
Cc: 'dgriffi6@jhmi.edu';'peggy@hbfam.net';LeDuc, James W.;'gaof@im.ac.cn';'liyin';'tongting@cashq.ac.cn';孙辉
Subject: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting
Attachments: NAS-CAS+meeting-Dr. Gao.pptx; Wang Gui-Qiang+in+COVID-19.pptx; Chinese Participants-0513.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Ben,

Thank you for efforts in organizing this vitual dialogue. Per your request, please find attached the slide presentations for Drs. Gao and Wang. I have not received any presentations from other participants.

I am also sending you the updated list of the participants from the Chinese side for the 2nd session.

Best wishes,

Sun Hui

2020-05-13

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： Rusek, Benjamin
发送时间： 2020-05-13 06:28:58
收件人： '孙辉'
抄送： 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; 'jwleduc@UTMB.EDU'; 'gaof@im.ac.cn'; 'liyin'; 'tongting@cashq.ac.cn'
主题： RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Here is the Zoom link for the second session:

FOIA Confidential Treatment Requested by Univ of Texas System

Meeting Time: **Thursday, May 14, 2020 9:00 -11:00 AM (Beijing time)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RpdU1YYVVZpT1pTZ1dHVFdKL1Qx09

Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 12:02 AM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; 'liyin' <liyin@cashq.ac.cn>; 'tongting@cashq.ac.cn' <tongting@cashq.ac.cn>
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi Mr. Sun,

Thank you again for setting up the dialogue session today with an outstanding group of Chinese experts. Would it be possible to get copies of the PPT slides that were shared with the group?

For the next session we might want to start discussing the questions right away, we can still use the existing agenda/list of questions. We prefer a discussion format but if during the next session members of the Chinese delegation have formal slide presentations, could you send the slides to us in advance so I can distribute them to the American group?

Zoom seemed to work well for most of the participants but we should try to move on quickly if a speaker's audio is not working. I will send you the new Zoom link tomorrow morning ET.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:40 PM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for the updated Chinese participant list. I have attached an updated (reordered) American version.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009351

We thought that at the beginning of the call, since both sides have these lists, we could ask that the Chinese and the American very briefly introduce themselves **in the order that they appear on the participant lists.** There will be many people on the call so it can get a bit chaotic if everyone is trying to talk at once.

Here is the Zoom link again with the password and meeting ID

May 12, 9:00 AM (Beijing time) meeting Link: https://nasem.zoom.us/j/94861505973?pwd=RG91NTRRRjQ1Y3ZaTVE5dFRKUT09

(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

FYI In case there is a problem with Zoom and we need to abandon the call and reconvene by phone, we have set up an alternative conference call in line (with a company called Conference America). The call in numbers for that service are: China North 108007141861 and China South 108001401891 (and then enter 12223052#), the American participants have access to this via a toll free U.S. phone number. Again this is just a back up, and we would only activate this line if we decide to abandon the Zoom call.

I will join the Zoom call one half hour before the meeting starts as we discussed. See you soon.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Monday, May 11, 2020 7:44 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

Thank you for sending us the Zoom link for the 1st session of the China-US vitural dialogue. Attached please find the updated list of the Chinese participants. Please note that some participants could only be available at one of the two sessions.We look forward to the dialogue tomorrow morning.

Best wishes,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009352

-----原始邮件-----

发件人:"孙辉" <sunhui@cashq.ac.cn>

发送时间:2020-05-10 20:30:03 (星期日)

收件人: "Rusek, Benjamin" <BRusek@nas.edu>

抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>

主题: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

Thank you for agreeing to accommodating the change of schedule and sharing with us the information of American participants. FYI, please find attached the list of the Chinese participants. Please note that some participants may only be available for one of the sessions. I am still waiting for the confirmation of Dr. Chen Wang, who might only be available on the 14th.

I don't see any problem of your using the feature of recording/transcription during the dialogue. We would be happy if you could share the notes with us.

We will do the test of connection with the zoom link you sent to us. See you tomorrow morning online.

Best wishes,

Sun Hui

-----原始邮件-----

发件人:"Rusek, Benjamin" <BRusek@nas.edu>

发送时间:2020-05-09 05:53:57 (星期六)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009353

收件人: "'孙辉'" <sunhui@cashq.ac.cn>
抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>
主题: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for your email. We are pleased to hear that your group will be able to participate for two sessions.

With regards to the exact timing, let's move the second session back 24 hours as you suggest. We can keep the first session scheduled for 9-11am on **May 12** (Beijing time) and then reschedule the second session for 9-11 am on **May 14** (Beijing Time).

Thank you for agreeing to conduct the call in English. One question: Zoom has a built in recording/transcription feature, does your group mind if we use this feature during the sessions? As noted in the letter "Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information…but remarks and discussion comments would not be attributed without permission of the speaker." The transcript would only be used for internal notes and we would be happy to share it with you.

I would be happy to test the connection with you at 9:00 AM on Monday, May 11 Beijing time (9:00 PM on Sunday, May 10 in Washington, DC). I will send you a Zoom link/meeting invitation for that test call after this email.

I have attached the list of American participants for your information, we look forward to seeing the list of Chinese participants.

Kind regards,

Ben

Benjamin Rusek

The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009354

1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Friday, May 8, 2020 8:58 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

I am writing to follow up on the virtual dialogue meeting next week on behalf of Dr. George Gao. The topical agenda sent by Dr. Griffin to Dr. Gao looks fine to us.

With regard to the timing of the dialogue, we could have two 2-hour sessions as you suggested. However, Dr. Gao has some other emergent commitment on May 13, so we would like to suggest the dialogues be rescheduled to 9-11am on May 11 and 12, or 9-11am on May 12 and 14, or 9-11am on May 12 and 15 (all Beijing Time). Please let us know which time slot you would prefer. We are sorry for any inconvenience this may cause you.

The dialogue could be in English, and we could use the zoom videoconference. We will test it 24 hours in advance following your guidance.

FYI, we have sent invitations to potential speakers on our side, hopefully we could finalize the list of speakers very soon. We will have no more than 13 speakers on each side as you suggested. Please share with us the name and title of participants from the US side when it becomes available, and we will do the same.

Best wishes,

SUN Hui(Mr.)

Director

Division of American and Oceanian Affairs

Bureau of International Cooperation

Chinese Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System

-----原始邮件-----

发件人:NASPresident <naspresident@nas.edu>

发送时间:2020-05-01 21:42:08 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "McNutt, Marcia K." <MMcNutt@nas.edu>, "Dzau, Victor J." <VDzau@nas.edu>, "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'jh-cao@cashq.ac.cn'" <jh-cao@cashq.ac.cn>, "'clbai@cas.cn'" <clbai@cas.cn>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, NASPresident <naspresident@nas.edu>

主题: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Colleagues:

Please find the attached letter from Drs. McNutt and Dzau.

Best regards,

Anna

Anna Bashkirova

Assistant to the President

National Academy of Sciences

Office: 2101 Constitution Ave NW | Washington, DC 20418

Mailing address: 500 5th St NW, NAS 215 | Washington, DC 20001

(202) 334-2635 | abashkirova@nas.edu | www.nasonline.org

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009356

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

FOIA Confidential Treatment Requested by Univ of Texas System

发件人： NASPresident

发送时间： 2020-04-23 20:50:33

收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'

抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'

主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009358

Chinese Participants

Ling Chen: Dr. Ling Chen is a professor and founding director of CAS Guangzhou Institute of Biomedicine and Health, former deputy director of State Key Lab of Respiratory Disease.

Zhu Chen: Dr. Zhu Chen is president of the Red Cross Society of China, CAS member. He was previously minister of the National Health Commission of China.

George F. Gao: Dr. George F. Gao is Director-General of CCDC, a professor at the CAS Institute of Microbiology, CAS member.

Dongfeng Gu: Dr. Dongfeng Gu is vice president of Southern University of Science and Technology, CAS member.

Zhengli Shi: Dr. Zhengli Shi is a professor at CAS Wuhan Institute of Virology.

Chen Wang: Dr. Chen Wang is vice president and a member of the Chinese Academy of Engineering, and president of the Chinese Academy of Medical Sciences.

Haiming Wei: Dr. Haiming Wei is Vice President of College of Life Sciences, the University of Science and Technology of China.

Guoping Zhao: Dr. Guoping Zhao is a professor at CAS Shanghai Institutes for Biological Sciences, CAS member.

Xi Zhou: Dr. Xi Zhou is a professor at CAS Wuhan Institute of Virology ， Deputy Director of State Key Laboratory of Virology

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, May 13, 2020 3:00 PM
To: 'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong;Dzau, Victor J.
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope;Kanarek, Morgan;Clark, David
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Attachments: NAS-CAS+meeting-Dr. Gao.pptx; Wang Gui-Qiang+in+COVID-19.pptx; Chinese Participants-0513.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

I have attached two ppts from the Monday evening Zoom call and an updated Chinese participant list for the Zoom call tonight. I look forward to seeing and speaking with you all again tonight.

Here is the Zoom link for the session tonight:
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RpdUlWWZotb2TZ1dHVTdkU1QyQT09
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 4:10 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008326

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Importance: High

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008327

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008328

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those

FOIA Confidential Treatment Requested by Univ of Texas System

listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008330

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008331

'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008332

'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008333

Chinese Participants

Ling Chen: Dr. Ling Chen is a professor and founding director of CAS Guangzhou Institute of Biomedicine and Health, former deputy director of State Key Lab of Respiratory Disease.

Zhu Chen: Dr. Zhu Chen is president of the Red Cross Society of China, CAS member. He was previously minister of the National Health Commission of China.

George F. Gao: Dr. George F. Gao is Director-General of CCDC, a professor at the CAS Institute of Microbiology, CAS member.

Dongfeng Gu: Dr. Dongfeng Gu is vice president of Southern University of Science and Technology, CAS member.

Zhengli Shi: Dr. Zhengli Shi is a professor at CAS Wuhan Institute of Virology.

Chen Wang: Dr. Chen Wang is vice president and a member of the Chinese Academy of Engineering, and president of the Chinese Academy of Medical Sciences.

Haiming Wei: Dr. Haiming Wei is Vice President of College of Life Sciences, the University of Science and Technology of China.

Guoping Zhao: Dr. Guoping Zhao is a professor at CAS Shanghai Institutes for Biological Sciences, CAS member.

Xi Zhou: Dr. Xi Zhou is a professor at CAS Wuhan Institute of Virology ， Deputy Director of State Key Laboratory of Virology

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, May 13, 2020 7:23 PM
To: Dave Franz (davidrfranz@gmail.com);LeDuc, James W.
Subject: FW: potential follow-up meetings

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

fyi

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Wednesday, May 13, 2020 8:13 PM
To: George GAO <gaof@im.ac.cn>
Cc: sunhui@cashq.ac.cn; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Subject: Re: potential follow-up meetings

George - Great - maybe at the end of tonight's meeting we can include this as a part of future collaborations.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: George GAO <gaof@im.ac.cn>
Sent: Wednesday, May 13, 2020 7:36 PM
To: Diane Griffin <dgriffi6@jhmi.edu>
Cc: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>; Rusek, Benjamin <BRusek@nas.edu>; Peggy Hamburg <peggy@hbfam.net>
Subject: Re: potential follow-up meetings

Diane, Yes, lets plan it.
George

发自我的iPhone

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008256

在 2020年5月14日，06:12，Diane Griffin <dgriffi6@jhmi.edu> 写道：

George - I'm looking forward to our discussions tonight. Members of the U.S. dialogue delegation feel that it would be valuable if CAS and NASEM continued to hold collaborative virtual meetings to address this international crisis. Keeping a channel of communication open between Chinese and American experts based on facts and science is critically important as China and the United States continue to mitigate the effects of COVID-19.

Therefore, we would like to propose holding a third, smaller session between a subset (no more than 6 experts on each side) of our CAS and NASEM expert groups on the morning of May 26 or 27 from 9:00-11:00 AM Beijing time. If you agree, then CAS and NAS staff will work together to outline topics for the next discussion (that builds on the two previous sessions) and designate appropriate experts to participate.

Let me know what you think.

Thanks,

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008257

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Thursday, May 14, 2020 7:01 AM
To: Rusek, Benjamin;'David A Relman';'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong;Dzau, Victor J.
Cc: 'Frances Sharples';Lowenthal, Micah;''Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope;Kanarek, Morgan;Clark, David
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben - busy time right now so only:
5-6 today
1:30-2:30 tomorrow

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, May 14, 2020 1:33 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; Diane Griffin <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008197

Thank you for participating in the call tonight. We thought it would be useful to have an American group conversation about the calls and discuss potential next steps.

Please let me know what times you are available between 2:00 PM - 6:00 PM ET today (Thursday, May 14) and on Friday, May 15 between 11:00 AM - 3:00 PM ET for a 30-45 min discussion.

Once we find the least worst time for folks I will send out a Zoom link.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 13, 2020 4:00 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

I have attached two ppts from the Monday evening Zoom call and an updated Chinese participant list for the Zoom call tonight. I look forward to seeing and speaking with you all again tonight.

Here is the Zoom link for the session tonight:
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 4:10 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008198

<harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Importance: High

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008199

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008200

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008201

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008202

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008203

To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008204

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008205

From: Baric, Toni C <antoinette_baric@med.unc.edu>
Sent: Thursday, May 14, 2020 7:25 AM
To: Rusek, Benjamin;'David A Relman';Baric, Ralph S;'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong;Dzau, Victor J.
Cc: 'Frances Sharples';Lowenthal, Micah;'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope;Kanarek, Morgan;Clark, David
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

HI Ben,
Ralph has availability only between 11-12 on Friday.
Toni

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, May 14, 2020 1:33 AM
To: 'David A Relman' <relman@stanford.edu>; Baric, Ralph S <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; Baric, Toni C <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

Thank you for participating in the call tonight. We thought it would be useful to have an American group conversation about the calls and discuss potential next steps.

Please let me know what times you are available between 2:00 PM - 6:00 PM ET today (Thursday, May 14) and on Friday, May 15 between 11:00 AM - 3:00 PM ET for a 30-45 min discussion.

Once we find the least worst time for folks I will send out a Zoom link.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008165

From: Rusek, Benjamin
Sent: Wednesday, May 13, 2020 4:00 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

I have attached two ppts from the Monday evening Zoom call and an updated Chinese participant list for the Zoom call tonight. I look forward to seeing and speaking with you all again tonight.

Here is the Zoom link for the session tonight:
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 4:10 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Importance: High

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008166

to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008167

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008168

1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008169

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008170

Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008171

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008172

Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008173

From: Saif, Linda <saif.2@osu.edu>
Sent: Thursday, May 14, 2020 7:28 AM
To: Rusek, Benjamin;'David A Relman';'Baric, Ralph S';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong;Dzau, Victor J.
Cc: 'Frances Sharples';Lowenthal, Micah;"'Baric, Toni C' (antoinette_baric@med.unc.edu)';'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope;Kanarek, Morgan;Clark, David
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Only available 3-4 pm on Fri
Linda
Linda J. Saif, PhD
Distinguished University Professor
Food Animal Health Research Program
OARDC/The Ohio State University
1680 Madison Ave
Wooster, Oh 44691

From: "Rusek, Benjamin" <BRusek@nas.edu>
Date: Thursday, May 14, 2020 1:33 AM
To: 'David A Relman' <relman@stanford.edu>, "rbaric@email.unc.edu" <rbaric@email.unc.edu>, Linda Saif <saif.2@osu.edu>, "Stanley-Perlman@uiowa.edu" <Stanley-Perlman@uiowa.edu>, 'Peter Daszak' <daszak@ecohealthalliance.org>, "'Harvey V. Fineberg'" <harvey.fineberg@moore.org>, 'Diane Griffin' <dgriffi6@jhmi.edu>, 'Peggy Hamburg' <peggy@hbfam.net>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'Dave Franz (davidrfranz@gmail.com)'" <davidrfranz@gmail.com>, "'Shi, Pei yong (peshi@UTMB.EDU)'" <peshi@UTMB.EDU>, "Dzau, Victor J." <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>, "Lowenthal, Micah" <mlowenth@nas.edu>, "'Baric, Toni C' (antoinette_baric@med.unc.edu)'" <antoinette_baric@med.unc.edu>, 'Alison Andre' <andre@ecohealthalliance.org>, 'Jennifer Ryan' <jennifer.ryan@moore.org>, "Bowman, Katherine" <KBowman@nas.edu>, "Hare, Hope" <HHare@nas.edu>, "Kanarek, Morgan" <MKanarek@nas.edu>, "Clark, David" <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

Thank you for participating in the call tonight. We thought it would be useful to have an American group conversation about the calls and discuss potential next steps.

Please let me know what times you are available between 2:00 PM - 6:00 PM ET today (Thursday, May 14) and on Friday, May 15 between 11:00 AM - 3:00 PM ET for a 30-45 min discussion.

Once we find the least worst time for folks I will send out a Zoom link.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008140

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 13, 2020 4:00 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

I have attached two ppts from the Monday evening Zoom call and an updated Chinese participant list for the Zoom call tonight. I look forward to seeing and speaking with you all again tonight.

Here is the Zoom link for the session tonight:
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=[redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 4:10 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008141

Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Importance: High

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008142

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008143

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those

FOIA Confidential Treatment Requested by Univ of Texas System

listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008145

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008146

'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008147

'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008148

From: David A Relman <relman@stanford.edu>
Sent: Thursday, May 14, 2020 9:18 AM
To: Rusek, Benjamin;'Baric, Ralph S';'Saif, Linda';'Perlman, Stanley';'Peter Daszak';'Harvey V. Fineberg';'Diane Griffin';'Peggy Hamburg';LeDuc, James W.;'Dave Franz (davidrfranz@gmail.com)';Shi, Pei yong;Dzau, Victor J.
Cc: 'Frances Sharples';Lowenthal, Micah;'Alison Andre';'Jennifer Ryan';Bowman, Katherine;Hare, Hope;Kanarek, Morgan;Clark, David;David A Relman
Subject: Re: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Ben-
Today and tomorrow are tight for me. Monday and Tues are much better for me.
My availability:
Today 4-5 pm ET
Tomorrow 2:30-3:00 pm ET
Best, David

From: "Rusek, Benjamin" <BRusek@nas.edu>
Date: Wednesday, May 13, 2020 at 10:33 PM
To: David A Relman <relman@stanford.edu>, "'Baric, Ralph S'" <rbaric@email.unc.edu>, "'Saif, Linda'" <saif.2@osu.edu>, "'Perlman, Stanley'" <stanley-perlman@uiowa.edu>, 'Peter Daszak' <daszak@ecohealthalliance.org>, "'Harvey V. Fineberg'" <harvey.fineberg@moore.org>, 'Diane Griffin' <dgriffi6@jhmi.edu>, 'Peggy Hamburg' <peggy@hbfam.net>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'Dave Franz (davidrfranz@gmail.com)'" <davidrfranz@gmail.com>, "'Shi, Pei yong (peshi@UTMB.EDU)'" <peshi@UTMB.EDU>, "Dzau, Victor J." <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>, "Lowenthal, Micah" <mlowenth@nas.edu>, "'Baric, Toni C' (antoinette_baric@med.unc.edu)'" <antoinette_baric@med.unc.edu>, 'Alison Andre' <andre@ecohealthalliance.org>, 'Jennifer Ryan' <jennifer.ryan@moore.org>, "Bowman, Katherine" <KBowman@nas.edu>, "Hare, Hope" <HHare@nas.edu>, "Kanarek, Morgan" <MKanarek@nas.edu>, "Clark, David" <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

Thank you for participating in the call tonight. We thought it would be useful to have an American group conversation about the calls and discuss potential next steps.

Please let me know what times you are available between 2:00 PM - 6:00 PM ET today (Thursday, May 14) and on Friday, May 15 between 11:00 AM - 3:00 PM ET for a 30-45 min discussion.

Once we find the least worst time for folks I will send out a Zoom link.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008646

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 13, 2020 4:00 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et

Greetings,

I have attached two ppts from the Monday evening Zoom call and an updated Chinese participant list for the Zoom call tonight. I look forward to seeing and speaking with you all again tonight.

Here is the Zoom link for the session tonight:
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: [redacted]
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 4:10 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System

Greetings,

Thank you for participating in and asking thoughtful questions during the Zoom call last night. Thanks especially to Diane Griffin for outstanding moderating, to Harvey Fineberg for giving a clear and concise overview of the U.S. situation and to Jim Le Duc for drafting a list (see attachment) of possible future areas of collaboration that came up during the discussion.

Although Zoom seemed to work well for most of the participants I asked CAS staff to help the group move on quickly if a Chinese speaker's audio is malfunctioning. I let CAS know that during the next session we want to start discussing the agenda / remaining list of questions right away. I reiterated that we find a discussion format to be the most useful and asked that they send any slide presentations to me in advance of the call (so I can send them to you). I also asked CAS for copies of the PPT slides that were shared with the group last night. Please let me know if you have any thoughts on how to make the Zoom session tomorrow night more productive.

Here is the Zoom link for the next session
Meeting Time: **Wednesday, May 13, 2020 9:00 -11:00 PM (ET)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RoeUlWVzondTZ1dHVFaK1tQT09
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:13 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; Clark, David <DClark@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)
Importance: High

Greetings,

I have attached all the documents that you need for **the first U.S. China dialogue Zoom call tonight [Monday, May 11 from 9:00 PM – 11:00 PM (ET)]** so you have them all in one place. They are 1) the slightly updated Chinese participant list (availability is Beijing time) 2) the American participant list and 3) the American version of the agenda. Please remember that because we want the Chinese participants to lead the discussion their version of the agenda does not include your names after the questions.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008648

At the beginning of the call Diane Griffin will ask each person to introduce themselves briefly (just say your name and affiliations). **Please do this in the order that you appear on the American participant list.** (FYI Peter Daszak and Victor Dzau will join the call later.) George Gao and then Harvey Fineberg will give the brief overviews and then we will discuss the Day 1 questions. Re this discussion, please try and prompt the Chinese participants to answer and address the questions and issues on the agenda, we will also need to mind the time closely if we are going to get through the entire Day 1 question list.

The Zoom link is here again:
Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: [redacted]
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

Re logistics, CAS agreed to allow us to use the Zoom record feature to produce a transcript of the call. I will have host access to Zoom and there will be an NAS IT professional (David Clark) in the Zoom call in case there is a problem. If for some reason we need to abandon the Zoom call and reconvene over the phone we have set up an alternative conference call in line (with Conference America). That number is 1-888-537-7715 (and then enter 12223052#), CAS will also be able to access the line via a toll free Chinese phone number. We will only activate this line if we decide to abandon the Zoom call.

If you have any final questions or concerns please feel free to email or call me (at the number below) before the meeting. Thank you again for agreeing to participate in the virtual dialogue, I looks forward to seeing and hearing you all later this evening.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 12:06 AM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Hare, Hope <HHare@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call

And here is the Zoom link for the call on Monday night.

Time: Monday, May 11, 2020 9:00 PM (ET)
Meeting Link: https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
Password: 613725

PS I tested Zoom with CAS and many of the Chinese group members earlier tonight, the video was clear and I could hear everyone well. Hopefully it will work well when we are all connected.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008649

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Sunday, May 10, 2020 12:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

The list of Chinese participants is attached.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Saturday, May 9, 2020 11:24 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7

Greetings,

We have created a proposed draft agenda (with topics slightly rearranged) that, as we discussed during the call on Thursday, starts with a brief introduction of the situation in China and the U.S. We hope that Harvey Fineberg can give a (very) brief overview of the situation in the U.S.

To ensure that each question is addressed during the discussion, we have listed the names of American delegation member after each question. We have asked and expect the Chinese group to take the lead but we hope that those listed can ensure that each question is covered. (FYI this version is for your information only, we will send an agenda

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008650

without the names listed after the questions to the Chinese.) Please let me know if you have thoughts or concerns about this plan.

FYI I plan to send a new version of the agenda to CAS and George Gao on Sunday evening (before I test the Zoom connection with CAS at 9:00 PM ET).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Friday, May 8, 2020 2:31 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; ''Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thanks for joining the call last night. We received good news from CAS this morning. They agreed to hold the two sessions as we requested. However because George Gao is not available on the second day they want to push the second session back by one day. That's not bad because as I noted on the call, Jim Le Duc and Harvey Fineberg were not available at that time anyway.

So for the Americans we will keep the time on Monday, May 11 (from 9-11:00 PM ET) as planned but move the second session back one day to Wednesday, May 13th (from 9-11:00 PM ET). I hope the new time for the second session works for most of you.

In addition they said that the topical agenda (topic list we sent) looks fine and that there would about a dozen Chinese experts (said no more than 13) on the call on their side.

I will send you more info later today.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin
Sent: Thursday, May 7, 2020 4:58 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>; 'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Below you will find an agenda for tonight's **(8:00 PM ET)** call. Diane is the U.S. chair so will lead the call (with input from others).

1) Introductions (Diane, Ben, group)
2) The China bio dialogue: brief background, previous meetings and key Chinese participants (Jim, Dave, Diane, Peggy, Pei-yong, Ben, others)
3) Recent work (2020) to set up the virtual dialogue sessions, purpose of the call and issues we should probably avoid (Diane, Ben, others)
4) Discussion topics/questions (see attachment), assign discussion leaders for each question (Diane, others)
5) Call logistics (best way to interact on the Zoom call, recording the sessions, plan between calls, etc.) (Ben, Micah, Diane)
6) Other questions or concerns (group)

I have re attached the "agenda" (list of topics/questions) for the dialogue meetings next week for your information. Also the Zoom call in information is below:

https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Wednesday, May 6, 2020 5:42 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>; 'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; 'Harvey V. Fineberg' <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; 'Shi, Pei yong (peshi@UTMB.EDU)' <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; "Baric, Toni C' (antoinette_baric@med.unc.edu)' <antoinette_baric@med.unc.edu>; 'Alison Andre' <andre@ecohealthalliance.org>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008652

'Jennifer Ryan' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: RE: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Information on how to join the planning call **at 8:00 PM ET, Thursday, May 7 is below:**

Zoom link: https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Meeting ID: 934 1863 7725
Password: 662746

Please join by Zoom (but the call in phone number is below my email signature if you need it). Thank you again for agreeing to participate in the planned virtual dialogue meeting next week.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

***

Benjamin Rusek is inviting you to a scheduled Zoom meeting.

Topic: Zoom meeting to discuss U.S. China dialogue
Time: May 7, 2020 08:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/93418637725?pwd=OHBnamM1cWs5MUl1TWFiNmlNdGMwQT09
Password: 662746

Or iPhone one-tap :
US: +16513728299,,93418637725# or +13017158592,,93418637725#
Or Telephone:
Dial(for higher quality, dial a number based on your current location) :
US: +1 651 372 8299 or +1 301 715 8592 or +1 312 626 6799 or +1 470 250 9358 or +1 646 518 9805 or +1 646 558 8656 or +1 213 338 8477 or +1 253 215 8782 or +1 602 753 0140 or +1 669 219 2599 or +1 669 900 6833 or +1 720 928 9299 or +1 971 247 1195 or 888 475 4499 (Toll Free) or 877 853 5257 (Toll Free)
Meeting ID: 934 1863 7725
Password: 662746
International numbers available: https://nasem.zoom.us/u/a5XnNJEND

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

From: Rusek, Benjamin
Sent: Monday, May 4, 2020 6:15 PM
To: 'David A Relman' <relman@stanford.edu>; 'Baric, Ralph S' <rbaric@email.unc.edu>; 'Saif, Linda' <saif.2@osu.edu>;

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008653

'Perlman, Stanley' <stanley-perlman@uiowa.edu>; 'Peter Daszak' <daszak@ecohealthalliance.org>; Harvey V. Fineberg <harvey.fineberg@moore.org>; 'Diane Griffin' <dgriffi6@jhmi.edu>; 'Peggy Hamburg' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'Dave Franz (davidrfranz@gmail.com)' <davidrfranz@gmail.com>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Cc: 'Frances Sharples' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'Baric, Toni C' (antoinette_baric@med.unc.edu) <antoinette_baric@med.unc.edu>; Alison Andre <andre@ecohealthalliance.org>; Jennifer Ryan <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>
Subject: Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7
Importance: High

Greetings,

Thank you for agreeing to participate in a virtual bilateral dialogue meeting between Chinese and American experts studying and fighting the COVID-19 pandemic. I am reaching out to you now so 1) the group is connected by email and 2) to organize the planning teleconference for the American participants on May 7. The purpose of the May 7 discussion is to fill you in on the dialogue background, discuss the topics/questions (list in your invitation letter and attached) and issues we should probably avoid (origin questions, politics), logistics, and address any other questions or concerns you may have.

We are proposing that this ~1 hour discussion take place over Zoom at 8:00 PM ET on Thursday, May 7. If this time does not work for someone we could push the time up or back slightly. Please let me know. Also if Thursday evening is impossible I can brief you on the discussion over the phone sometime on Friday.

Re the actually dialogue meeting with the Chinese group, as your invitation letter notes we have proposed that the dialogue meeting take place on the evenings of Monday, May 11th (to address the first set of bullet points) and Tuesday, May 12th (to ask/answer follow-up questions and address the second set of bullet points), at 9:00 PM ET for the Americans. George Gao has not yet let us know if these exact times work but we should hear back from him soon (the Chinese May day holidays end on the 5th).

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_008654

From: LeDuc, James W. [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=937DF08E29C4439E88A04BABFFB162AD-JWLEDUC]
Sent: 5/14/2020 10:44:31 AM
To: Benjamin Rusek (BRusek@nas.edu) [BRusek@nas.edu]
CC: Dave Franz (davidrfranz@gmail.com) [davidrfranz@gmail.com]; Shi, Pei yong [peshi@UTMB.EDU]; Diane Griffin [dgriffi6@jhmi.edu]; Peggy Hamburg [peggy@hbfam.net]; Fran Sharples (FSharples@nas.edu) [FSharples@nas.edu]
Subject: Draft topics for future collab from Day 2
Attachments: NAS-CAS Topics for future collab on COVID-day 2 drft.docx

Please see attached and modify as needed. I'm sure I missed some important comments.

Did Dr Shi from Wuhan say that they found infectious virus in sperm among those in convalescence?

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(m) 409-789-2012

FOIA Confidential Treatment Requested by Univ of Texas System

NASEM-CAS Topics for Future Collaborations on COVID-19, Day 2 discussions

14 Mary 2020

1. Viral shedding
    a. Duration of shedding
    b. Does PCR positive result correspond to infectious virus shedding, especially among specimens drawn late in disease or in convalescence?
    c. Role of children in transmission of SARS CoV-2 transmission, especially as we consider reopening schools
2. Immunity
    a. Characterization of the humoral immune response
    b. Characterization of cellular immune response
    c. Durability of neutralizing antibody
    d. Is there reactivation of latent virus or re-infection among survivors?
3. Immunotherapy
    a. Discussion of human monoclonal antibodies for treatment (and prevention?)
    b. Efficacy of immune plasma for the treatment of severely ill patients (not discussed but relevant with clinical trials underway)
4. Vaccines
    a. Various candidate vaccines are in development, some of which are already into human phase 1 or phase 2 clinical trials.
    b. Strategies for accelerated efficacy testing of vaccines
    c. Strategies to detect adverse impact of vaccination on the course of disease
5. Animal models
    a. Small animal models (mice; transgenic mice; others not discusses such as hamsters, ferrets)
    b. Non-human primates
6. Animals as possible novel reservoir hosts for SARS CoV-2 virus in nature
    a. Felines
    b. Mink in Netherlands
7. Virus evolution
    a. Genomic mutations and their possible association with resulting clinical disease and/or transmission characteristics

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 18, 2020 9:18 AM
To: Hare, Hope;'relman@stanford.edu';'rbaric@email.unc.edu';'saif.2@osu.edu';'stanley-perlman@uiowa.edu';'daszak@ecohealthalliance.org';'harvey.fineberg@moore.org';'dgriffi6@jhmi.edu';'peggy@hbfam.net';LeDuc, James W.;'davidrfranz@gmail.com';Shi, Pei yong;Dzau, Victor J.;'fsharples_3@hotmail.com';Lowenthal, Micah;'antoinette_baric@med.unc.edu';'andre@ecohealthalliance.org';'jennifer.ryan@moore.org';Bowman, Katherine;Kanarek, Morgan;'Raymond JEANLOZ'
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19
Attachments: Draft Covid-19 US-China dialogue agenda v4.docx; Topics for future collaborations between the NAS and CAS on COVID-draft 1 Day 1 and 2.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Thought it would be helpful to send you a basic outline for the follow up call (**at 11:30 ET today**).

1) Intro
2) Comments on the Day 1 and Day 2 discussion
3) Ideas for topics (and additional American experts) for future virtual dialogue sessions
4) Discussion of George Gao's joint statement idea
5) CAS idea to post a blurb about the meetings on the CAS website
6) Other issues, concerns

I have attached the dialogue agenda (American version) for reference along with Jim's summaries of future collaboration ideas from the sessions.

I know a few people can't make it but I would be happy to follow up with you individually over the phone or email.

I look forward to talking to the group soon.
Zoom link: https://nasem.zoom.us/j/99436678170?pwd=cDM4WVM3Y0hESDFaWGtKY0lVUm02Zz09

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hare, Hope <HHare@nas.edu>
Sent: Friday, May 15, 2020 4:26 PM
To: 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007830

<daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

It is very difficult to find a time suitable for all—we apologize, but the one time that seemed to work is Monday, May 18th, at 11:30 AM. We understand that not all of you will be able to participate.
Here is the Zoom link for this meeting:

We look forward to seeing you on Monday at 11:30 am.
Best wishes,
Hope

From: Hare, Hope
Sent: Thursday, May 14, 2020 3:16 PM
Subject: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

Ben has asked me to contact you to schedule a time for the follow up call. We need to do this early next week, as there was not a time that worked well for everyone this week. Please send me your availability for a one hour Zoom meeting between 9AM - 6PM ET, Monday - Wednesday next week.

Thank you and best wishes,

Hope Hare
Administrative Assistant
The National Academies of Sciences, Engineering, and Medicine
500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-3435

The National Academies of
SCIENCES · ENGINEERING · MEDICINE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007831

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Monday, May 18, 2020 10:13 AM
To: Rusek, Benjamin;Hare, Hope;'relman@stanford.edu';'rbaric@email.unc.edu';'saif.2@osu.edu';'stanley-perlman@uiowa.edu';'daszak@ecohealthalliance.org';'harvey.fineberg@moore.org';'peggy@hbfam.net';LeDuc, James W.;'davidrfranz@gmail.com';Shi, Pei yong;Dzau, Victor J.;'fsharples_3@hotmail.com';Lowenthal, Micah;'antoinette_baric@med.unc.edu';'andre@ecohealthalliance.org';'jennifer.ryan@moore.org';Bowman, Katherine;Kanarek, Morgan;'Raymond JEANLOZ'
Subject: Re: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Ben et al - They changed the time of my student's presentation, now ends at 11:45, so I will be late. Start without me and i'll join as soon as I can.

Diane

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 18, 2020 10:18 AM
To: Hare, Hope <HHare@nas.edu>; 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; Diane Griffin <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

Greetings,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007827

Thought it would be helpful to send you a basic outline for the follow up call (**at 11:30 ET today**).

1) Intro
2) Comments on the Day 1 and Day 2 discussion
3) Ideas for topics (and additional American experts) for future virtual dialogue sessions
4) Discussion of George Gao's joint statement idea
5) CAS idea to post a blurb about the meetings on the CAS website
6) Other issues, concerns

I have attached the dialogue agenda (American version) for reference along with Jim's summaries of future collaboration ideas from the sessions.

I know a few people can't make it but I would be happy to follow up with you individually over the phone or email.

I look forward to talking to the group soon.
Zoom link: https://nasem.zoom.us/j/97355621870?pwd=cDM4MVE2MzFES2F4WGtGY0lMRHdZZz09

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hare, Hope <HHare@nas.edu>
Sent: Friday, May 15, 2020 4:26 PM
To: 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

It is very difficult to find a time suitable for all—we apologize, but the one time that seemed to work is Monday, May 18th, at 11:30 AM. We understand that not all of you will be able to participate.
Here is the Zoom link for this meeting:
https://nasem.zoom.us/j/97355621870?pwd=cDM4MVE2MzFES2F4WGtGY0lMRHdZZz09
We look forward to seeing you on Monday at 11:30 am.
Best wishes,
Hope

From: Hare, Hope
Sent: Thursday, May 14, 2020 3:16 PM
Subject: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007828

Ben has asked me to contact you to schedule a time for the follow up call. We need to do this early next week, as there was not a time that worked well for everyone this week. Please send me your availability for a one hour Zoom meeting between 9AM - 6PM ET, Monday - Wednesday next week.

Thank you and best wishes,

Hope Hare
Administrative Assistant
The National Academies of Sciences, Engineering, and Medicine
500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-3435

The National Academies of
SCIENCES · ENGINEERING · MEDICINE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007829

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Monday, May 18, 2020 10:35 AM
To: Hare, Hope;'relman@stanford.edu';'rbaric@email.unc.edu';'saif.2@osu.edu';'stanley-perlman@uiowa.edu';'daszak@ecohealthalliance.org';'harvey.fineberg@moore.org';'dgriffi6@jhmi.edu';'peggy@hbfam.net';LeDuc, James W.;'davidrfranz@gmail.com';Shi, Pei yong;Dzau, Victor J.;'fsharples_3@hotmail.com';Lowenthal, Micah;'antoinette_baric@med.unc.edu';'andre@ecohealthalliance.org';'jennifer.ryan@moore.org';Bowman, Katherine;Kanarek, Morgan;'Raymond JEANLOZ'
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19
Attachments: News draft.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the copy of the CAS draft website posting.

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 18, 2020 10:18 AM
To: Hare, Hope <HHare@nas.edu>; 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19
Importance: High

Greetings,

Thought it would be helpful to send you a basic outline for the follow up call (**at 11:30 ET today**).

1) Intro
2) Comments on the Day 1 and Day 2 discussion
3) Ideas for topics (and additional American experts) for future virtual dialogue sessions
4) Discussion of George Gao's joint statement idea
5) CAS idea to post a blurb about the meetings on the CAS website
6) Other issues, concerns

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007819

I have attached the dialogue agenda (American version) for reference along with Jim's summaries of future collaboration ideas from the sessions.

I know a few people can't make it but I would be happy to follow up with you individually over the phone or email.

I look forward to talking to the group soon.
Zoom link: [redacted]

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hare, Hope <HHare@nas.edu>
Sent: Friday, May 15, 2020 4:26 PM
To: 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

It is very difficult to find a time suitable for all—we apologize, but the one time that seemed to work is Monday, May 18th, at 11:30 AM. We understand that not all of you will be able to participate.
Here is the Zoom link for this meeting:
[redacted]
We look forward to seeing you on Monday at 11:30 am.
Best wishes,
Hope

From: Hare, Hope
Sent: Thursday, May 14, 2020 3:16 PM
Subject: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

Ben has asked me to contact you to schedule a time for the follow up call. We need to do this early next week, as there was not a time that worked well for everyone this week. Please send me your availability for a one hour Zoom meeting between 9AM - 6PM ET, Monday - Wednesday next week.

Thank you and best wishes,

Hope Hare
Administrative Assistant
The National Academies of Sciences, Engineering, and Medicine
500 Fifth Street, NW
Washington, DC 20001

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007820

Phone: 202-334-3435

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007821

Scientists from China and US Share Experience in COVID-19 Prevention and Control

About 30 scientists from China and the United States held an online dialogue to share their experience in COVID-19 prevention and control and opinions on the prevention of future pandemic on May 12th and 14th (Beijing time).

The virtual dialogue was jointly organized by the Chinese Academy of Sciences (CAS), the National Academy of Sciences (NAS) and the National Academy of Medicine (NAM).

Participants shared their experience in fighting against COVID-19 and exchanged views on such topics as clinical issues related to treatment and management of patients, and limiting the spread of COVID-19 and steps towards restarting society.

COVID-19, an infectious disease caused by the most recently discovered coronavirus, has so far spread to 216 countries, areas and territories, with over 4.5 million confirmed cases and claiming 300 thousand deaths globally, according to the World Health Organization.

"The pandemic will not really be controlled in any country, until it is ultimately controlled in every country. So it's in our mutual interest to do our best to learn as rapidly and as effectively as we can from one another," said Dr. Harvey Fineberg, President of the Gordon and Betty Moore Foundation, one participant of the dialogue.

Experts taking part in the dialogue agreed that it is of great importance to have a discussion to promote exchanges between the scientific communities of the two countries.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007822

"It's an extension of a dialogue that's been going between scientists in China and the U.S.. We are very happy to be able to continue this dialogue in this time when actually all the work we are doing becomes very important," said Diane Griffin, Vice President of NAS, in the dialogue.

Dr. George F. Gao, convener from the Chinese side, Director-General of the Chinese Center for Disease Prevention and Control, said, "This is a great dialogue. We hope that both sides could continue to organize dialogues like this, and contribute to the global efforts in fighting against the COVID-19 pandemic from the scientific perspective."

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, May 19, 2020 5:23 PM
To: 'Diane Griffin';'peggy@hbfam.net';LeDuc, James W.;Dave Franz (davidrfranz@gmail.com)
Cc: Lowenthal, Micah;Sharples, Fran;Bowman, Katherine;Shi, Pei yong
Subject: Topic list for 3rd China U.S. Dialogue
Attachments: Immunity topics for 3rd China U.S. Dialogue fs br.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

Fran pulled together a list of possible discussion questions for the next call. It is attached for your review and comment.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, May 19, 2020 8:18 AM
To: Rusek, Benjamin <BRusek@nas.edu>; '孙辉' <sunhui@cashq.ac.cn>
Cc: 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: Re: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Looks good

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, May 19, 2020 12:56 AM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007483

<jwleduc@UTMB.EDU>
Subject: RE: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Sun Hui,

Thank you for your note consulting us regarding the draft press release proposal. Dr. McNutt and Dr. Dzau proposed in their letter dated April 22 that we not include government officials or members of the press: "Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker." This practice continues the approach that we have taken over several years.

Since we are just at the start of valuable dialogue sessions between Chinese and American experts designed to learn about and improve efforts to mitigate the impact of COVID-19, efforts that we hope will continue, we consider it best not to issue a press release at the present time. If there is a reason why you think we really should inform news media now, please tell us and we can discuss this matter further.

As stated in the last Zoom meeting, NAS and NAM hope that CAS will be able to assemble a group of experts so that we can hold a third smaller Zoom meeting on the morning of May 27 (9:00-11:00 AM Beijing time). The American group proposes having a detailed exchange about what is known about COVID-19 immunity, including the relationship between previous infection, antibody response, reinfection and convalescent plasma, preparing for a possible Fall 2020 resurgence of the virus. We plan to send you a more detailed list of questions about these topics very soon.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Monday, May 18, 2020 10:06 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: Re: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Attached please find the draft of news report about the virtual dialogue. If you agree, we are going to post it on the CAS English website, and push the link to the news through the CAS Linkedin account. as well

We quote the remarks by Drs. Griffin and Fineberg in the news report. Please help check if it is fine with your side. Thank you very much in advance.

Best wishes,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007484

-----原始邮件-----

发件人:"Rusek, Benjamin" <BRusek@nas.edu>

发送时间:2020-05-15 08:34:46 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>

主题: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi Hui,

Thanks for the ppt. We have put the Zoom produced audio recordings of the two meetings here: https://www.dropbox.com/sh/x8ii8kj86ykmb30/AABREPedljjlU5iz_03777-Xa?dl=0

Access is password protected [pw is: [redacted]

As I noted Zoom also auto generates and produces a transcript (from the recorded audio file) but it's not very good. We are editing it a bit and will send those Word files to you tomorrow.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Thursday, May 14, 2020 5:10 AM
To: sunhui@cashq.ac.cn; Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: Re: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Attached please find the presentation of Dr. Guiqiang Wang during the 1st session. I am sorry for sending you the wrong document yesterday.

Would you please share with us your notes by recording? Thank you.

Best wishes,

Sun Hui

2020-05-14

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System

52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： sunhui@cashq.ac.cn
发送时间： 2020-05-13 17:09:41
收件人： Rusek, Benjamin
抄送： 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; 'jwleduc@UTMB.EDU'; 'gaof@im.ac.cn'; 'liyin'; 'tongting@cashq.ac.cn'; 孙辉
主题： Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Thank you for efforts in organizing this vitual dialogue. Per your request, please find attached the slide presentations for Drs. Gao and Wang. I have not received any presentations from other participants.

I am also sending you the updated list of the participants from the Chinese side for the 2nd session.

Best wishes,

Sun Hui

2020-05-13

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： Rusek, Benjamin
发送时间： 2020-05-13 06:28:58
收件人： '孙辉'
抄送： 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; 'jwleduc@UTMB.EDU'; 'gaof@im.ac.cn'; 'liyin'; 'tongting@cashq.ac.cn'
主题： RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Here is the Zoom link for the second session:

Meeting Time: **Thursday, May 14, 2020 9:00 -11:00 AM (Beijing time)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RpdUlYVVZpT1pTZ1dHVFdKL1QyQT09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007486

Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 12:02 AM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; 'liyin' <liyin@cashq.ac.cn>; 'tongting@cashq.ac.cn' <tongting@cashq.ac.cn>
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi Mr. Sun,

Thank you again for setting up the dialogue session today with an outstanding group of Chinese experts. Would it be possible to get copies of the PPT slides that were shared with the group?

For the next session we might want to start discussing the questions right away, we can still use the existing agenda/list of questions. We prefer a discussion format but if during the next session members of the Chinese delegation have formal slide presentations, could you send the slides to us in advance so I can distribute them to the American group?

Zoom seemed to work well for most of the participants but we should try to move on quickly if a speaker's audio is not working. I will send you the new Zoom link tomorrow morning ET.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:40 PM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007487

Thank you for the updated Chinese participant list. I have attached an updated (reordered) American version.

We thought that at the beginning of the call, since both sides have these lists, we could ask that the Chinese and the American very briefly introduce themselves **in the order that they appear on the participant lists.** There will be many people on the call so it can get a bit chaotic if everyone is trying to talk at once.

Here is the Zoom link again with the password and meeting ID
May 12, 9:00 AM (Beijing time) meeting Link:
https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRlQrY2ZnTy9SclRsK05sQT09
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

FYI In case there is a problem with Zoom and we need to abandon the call and reconvene by phone, we have set up an alternative conference call in line (with a company called Conference America). The call in numbers for that service are: China North 108007141861 and China South 108001401891 (and then enter 12223052#), the American participants have access to this via a toll free U.S. phone number. Again this is just a back up, and we would only activate this line if we decide to abandon the Zoom call.

I will join the Zoom call one half hour before the meeting starts as we discussed. See you soon.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Monday, May 11, 2020 7:44 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

Thank you for sending us the Zoom link for the 1st session of the China-US vitural dialogue. Attached please find the updated list of the Chinese participants. Please note that some participants could only be available at one of the two sessions.We look forward to the dialogue tomorrow morning.

Best wishes,

Sun Hui

-----原始邮件-----
发件人:"孙辉" <sunhui@cashq.ac.cn>
发送时间:2020-05-10 20:30:03 (星期日)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007488

收件人: "Rusek, Benjamin" <BRusek@nas.edu>
抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>
主题: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

Thank you for agreeing to accommodating the change of schedule and sharing with us the information of American participants. FYI, please find attached the list of the Chinese participants. Please note that some participants may only be available for one of the sessions. I am still waiting for the confirmation of Dr. Chen Wang, who might only be available on the 14th.

I don't see any problem of your using the feature of recording/transcription during the dialogue. We would be happy if you could share the notes with us.

We will do the test of connection with the zoom link you sent to us. See you tomorrow morning online.

Best wishes,

Sun Hui

-----原始邮件-----
发件人:"Rusek, Benjamin" <BRusek@nas.edu>
发送时间:2020-05-09 05:53:57 (星期六)
收件人: "'孙辉'" <sunhui@cashq.ac.cn>
抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>
主题: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for your email. We are pleased to hear that your group will be able to participate for two sessions.

With regards to the exact timing, let's move the second session back 24 hours as you suggest. We can keep the first session scheduled for 9-11am on **May 12** (Beijing time) and then reschedule the second session for 9-11 am on **May 14** (Beijing Time).

Thank you for agreeing to conduct the call in English. One question: Zoom has a built in recording/transcription feature, does your group mind if we use this feature during the sessions? As noted in the letter "Information and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007489

insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information…but remarks and discussion comments would not be attributed without permission of the speaker." The transcript would only be used for internal notes and we would be happy to share it with you.

I would be happy to test the connection with you at 9:00 AM on Monday, May 11 Beijing time (9:00 PM on Sunday, May 10 in Washington, DC). I will send you a Zoom link/meeting invitation for that test call after this email.

I have attached the list of American participants for your information, we look forward to seeing the list of Chinese participants.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Friday, May 8, 2020 8:58 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

I am writing to follow up on the virtual dialogue meeting next week on behalf of Dr. George Gao. The topical agenda sent by Dr. Griffin to Dr. Gao looks fine to us.

With regard to the timing of the dialogue, we could have two 2-hour sessions as you suggested. However, Dr. Gao has some other emergent commitment on May 13, so we would like to suggest the dialogues be rescheduled to 9-11am on May 11 and 12, or 9-11am on May 12 and 14, or 9-11am on May 12 and 15 (all Beijing Time). Please let us know which time slot you would prefer. We are sorry for any inconvenience this may cause you.

The dialogue could be in English, and we could use the zoom videoconference. We will test it 24 hours in advance following your guidance.

FYI, we have sent invitations to potential speakers on our side, hopefully we could finalize the list of speakers very soon. We will have no more than 13 speakers on each side as you suggested. Please share with us the name and title of participants from the US side when it becomes available, and we will do the same.

Best wishes,

SUN Hui(Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007490

-----原始邮件-----

发件人:NASPresident <naspresident@nas.edu>

发送时间:2020-05-01 21:42:08 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "McNutt, Marcia K." <MMcNutt@nas.edu>, "Dzau, Victor J." <VDzau@nas.edu>, "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'jh-cao@cashq.ac.cn'" <jh-cao@cashq.ac.cn>, "'clbai@cas.cn'" <clbai@cas.cn>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, NASPresident <naspresident@nas.edu>

主题: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Colleagues:

Please find the attached letter from Drs. McNutt and Dzau.

Best regards,

Anna

Anna Bashkirova
Assistant to the President
National Academy of Sciences
Office: 2101 Constitution Ave NW | Washington, DC 20418
Mailing address: 500 5th St NW, NAS 215 | Washington, DC 20001
(202) 334-2635 | abashkirova@nas.edu | www.nasonline.org

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007491

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007492

From: Diane Griffin [dgriffi6@jhmi.edu]
Sent: 5/20/2020 4:26:27 PM
To: Rusek, Benjamin [BRusek@nas.edu]; 'peggy@hbfam.net' [peggy@hbfam.net]; LeDuc, James W. [jwleduc@UTMB.EDU]; Dave Franz (davidrfranz@gmail.com) [davidrfranz@gmail.com]
CC: Lowenthal, Micah [mlowenth@nas.edu]; Sharples, Fran [FSharples@nas.edu]; Bowman, Katherine [KBowman@nas.edu]; Shi, Pei yong [peshi@UTMB.EDU]
Subject: Re: Topic list for 3rd China U.S. Dialogue
Attachments: Immunity topics for 3rd China U.S. Dialogue fs brDEG.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

good list - my edits

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, May 19, 2020 6:23 PM
To: Diane Griffin <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; Dave Franz (davidrfranz@gmail.com) <davidrfranz@gmail.com>
Cc: Lowenthal, Micah <mlowenth@nas.edu>; Sharples, Fran <FSharples@nas.edu>; Bowman, Katherine <KBowman@nas.edu>; Shi, Pei yong (peshi@UTMB.EDU) <peshi@UTMB.EDU>
Subject: Topic list for 3rd China U.S. Dialogue

Greetings,

Fran pulled together a list of possible discussion questions for the next call. It is attached for your review and comment.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Diane Griffin <dgriffi6@jhmi.edu>
Sent: Tuesday, May 19, 2020 8:18 AM
To: Rusek, Benjamin <BRusek@nas.edu>; '孙辉' <sunhui@cashq.ac.cn>
Cc: 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: Re: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Looks good

Diane E. Griffin, MD PhD
Vice President, National Academy of Sciences
University Distinguished Service Professor
W. Harry Feinstone Department of Molecular Microbiology and Immunology
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe St, Rm E5636
Baltimore, MD 21205
410-955-3459
dgriffi6@jhu.edu

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, May 19, 2020 12:56 AM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: Diane Griffin <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: RE: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Sun Hui,

Thank you for your note consulting us regarding the draft press release proposal. Dr. McNutt and Dr. Dzau proposed in their letter dated April 22 that we not include government officials or members of the press: "Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information, as that is the purpose of the meeting, but remarks and discussion comments would not be attributed without permission of the speaker." This practice continues the approach that we have taken over several years.

Since we are just at the start of valuable dialogue sessions between Chinese and American experts designed to learn about and improve efforts to mitigate the impact of COVID-19, efforts that we hope will continue, we consider it best not to issue a press release at the present time. If there is a reason why you think we really should inform news media now, please tell us and we can discuss this matter further.

As stated in the last Zoom meeting, NAS and NAM hope that CAS will be able to assemble a group of experts so that we can hold a third smaller Zoom meeting on the morning of May 27 (9:00-11:00 AM Beijing time). The American group proposes having a detailed exchange about what is known about COVID-19 immunity, including the relationship between previous infection, antibody response, reinfection and convalescent plasma, preparing for a possible Fall 2020 resurgence of the virus. We plan to send you a more detailed list of questions about these topics very soon.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Monday, May 18, 2020 10:06 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU'

FOIA Confidential Treatment Requested by Univ of Texas System

<jwleduc@UTMB.EDU>
Subject: Re: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Attached please find the draft of news report about the virtual dialogue. If you agree, we are going to post it on the CAS English website, and push the link to the news through the CAS Linkedin account. as well

We quote the remarks by Drs. Griffin and Fineberg in the news report. Please help check if it is fine with your side. Thank you very much in advance.

Best wishes,

Sun Hui

-----原始邮件-----

发件人:"Rusek, Benjamin" <BRusek@nas.edu>

发送时间:2020-05-15 08:34:46 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>

主题: RE: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi Hui,

Thanks for the ppt. We have put the Zoom produced audio recordings of the two meetings here: https://www.dropbox.com/sh/x8ii8kj86ykmb30/AABREPedljjlU5iz_03777-Xa?dl=0

Access is password protected [pw is [redacted]

As I noted Zoom also auto generates and produces a transcript (from the recorded audio file) but it's not very good. We are editing it a bit and will send those Word files to you tomorrow.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Thursday, May 14, 2020 5:10 AM
To: sunhui@cashq.ac.cn; Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>
Subject: Re: Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Attached please find the presentation of Dr. Guiqiang Wang during the 1st session. I am sorry for sending you the wrong document yesterday.

Would you please share with us your notes by recording? Thank you.

Best wishes,

Sun Hui

2020-05-14

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： sunhui@cashq.ac.cn
发送时间： 2020-05-13 17:09:41
收件人： Rusek, Benjamin
抄送： 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; 'jwleduc@UTMB.EDU'; 'gaof@im.ac.cn'; 'liyin'; 'tongting@cashq.ac.cn'; 孙辉
主题： Re: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Ben,

Thank you for efforts in organizing this vitual dialogue. Per your request, please find attached the slide presentations for Drs. Gao and Wang. I have not received any presentations from other participants.

I am also sending you the updated list of the participants from the Chinese side for the 2nd session.

Best wishes,

Sun Hui

2020-05-13

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： Rusek, Benjamin

发送时间： 2020-05-13 06:28:58

收件人： '孙辉'

抄送： 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; 'jwleduc@UTMB.EDU'; 'gaof@im.ac.cn'; 'liyin'; 'tongting@cashq.ac.cn'

主题： RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Here is the Zoom link for the second session:

Meeting Time: **Thursday, May 14, 2020 9:00 -11:00 AM (Beijing time)**
Meeting link: https://nasem.zoom.us/j/98730322332?pwd=d2RpdUlYVVZpT1pTZ1dHVFdKL1QyQT09
Meeting ID: 987 3032 2332
Meeting Password: 569674

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Tuesday, May 12, 2020 12:02 AM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; 'liyin' <liyin@cashq.ac.cn>; 'tongting@cashq.ac.cn' <tongting@cashq.ac.cn>
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Hi Mr. Sun,

Thank you again for setting up the dialogue session today with an outstanding group of Chinese experts. Would it be possible to get copies of the PPT slides that were shared with the group?

For the next session we might want to start discussing the questions right away, we can still use the existing agenda/list of questions. We prefer a discussion format but if during the next session members of the Chinese delegation have formal slide presentations, could you send the slides to us in advance so I can distribute them to the American group?

Zoom seemed to work well for most of the participants but we should try to move on quickly if a speaker's audio is not working. I will send you the new Zoom link tomorrow morning ET.

Kind regards,

Ben

FOIA Confidential Treatment Requested by Univ of Texas System

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 11, 2020 6:40 PM
To: '孙辉' <sunhui@cashq.ac.cn>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: RE: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for the updated Chinese participant list. I have attached an updated (reordered) American version.

We thought that at the beginning of the call, since both sides have these lists, we could ask that the Chinese and the American very briefly introduce themselves **in the order that they appear on the participant lists.** There will be many people on the call so it can get a bit chaotic if everyone is trying to talk at once.

Here is the Zoom link again with the password and meeting ID
May 12, 9:00 AM (Beijing time) meeting Link:
https://nasem.zoom.us/j/94861525373?pwd=RG9LNTRRRjQrY3ZqTy9SclR5K05SQT09
(Password: 613725, Meeting ID: 948 6152 5373, but you should not need it, it's in the link)

FYI In case there is a problem with Zoom and we need to abandon the call and reconvene by phone, we have set up an alternative conference call in line (with a company called Conference America). The call in numbers for that service are: China North 108007141861 and China South 108001401891 (and then enter 12223052#), the American participants have access to this via a toll free U.S. phone number. Again this is just a back up, and we would only activate this line if we decide to abandon the Zoom call.

I will join the Zoom call one half hour before the meeting starts as we discussed. See you soon.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Monday, May 11, 2020 7:44 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

FOIA Confidential Treatment Requested by Univ of Texas System

Thank you for sending us the Zoom link for the 1st session of the China-US vitural dialogue. Attached please find the updated list of the Chinese participants. Please note that some participants could only be available at one of the two sessions.We look forward to the dialogue tomorrow morning.

Best wishes,

Sun Hui

-----原始邮件-----

发件人:"孙辉" <sunhui@cashq.ac.cn>

发送时间:2020-05-10 20:30:03 (星期日)

收件人: "Rusek, Benjamin" <BRusek@nas.edu>

抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>

主题: Re: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

Thank you for agreeing to accommodating the change of schedule and sharing with us the information of American participants. FYI, please find attached the list of the Chinese participants. Please note that some participants may only be available for one of the sessions. I am still waiting for the confirmation of Dr. Chen Wang, who might only be available on the 14th.

I don't see any problem of your using the feature of recording/transcription during the dialogue. We would be happy if you could share the notes with us.

We will do the test of connection with the zoom link you sent to us. See you tomorrow morning online.

Best wishes,

Sun Hui

-----原始邮件-----

发件人:"Rusek, Benjamin" <BRusek@nas.edu>

发送时间:2020-05-09 05:53:57 (星期六)

收件人: "'孙辉'" <sunhui@cashq.ac.cn>

抄送: "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin

<liyin@cashq.ac.cn>, "tongting@cashq.ac.cn" <tongting@cashq.ac.cn>
主题: RE: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Greetings Mr. Sun,

Thank you for your email. We are pleased to hear that your group will be able to participate for two sessions.

With regards to the exact timing, let's move the second session back 24 hours as you suggest. We can keep the first session scheduled for 9-11am on **May 12** (Beijing time) and then reschedule the second session for 9-11 am on **May 14** (Beijing Time).

Thank you for agreeing to conduct the call in English. One question: Zoom has a built in recording/transcription feature, does your group mind if we use this feature during the sessions? As noted in the letter "Information and insights from the meeting that may promote improved response to the pandemic would be shared with those government officials and researchers who need the information...but remarks and discussion comments would not be attributed without permission of the speaker." The transcript would only be used for internal notes and we would be happy to share it with you.

I would be happy to test the connection with you at 9:00 AM on Monday, May 11 Beijing time (9:00 PM on Sunday, May 10 in Washington, DC). I will send you a Zoom link/meeting invitation for that test call after this email.

I have attached the list of American participants for your information, we look forward to seeing the list of Chinese participants.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: 孙辉 <sunhui@cashq.ac.cn>
Sent: Friday, May 8, 2020 8:58 AM
To: Rusek, Benjamin <BRusek@nas.edu>
Cc: 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>; tongting@cashq.ac.cn
Subject: Re: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Mr. Rusek,

I am writing to follow up on the virtual dialogue meeting next week on behalf of Dr. George Gao. The topical agenda sent by Dr. Griffin to Dr. Gao looks fine to us.

With regard to the timing of the dialogue, we could have two 2-hour sessions as you suggested. However, Dr. Gao has some other emergent commitment on May 13, so we would like to suggest the dialogues be rescheduled to 9-11am on May 11 and 12, or 9-11am on May 12 and 14, or 9-11am on May 12 and 15 (all Beijing Time). Please let us know which time slot you would prefer. We are sorry for any inconvenience this may cause you.

The dialogue could be in English, and we could use the zoom videoconference. We will test it 24 hours in advance following your guidance.

FOIA Confidential Treatment Requested by Univ of Texas System

FYI, we have sent invitations to potential speakers on our side, hopefully we could finalize the list of speakers very soon. We will have no more than 13 speakers on each side as you suggested. Please share with us the name and title of participants from the US side when it becomes available, and we will do the same.

Best wishes,

SUN Hui(Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences

-----原始邮件-----

发件人:NASPresident <naspresident@nas.edu>

发送时间:2020-05-01 21:42:08 (星期五)

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>

抄送: "McNutt, Marcia K." <MMcNutt@nas.edu>, "Dzau, Victor J." <VDzau@nas.edu>, "'dgriffi6@jhmi.edu'" <dgriffi6@jhmi.edu>, "'peggy@hbfam.net'" <peggy@hbfam.net>, JohnHildebrand <jhildebr@email.arizona.edu>, "Boright, John" <JBoright@nas.edu>, "Rusek, Benjamin" <BRusek@nas.edu>, "'jwleduc@UTMB.EDU'" <jwleduc@UTMB.EDU>, "'jh-cao@cashq.ac.cn'" <jh-cao@cashq.ac.cn>, "'clbai@cas.cn'" <clbai@cas.cn>, "'gaof@im.ac.cn'" <gaof@im.ac.cn>, liyin <liyin@cashq.ac.cn>, NASPresident <naspresident@nas.edu>

主题: RE: Letter from the NASEM re: Virtual Dialogue Meeting

Dear Colleagues:

Please find the attached letter from Drs. McNutt and Dzau.

Best regards,

Anna

Anna Bashkirova
Assistant to the President
National Academy of Sciences
Office: 2101 Constitution Ave NW | Washington, DC 20418
Mailing address: 500 5th St NW, NAS 215 | Washington, DC 20001
(202) 334-2635 | abashkirova@nas.edu | www.nasonline.org

From: sunhui@cashq.ac.cn <sunhui@cashq.ac.cn>
Sent: Wednesday, April 29, 2020 5:40 AM
To: NASPresident <naspresident@nas.edu>
Cc: McNutt, Marcia K. <MMcNutt@nas.edu>; Dzau, Victor J. <VDzau@nas.edu>; 'dgriffi6@jhmi.edu'

FOIA Confidential Treatment Requested by Univ of Texas System

<dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; JohnHildebrand <jhildebr@email.arizona.edu>; Boright, John <JBoright@nas.edu>; Rusek, Benjamin <BRusek@nas.edu>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'jh-cao@cashq.ac.cn' <jh-cao@cashq.ac.cn>; 'clbai@cas.cn' <clbai@cas.cn>; 'gaof@im.ac.cn' <gaof@im.ac.cn>; liyin <liyin@cashq.ac.cn>
Subject: Re: Letter from the NASEM re: Virtual Dialogue Meeting
Importance: High

Dear colleagues,

Attached please find the letter replied by Prof. Chunli Bai and Prof. Fu Gao.

Best Regards,

Sun Hui

2020-04-29

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597282
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/
http://international-talent.cas.cn

发件人： NASPresident
发送时间： 2020-04-23 20:50:33
收件人： 'jh-cao@cashq.ac.cn'; 'clbai@cas.cn'; 'gaof@im.ac.cn'; 'sunhui@cashq.ac.cn'
抄送： McNutt, Marcia K.; Dzau, Victor J.; 'dgriffi6@jhmi.edu'; 'peggy@hbfam.net'; JohnHildebrand; Boright,John; Rusek, Benjamin; 'jwleduc@UTMB.EDU'
主题： Letter from the NASEM re: Virtual Dialogue Meeting

Please find the attached letter from Drs. McNutt, Dzau, Griffin, and Hamburg.

FOIA Confidential Treatment Requested by Univ of Texas System

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Wednesday, May 20, 2020 10:44 PM
To: 'relman@stanford.edu';'rbaric@email.unc.edu';'saif.2@osu.edu';'stanley-perlman@uiowa.edu';'daszak@ecohealthalliance.org';'harvey.fineberg@moore.org';'dgriffi6@jhmi.edu';'peggy@hbfam.net';LeDuc, James W.;Shi, Pei yong;Dzau, Victor J.
Cc: 'fsharples_3@hotmail.com';Lowenthal, Micah;'antoinette_baric@med.unc.edu';'andre@ecohealthalliance.org';'jennifer.ryan@moore.org';Bowman, Katherine;Kanarek, Morgan;'Raymond JEANLOZ';Hare, Hope;'davidrfranz@gmail.com'
Subject: 3rd Virtual U.S. China dialogue meeting on COVID-19
Attachments: Immunity topics for 3rd China U.S. Dialogue.docx

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Greetings,

As we discussed during our meeting on Monday we hope to hold a third virtual dialogue meeting with CAS and CCDC experts to discuss what is known about COVID-19 immunity, including the relationship between previous infection, antibody response, reinfection and convalescent plasma and preparing for a possible Fall 2020 resurgence of the virus.

We have proposed to CAS that this meeting take place on **Tuesday evening, May 26 from 9:00 -11:00 PM ET for the Americans** (and the morning of Wednesday, May 27 for the Chinese). I have attached the list of questions on these topics we sent to CAS for your information. **Please let me know if you are interested and available to participate in the 3rd virtual dialogue meeting.**

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Rusek, Benjamin
Sent: Monday, May 18, 2020 10:18 AM
To: Hare, Hope <HHare@nas.edu>; 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071562

Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19
Importance: High

Greetings,

Thought it would be helpful to send you a basic outline for the follow up call (**at 11:30 ET today**).

1) Intro
2) Comments on the Day 1 and Day 2 discussion
3) Ideas for topics (and additional American experts) for future virtual dialogue sessions
4) Discussion of George Gao's joint statement idea
5) CAS idea to post a blurb about the meetings on the CAS website
6) Other issues, concerns

I have attached the dialogue agenda (American version) for reference along with Jim's summaries of future collaboration ideas from the sessions.

I know a few people can't make it but I would be happy to follow up with you individually over the phone or email.

I look forward to talking to the group soon.
Zoom link: https://nasem.zoom.us/j/99830621870?pwd=cDM4WVE0YmZlTlBDdTlWQlk5Y0UvUT09

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Hare, Hope <HHare@nas.edu>
Sent: Friday, May 15, 2020 4:26 PM
To: 'relman@stanford.edu' <relman@stanford.edu>; 'rbaric@email.unc.edu' <rbaric@email.unc.edu>; 'saif.2@osu.edu' <saif.2@osu.edu>; 'stanley-perlman@uiowa.edu' <stanley-perlman@uiowa.edu>; 'daszak@ecohealthalliance.org' <daszak@ecohealthalliance.org>; 'harvey.fineberg@moore.org' <harvey.fineberg@moore.org>; 'dgriffi6@jhmi.edu' <dgriffi6@jhmi.edu>; 'peggy@hbfam.net' <peggy@hbfam.net>; 'jwleduc@UTMB.EDU' <jwleduc@UTMB.EDU>; 'davidrfranz@gmail.com' <davidrfranz@gmail.com>; 'peshi@UTMB.EDU' <peshi@UTMB.EDU>; Dzau, Victor J. <VDzau@nas.edu>; 'fsharples_3@hotmail.com' <fsharples_3@hotmail.com>; Lowenthal, Micah <mlowenth@nas.edu>; 'antoinette_baric@med.unc.edu' <antoinette_baric@med.unc.edu>; 'andre@ecohealthalliance.org' <andre@ecohealthalliance.org>; 'jennifer.ryan@moore.org' <jennifer.ryan@moore.org>; Bowman, Katherine <KBowman@nas.edu>; Kanarek, Morgan <MKanarek@nas.edu>; 'Raymond JEANLOZ' <jeanloz@berkeley.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>
Subject: RE: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

It is very difficult to find a time suitable for all—we apologize, but the one time that seemed to work is Monday, May 18th, at 11:30 AM. We understand that not all of you will be able to participate.
Here is the Zoom link for this meeting:
https://nasem.zoom.us/j/99830621870?pwd=cDM4WVE0YmZlTlBDdTlWQlk5Y0UvUT09
We look forward to seeing you on Monday at 11:30 am.
Best wishes,
Hope

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071563

From: Hare, Hope
Sent: Thursday, May 14, 2020 3:16 PM
Subject: Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19

Ben has asked me to contact you to schedule a time for the follow up call. We need to do this early next week, as there was not a time that worked well for everyone this week. Please send me your availability for a one hour Zoom meeting between 9AM - 6PM ET, Monday - Wednesday next week.

Thank you and best wishes,

Hope Hare
Administrative Assistant
The National Academies of Sciences, Engineering, and Medicine
500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-3435

The National Academies of
SCIENCES · ENGINEERING · MEDICINE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_071564

Thanks for sharing
Larry

Prof. Lawrence Steinman
Zimmermann Professor of Pediatrics, Neurology and Neurological Sciences
Beckman Center for Molecular Medicine
279 Campus Drive
Stanford, CA 94305-5316

From: vinu arumugham <vaccine.safety@aol.com>
Sent: Saturday, June 6, 2020 5:44 PM
To: Lawrence Steinman <steiny@stanford.edu>
Subject: Confirmation of my predictions on the role of mast cells, histamine in COVID-19
ï¿½
Prof. Steinman,

Thought this may be of interest:

I have been predicting for 4 months now that mast cell stabilizers and antihistamines (like H1/H2 blockers) can help in COVID-19.

I described the details, connecting mast cells, histamine, COVID-19 and dengue in my article below (uploaded Apr 11'20):

Immunological mechanisms explaining the role of IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines, Vitamin C, hydroxychloroquine, ivermectin and azithromycin
https://doi.org/10.5281/zenodo.3748303

As you may have read, famotidine (an antihistamine, H2 blocker) has been found to help in COVID-19, just like I predicted.

A large group of experts with expertise covering drug discovery, vaccines, pathology etc. recently (May 24'20 report) hypothesized and investigated numerous potential mechanisms involved in famotidine's beneficial effect in COVID-19. The study was funded by the "Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), and the Joint Science and Technology Office (JSTO) of the Chemical and Biological Defense Program (CBDP) for funding under the Discovery of Medical countermeasures Against Novel Entities (DOMANE) initiative."

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
www.researchsquare.com/article/rs-30934/v1

They conclude: "We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H2 activity, and that development of clinical COVID-19 involves dysfunctional mast cell activation and histamine release."

They write: " ... COVID-19 disease progression could share an immunologic basis with Dengue hemorrhagic fever" and

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124863

"This model is also supported by the significant overlap in the clinical signs and symptoms of the initial phase of COVID-19 disease and those of mast cell activation syndrome (MCAS) 89-92 as well similarities to Dengue hemorrhagic fever and shock syndrome (including T cell depletion) during the later phase of COVID-19"

"If COVID-19 is partially driven by dysfunctional mast cell degranulation, then a variety of medical interventions employing marketed drugs useful for treating mast cell-related disorders may help to reduce death and disease associated with SARS-CoV-2 infection. Examples include drugs with mast cell stabilizing activity, other histamine antagonists (for example H1 and H4 types), leukotriene antagonists and leukotriene receptor antagonists"

In other words, their findings are in perfect agreement with my prediction and analysis.

Thanks,
Vinu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124864

From: vinu arumugham <vaccine.safety@aol.com>
Sent: Saturday, June 13, 2020 12:17 AM
To: kanchanmvk@yahoo.com; ushamvk@yahoo.co.in; mike.agogliati@wfsb.com; kienym@who.int; Pasi.Penttinen@ecdc.europa.eu; sbaldwin@idri.org; friedem@who.int; angela.shen@hhs.gov; Bruce.Gellin@sabin.org; cww@austin.utexas.edu; mail@wired.com; submit@wired.com; megan_molteni@wired.com; wjbkwebteam@foxtv.com;; fox2newsdesk@foxtv.com; tyagi@ebi.ac.uk; Nick.Furnham@lshtm.ac.uk; betsy.mckay@wsj.com; spencer.macnaughton@wsj.com; conall.jones@wsj.com; brianna.abbott@wsj.com; Christopher.Weaver@wsj.com; dschui@cuhk.edu.hk; wpchnwr@who.int; wpchnmedia@who.int; wprocom@who.int; mediainquiries@who.int; 13698665 @qq.com; lifang@umn.edu; LDu@nybc.org; kyyuen@hku.hk; mark.woolhouse@ed.ac.uk; Christopher.Whitty@lshtm.ac.uk; Menachery, Vineet; jiwei_yunlong@126.com; Jennifer.Layden@Illinois.gov; rothe@lrz.uni-muenchen.de; zhangyongzhen@shphc.org.cn; sanchak@gmail.com; badrishanthi@hotmail.com; ljli@zju.edu.cn; gmaclaren@iinet.net.au; wiv@wh.iov.cn; suoban@simm.ac.cn; yqi@implad.ac.cn; sunguibo@126.com; kalisvar_marimuthu@ncid.sg; oon_tek_ng@ncid.sg; david.szymkowski@xencor.com; media.relations@roche.com; murthy.aditya@gene.com; joshua.wallach@yale.edu; alexander.egilman@yale.edu; margaret.e.mccarthy@yale.edu; jennifer.miller@nyumc.org; steven.woloshin@dartmouth.edu; lisa.schwartz@dartmouth.edu; joseph.ross@yale.edu; zlshi@wh.iov.cn; Linfa.wang@csiro.au
Subject: Fwd: Re: Confirmation of my predictions on the role of mast cells, histamine in COVID-19

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

COVID-19 severity is caused by an allergic reaction to the coronavirus involving mast cell degranulation and histamine release (elicitation). The development of this allergy (sensitization) was caused by vaccine components that are similar to coronavirus proteins.

Sharing with permission.

-------- Forwarded Message --------
Subject: Re: Confirmation of my predictions on the role of mast cells, histamine in COVID-19
Date: Sun, 7 Jun 2020 04:07:28 +0000
From: Lawrence Steinman <steiny@stanford.edu>
To:vinu arumugham <vaccine.safety@aol.com>

Dear Vinu,

All very interesting.
Congratulations to you for being correct, on point and prescient!
Thanks for sharing

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_139271

Larry

Prof. Lawrence Steinman
Zimmermann Professor of Pediatrics, Neurology and Neurological Sciences
Beckman Center for Molecular Medicine
279 Campus Drive
Stanford, CA 94305-5316

From: vinu arumugham <vaccine.safety@aol.com>
Sent: Saturday, June 6, 2020 5:44 PM
To: Lawrence Steinman <steiny@stanford.edu>
Subject: Confirmation of my predictions on the role of mast cells, histamine in COVID-19
ï¿½
Prof. Steinman,

Thought this may be of interest:

I have been predicting for 4 months now that mast cell stabilizers and antihistamines (like H1/H2 blockers) can help in COVID-19.

I described the details, connecting mast cells, histamine, COVID-19 and dengue in my article below (uploaded Apr 11'20):

Immunological mechanisms explaining the role of IgE, mast cells, histamine, elevating ferritin, IL-6, D-dimer, VEGF levels in COVID-19 and dengue, potential treatments such as mast cell stabilizers, antihistamines, Vitamin C, hydroxychloroquine, ivermectin and azithromycin
https://doi.org/10.5281/zenodo.3748303

As you may have read, famotidine (an antihistamine, H2 blocker) has been found to help in COVID-19, just like I predicted.

A large group of experts with expertise covering drug discovery, vaccines, pathology etc. recently (May 24'20 report) hypothesized and investigated numerous potential mechanisms involved in famotidine's beneficial effect in COVID-19. The study was funded by the "Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), and the Joint Science and Technology Office (JSTO) of the Chemical and Biological Defense Program (CBDP) for funding under the Discovery of Medical countermeasures Against Novel Entities (DOMANE) initiative."

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
www.researchsquare.com/article/rs-30934/v1

They conclude: "We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H2 activity, and that development of clinical COVID-19 involves dysfunctional mast cell activation and histamine release."

They write: " ... COVID-19 disease progression could share an immunologic basis with Dengue hemorrhagic fever" and

"This model is also supported by the significant overlap in the clinical signs and symptoms of the initial phase of COVID-19 disease and those of mast cell activation syndrome (MCAS) 89-92 as well similarities to Dengue hemorrhagic fever and shock syndrome (including T cell depletion) during the later phase of COVID-19"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_139272

"If COVID-19 is partially driven by dysfunctional mast cell degranulation, then a variety of medical interventions employing marketed drugs useful for treating mast cell-related disorders may help to reduce death and disease associated with SARS-CoV-2 infection. Examples include drugs with mast cell stabilizing activity, other histamine antagonists (for example H1 and H4 types), leukotriene antagonists and leukotriene receptor antagonists"

In other words, their findings are in perfect agreement with my prediction and analysis.

Thanks,
Vinu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_139273

From: Tang, Qiyi <qiyi.tang@Howard.edu>
Sent: Tuesday, July 7, 2020 10:47 PM
To: Liu, Shan-Lu; zhengzhiming4@gmail.com; haitguo@iupui.edu; tzhou@mail.nih.gov; GCheng@mednet.ucla.edu; liangy@umn.edu; rli@vcu.edu; wjma@ksu.edu; xjmeng@vt.edu; Zhijian.Chen@UTSouthwestern.edu; mluo@gsu.edu; zhangyj@umd.edu; xzhu1@umd.edu; jqiu@kumc.edu; lijun@uic.edu; fengwei.bai@usm.edu; andyu@iupui.edu; reachxw@vt.edu; gluo@uab.edu; ldu@nybc.org; hxu@tulane.edu; liu_fy@berkeley.edu; shitao.li@okstate.edu; Shan.lu@umassmed.edu; Hu, Haitao; wenzheho@temple.edu; Qfeng4 @central.uh.edu; tang@bio.fsu.edu; feng.li@sdstate.edu; ruilu@lsu.edu; sxiang2 @unl.edu; dingsw@ucr.edu; guohua@missouri.edu; bling@tulane.edu; junwang@pharmacy.arizona.edu; lifang@umn.edu; wang518@umd.edu; gaos8 @upmc.edu; Wang,Penghua; xiangy@uthscsa.edu; fzhu@bio.fsu.edu; chen.liang@mcgill.ca; lyuan@vt.edu; fgao@duke.edu; wangjw28@163.com; xfyu1 @zju.edu.cn; bzhao@partners.org; jianw@musc.edu; zyang@ksu.edu; yu.cong@nih.gov; weiming.yuan@usc.edu; Zongdi.feng@nationwidechildrens.org; juh13@psu.edu; hengx@missouri.edu; lsu@med.unc.edu; ywu8@gmu.edu; jwu@whu.edu.cn; tshuo@uic.edu; Shibojiang@fudan.edu.cn; sjiang@nybc.org; pinwang@usc.edu; rzhao@som.umaryland.edu; shuylong@mail.sysu.edu.cn; xuefeng.liu@georgetown.edu; yuxingli@som.umaryland.edu; shixia.wang@umassmed.edu; yhe@ipbcams.ac.cn; Pinghui.feng@usc.edu; ju-tao.guo@bblumberg.org; lin.liu@okstate.edu; hua.zhu@rutgers.edu; Jinhong.chang@bblumberg.org; jianzhu1012@gmail.com; ronghai@ucr.edu; jun.zhu@nih.gov; jliu4@uams.edu; xiangpeng.kong@med.nyu.edu; haoquanwu@outlook.com; Wenjun.liu@defence.gov.au; Liang.shan@wustl.edu; hliao@duke.edu; yuan2@upenn.edu; zxing@umn.edu; hongmin.li@health.ny.gov; pzheng@ihv.umaryland.edu; yaliu@ihv.umaryland.edu; jxw103@case.edu; xiangguo.qiu@canada.ca; Feng Shao; zlshi@wh.iov.cn; klan@whu.edu.cn; zengmsh@mail.sysu.edu.cn; Nan Yan; Zhang, Rong; liliwang@upenn.edu; Linheng Li; kli1@uthsc.edu; tsx@case.edu; ssun@mdanderson.org; ysang@tnstate.edu; wu@crystal.harvard.edu; Sun.Jie@mayo.edu; peijun@strubi.ox.ac.uk; jiayu@coh.org; bchen@crystal.harvard.edu; Wen, Haitao; Qu, Feng; Hezhao.Ji@umanitoba.ca; Li, Zihai; zhengyo@msu.edu; zhanglinqi@tsinghua.edu.cn; wxiao@temple.edu; Whu@temple.edu; RSun@mednet.ucla.edu; Guangping.Gao@umassmed.edu; pzheng@ihv.umaryland.edu; GMSWANG@nus.edu.sg; Shi, Pei yong; yaliu@ihv.umaryland.edu; ziying-yan@uiowa.edu; lqiao@luc.edu; yong.xiong@yale.edu; Wang, Qiuhong; shuping_tong_md@brown.edu; pinghuif@usc.edu; gaof@im.ac.cn
Subject: Re: Happy Thanksgiving and meeting next year, June 12-13, 2020

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi professors,

I apologize if you are bothered by this email. I am helping my friend, Ed Seto to advertise his recruiting post-doc:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125909

Postdoctoral Position

Applications are invited for a postdoctoral fellowship to study the structures, functions, and mechanisms of histone deacetylases. Candidates with experiences in biochemical, molecular, and cell biological approaches are preferred.

Recent selected articles from our lab:
PMID: 32540961
PMID: 32457045
PMID: 31162605
PMID: 30517871
PMID: 30456376
PMID: 29958910

Please send a CV and names of three references to:

Ed Seto, Ph.D.
Email: seto@gwu.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125910